Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions comprising thereof, as an active ingredient

Information

  • Patent Grant
  • 7119091
  • Patent Number
    7,119,091
  • Date Filed
    Friday, December 1, 2000
    23 years ago
  • Date Issued
    Tuesday, October 10, 2006
    17 years ago
Abstract
Triazaspiro[5.5]undecane derivatives, quaternary ammonium salts thereof, N-oxides thereof, non-toxic salts thereof, or pharmaceutical compositions comprising them, as an active ingredient.
Description

This application was filed under 35 U.S.C. 371, and is the U.S. National Stage of PCT/JP00/08517, filed Dec. 1, 2000.


TECHNICAL FIELD

The present invention relates to triazaspiro[5.5]undecane derivatives and pharmaceutical compositions comprising thereof, as an active ingredient.


More particularly, it relates to triazaspiro[5.5]undecane derivatives of the formula (I)




embedded image



(wherein all the symbols have the same meaning as defined hereinafter), quaternary ammonium salts thereof, N-oxides thereof, non-toxic salts thereof, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient.


BACKGROUND OF THE INVENTION

Chemokine is known as a basic protein having endogeneous leukocyte chemotactic and activating abilities and strong heparin-binding ability. At present, it is considered that chemokine is related to not only the control of infiltration of specific leukocyte at the time of inflammations and immune responses but also the development and homing of lymphocyte under physiological conditions and migration of hemocyte precursor cells and somatic cells.


Differentiation, proliferation and cell death of hemocytes are controlled by various types of cytokine. In the living body, inflammations are found topically and differentiation, maturation and the like of lymphocytes are carried out at certain specified sites. That is, various necessary cells migrate into certain specified sites and accumulate therein to cause a series of inflammations and immune responses. Accordingly, migration of cells is also an indispensable phenomenon in addition to differentiation, proliferation and death of cells.


Migration of hemocytes in the living body starts firstly in the development stage by the shift of hematopoiesis started in the AGM region into permanent hematopoiesis in bone marrow via fetal liver. Furthermore, precursor cells of T cells and thymus dendritic cells migrate from the fetal liver into the bone marrow and then into the thymus gland and cytodifferentiate under thymus environment. The T cell which received clone selection migrates into secondary lymphoid tissues and takes part in an immune response in the periphery. The Langerhans' cell of the skin activated and differentiated by capturing an antigen migrates into the T cell region of a topical lymph node and activates naïive T cell therein as a dendritic cell. The memory T cell performs its homing again into the lymph node via lymphatic and blood vessels. Also, B cell, T cell in the intestinal epithelium, γδ T cell, NKT cell and dendritic cell migrate from bone marrow without passing through the thymus gland and differentiate to take part in an immune response.


Chemokine is deeply related to the migration of these various cells. For example, MIP3β, SLC and its receptor CCR7 play an important role in the migration and homing of naïve T cell, memory T cell and the mature dendritic cell which captured an antigen into a topical lymphoid tissue for the dendritic cells to encounter efficiently with the T cells. The T cell and dendritic cell necessary for controlling antigen-specific immune responses are hardly observed in the secondary lymph node of a PLT mouse having deficiency in the expression of SLC (J. Exp. Med., 189(3), 451 (1999)).


MDC, TARC and its receptor CCR4 play an important role in the migration of Th2 cell into topical sites in immune and inflammatory responses in which the Th2 cell is related. In a rat fluminant hepatitis model (P. acnes+LPS), an anti-TARC antibody suppressed increase of the amount of ALT in blood and increase of the expressing amounts of TNFα and FasL in the liver and also improved lethality of the rats (J. Clin. Invest., 102, 1933 (1998)). Also, an anti-MDC antibody decreased the number of eosinophils accumulated in the lung interstitium and suppressed airway hypersensitivity in a mouse OVA-induced airway hypersensitivity model (J. Immunology, 163, 403 (1999)).


MCP-1 and its receptor CCR2 are related to the infiltration of macrophage into inflammation sites. An anti-MCP-1 antibody showed an effect to suppress infiltration of monocyte and macrophage into glomerulus in a rat anti-Thy1.1 antibody glomerular nephritis model (Kidney Int., 51, 770 (1997)).


Thus, chemokine receptors are greatly related to the control of inflammation and immune responses through a mechanism in which they are expressed at certain specified periods in variously specific cells and the effector cells are accumulated in a region where chemokine is produced.


Acquired immunodeficiency syndrome (called AIDS) which is induced by human immunodeficiency virus (hereinafter referred to as “HIV”) is one of the diseases of which their therapeutic methods are most earnestly desired in recent years. Once infection with HIV is completed in a CD4-positive cell which is a principal target cell, HIV repeats its proliferation in the body of the patient and, sooner or later, completely destroys T cell which takes charge of the immunological function. During this process, the immunological function is gradually reduced to cause fever, diarrhea, lymph node enlargement and the like various immunodeficiency conditions which are apt to cause complications with pneumocystis carinii pneumonia and the like various opportunistic infections. Such conditions are the onset of AIDS, and it is well known that they induce and worsen Kaposi sarcoma and the like malignant tumors.


As the recent preventive and therapeutic methods for AIDS, attempts have been made to, e.g., (1) inhibit growth of HIV by the administration of a reverse transcriptase inhibitor or a protease inhibitor and (2) prevent or alleviate opportunistic infections by the administration of a drug having immunopotentiation activity.


Helper T cells which take charge of the central of immune system are mainly infected with HIV. It is known since 1985 that HIV uses the membrane protein CD4 expressing on the membrane of T cells in the infection (Cell, 52, 631 (1985)). The CD4 molecule is composed of 433 amino acid residues, and its expression can be found in macrophages, some B cells, vascular endothelial cells, Langerhans' cells in skin tissues, dendritic cells in lymphoid tissues, glia cells of the central nervous system and the like, in addition to the mature helper T cells. However, since it has been revealed that the infection with HIV is not completed by the CD4 molecule alone, a possibility has been suggested on the presence of factors other than the CD4 molecule, which are related to the infection of cells with HIV.


In 1996, a cell membrane protein called Fusin was identified as a factor other than the CD4 molecule, which is related to the HIV infection (Science, 272, 872 (1996)). It was confirmed that this Fusin molecule is a receptor (namely, CXCR4) of stromal derived factor-1 (hereinafter referred to as “SDF-1”). In addition, it was confirmed also in vitro that the SDF-1 specifically inhibits infection of T cell tropic (X4) HIV (Nature, 382, 829 (1996), Nature, 32, 833 (1996)). That is, it is considered that the HIV infection was inhibited by the binding of SDF-1 to CXCR4 preceding HIV, thereby depriving HIV of a foothold for infecting cells.


Also at that time, it was discovered that another chemokine receptor CCR5, which is a receptor of RANTES, MIP-1α and MIP-1β, is also used at the time of the infection with a macrophage tropic (R5) HIV (Science, 212, 1955 (1996)).


Accordingly, substances which can compete with CXCR4 and CCR5 for HIV, or which can bind to HIV virus thus causing the virus unable to bind to CXCR4 and CCR5, could become HIV infection inhibitors. Also, there is a case in which a low molecular compound initially discovered as an HIV infection inhibitor was actually a CXCR4 antagonist (Nature Medicine, 4, 72 (1998)).


Based on the above, it is considered that the chemokine/chemokine receptors are deeply related to the inflammation, immune disease or HIV infection. For example, it is considered that they are related to the inhibition of various inflammatory diseases, asthma, atopic dermatitis, nettle rash, allergic diseases (allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis and the like), glomerular nephritis, nephropathy, hepatitis, arthritis, chronic rheumatoid arthritis, psoriasis, rhinitis, conjunctivitis and ischemia-reperfusion injury, in the treatment of multiple sclerosis, ulcerative colitis, acute respiratory distress syndrome, shock accompanied by bacterial infection, diabetes mellitus and autoimmune diseases, and in transplanted organ rejection reactions, immunosuppression, metastasis prevention and acquired immunodeficiency syndrome.


On the other hand, in specification of WO97/11940, it is described that compounds of the formula (Z)




embedded image



(wherein the atoms AiZ and BiZ are independently selected from carbon, nitrogen, oxygen or sulfur, provided that at least one atom of AiZ is carbon, and at least one atom BiZ is carbon;

  • the rings of the spirobicycle formed by AiZ and BiZ, respectively, may optionally be partly unsaturated,
  • pZ and qZ are independently numbers from 2 to 6,
  • mZ is a number from 0 to pZ,
  • R10Z is the same or different and is a non-interfering substituent independently selected from hydrogen, alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, ═O, ═S etc.,
  • nZ is a number from 0 to qZ,
  • R0Z is the same or different and is a non-interfering substituent independently selected from hydrogen, alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, ═O, ═S etc.,
  • the linking group -(LZ)- is a bond or a divalent substituted or unsubstituted chain of from 1 to 10 atoms selected from the group consisting of carbon, nitrogen, sulfur, and oxygen,
  • QZ is a basic group containing one or more basic radicals, and
  • R3Z is an acidic group containing one or more acid radicals) are useful in inhibition platelet aggregation.


In specification of WO98/25605, it is described that compounds of the formula (Y)




embedded image



(wherein mY or lY are each independently 0, 1, 2, 3, 4 or 5,

  • R1Y is hydrogen, C1–8 alkyl, C2–8 alkenyl, C2–8 alkynyl etc.,
  • WY is a bond, C1–3 alkyl or C1–3 alkyl substituted with oxo etc.,
  • QY is —NR2—, —O—, —S—, —S(O)— or —SO2—,
  • XY is a bond, C1–3 alkyl or C1–3 alkyl substituted with oxo etc.,
  • YY-ZY ring is phenyl, naphthyl or hetero aryl.


    With the proviso that the definition of each symbol is a excerpt partially.) are useful as modulators of the chemokine receptors.


DISCLOSURE OF THE INVENTION

The present inventors have investigated to find compounds regulating chemokine/chemokine receptors, so that the present inventors have found that the purpose has been achieved by triazaspiro[5.5]undecane derivatives of the formula (I).


The present invention relates to

  • i) triazaspiro[5.5]undecane derivatives of the formula (I)




embedded image



[wherein R1 is

  • (1) hydrogen,
  • (2) C1–18 alkyl,
  • (3) C2–18 alkenyl,
  • (4) C2–18 alkynyl,
  • (5) —COR6,
  • (6) —CONR7R8,
  • (7) —COOR9,
  • (8) —SO2R10,
  • (9) —COCOOR11,
  • (10) —CONR12COR13,
  • (11) Cyc 1, or
  • (12) C1–18 alkyl, C2–18 alkenyl or C2–18 alkynyl substituted by 1–5 of optionally selected from (a) halogen, (b) —CONR7R8, (c) —COOR9, (d) —OR14, (e) —SR15, (f) —NR16R17, (g) —NR18COR19, (h) —SO2NR20R21, (i) —OCOR22, (j) —NR23SO2R24, (k) —NR25COOR26, (l) —NR27CONR28R29, (m) Cyc 1, (n) keto or (o) —N(SO2R24)2,
  • (wherein R6–R9, R11–R21, R23, R25 and R27–R29 are each independently,
  • (1) hydrogen,
  • (2) C1–8alkyl,
  • (3) C2–8 alkenyl,
  • (4) C2–8 alkynyl,
  • (5) Cyc 1, or
  • (6) C1–8 alkyl, C2–8 alkenyl or C2–8 alkynyl substituted by 1–5 of optionally selected from (a) Cyc 1, (b) halogen, (c) —OR30, (d) —SR31, (e) —NR32R33, (f) —COOR34, (g) —CONR35R36, (h) —NR37COR38, (i) —NR39SO2R40 or (j) —N(SO2R40)2, or
  • R7 and R8, R20 and R21, R23 and R29, taken together, are 1) C2–6 alkylene, 2) —(C2–6 alkylene)-O—(C2–6 alkylene)-, 3) —(C2–6 alkylene)-S—(C2–6 alkylene)- or 4) —(C2–6 alkylene)-NR195—(C2–6 alkylene)-, (wherein R195 is hydrogen, C1–8 alkyl, phenyl or C1–8alkyl substituted by phenyl.),
  • R10, R22, R24 and R26 are each independently,
  • (1) C1–8alkyl,
  • (2) C2–8 alkenyl,
  • (3) C2–8 alkynyl,
  • (4) Cyc 1, or
  • (5) C1–8 alkyl, C2–8 alkenyl or C2–8 alkynyl substituted by 1–5 of optionally selected from (a) Cyc 1, (b) halogen, (c) —OR30, (d) —SR31, (e) —NR32R33, (f) —COOR34, (g) —CONR35R36, (h) —NR37COR38, (i) —NR39SO2R40 or (j) —N(SO2R40)2,
  • (wherein R30–R37 and R39 are each independently, hydrogen, C1–8 alkyl, Cyc 1 or C1–8 alkyl substituted by Cyc 1, or
  • R35 and R36, taken together, are 1) C2–6 alkylene, 2) —(C2–6 alkylene)-O—(C2–6 alkylene)-, 3) —(C2–6 alkylene)-S—(C2–6 alkylene)- or 4) –(C2–6 alkylene)-NR196—(C2–6 alkylene)-, (wherein R196 is hydrogen, C1–8 alkyl, phenyl or C1–8 alkyl substituted by phenyl.),
  • R38 and R40 are each independently C1–8 alkyl, Cyc 1 or C1–8 alkyl substituted by Cyc 1.)
  • Cyc 1 is C3–15 mono-, bi- or tri-(fused or spiro) carbocyclic ring or 3–15 membered mono-, bi- or tri-(fused or spiro) cyclic hetero ring containing 1–4 nitrogen atom(s), 1–3 oxygen atom(s) and/or 1–3 sulfur atom(s).


    With the proviso that, Cyc 1 may be optionally substituted by 1–5 of R51,
  • R5 is
  • (1) C1–8 alkyl,
  • (2) C2–8 alkenyl,
  • (3) C2–8 alkynyl,
  • (4) halogen,
  • (5) nitro,
  • (6) trifluoromethyl,
  • (7) trifluoromethoxy,
  • (8) nitrile,
  • (9) keto,
  • (10) Cyc 2
  • (11) —OR52,
  • (12) —SR53,
  • (13) —NR54R55,
  • (14) —COOR56,
  • (15) —CONR57R56,
  • (16) —NR59COR60,
  • (17) —SO2NR61R62,
  • (18) —OCOR63,
  • (19) —NR64SO2R65,
  • (20) —NR66COOR67,
  • (21) —NR68CONR69R70,
  • (22) —B(OR71)2,
  • (23) —SO2R72,
  • (24) —N(SO2R72)2, or
  • (25) C1–8 alkyl, C2–8 alkenyl or C2–8 alkynyl substituted by 1–5 of optionally selected from (a) halogen, (b) Cyc 2, (c) —OR52, (d) —SR53, (e) —NR54R55, (f) —COOR56, (g) —CONR57R58, (h) —NR59COR60, (i) —SO2NR61R62, (j) —OCOR63, (k) —NR64SO2R65, (l) —NR66COOR67, (m) —NR68CON R69R70, (n) —B(OR71)2, (o) —SO2R72 or (p) —N(SO2R72)2.)
  • (wherein R52–R62, R64, R66 and R68–R71 are each independently 1) hydrogen, 2) C1–8 alkyl, 3) C2–8 alkenyl, 4) C2–8 alkynyl, 5) Cyc 2 or 6) C1–8 alkyl, C2-8 alkenyl or C2–8 alkynyl substituted by Cyc 2, —OR73, —COOR74 or —NR75R76, or R57 and R58, R61 and R67, R69 and R70, taken together, are 1) C2–6 alkylene, 2) —(C2–6 alkylene)-O—(C2–6 alkylene)-, 3) —(C2–6 alkylene)-S—(C2–6 alkylene)- or 4) —(C2–6 alkylene)-NR197—(C2–6 alkylene)-, (wherein R197 is hydrogen, C1–8 alkyl, phenyl or C1–8alkyl substituted by phenyl.),
  • R63, R65, R67 and R72 are each independently 1) C1–8 alkyl, 2) C2–8 alkenyl, 3) C2–8 alkynyl, 4) Cyc 2 or 5) C1–8 alkyl, C2–8 alkenyl or C2–8 alkynyl substituted by Cyc 2, —OR73, —COOR74 or —NR75R76,
  • (wherein R73–R76 are independently hydrogen, C1–8 alkyl, Cyc 2 or C1–8 alkyl substituted by Cyc 2.)
  • Cyc 2 is the same meaning as Cyc 1.


    With the proviso that, Cyc 2 may be optionally substituted by 1–5 of R77,
  • R77 is
  • 1) C1–8alkyl,
  • 2) halogen,
  • 3) nitro,
  • 4) trifluoromethyl,
  • 5) trifluoromethoxy,
  • 6) nitrile,
  • 7) —OR78,
  • 8) —NR79R80,
  • 9) —COOR81,
  • 10) —SR82,
  • 11) —CONR83R84,
  • 12) C2–8 alkenyl,
  • 13) C2–8 alkynyl,
  • 14) keto,
  • 15) Cyc 6,
  • 16) —NR161COR162,
  • 17) —SO2NR163R164,
  • 18) —OCOR165,
  • 19) —NR166SO2R167,
  • 20) —NR168COOR169,
  • 21) —NR170CONR171R172,
  • 22) —SO2R173,
  • 23) —N(SO2R167)2, or
  • 24) C1–8 alkyl, C2–8 alkenyl or C2–8 alkynyl substituted by 1–5 of optionally selected from (a) halogen, (b) —OR78, (c) —NR79R80, (d) —COOR81, (e) —SR82, (f) —CONR83R84, (g) keto, (h) Cyc 6, (i) —NR161COR162, (j) —SO2NR163R164 (k) —OCOR165, (l) —NR166SO2R167, (m) —NR168COOR169, (n) —NR170CONR171R172, (o) —SO2R173 or (p) —N(SO2R167)2.)
  • (wherein R78–R84, R161–R164, R166, R168 and R170–R172 are each independently (a) hydrogen, (b) C1–8 alkyl, (c) C2–8 alkenyl, (d) C2–8 alkynyl, (e) Cyc 6 or (f) C1–8 alkyl, C2–8 alkenyl or C2–8 alkynyl substituted by Cyc 6, —OR174, —COOR175, —NR176R177 or —CONR178R179, or
  • R83 and R84, R163 and R164, R171 and R172, taken together, are 1) C2–6 alkylene, 2) —(C2–6 alkylene)-O—(C2–6 alkylene)-, 3) —(C2–6 alkylene)-S—(C2–6 alkylene)- or 4) —(C2–6 alkylene)-NR198—(C2–6 alkylene)-, (wherein R198 is hydrogen, C1–8 alkyl, phenyl or C1–8 alkyl substituted by phenyl.),
  • R165, R167, R169 and R173 are each independently (a) C1–8 alkyl, (b) C2–8 alkenyl, (c) C2–8 alkynyl, (d) Cyc 6 or (e) C1–8 alkyl, C2–8 alkenyl, C2–8 alkynyl substituted by Cyc 6, —OR174, —COOR175, —NR176R177 or —CONR178R179.)
  • (wherein R174–R177 are each independently 1) hydrogen, 2) C1–8 alkyl, 3) Cyc 6 or 4) C1–8 alkyl substituted by Cyc 6, or
  • R178 and R179, taken together, are 1) C2–6 alkylene, 2) —(C2–6 alkylene)-O—(C2–6 alkylene)-, 3) —(C2–6 alkylene)-S—(C2–6 alkylene)- or 4) —(C2–6 alkylene)-NR199—(C2–6 alkylene)-(wherein R199 is hydrogen, C1–8 alkyl, phenyl or C1–8 alkyl substituted by phenyl.),
  • Cyc 6 is C3–8 mono-carbocyclic ring or 3–8 membered mono-cyclic hetero ring containing 1–4 nitrogen atom(s), 1–2 oxygen atom(s) and/or 1–2 sulfur atom(s).


    With the proviso that, Cyc 6 may be optionally substituted by 1–5 of R180, R180 is,
  • (1) C1–8 alkyl,
  • (2) halogen,
  • (3) nitro,
  • (4) trifluoromethyl,
  • (5) trifluoromethoxy,
  • (6) nitrile,
  • (7) —OR181,
  • (8) —NR182R183,
  • (9) —COOR184,
  • (10) —SR185, or
  • (11) —CONR186R187,
  • (wherein R181–R187 are each independently 1) hydrogen, 2) C1–8 alkyl, 3) phenyl or 4) C1–8 alkyl substituted by phenyl,
  • R182 and R183, R186 and R187, taken together, are 1) C2–6 alkylene, 2) —(C2–6 alkylene)-O—(C2–6 alkylene)-, 3) —(C2–6 alkylene)-S—(C2–6 alkylene)- or 4) —(C2–6 alkylene)-NR200—(C2–6 alkylene)-, (wherein R200 is hydrogen, C1–8 alkyl, phenyl or C1–8 alkyl substituted by phenyl.).),
  • R2 is
  • (1) hydrogen,
  • (2) C1–8 alkyl,
  • (3) C2–8 alkenyl,
  • (4) C2–8 alkynyl,
  • (5) —OR90,
  • (6) Cyc 3, or
  • (7) C1–8 alkyl, C2–8 alkenyl or C2–8 alkynyl substituted by 1–5 of optionally selected from (a) halogen, (b) —OR90, (c) —SR91, (d) —NR92R93, (e) —COOR94, (f) —CONR95R96, (g) —NR97COR98, (h) —SO2NR99R100, (i) —OCOR101, (j) —NR102SO2R103, (k) —NR104COOR105, (l) —NR106CONR107R108, (m) Cyc3, (n) keto or (o) —N(SO2R103)2,
  • (wherein R90–R100, R102, R104 and R106–R108 are each independently 1) hydrogen, 2) C1–8 alkyl, 3) C2–8 alkenyl, 4) C2–8 alkynyl, 5) Cyc 3 or 6) C1–8 alkyl, C2–8 alkenyl or C2–8 alkynyl substituted by Cyc 3, or
  • R95 and R96, R99 and R100, R107 and R108, taken together, are 1) C2–6 alkylene 2) —(C2–6 alkylene)-O—(C2–6 alkylene)-, 3) —(C2–6 alkylene)-S—(C2–6 alkylene)- or 4) —(C2–6 alkylene)-NR201—(C2–6 alkylene)-, (wherein R201 is hydrogen, C1–8 alkyl, phenyl or C1–8 alkyl substituted by phenyl.),
  • R101, R103 and R105 are each independently 1) C1–8 alkyl, 2) C2–8 alkenyl, 3) C2–8 alkynyl or 4) Cyc 3, or C1–8 alkyl, C2–8alkenyl or C2–8alkynyl substituted by Cyc 3,
  • Cyc 3 is the same meaning as Cyc 1.


    With the proviso that, Cyc 3 may be optionally substituted by 1–5 of R109,
  • R109 is the same meaning as R51)
  • R3 and R4 are each independently
  • (1) hydrogen,
  • (2) C1–8 alkyl,
  • (3) C2–8 alkenyl,
  • (4) C2–8 alkynyl,
  • (5) —COOR120,
  • (6) —CONR121R122,
  • (7) Cyc 4, or
  • (8) C1–8 alkyl, C2–8 alkenyl or C2–8 alkynyl substituted by 1–5 of optionally selected from (a) halogen, (b) nitrile, (c) Cyc 4, (d) —COOR120, (e) —CONR121R122, (f) —OR123, (g) —SR124, (h) —NR125R126, (i) —NR127COR128, (j) —SO2NR129R130, (k) —OCOR131, (l) —NR132SO2R133, (m) —NR134COOR135, (n) —NR136CONR137R138, (o) —S—SR139, (p) —NHC(═NH)NHR140, (q) keto, (r) —NR145CONR146COR147 or (s) —N(SO2R133)2,
  • (wherein R120–R130 R132 R134 R136–R138, R145 and R146 are each independently 1) hydrogen, 2) C1–8 alkyl, 3) C2–8 alkenyl, 4) C2–8 alkynyl, 5) Cyc 4 or 6) C1–8 alkyl, C2–8 alkenyl or C2–8 alkynyl substituted by Cyc 4, halogen, —OR148, —SR149, —COOR150 or —NHCOR141, or
  • R121 and R122 R129 and R130, R137 and R138, taken together, are 1) C2–6 alkylene, 2) —(C2–6 alkylene)-O—(C2–6 alkylene)-, 3) —(C2–6 alkylene)-S—(C2–6 alkylene)- or 4) —(C2–6 alkylene)-NR201—(C2–6 alkylene)-, (wherein R202 is hydrogen, C1–8 alkyl, phenyl or C1–8 alkyl substituted by phenyl.),
  • R131, R133, R135, R139 and R147 are each independently 1) C1–8 alkyl, 2) C2–8 alkenyl, 3) C2–8 alkynyl, 4) Cyc 4 or 5) C1–8 alkyl, C2–8 alkenyl or C2–8 alkynyl substituted by Cyc 4, halogen, —OR148, —SR149, —COOR150 or —NHCOR141,
  • R140 is hydrogen, —COOR142 or —SO2R143,
  • (wherein R141–R143 are each independently 1) C1–8 alkyl, 2) C2–8 alkenyl, 3) C2–8 alkynyl, 4) Cyc 4 or 5) C1–8 alkyl, C2–8 alkenyl or C2–8 alkynyl substituted by Cyc 4,
  • R148–R150 are each independently 1) hydrogen, 2) C1–8 alkyl, 3) C2–8 alkenyl, 4) C2–8 alkynyl, 5) Cyc 4 or 6) C1–8 alkyl, C2–8 alkenyl or C2–8 alkynyl substituted by Cyc 4,
  • Cyc 4 is the same meaning as Cyc 1.


    With the proviso that, Cyc 4 may be optionally substituted by 1–5 of R144,
  • R144 is the same meaning as R51.) or
  • R3 and R4, taken together, are




embedded image


  • (wherein R190 and R191 are each independently the same meaning as R3 or R4.),

  • R5 is

  • (1) hydrogen,

  • (2) C1–8 alkyl,

  • (3) Cyc 5, or

  • (4) C1–8alkyl substituted by Cyc 5.

  • (wherein Cyc 5 is the same meaning as Cyc 1.


    With the proviso that, Cyc 5 may be optionally substituted by 1–5 of R160, R160 is the same meaning as R51.)],

  • quaternary ammonium salts thereof, N-oxides thereof or non-toxic salts thereof,

  • ii) the methods for preparation of compounds of the formula (I), quaternary ammonium salts thereof, N-oxides thereof or non-toxic salts thereof, and

  • iii) pharmaceutical compositions comprising compounds of the formula (I), quaternary ammonium salts thereof, N-oxides thereof or non-toxic salts thereof, as an active ingredient.



In the present invention, C1–18 alkyl means methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl or isomeric groups thereof.


C2–18 alkenyl means C2–18 alkylene optionally having 1–9 double bond(s) (preferably 1–4 double bond(s)), concretely, vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tridecenyl, tetradecenyl, pentadecenyl, hexadecenyl, heptadecenyl, octadecenyl, butadienyl, pentadienyl, hexadienyl, heptadienyl, octadienyl, nonadienyl, decadienyl, undecadienyl, dodecadienyl, tridecadienyl, tetradecadienyl, pentadecadienyl, hexadecadienyl, heptadecadienyl, octadecadienyl, hexatrienyl, heptatrienyl, octatrienyl, nonatrienyl, decatrienyl, undecatrienyl, dodecatrienyl, tridecatrienyl, tetradecatrienyl, pentadecatrienyl, hexadecatrienyl, heptadecatrienyl, octadecatrienyl or isomeric groups thereof.


C2–18 alkynyl means C2–18 alkylene optionally having 1–9 triple bond(s) (preferably 1–4 triple bond(s)), concretely, ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, undecynyl, dodecynyl, tridecynyl, tetradecynyl, pentadecynyl, hexadecynyl, heptadecynyl, octadecynyl, butadiynyl, pentadiynyl, hexadiynyl, heptadiynyl, octadiynyl, nonadiynyl, decadiynyl, undecadiynyl, dodecadiynyl, tridecadiynyl, tetradecadiynyl, pentadecadiynyl, hexadecadiynyl, heptadecadiynyl, octadecadiynyl, hexatriynyl, heptatriynyl, octatriynyl, nonatriynyl, decatriynyl, undecatriynyl, dodecatriynyl, tridecatriynyl, tetradecatriynyl, pentadecatriynyl, hexadecatriynyl, heptadecatriynyl, octadecatriynyl or isomeric groups thereof.


Halogen is chlorine, bromine, fluorine or iodine.


C1–8 alkyl means methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl or isomeric groups thereof.


C2–8 alkenyl means C2–8 alkylene optionally having 1–4 double bond(s), concretely, vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, butadienyl, pentadienyl, hexadienyl, heptadienyl, octadienyl, hexatrienyl, heptatrienyl, octatrienyl or isomeric groups thereof.


C2–8 alkynyl means C2–8 alkylene optionally having 1–4 triple bond(s), concretely, ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, butadiynyl, pentadiynyl, hexadiynyl, heptadiynyl, octadiynyl, hexatriynyl, heptatriynyl, octatriynyl or isomeric groups thereof.


C2–6 alkylene means methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene or isomeric groups thereof.


C3–15 mono-, bi- or tri-(fused or spiro)carbocyclic ring means concretely, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclopentene, cyclohexene, cycloheptene, cyclooctene, cyclopentadiene, cyclohexadiene, cycloheptadiene, cyclooctadiene, benzene, indene, naphthalene, indan, tetrahydronaphthalene, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, bicyclo[4.4.0]decane, spiro[4.4]nonane, spiro[4.5]decane, spiro[5.5]undecane, bicyclo[3.1.1]heptane, bicyclo[3.3.1]hept-2-ene, fluorene or anthracene etc.


3–15 membered mono-, bi- or tri-(fused or spiro)cyclic hetero ring containing 1–4 nitrogen atom(s), 1–3 oxygen atom(s) and/or 1–3 sulfur atom(s) means 3–15 membered mono-, bi- or tri-(fused or spiro)cyclic hetero aryl containing 1–4 nitrogen atom(s), 1–3 oxygen atom(s) and/or 1–3 sulfur atom(s), and partially or fully saturated one.


3–15 membered mono-, bi- or tri-(fused or spiro)cyclic hetero aryl containing 1–4 nitrogen atom(s), 1–3 oxygen atom(s) and/or 1–3 sulfur atom(s) is pyrrole, imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, azepine, diazepine, furan, pyran, oxepine, thiophene, thiain (thiopyran), thiepine, oxazole, isoxazole, thiazole, isothiazole, furazan, oxadiazole, oxazine, oxadiazine, oxazepine, oxadiazepine, thiadiazole, thiazine, thiadiazine, thiazepine, thiadiazepine, indole, isoindole, benzofuran, isobenzofuran, benzothiophene, isobenzothiophene, indazole, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, benzoxazole, benzothiazole, benzimidazole, benzoxepine, benzoxazepine, benzoxadiazepine, benzothiepine, benzothiazepine, benzothiadiazepine, benzazepine, benzodiazepine, benzofurazan, benzothiadiazole, benzotriazole, carbazole, acridine, dibenzofuran or dibenzothiophene etc.


In above 3–15 membered mono-, bi- or tri-(fused or spiro)cyclic hetero ring containing 1–4 nitrogen atom(s), 1–3 oxygen atom(s) and/or 1–3 sulfur atom(s), partially or fully saturated one is pyrroline, pyrrolidine, imidazoline, imidazolidine, pyrazoline, pyrazolidine, triazoline, triazolidine, tetrazoline, tetrazolidine, dihydropyridine, tetrahydropyridine, piperidine, dihydropyrazine, tetrahydropyrazine, piperazine, dihydropyrimidine, tetrahydropyrimidine, perhydropyrimidine, dihydropyridazine, tetrahydropyridazine, perhydropyridazine, dihydroazepine, tetrahydroazepine, perhydroazepine, dihydrodiazepine, tetrahydrodiazepine, perhydrodiazepine, dihydrofuran, tetrahydrofuran, dihydropyran, tetrahydropyran, dihydrothiophene, tetrahydrothiophene, dihydrothiain (dihydrothiopyran), tetrahydrothiain (tetrahydrothiopyran), dihydrooxazole, tetrahydrooxazole, dihydroisoxazole, tetrahydroisoxazole, dihydrothiazole, tetrahydrothiazole, dihydroisothiazole, tetrahydroisothiazole, dihydrooxadiazole, tetrahydrooxadiazole, dihydrothiodiazole, tetrahydrothiodiazole, tetrahydrooxadiazine, tetrahydrothiadiazine, tetrahydrooxazepine, tetrahydrooxadiazepine, perhydrooxazepine, perhydrooxadiazepine, tetrahydrothiazepine, tetrahydrothiadiazepine, perhydrothiazepine, perhydrothiadiazepine, morpholine, thiomorpholine, indoline, isoindoline, dihydrobenzofuran, perhydrobenzofuran, dihydroisobenzofuran, perhydroisobenzofuran, dihydrobenzothiophene, perhydrobenzothiophene, dihydroisobenzothiophene, perhydroisobenzothiophene, dihydroindazole, perhydroindazole, dihydroquinoline, tetrahydroquinoline, perhydroquinoline, dihydroisoquinoline, tetrahydroisoquinoline, perhydroisoquinoline, dihydrophthalazine, tetrahydrophthalazine, perhydrophthalazine, dihydronaphthyridine, tetrahydronaphthyridine, perhydronaphthyridine, dihydroquinoxaline, tetrahydroquinoxaline, perhydroquinoxaline, dihydroquinazoline, tetrahydroquinazoline, perhydroquinazoline, dihydrocinnoline, tetrahydrocinnoline, perhydrocinnoline, dihydrobenzoxazole, perhydrobenzoxazole, dihydrobenzothiazole, perhydrobenzothiazole, dihydrobenzimidazole, perhydrobenzimidazole, dihydrocarbazole, tetrahydrocarbazole, perhydrocarbazole, dihydroacridine, tetrahydroacridine, perhydroacridine, dihydrodibenzofuran, dihydrodibenzothiophene, tetrahydrodibenzofuran, tetrahydrodibenzothiophene, perhydrodibenzofuran, perhydrodibenzothiophene, dioxolane, dioxane, dithiolane, dithiane, benzodioxalane, benzodioxane, benzodithiolane, benzodithiane, 2,4,6-trioxaspiro[bicyclo[3.3.0]octane-3,1′-cyclohexane], 1,3-dioxolano[4,5-g]chromene or 2-oxabicyclo[2.2.1]heptane etc.


C3–8 mono-carbocyclic ring is concretely, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclopentene, cyclohexene, cycloheptene, cyclooctene, cyclopentadiene, cyclohexadiene, cycloheptadiene, cyclooctadiene or benzene etc.


3–8 membered mono-cyclic hetero ring containing 1–4 nitrogen atom(s), 1–2 oxygen atom(s) and/or 1–2 sulfur atom(s) means 3–8 membered mono-cyclic hetero aryl containing 1–4 nitrogen atom(s), 1–2 oxygen atom and/or 1–2 sulfur atom(s) and partially or fully saturated one.


3–8 membered mono-cyclic hetero aryl containing 1–4 nitrogen atom(s), 1–2 oxygen atom(s) and/or 1–2 sulfur atom(s) is pyrrole, imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, azepine, diazepine, furan, pyran, oxepine, thiophene, thiain (thiopyran), thiepine, oxazole, isoxazole, thiazole, isothiazole, furazan, oxadiazole, oxazine, oxadiazine, oxazepine, oxadiazepine, thiadiazole, thiazine, thiadiazine, thiazepine or thiadiazepine etc.


In above 3–8 membered mono-cyclic hetero ring containing 1–4 nitrogen atom(s), 1–2 oxygen atom(s) and/or 1–2 sulfur atom(s), partially or fully saturated one is pyrroline, pyrrolidine, imidazoline, imidazolidine, pyrazoline, pyrazolidine, triazoline, triazolidine, tetrazoline, tetrazolidine, dihydropyridine, tetrahydropyridine, piperidine, dihydropyrazine, tetrahydropyrazine, piperazine, dihydropyrimidine, tetrahydropyrimidine, perhydropyrimidine, dihydropyridazine, tetrahydropyridazine, perhydropyridazine, dihydroazepine, tetrahydroazepine, perhydroazepine, dihydrodiazepine, tetrahydrodiazepine, perhydrodiazepine, dihydrofuran, tetrahydrofuran, dihydropyran, tetrahydropyran, dihydrothiophene, tetrahydrothiophene, dihydrothiain (dihydrothiopyran), tetrahydrothiain (tetrahydrothiopyran), dihydrooxazole, tetrahydrooxazole, dihydroisoxazole, tetrahydroisoxazole, dihydrothiazole, tetrahydrothiazole, dihydroisothiazole, tetrahydroisothiazole, dihydrooxadiazole, tetrahydrooxadiazole, dihydrothiodiazole, tetrahydrothiodiazole, tetrahydrooxadiazine, tetrahydrothiadiazine, tetrahydrooxazepine, tetrahydrooxadiazepine, perhydrooxazepine, perhydrooxadiazepine, tetrahydrothiazepine, tetrahydrothiadiazepine, perhydrothiazepine, perhydrothiadiazepine, morpholine, thiomorpholine, dioxolane, dioxane, dithiolane or dithiane etc.


In the present invention, each group represented by R1, R2, R3, R4 or R5 is all preferable.


Preferred R1 is C1–18 alkyl substituted by Cyc 1, C2–18 alkenyl substituted by Cyc 1 or C2–18 alkynyl substituted by Cyc 1, and more preferred R1 is C1–6 alkyl substituted by Cyc 1.


Preferred Cyc 1 is C3–10 mono- or bi-(fused or spiro) carbocyclic ring or 3–10 membered mono- or bi-(fused or spiro) cyclic hetero ring containing 1–4 nitrogen atom(s), 1–2 oxygen atom(s) and/or 1–2 sulfur atom(s), and more preferred Cyc 1 is C5–7 mono-carbocyclic aryl or 5–10 membered mono-cyclic hetero ring containing 1–4 nitrogen atom(s), 2 oxygen atoms and/or 1 sulfur atom.


Preferred Cyc 1 concretely is benzene, pyrazole, imidazole, furan, thiophene, benzodioxane, thiazole or quinoline.


Preferred R51 which is a substituent of Cyc 1, is Cyc 2, —OR52, —SR53 or —NR54R55. Preferred R52, R53, R54 and R55 are C1–8 alkyl or Cyc 2, and more preferred R52, R53, R54 and R55 are methyl, ethyl, propyl or phenyl.


Preferred Cyc 2 is C5–7 mono-carbocyclic aryl or 5–7 membered mono-cyclic hetero aryl containing 1–4 nitrogen atom(s), 1 oxygen atom and/or 1 sulfur atom, and more preferred Cyc 2 is benzene.


Preferred R77 which is a substituent of Cyc 2 is —CONR83R84, —NR161COR162, —SO2NR163R164, —NR166SO2R167, C1–8 alkyl substituted by —CONR83R84, C1–8 alkyl substituted by —NR161COR162, C1–8 alkyl substituted by —SO2NR163R164 or C1–8 alkyl substituted by —NR166SO2R167. Preferred R83, R84, R161, R162, R163, R164, R166 and R167 are C1–8 alkyl, Cyc 6, C1–8 alkyl substituted by —NR176R177, and more preferred R83, R84, R161, R162, R163, R164, R166 and R167 are methyl, ethyl, propyl, phenyl or dimethylaminoethyl etc.


Most preferred R1 is phenylethyl, phenylpropyl, phenylbutyl, phenylpentyl, phenylhexyl, 4-methoxyphenylmethyl, 4-propyloxyphenylmethyl, 4-phenyloxyphenylmethyl, 3,5-dimethyl-1-phenylpyrazol-4-ylmethyl, 2-phenylimidazol-4-ylmethyl, 5-ethylfuran-2-ylmethyl, 5-ethylthiophen-2-ylmethyl, 3-chloro-5-methyl-1-phenylpyrazol-4-ylmethyl, 1,4-benzodioxan-6-ylmethyl, 4-(4-methylsulfonylaminophenyloxy)phenylmethyl, 4-(4-(2-dimethylaminoethylsulfonylamino)phenyloxy)phenylmethyl, 4-(4-dimethylaminosulfonylphenyloxy)phenylmethyl, 4-(4-methylcarbonylaminophenyloxy)phenylmethyl, 4-(4-(2-dimethylaminoethylcarbonylamino)phenyloxy)phenylmethyl or 4-(4-dimethylaminocarbonylphenyloxy)phenylmethyl etc.


Preferred R2 is C1–8 alkyl, C2–8 alkenyl, C2–8 alkynyl, C1–8 alkyl substituted by Cyc 3. Most preferred R2 is C1–4 alkyl, C2–4 alkenyl or C2–4 alkynyl.


Most preferred R2 is ethyl, propyl, butyl, 2-propenyl, 2-butenyl, 2-propynyl, phenylmethyl, thiophen-2-ylmethyl or 2-butynyl etc.


Preferred R3 or R4 is hydrogen, C1–8 alkyl, C1–8 alkyl substituted by Cyc4, C1–8alkyl substituted by —OR123, C1–8 alkyl substituted by Cyc4 and —OR123, C1–8 alkyl substituted by —NR127COR128, C1–8 alkyl substituted by —NR132SO2R133, C1–8 alkyl substituted by —NR134COOR135 or C1–8 alkyl substituted by —NR136CONR137R138. More preferred R3 or R4 is C1–4 alkyl, C1–4 alkyl substituted by Cyc4, C1–4 alkyl substituted by —OR123, C1–4 alkyl substituted by Cyc4 and —OR123, C1–4 alkyl substituted by —NR127COR128, C1–4 alkyl substituted by —NR132SO2R133, C1–4 alkyl substituted by —NR134COOR135 or C1–4 alkyl substituted by —NR136CONR137R138.


Preferred Cyc 4 is benzene or cyclohexane.


Preferred R123 is hydrogen, C1–4 alkyl, Cyc 4 or C1–4 alkyl substituted by Cyc 4, and more preferred R123 is hydrogen, methyl, ethyl, phenyl or phenylmethyl.


Preferred R127, R132, R134, R136 and R138 are hydrogen or methyl.


Preferred R128, R133, R135 and R137 are Cyc 4 or C1–4 alkyl substituted by Cyc 4, and more preferred R128, R133, R135 and R137 are phenyl, phenylmethyl or phenylethyl.


Preferred R144 which is a substitute of Cyc 4, is C1–4 alkyl, halogen, phenyl or phenyloxy, and more preferred R144 is methyl, fluorine, chlorine, phenyl or phenyloxy.


Most preferred R3 or R4 is propyl, 1-methylpropyl, 2-methylpropyl, cyclohexylmethyl, 1-hydroxy-2-methylpropyl, 1-hydroxy-1-cyclohexylmethyl, 3-(cyclopentylethylcarbonyl)aminobutyl, 3-(benzyloxycarbonyl) aminopropyl, 3-(phenylcarbonyl)aminobutyl, 3-(phenylmethylcarbonyl)aminobutyl, 3-(phenylethylcarbonyl)aminobutyl, 3-(phenylethenylcarbonyl)aminobutyl, 3-(4-phenylphenylcarbonyl)aminobutyl, 3-(4-phenyloxyphenylaminocarbonyl)aminobutyl, 3-(4-chlorophenylaminocarbonyl)aminobutyl, 3-(4-fluorophenylaminocarbonyl)aminobutyl, 3-(phenylmethylaminocarbonyl)aminobutyl, 3-(4-trifluoromethylsulfonyl)aminobutyl, 4-(cyclopentylethylcarbonyl)aminobutyl, 4-(benzyloxycarbonyl)aminobutyl, 4-(phenylcarbonyl)aminobutyl, 4-(phenylmethylcarbonyl)aminobutyl, 4-(phenylethylcarbonyl)aminobutyl, 4-(phenylethenylcarbonyl)aminobutyl, 4-(4-phenylphenylcarbonyl)aminobutyl, 4-(4-phenyloxyphenylaminocarbonyl)aminobutyl, 4-(4-chlorophenylaminocarbonyl)aminobutyl, 4-(4-fluorophenylaminocarbonyl)aminobutyl, 4-(phenylmethylaminocarbonyl)aminobutyl or 4-(4-trifluoromethylsulfonyl) aminobutyl.


Preferred R5 is hydrogen or methyl.


In the compounds of the present invention of the formula (I), the compound of the formula (Ia)




embedded image


  • (wherein R2 is C1–8 alkyl,

  • R3 is C1–8 alkyl or C3–7 cycloalkyl(C1–4)alkyl,

  • R5 is hydrogen or C1–8alkyl,

  • A is a bond or C1–10 alkylene,

  • D ring is C3–10 mono- or bi-(fused or spiro) carbocyclic ring or 3–10 membered mono- or bi-(fused or spiro)cyclic hetero ring,

  • m is 0 or an integer of 1–4,

  • R300 is C1–4 alkyl, C1–4 alkoxy, phenyl, phenoxy or benzyloxy.)

  • is preferable.



Preferred C3–10 carbocyclic ring represented by D ring is C3–10 mono- or bi-carbocyclic ring, and more preferred C3–10 carbocyclic ring is C3–7 mono-carbocyclic ring or C8–10 bi-carbocyclic ring.


Preferred 3–10 membered cyclic hetero ring represented by D ring is 3–10 membered mono- or bi-cyclic hetero aryl containing 1–4 nitrogen atom(s), 1–2 oxygen atom(s) and/or 1 sulfur atom or partially or fully saturated one. More preferred 3–10 membered cyclic hetero ring is 5–7 membered mono- or 8–10 membered bi-cyclic hetero aryl containing 1–4 nitrogen atom(s), 1–2 oxygen atom(s) and/or 1 sulfur atom or partially or fully saturated one.


Unless otherwise specified, all isomers are included in the present invention. For example, alkyl, alkoxy and alkylene groups include straight or branched ones. In addition, isomers on double bond, ring, fused ring (E-, Z-, cis-, trans-isomer), isomers generated from asymmetric carbon atom(s) (R-, S-, α-, β-isomer, enantiomer, diastereomer), optically active isomer (D-, L-, d-, l-isomer), polar compounds generated by chromatographic separation (more polar compound, less polar compound), equilibrium compounds, mixtures thereof at voluntary ratios and racemic mixtures are also included in the present invention.


[Salts]


Non-toxic salts of the present invention include all pharmaceutically acceptable salts, for example, general salts, acid addition salts, hydrate salts.


The compounds of the present invention represented by the formula (I) may be converted into the corresponding salts by conventional means. Water-soluble salts are preferred. Suitable salts, for example, include: salts of alkali metals (e.g. potassium, sodium), salts of alkaline earth metals (e.g. calcium, magnesium), ammonium salts, salts of pharmaceutically acceptable organic amines (e.g. tetramethylammonium, triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris(hydroxymethyl)amine, lysine, arginine, N-methyl-D-glucamine).


The compounds of the present invention represented by the formula (I) may be converted into the corresponding acid addition salts by conventional means. Water-soluble salts are preferred. Suitable salts, for example, include: salts of inorganic acids e.g. hydrochloride, hydrobromide, sulfate, phosphate, nitrate; salts of organic acids e.g. acetate, trifluoroacetate, lactate, tartrate, oxalate, fumarate, maleate, citrate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, isethionate, glucuronate, gluconate.


The compounds of the present invention of the formula (I) and salts thereof may be converted into the corresponding hydrates by conventional means.


All of the compounds of the formula (I) or non-toxic salts thereof are preferable, concretely, the compounds described in the example or non-toxic salts thereof.


Quaternary ammonium salts of the compounds of the formula (I) are the compounds where nitrogen of the compounds represented by the formula (I) is quaternalized by R0.


R0 is C1–8 alkyl or C1–8 alkyl substituted by phenyl.


N-oxides of the compounds represented by the formula (I) are the compounds where nitrogen of the compounds represented by the formula (I) is oxidized.


[Methods for Preparation of the Compounds of the Present Invention]


The compounds of the present invention of the formula (I) may be prepared by the following methods or the methods described in examples.


Among the compounds of the present invention of the formula (I), the compounds where nitrogens are not quaternary ammonium salts or N-oxides, i.e., the compounds of the formula (I-1)




embedded image



(wherein R1-1, R2-1 R3-1, R4-1 and R5-1 have the same meaning as R1, R2, R3, R4 and R5 respectively, and N1 is nitrogen. With the proviso that, any nitrogen are not quaternary ammonium salts or N-oxides.)


may be prepared by the following methods.


Among the compounds of the present invention represented by the formula (I-1), the compounds in which any R1-1, R2-1, R3-1, R4-1 and R5-1 are not a group containing carboxyl, hydroxy, amino or thiol, i.e., the compounds of the formula (I-1A)




embedded image



(wherein R1-1A, R2-1A, R3-1A, R4-1A and R5-1A have the same meaning as R1-1, R2-1, R3-1, R4-1 and R5-1 respectively. With the proviso that, all of them are not a group containing carboxyl, hydroxy, amino or thiol, and the other symbol have the same meanings as defined hereinbefore.)


may be prepared by the following methods.


Among the compounds of the formula (I-1 A), the compounds in which R1 does not represent hydrogen, i.e., the compounds of the formula (I-1A-1)




embedded image



(wherein R1-1A-1 have the same meaning as R1-1A. With the proviso that, R1-1A-1 is not hydrogen and the other symbols have the same meanings as defined hereinbefore.)


may be prepared by cyclization of the compounds of the formula (II-1)




embedded image



(wherein X-L-NH— is an amino terminus of aminated polystyrene resin, and the other symbols have the same meaning as defined hereinbefore.), or the compounds of the formula (II-2)




embedded image



(wherein T is C1–8 alkyl, C3–8 mono-carbocyclic ring or C1–8 alkyl substituted by C3–8 mono-carbocyclic ring.).


The cyclization of compounds of the formula (II-1) is well known. For example, it may be carried out by heating in an organic solvent (toluene etc.) in the presence of acid (acetic acid, trifluoroacetic acid or hydrochloric acid etc.) at 60–120° C. This cyclization reaction is carried out with the cleavage from polystyrene resin.


If necessary, the conversion to desired non-toxic salts may be carried out by the conventional method in succession to this reaction.


The cyclization of compounds of the formula (II-2) is well known. For example, it may be carried out by heating in an organic solvent (dichloroethane or toluene etc.), with tertiary amine (triethylamine or diisopropylethylamine etc.) at 60–120° C. This cyclization reaction is carried out with the cleavage of T group.


Among the compounds of the formula (I-1A), the compounds in which R1 is hydrogen, i.e., the compounds of the formula (I-1A)




embedded image



(wherein all of the symbols have the same meanings as defined hereinbefore.)


may be prepared by the removal of an amino-protecting group of the compounds in which R1A-1 is an amino-protecting group, i.e., the compounds of the formula (I-1A-1-1)




embedded image



(wherein R1-1A-1-1 is an amino-protecting group, and the other symbols have the same meaning as defined hereinbefore.)


A protecting group of amino includes, for example, benzyl, benzyloxycarbonyl, allyloxycarbonyl, t-butoxycarbonyl or trifluoroacetyl etc.


The protecting group of amino includes the above one, in addition, the other protecting group which is removable selectively and easily, for example, one described in T. W. Greene et. al., Protective Groups in Organic Synthesis, Third Edition, Wiley-Interscience, New York, 1999.


The removal of a protecting group of amino is well known. For example, it is

  • (1) the alkaline hydrolysis,
  • (2) the removal of a protecting group in an acidic condition,
  • (3) the removal of a protecting group by hydrogenolysis, or
  • (4) the removal of a protecting group using metal complex etc.


Concrete descriptions of these methods are as follows:


(1) The removal of protecting group by alkaline hydrolysis condition (e.g. trifluoroacetyl group) may be carried out, for example, in an organic solvent (methanol, tetrahydrofuran or dioxane etc.) with hydroxide of alkaline metal (sodium hydroxide, potassium hydroxide or lithium hydroxide etc.), hydroxide of alkaline earth metal (barium hydroxide or calcium hydroxide etc.), carbonate (sodium carbonate or potassium carbonate etc.), or an aqueous solution thereof or a mixture thereof at 0–40° C.


(2) The removal of protecting group in an acidic condition (e.g. t-butoxycarbonyl group) may be carried out, for example, in an organic solvent (dichloromethane, chloroform, dioxane, ethyl acetate or anisole etc.), organic acid (acetic acid, trifluoroacetic acid or methanesulfonic acid etc.) or inorganic acid (hydrochloric acid or sulfuric acid etc.), or a mixture thereof (hydrogen bromide/acetic acid etc.) at 0–100° C.


(3) The removal of a protecting group by hydrogenolysis (e.g. benzyl, benzyloxycarbonyl or allyloxycarbonyl) may be carried out, for example, in a solvent (ether (tetrahydrofuran, dioxane, dimethoxyethane or diethylether etc.), alcohol(methanol or ethanol etc.), benzene(benzene or toluene etc.), ketone (acetone or methylethylketone etc.), nitrile (acetonitrile etc.), amide (dimethylformamide etc.), water, ethyl acetate, acetic acid or a mixture thereof etc.) in the presence of a catalyst (palladium on carbon, palladium black, palladium hydroxide, platinum oxide, Raney nickel etc.), at atmospheric or positive pressure under an atmosphere of hydrogen or in the presence of ammonium formate at 0–200° C.


(4) The removal of a protecting group using metal complex may be carried out, for example, in an organic solvent (dichloromethane, dimethylformamide or tetrahydrofuran etc.) in the presence of a trap reagent (tributyltin hydride or dimedone etc.) and/or an organic acid (acetic acid etc.) with metal complex (tetrakis(triphenylphosphine)palladium(O) complex etc.) at 0–40° C.


Moreover, the compounds of the formula (I-1A-1) may be prepared with the compounds of the formula (I-1A-2) by the following methods of (a)–(g).


(a) Among the compounds of the formula (I-1A-1), the compounds, in which R1A-1 is C1–18 alkyl, C2–18 alkenyl, C2–18 alkynyl, or C1–18 alkyl, C2–18 alkenyl or C2–18 alkynyl substituted by various substituents, and in which R1A-1 bonds with N1 through —CH2—, i.e., the compounds of the formula (I-1A-1a)




embedded image



(wherein R1-1A-1a is C1–17 alkyl, C2–17 alkenyl, C2–17 alkynyl, or C1–17 alkyl, C2–17 alkenyl or C2–17 alkynyl substituted by 1–5 of optionally selected from (a) halogen, (b) —CONR7R8, (c) —COOR9, (d) —OR14, (e) —SR15, (f) —NR16R17, (g) —NR18COR19, (h) —SO2NR20R21, (i) —OCOR22, (j) —NR23SO2R24, (k) —NR25COOR26, (l) —NR27CONR28R29, (m) Cyc 1, (n) keto, (o) —N(SO2R24)2. With the proviso that, R1-1A-1a is not a group containing carboxyl, hydroxy, amino or thiol, and the other symbols have the same meaning as defined hereinbefore.)


may be prepared by the reductive amination of the compounds of the formula (I-1A-2) with the compounds the formula (III)

R1-1A-1a—CHO  (III)

(wherein all of the symbols have the same meanings as defined hereinbefore.)


The reductive amination is well known. For example, it may be carried out in an organic solvent (dichloroethane, dichloromethane, dimethylformamide, acetic acid or a mixture thereof etc.) in the presence of a reducing agent (sodium triacetoxyborohydride or sodium cyanoborohydride etc.) at 0–40° C.


Moreover, the reductive amination may be carried out with the compounds in which nitrogen of R1 is oxidized to N-oxide.


(b) Among the compounds of the formula (I-1A-1), the compounds, in which R1A-1 is C1–18 alkyl, C2–18 alkenyl, C2–18 alkynyl, or C1–18 alkyl, C2–18 alkenyl or C2–18 alkynyl substituted by various substituents, and in which R1A-1 bonds with N1 through —CHRA-1b— (wherein RA-1b is C1–17 alkyl, C2–17 alkenyl or C2–17 alkynyl.), i.e., the compounds of the formula (I-1A-1b)




embedded image



(wherein RA-1b is C1–17 alkyl, C2–17 alkenyl or C2–17 alkynyl, and the other symbols have the same meanings as defined hereinbefore.)


may be prepared by reductive amination of the compounds of the formula (1-1A-2) with the compounds the formula (IV)




embedded image



(wherein all of the symbols have the same meanings as defined hereinbefore.)


The reductive amination is well known. For example, it may be carried out in an organic solvent (dichloroethane or dichloromethane etc.) in the presence of tertiary amine (triethylamine or diisopropylethylamine etc.) with Lewis acid (titanium tetrachloride etc.), at 0–40° C., and subsequently by the addition of a reducing agent (sodium triacetoxyborohydride or sodium cyanoborohydride etc.) at 0–40° C.


(c) Among the compounds of the formula (I-1A-1), the compounds in which R1A-1 is COR6, i.e., the compounds of the formula (I-1A-1c)




embedded image



(wherein R6-1A-1c has the same meaning as R6. With the proviso that, R6A-1A-1c is not a group containing carboxyl, hydroxy, amino or thiol, and any nitrogen atoms are not quaternary ammonium salt nor N-oxide, and the other symbols have the same meaning as defined hereinbefore.)


may be prepared by the amidation of the compounds of the formula (I-1A-2) with the compounds of the formula (V)




embedded image



(wherein all of the symbols have the same meanings as defined hereinbefore.).


The amidation is well known. For example, it may be carried out in an organic solvent (chloroform, dichloromethane, diethylether, tetrahydrofuran, dioxane or dimethylformamide etc.) in the presence of tertiary amine (isopropylethylamine, pyridine, triethylamine, dimethylaniline or dimethylaminopyridine etc.) or an aqueous alkali solution (solution of bicarbonate or solution of sodium hydroxide etc.) at 0–40° C.


(d) Among the compounds of the formula (I-1A-1), the compounds in which R1-1A-1 is SO2R10, i.e., the compounds of the formula (I-1A-1d)




embedded image



(wherein R10-1A-1d has the same meaning as R10, With the proviso that, R10-1A-1d is not a group containing carboxyl, hydroxy, amino or thiol, and any nitrogen atoms are not quaternary ammonium salt nor N-oxide, and the other symbols have the same meaning as defined hereinbefore.)


may be prepared by the sulfonamidation of the compounds of the formula (I-1A-2) with the compounds of the formula (VI)




embedded image



(wherein all of the symbols have the same meanings as defined hereinbefore.).


The sulfonamidation is well known. For example, it may be carried out in an inert organic solvent (chloroform, dichloromethane, dichloroethane, diethylether or tetrahydrofuran etc.) in the presence of tertiary amine (diisopropylethylamine, pyridine, triethylamine, dimethylaniline or dimethylaminopyridine etc.) at 0–40° C.


(e) Among the compounds of the formula (I-1A-1), the compounds in which RI-1A-1 is CONR7R8, i.e., the compounds of the formula (I-1A-1e)




embedded image



(wherein R7-1A-1e and R8-1A-1e have the same meaning as R7 and R8, With the proviso that, R10-1A-1d is not a group containing carboxyl, hydroxy, amino or thiol, and any nitrogen atoms are not quaternary ammonium salt nor N-oxide, and the other symbols have the same meaning as defined hereinbefore.)


may be prepared by the reaction of the compounds of the formula (I-1A-2) with the compounds of the formula (VII-1)




embedded image



(wherein all of the symbols have the same meanings as defined hereinbefore.)


or with the compounds of the formula (VII-2)




embedded image



(wherein all of the symbols have the same meanings as defined hereinbefore.)


The reaction with the compounds of the formula (VII-1) is well known. For example, it may be carried out in an organic solvent (chloroform, dichloromethane, diethylether or tetrahydrofuran etc.), in the presence of a tertiary amine (isopropylethylamine, pyridine, triethylamine, dimethylaniline or dimethylaminopyridine etc.) at 0–40° C.


The reaction with the compounds of the formula (VII-2) is well known. For example, it may be carried out in an inert organic solvent (chloroform, dichloromethane, dichloroethane, dimethylformamide, diethylether or tetrahydrofuran etc.) at 0–40° C.


(f) Among the compounds of the formula (I-1A-1), the compounds in which R1-1A-1 is —CH2—CH(OH)—RA-1f(RA-1f is C1–16 alkyl, C2–16 alkenyl, C2–16 alkynyl, or C1–16 alkyl, C2–16 alkenyl or C2–16 alkynyl substituted by various substituents.), i.e., the compounds of the formula (I-1A-1f)




embedded image



(wherein RA-1f is C1–16alkyl, C2–16 alkenyl, C2–16 alkynyl, or C1–16 alkyl, C2–16 alkenyl or C2–16 alkynyl substituted by 1–4 of optionally selected from (a) halogen, (b) —CONR7R8, (c) —COOR9, (d) —OR14, (e) —SR15, (f) —NR16R17, (g) —NR18COR19, (h) —SO2NR20R21, (i) —OCOR22, (j) —NR23SO2R24, (k) —NR25COOR26, (l) —NR27CONR28R29, (m) Cyc 1, (n) keto, (o) —(SO2R24)2, and any nitrogen atoms are not quaternary ammonium salt nor N-oxide and the other symbols have the same meaning as defined hereinbefore.)


may be prepared by the reaction of the compounds of the formula (1–1A-2) with the compounds the formula (VIII)




embedded image



(wherein all of the symbols have the same meanings as defined hereinbefore.).


The reaction is well known, and it may be carried out in an organic solvent (methanol, ethanol, 2-propanol, tetrahydrofuran or acetonitrile etc.), in the presence or absence of a tertiary amine (triethylamine or N-methylmorpholine etc.) at 40–100° C.


(g) Among the compounds of the formula (I-1A-1), the compounds in which R1-1A-1 is —CH2—C(═O)—RA-1g (RA-1g has the same meaning as RA-1f), i.e., the compounds of the formula (I-1A-1g)




embedded image



(wherein RA-1g has the same meaning as RA-1f, and the other symbols have the same meanings as defined hereinbefore.)


may be prepared by the reaction of the compounds of the formula (I-1A-2) with the compounds of the formula (IX-1)




embedded image



(wherein all of the symbols have the same meanings as defined hereinbefore.)


or with the compounds of the formula (IX-2)




embedded image



(wherein all of the symbols have the same meanings as defined hereinbefore.).


The reaction is well known, and it may be carried out in an organic solvent (chloroform, dichloromethane, diethylether, tetrahydrofuran, dioxane or dimethylformamide etc.) in the presence of a tertiary amine (isopropylethylamine, pyridine, triethylamine, dimethylaniline or dimethylaminopyridine etc.) at 0–40° C.


Moreover, the compounds of the formula (I-1A-1) may be prepared by the methods described in (h).


(h) Among the compounds of the formula (I-1A-1), the compounds in which R1-1A-1 is 2-propenyl (—CH2CH═CH2), i.e., the compounds of the formula (I-1A-1h)




embedded image



(wherein all of the symbols have the same meanings as defined hereinbefore.)


may be prepared by the reaction of the compounds in which R1-1A-1 is 2-propenyloxycarbonyl (—COO—CH2CH═CH2) among the compounds of the formula (I-1A-1) prepared by the above method, i.e., the compounds of the formula (I-1A-1–2)




embedded image



(wherein all of the symbols have the same meanings as defined hereinbefore.) with a metal complex.


The reaction with a metal complex is well known, and it may be carried out, for example, in an organic solvent (tetrahydrofuran or acetic acid etc.), with a metal complex (tetrakis(triphenylphosphine)palladium(0) complex etc.), at 0–40° C.


Among the compounds of the (I-1), the compounds in which at least one group of R1, R2, R3, R4 and R5 represents a group containing carboxyl, hydroxy, amino or thiol, i.e., the compounds of the formula (I-1B)




embedded image



(wherein R1-1B, R2-1B, R3-1B, R4-1B and R5-1B have the same meanings as R1-1, R2-1, R3-1, R4-1 and R5-1, respectively. With the proviso that, at least one group represents a group containing carboxyl, hydroxy, amino or thiol, and the other symbols have the same meanings as defined hereinbefore.)


may be prepared by the removal of a protecting group of the compounds in which at least one group of R1-1, R2-1, R3-1, R4-1 or R5-1 represents a group containing carboxyl, hydroxy, amino and thiol protected by a protecting group, i.e., the compounds of the formula (I-1A-3)




embedded image



(wherein R1-1A-3 R2-1A-3, R3-1A-3, R4-1A-3 and R5-1A-3 have the same meanings of R1-1, R2-1, R3-1, R4-1 and R5-1, respectively. With the proviso that, at least one group represents a group containing carboxyl, hydroxy, amino or thiol protected by a protecting group and the other symbols have the same meanings as defined hereinbefore.)


A protecting group of carboxyl includes, for example, methyl, ethyl, t-butyl, benzyl or allyl.


A protecting group of hydroxy includes, for example, methoxymethyl, 2-tetrahydropyranyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, acetyl or benzyl.


A protecting group of amino includes, for example, benzyloxycarbonyl, allyloxycarbonyl, t-butoxycarbonyl, trifluoroacetyl or 9-fluorenylmethoxycarbonyl.


A protecting group of thiol includes, for example, benzyl, methoxybenzyl, acetoamidomethyl, triphenylmethyl or acetyl.


The protecting group of carboxyl, hydroxy, amino or thiol includes the above one, and in addition the other protecting group which is removable selectively and easily, for example, one described in T. W. Greene et. al., Protective Groups in Organic Synthesis, Third Edition, Wiley-Interscience, New York, 1999.


The removal of a protecting group of amino may be carried out by the method described hereinbefore.


The removal of a protecting group of carboxyl, hydroxy or thiol is well known. For example, it is

  • (1) the alkaline hydrolysis,
  • (2) the removal of a protecting group in an acidic condition,
  • (3) the removal of a protecting group by hydrogenolysis, or
  • (4) the removal of a protecting group containing silyl or
  • (5) the removal of a protecting group using metal complex etc.


Among these methods, (1), (2), (3) and (5) may be carried out by the same methods of the removal of a protecting group of amino.


Concretely describing (4), the removal of a protecting group containing silyl may be carried out, for example, in an organic solvent (tetrahydrofuran or acetonitrile etc.), with tetrabutylammoniumfluoride at 0–40° C.


As well known to the person in the art, the aimed compounds of the present invention may be prepared easily by choice of these removal of a protecting group.


Moreover, the compounds of the formula (I-1A-1) may be prepared by the methods described in (j)-(m) with the compounds of the formula (I-1B-1)




embedded image



(wherein R1-1B-1, R2-1B-1, R3-1B-1, R4-1B-1 and R5-1B-1 have the same meanings of R1-1, R2-1, R3-1, R4-1 and R5-1, respectively. With the proviso that, at least one group represents a group containing amino, and the other symbols have the same meanings as defined hereinbefore.)


(j) Among the compounds of the formula (I-1A-1), the compounds in which at least one group of R1-1A-1, R2-1A, R3-1A, R4-1A and R5-1A represent a group containing amide, i.e., the compounds of the formula (I-1A-1j)




embedded image



(wherein R1-1A-1j, R2-1A-1j, R3-1A-1j; R4-1A-1j and R5-1A-1j have the same meanings as R1-1, R2-1, R3-1, R4-1 and R5-1, respectively. With the proviso that, at least one group represents a group containing amide and the other symbols have the same meanings as defined hereinbefore.)


may be prepared by the amidation of the compounds of the formula (I-1B-1).


The amidation may be carried out by the method described herein before.


(k) Among the compounds of the formula (I-1A-1), the compounds in which at least one group of R1-1A-1, R2-1A, R3-1A, R4-1A and R5-1A represents a group containing sulfonamide, i.e., the compounds of the formula (I-1A-1k)




embedded image



(wherein R1-1A-1k, R2-1A-1k, R3-1A-1k, R4-1A-1k and R5-1A-1k have the same meanings as R1-1, R2-1, R3-1, R4-1 and R5-1, respectively. With the proviso that, at least one group represents a group containing sulfon amide and the other symbols have the same meanings as defined hereinbefore.)


may be prepared by the sulfonamidation of the compounds of the formula (I-1B-1).


The sulfonamidation may be carried out the method described hereinbefore.


(m) Among the compounds of the formula (I-1A-1), the compounds in which at least one group of R1-1A-1, R2-1A, R3-1A, R4-1A and R5-1A represents a group containing urea, i.e., the compounds of the formula (I-1A-1m)




embedded image



(wherein R1-1A-1m, R2-1A-1m, R3-1A-1m, R4-1A-1m and R5-1A-1m have the same meanings as R1-1, R2-1, R3-1 R4-1 and R5-1, respectively. With the proviso that, at least one group represents a group containing urea and the other symbols have the same meanings as defined hereinbefore.)


may be prepared by the urea formation of the compounds of the formula (I-1B-1).


The urea formation may be carried out the method described hereinbefore.


Among the compounds of the formula (I-1), the compounds in which at least one group of R1-1, R2-1, R3-1, R4-1 and R5-1 represents a group containing hydroxy, and/or R1 represents a group containing carboxyl, i.e., the compounds of the formula (I-1B-2)




embedded image



(wherein R1-1B-2, R2-1B-2, R3-1B-2, R4-1B-2 and R5-1B-2 have the same meanings as R1-1, R2-1, R3-1, R4-1 and R5-1, respectively. With the proviso that, at least one group of R1-1B-2, R2-1B-2, R3-1B-2, R4-1B-2 and R5-1B-2 represents a group containing hydroxy and/or R1B-2 includes carboxyl and the other symbols have the same meanings as defined hereinbefore.) may be prepared by the method described in (n).


(n) Among the compounds of the formula (I-1B-2), the compounds in which R1-1B-2 is C1–18 alkyl, C2–18 alkenyl, C2–18 alkynyl or C1–18 alkyl, C2–18 alkenyl or C2–18 alkynyl substituted by various substituent, and in which that R1-1B-2 bonds to N1 atom through —CH2—, i.e., the compounds of the formula (I-1B-1n)




embedded image



(wherein R1-1B-2n is C1–17alkyl, C2–17 alkenyl, C2–17 alkynyl, or C1–17 alkyl, C2–17 alkenyl or C2–17 alkynyl substituted by 1–5 of optionally selected from (a) halogen, (b) —CONR7R8, (c) —COOR9, (d) —OR14, (e) —SR15, (f) —NR16R17, (g) —NR18COR19, (h) —SO2NR20R21, (i) —OCOR22, (j) —NR23SO2R24, (k) —NR25COOR26, (l) —NR27CONR28R29, (m) Cyc 1, (n) keto, (o) —N(SO2R24)2. With the proviso that, at least one group of R1-1B-2n, R2-1B-2, R3-1B-2, R4-1B-2 and R5-1B-2 represents a group containing hydroxy, and/or R1B-2n represents a group containing carboxyl, and any nitrogen atoms are not quaternary ammonium salt nor N-oxide and the other symbols have the same meaning as defined hereinbefore.)


may be prepared by the reductive amination of the compounds in which R1 is hydrogen, and at least one group of R2-1, R3-1, R4-1 and R5-1 represents a group containing hydroxy among the compounds of the formula (I-1B) prepared by the above method, i.e., the compounds of the formula (I-1B-3)




embedded image



(wherein all of the symbols have the same meanings as defined hereinbefore.)


with the compounds of the formula (X)

R1-1B-2n—CHO  (X)

(wherein all of the symbols have the same meanings as defined hereinbefore.)


The reductive amination may be carried out by the method described hereinbefore.


Moreover, the reductive amination may be carried out in the compounds in which nitrogen in R1 represents N-oxide.


Among the compounds of the present invention of the formula (I), the compounds in which at least one nitrogen is quaternary ammonium salt, i.e., the compounds of the formula (I-2)




embedded image



(wherein R1-2, R2-2, R3-2, R4-2 and R5-2 have the same meanings as R1, R2, R3, R4 and R5, respectively, and N2 is nitrogen. With the proviso that, at least one nitrogen is quaternary ammonium salt and Q is halogen.)


may be prepared by the reaction of the compounds of the formula (I-1) with the compounds of the formula (XI)

R0-Q  (XI)

(wherein R0 is C1–8 alkyl or C1–8 alkyl substituted by phenyl and Q is halogen.)


The reaction is well known and it may be carried out, for example, in an organic solvent (acetone, dimethylformamide or methyl ethyl ketone etc.) at 0–40° C.


Among the compounds of the formula (I), the compounds in which at least one nitrogen represents N-oxide, i.e. the compounds of the formula (I-3)




embedded image



(wherein R1-3, R2-3, R3-3, R4-3 and R5-3 have the same meanings of R1, R2, R3, R4 and R5, respectively, and N3 is nitrogen. With the proviso that, at least one nitrogen represents N-oxide.)


may be prepared by the oxidation of the compounds of the formula (I-1).


The oxidation is well known and it may be carried out, for example, in a suitable organic solvent (dichloromethane, chloroform, benzene, hexane or t-butyl alcohol etc.) in the presence of a excessive oxidizing reagent (hydrogen peroxide, sodium periodate, acyl nitrite, sodium perborate, peroxidized acid (for example, 3-chloroperbenzoic acid, peracetic acid etc.), OXONE (brand name, Potassium peroxymonosulfate is abbreviated as. OXONE.), potassium permanganate or chromic acid etc.) at 20–60° C.


The compounds of the (II-1) may be prepared according to the following Schemes 1–3.




embedded image




embedded image




embedded image


In Schemes, X is polystyrene resin, L is bivalent group, and the other symbols have the same meanings as defined hereinbefore.


Bivalent group represented by L is, though it depends on the type of the used resin, e.g. methylene or Rink. Rink is 4-(2,4-dimethoxybenzyl) phenoxymethyl.


In the present invention, e.g. aminomethylated polystyrene resin or 9-fluorenylmethyloxycarbonylamino-Rink resin etc. can be used as terminal amino polystyrene resin.


As shown the following reaction scheme, the resin of the formula (XVI) may be prepared from aminomethylated polystyrene resin or 9-fluorenylmethyloxycarbonylamino-Rink resin.




embedded image


In the reaction using polystyrene resin in the present invention, the reaction products may be purified by the conventional methods, for example, washing with a solvent (dimethylformamide, dichloromethane, methanol, tetrahydrofuran, toluene or acetic acid/toluene etc.) at several times. Moreover the obtained products may be purified by conventional techniques. For example, purification may be carried out by distillation at atmospheric or reduced pressure, by high performance liquid chromatography, by thin layer chromatography or by column chromatography using silica gel or magnesium silicate, by washing or by recrystallization.


The compounds of the formula (II-2) may be prepared according to the following Scheme 5.




embedded image


The other starting materials and each test compounds in t he present invention have been known per se or may be prepared by known methods.


[Pharmacological Activities]


Efficacy of the compounds of the invention represented by general formula (I) was confirmed, e.g., by the following tests.


As described in the foregoing, in order to carry out screening of a compound capable of inhibiting binding of HIV to CXCR4 or CCR5 which is a receptor on the CD4-postive cell, it is a more directive method to carry out it in an assay system that uses HIV virus. However, the use of a large amount of HIV virus in the screening is not practical due to a difficulty in handling it. On the other hand, since both the macrophage tropic (R5) HIV-1 and the ligands, that is, RANTES, MIP-1α and MIP-1β, bind to CCR5, it can be presumed that certain common characteristics are present in the CCR5 binding sites of the HIV side and the RANTES, MIP-1α and MIP-1β sides, and in the binding sides of CCR5 to the ligands, that is, RANTES, MIP-1α and MIP-1β, and HIV. Accordingly, in order to find a compound capable of inhibiting adsorption of HIV virus to cells, which has an inhibitory mechanism different from the current anti-AIDS drugs (reverse transcription inhibitors and protease inhibitors), it is possible to use an assay system that uses an endogeneous CCR5 ligand, RANTES, MIP-1α or MIP-1β instead of HIV.


Specifically, e.g., since CCR5 is a G protein-coupled seven transmembrane type receptor, an assay system in which the effect of RANTES on the transient increase of Ca ion induced via CCR5 is measured can be carried out as an assay system for screening a compound capable of inhibiting binding of RANTES to CCR5. Since both of the T cell tropic (X4) HIV and SDF-1 bind to CXCR4, similar idea can be considered.


[Test Methods]


(1) Isolation of Human CCR5 Gene


Human placental cDNA was prepared using Marathon cDNA amplification kit (Clontech). PCR primers hCCR5XbaI-F1: 5′-AGCTAGTCTAGATCCGTTCCCCTACMGAAACTCTCC-3′ (SEQ ID NO:1) and hCCR5XbaI-R1: 5′-AGCTAGTCTAGAGTGCACAACTCTGACTGGGTCACCA-3′ (SEQ ID NO:2) were designed based on the sequence of GenBank U54994.


Using the human placental cDNA as the template and using Ex Taq (Takara), PCR reaction (2 minutes at 95° C.→(30 seconds at 95° C., 45 seconds at 60° C., 1 minute at 72° C.)×35 times) was carried out. The thus amplified PCR product was subjected to a 1% agarose gel electrophoresis, purified using QIAquick Gel Extraction Kit (QUIAGEN) and then digested with a restriction enzyme XbaI. The digested fragments were ligated to an expression vector pEF-BOS-bsr using DNA Ligation Kit Ver. 2 (Takara) and transformed into Escherichia coli DH5a. By preparing the resulting plasmid pEF-BOS-bsr/hCCR5, its DNA sequence was verified.


(2) Culturing of CHO Cell


CHO-dhfr(−) was cultured using Ham's F-12 (containing fetal bovine serum (10%), penicillin (50 U/ml) and streptomycin (50 mg/ml)). Also, the transduced cell was cultured by adding blasticidin (5 mg/ml) to the above medium.


(3) Transduction into CHO Cell


The plasmid pEF-BOS-bsr/hCCR5 was transduced into the CHO-dhfr(−) cell using DMRIE-C reagent (Gibco BRL). After 48 hours, the medium was replaced with a medium containing 5 mg/ml of blasticidin to carry out the selection, thereby establishing a stably over-expressing cell.


(4) Inhibition Test on the Binding of RANTES to CCR5 (Activity of RANTES to Induce Transient Increase of Ca Ion)


The thus established human CCR5 stably over-expressing CHO cell (CCR5/CHO cell) was suspended in Ham's F-12 medium containing FBS (10%) and dispensed in 3.0×106 cells/well portions into a 96 well plate. One day after culturing at 37° C., the culture supernatant was discarded, and Ham's F-12 medium (containing Fura-2AM (5 μM), Probenecid (2.5 mM) and HEPES (20 mM; pH 7.4)) was dispensed in 80 μl/well portions to carry out 1 hour of incubation at 37° C. under shaded condition. After washing twice with 1×Hanks/HEPES (20 mM; pH 7.4) solution, the same solution was dispensed in 100 μl/well portions. Each of the test compounds was added to the thus Fura-2AM-incorporated CCR5/CHO cell, and 3 minutes thereafter, a recombinant human RANTES (PeproTach) diluted with 1×Hanks/HEPES (20 mM; pH 7.4) solution was added thereto to a final concentration of 10 nM. Transient increase in the intracellular Ca2+ concentration induced by the human RANTES was measured using a Ca2+ detector for 96 well use (Hamamatsu Photonics), and inhibition ratio (%) of the test compound was calculated by the following calculation formula.

Inhibition ratio=(Ec−Ea)/Ec×100

  • Ec: measured value of Ca2+ transient increase by RANTES
  • Ea: measured value of Ca2+ transient increase by RANTES when a test compound was added


As a result, the compounds of the invention showed an inhibition ratio of 50% or more at 10 μM. For example, the compound of Example 2(1) showed an IC50 value of 0.05 μM, and the compound of Example 2(2) an IC50 value of 0.05 μM.


An assay system for finding a compound having adsorption inhibition effect on CCR5 directional HIV strain was described in the foregoing, and it is possible as a matter of course to find a compound capable of inhibiting the activity of CCR5 or a ligand thereof using this system. In the same manner, it is possible to find a compound capable of inhibiting the activity of other chemokine receptor or a ligand thereof. For example, a system for finding a compound capable of inhibiting the activity of CCR2 or a ligand thereof can be constructed. Since CCR2 is a G protein-coupled seven transmembrane type receptor similar to the case of CCR5, it can be carried out by measuring the effect of a ligand of CCR2, e.g., MCP-1 on the transient increase of Ca ion induced via CCR2.


(5) Inhibition Test on the Binding of MCP-1 to CCR2 (Activity of MCP-1 to Induce Transient Increase of Ca Ion)


A human CCR2-expressing cell, e.g., a human monocyte cell strain THP-1 (ATCC No. TIB-202), was suspended in RPMI 1640 medium containing FBS (10%), Fura-2AM (5 μM), Probenecid (2.5 mM) and HEPES (20 mM, pH 7.4) to a density of 5.0×106 cells/ml and incubated at 37° C. for 30 minutes under shaded condition. This was mixed with 4 to 8 volumes of 1× Hanks/HEPES (20 mM, pH 7.4)/Probenecid (2.5 mM) and further incubated at 37° C. for 30 minutes under shaded condition. After washing with 1× Hanks/HEPES (20 mM, pH 7.4)/Probenecid (2.5 mM) solution, the thus washed cells were re-suspended in the same solution to a density of 2.0×106 cells/ml and dispensed in 100 μl/well portions into a 96 well plate. Each of the test compound solutions was added thereto, and 3 minutes thereafter, a recombinant human MCP-1 (PeproTach) diluted with 1× Hanks/HEPES (20 mM, pH 7.4)/Probenecid (2.5 mM)was added thereto to a final concentration of 30 nM. Transient increase in the intracellular Ca 2+concentration induced by the human MCP-1 was measured using a Ca2+ detector for 96 well use (Hamamatsu Photonics), and inhibition ratio (%) of the test compound was calculated by the following calculation formula.

Inhibition ratio=(Ec−Ea)/Ec×100

  • Ec: measured value of Ca2+ transient increase by MCP-1
  • Ea: measured value of Ca2+ transient increase by MCP-1 when a test compound was added


As a result, the compounds of the invention showed an inhibition ratio of 50% or more at 10 μM. For example, the compound of Example 5(2) showed an IC50 value of 3 μM.


[Toxicity]


The toxicity of the compounds of the present invention is very low and therefore the compounds may be considered safe for pharmaceutical use.


INDUSTRIAL APPLICABILITY

[Application for Pharmaceuticals]


The compounds of the present invention of the formula (I) regulate the effect of chemokine/chemokine receptor in animal included human, especially human, so they are used for prevention and/or treatment of various inflammatory diseases, asthma, atopic dermatitis, urticaria, allergic diseases (allergic bronchopulmonary aspergillosis, allergic eosinophilic gastroenteritis est.), nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, psoriasis, rhinitis, conjunctivitis, ischemic reperfusion disorder, multiple sclerosis, ulcerative colitis, adult respiratory distress syndrome, cytotoxic shock, diabetes, autoimmune disease, multiple organ failure, immunosuppression, cancer metastasis and acquired immune deficiency syndrome.


For the purpose above described, the compounds of formula (I), non-toxic salts thereof, acid addition salts or hydrates thereof may be normally administered systemically or locally, usually by oral or parenteral administration.


The doses to be administered are determined depending upon, for example, age, body weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment. In the human adult, the doses per person are generally from 1 mg to 1000 mg, by oral administration, up to several times per day, and from 1 mg to 100 mg, by parenteral administration (preferably intravenous administration), up to several times per day, or continuous administration from 1 to 24 hours per day from vein.


As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.


The compounds of the present invention may be administered in the form of, for example, solid forms for oral administration, liquid forms for oral administration, injections, liniments or suppositories for parenteral administration.


Solid forms for oral administration include compressed tablets, pills, capsules, dispersible powders, and granules. Capsules include hard capsules and soft capsules.


In such solid forms, one or more of the active compound(s) may be admixed with vehicles (such as lactose, mannitol, glucose, microcrystalline cellulose, starch), binders (such as hydroxypropyl cellulose, polyvinylpyrrolidone or magnesium metasilicate aluminate), disintegrants (such as cellulose calcium glycolate), lubricants (such as magnesium stearate), stabilizing agents, and solution adjuvants (such as glutamic acid or aspartic acid) and prepared according to methods well known in normal pharmaceutical practice. The solid forms may, if desired, be coated with coating agents (such as sugar, gelatin, hydroxypropyl cellulose or hydroxypropylmethyl cellulose phthalate), or be coated with two or more films. And further, coating may include containment within capsules of absorbable materials such as gelatin.


Liquid forms for oral administration include pharmaceutically acceptable solutions, suspensions and emulsions, syrups and elixirs. In such forms, one or more of the active compound(s) may be dissolved, suspended or emulized into diluent(s) commonly used in the art (such as purified water, ethanol or a mixture thereof). Besides such liquid forms may also comprise some additives, such as wetting agents, suspending agents, emulsifying agents, sweetening agents, flavoring agents, aroma, preservative or buffering agent.


Injections for parenteral administration include sterile aqueous, suspensions, emulsions and solid forms which are dissolved or suspended into solvent(s) for injection immediately before use. In injections, one or more of the active compound(s) may be dissolved, suspended or emulized into solvent(s). The solvents may include distilled water for injection, physiological salt solution, vegetable oil, propylene glycol, polyethylene glycol, alcohol, e.g. ethanol, or a mixture thereof. Injections may comprise some additives, such as stabilizing agents, solution adjuvants (such as glutamic acid, aspartic acid or POLYSORBATE80 (registered trade mark)), suspending agents, emulsifying agents, soothing agent, buffering agents, preservative. They may be sterilized at a final step, or may be prepared and compensated according to sterile methods. They may also be manufactured in the form of sterile solid forms such as freeze-dried products, which may be dissolved in sterile water or some other sterile diluent(s) for injection immediately before use.


Other forms for parenteral administration include liquids for external use, ointments and endermic liniments, inhalations, sprays, suppositories and pessaries for vaginal administration which comprise one or more of the active compound(s) and may be prepared by methods known per se.


Sprays may comprise additional substances other than diluents, such as stabilizing agents (such as sodium sulfate), isotonic buffers (such as sodium chloride, sodium citrate or citric acid). For preparation of such sprays, for example, the method described in the U.S. Pat. Nos. 2,868,691 or 3,095,355 may be used.







BEST MODE FOR CARRYING OUT THE INVENTION

The following Reference Examples and Examples are intended to illustrate the present invention, but do not limit them.


In chromatographic separations and TLC, the solvents in parenthesis show the eluting and developing solvents and the ratios of the solvents used are by volume.


The solvents in parenthesis in NMR show the solvents used for measurement.


R* and S* do not represent the absolute position but the relative position.


REFERENCE EXAMPLE 1
Preparation of Resin (2)



embedded image


Aminomethylpolystyrene resin hydrochloride (Resin (1); X is polystyrene resin.) (30.0 g) (1% divinylbenzene copolymer, Watanabe Kagaku, Catalog No A00062) was washed with dimethylformamide (300 ml), 10% diisopropylethylamine-dimethylformamide solution (300 ml) and dimethylformamide (300 ml) successively, and was suspended in dimethylformamide (200 ml). To the suspension were added formic acid (10.2 ml) and diisopropylcarbodiimide (42.3 ml) under cooling with ice, and it was stirred for 1 hour at room temperature. The resin was collected by filtration from the reaction solution, and was washed with dimethylformamide (250 ml×3), dichloromethane (250 ml×4), methanol (250 ml×2) and dichloromethane (250 ml×4) to give Resin (2).


IR (KBr): ν 1682 cm−1.


REFERENCE EXAMPLE 2
Preparation of Resin (3)



embedded image


To a suspension of Resin (2) prepared in Reference Example 1 in dichloromethane (300 ml) were added triethylamine (18.8 ml), carbon tetrachloride (13.0 ml) and triphenylphosphine (35.4 g), and it was refluxed for 1 hour. The reaction solution was cooled to room temperature, and the resin was collected by filtration. The resin was washed with dichloromethane (250 ml×3), methanol (250 ml×1) and dichloromethane (250 ml×2) and dried under reduced pressure to give Resin (3) 28.2 g).


IR (KBr): ν 2147 cm−1.


REFERENCE EXAMPLE 3
Preparation of Compound (1)



embedded image


To a suspension of Resin (3) prepared in Reference Example 2 (2.5 g) in tetrahydrofuran/methanol (1:1; 25 ml) were added N-allyloxycarbonyl-4-piperidone (2.15 g), n-propylamine (0.97 ml) and N-(t-butyloxycarbonyl) leucine (2.93 g), and it was stirred for 16 hours at 65° C. The reaction solution was cooled to room temperature, and the resin was collected by filtration. The obtained resin was washed with tetrahydrofuran (25 ml×2), methanol (25 ml×2) and dichloromethane (25 ml×2) to give compound (1).


REFERENCE EXAMPLE 4
Preparation of Compound (2)



embedded image


To a suspension of the compound (1) prepared in Reference Example 3 in dichloromethane (25 ml) were added acetic acid (0.81 ml), tributyltin hydride (1.90 ml) and tetrakis(triphenylphosphine)palladium (0) complex (270 mg), and it was stirred for 6 hours at room temperature. The resin was collected by filtration from the reaction solution, and was washed with dichloromethane (25 ml×3), methanol (25 ml×2), dichloromethane (25 ml×2) and dimethylformamide (25 ml×3) to give compound (2).


REFERENCE EXAMPLE 5
Preparation of Compound (3)



embedded image


To a suspension of the compound (2) prepared in Reference Example 4 in dimethylformamide (25 ml) were added 3,5-dimethyl-1-phenyl-4-formylpyrazole (1.41 g), sodium triacetoxyborohydride (1.50 g) and acetic acid (0.2 ml), and it was stirred for 16 hours at room temperature. The resin was collected by filtration from the reaction solution, and was washed with dimethylformamide (20 ml×2), dichloromethane (20 ml×2), methanol (20 ml×2) and dichloromethane (20 ml×4) to give compound (3).


REFERENCE EXAMPLE 6
Preparation of Compound (4)



embedded image


The compound (3) prepared in Reference Example 5 was suspended in 50% trifluoroacetic acid-dichloromethane solution (25 ml), and the suspension was stirred for 5 minutes at room temperature. The reaction solution was filtrated. The obtained resin was suspended in 50% trifluoroacetic acid-dichloromethane solution (25 ml), and it was stirred for 30 minutes at room temperature. The resin was collected by filtration from the reaction solution and was washed with dichloromethane (25 ml×4), toluene (25 ml×4), and 1.25 M acetic acid-toluene solution (25 ml×1) to give compound (4).


REFERENCE EXAMPLE 7
Preparation of Resin (5)



embedded image


9-fluorenylmethyloxycarbonylamino-Rink resin (Resin (4)) (5.0 g) (1% divinylbenzene copolymer, Watanabe Kagaku, Catalog No A00102) was washed with dimethylformamide (50 ml×3), and 20% piperidine-dimethylformamide solution (50 ml×2). The washed resin was suspended in 20% piperidine-dimethylformamide solution (50 ml), and the suspension was stirred for 30 minutes at room temperature. The reaction solution was filtrated. The obtained resin was washed with dimethylformamide (50 ml×5). To a suspension of the washed resin in dimethylformamide (20 ml) was added ethyl formate (30 ml), and it was refluxed for 6 hours. The reaction solution was cooled to room temperature and was filtrated. The filtrated resin was washed with dimethylformamide (50 ml×2), dichloromethane (50 ml×4), methanol (50 ml×4) and dichloromethane (50 ml×4), and dried under reduced pressure to give Resin (5) (4.34 g).


IR (KBr): ν 1693 cm−1.


REFERENCE EXAMPLE 8
Preparation of Resin (6)



embedded image


By the same procedure as described in Reference Example 2 using Resin (4) prepared in Reference Example 7 (4.0 g), Resin (6) (3.56 g) was obtained.


IR (KBr): ν 2136 cm−1.


REFERENCE EXAMPLE 9
Preparation of Compound (5)



embedded image


By the same procedure as described in Reference Example 3 using Resin (6) prepared in Reference Example 8 (1.0 g), N-(6-phenylhexyl)-4-piperidone (0.44 g), n-propylamine (0.14 ml) and N-(t-butyloxycarbonyl)-L-leucine (0.42 g), compound (5) was obtained.


REFERENCE EXAMPLE 10
Preparation of Compound (6)



embedded image


To a suspension of the compound (5) prepared in Reference Example 9 in 1.5 M 2,6-lutidine-dichloromethane (4 ml) was added 1M trimethylsilyl trifluoromethanesulfonate-dichloromethane solution (4 ml), and it was stirred for 30 minutes at room temperature. The resin was collected by filtration from the reaction solution. The obtained resin was again suspended in 1.5 M 2,6-lutidine-dichloromethane solution (4 ml), and 1M trimethylsilyl trifluoromethanesulfonate-dichloromethane solution (4 ml) was added thereto. It was stirred for 30 minutes at room temperature. The resin was collected by filtration from the reaction solution. The resin was washed with dichloromethane (6 ml×4), methanol (6 ml×4), and toluene (6 ml×5) to give compound (6).


EXAMPLE 1
9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-2,5-dioxo-3-(2-methyl-1-propyl)-1-propyl-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


The compound (4) prepared in Reference Example 6 was suspended in 1.25 M acetic acid-toluene solution (25 ml), and the suspension was stirred for 24 hours at 90° C., and was stirred for 16 hours at room temperature. The reaction solution was filtrated. The obtained resin was washed with chloroform-methanol (1:1; 20 ml×2). The filtrate and the washings were concentrated. The residue was purified by column chromatography on silica gel (Fuji Silysia Chemical Ltd., FL60D; chloroform:methanol=30:1). A solution of the obtained residue in methanol was acidified by adding 1N hydrochloric acid, and was concentrated to give the title compound (703 mg) having the following physical data.


TLC: Rf 0.50 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.68–7.50 (m, 5H), 4.36 (s, 2H), 4.03 (dd, J=7.8, 5.2 Hz, 1H), 3.83 (m, 2H), 3.64 (m, 2H), 3.47 (m, 2H), 2.64 (m, 2H), 2.49 (s, 3H), 2.44 (s, 3H), 2.20 (m, 2H), 1.81 (m, 1H), 1.68 (m, 2H), 1.60 (m, 2H), 1.05–0.90 (m, 9H);


IR (KBr): ν 3424, 3215, 2960, 2873, 2492, 1671, 1645, 1554, 1501, 1468, 1418, 1370, 1330, 1297, 1243, 1148, 958, 928, 754, 698 cm−1;


MS (MALDI, Pos., α-CHCA): 488 (M+Na)+, 466 (M+H)+, 185.


elemental analysis: calculated (C27H39N5O2. 2HCl): C, 60.22%; H, 7.67%; N, 13.00%.


Found: C, 59.89%; H, 7.67%; N, 12.79%.


EXAMPLE 2(1)˜2(3)

By the same procedure as described in Reference Example 3→Reference Example 4 using Resin (3) prepared in Reference Example 2 and N-allyloxycarbonyl-4-piperidone, using the corresponding compounds respectively instead of n-propylamine and N-(t-butyloxycarbonyl)leucine, and furthermore by the same procedure as described in Reference Example 5→Reference Example 6→Example 1 using the corresponding compound instead of 3,5-dimethyl-1-phenyl-4-formylpyrazole, the following compounds of the present invention were obtained.


EXAMPLE 2(1)
9-(1,4-benzodioxan-6-ylmethyl)-1-butyl-3-cyclohexylmethyl-2,5-dioxo-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.63 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.08 (d, J=2.2 Hz, 1H), 6.99 (dd, J=8.0, 2.2 Hz, 1H), 6.92 (d, J=8.0 Hz, 1H), 4.27 (s, 4H), 4.23 (s, 2H), 4.04 (dd, J=7.6, 4.8 Hz, 1H), 3.74 (m, 2H), 3.60–3.35 (m, 4H), 2.43 (m, 2H), 2.15 (m, 2H), 1.90–1.60 (m, 7H), 1.60–1.45 (m, 2H), 1.45–1.30 (m, 2H), 1.30–1.10 (m, 4H), 1.10–0.80 (m, 5H);


IR (KBr): ν 3436, 2926, 2852, 2511, 1675, 1645, 1591, 1511, 1418, 1374, 1294, 1261, 1068, 1050, 930, 888 cm−1;


MS (MALDI, Pos., α-CHCA): 484 (M+H)+, 149.


elemental analysis: calculated (C28H41N3O4.HCl): C, 64.66%; H, 8.14%; N, 8.08%.


Found: C, 64.00%; H, 7.94%; N, 7.90%.


EXAMPLE 2(2)
1-butyl-3-cyclohexylmethyl-2,5-dioxo-9-(2-phenylimidazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.25 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.05–7.94 (m, 3H), 7.75–7.60 (m, 3H), 4.59 (s, 2H), 4.05 (dd, J=7.4, 4.8 Hz, 1H), 3.88 (m, 2H), 3.65 (m, 2H), 3.51 (m, 2H), 2.68 (m, 2H), 2.19 (m, 2H), 1.90–1.60 (m, 6H), 1.60–1.45 (m, 3H), 1.45–1.30 (m, 3H), 1.30–1.10 (m, 3H), 1.10–0.80 (m, 5H);


IR (KBr): ν 3423, 2927, 2854, 2664, 1672, 1644, 1421, 1373, 1177, 775, 709, 688 cm−1;


MS (MALDI, Pos., α-CHCA): 492 (M+H)+.


elemental analysis: calculated (C29H41N5O2.2HCl 2.8H2O): C, 56.63%; H, 7.96%; N, 11.39%.


Found: C, 56.90%; H, 7.23%; N, 10.78%.


EXAMPLE 2(3)
1-butyl-3-(2-methyl-1-propyl)-2,5-dioxo-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.63 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.54 (d, J=8.8 Hz, 2H), 7.40 (m, 2H), 7.18 (m, 1H), 7.11–7.00 (m, 4H), 4.33 (s, 2H), 4.01 (dd, J=7.6, 4.8 Hz, 1H), 3.80 (m, 2H), 3.60–3.35 (m, 4H), 2.46 (m, 2H), 2.18 (m, 2H), 1.80 (m, 1H), 1.70 (m, 1H), 1.54 (m, 2H), 1.37 (m, 3H), 1.00–0.90 (m, 9H);


IR (KBr): ν 3440, 3221, 3066, 2957, 2871, 2559, 1673, 1590, 1509, 1489, 1419, 1371, 1329, 1242, 1172, 873, 693 cm−1;


MS (MALDI, Pos., α-CHCA): 478 (M+H)+, 183.


elemental analysis: calculated (C29H39N3O3.HCl): C, 67.75%; H, 7.84%; N, 8.17%.


Found: C, 67.29%; H, 7.70%; N, 8.06%.


EXAMPLE 2(4)
(3S)-2,5-dioxo-3-(2-methylpropyl)-9-(6-phenylhexyl)-1-propyl-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


By the same procedure as described in Example 1 using the compound (6) prepared in Reference Example 10, the title compound (69 mg) having the following physical data was obtained.


TLC: Rf 0.46 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.18 (m, 5H), 4.02 (dd, J=7.6, 4.8 Hz, 1H), 3.70 (m, 2H), 3.56 (m, 2H), 3.39 (m, 2H), 3.11 (m, 2H), 2.63 (dd, J=7.8, 7.2 Hz, 2H), 2.48 (m, 2H), 2.17 (m, 2H), 1.95–1.50 (m, 9H), 1.42 (m, 4H), 1.00–0.89 (m, 9H);


IR (KBr): ν 3435, 3205, 3082, 3026, 2935, 2870, 2493, 2361, 1674, 1454, 1417, 1370, 1331, 1155, 1071, 1004, 961, 750, 700 cm−1;


MS (FAB, Pos., glycerin-m-nitrobenzyl alcohol): 442 (M+H)+, 232, 171, 79 (base peak).


elemental analysis: calculated (C27H43N3O2.HCl): C, 67.83%; H, 9.28%; N, 8.79%.


Found: C, 67.56%; H, 9.50%; N, 8.71%.


EXAMPLE 2(5)
(3R)-2,5-dioxo-3-(2-methylpropyl)-9-(6-phenylhexyl)-1-propyl-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


By the same procedure as described in Reference Example 9→Reference Example 10→Example 1 using Resin (6) prepared in Reference Example 8 (1.0 g), N-(6-phenylhexyl)-4-piperidone (0.44 g), n-propylamine (0.14 ml) and N-(t-butyloxycarbonyl)-D-leucine (0.42 g), the title compound (63 mg) having the following physical data was obtained.


TLC: Rf 0.46 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.18 (m, 5H), 4.02 (dd, J=7.6, 4.6 Hz, 1H), 3.70 (m, 2H), 3.56 (m, 2H), 3.39 (m, 2H), 3.11 (m, 2H), 2.63 (dd, J=7.8, 7.2 Hz, 2H), 2.48 (m, 2H), 2.17 (m, 2H), 1.95–1.50 (m, 9H), 1.42 (m, 4H), 1.00–0.89 (m, 9H);


IR (KBr): ν 3441, 3204, 3082, 3026, 2935, 2870, 2660, 2499, 2413, 2361, 1674, 1455, 1417, 1370, 1330, 1267, 1205, 1154, 1070, 1003, 960, 928, 899, 750, 700 cm−1;


MS (FAB, Pos., glycerin-m-nitrobenzyl alcohol): 442 (M+H)+ (base peak), 294, 232, 202, 171, 79.


elemental analysis: calculated (C27H43N3O2.HCl): C, 67.83%; H, 9.28%; N, 8.79%.


Found: C, 67.52%; H, 9.51%; N, 8.70%.


EXAMPLE 3(1)˜3(4)

By the same procedure as described in Reference Example 3→Reference Example 4 using Resin (3) prepared in Reference Example 2 and N-allyloxycarbonyl-4-piperidone, using the corresponding compounds respectively instead of n-propylamine and N-(t-butyloxycarbonyl) leucine, and furthermore by the same procedure as described in Reference Example 5→Reference Example 6 Example 1 using the corresponding compound instead of 3,5-dimethyl-1-phenyl-4-formylpyrazole, the following compounds of the present invention were obtained.


EXAMPLE 3(1)
1-butyl-9-((3,5-dimethyl-1-phenyl)-4-pyrazolyl) methyl)-2,5-dioxo-3-(2-methyl-1-propyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.52 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.70–7.48 (m, 5H), 4.35 (s, 2H), 4.03 (dd, J=7.8, 4.8 Hz, 1H), 3.83 (m, 2H), 3.63 (m, 2H), 3.51 (m, 2H), 2.64 (m, 2H), 2.48 (s, 3H), 2.43 (s, 3H), 2.20 (m, 2H), 1.81 (m, 2H), 1.71 (m, 2H), 1.55 (m, 2H), 1.50–1.35 (m, 4H), 1.05–0.90 (m, 6H).


EXAMPLE 3(2)
1-butyl-3-cyclohexylmethyl-2,5-dioxo-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.73 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.74–7.56 (m, 1H), 7.53 (d, J=8.8 Hz, 2H), 7.40 (m, 2H), 7.18 (m, 1H), 7.10–7.00 (m, 3H), 4.33 (s, 2H), 4.04 (dd, J=7.4, 4.8 Hz, 1H), 3.80 (m, 2H), 3.60–3.35 (m, 4H), 2.43 (m, 2H), 2.17 (m, 2H), 1.90–1.60 (m, 7H), 1.60–1.45 (m, 2H), 1.45–1.30 (m, 2H), 1.30–1.15 (m, 4H), 1.10–0.80 (m, 5H).


EXAMPLE 3(3)
9-(1,4-benzodioxan-6-ylmethyl)-1-butyl-3-(2-methyl-1-propyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.53 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.08 (d, J=2.2 Hz, 1H), 7.01 (dd, J=8.2, 2.2 Hz, 1H), 6.93 (d, J=8.2 Hz, 1H), 4.27 (s, 4H), 4.23 (s, 2H), 4.01 (dd, J=7.8, 4.8 Hz, 1H), 3.72 (m, 2H), 3.55–3.35 (m, 4H), 2.43 (m, 2H), 2.16 (m, 2H), 1.80 (m, 1H), 1.67 (m, 2H), 1.55 (m, 2H), 1.37 (m, 2H), 1.00–0.90 (m, 9H).


EXAMPLE 3(4)
9-(4-benzyl oxyphenylmethyl)-1-butyl-2,5-dioxo-3-(2-methyl-1-propyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.59 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.54–7.25 (m, 7H), 7.10 (m, 2H), 5.13 (s, 2H), 4.27 (s, 2H), 4.00 (dd, J=8.2, 4.8 Hz, 1H), 3.72 (m, 2H), 3.55–3.35 (m, 4H), 2.42 (m, 2H), 2.16 (m, 2H), 1.90–1.25 (m, 7H), 1.00–0.90 (m, 9H).


EXAMPLE 4
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


By the same procedure as described in Reference Example 3→Reference Example 6→Example 1 using Resin (3) prepared in Reference Example 2, N-(6-phenylhexyl)-4-piperidone, n-butylamine and N-(t-butyloxycarbonyl)leucine, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.62 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.30–7.06 (m, 5H), 4.02 (dd, J=7.8, 4.8 Hz, 1H), 3.70 (m, 2H), 3.56 (m, 2H), 3.43 (m, 2H), 3.11 (m, 2H), 2.63 (t, J=7.8 Hz, 2H), 2.46 (m, 2H), 2.18 (m, 2H), 1.95–1.50 (m, 9H), 1.50–1.25 (m, 6H), 0.97 (m, 9H).


EXAMPLE 5(1)˜5(12)

By the same procedure as described in Reference Example 9→Reference Example 10→Example 1 using the corresponding compounds respectively instead of N-(6-phenylhexyl)-4-piperidone, n-propylamine and N-(t-butyloxycarbonyl)-L-leucine, using Resin (6) prepared in Reference Example 8, the following compounds of the present invention were obtained.


EXAMPLE 5(1)
(3S)-1-(2-methylpropyl)-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.52 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.33 (m, 10H), 5.07 (s, 2H), 4.12 (m, 1H), 3.94 (m, 1H), 3.61 (m, 5H), 3.39 (m, 2H), 3.13 (m, 4H), 2.31 (m, 4H), 1.92 (m, 3H), 1.51 (m, 2H), 1.39 (m, 2H), 0.93 (t, J=6.4 Hz, 6H).


EXAMPLE 5(2)
(3S)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.41 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.33 (m, 10H), 5.06 (m, 2H), 4.07 (m, 1H), 3.86 (m, 1H), 3.76 (m, 1H), 3.63 (m, 2H), 3.37 (m, 4H), 3.12 (m, 4H), 2.43 (m, 2H), 2.21 (m, 2H), 1.86 (m, 2H), 1.55 (m, 4H), 1.37 (m, 2H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 5(3)
(3R)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl) aminobutyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.41 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.33 (m, 10H), 5.06 (s, 2H), 4.07 (m, 1H), 3.86 (m, 1H), 3.76 (m, 1H), 3.63 (m, 2H), 3.37 (m, 4H), 3.12 (m, 4H), 2.43 (m, 2H), 2.21 (m, 2H), 1.86 (m, 2H), 1.55 (m, 4H), 1.37 (m, 2H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 5(4)
(3S)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(3-phenylpropyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.43 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.33 (m, 5H), 7.26 (m, 5H), 5.05 (s, 2H), 4.05(m, 1H), 3.85–3.30 (m, 6H), 3.12 (m, 4H), 2.73 (t, J=7.6 Hz, 2H), 2.44 (m, 2H), 2.13 (m, 4H), 1.85 (m, 2H), 1.54 (m, 4H), 1.38 (m, 2H), 0.94 (t, J=7.2 Hz, 3H).


EXAMPLE 5(5)
(3R)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(3-phenylpropyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.43 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.33 (m, 5H), 7.26 (m, 5H), 5.05 (s, 2H), 4.05(m, 1H), 3.85–3.30 (m, 6H), 3.12 (m, 4H), 2.73 (t, J=7.2 Hz, 2H), 2.44 (m, 2H), 2.13 (m, 4H), 1.85 (m, 2H), 1.54 (m, 4H), 1.38 (m, 2H), 0.94 (t, J=7.2 Hz, 3H).


EXAMPLE 5(6)
(3S)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.44 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.33 (m, 5H), 7.22 (m, 5H), 5.06 (s, 2H), 4.05(m, 1H), 3.85–3.38 (m, 6H), 3.12 (m, 4H), 2.70 (m, 2H), 2.40 (m, 2H), 2.18 (m, 2H), 1.74 (m, 6H), 1.54 (m, 4H), 1.38 (m, 2H), 0.94 (t, J=7.0 Hz, 3H).


EXAMPLE 5(7)
(3R)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.44 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.33 (m, 5H), 7.22 (m, 5H), 5.06 (s, 2H), 4.05(m, 1H), 3.85–3.38 (m, 6H), 3.12 (m, 4H), 2.70 (m, 2H), 2.40 (m, 2H), 2.18 (m, 2H), 1.74 (m, 6H), 1.54 (m, 4H), 1.38 (m, 2H), 0.94 (t, J=7.0 Hz, 3H).


EXAMPLE 5(8)
(3S)-1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-benzyl-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.57 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.48 (m, 5H), 7.23 (m, 5H), 4.82 (m, 2H), 4.31 (s, 2H), 4.17 (dd, J=8.0, 4.6 Hz, 1H), 3.72 (m, 2H), 3.40 (m, 2H), 2.52 (m, 2H), 2.08 (m, 2H), 2.00–1.60 (m, 3H), 0.98 (d, J=6.0 Hz, 6H).


EXAMPLE 5(9)

(3R)-1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-benzyl-1,4,9-triazaspiro[5.5]undecane.hydrochloride




embedded image


TLC: Rf 0.57 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.48 (m, 5H), 7.23 (m, 5H), 4.82 (m, 2H), 4.31 (s, 2H), 4.17 (dd, J=8.0, 4.6 Hz, 1H), 3.72 (m, 2H), 3.40 (m, 2H), 2.52 (m, 2H), 2.08 (m, 2H), 2.00–1.60 (m, 3H), 0.98 (d, J=6.0 Hz, 6H).


EXAMPLE 5(10)
(3S)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(2-(2-phenyl-5-methyloxazol-4-yl) ethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.45 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.01 (m, 2H), 7.53 (m, 3H), 7.34 (m, 5H), 5.07 (s, 2H), 4 .08 (dd, J=5.4, 4.4 Hz, 1H), 4.00–3.60 (m, 4H), 3.47 (m, 4H), 3.13 (m, 4H), 2.56 (m, 2H), 2.46 (s, 3H), 2.25 (m, 2H), 1.87 (m, 2H), 1.75–1.25 (m, 6H), 0.94 (t, J=7.2 Hz, 3H).


EXAMPLE 5(11)
(3S)-1-propyl-2,5-dioxo-3-(4-(N-(2-chlorophenylmethyl)oxycarbonyl)aminobutyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.33 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.33 (m, 9H), 5.17 (s, 2H), 4.08 (dd, J=5.2, 4.8 Hz, 1H), 3.80 (m, 2H), 3.65 (m, 3H), 3.39 (m, 3H), 3.14 (m, 4H), 2.50 (m, 2H), 2.22 (m, 2H), 1.85 (m, 2H), 1.70–1.20 (m, 6H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 5(12)
(3S)-1-propyl-2,5-dioxo-3-[3-(3-(2,4,6-trimethylphenylsulfonyl)guanidino)propyl]-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.39 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.32 (m, 5H), 7.05 (s, 2H), 4.10 (m, 1H), 3.88 (m, 1H), 3.67 (m, 3H), 3.40 (m, 4H), 3.18(m, 4H), 2.66 (s, 6H), 2.51 (m, 2H), 2.31 (s, 3H), 2.21 (m, 2H), 1.82 (m, 2H), 1.60 (m, 4H), 0.96 (t, J=7.2 Hz, 3H).


EXAMPLE 6(1)˜6(32)

By the same procedure as described in Reference Example 3→Reference Example 4 using Resin (3) prepared in Reference Example 2, N-allyloxycarbonyl-4-piperidone, the corresponding amine derivatives and the corresponding amino acid derivatives, and furthermore by the same procedure as described in Reference Example 5→Reference Example 6→Example 1 using the corresponding aldehyde derivatives, the following compounds of the present invention were obtained.


EXAMPLE 6(1)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.61 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.55 (m, 2H), 7.40 (m, 2H), 7.18 (m, 1H), 7.05 (m, 4H), 4.33 (s, 2H), 4.01 (dd, J=7.6, 4.8 Hz, 1H), 3.79 (m, 2H), 3.60–3.30 (m, 4H), 2.46 (m, 2H), 2.17 (m, 2H), 1.95–1.40 (m, 5H), 0.94 (m, 9H).


EXAMPLE 6(2)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-methoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.63 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.47 (d, J=8.8 Hz, 2H), 7.03 (d, J=8.8 Hz, 2H), 4.29 (s, 2H), 4.04 (dd, J=7.6, 4.8 Hz, 1H), 3.83 (s, 3H), 3.74 (m, 2H), 3.55–3.35 (m, 4H), 2.41 (m, 2H), 2.15 (m, 2H), 1.85–1.55 (m, 7H), 1.55–1.42 (m, 3H), 1.42–1.30 (m, 3H), 1.30–1.10 (m, 2H), 1.08–0.80 (m, 5H).


EXAMPLE 6(3)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-allyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.57 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.46 (d, J=8.4 Hz, 2H), 7.04 (d, J=8.4 Hz, 2H), 6.06 (m, 1H), 5.41 (m, 1H), 5.28 (m, 2H), 4.59 (m, 2H), 4.28 (s, 2H), 4.04 (dd, J=7.2, 4.8 Hz, 1H), 3.77 (m, 2H), 3.55–3.35 (m, 4H), 2.39 (m, 2H), 2.16 (m, 2H), 1.90–1.60 (m, 7H), 1.60–1.45 (m, 2H), 1.45–1.30 (m, 2H), 1.30–1.10 (m, 3H), 1.10–0.80 (m, 5H).


EXAMPLE 6(4)
(3S)-1-propyl-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-2,5-dioxo-3-(2-methyl-1-propyl)-1,4,9-triazaspiro[5.5]undecane.2 Hydrochloride



embedded image


TLC: Rf 0.50 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.65–7.45 (m, 5H), 4.33 (s, 2H), 4.03 (dd, J=7.8, 5.2 Hz, 1H), 3.85 (m, 2H), 3.62 (m, 2H), 3.44 (m, 2H), 2.59 (m, 2H), 2.43 (s, 3H), 2.41 (s, 3H), 2.20 (m, 2H), 1.81 (m, 1H), 1.71 (m, 2H), 1.64 (m, 2H), 1.00–0.90 (m, 9H).


EXAMPLE 6(5)
(3R)-1-propyl-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-2,5-dioxo-3-(2-methyl-1-propyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.50 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.65–7.45 (m, 5H), 4.33 (s, 2H), 4.03 (dd, J=7.8, 5.2 Hz, 1H), 3.85 (m, 2H), 3.62 (m, 2H), 3.44 (m, 2H), 2.59 (m, 2H), 2.43 (s, 3H), 2.41 (s, 3H), 2.20 (m, 2H), 1.81 (m, 1H), 1.71 (m, 2H), 1.64 (m, 2H), 1.00–0.90 (m, 9H).


EXAMPLE 6(6)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-phenylmethyl-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.54 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.64–7.44 (m, 5H), 4.36 (s, 2H), 4.01 (dd, J=7.8, 4.8 Hz, 1H), 3.77 (m, 2H), 3.55–3.35 (m, 4H), 2.60–2.30 (m, 2H), 2.17 (m, 2H), 1.95–1.75 (m, 1H), 1.75–1.60 (m, 2H), 1.60–1.45 (m, 2H), 1.45–1.20 (m, 2H), 1.10–0.80 (m, 9H).


EXAMPLE 6(7)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-benzyloxycarbonyl-1,4,9-triazaspiro[5.5]undecane



embedded image


TLC: Rf 0.41 (chloroform:methanol=20:1);


NMR (CDCl3): δ 7.45–7.28 (m, 5H), 6.31 (m, 1H), 5.15 (s, 2H), 4.14 (m, 2H), 3.96 (m, 1H), 3.63 (m, 1H), 3.44 (m, 1H), 3.26 (m, 2H), 1.99–1.14 (m, 11H), 1.02–0.88 (m, 9H).


EXAMPLE 6(8)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-benzyloxycarbonyl-1,4,9-triazaspiro[5.5]undecane



embedded image


TLC: Rf 0.46 (chloroform:methanol=20:1);


NMR (CDCl3): δ 7.40–7.29 (m, 5H), 5.98 (m, 1H), 5.15 (s, 2H), 4.14 (m, 2H), 4.00 (m, 1H), 3.65 (m, 1H), 3.43 (m, 1H), 3.26 (m, 2H), 2.03–1.81 (m, 4H), 1.80–1.60 (m, 5H), 1.60–1.10 (m, 10H), 1.10–0.85 (m, 5H).


EXAMPLE 6(9)
1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.66 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.50 (d, J=8.4 Hz, 2H), 7.45–7.12 (m, 8H), 7.10–6.98 (m, 4H), 4.82 (m, 2H), 4.29 (s, 2H), 4.18 (dd, J=8.0, 4.6 Hz, 1H), 3.73 (m, 2H), 3.42 (m, 2H), 2.65–2.30 (m, 2H), 2.20–2.05 (m, 2H), 2.00–1.60 (m, 3H), 0.98 (d, J=6.2 Hz, 6H).


EXAMPLE 6(10)
1-butyl-2,5-dioxo-3-propyl-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.36 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.51 (d, J=8.7 Hz, 2H), 7.39 (dd, J=8.7, 7.5 Hz, 2H), 7.18 (t, J=7.5 Hz, 1H), 7.10–7.00 (m, 4H), 4.33 (s, 2H), 4.04 (dd, J=5.7, 4.5 Hz, 1H), 3.93–3.66 (m, 2H), 3.55–3.31 (m, 4H), 2.47–2.09 (m, 4H), 1.92–1.68 (m, 2H), 1.61–1.21 (m, 6H), 1.01–0.90 (m, 6H).


EXAMPLE 6(11)
1-butyl-2,5-dioxo-3-methoxymethyl-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.48 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.51 (d, J=8.7 Hz, 2H), 7.39 (dd, J=8.7, 7.2 Hz, 2H), 7.17 (t, J=7.2 Hz, 1H), 7.09–6.99 (m, 4H), 4.30 (s, 2H), 4.07 (t, J=3.0 Hz, 1H), 3.91 (m, 1H), 3.77 (dd, J=9.0, 3.0 Hz, 1H), 3.67 (m, 1H), 3.58–3.39 (m, 4H), 3.31 (s, 3H), 3.26 (m, 1H), 2.48–2.13 (m, 4H), 1.65 (m, 1H), 1.53–1.28 (m, 3H), 0.95 (t, J=7.5 Hz, 3H).


EXAMPLE 6(12)
1-(1-methylpropyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.43 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.46 (d, J=8.4 Hz, 2H), 7.38 (dd, J=8.4, 7.5 Hz, 2H), 7.16 (t, J=7.5 Hz, 1H), 7.08–6.99 (m, 4H), 4.15 (s, 2H), 3.91–3.82 (m, 1H), 3.81–3.65 (m, 1H), 3.64–3.44 (m, 1H), 3.44–3.15 (m, 3H), 2.42–2.00 (m, 4H), 1.88–1.56 (m, 5H), 1.46–1.37 (m, 3H), 0.99–0.85 (m, 9H).


EXAMPLE 6(13)
1-(2-methyl butyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.49 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.49 (d, J=8.7 Hz, 2H), 7.39 (dd, J=8.7, 7.2 Hz, 2H), 7.17 (t, J=7.2 Hz, 1H), 7.08–6.94 (m, 4H), 4.27 (s, 2H), 4.04 (dd, J=8.4, 4.5 Hz, 1H), 3.83–3.21 (m, 6H), 2.45–2.12 (m, 4H), 1.92–1.56 (m, 4H), 1.42 (m, 1H), 1.14 (m, 1H), 1.00–0.83 (m, 12H).


EXAMPLE 6(14)
1-(2-methylpropyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.50 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.50 (d, J=8.7 Hz, 2H), 7.39 (dd, J=8.7, 7.5 Hz, 2H), 7.17 (t, J=7.5 Hz, 1H), 7.13–7.04 (m, 4H), 4.28 (s, 2H), 4.04 (dd, J=8.1, 4.2 Hz, 1H), 3.81–3.54 (m, 2H), 3.52–3.21 (m, 4H), 2.46–2.11 (m, 4H), 2.00–1.57 (m, 4H), 0.94 (d, J=6.3 Hz, 6H), 0.90 (d, J=6.3 Hz, 3H), 0.90 (d, J=6.3 Hz, 3H).


EXAMPLE 6(15)
1-(2-dimethylaminoethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.87 (chloroform:methanol:28% NH4OH=80:10:1);


NMR (CD3OD): δ 7.60 (d, J=8.7 Hz, 2H), 7.39 (dd, J=8.7, 7.5 Hz, 2H), 7.17 (t, J=7.5 Hz, 1H), 7.07–6.99 (m, 4H), 4.33 (s, 2H), 4.07 (dd, J=8.4, 4.8 Hz, 1H), 3.99–3.63 (m, 4H), 3.53–3.42 (m, 2H), 3.32–3.21 (m, 2H), 2.99 (s, 3H), 2.96 (s, 3H), 2.70–2.49 (m, 2H), 2.30–2.10 (m, 2H), 1.93–1.56 (m, 3H), 0.94 (d, J=6.6 Hz, 6H).


EXAMPLE 6(16)
1-(2-methoxyethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.40 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.47 (d, J=8.7 Hz, 2H), 7.39 (dd, J=8.7, 7.5 Hz, 2H), 7.17 (t, J=7.5 Hz, 1H), 7.09–6.99 (m, 4H), 4.25 (s, 2H), 4.03 (dd, J=7.8, 4.8 Hz, 1H), 3.75–3.34 (m, 8H), 3.31 (s, 3H), 2.48–2.28 (m, 2H), 2.25–2.06 (m, 2H), 1.90–1.57 (m, 3H), 0.94 (d, J=6.3 Hz, 3H), 0.93 (d, J=6.3 Hz, 3H).


EXAMPLE 6(17)
1-(2-methylthioethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.43 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.48 (d, J=8.7 Hz, 2H), 7.39 (dd, J=8.7, 7.8 Hz, 2H), 7.17 (t, J=7.8 Hz, 1H), 7.08–6.99 (m, 4H), 4.25 (s, 2H), 4.02 (dd, J=7.8, 4.5 Hz, 1H), 3.81–3.49 (m, 4H), 3.48–3.33 (m, 2H), 2.74–2.51 (m, 2H), 2.39–2.10 (m, 7H), 1.90–1.56 (m, 3H), 0.94 (d, J=6.6 Hz, 3H), 0.93 (d, J=6.6 Hz, 3H).


EXAMPLE 6(18)
1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.55 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.40–7.15 (m, 5H), 7.03 (d, J=2.0 Hz, 1H), 6.96 (dd, J=8.2, 2.0 Hz, 1H), 6.90 (d, J=8.2 Hz, 1H), 4.80 (m, 2H), 4.25 (s, 4H), 4.21–4.10 (m, 3H), 3.80–3.55 (m, 2H), 3.50–3.30 (m, 2H), 2.60–2.25 (m, 2H), 2.20–2.00 (m, 2H), 2.00–1.60 (m, 3H), 0.98 (d, J=6.4 Hz, 6H).


EXAMPLE 6(19)
1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-benzyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.53 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.50–7.15 (m, 12H), 7.07 (d, J=8.8 Hz, 2H), 5.12 (s, 2H), 4.81 (m, 2H), 4.24 (s, 2H), 4.17 (dd, J=8.4, 4.8 Hz, 1H), 3.70–3.55 (m, 2H), 3.50–3.35 (m, 2H), 2.60–2.25 (m, 2H), 2.20–2.00 (m, 2H), 2.00–1.60 (m, 3H), 0.98 (d, J=6.0 Hz, 6H).


EXAMPLE 6(20)
1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.50 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.70–7.45 (m, 5H), 7.40–7.15 (m, 5H), 4.92 (m, 2H), 4.29 (s, 2H), 4.20 (dd, J=8.4, 4.8 Hz, 1H), 3.90–3.65 (m, 2H), 3.65–3.45 (m, 2H), 2.85–2.50 (m, 2H), 2.44 (s, 3H), 2.39 (s, 3H), 2.20–2.00 (m, 2H), 2.00–1.60 (m, 3H), 1.00 (d, J=5.4 Hz, 6H).


EXAMPLE 6(21)
1-(3-methylphenylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.56 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.18 (t, J=7.8 Hz, 1H), 7.10–6.85 (m, 6H), 4.77 (m, 2H), 4.25 (s, 4H), 4.19 (m, 3H), 3.68 (m, 2H), 3.40 (m, 2H), 2.60–2.30 (m, 2H), 2.29 (s, 3H), 2.20–2.00 (m, 2H), 2.00–1.60 (m, 3H), 0.99 (d, J=6.2 Hz, 6H).


EXAMPLE 6(22)
1-(3-methylphenylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.59 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.70–7.45 (m, 5H), 7.18 (t, J=7.4 Hz, 1H), 7.10–7.00 (m, 3H), 4.88 (s, 2H), 4.31 (s, 2H), 4.20 (dd, J=8.2, 4.8 Hz, 1H), 3.76 (m, 2H), 3.60 (m, 2H), 2.90–2.50 (m, 2H), 2.47 (s, 3H), 2.41 (s, 3H), 2.30 (s, 3H), 2.10 (m, 2H), 1.88 (m, 1H), 1.85–1.65 (m, 2H), 1.00 (d, J=5.8 Hz, 6H).


EXAMPLE 6(23)
1-(1-methyl butyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.49, 0.56 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.49 (d, J=8.7 Hz, 2H), 7.39 (dd, J=8.7, 7.5 Hz, 2H), 7.17 (t, J=7.5 Hz, 1H), 7.08–6.99 (m, 4H), 4.26 (s, 2H), 3.97–3.79 (m, 2H), 3.78–3.60 (m, 1H), 3.54–3.33 (m, 3H), 2.47–2.29 (m, 2H), 2.26–2.03 (m, 3H), 1.87–1.71 (m, 1H), 1.70–1.53 (m, 3H), 1.48–1.16 (m, 5H), 1.02–0.90 (m, 9H).


EXAMPLE 6(24)
1-(3-methylbutyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.54 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.51 (d, J=8.7 Hz, 2H), 7.39 (dd, J=8.7, 7.5 Hz, 2H), 7.18 (t, J=7.5 Hz, 1H), 7.10–7.00 (m, 4H), 4.33 (s, 2H), 4.00 (dd, J=8.1, 4.8 Hz, 1H), 3.90–3.71 (m, 2H), 3.56–3.34 (m, 4H), 2.46–2.29 (m, 2H), 2.28–2.10 (m, 2H), 1.90–1.56 (m, 4H), 1.55–1.32 (m, 2H), 1.04–0.85 (m, 12H).


EXAMPLE 6(25)
1-(2-methoxyphenylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-((3,5-dimethyl-1-phenyl)-4-pyrazolyl)methyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.38 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.59–7.41 (m, 5H), 7.26–7.17 (m, 1H), 6.99–6.84 (m, 3H), 4.74 (brs, 2H), 4.27 (s, 2H), 4.19 (dd, J=8.4, 4.5 Hz, 1H), 3.88 (s, 3H), 3.90–3.68 (m, 2H), 3.62–3.45 (m, 2H), 2.60–2.14 (m, 4H), 2.35 (s, 3H), 2.33 (s, 3H), 2.00–1.63 (m, 3H), 0.99 (d, J=6.3 Hz, 6H).


EXAMPLE 6(26)
1-(3-methoxyphenylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-((3,5-dimethyl-1-phenyl)-4-pyrazolyl)methyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.33 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.65–7.48 (m, 5H), 7.20 (t, J=8.1 Hz, 1H), 6.85–6.80 (m, 2H), 6.77 (dd, J=7.8, 2.1 Hz, 1H), 4.90 (brs, 2H), 4.31 (s, 2H), 4.20 (dd, J=8.1, 4.8 Hz, 1H), 3.84–3.65 (m, 2H), 3.75 (s, 3H), 3.65–3.48 (m, 2H), 2.84–2.56 (m, 2H), 2.47 (s, 3H), 2.40 (s, 3H), 2.19–2.03 (m, 2H), 2.00–1.65 (m, 3H), 0.99 (d, J=6.3 Hz, 6H).


EXAMPLE 6(27)
1-(2-methylphenylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.35 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.63–7.46 (m, 5H), 7.18–7.06 (m, 3H), 6.99–6.91 (m, 1H), 4.81 (brs, 2H), 4.29 (s, 2H), 4.20 (dd, J=8.4, 4.5 Hz, 1H), 3.90–3.66 (m, 2H), 3.63–3.57 (m, 2H), 2.75–2.40 (m, 2H), 2.44 (s, 3H), 2.40 (s, 3H), 2.38 (s, 3H), 2.30–2.10 (m, 2H), 2.00–1.65 (m, 3H), 0.99 (d, J=6.3 Hz, 6H).


EXAMPLE 6(28)
1-(3-methylphenylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.48 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.53–7.46 (m, 2H), 7.42–7.36 (m, 2H), 7.22–7.14 (m, 2H), 7.06–6.96 (m, 7H), 4.85–4.65 (m, 2H), 4.28 (s, 2H), 4.18 (dd, J=8.1, 4.5 Hz, 1H), 3.80–3.62 (m, 2H), 3.50–3.30 (m, 2H), 2.58–2.25 (m, 2H), 2.29 (s, 3H), 2.18–2.04 (m, 2H), 1.95–1.62 (m, 3H), 0.98 (d, J=6.3 Hz, 6H).


EXAMPLE 6(29)
1-butyl-2,5-dioxo-3-cyclohexyl methyl-9-(5-ethylthiophen-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.62 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.17 (d, J=3.6 Hz, 1H), 6.85 (d, J=3.6 Hz, 1H), 4.53 (s, 2H), 4.04 (dd, J=7.8, 4.5 Hz, 1H), 3.88–3.72 (m, 2H), 3.58–3.45 (m, 2H), 3.43–3.33 (m, 2H), 2.87 (q, J=7.5 Hz, 2H), 2.50–2.30 (m, 2H), 2.30–2.08 (m, 2H), 1.83–1.10 (m, 17H), 1.31 (t, J=7.5 Hz, 3H), 1.05–0.85 (m, 2H), 0.95 (t, J=7.5 Hz, 3H).


EXAMPLE 6(30)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(5-ethylfuran-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.62 (chloroform:methanol=20:1);


NMR (CD3OD): δ 6.63 (d, J=3.0 Hz, 1H), 6.14 (d, J=3.0 Hz, 1H), 4.39 (s, 2H), 4.04 (dd, J=7.5, 4.5 Hz, 1H), 3.90–3.70 (m, 2H), 3.55–3.40 (m, 2H), 3.40–3.35 (m, 2H), 2.69 (q, J=7.5 Hz, 2H), 2.50–2.30 (m, 2H), 2.30–2.10 (m, 2H), 1.85–1.05 (m, 17H), 1.25 (t, J=7.5 Hz, 3H), 1.05–0.85 (m, 2H), 0.96 (t, J=7.5 Hz, 3H).


EXAMPLE 6(31)
(3S)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.47 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.52 (d, J=9.0 Hz, 2H), 7.44–7.35 (m, 2H), 7.18 (t, J=7.5 Hz, 1H), 7.10–7.00 (m, 4H), 4.33 (s, 2H), 4.16–4.00 (m, 2H), 3.75–3.40 (m, 5H), 3.26–3.09 (m, 1H), 2.56–2.08 (m, 4H), 1.82–1.60 (m, 2H), 1.50–1.30 (m, 3H), 1.05–0.89 (m, 9H).


EXAMPLE 6(32)
(3R)-1-butyl-2,5-dioxo-3-((1S)-1-hydroxy-2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.47 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.52 (d, J=9.0 Hz, 2H), 7.44–7.35 (m, 2H), 7.18 (t, J=7.5 Hz, 1H), 7.10–7.00 (m, 4H), 4.33 (s, 2H), 4.16–4.00 (m, 2H), 3.75–3.40 (m, 5H), 3.26–3.09 (m, 1H), 2.56–2.08 (m, 4H), 1.82–1.60 (m, 2H), 1.50–1.30 (m, 3H), 1.05–0.89 (m, 9H).


EXAMPLE 7
(3S)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-allyloxycarbonyl-1,4,9-triazaspiro[5.5]undecane



embedded image


By the same procedure as described in Reference Example 9→Reference Example 10→Example 1 using Resin (6) prepared in Reference Example 8, N-allyloxycarbonyl-4-piperidone, n-propylamine and N-(t-butyloxycarbonyl)-N′-(benzyloxycarbonyl)-L-lysine, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.24 (ethyl acetate:hexane=4:1);


NMR (CD3OD): δ 7.35 (m, 5H), 6.40 (m, 1H), 5.96 (ddt, J=17.2, 10.2, 5.6 Hz, 1H), 5.34 (m, 1H), 5.24 (m, 1H), 5.12 (s, 2H), 4.88 (m, 1H), 4.62 (m, 2H), 4.10 (m, 2H), 4.00 (m, 1H), 3.75 (m, 1H), 3.36 (m, 2H), 3.18 (m, 3H), 1.94 (m, 6H), 1.51 (m, 6H), 0.90 (t, J=7.2 Hz, 3H).


EXAMPLE 8
(3S)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-1,4,9-triazaspiro[5.5]undecane



embedded image


By the same procedure as described in Reference Example 4 using the compound prepared in Example 7, and furthermore, purification by cation-exchange resin and column chromatography on silica gel, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.56 (chloroform:methanol:28% NH4OH=20:5:1);


NMR (CD3OD): δ 7.40–7.20 (m, 10H), 5.06 (s, 2H), 4.03 (t, J=5.0 Hz, 1H), 3.55–3.18 (m, 4H), 3.12 (t, J=6.6 Hz, 2H), 3.08–2.98 (m, 2H), 2.20–1.70 (m, 6H), 1.70–1.20 (m, 6H), 0.93 (t, J=7.2 Hz, 3H).


EXAMPLE 8(1)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-1,4,9-triazaspiro[5.5]undecane



embedded image


By the same procedure as described in Example 7→Example 8 using N-(t-butyloxycarbonyl)leucine instead of N-(t-butyloxycarbonyl)-N′-(benzyloxycarbonyl)-L-lysine, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.44 (chloroform:methanol:triethylamine=18:2:1);


NMR (CD3OD): δ 3.99 (d, J=7.8, 4.4 Hz, 1H), 3.50–3.20 (m, 4H), 3.05–2.85 (m, 2H), 2.10–1.75 (m, 5H), 1.75–1.40 (m, 4H), 1.00–0.85 (m, 9H).


EXAMPLE 9
1-butyl-2,5-dioxo-3-(2-methylpropyl)-1,4,9-triazaspiro[5.5]undecane



embedded image


To a solution of the compound prepared in Example 6(7) (202 mg) in methanol (5 ml) was added 5% palladium on carbon (20 mg). Under an atmosphere of hydrogen, the reaction mixture was stirred for 3 hours at room temperature. The reaction mixture was filtrated through Celite (brand name). The filtrate was concentrated to give the compound of the present invention (127 mg) having the following physical data.


TLC: Rf 0.61 (chloroform:methanol:28% NH4OH=20:5:1);


NMR (CD3OD): δ 3.97 (dd, J=7.8 Hz, 4.5 Hz, 1H), 3.48–3.22 (m, 4H), 3.00–2.90 (m, 2H), 2.12–1.60 (m, 11H), 0.95 (t, J=7.2 Hz, 3H), 0.94 (d, J=6.6 Hz, 3H), 0.93 (d, J=6.6 Hz, 3H).


EXAMPLE 9(1)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-1,4,9-triazaspiro[5.5]undecane



embedded image


By the same procedure as described in Example 9 using the compound prepared in Example 6(8) instead of the compound prepared in Example 6(7), the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.65 (chloroform:methanol:28% NH4OH=20:5:1);


NMR (CD3OD): δ 4.00 (dd, J=7.8 Hz, 4.5 Hz, 1H), 3.46–3.24 (m, 4H), 3.03–2.92 (m, 2H), 2.08–1.08 (m, 19H), 1.05–0.84 (m, 5H).


EXAMPLE 10
(3S)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl) aminobutyl)-9-(4-dihydroxyboranephenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


The compound prepared in Example 8 (70 mg) was dissolved in 1% acetic acid-dimethylformamide solution (2 ml). To this solution were added sodium triacetoxyborohydride (46 mg) and 4-formylphenylboronic acid (30 mg). The reaction mixture was stirred for 46 hours at room temperature. To the reaction mixture was added 10% acetic acid-methanol solution. This solution was loaded on cation-exchange resin (BondElut-SCX, Varian Co. Ltd., 0.6 mmol/g, 500 mg/3 ml), and the resin was washed with methanol, and furthermore, was eluted with 10% triethylamine-methanol solution. Only solution which was eluted with 10% triethylamine-methanol solution, was concentrated. The obtained residue was purified by column chromatography on silica gel (chloroform:methanol=1:0→30:1→10:1) to give the compound of the present invention (45 mg) having the following physical data.


TLC: Rf 0.24 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.73 (br, 2H), 7.52 (br, 2H), 7.32 (m, 5H), 5.03 (s, 2H), 4.36 (s, 2H), 4.05 (t, J=4.8 Hz, 1H), 3.81 (m, 2H), 3.46 (m, 3H), 3.10 (t, J=6.6 Hz, 2H), 2.37 (br, 2H), 2.22 (br, 2H), 1.92–1.66 (m, 2H), 1.60–1.28 (m, 7H), 0.91 (t, J=7.5 Hz, 3H).


EXAMPLE 10(1)

(3S)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(1,3-benzodioxalan-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride




embedded image


By the same procedure as described in Example 10 using 2,3-(methylenedioxy)benzaldehyde instead of 4-formylphenylboronic acid, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.25 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.32 (m, 5H), 6.96 (m, 3H), 6.05 (s, 2H), 5.04 (s, 2H), 4.33 (s, 2H), 4.05 (t, J=4.5 Hz, 1H), 3.98–3.54 (m, 2H), 3.53 (m, 2H), 3.38 (m, 3H), 3.11 (t, J=6.6 Hz, 2H), 2.37 (br, 2H), 2.22 (br, 2H), 1.98–1.76 (m, 2H), 1.61–1.28 (m, 5H), 0.92 (t, J=7.2 Hz, 3H).


EXAMPLE 11
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(1-(1,4-benzodioxan-6-yl)ethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


Under an atmosphere of argon, to a solution of the compound prepared in Example 9 (315 mg) in dichloromethane (5 ml) were added 1,4-benzodioxan-6-yl methyl ketone (285 mg), triethylamine (0.354 ml) and a solution of titanium tetrachloride in dichloromethane (1.0 M, 0.63 ml). The reaction mixture was stirred for 16 hours at room temperature. To the reaction mixture was added a solution of sodium cyanoborohydride (133 mg) in methanol (2 ml). The reaction mixture was stirred for 1 hour at room temperature. To the reaction mixture was added 2N aqueous solution of sodium hydroxide, and was extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated. The obtained residue was purified by column chromatography on silica gel (Fuji Silysia Chemical Ltd., BW235; chloroform:methanol=50:1). The obtained residue was dissolved in methanol. The solution was acidified by adding 1N hydrochloric acid, and was concentrated to give the compound of the present invention (176 mg) having the following physical data.


TLC: Rf 0.46 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.04 (d, J=2.1 Hz, 1H), 6.98 (dd, J=8.4, 2.1 Hz, 1H), 6.92 (d, J=8.4 Hz, 1H), 4.40 (q, J=6.9 Hz, 1H), 4.26 (s, 4H), 3.98 (dd, J=8.1, 4.5 Hz, 1H), 3.82–3.17 (m, 6H), 2.55–2.04 (m, 4H), 1.87–1.28 (m, 10H), 1.04–0.85 (m, 9H).


EXAMPLE 11(1)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(1-(4-phenyloxyphenyl)ethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


By the same procedure as described in Example 11 using 4-phenoxyacetophenone instead of 1,4-benzodioxan-6-yl methyl ketone, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.58, 0.62 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.51 (d, J=8.7 Hz, 2H), 7.39 (dd, J=8.7, 7.5 Hz, 2H), 7.17 (t, J=7.5 Hz, 1H), 7.09–7.01 (m, 4H), 4.48 (m, 1H), 3.98 (dd, J=7.8, 4.8 Hz, 1H), 3.80–3.17 (m, 6H), 2.56–2.28 (m, 2H), 2.28–2.03 (m, 2H), 1.88–1.24 (m, 7H), 1.76 (d, J=6.9 Hz, 3H), 1.04–0.86 (m, 9H).


EXAMPLE 12
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(1-(1,4-benzodioxan-6-yl)ethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


By the same procedure as described in Example 11 using the compound prepared in Example 9(1) instead of the compound prepared in Example 9, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.50 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.02 (d, J=1.8 Hz, 1H), 6.96 (dd, J=8.4, 1.8 Hz, 1H), 6.92 (d, J=8.4 Hz, 1H), 4.39 (m, 1H), 4.26 (s, 4H), 4.01 (dd, J=7.5, 4.5 Hz, 1H), 3.80–3.20 (m, 6H), 2.50–2.02 (m, 4H), 1.82–1.13 (m, 18H), 1.04–0.83 (m, 5H).


EXAMPLE 13
(3S)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl) aminobutyl)-9-allyl-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


Under an atmosphere of argon, to a solution of the compound prepared in Example 7 (225 mg) in tetrahydrofuran (5 ml) was added tetrakis(triphenylphosphine)palladium (0) (51 mg) at room temperature. The reaction mixture was stirred for 16 hours at room temperature. The reaction mixture was loaded on cation-exchange resin (BondElut-SCX, Varian Co. Ltd., 0.6 mmol/g, 500 mg/3 ml), and the resin was washed with methanol, and furthermore, was eluted with 10% triethylamine-methanol solution (20 ml). Only solution which was eluted with 10% triethylamine-methanol solution, was concentrated. The obtained residue was purified by column chromatography on silica gel (chloroform:methanol=20:1) to give the compound of the present invention (122 mg) having the following physical data.


TLC: Rf 0.34 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.34 (m, 5H), 6.00 (m, 1H), 5.62 (m, 1H), 5.61 (m, 1H), 5.06 (s, 2H), 4.07 (t, J=5.2 Hz, 1H), 3.77 (m, 4H), 3.44 (m, 4H), 3.12 (t, J=6.6 Hz, 2H), 2.39 (m, 2H), 2.20 (m, 2H), 1.84 (m, 2H), 1.54 (m, 4H), 1.37 (m, 2H), 0.94 (t, J=7.2 Hz, 3H).


EXAMPLE 14

(3S)-1-propyl-2,5-dioxo-3-(4-aminobutyl)-9-phenylethyl-1,4,9-triazaspiro[5.5]undecane




embedded image


By the same procedure as described in Example 9 using the compound prepared in Example 5(11) instead of the compound prepared in Example 6(7), the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.66 (chloroform:methanol:28% NH4OH=20:5:1);


NMR (CD3OD): δ 7.23 (m, 5H), 4.05 (t, J=5.2 Hz, 1H), 3.42 (m, 2H), 2.98 (m, 3H), 2.81 (m, 3H), 2.65 (m, 4H), 2.16 (m, 2H), 1.99 (m, 1H), 1.89 (m, 3H), 1.53 (m, 3H), 1.48 (m, 3H), 0.94 (t, J=7.2 Hz, 3H).


EXAMPLE 15
(3S)-1-propyl-2,5-dioxo-3-(4-(N-(4-phenyl)phenylcarbonyl)aminobutyl)-9-phenylethyl-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


To a solution of the compound prepared in Example 14 (42 mg) in dichloroethane (2 ml) were added diisopropylethylamine (35 μl) and 4-phenylbenzoyl chloride (33 mg). The reaction mixture was stirred for 3 hours at room temperature. The reaction mixture was loaded on cation-exchange resin (BondElut-SCX, Varian Co. Ltd., 0.6 mmol/g, 500 mg/3 ml), and the resin was washed with methanol, and furthermore, was eluted with 10% triethylamine-methanol solution (20 ml). Only solution which was eluted with 10% triethylamine-methanol solution, was concentrated. The obtained residue was purified by column chromatography on silica gel (chloroform:methanol=10:0→10:1). To the obtained compound was added 4N hydrogen chloride-ethyl acetate solution to give the compound of the present invention (66 mg) having the following physical data.


TLC: Rf 0.50 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.89 (d, J=8.1 Hz, 2H), 7.72 (d, J=8.1 Hz, 2H), 7.65 (d, J=7.2 Hz, 2H), 7.45 (t, J=7.2 Hz, 2H), 7.39–7.26 (m, 6H), 4.11 (m, 1H), 3.86–3.71 (m, 2H), 3.63–3.53 (m, 2H), 3.45–3.30 (m, 4H), 3.07 (m, 2H), 2.42 (br, 2H), 2.19 (m, 2H), 1.99–1.78 (m, 2H), 1.68–1.28 (m, 7H), 0.86 (t, J=7.5 Hz, 3H).


EXAMPLE 16
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-methyl-9-(1-(1,4-benzodioxan-6-yl)ethyl)-1,4,-diaza-9-azoniaspiro[5.5]undecane iodide



embedded image


To a solution of the compound prepared in Example 2(1) (50 mg) in chloroform (2 ml) was added 1 N aqueous solution of sodium hydroxide (2 ml). The reaction mixture was stirred for 10 minutes at room temperature. The aqueous layer of the reaction mixture was removed. The organic layer was washed with water, dried over anhydrous magnesium sulfate and concentrated. To a solution of the obtained residue in acetone (2 ml) was added methyl iodide (118 μl). The reaction mixture was stirred for 18 hours at room temperature. The reaction mixture was concentrated. The obtained residue was solidified by diethyl ether to give the compound of the present invention (58 mg) having the following physical data.


TLC: Rf 0.23(ethyl acetate:acetic acid:water=8:1:1);


NMR (CD3OD): δ 7.10–6.90 (m, 3H), 4.60+4.49 (s+s, 2H), 4.29 (s, 4H), 4.20–4.00 (m, 3H), 3.70–3.35 (m, 4H), 3.11+2.99 (s+s, 3H), 2.80–2.30 (m, 2H), 2.30–2.00 (m, 2H), 1.90–1.10 (m, 15H), 1.10–0.80 (m, 5H).


EXAMPLE 17
(3S)-3-(4-(N-benzyloxycarbonyl)aminobutyl)-2,5-dioxo-9-(2-hydroxy-2-phenylethyl)-1-propyl-1,4,9-triazaspiro[5.5]undecane



embedded image


To a solution of the compound prepared in Example 8 (0.01 g) in 2-propanol (0.4 ml) was added styrene oxide (10 μl). The reaction mixture was refluxed for 4 hours. The reaction mixture was cooled to room temperature, and was loaded on ion exchange resin (OASIS MCX, Waters, 60 mg) washed with methanol (3 ml) prior to use. The resin was washed with methanol (2 ml), and was eluted with 10% triethylamine-methanol solution (2 ml). The elution was concentrated to give the compound of the present invention (13 mg) having the following physical data.


TLC: Rf 0.34 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.40–7.20 (m, 10H), 5.06 (s, 2H), 4.03 (m, 1H), 3.40 (m, 2H), 3.12 (m, 2H), 3.10–2.60 (m, 6H), 2.50 (m, 1H), 2.40–2.00 (m, 2H), 2.00–1.70 (m, 4H), 1.70–1.20 (m, 6H), 0.93 (t, J=7.2 Hz, 3H).


EXAMPLE 18
(3S)-3-(4-(N-benzyloxycarbonyl) aminobutyl)-2,5-dioxo-9-(2-oxo-2-phenylethyl)-1-propyl-1,4,9-triazaspiro[5.5]undecane



embedded image


To a solution of the compound prepared in Example 8 (0.01 g) in dimethylformamide (0.4 ml) were added triethylamine (6 μl), and phenacyl bromide (9 mg). The reaction mixture was allowed to stand for 24 hours at room temperature. The reaction mixture was acidified by adding acetic acid (0.4 ml). The reaction mixture was loaded on ion exchange resin (OASIS MCX, Waters, 120 mg) washed with methanol (6 ml) prior to use. The resin was washed with methanol (2 ml), and was eluted with 10% triethylamine-methanol solution (4 ml). The elution was concentrated to give the compound of the present invention (12 mg) having the following physical data.


TLC: Rf 0.33 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.01 (m, 2H), 7.54 (m, 3H), 7.33 (m, 5H), 5.05 (s, 2H), 4.02 (m, 1H), 4.00 (s, 2H), 3.44 (m, 2H), 3.12 (t, J=6.6 Hz, 2H), 2.95 (m, 2H), 2.40–2.10 (m, 2H), 2.00–1.70 (m, 5H), 1.68–1.20 (m, 7H), 0.94 (t, J=7.2 Hz, 3H).


EXAMPLE 19
(3S)-1-(2-methylpropyl)-2,5-dioxo-3-methyl-9-allyloxycarbonyl-1,4,9-triazaspiro[5.5]undecane



embedded image


To a suspension of Resin (6) prepared in Reference Example 8 (300 mg) in tetrahydrofuran (1.5 ml) and methanol (1.5 ml) were added N-allyloxycarbonyl-4-piperidone (403 mg), isobutylamine (0.22 ml) and N-(t-butyloxycarbonyl)-L-alanine (381 mg) at room temperature. The reaction mixture was stirred for 20 hours at 65° C. The reaction mixture was cooled to room temperature and the resin was collected by filtration. The obtained resin was washed with tetrahydrofuran (3 ml×4) and dichloromethane (3 ml×5), and dried. The resin (384 mg) was obtained. To a suspension of the obtained resin (146 mg) in 1.5 M 2,6-lutidine-dichloromethane (2 ml) was added 1M trimethylsilyl trifluoromethanesulfonate-dichloromethane solution (2 ml). It was stirred for 30 minutes at room temperature. The reaction mixture was filtrated, and the resin was washed with dichloromethane (2 ml×3). The obtained resin was suspended in 1.5 M 2,6-lutidine-dichloromethane solution (2 ml) and 1 M trimethylsilyl trifluoromethanesulfonate-dichloromethane solution (2 ml) was added thereto. The reaction mixture was stirred for 30 minutes at room temperature. The resin was collected by filtration from the reaction solution, and was washed with dichloromethane (2 ml×4), methanol (2 ml×4) and dichloromethane (2 ml×4), dried and the resin was obtained. The obtained resin was suspended in 1.25M acetic acid-toluene solution (2 ml). The reaction mixture was stirred for 20 hours at 90° C. The reaction mixture was filtrated, and the resin was washed with toluene (2 ml×3) and methanol (2 ml×4). The filtrate was concentrated to give the compound of the present invention (19 mg) having the following physical data.


TLC: Rf 0.39 (chloroform:methanol=10:1);


MS (ESI, Pos., 20 V): 388 (M+H)+;


HPLC condition: F;


HPLC retention time: 3.40 min;


NMR (CD3OD): δ 5.98 (ddt, J=15.8, 10.4, 5.4 Hz, 1H), 5.30 (m, 1H), 5.21 (m, 1H), 4.59 (m, 2H), 4.20–4.00 (m, 3H), 3.85–3.60 (m, 2H), 3.41 (dd, J=14.2, 8.0 Hz, 1H), 3.18 (dd, J=14.2, 7.2 Hz, 1H), 2.10–1.70 (m, 5H), 1.43 (d, J=6.8 Hz, 3H), 0.89 (t, J=6.2 Hz, 6H).


EXAMPLE 19(1)
(3S)-1-(2-methylpropyl)-2,5-dioxo-3-methyl-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane.acetate



embedded image


By the same procedure as described in Example 19 using Resin (6) prepared in Reference Example 8 (200 mg), N-(2-phenylethyl)-4-piperidone (252 mg), isobutylamine (0.123 ml) and N-(t-butyloxycarbonyl)-L-alanine (235 mg), the compound of the present invention (50 mg) having the following physical data was obtained.


TLC: Rf 0.46 (chloroform:methanol=10:1);


MS (ESI, Pos., 20 V): 358 (M+H)+;


HPLC condition: F;


HPLC retention time: 3.14 min;


NMR (CD3OD): δ 7.40–7.20 (m, 5H), 4.15 (q, J=6.8 Hz, 1H), 3.65 (m, 1H), 3.55–3.35 (m, 3H), 3.25–3.05 (m, 3H), 3.05–2.90 (m, 3H), 2.50–2.05 (m, 4H), 1.98 (s, 3H), 1.92 (m, 1H), 1.43 (d, J=6.8 Hz, 3H), 0.92 (t, J=6.4 Hz, 6H).


EXAMPLE 19(2)
(3S)-1-(2-methylpropyl)-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane.acetate



embedded image


By the same procedure as described in Example 19 using Resin (6) prepared in Reference Example 8 (200 mg), N-(2-phenylethyl)-4-piperidone (252 mg), isobutylamine (0.123 ml) and N-(t-butyloxycarbonyl)-N′-(benzyloxycarbonyl)-L-lysine (472 mg), the compound of the present invention (71 mg) having the following physical data was obtained.


TLC: Rf 0.44 (chloroform:methanol=10:1);


MS (ESI, Pos., 20 V): 549 (M+H)+;


HPLC condition: F;


HPLC retention time: 3.49 min;


NMR (CD3OD): δ7.40–7.20 (m, 10H), 5.06 (s, 2H), 4.10 (m, 1H), 3.67 (m, 1H), 3.60–3.40 (m, 3H), 3.28–3.05 (m, 5H), 3.05–2.90 (m, 3H), 2.50–2.10 (m, 4H), 1.98 (s, 3H), 2.05–1.70 (m, 3H), 1.65–1.20 (m, 4H), 0.92 (t, J=6.2 Hz, 6H).


EXAMPLE 19(3)
(3S)-1-(1-benzyl piperidin-4-yl)-2,5-dioxo-3-methyl-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane.2 acetate



embedded image


By the same procedure as described in Example 19 using Resin (6) prepared in Reference Example 8 (200 mg), N-(2-phenylethyl)-4-piperidone (252 mg), 4-amino-1-benzylpiperidine (0.253 ml) and N-(t-butyloxycarbonyl)-L-alanine (235 mg), the compound of the present invention (41 mg) having the following physical data was obtained.


TLC: Rf 0.10 (chloroform:methanol=10:1);


MS (ESI, Pos., 20 V): 475 (M+H)+;


HPLC condition: F;


HPLC retention time: 3.09 min;


NMR (CD3OD): δ 7.47 (m, 5H), 7.40–7.20 (m, 5H), 4.19 (s, 2H), 4.00 (q, J=6.8 Hz, 1H), 3.80–3.53 (m, 4H), 3.53–3,35 (m, 4H), 3.30–3.15 (m, 2H), 3.15–2.90 (m, 3H), 2,55–2.30 (m, 3H), 2.30–2.00 (m, 2H), 1.98 (s, 6H), 1.85–1.70 (m, 3H), 1.42 (d, J=7.0 Hz, 3H).


EXAMPLE 19(4)
(3S)-1-(1-benzylpiperidin-4-yl)-2,5-dioxo-3-(4-(N -benzyloxycarbonyl)aminobutyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane.2 acetate



embedded image


By the same procedure as described in Example 19 using Resin (6) prepared in Reference Example 8 (200 mg), N-(2-phenylethyl)-4-piperidone (252 mg), 4-amino-1-benzylpiperidine (0.253 ml) and N-(t-butyloxycarbonyl)-N′-(benzyloxycarbonyl)-L-lysine (472 mg), the compound of the present invention (33 mg) having the following physical data was obtained.


TLC: Rf 0.12 (chloroform:methanol=10:1);


MS (ESI, Pos., 20 V): 666 (M+H)+;


HPLC condition: F;


HPLC retention time: 3.36 min;


NMR (CD3OD): δ7.46 (m, 5H), 7.40–7.20 (m, 10H), 5.03 (s, 2H), 4.19 (s, 2H), 3.99 (m, 1H), 3.80–3.40 (m, 6H), 3.30–2.85 (m, 9H), 2.50–2.10 (m, 6H), 1.98 (s, 6H), 1.95–1.60 (m, 4H), 1.60–1.40 (m, 4H).


EXAMPLE 19(5)
(3S)1-(2,2-diphenylpropyl)-2,5-dioxo-3-methyl-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane.acetate



embedded image


By the same procedure as described in Example 19 using Resin (6) prepared in Reference Example 8 (200 mg), N-(2-phenylethyl)-4-piperidone (252 mg), 2,2-diphenylpropylamine (307 mg) and N-(t-butyloxycarbonyl)-L-alanine (235 mg), the compound of the present invention (22 mg) having the following physical data was obtained.


TLC: Rf 0.42 (chloroform:methanol=10:1);


MS (ESI, Pos., 20 V): 496 (M+H)+;


HPLC condition: F;


HPLC retention time: 3.58 min;


NMR (CD3OD): δ 7.40–7.10 (m, 15H), 4.79 (m, 1H), 4.16 (m, 1H), 3.93 (m, 1H), 3.71 (s, 2H), 3.23 (m, 1H), 3.10–2.80 (m, 5H), 1.98 (s, 3H), 1.95–1.82 (m, 2H), 1.70–1.15 (m, 1H), 1.58 (s, 3H), 1.49 (d, J=6.8 Hz, 3H), 0.70 (m, 1H).


EXAMPLE 19(6)
(3S)-1-(2,2-diphenylpropyl)-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane.acetate



embedded image


By the same procedure as described in Example 19 using Resin (6) prepared in Reference Example 8 (200 mg), N-(2-phenylethyl)-4-piperidone (252 mg), 2,2-diphenylpropylamine (307 mg) and N-(t-butyloxycarbonyl)-N′-(benzyloxycarbonyl)-L-lysine (472 mg), the compound of the present invention (18 mg) having the following physical data was obtained. MS (ESI, Pos., 20 V): 687 (M+H)+;


HPLC condition: F;


HPLC retention time: 3.80 min;


TLC: Rf 0.46 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.40–7.00 (m, 20H), 5.06 (s, 2H), 4.16 (m, 1H), 3.93 (m, 1H), 3.70 (s, 2H), 3.55 (m, 1H), 3.30–3.10 (m, 2H), 3.10–2.80 (m, 6H), 1.98 (s, 3H), 1.95–1.85 (m, 2H), 1.80 (s, 3H), 1.70–1.30 (m, 8H).


EXAMPLE 19(7)
(3S)-1-propyl-2,5-dioxo-3-(4-benzyloxyphenylmethyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane.acetate



embedded image


By the same procedure as described in Example 19 using Resin (6) prepared in Reference Example 8 (0.5 g), N-(2-phenylethyl)-4-piperidone (0.32 g), n-propylamine (0.13 ml) and N-(t-butyloxycarbonyl)-O-benzyl-L-tyrosine (0.58 g), the compound of the present invention (68 mg) having the following physical data was obtained.


TLC: Rf 0.51 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.50–7.10 (m, 10H), 7.06 (d, J=8.8 Hz, 2H), 6.92 (d, J=8.8 Hz, 2H), 5.07 (s, 2H), 4.31 (m, 1H), 3.68 (m, 1H), 3.40 (m, 1H), 3.28–3.13 (m, 4H), 3.13–2.80 (m, 6H), 2.30–2.00 (m, 2H), 1.80–1.35 (m, 4H), 0.91 (t, J=7.2 Hz, 3H).


EXAMPLE 19(H1-1)˜19(H13-62)

By the same procedure as described in Example 19 using Resin (6) prepared in Reference Example 8, the corresponding 4-piperidone derivatives, the corresponding amine derivatives and the corresponding amino acid derivatives, the compounds of the present invention, whose names were shown in the following Table 1A-1˜13A-9, and whose structures were shown in the following Table 1B-1˜13B-7, were obtained. Also, physical data of the above compounds were shown in the following Table 1C-1˜13C-3.


In Tables in the present specification,




  • X1 is binding site of R1,

  • X2 is binding site of R2,

  • X3 is binding site of R3,

  • X4 is binding site of R4,

  • X5 is binding site of R5.



For example, the structure of Example 19(H1-1) is shown as follows:




embedded image


Furthermore, the conditions of high performance liquid chromatography (HPLC) in Tables in the present specification, were shown below:


Condition A




  • Column: YMC-Pack FL-ODS, 50×4.6 mm I.D., S-5um, 120A

  • Flow rate: 1 mL/min

  • Eluent

  • Component A: 0.1% trifluoroacetic acid aqueous solution

  • Component B: methanol



The mixture ratio of A and B was fixed in 90/10 for 2 minutes from starting of measurement. The mixture ratio of A and B was linearly changed to 20/80 for 20 minutes. The mixture ratio of A and B was fixed in 20/80 for 5 minutes. The mixture ratio of A and B was linearly changed to 90/10 for 1 minute.


Condition B




  • Column: YMC-Pack FL-ODS, 50×4.6 mm I.D., S-5um, 120A

  • Flow rate: 1 mL/min

  • Eluent

  • Component A: 0.1% trifluoroacetic acid aqueous solution

  • Component B: methanol



The mixture ratio of A and B was fixed in 80/20 for 2 minutes from starting of measurement. The mixture ratio of A and B was linearly changed to 20/80 for 20 minutes. The mixture ratio of A and B was fixed in 20/80 for 5 minutes. The mixture ratio of A and B was linearly changed to 80/20 for 1 minute.


Condition C




  • Column: YMC-Pack FL-ODS, 50×4.6 mm I.D., S-5um, 120A

  • Flow rate: 1 mL/min

  • Eluent

  • Component A: 0.1% trifluoroacetic acid aqueous solution

  • Component B: methanol



The mixture ratio of A and B was fixed in 90/10 for 1 minute from starting of measurement. The mixture ratio of A and B was linearly changed to 10/90 for 16 minutes. The mixture ratio of A and B was fixed in 10/90 for 1 minute. The mixture ratio of A and B was linearly changed to 90/10 for 1 minute.


Condition D




  • Column: YMC-Pack FL-ODS, 50×4.6 mm I.D., S-5um, 120A

  • Flow rate: 1 mL/min

  • Eluent

  • Component A: 0.1% trifluoroacetic acid aqueous solution

  • Component B: methanol



The mixture ratio of A and B was fixed in 90/10 at starting of measurement. The mixture ratio of A and B was linearly changed to 10/90 for 16 minutes. The mixture ratio of A and B was fixed in 10/90 for 0.5 minute. The mixture ratio of A and B was linearly changed to 90/10 for 0.5 minute.


Condition E




  • Column: YMC-Pack FL-ODS, 50×4.6 mm I.D., S-5um, 120A

  • Flow rate: 3 mL/min

  • Eluent

  • Component A: 0.1% trifluoroacetic acid aqueous solution

  • Component B: methanol



The mixture ratio of A and B was fixed in 90/10 at starting of measurement. The mixture ratio of A and B was linearly changed to 10/90 for 5 minutes. The mixture ratio of A and B was fixed in 10/90 for 0.5 minute. The mixture ratio of A and B was linearly changed to 90/10 for 0.1 minute.


Condition F




  • Column: Xterra™ MS C18 5 um, 4.6×50 mm I.D.

  • Flow rate: 3 mL/min

  • Eluent

  • Component A: 0.1% trifluoroacetic acid aqueous solution

  • Component B: 0.1% trifluoroacetic acid-acetonitrile solution



The mixture ratio of A and B was fixed in 95/5 for 0.5 minute from starting of measurement. The mixture ratio of A and B was linearly changed to 0/100 for 2.5 minute. The mixture ratio of A and B was fixed in 0/100 for 0.5 minute. The mixture ratio of A and B was linearly changed to 95/5 for 0.01 minute.










TABLE 1A-1





Example No
Compound Name







19(H1-1)
1-(furan-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-



benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-2)
1-(furan-2-ylmethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-



benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-3)
1-(furan-2-ylmethyl)-2,5-dioxo-3-benzyloxycarbonyl-



methyl-9-benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-4)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-9-benzyl-1,4,9-



triazaspiro[5.5]undecane


19(H1-5)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(2-methyl-



propyl)-9-benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-6)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-phenylmethyl-



9-benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-7)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(indol-3-yl-



methyl)-9-benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-8)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-benzyloxy-



methyl-9-benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-9)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-benzyl-1,4,9-



triazaspiro[5.5]undecane




















TABLE 1A-2





Example No
Compound Name







19(H1-10)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-benzyl-1,4,9-



triazaspiro[5.5]undecane


19(H1-11)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-(2-methylpropyl)-9-



benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-12)
1(2-(indol-3-yl)ethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-



benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-13)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-benzyloxymethyl-9-



benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-14)
1-benzyl-2,5-dioxo-9-benzyl-1,4,9-triaza-



spiro[5.5]undecane


19(H1-15)
1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-benzyl-1,4,9-



triazaspiro[5.5]undecane


19(H1-16)
1-benzyl-2,5-dioxo-3-phenylmethyl-9-benzyl-1,4,9-



triazaspiro[5.5]undecane


19(H1-17)
1-benzyl-2,5-dioxo-3-(indol-3-ylmethyl)-9-benzyl-1,4,9-



triazaspiro[5.5]undecane


19(H1-18)
1-benzyl-2,5-dioxo-3-benzyloxymethyl-9-benzyl-1,4,9-



triazaspiro[5.5]undecane




















TABLE 1A-3





Example No
Compound Name







19(H1-19)
1-benzyl-2,5-dioxo-3-benzyloxycarbonylmethyl-9-benzyl-



1,4,9-triazaspiro[5.5]undecane


19(H1-20)
1-benzyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)butyl)-



9-benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-21)
1-(2,2-diphenylethyl)-2,5-dioxo-9-benzyl-1,4,9-



triazaspiro[5.5]undecane


19(H1-22)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(2-methylpropyl)-9-



benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-23)
1-(2,2-diphenylethyl)-2,5-dioxo-3-phenylmethyl-9-benzyl-



1,4,9-triazaspiro[5.5]undecane


19(H1-24)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-



benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-25)
1-(2,2-diphenylethyl)-2,5-dioxo-3-benzyloxymethyl-9-



benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-26)
1-(2,2-diphenylethyl)-2,5-dioxo-3-benzyloxycarbonyl-



methyl-9-benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-27)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-benzyl-1,4,9-



triazaspiro[5.5]undecane




















TABLE 1A-4





Example No
Compound Name







19(H1-28)
1-(2-phenylethyl)-2,5-dioxo-9-benzyl-1,4,9-



triazaspiro[5.5]undecane


19(H1-29)
1-(2-phenylethyl)-2,5-dioxo-3-(2-methylpropyl)-9-benzyl-



1,4,9-triazaspiro[5.5]undecane


19(H1-30)
1-(2-phenylethyl)-2,5-dioxo-3-phenylmethyl-9-benzyl-



1,4,9-triazaspiro[5.5]undecane


19(H1-31)
1-(2-phenylethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-benzyl-



1,4,9-triazaspiro[5.5 ]undecane


19(H1-32)
1-(2-phenylethyl)-2,5-dioxo-3-benzyloxymethyl-9-benzyl-



1,4,9-triazaspiro[5.5]undecane


19(H1-33)
1-(2-phenylethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-9-



benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-34)
1-(2-phenylethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-benzyl-1,4,9-



triazaspiro[5.5]undecane


19(H1-35)
1-propyl-2,5-dioxo-9-benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-36)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-benzyl-1,4,9-



triazaspiro[5.5]undecane


19(H1-37)
1-propyl-2,5-dioxo-3-phenylmethyl-9-benzyl-1,4,9-



triazaspiro[5.5]undecane




















TABLE 1A-5





Example No
Compound Name







19(H1-38)
1-propyl-2,5-dioxo-3-(indol-3-ylmethyl)-9-benzyl-1,4,9-



triazaspiro[5.5]undecane


19(H1-39)
1-propyl-2,5-dioxo-3-benzyloxymethyl-9-benzyl-1,4,9-



triazaspiro[5.5[undecane


19(H1-40)
1-propyl-2,5-dioxo-3-benzyloxycarbonylmethyl-9-benzyl-



1,4,9-triazaspiro[5.5]undecane


19(H1-41)
1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)butyl)-



9-benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-42)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-9-benzyl-1,4,9-



triazaspiro[5.5]undecane


19(H1-43)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-(2-methyl-



propyl)-9-benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-44)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-phenylmethyl-



9-benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-45)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-(indol-3-yl-



methyl)-9-benzyl-1,4,9-triazaspiro[5.5 ]undecane


19(H1-46)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-benzyloxy-



methyl-9-benzyl-1,4,9-triazaspiro[5.5]undecane




















TABLE 1A-6





Example



No
Compound Name







19(H1-47)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-benzyl-1,4,9-



triazaspiro[5.5]undecane


19(H1-48)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-benzyl-1,4,9-



triazaspiro[5.5]undecane


19(H1-49)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-9-benzyl-1,4,9-



triazaspiro[5.5]undecane


19(H1-50)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(2-methylpropyl)-9-



benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-51)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-phenylmethyl-9-



benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-52)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-



benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-53)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-benzyloxymethyl-9-



benzyl-1,4,9-triazaspiro[5.5]undecane


19(H1-54)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-benzyl-1,4,9-



triazaspiro[5.5]undecane






















TABLE 1A-7







Example




No
Compound Name









19(H1-55)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(4-




benzyloxycarbonylamino)butyl)-9-benzyl-1,4,9-




triazaspiro[5.5]undecane





















TABLE 2A-1





Example



No
Compound Name







19(H2-1)
1-(furan-2-ylmethyl)-2,5-dioxo-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H2-2)
1-(furan-2-ylmethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-3)
1-(furan-2-ylmethyl)-2,5-dioxo-3-benzyloxymethyl-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-4)
1-(furan-2-ylmethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-9-



(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-5)
1-(furan-2-ylmethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H2-6)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


19(H2-7)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-8)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-phenylmethyl-9-



(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 2A-2





Example



No
Compound Name







19(H2-9)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(indol-3-



ylmethyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]



undecane


19(H2-10)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-benzyloxymethyl-



9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-11)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H2-12)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H2-13)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H2-14)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-15)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-phenylmethyl-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-16)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 2A-3





Example



No
Compound Name







19(H2-17)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-benzyloxymethyl-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-18)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-



9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-19)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H2-20)
1-benzyl-2,5-dioxo-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H2-21)
1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


19(H2-22)
1-benzyl-2,5-dioxo-3-phenylmethyl-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H2-23)
1-benzyl-2,5-dioxo-3-(indol-3-ylmethyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


19(H2-24)
1-benzyl-2,5-dioxo-3-benzyloxymethyl-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


19(H2-25)
1-benzyl-2,5-dioxo-3-benzyloxycarbonylmethyl-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 2A-4





Example



No
Compound Name







19(H2-26)
1-benzyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)butyl)-9-



(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-27)
1-(2,2-diphenylethyl)-2,5-dioxo-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H2-28)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-29)
1-(2,2-diphenylethyl)-2,5-dioxo-3-phenylmethyl-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-30)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-31)
1-(2,2-diphenylethyl)-2,5-dioxo-3-benzyloxymethyl-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-32)
1-(2,2-diphenylethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-



9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-33)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H2-34)
1-(2-phenylethyl)-2,5-dioxo-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 2A-5





Example



No
Compound Name







19(H2-35)
1-(2-phenylethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-36)
1-(2-phenylethyl)-2,5-dioxo-3-phenylmethyl-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-37)
1-(2-phenylethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-38)
1-(2-phenylethyl)-2,5-dioxo-3-benzyloxymethyl-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-39)
1-(2-phenylethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-40)
1-(2-phenylethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H2-41)
1-propyl-2,5-dioxo-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H2-42)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


19(H2-43)
1-propyl-2,5-dioxo-3-phenylmethyl-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 2A-6





Example



No
Compound Name







19(H2-44)
1-propyl-2,5-dioxo-3-(indol-3-ylmethyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


19(H2-45)
1-propyl-2,5-dioxo-3-benzyloxymethyl-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


19(H2-46)
1-propyl-2,5-dioxo-3-benzyloxycarbonylmethyl-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-47)
1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)butyl)-9-



(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-48)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


19(H2-49)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-50)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-phenylmethyl-9-



(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-51)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-(indol-3-



ylmethyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]



undecane




















TABLE 2A-7





Example



No
Compound Name







19(H2-52)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-benzyloxymethyl-



9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-53)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H2-54)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H2-55)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H2-56)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(2-methylpropyl)-9-



(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-57)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-phenylmethyl-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-58)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-



(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H2-59)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-benzyloxymethyl-9-



(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 2A-8





Example No
Compound Name







19(H2-60)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H2-61)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 3A-1





Example



No
Compound Name







19(H3-1)
1-(furan-2-ylmethyl)-2,5-dioxo-9-(3-phenylpropyl)-1,4,9-



triazaspiro[5.5]undecane


19(H3-2)
1-(furan-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(3-



phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-3)
1-(furan-2-ylmethyl)-2,5-dioxo-3-benzyl-9-(3-phenylpropyl)-



1,4,9-triazaspiro[5.5]undecane


19(H3-4)
1-(furan-2-ylmethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-(3-



phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-5)
1-(furan-2-ylmethyl)-2,5-dioxo-3-benzyloxymethyl-9-(3-



phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-6)
1-(furan-2-ylmethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-9-



(3-phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-7)
1-(furan-2-ylmethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(3-phenylpropyl)-1,4,9-



triazaspiro[5.5]undecane


19(H3-8)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-9-(3-phenylpropyl)-



1,4,9-triazaspiro[5.5]undecane


19(H3-9)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(3-phenylpropyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 3A-2





Example



No
Compound Name







19(H3-10)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-phenylmethyl-9-



(3-phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-11)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(indol-3-



ylmethyl)-9-(3-phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-12)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-benzyloxymethyl-



9-(3-phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-13)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-(3-phenylpropyl)-1,4,9-



triazaspiro[5.5]undecane


19(H3-14)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(3-phenylpropyl)-1,4,9-



triazaspiro[5.5]undecane


19(H3-15)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-9-(3-phenylpropyl)-1,4,9-



triazaspiro[5.5]undecane


19(H3-16)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(3-



phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-17)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-phenylmethyl-9-(3-



phenylpropyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 3A-3





Example



No
Compound Name







19(H3-18)
1-(2-indol-3-yl)ethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-(3-



phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-19)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-benzyloxymethyl-9-(3-



phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-20)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-



9-(3-phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-21)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(3-phenylpropyl)-1,4,9-



triazaspiro[5.5]undecane


19(H3-22)
1-benzyl-2,5-dioxo-9-(3-phenylpropyl)-1,4,9-



triazaspiro[5.5]undecane


19(H3-23)
1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-phenylpropyl)-



1,4,9-triazaspiro[5.5]undecane


19(H3-24)
1-benzyl-2,5-dioxo-3-phenylmethyl-9-(3-phenylpropyl)-1,4,9-



triazaspiro[5.5]undecane


19(H3-25)
1-benzyl-2,5-dioxo-3-(indol-3-ylmethyl)-9-(3-phenylpropyl)-



1,4,9-triazaspiro[5.5]undecane




















TABLE 3A-4





Example



No
Compound Name







19(H3-26)
1-benzyl-2,5-dioxo-3-benzyloxymethyl-9-(3-phenylpropyl)-



1,4,9-triazaspiro[5.5]undecane


19(H3-27)
1-benzyl-2,5-dioxo-3-benzyloxycarbonylmethyl-9-(3-



phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-28)
1-benzyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)butyl)-9-



(3-phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-29)
1-(2,2-diphenylethyl)-2,5-dioxo-9-(3-phenylpropyl)-1,4,9-



triazaspiro[5.5]undecane


19(H3-30)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(3-



phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-31)
1-(2,2-diphenylethl)-2,5-dioxo-3-phenylmethyl-9-(3-



phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-32)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-(3-



phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-33)
1-(2,2-diphenylethyl)-2,5-dioxo-3-benzyloxymethyl-9-(3-



phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-34)
1-(2,2-diphenylethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-



9-(3-phenylpropyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 3A-5





Example



No
Compound Name







19(H3-35)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(3-phenylpropyl)-1,4,9-



triazaspiro[5.5]undecane


19(H3-36)
1-(2-phenylethyl)-2,5-dioxo-9-(3-phenylpropyl)-1,4,9-



triazaspiro[5.5]undecane


19(H3-37)
1-(2-phenylethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(3-



phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-38)
1-(2-phenylethyl)-2,5-dioxo-3-phenylmethyl-9-(3-



phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-39)
1-(2-phenylethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-(3-



phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-40)
1-(2-phenylethyl)-2,5-dioxo-3-benzyloxymethyl-9-(3-



phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-41)
1-(2-phenylethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-9-(3-



phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-42)
1-(2-phenylethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(3-phenylpropyl)-1,4,9-



triazaspiro[5.5]undecane


19(H3-43)
1-propyl-2,5-dioxo-9-(3-phenylpropyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 3A-6





Example



No
Compound Name







19(H3-44)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-phenylpropyl)-



1,4,9-triazaspiro[5.5]undecane


19(H3-45)
1-propyl-2,5-dioxo-3-phenylmethyl-9-(3-phenylpropyl)-1,4,9-



triazaspiro[5.5]undecane


19(H3-46)
1-propyl-2,5-dioxo-3-(indol-3-ylmethyl)-9-(3-phenylpropyl)-



1,4,9-triazaspiro[5.5]undecane


19(H3-47)
1-propyl-2,5-dioxo-3-benzyloxymethyl-9-(3-phenylpropyl)-



1,4,9-triazaspiro[5.5]undecane


19(H3-48)
1-propyl-2,5-dioxo-3-benzyloxycarbonylmethyl-9-(3-



phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-49)
1-propyl-2,5-dioxo-3-(4-benzyloxycarbonylamino)butyl)-9-(3-



phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-50)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-9-(3-phenylpropyl)-



1,4,9-triazaspiro[5.5]undecane


19(H3-51)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(3-phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-52)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-phenylmethyl-9-



(3-phenylpropyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 3A-7





Example



No
Compound Name







19(H3-53)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-(indol-3-



ylmethyl)-9-(3-phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-54)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-



benzyloxymethyl-9-(3-phenylpropyl)-1,4,9-



triazaspiro[5.5]undecane


19(H3-55)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-(3-phenylpropyl)-1,4,9-



triazaspiro[5.5]undecane


19(H3-56)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(3-phenylpropyl)-1,4,9-



triazaspiro[5.5]undecane


19(H3-57)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-9-(3-



phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-58)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(2-



methylpropyl)-9-(3-phenylpropyl)-1,4,9-



triazaspiro[5.5]undecane


19(H3-59)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-phenylmethyl-9-(3-



phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-60)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(indol-3-



ylmethyl)-9-(3-phenylpropyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 3A-8





Example



No
Compound Name







19(H3-61)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-benzyloxymethyl-



9-(3-phenylpropyl)-1,4,9-triazaspiro[5.5]undecane


19(H3-62)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-(3-phenylpropyl)-1,4,9-



triazaspiro[5.5]undecane


19(H3-63)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(3-phenylpropyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 4A-1





Example



No
Compound Name







19(H4-1)
1-(furan-2-ylmethyl)-2,5-dioxo-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H4-2)
1-(furan-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-3)
1-(furan-2-ylmethyl)-2,5-dioxo-3-benzyl-9-(4-phenylbutyl)-



1,4,9-triazaspiro[5.5]undecane


19(H4-4)
1-(furan-2-ylmethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-5)
1-(furan-2-ylmethyl)-2,5-dioxo-3-benzyloxymethyl-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-6)
1-(furan-2-ylmethyl)-2,5-



dioxo-3-benzyloxycarbonylmethyl-



9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-7)
1-(furan-2-ylmethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H4-8)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-9)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 4A-2





Example



No
Compound Name







19(H4-10)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-phenylmethyl-9-



(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-11)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(indol-3-



ylmethyl)-9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-12)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-benzyloxymethyl-



9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-13)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H4-14)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H4-15)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H4-16)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-17)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-phenylmethyl-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 4A-3





Example



No
Compound Name







19(H4-18)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-19)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-benzyloxymethyl-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-20)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-



9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-21)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H4-22)
1-benzyl-2,5-dioxo-9-(4-phenylbutyl)-1,4, 9-



triazaspiro[5.5]undecane


19(H4-23)
1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenylbutyl)-



1,4,9-triazaspiro[5.5]undecane


19(H4-24)
1-benzyl-2,5-dioxo-3-phenylmethyl-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H4-25)
1-benzyl-2,5-dioxo-3-(indol-3-ylmethyl)-9-(4-phenylbutyl)-



1,4,9-triazaspiro[5.5]undecane


19(H4-26)
1-benzyl-2,5-dioxo-3-benzyloxymethyl-9-(4-phenylbutyl)-



1,4,9-triazaspiro[5.5]undecane




















TABLE 4A-4





Example



No
Compound Name







19(H4-27)
1-benzyl-2,5-dioxo-3-benzyloxycarbonylmethyl-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-28)
1-benzyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)butyl)-9-



(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-29)
1-(2,2-diphenylethyl)-2,5-dioxo-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H4-30)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-31)
1-(2,2-diphenylethyl)-2,5-dioxo-3-phenylmethyl-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-32)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-33)
1-(2,2-diphenylethyl)-2,5-dioxo-3-benzyloxymethyl-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-34)
1-(2,2-diphenylethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-



9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-35)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 4A-5





Example



No
Compound Name







19(H4-36)
1-(2-phenylethyl)-2,5-dioxo-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H4-37)
1-(2-phenylethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-38)
1-(2-phenylethyl)-2,5-dioxo-3-phenylmethyl-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-39)
1-(2-phenylethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-40)
1-(2-phenylethyl)-2,5-dioxo-3-benzyloxymethyl-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-41)
1-(2-phenylethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-42)
1-(2-phenylethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H4-43)
1-propyl-2,5-dioxo-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H4-44)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenylbutyl)-



1,4,9-triazaspiro[5.5]undecane




















TABLE 4A-6





Example



No
Compound Name







19(H4-45)
1-propyl-2,5-dioxo-3-phenylmethyl-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H4-46)
1-propyl-2,5-dioxo-3-(indol-3-ylmethyl)-9-(4-phenylbutyl)-



1,4,9-triazaspiro[5.5]undecane


19(H4-47)
1-propyl-2,5-dioxo-3-benzyloxymethyl-9-(4-phenylbutyl)-



1,4,9-triazaspiro[5.5]undecane


19(H4-48)
1-propyl-2,5-dioxo-3-benzyloxycarbonylmethyl-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-49)
1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)butyl)-9-



(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-50)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-9-(4-phenylbutyl)-



1,4,9-triazaspiro[5.5]undecane


19(H4-51)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-52)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-phenylmethyl-9-



(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-53)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-(indol-3-



ylmethyl)-9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 4A-7





Example



No
Compound Name







19(H4-54)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-benzyloxymethyl-



9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-55)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H4-56)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H4-57)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H4-58)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(2-methylpropyl)-9-



(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-59)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-phenylmethyl-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-60)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-



(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H4-61)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-benzyloxymethyl-



9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 4A-8





Example



No
Compound Name







19(H4-62)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H4-63)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 5A-1





Example



No
Compound Name







19(H5-1)
1-(furan-2-ylmethyl)-2,5-dioxo-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-2)
1-(furan-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-phenyl-



1,4,9-triazaspiro[5.5]undecane


19(H5-3)
1-(furan-2-ylmethyl)-2,5-dioxo-3-benzyl-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-4)
1-(furan-2-ylmethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-phenyl-



1,4,9-triazaspiro[5.5]undecane


19(H5-5)
1-(furan-2-ylmethyl)-2,5-dioxo-3-benzyloxymethyl-9-phenyl-



1,4,9-triazaspiro[5.5]undecane


19(H5-6)
1-(furan-2-ylmethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-9-



phenyl-1,4,9-triazaspiro[5.5]undecane


19(H5-7)
1-(furan-2-ylmethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-8)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-9)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-



9-phenyl-1,4,9-triazaspiro[5.5]undecane




















TABLE 5A-2





Example



No
Compound Name







19(H5-10)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-phenylmethyl-9-



phenyl-1,4,9-triazaspiro[5.5]undecane


19(H5-11)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(indol-3-



ylmethyl)-9-phenyl-1,4,9-triazaspiro[5.5]undecane


19(H5-12)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-benzyloxymethyl-



9-phenyl-1,4,9-triazaspiro[5.5]undecane


19(H5-13)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-14)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-15)
1-(2-(indol-3-yl) ethyl)-2,5-dioxo-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-16)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-(2-methylpropyl)-9-



phenyl-1,4,9-triazaspiro[5.5]undecane


19(H5-17)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-phenylmethyl-9-phenyl-



1,4,9-triazaspiro[5.5]undecane


19(H5-18)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-



phenyl-1,4,9-triazaspiro[5.5]undecane




















TABLE 5A-3





Example



No
Compound Name







19(H5-19)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-benzyloxymethyl-9-



phenyl-1,4,9-triazaspiro[5.5]undecane


19(H5-20)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-



9-phenyl-1,4,9-triazaspiro[5.5]undecane


19(H5-21)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-22)
1-benzyl-2,5-dioxo-9-phenyl-1,4,9-triazaspiro[5.5]undecane


19(H5-23)
1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-24)
1-benzyl-2,5-dioxo-3-phenylmethyl-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-25)
1-benzyl-2,5-dioxo-3-(indol-3-ylmethyl)-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-26)
1-benzyl-2,5-dioxo-3-benzyloxymethyl-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-27)
1-benzyl-2,5-dioxo-3-benzyloxycarbonylmethyl-9-phenyl-



1,4,9-triazaspiro[5.5]undecane




















TABLE 5A-4





Example



No
Compound Name







19(H5-28)
1-benzyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)butyl)-9-



phenyl-1,4,9-triazaspiro[5.5]undecane


19(H5-29)
1-(2,2-diphenylethyl)-2,5-dioxo-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-30)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(2-methylpropyl)-9-phenyl-



1,4,9-triazaspiro[5.5]undecane


19(H5-31)
1-(2,2-diphenylethyl)-2,5-dioxo-3-phenylmethyl-9-phenyl-



1,4,9-triazaspiro[5.5]undecane


19(H5-32)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-



phenyl-1,4,9-triazaspiro[5.5]undecane


19(H5-33)
1-(2,2-diphenylethyl)-2,5-dioxo-3-benzyloxymethyl-9-phenyl-



1,4,9-triazaspiro[5.5]undecane


19(H5-34)
1-(2,2-diphenylethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-



9-phenyl-1,4,9-triazaspiro[5.5]undecane


19(H5-35)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-36)
1-(2-phenylethyl)-2,5-dioxo-9-phenyl-1,4,9-



triazaspiro[5.5]undecane




















TABLE 5A-5





Example



No
Compound Name







19(H5-37)
1-(2-phenylethyl)-2,5-dioxo-3-(2-methylpropyl)-9-phenyl-



1,4,9-triazaspiro[5.5]undecane


19(H5-38)
1-(2-phenylethyl)-2,5-dioxo-3-phenylmethyl-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-39)
1-(2-phenylethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-phenyl-



1,4,9-triazaspiro[5.5]undecane


19(H5-40)
1-(2-phenylethyl)-2,5-dioxo-3-benzyloxymethyl-9-phenyl-



1,4,9-triazaspiro[5.5]undecane


19(H5-41)
1-(2-phenylethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-9-



phenyl-1,4,9-triazaspiro[5.5]undecane


19(H5-42)
1-(2-phenylethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-43)
1-propyl-2,5-dioxo-9-phenyl-1,4,9-triazaspiro[5.5]undecane


19(H5-44)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-45)
1-propyl-2,5-dioxo-3-phenylmethyl-9-phenyl-1,4,9-



triazaspiro[5.5]undecane




















TABLE 5A-6





Example



No
Compound Name







19(H5-46)
1-propyl-2,5-dioxo-3-(indol-3-ylmethyl)-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-47)
1-propyl-2,5-dioxo-3-benzyloxymethyl-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-48)
1-propyl-2,5-dioxo-3-benzyloxycarbonylmethyl-9-phenyl-



1,4,9-triazaspiro[5.5]undecane


19(H5-49)
1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)butyl)-9-



phenyl-1,4,9-triazaspiro[5.5]undecane


19(H5-50)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-51)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-(2-methylpropyl)-



9-phenyl-1,4,9-triazaspiro[5.5]undecane


19(H5-52)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-phenylmethyl-9-



phenyl-1,4,9-triazaspiro[5.5]undecane


19(H5-53)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-



(indol-3-ylmethyl)-9-phenyl-1,4,9-triazaspiro[5.5]undecane


19(H5-54)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-benzyloxymethyl-



9-phenyl-1,4,9-triazaspiro[5.5]undecane




















TABLE 5A-7





Example



No
Compound Name







19(H5-55)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-56)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-57)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(2-methylpropyl)-9-



phenyl-1,4,9-triazaspiro[5.5]undecane


19(H5-58)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-phenylmethyl-9-



phenyl-1,4,9-triazaspiro[5.5]undecane


19(H5-59)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-



phenyl-1,4,9-triazaspiro[5.5]undecane


19(H5-60)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-benzyloxymethyl-9-



phenyl-1,4,9-triazaspiro[5.5]undecane


19(H5-61)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-phenyl-1,4,9-



triazaspiro[5.5]undecane


19(H5-62)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-phenyl-1,4,9-



triazaspiro[5.5]undecane




















TABLE 6A-1





Example



No
Compound Name







19(H6-1)
1-(furan-2-ylmethyl)-2,5-dioxo-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H6-2)
1-(furan-2-ylmethyl)-2,5-dioxo-3-benzyloxymethyl-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-3)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-9-(5-phenylpentyl)-



1,4,9-triazaspiro[5.5]undecane


19(H6-4)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-5)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-phenylmethyl-9-



(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-6)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(indol-3-



ylmethyl)-9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-7)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-benzyloxymethyl-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-8)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 6A-2





Example



No
Compound Name







19(H6-9)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H6-10)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H6-11)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-12)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-phenylmethyl-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-13)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-14)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-benzyloxymethyl-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-15)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-16)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 6A-3





Example



No
Compound Name







19(H6-17)
1-benzyl-2,5-dioxo-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H6-18)
1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-phenylpentyl)-



1,4,9-triazaspiro[5.5]undecane


19(H6-19)
1-benzyl-2,5-dioxo-3-phenylmethyl-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H6-20)
1-benzyl-2,5-dioxo-3-indol-3-ylmethyl)-9-(5-phenylpentyl)-



1,4,9-triazaspiro[5.5]undecane


19(H6-21)
1-benzyl-2,5-dioxo-3-benzyloxymethyl-9-(5-phenylpentyl)-



1,4,9-triazaspiro[5.5]undecane


19(H6-22)
1-benzyl-2,5-dioxo-3-benzyloxycarbonylmethyl-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-23)
1-benzyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)butyl)-9-



(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-24)
1-(2,2-diphenylethyl)-2,5-dioxo-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H6-25)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 6A-4





Example



No
Compound Name







19(H6-26)
1-(2,2-diphenylethyl)-2,5-dioxo-3-phenylmethyl-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-27)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-28)
1-(2,2-diphenylethyl)-2,5-dioxo-3-benzyloxymethyl-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-29)
1-(2,2-diphenylethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-30)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H6-31)
1-(2-phenylethyl)-2,5-dioxo-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H6-32)
(1-(2-phenylethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-33)
1-(2-phenylethyl)-2,5-dioxo-3-phenylmethyl-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 6A-5





Example



No
Compound Name







19(H6-34)
1-(2-phenylethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-35)
1-(2-phenylethyl)-2,5-dioxo-3-benzyloxymethyl-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-36)
1-(2-phenylethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-37)
1-(2-phenylethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H6-38)
1-propyl-2,5-dioxo-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H6-39)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-phenylpentyl)-



1,4,9-triazaspiro[5.5]undecane


19(H6-40)
1-propyl-2,5-dioxo-3-phenylmethyl-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H6-41)
1-propyl-2,5-dioxo-3-(indol-3-ylmethyl)-9-(5-phenylpentyl)-



1,4,9-triazaspiro[5.5]undecane


19(H6-42)
1-propyl-2,5-dioxo-3-benzyloxymethyl-9-(5-phenylpentyl)-



1,4,9-triazaspiro[5.5]undecane




















TABLE 6A-6





Example



No
Compound Name







19(H6-43)
1-propyl-2,5-dioxo-3-benzyloxycarbonylmethyl-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-44)
1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)butyl)-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-45)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-9-(5-phenylpentyl)-



1,4,9-triazaspiro[5.5]undecane


19(H6-46)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-47)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-phenylmethyl-9-



(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-48)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-(indol-3-



ylmethyl)-9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-49)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-benzyloxymethyl-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-50)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 6A-7





Example



No
Compound Name







19(H6-51)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H6-52)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-9-(5-phenylpentyl)-



1,4,9-triazaspiro[5.5]undecane


19(H6-53)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(2-methylpropyl)-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-54)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-phenylmethyl-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-55)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(indol-3-ylmethyl)-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-56)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-benzyloxymethyl-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H6-57)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H6-58)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 7A-1





Example



No
Compound Name







19(H7-1)
1-(furan-2-ylmethyl)-2,5-dioxo-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H7-2)
1-(furan-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-3)
1-(furan-2-ylmethyl)-2,5-dioxo-3-benzyl-9-(6-phenylhexyl)-



1,4,9-triazaspiro[5.5]undecane


19(H7-4)
1-(furan-2-ylmethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-5)
1-(furan-2-ylmethyl)-2,5-dioxo-3-benzyloxymethyl-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-6)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-9-(6-phenylhexyl)-



1,4,9-triazaspiro[5.5]undecane


19(H7-7)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-8)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-phenylmethyl-9-



(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-9)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(indol-3-



ylmethyl)-9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 7A-2





Example



No
Compound Name







19(H7-10)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-benzyloxymethyl-



9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-11)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H7-12)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H7-13)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H7-14)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-15)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-phenylmethyl-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-16)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-17)
1-(2-(indol-3-yl) ethyl)-2,5-dioxo-3-benzyloxymethyl-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 7A-3





Example



No
Compound Name







19(H7-18)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-



9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-19)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H7-20)
1-benzyl-2,5-dioxo-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H7-21)
1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-(6-phenylhexyl)-



1,4,9-triazaspiro[5.5]undecane


19(H7-22)
1-benzyl-2,5-dioxo-3-phenylmethyl-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H7-23)
1-benzyl-2,5-dioxo-3-(indol-3-ylmethyl)-9-(6-phenylhexyl)-



1,4,9-triazaspiro[5.5]undecane


19(H7-24)
1-benzyl-2,5-dioxo-3-benzyloxymethyl-9-(6-phenylhexyl)-



1,4,9-triazaspiro[5.5]undecane


19(H7-25)
1-benzyl-2,5-dioxo-3-benzyloxycarbonylmethyl-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-26)
1-benzyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)butyl)-9-



(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 7A-4





Example



No
Compound Name







19(H7-27)
1-(2,2-diphenylethyl)-2,5-dioxo-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H7-28)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-29)
1-(2,2-diphenylethyl)-2,5-dioxo-3-phenylmethyl-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-30)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-31)
1-(2,2-diphenylethyl)-2,5-dioxo-3-benzyloxymethyl-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-32)
1-(2,2-diphenylethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-



9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-33)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H7-34)
1-(2-phenylethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 7A-5





Example



No
Compound Name







19(H7-35)
1-(2-phenylethyl)-2,5-dioxo-3-phenylmethyl-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-36)
1-(2-phenylethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-37)
1-(2-phenylethyl)-2,5-dioxo-3-benzyloxymethyl-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-38)
1-(2-phenylethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-39)
1-(2-phenylethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H7-40)
1-propyl-2,5-dioxo-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H7-41)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(6-phenylhexyl)-



1,4,9-triazaspiro[5.5]undecane


19(H7-42)
1-propyl-2,5-dioxo-3-phenylmethyl-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H7-43)
1-propyl-2,5-dioxo-3-(indol-3-ylmethyl)-9-(6-phenylhexyl)-



1,4,9-triazaspiro[5.5]undecane




















TABLE 7A-6





Example



No
Compound Name







19(H7-44)
1-propyl-2,5-dioxo-3-benzyloxymethyl-9-(6-phenylhexyl)-



1,4,9-triazaspiro[5.5]undecane


19(H7-45)
1-propyl-2,5-dioxo-3-benzyloxycarbonylmethyl-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-46)
1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)butyl)-



9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-47)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-9-(6-phenylhexyl)-



1,4,9-triazaspiro[5.5]undecane


19(H7-48)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-49)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-phenylmethyl-9-



(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-50)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-(indol-3-



ylmethyl)-9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-51)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-benzyloxymethyl-



9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 7A-7





Example



No
Compound Name







19(H7-52)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H7-53)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H7-54)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-9-(6-phenylhexyl)-



1,4,9-triazaspiro[5.5]undecane


19(H7-55)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(2-methylpropyl)-



9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-56)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-phenylmethyl-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-57)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(indol-3-ylmethyl)-



9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-58)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-benzyloxymethyl-



9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H7-59)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 7A-8





Example



No
Compound Name







19(H7-60)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 8A-1





Example



No
Compound Name







19(H8-1)
1-(furan-2-ylmethyl)-2,5-dioxo-3-benzyl-9-methyl-1,4,9-



triazaspiro[5.5]undecane


19(H8-2)
1-(furan-2-ylmethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-



methyl-1,4,9-triazaspiro[5.5]undecane


19(H8-3)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-9-methyl-1,4,9-



triazaspiro[5.5]undecane


19(H8-4)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-



9-methyl-1,4,9-triazaspiro[5.5]undecane


19(H8-5)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-phenylmethyl-9-



methyl-1,4,9-triazaspiro[5.5]undecane


19(H8-6)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(indol-3-



ylmethyl)-9-methyl-1,4,9-triazaspiro[5.5]undecane


19(H8-7)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-benzyloxymethyl-



9-methyl-1,4,9-triazaspiro[5.5]undecane


19(H8-8)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-methyl-1,4,9-



triazaspiro[5.5]undecane


19(H8-9)
1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-methyl-1,4,9-



triazaspiro[5.5]undecane




















TABLE 8A-2





Example



No
Compound Name







19(H8-10)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-9-methyl-1,4,9-



triazaspiro[5.5]undecane


19(H8-11)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-(2-methylpropyl)-9-



methyl-1,4,9-triazaspiro[5.5]undecane


19(H8-12)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-phenylmethyl-9-methyl-



1,4,9-triazaspiro[5.5]undecane


19(H8-13)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-



methyl-1,4,9-triazaspiro[5.5]undecane


19(H8-14)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-benzyloxymethyl-9-



methyl-1,4,9-triazaspiro[5.5]undecane


19(H8-15)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-



9-methyl-1,4,9-triazaspiro[5.5]undecane


19(H8-16)
1-(2-(indol-3-yl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-methyl-1,4,9-



triazaspiro[5.5]undecane


19(H8-17)
1-benzyl-2,5-dioxo-9-methyl-1,4,9-triazaspiro[5.5]undecane


19(H8-18)
1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-methyl-1,4,9-



triazaspiro[5.5]undecane




















TABLE 8A-3





Example



No
Compound Name







19(H8-19)
1-benzyl-2,5-dioxo-3-phenylmethyl-9-methyl-1,4,9-



triazaspiro[5.5]undecane


19(H8-20)
1-benzyl-2,5-dioxo-3-(indol-3-ylmethyl)-9-methyl-1,4,9-



triazaspiro[5.5]undecane


19(H8-21)
1-benzyl-2,5-dioxo-3-benzyloxymethyl-9-methyl-1,4,9-



triazaspiro[5.5]undecane


19(H8-22)
1-benzyl-2,5-dioxo-3-benzyloxycarbonylmethyl-9-methyl-



1,4,9-triazaspiro[5.5]undecane


19(H8-23)
1-benzyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)butyl)-9-



methyl-1,4,9-triazaspiro[5.5]undecane


19(H8-24)
1-(2,2-diphenylethyl)-2,5-dioxo-9-methyl-1,4,9-



triazaspiro[5.5]undecane


19(H8-25)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(2-methylpropyl)-9-methyl-



1,4,9-triazaspiro[5.5]undecane


19(H8-26)
1-(2,2-diphenylethyl)-2,5-dioxo-3-phenylmethyl-9-methyl-



1,4,9-triazaspiro[5.5]undecane


19(H8-27)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-



methyl-1,4,9-triazaspiro[5.5]undecane




















TABLE 8A-4





Example



No
Compound Name







19(H8-28)
1-(2,2-diphenylethyl)-2,5-dioxo-3-benzyloxymethyl-9-methyl-



1,4,9-triazaspiro[5.5]undecane


19(H8-29)
1-(2,2-diphenylethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-



9-methyl-1,4,9-triazaspiro[5.5]undecane


19(H8-30)
1-(2,2-diphenylethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-methyl-1,4,9-



triazaspiro[5.5]undecane


19(H8-31)
1-(2-phenylethyl)-2,5-dioxo-9-methyl-1,4,9-



triazaspiro[5.5]undecane


19(H8-32)
1-(2-phenylethyl)-2,5-dioxo-3-(2-methylpropyl)-9-methyl-



1,4,9-triazaspiro[5.5]undecane


19(H8-33)
1-(2-phenylethyl)-2,5-dioxo-3-phenylmethyl-9-methyl-1,4,9-



triazaspiro[5.5]undecane


19(H8-34)
1-(2-phenylethyl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-methyl-



1,4,9-triazaspiro[5.5]undecane


19(H8-35)
1-(2-phenylethyl)-2,5-dioxo-3-benzyloxymethyl-9-methyl-



1,4,9-triazaspiro[5.5]undecane


19(H8-36)
1-(2-phenylethyl)-2,5-dioxo-3-benzyloxycarbonylmethyl-9-



methyl-1,4,9-triazaspiro[5.5]undecane




















TABLE 8A-5





Example



No
Compound Name







19(H8-37)
1-(2-phenylethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-methyl-1,4,9-



triazaspiro[5.5]undecane


19(H8-38)
1-propyl-2,5-dioxo-9-methyl-1,4,9-triazaspiro[5.5]undecane


19(H8-39)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-methyl-1,4,9-



triazaspiro[5.5]undecane


19(H8-40)
1-propyl-2,5-dioxo-3-phenylmethyl-9-methyl-1,4,9-



triazaspiro[5.5]undecane


19(H8-41)
1-propyl-2,5-dioxo-3-(indol-3-ylmethyl)-9-methyl-1,4,9-



triazaspiro[5.5]undecane


19(H8-42)
1-propyl-2,5-dioxo-3-benzyloxymethyl-9-methyl-1,4,9-



triazaspiro[5.5]undecane


19(H8-43)
1-propyl-2,5-dioxo-3-benzyloxycarbonylmethyl-9-methyl-



1,4,9-triazaspiro[5.5]undecane


19(H8-44)
1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)butyl)-9-



methyl-1,4,9-triazaspiro[5.5]undecane


19(H8-45)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-9-methyl-1,4,9-



triazaspiro[5.5]undecane




















TABLE 8A-6





Example



No
Compound Name







19(H8-46)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-phenylmethyl-9-



methyl-1,4,9-triazaspiro[5.5]undecane


19(H8-47)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-(indol-3-



ylmethyl)-9-methyl-1,4,9-triazaspiro[5.5]undecane


19(H8-48)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-benzyloxymethyl-



9-methyl-1,4,9-triazaspiro[5.5]undecane


19(H8-49)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-methyl-1,4,9-



triazaspiro[5.5]undecane


19(H8-50)
1-(2-(t-butyloxycarbonyl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-methyl-1,4,9-



triazaspiro[5.5]undecane


19(H8-51)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-9-methyl-1,4,9-



triazaspiro[5.5]undecane


19(H8-52)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(2-methylpropyl)-9-



methyl-1,4,9-triazaspiro[5.5]undecane


19(H8-53)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-phenylmethyl-9-



methyl-1,4,9-triazaspiro[5.5]undecane


19(H8-54)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(indol-3-ylmethyl)-9-



methyl-1,4,9-triazaspiro[5.5]undecane




















TABLE 8A-7





Example



No
Compound Name







19(H8-55)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-benzyloxymethyl-9-



methyl-1,4,9-triazaspiro[5.5]undecane


19(H8-56)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-



benzyloxycarbonylmethyl-9-methyl-1,4,9-



triazaspiro[5.5]undecane


19(H8-57)
1-(1-benzylpyrrolidin-3-yl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-methyl-1,4,9-



triazaspiro[5.5]undecane




















TABLE 9A-1





Example



No
Compound Name







19(H9-1)
(3S)-1-cyclopropyl-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-2)
(3S)-1-cyclobutyl-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-3)
(3S)-1-((1S,2S,5S)-6,6-dimethylbicyclo[3.1.1]heptan-2-



ylmethyl)-2,5-dioxo-3-(4-(benzyloxycarbonylamino)butyl)-9-



(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H9-4)
(3S)-1-cyclopentyl-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-5)
(3S)-1-cyclohexyl-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-6)
(3S)-1-(cyclohexylmethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-7)
(3S)-1-(2-(1-methylpyrrolidin-2-yl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 9A-2





Example



No
Compound Name







19(H9-8)
(3S)-1-((1-ethylpyrrolidin-2-yl)methyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-9)
(3S)-1-(indan-5-yl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-10)
(3S)-1-cycloheptyl-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-11)
(3S)-1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-12)
(3S)-1-(2-(morpholin-4-yl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-13)
(3S)-1-(3-(morpholin-4-yl)propyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-14)
(3S)-1-(2-(pyridin-2-yl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 9A-3





Example



No
Compound Name







19(H9-15)
(3S)-1-(pyridin-3-ylmethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-16)
(3S)-1-(pyridin-4-ylmethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-17)
(3S)-1-(1-(ethoxycarbonyl)piperidin-4-yl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-18)
(3S)-1-(2-(piperidin-1-yl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-19)
(3S)-1-(1-phenylethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-20)
(3S)-1-(1-methylethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-21)
(3S)-1-(1,3-dimethylbutyl)-2,5-dioxo-3-(4



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 9A-4





Example



No
Compound Name







19(H9-22)
(3S)-1-(1-methyl-3-phenylpropyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-23)
(3S)-1-(1-methylpropyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-24)
(3S)-1-(1-methylbutyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-25)
(3S)-1-((2-fluorophenyl)methyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-26)
(3S)-1-((2-methoxyphenyl)methyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-27)
(3S)-1-((3-fluorophenyl)methyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-28)
(3S)-1-((3-methoxyphenyl)methyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 9A-5





Example



No
Compound Name







19(H9-29)
(3S)-1-((4-fluorophenyl)methyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-30)
(3S)-1-((4-methoxyphenyl)methyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-31)
(3S)-1-((4-methylphenyl)methyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-32)
(3S)-1-(2,2-dimethylpropyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-33)
(3S)-1-(2-phenylpropyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-34)
(3S)-1-(2-methylpropyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-35)
(3S)-1-(2-methylbutyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 9A-6





Example



No
Compound Name







19(H9-36)
(3S)-1-benzyl-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-37)
(3S)-1-(2-(N,N-dimethylamino)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-38)
(3S)-1-(2-methoxyethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-39)
(3S)-1-(2-propynyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-40)
(3S)-1-(2-propenyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-41)
(3S)-1-(3-hydroxypropyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-42)
(3S)-1-(3-methylbutyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 9A-7





Example



No
Compound Name







19(H9-43)
(3S)-1-propyl-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-



9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H9-44)
(3S)-1-(3-(N,N-dimethylamino)propyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-45)
(3S)-1-(3-ethoxypropyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-46)
(3S)-1-(3-phenylpropyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-47)
(3S)-1-(4-phenylbutyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-48)
(3S)-1-pentyl-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-



9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H9-49)
(3S)-1-(3-(imidazol-1-yl)propyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 9A-8





Example



No
Compound Name







19(H9-50)
(3S)-1-butyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)butyl)-



9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H9-51)
(3S)-1-(2-(1-cyclohexenyl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-52)
(3S)-1-(cyclopropylmethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-53)
(3S)-1-ethyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)butyl)-



9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H9-54)
(3S)-1-(3-methoxypropyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-55)
(3S)-1-(2-(pyridin-4-yl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-56)
(3S)-1-((3-chlorophenyl)methyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 9A-9





Example



No
Compound Name







19(H9-57)
(3S)-1-(3-methylthiopropyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-58)
(3S)-1-(2-(thiophen-2-yl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-59)
(3S)-1-(2-(1,1-dimethylethylthio)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-60)
(3S)-1-((t-butoxycarbonyl)methyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-61)
(3S)-1-((5-methylfuran-2-yl)methyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H9-62)
(3S)-1-(2-(pyridin-3-yl)ethyl)-2,5-dioxo-3-(4-



(benzyloxycarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 10A-1





Example



No
Compound Name







19(H10-1)
(3S)-1-cyclopropyl-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-2)
(3S)-1-cyclobutyl-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-3)
(3S)-1-((1S,2S,5S)-6,6-dimethylbicyclo[3.1.1]heptan-2-



ylmethyl)-2,5-dioxo-3-(3-(benzyloxycarbonylamino)propyl)-9-



(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H10-4)
(3S)-1-cyclopentyl-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-5)
(3S)-1-cyclohexyl-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-6)
(3S)-1-(cyclohexylmethyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-7)
(3S)-1-cyclooctyl-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 10A-2





Example



No
Compound Name







19(H10-8)
(3S)-1-(2-(1-methylpyrrolidin-2-yl)ethyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-9)
(3S)-1-((1-ethylpyrrolidin-2-yl)methyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-10)
(3S)-1-(indan-5-yl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-11)
(3S)-1-cycloheptyl-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-12)
(3S)-1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-13)
(3S)-1-(2-(morpholin-4-yl)ethyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-14)
(3S)-1-(3-(morpholin-4-yl)propyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 10A-3





Example



No
Compound Name







19(H10-15)
(3S)-1-(2-(pyridin-2-yl)ethyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-16)
(3S)-1-(pyridin-3-ylmethyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-17)
(3S)-1-(pyridin-4-ylmethyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-18)
(3S)-1-(1-(ethoxycarbonyl)piperidin-4-yl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-19)
(3S)-1-(2-(piperidin-1-yl)ethyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-20)
(3S)-1-phenyl-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-21)
(3S)-1-(1-phenylethyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 10A-4





Example



No
Compound Name







19(H10-22)
(3S)-1-(1-methylethyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-23)
(3S)-1-(1,3-dimethylbutyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-24)
(3S)-1-(1-methyl-3-phenylpropyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamnio)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-25)
(3S)-1-(1-methylpropyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-26)
(3S)-1-(1-ethylpropyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-27)
(3S)-1-(1-methylbutyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-28)
(3S)-1-((2-fluorophenyl)methyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 10A-5





Example



No
Compound Name







19(H10-29)
(3S)-1-((2-methoxyphenyl)methyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-30)
(3S)-1-((3-fluorophenyl)methyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-31)
(3S)-1-((3-methoxyphenyl)methyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-32)
(3S)-1-((4-fluorophenyl)methyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-33)
(3S)-1-((4-methoxyphenyl)methyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-34)
(3S)-1-((4-methylphenyl)methyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-35)
(3S)-1-(2,2-dimethylpropyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 10A-6





Example



No
Compound Name







19(H10-36)
(3S)-1-(2-phenylpropyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-37)
(3S)-1-(2-methylpropyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-38)
(3S)-1-(2-methylbutyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-39)
(3S)-1-benzyl-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-40)
(3S)-1-(2-(N,N-dimethylamino)ethyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-41)
(3S)-1-(2-methoxyethyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-42)
(3S)-1-(2-propynyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 10A-7





Example



No
Compound Name







19(H10-43)
(3S)-1-(2-propenyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-44)
(3S)-1-(3-hydroxypropyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-45)
(3S)-1-(3-methylbutyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-46)
(3S)-1-propyl-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-47)
(3S)-1-(3-(N,N-dimethylamino)propyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-48)
(3S)-1-(3-ethoxypropyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-49)
(3S)-1-(3-phenylpropyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 10A-8





Example



No
Compound Name







19(H10-50)
(3S)-1-(4-phenylbutyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


19(H10-51)
(3S)-1-pentyl-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


19(H10-52)
(3S)-1-(3-(imidazol-1-yl)propyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


19(H10-53)
(3S)-1-butyl-2,5-dioxo-3-(3-(benzyloxycarbonylamino)



propyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H10-54)
(3S)-1-(2-(1-cyclohexenyl)ethyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


19(H10-55)
(3S)-1-(cyclopropylmethyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


19(H10-56)
(3S)-1-ethyl-2,5-dioxo-3-(3-(benzyloxycarbonylamino)



propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 10A-9





Example



No
Compound Name







19(H10-57)
(3S)-1-(3-methoxypropyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-58)
(3S)-1-(2-(N-ethyl-N-(3-methylphenyl)amino)ethyl)-2,5-



dioxo-3-(3-(benzyloxycarbonylamino)propyl)-9-



(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


19(H10-59)
(3S)-1-(2-(pyridin-4-yl)ethyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-60)
(3S)-1-((3-chlorophenyl)methyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-61)
(3S)-1-(3-methylthiopropyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-62)
(3S)-1-(2-(thiophen-2-yl)ethyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-63)
(3S)-1-(2-(1,1-dimethylethylthio)ethyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 10A-10





Example



No
Compound Name







19(H10-64)
(3S)-1-((t-butoxycarbonyl)methyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-65)
(3S)-1-((2S)-2-hydroxypropyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-66)
(3S)-1-((5-methylfuran-2-yl)methyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-67)
(3S)-1-((1R)-1-(4-methylphenyl)ethyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


19(H10-68)
(3S)-1-(2-(pyridin-3-yl)ethyl)-2,5-dioxo-3-(3-



(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane

















TABLE 11A-1





Example



No
Compound Name







19(H11-1)
(3S)-1-cyclopropyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-2)
(3S)-1-cyclobutyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-3)
(3S)-1-((1S,2S,5S)-6,6-dimethylbicyclo[3.1.1]heptan-2-



ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenylbutyl)-



1,4,9-triazaspiro[5.5]undecane


19(H11-4)
(3S)-1-cyclopentyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-5)
(3S)-1-cyclohexyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-6)
(3S)-1-(cyclohexylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-7)
(3S)-1-(2-(1-methylpyrrolidin-2-yl)ethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H11-8)
(3S)-1-((1-ethylpyrrolidin-2-yl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 11A-2





Example



No
Compound Name







19(H11-9)
(3S)-1-(indan-5-yl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-10)
(3S)-1-cycloheptyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-11)
(3S)-1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H11-12)
(3S)-1-(2-(morpholin-4-yl)ethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H11-13)
(3S)-1-(3-(morpholin-4-yl)propyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H11-14)
(3S)-1-(2-(pyridin-2-yl)ethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H11-15)
(3S)-1-(pyridin-3-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 11A-3





Example



No
Compound Name







19(H11-16)
(3S)-1-(pyridin-4-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-17)
(3S)-1-(1-(ethoxycarbonyl)piperidin-4-yl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H11-18)
(3S)-1-(2-(piperidin-1-yl)ethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H11-19)
(3S)-1-(1-phenylethyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-20)
(3S)-1-(1-methylethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-21)
(3S)-1-((2-fluorophenyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H11-22)
(3S)-1-((2-methoxyphenyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 11A-4





Example



No
Compound Name







19(H11-23)
(3S)-1-((3-fluorophenyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H11-24)
(3S)-1-((3-methoxyphenyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H11-25)
(3S)-1-((4-fluorophenyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H11-26)
(3S)-1-((4-methoxyphenyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H11-27)
(3S)-1-((4-methylphenyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H11-28)
(3S)-1-(2,2-dimethylpropyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-29)
(3S)-1-(2-phenylpropyl)-2,5-dioxo-3-(2-methylpropyl)-9-



(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 11A-5





Example



No
Compound Name







19(H11-30)
(3S)-1-(2-methylpropyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-31)
(3S)-1-(2-methylbutyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-32)
(3S)-1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-33)
(3S)-1-(2-(N,N-dimethylamino)ethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H11-34)
(3S)-1-(2-methoxyethyl)-2,5-dioxo-3-(2-methylpropyl)-9-



(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-35)
(3S)-1-(2-propynyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-36)
(3S)-1-(2-propenyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-37)
(3S)-1-(3-hydroxypropyl)-2,5-dioxo-3-(2-methylpropyl)-9-



(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 11A-6





Example



No
Compound Name







19(H11-38)
(3S)-1-(3-methylbutyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-39)
(3S)-1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-40)
(3S)-1-(3-(N,N-dimethylamino)propyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H11-41)
(3S)-1-(3-ethoxypropyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-42)
(3S)-1-(3-phenylpropyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-43)
(3S)-1-(4-phenylbutyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-44)
(3S)-1-pentyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-45)
(3S)-1-(3-(imidazol-1-yl)propyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 11A-7





Example



No
Compound Name







19(H11-46)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-47)
(3S)-1-(2-(1-cyclohexenyl)ethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H11-48)
(3S)-1-(cyclopropylmethyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-49)
(3S)-1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-50)
(3S)-1-(3-methoxypropyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane


19(H11-51)
(3S)-1-(2-(pyridin-4-yl)ethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H11-52)
(3S)-1-((3-chlorophenyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H11-53)
(3S)-1-(3-methylthiopropyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 11A-8





Example



No
Compound Name







19(H11-54)
(3S)-1-(2-(thiophen-2-yl)ethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H11-55)
(3S)-1-(2-(1,1-dimethylethylthio)ethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H11-56)
(3S)-1-((t-butoxycarbonyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenlybutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H11-57)
(3S)-1-((5-methylfuran-2-yl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane


19(H11-58)
(3S)-1-(2-(pyridin-3-yl)ethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenylbutyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 12A-1





Example



No
Compound Name







19(H12-1)
(3S)-1-cyclopropyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-2)
(3S)-1-cyclobutyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-3)
(3S)-1-((1S,2S,5S)-6,6-dimethylbicyclo[3.1.1]heptan-2-



ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(5-phenylpentyl)-



1,4,9-triazaspiro[5.5]undecane


19(H12-4)
(3S)-1-cyclopentyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-5)
(3S)-1-cyclohexyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-6)
(3S)-1-(cyclohexylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-7)
(3S)-1-(1,2,3,4-tetrahydronaphthyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-8)
(3S)-1-cyclooctyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 12A-2





Example



No
Compound Name







19(H12-9)
(3S)-1-(2-(1-methylpyrrolidin-2-yl)ethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-10)
(3S)-1-((1-ethylpyrrolidin-2-yl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-11)
(3S)-1-(indan-5-yl)-2,5-dioxo-3-(2-methylpropyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-12)
(3S)-1-cycloheptyl-2,5-dioxo-3-(2-methylpropyl)-9-



(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-13)
(3S)-1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-14)
(3S)-1-(2-(morpholin-4-yl)ethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-15)
(3S)-1-(3-(morpholin-4-yl)propyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 12A-3





Example



No
Compound Name







19(H12-16)
(3S)-1-(2-(pyridin-2-yl)ethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-17)
(3S)-1-(pyridin-3-ylmethyl)-2,5-dioxo-3-(2-methyipropyl)-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-18)
(3S)-1-(pyridin-4-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-19)
(3S)-1-(2-(piperidin-1-yl)ethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-20)
(3S)-1-phenyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-21)
(3S)-1-(1-phenylethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-22)
(3S)-1-(1-methylethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 12A-4





Example



No
Compound Name







19(H12-23)
(3S)-1-(1,3-dimethylbutyl)-2,5-dioxo-3-(2-methylpropyl)-9-



(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-24)
(3S)-1-(1-methyl-3-phenylpropyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-25)
(3S)-1-(1-methylpropyl)-2,5-dioxo-3-(2-methylpropyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-26)
(3S)-1-(1-ethylpropyl)-2,5-dioxo-3-(2-methylpropyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-27)
(3S)-1-(1-methylbutyl)-2,5-dioxo-3-(2-methylpropyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-28)
(3S)-1-((2-fluorophenyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-29)
(3S)-1-((2-methoxyphenyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 12A-5





Example



No
Compound Name







19(H12-30)
(3S)-1-((3-fluorophenyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-31)
(3S)-1-((3-methoxyphenyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-32)
(3S)-1-((4-fluorophenyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-33)
(3S)-1-((4-methoxyphenyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-34)
(3S)-1-((4-methylphenyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-35)
(3S)-1-(2,2-dimethylpropyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-36)
(3S)-1-(2-phenylpropyl)-2,5-dioxo-3-(2-methylpropyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 12A-6





Example



No
Compound Name







19(H12-37)
(3S)-1-(2-methylpropyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-38)
(3S)-1-(2-methylbutyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(5-phenylpentyl-1,4,9-triazaspiro[5.5]undecane


19(H12-39)
(3S)-1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-40)
(3S)-1-(2-(N,N-dimethylamino)ethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-41)
(3S)-1-(2-methoxyethyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-42)
(3S)-1-(2-propynyl)-2,5-dioxo-3-(2-methylpropyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-43)
(3S)-1-(2-propenyl)-2,5-dioxo-3-(2-methylpropyl)-9-(5-



phenylpentyl-1,4,9-triazaspiro[5.5]undecane


19(H12-44)
(3S)-1-(3-hydroxypropyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(5-penylpentyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 12A-7





Example



No
Compound Name







19(H12-45)
(3S)-1-(3-methylbutyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-46)
(3S)-1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-47)
(3S)-1-(3-(N,N-dimethylamino)propyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-48)
(3S)-1-(3-ethoxypropyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-49)
(3S)-1-(3-phenylpropyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-50)
(3S)-1-(4-phenylbutyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-51)
(3S)-1-pentyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-



phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-52)
(3S)-1-(3-(imidazol-1-yl)propyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 12A-8





Example



No
Compound Name







19(H12-53)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-54)
(3S)-1-(2-(1-cyclohexenyl)ethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-55)
(3S)-1-(cyclopropylmethyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-56)
(3S)-1-ethyl-2,5-dioxo-3-(2-methylpropyl)-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-57)
(3S)-1-(1-propylbutyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-58)
(3S)-1-(3-methoxypropyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(5-phenylpentyl)-1,4,9-triazaspiro[5.5]undecane


19(H12-59)
(3S)-1-(2-(pyridin-4-yl)ethyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-60)
(3S)-1-((3-chlorophenyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 12A-9





Example



No
Compound Name







19(H12-61)
(3S)-1-(3-methylthiopropyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-62)
(3S)-1-(2-(thiophen-2-yl)ethyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-63)
(3S)-1-(2-(1,1-dimethylethylthio)ethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-64)
(3S)-1-((t-butoxycarbonyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-65)
(3S)-1-((2R)-2-hydroxypropyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-66)
(3S)-1-((2S)-2-hydroxypropyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-67)
(3S)-1-((5-methylfuran-2-yl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 12A-10





Example



No
Compound Name







19(H12-68)
(3S)-1-((1R)-1-(4-methylphenyl)ethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro[5.5]undecane


19(H12-69)
(3S)-1-(2-(pyridin-3-yl)ethyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(5-phenylpentyl)-1,4,9-



triazaspiro-[5.5]undecane




















TABLE 13A-1





Example



No
Compound Name







19(H13-1)
(3S)-1-cyclopropyl-2,5-dioxo-3-(2-methylpropyl)-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H13-2)
(3S)-1-cyclobutyl-2,5-dioxo-3-(2-methylpropyl)-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H13-3)
(3S)-1-((1S,2S,5S)-6,6-dimethylbicyclo[3.1.1]heptan-2-



ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-



(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H13-4)
(3S)-1-cyclopentyl-2,5-dioxo-3-(2-methylpropyl)-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H13-5)
(3S)-1-cyclohexyl-2,5-dioxo-3-(2-methylpropyl)-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H13-6)
(3S)-1-(cyclohexylmethyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-7)
(3S)-1-(1,2,3,4-tetrahydronaphthyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-8)
(3S)-1-cyclooctyl-2,5-dioxo-3-(2-methylpropyl)-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 13A-2





Example



No
Compound Name







19(H13-9)
(3S)-1-(2-(1-methylpyrrolidin-2-yl)ethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-10)
(3S)-1-((1-ethylpyrrolidin-2-yl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-11)
(3S)-1-(indan-5-yl)-2,5-dioxo-3-(2-methylpropyl)-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H13-12)
(3S)-1-cycloheptyl-2,5-dioxo-3-(2-methylpropyl)-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H13-13)
(3S)-1-(thiophen-2-ylmethyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-14)
(3S)-1-(2-(morpholin-4-yl)ethyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-15)
(3S)-1-(3-(morpholin-4-yl)propyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 13A-3





Example



No
Compound Name







19(H13-16)
(3S)-1-(2-(pyridin-2-yl)ethyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-17)
(3S)-1-(pyridin-3-ylmethyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-18)
(3S)-1-(1-(ethoxycarbonyl)piperidin-4-yl)-2,5-dioxo-3-(2-



methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-19)
(3S)-1-(2-(piperidin-1-yl)ethyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-20)
(3S)-1-(1-phenylethyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-21)
(3S)-1-(1,2-dimethylpropyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-22)
(3S)-1-(1,3-dimethylbutyl)-2,5-dioxo-3-(2-methylpropyl)



-9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 13A-4





Example



No
Compound Name







19(H13-23)
(3S)-1-(1-ethylpropyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-24)
(3S)-1-((2-fluorophenyl)methyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-25)
(3S)-1-((2-methoxyphenyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-26)
(3S)-1-((3-fluorophenyl)methyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-27)
(3S)-1-((3-methoxyphenyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-28)
(3S)-1-((4-fluorophenyl)methyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-29)
(3S)-1-((4-methoxyphenyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 13A-5





Example



No
Compound Name







19(H13-30)
(3S)-1-((4-methylphenyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-31)
(3S)-1-(2,2-dimethylpropyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-32)
(3S)-1-(2-phenylpropyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H13-33)
(3S)-1-(2-methylpropyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H13-34)
(3S)-1-(2-methylbutyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H13-35)
(3S)-1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H13-36)
(3S)-1-(2-(N,N-dimethylamino)ethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-37)
(3S)-1-(2-methoxyethyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 13A-6





Example



No
Compound Name







19(H13-38)
(3S)-1-(2-propynyl)-2,5-dioxo-3-(2-methylpropyl)-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H13-39)
(3S)-1-(2-propenyl)-2,5-dioxo-3-(2-methylpropyl)-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H13-40)
(3S)-1-(3-hydroxypropyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H13-41)
(3S)-1-(3-methylbutyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-42)
(3S)-1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-



(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H13-43)
(3S)-1-(3-(N,N-dimethylamino)propyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-44)
(3S)-1-(3-ethoxypropyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H13-45)
(3S)-1-(3-phenylpropyl)-2,5-dioxo-3-(2-methylpropyl)-



9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 13A-7





Example



No
Compound Name







19(H13-46)
(3S)-1-(4-phenylbutyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-47)
(3S)-1-pentyl-2,5-dioxo-3-(2-methylpropyl)-9-



(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H13-48)
(3S)-1-(3-(imidazol-1-yl)propyl)-2,5-dioxo-



3-(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-49)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-



9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H13-50)
(3S)-1-(2-(1-cyclohexenyl)ethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-51)
(3S)-1-(cyclopropylmethyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-52)
(3S)-1-ethyl-2,5-dioxo-3-(2-methylpropyl)-



9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


19(H13-53)
(3S)-1-(1-propylbutyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 13A-8





Example



No
Compound Name







19(H13-54)
(3S)-1-(3-methoxypropyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-55)
(3S)-1-(2-(pyridin-4-yl)ethyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-56)
(3S)-1-((3-chlorophenyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-57)
(3S)-1-(3-methylthiopropyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]-undecane


19(H13-58)
(3S)-1-(2-(thiophen-2-yl)ethyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-59)
(3S)-1-(2-(1,1-dimethylethylthio)ethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-6O)
(3S)-1-((t-butoxycarbonyl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 13A-9





Example



No
Compound Name







19(H13-61)
(3S)-1-((5-methylfuran-2-yl)methyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


19(H13-62)
(3S)-1-(2-(pyridin-3-yl)ethyl)-2,5-dioxo-3-



(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane



















TABLE 1B-1









embedded image
















Example No
R2
R3
R4
R5





19(H1-1)


embedded image


H


embedded image


H





19(H1-2)


embedded image


H


embedded image


H





19(H1-3)


embedded image


H


embedded image


H





19(H1-4)


embedded image


H
H
H





19(H1-5)


embedded image


H


embedded image


H





19(H1-6)


embedded image


H


embedded image


H





19(H1-7)


embedded image


H


embedded image


H





19(H1-8)


embedded image


H


embedded image


H



















TABLE 1B-2









embedded image
















Example No
R2
R3
R4
R5





19(H1-9)


embedded image


H


embedded image


H





19(H1-10)


embedded image


H


embedded image


H





19(H1-11)


embedded image


H


embedded image


H





19(H1-12)


embedded image


H


embedded image


H





19(H1-13)


embedded image


H


embedded image


H





19(H1-14)


embedded image


H
H
H





19(H1-15)


embedded image


H


embedded image


H





19(H1-16)


embedded image


H


embedded image


H



















TABLE 1B-3









embedded image
















Example No
R2
R3
R4
R5





19(H1-17)


embedded image


H


embedded image


H





19(H1-18)


embedded image


H


embedded image


H





19(H1-19)


embedded image


H


embedded image


H





19(H1-20)


embedded image


H


embedded image


H





19(H1-21)


embedded image


H
H
H





19(H1-22)


embedded image


H


embedded image


H





19(H1-23)


embedded image


H


embedded image


H



















TABLE 1B-4









embedded image
















Example No
R2
R3
R4
R5





19(H1-24)


embedded image


H


embedded image


H





19(H1-25)


embedded image


H


embedded image


H





19(H1-26)


embedded image


H


embedded image


H





19(H1-27)


embedded image


H


embedded image


H





19(H1-28)


embedded image


H
H
H





19(H1-29)


embedded image


H


embedded image


H





19(H1-30)


embedded image


H


embedded image


H





19(H1-31)


embedded image


H


embedded image


H



















TABLE 1B-5









embedded image
















Example No
R2
R3
R4
R5





19(H1-32)


embedded image


H


embedded image


H





19(H1-33)


embedded image


H


embedded image


H





19(H1-34)


embedded image


H


embedded image


H





19(H1-35)


embedded image


H
H
H





19(H1-36)


embedded image


H


embedded image


H





19(H1-37)


embedded image


H


embedded image


H





19(H1-38)


embedded image


H


embedded image


H





19(H1-39)


embedded image


H


embedded image


H





19(H1-40)


embedded image


H


embedded image


H



















TABLE 1B-6









embedded image
















Example No
R2
R3
R4
R5





19(H1-41)


embedded image


H


embedded image


H





19(H1-42)


embedded image


H
H
H





19(H1-43)


embedded image


H


embedded image


H





19(H1-44)


embedded image


H


embedded image


H





19(H1-45)


embedded image


H


embedded image


H





19(H1-46)


embedded image


H


embedded image


H





19(H1-47)


embedded image


H


embedded image


H





19(H1-48)


embedded image


H


embedded image


H



















TABLE 1B-7









embedded image
















Example No
R2
R3
R4
R5





19(H1-49)


embedded image


H
H
H





19(H1-50)


embedded image


H


embedded image


H





19(H1-51)


embedded image


H


embedded image


H





19(H1-52)


embedded image


H


embedded image


H





19(H1-53)


embedded image


H


embedded image


H





19(H1-54)


embedded image


H


embedded image


H





19(H1-55)


embedded image


H


embedded image


H



















TABLE 2B-1









embedded image
















Example No
R2
R3
R4
R5





19(H2-1)


embedded image


H
H
H





19(H2-2)


embedded image


H


embedded image


H





19(H2-3)


embedded image


H


embedded image


H





19(H2-4)


embedded image


H


embedded image


H





19(H2-5)


embedded image


H


embedded image


H





19(H2-6)


embedded image


H
H
H





19(H2-7)


embedded image


H


embedded image


H





19(H2-8)


embedded image


H


embedded image


H



















TABLE 2B-2









embedded image
















Example No
R2
R3
R4
R5





19(H2-9)


embedded image


H


embedded image


H





19(H2-10)


embedded image


H


embedded image


H





19(H2-11)


embedded image


H


embedded image


H





19(H2-12)


embedded image


H


embedded image


H





19(H2-13)


embedded image


H
H
H





19(H2-14)


embedded image


H


embedded image


H





19(H2-15)


embedded image


H


embedded image


H



















TABLE 2B-3









embedded image
















Example No
R2
R3
R4
R5





19(H2-16)


embedded image


H


embedded image


H





19(H2-17)


embedded image


H


embedded image


H





19(H2-18)


embedded image


H


embedded image


H





19(H2-19)


embedded image


H


embedded image


H





19(H2-20)


embedded image


H
H
H





19(H2-21)


embedded image


H


embedded image


H





19(H2-22)


embedded image


H


embedded image


H





19(H2-23)


embedded image


H


embedded image


H



















TABLE 2B-4









embedded image
















Example No
R2
R3
R4
R5





19(H2-24)


embedded image


H


embedded image


H





19(H2-25)


embedded image


H


embedded image


H





19(H2-26)


embedded image


H


embedded image


H





19(H2-27)


embedded image


H
H
H





19(H2-28)


embedded image


H


embedded image


H





19(H2-29)


embedded image


H


embedded image


H





19(H2-30)


embedded image


H


embedded image


H





19(H2-31)


embedded image


H


embedded image


H



















TABLE 2B-5









embedded image
















Example No
R2
R3
R4
R5





19(H2-32)


embedded image


H


embedded image


H





19(H2-33)


embedded image


H


embedded image


H





19(H2-34)


embedded image


H
H
H





19(H2-35)


embedded image


H


embedded image


H





19(H2-36)


embedded image


H


embedded image


H





19(H2-37)


embedded image


H


embedded image


H





19(H2-38)


embedded image


H


embedded image


H





19(H2-39)


embedded image


H


embedded image


H



















TABLE 2B-6









embedded image
















Example No
R2
R3
R4
R5





19(H2-40)


embedded image


H


embedded image


H





19(H2-41)


embedded image


H
H
H





19(H2-42)


embedded image


H


embedded image


H





19(H2-43)


embedded image


H


embedded image


H





19(H2-44)


embedded image


H


embedded image


H





19(H2-45)


embedded image


H


embedded image


H





19(H2-46)


embedded image


H


embedded image


H





19(H2-47)


embedded image


H


embedded image


H





19(H2-48)


embedded image


H
H
H



















TABLE 2B-7









embedded image
















Example No
R2
R3
R4
R5





19(H2-49)


embedded image


H


embedded image


H





19(H2-50)


embedded image


H


embedded image


H





19(H2-51)


embedded image


H


embedded image


H





19(H2-52)


embedded image


H


embedded image


H





19(H2-53)


embedded image


H


embedded image


H





19(H2-54)


embedded image


H


embedded image


H





19(H2-55)


embedded image


H
H
H





19(H2-56)


embedded image


H


embedded image


H



















TABLE 2B-8









embedded image
















Example No
R2
R3
R4
R5





19(H2-57)


embedded image


H


embedded image


H





19(H2-58)


embedded image


H


embedded image


H





19(H2-59)


embedded image


H


embedded image


H





19(H2-60)


embedded image


H


embedded image


H





19(H2-61)


embedded image


H


embedded image


H



















TABLE 3B-1









embedded image
















Example No
R2
R3
R4
R5





19(H3-1)


embedded image


H
H
H





19(H3-2)


embedded image


H


embedded image


H





19(H3-3)


embedded image


H


embedded image


H





19(H3-4)


embedded image


H


embedded image


H





19(H3-5)


embedded image


H


embedded image


H





19(H3-6)


embedded image


H


embedded image


H





19(H3-7)


embedded image


H


embedded image


H





19(H3-8)


embedded image


H
H
H



















TABLE 3B-2









embedded image
















Example No
R2
R3
R4
R5





19(H3-9)


embedded image


H


embedded image


H





19(H3-10)


embedded image


H


embedded image


H





19(H3-11)


embedded image


H


embedded image


H





19(H3-12)


embedded image


H


embedded image


H





19(H3-13)


embedded image


H


embedded image


H





19(H3-14)


embedded image


H


embedded image


H





19(H3-15)


embedded image


H
H
H





19(H3-16)


embedded image


H


embedded image


H



















TABLE 3B-3









embedded image
















Example No
R2
R3
R4
R5





19(H3-17)


embedded image


H


embedded image


H





19(H3-18)


embedded image


H


embedded image


H





19(H3-19)


embedded image


H


embedded image


H





19(H3-20)


embedded image


H


embedded image


H





19(H3-21)


embedded image


H


embedded image


H





19(H3-22)


embedded image


H
H
H





19(H3-23)


embedded image


H


embedded image


H





19(H3-24)


embedded image


H


embedded image


H



















TABLE 3B-4









embedded image
















Example No
R2
R3
R4
R5





19(H3-25)


embedded image


H


embedded image


H





19(H3-26)


embedded image


H


embedded image


H





19(H3-27)


embedded image


H


embedded image


H





19(H3-28)


embedded image


H


embedded image


H





19(H3-29)


embedded image


H
H
H





19(H3-30)


embedded image


H


embedded image


H





19(H3-31)


embedded image


H


embedded image


H



















TABLE 3B-5









embedded image
















Example No
R2
R3
R4
R5





19(H3-32)


embedded image


H


embedded image


H





19(H3-33)


embedded image


H


embedded image


H





19(H3-34)


embedded image


H


embedded image


H





19(H3-35)


embedded image


H


embedded image


H





19(H3-36)


embedded image


H
H
H





19(H3-37)


embedded image


H


embedded image


H





19(H3-38)


embedded image


H


embedded image


H





19(H3-39)


embedded image


H


embedded image


H



















TABLE 3B-6









embedded image
















Example No
R2
R3
R4
R5





19(H3-40)


embedded image


H


embedded image


H





19(H3-41)


embedded image


H


embedded image


H





19(H3-42)


embedded image


H


embedded image


H





19(H3-43)


embedded image


H
H
H





19(H3-44)


embedded image


H


embedded image


H





19(H3-45)


embedded image


H


embedded image


H





19(H3-46)


embedded image


H


embedded image


H





19(H3-47)


embedded image


H


embedded image


H





19(H3-48)


embedded image


H


embedded image


H



















TABLE 3B-7









embedded image
















Example No
R2
R3
R4
R5





19(H3-49)


embedded image


H


embedded image


H





19(H3-50)


embedded image


H
H
H





19(H3-51)


embedded image


H


embedded image


H





19(H3-52)


embedded image


H


embedded image


H





19(H3-53)


embedded image


H


embedded image


H





19(H3-54)


embedded image


H


embedded image


H





19(H3-55)


embedded image


H


embedded image


H





19(H3-56)


embedded image


H


embedded image


H



















TABLE 3B-8









embedded image
















Example No
R2
R3
R4
R5





19(H3-57)


embedded image


H
H
H





19(H3-58)


embedded image


H


embedded image


H





19(H3-59)


embedded image


H


embedded image


H





19(H3-60)


embedded image


H


embedded image


H





19(H3-61)


embedded image


H


embedded image


H





19(H3-62)


embedded image


H


embedded image


H





19(H3-63)


embedded image


H


embedded image


H



















TABLE 4B-1









embedded image
















Example No
R2
R3
R4
R5





19(H4-1)


embedded image


H
H
H





19(H4-2)


embedded image


H


embedded image


H





19(H4-3)


embedded image


H


embedded image


H





19(H4-4)


embedded image


H


embedded image


H





19(H4-5)


embedded image


H


embedded image


H





19(H4-6)


embedded image


H


embedded image


H





19(H4-7)


embedded image


H


embedded image


H





19(H4-8)


embedded image


H
H
H



















TABLE 4B-2









embedded image
















Example No
R2
R3
R4
R5





19(H4-9)


embedded image


H


embedded image


H





19(H4-10)


embedded image


H


embedded image


H





19(H4-11)


embedded image


H


embedded image


H





19(H4-12)


embedded image


H


embedded image


H





19(H4-13)


embedded image


H


embedded image


H





19(H4-14)


embedded image


H


embedded image


H





19(H4-15)


embedded image


H
H
H





19(H4-16)


embedded image


H


embedded image


H



















TABLE 4B-3









embedded image
















Example No
R2
R3
R4
R5





19(H4-17)


embedded image


H


embedded image


H





19(H4-18)


embedded image


H


embedded image


H





19(H4-19)


embedded image


H


embedded image


H





19(H4-20)


embedded image


H


embedded image


H





19(H4-21)


embedded image


H


embedded image


H





19(H4-22)


embedded image


H
H
H





19(H4-23)


embedded image


H


embedded image


H





19(H4-24)


embedded image


H


embedded image


H



















TABLE 4B-4









embedded image
















Example No
R2
R3
R4
R5





19(H4-25)


embedded image


H


embedded image


H





19(H4-26)


embedded image


H


embedded image


H





19(H4-27)


embedded image


H


embedded image


H





19(H4-28)


embedded image


H


embedded image


H





19(H4-29)


embedded image


H
H
H





19(H4-30)


embedded image


H


embedded image


H





19(H4-31)


embedded image


H


embedded image


H



















TABLE 4B-5









embedded image
















Example No
R2
R3
R4
R5





19(H4-32)


embedded image


H


embedded image


H





19(H4-33)


embedded image


H


embedded image


H





19(H4-34)


embedded image


H


embedded image


H





19(H4-35)


embedded image


H


embedded image


H





19(H4-36)


embedded image


H
H
H





19(H4-37)


embedded image


H


embedded image


H





19(H4-38)


embedded image


H


embedded image


H





19(H4-39)


embedded image


H


embedded image


H



















TABLE 4B-6









embedded image
















Example No
R2
R3
R4
R5





19(H4-40)


embedded image


H


embedded image


H





19(H4-41)


embedded image


H


embedded image


H





19(H4-42)


embedded image


H


embedded image


H





19(H4-43)


embedded image


H
H
H





19(H4-44)


embedded image


H


embedded image


H





19(H4-45)


embedded image


H


embedded image


H





19(H4-46)


embedded image


H


embedded image


H





19(H4-47)


embedded image


H


embedded image


H





19(H4-48)


embedded image


H


embedded image


H



















TABLE 4B-7









embedded image
















Example No
R2
R3
R4
R5





19(H4-49)


embedded image


H


embedded image


H





19(H4-50)


embedded image


H
H
H





19(H4-51)


embedded image


H


embedded image


H





19(H4-52)


embedded image


H


embedded image


H





19(H4-53)


embedded image


H


embedded image


H





19(H4-54)


embedded image


H


embedded image


H





19(H4-55)


embedded image


H


embedded image


H





19(H4-56)


embedded image


H


embedded image


H



















TABLE 4B-8









embedded image
















Example No
R2
R3
R4
R5





19(H4-57)


embedded image


H
H
H





19(H4-58)


embedded image


H


embedded image


H





19(H4-59)


embedded image


H


embedded image


H





19(H4-60)


embedded image


H


embedded image


H





19(H4-61)


embedded image


H


embedded image


H





19(H4-62)


embedded image


H


embedded image


H





19(H4-63)


embedded image


H


embedded image


H



















TABLE 5B-1









embedded image
















Example No
R2
R3
R4
R5





19(H5-1)


embedded image


H
H
H





19(H5-2)


embedded image


H


embedded image


H





19(H5-3)


embedded image


H


embedded image


H





19(H5-4)


embedded image


H


embedded image


H





19(H5-5)


embedded image


H


embedded image


H





19(H5-6)


embedded image


H


embedded image


H





19(H5-7)


embedded image


H


embedded image


H





19(H5-8)


embedded image


H
H
H



















TABLE 5B-2









embedded image
















Example No
R2
R3
R4
R5





19(H5-9) 


embedded image


H


embedded image


H





19(H5-10)


embedded image


H


embedded image


H





19(H5-11)


embedded image


H


embedded image


H





19(H5-12)


embedded image


H


embedded image


H





19(H5-13)


embedded image


H


embedded image


H





19(H5-14)


embedded image


H


embedded image


H





19(H5-15)


embedded image


H
H
H





19(H5-16)


embedded image


H


embedded image


H



















TABLE 5B-3









embedded image
















Example No
R2
R3
R4
R5





19(H5-17)


embedded image


H


embedded image


H





19(H5-18)


embedded image


H


embedded image


H





19(H5-19)


embedded image


H


embedded image


H





19(H5-20)


embedded image


H


embedded image


H





19(H5-21)


embedded image


H


embedded image


H





19(H5-22)


embedded image


H
H
H





19(H5-23)


embedded image


H


embedded image


H





19(H5-24)


embedded image


H


embedded image


H



















TABLE 5B-4









embedded image
















Example No
R2
R3
R4
R5





19(H5-25)


embedded image


H


embedded image


H





19(H5-26)


embedded image


H


embedded image


H





19(H5-27)


embedded image


H


embedded image


H





19(H5-28)


embedded image


H


embedded image


H





19(H5-29)


embedded image


H
H
H





19(H5-30)


embedded image


H


embedded image


H





19(H5-31)


embedded image


H


embedded image


H



















TABLE 5B-5









embedded image
















Example No
R2
R3
R4
R5





19(H5-32)


embedded image


H


embedded image


H





19(H5-33)


embedded image


H


embedded image


H





19(H5-34)


embedded image


H


embedded image


H





19(H5-35)


embedded image


H


embedded image


H





19(H5-36)


embedded image


H
H
H





19(H5-37)


embedded image


H


embedded image


H





19(H5-38)


embedded image


H


embedded image


H





19(H5-39)


embedded image


H


embedded image


H



















TABLE 5B-6









embedded image
















Example No
R2
R3
R4
R5





19(H5-40)


embedded image


H


embedded image


H





19(H5-41)


embedded image


H


embedded image


H





19(H5-42)


embedded image


H


embedded image


H





19(H5-43)


embedded image


H
H
H





19(H5-44)


embedded image


H


embedded image


H





19(H5-45)


embedded image


H


embedded image


H





19(H5-46)


embedded image


H


embedded image


H





19(H5-47)


embedded image


H


embedded image


H





19(H5-48)


embedded image


H


embedded image


H



















TABLE 5B-7









embedded image
















Example No
R2
R3
R4
R5





19(H5-49)


embedded image


H


embedded image


H





19(H5-50)


embedded image


H
H
H





19(H5-51)


embedded image


H


embedded image


H





19(H5-52)


embedded image


H


embedded image


H





19(H5-53)


embedded image


H


embedded image


H





19(H5-54)


embedded image


H


embedded image


H





19(H5-55)


embedded image


H


embedded image


H





19(H5-56)


embedded image


H


embedded image


H



















TABLE 5B-8









embedded image
















Example No
R2
R3
R4
R5





19(H5-57)


embedded image


H


embedded image


H





19(H5-58)


embedded image


H


embedded image


H





19(H5-59)


embedded image


H


embedded image


H





19(H5-60)


embedded image


H


embedded image


H





19(H5-61)


embedded image


H


embedded image


H





19(H5-62)


embedded image


H


embedded image


H



















TABLE 6B-1









embedded image
















Example No
R2
R3
R4
R5





19(H6-1)


embedded image


H
H
H





19(H6-2)


embedded image


H


embedded image


H





19(H6-3)


embedded image


H
H
H





19(H6-4)


embedded image


H


embedded image


H





19(H6-5)


embedded image


H


embedded image


H





19(H6-6)


embedded image


H


embedded image


H





19(H6-7)


embedded image


H


embedded image


H





19(H6-8)


embedded image


H


embedded image


H



















TABLE 6B-2









embedded image
















Example No
R2
R3
R4
R5





19(H6-9) 


embedded image


H


embedded image


H





19(H6-10)


embedded image


H
H
H





19(H6-11)


embedded image


H


embedded image


H





19(H6-12)


embedded image


H


embedded image


H





19(H6-13)


embedded image


H


embedded image


H





19(H6-14)


embedded image


H


embedded image


H





19(H6-15)


embedded image


H


embedded image


H





19(H6-16)


embedded image


H


embedded image


H



















TABLE 6B-3









embedded image
















Example No
R2
R3
R4
R5





19(H6-17)


embedded image


H
H
H





19(H6-18)


embedded image


H


embedded image


H





19(H6-19)


embedded image


H


embedded image


H





19(H6-20)


embedded image


H


embedded image


H





19(H6-21)


embedded image


H


embedded image


H





19(H6-22)


embedded image


H


embedded image


H





19(H6-23)


embedded image


H


embedded image


H





19(H6-24)


embedded image


H
H
H



















TABLE 6B-4









embedded image
















Example No
R2
R3
R4
R5





19(H6-25)


embedded image


H


embedded image


H





19(H6-26)


embedded image


H


embedded image


H





19(H6-27)


embedded image


H


embedded image


H





19(H6-28)


embedded image


H


embedded image


H





19(H6-29)


embedded image


H


embedded image


H





19(H6-30)


embedded image


H


embedded image


H





19(H6-31)


embedded image


H
H
H





19(H6-32)


embedded image


H


embedded image


H



















TABLE 6B-5









embedded image
















Example No
R2
R3
R4
R5





19(H6-33)


embedded image


H


embedded image


H





19(H6-34)


embedded image


H


embedded image


H





19(H6-35)


embedded image


H


embedded image


H





19(H6-36)


embedded image


H


embedded image


H





19(H6-37)


embedded image


H


embedded image


H





19(H6-38)


embedded image


H
H
H





19(H6-39)


embedded image


H


embedded image


H





19(H6-40)


embedded image


H


embedded image


H



















TABLE 6B-6









embedded image
















Example No
R2
R3
R4
R5





19(H6-41)


embedded image


H


embedded image


H





19(H6-42)


embedded image


H


embedded image


H





19(H6-43)


embedded image


H


embedded image


H





19(H6-44)


embedded image


H


embedded image


H





19(H6-45)


embedded image


H
H
H





19(H6-46)


embedded image


H


embedded image


H





19(H6-47)


embedded image


H


embedded image


H





19(H6-48)


embedded image


H


embedded image


H



















TABLE 6B-7









embedded image
















Example No
R2
R3
R4
R5





19(H6-49)


embedded image


H


embedded image


H





19(H6-50)


embedded image


H


embedded image


H





19(H6-51)


embedded image


H


embedded image


H





19(H6-52)


embedded image


H
H
H





19(H6-53)


embedded image


H


embedded image


H





19(H6-54)


embedded image


H


embedded image


H





19(H6-55)


embedded image


H


embedded image


H





19(H6-56)


embedded image


H


embedded image


H



















TABLE 6B-8









embedded image
















Example No
R2
R3
R4
R5





19(H6-57)


embedded image


H


embedded image


H





19(H6-58)


embedded image


H


embedded image


H



















TABLE 7B-1









embedded image
















Example






No
R2
R3
R4
R5





19(H7-1)


embedded image


H
H
H





19(H7-2)


embedded image


H


embedded image


H





19(H7-3)


embedded image


H


embedded image


H





19(H7-4)


embedded image


H


embedded image


H





19(H7-5)


embedded image


H


embedded image


H





19(H7-6)


embedded image


H
H
H





19(H7-7)


embedded image


H


embedded image


H





19(H7-8)


embedded image


H


embedded image


H



















TABLE 7B-2









embedded image
















Example No
R2
R3
R4
R5





19(H7-9) 


embedded image


H


embedded image


H





19(H7-10)


embedded image


H


embedded image


H





19(H7-11)


embedded image


H


embedded image


H





19(H7-12)


embedded image


H


embedded image


H





19(H7-13)


embedded image


H
H
H





19(H7-14)


embedded image


H


embedded image


H





19(H7-15)


embedded image


H


embedded image


H



















TABLE 7B-3









embedded image
















Example No
R2
R3
R4
R5





19(H7-16)


embedded image


H


embedded image


H





19(H7-17)


embedded image


H


embedded image


H





19(H7-18)


embedded image


H


embedded image


H





19(H7-19)


embedded image


H


embedded image


H





19(H7-20)


embedded image


H
H
H





19(H7-21)


embedded image


H


embedded image


H





19(H7-22)


embedded image


H


embedded image


H





19(H7-23)


embedded image


H


embedded image


H



















TABLE 7B-4









embedded image
















Example No
R2
R3
R4
R5





19(H7-24)


embedded image


H


embedded image


H





19(H7-25)


embedded image


H


embedded image


H





19(H7-26)


embedded image


H


embedded image


H





19(H7-27)


embedded image


H
H
H





19(H7-28)


embedded image


H


embedded image


H





19(H7-29)


embedded image


H


embedded image


H





19(H7-30)


embedded image


H


embedded image


H





19(H7-31)


embedded image


H


embedded image


H



















TABLE 7B-5









embedded image
















Example No
R2
R3
R4
R5





19(H7-32)


embedded image


H


embedded image


H





19(H7-33)


embedded image


H


embedded image


H





19(H7-34)


embedded image


H


embedded image


H





19(H7-35)


embedded image


H


embedded image


H





19(H7-36)


embedded image


H


embedded image


H





19(H7-37)


embedded image


H


embedded image


H





19(H7-38)


embedded image


H


embedded image


H





19(H7-39)


embedded image


H


embedded image


H



















TABLE 7B-6









embedded image
















Example No
R2
R3
R4
R5





19(H7-40)


embedded image


H
H
H





19(H7-41)


embedded image


H


embedded image


H





19(H7-42)


embedded image


H


embedded image


H





19(H7-43)


embedded image


H


embedded image


H





19(H7-44)


embedded image


H


embedded image


H





19(H7-45)


embedded image


H


embedded image


H





19(H7-46)


embedded image


H


embedded image


H





19(H7-47)


embedded image


H
H
H





19(H7-48)


embedded image


H


embedded image


H



















TABLE 7B-7









embedded image
















Example No
R2
R3
R4
R5





19(H7-49)


embedded image


H


embedded image


H





19(H7-50)


embedded image


H


embedded image


H





19(H7-51)


embedded image


H


embedded image


H





19(H7-52)


embedded image


H


embedded image


H





19(H7-53)


embedded image


H


embedded image


H





19(H7-54)


embedded image


H
H
H





19(H7-55)


embedded image


H


embedded image


H





19(H7-56)


embedded image


H


embedded image


H



















TABLE 7B-8









embedded image
















Example No
R2
R3
R4
R5





19(H7-57)


embedded image


H


embedded image


H





19(H7-58)


embedded image


H


embedded image


H





19(H7-59)


embedded image


H


embedded image


H





19(H7-60)


embedded image


H


embedded image


H



















TABLE 8B-1









embedded image
















Example No
R2
R3
R4
R5





19(H8-1)


embedded image


H


embedded image


H





19(H8-2)


embedded image


H


embedded image


H





19(H8-3)


embedded image


H
H
H





19(H8-4)


embedded image


H


embedded image


H





19(H8-5)


embedded image


H


embedded image


H





19(H8-6)


embedded image


H


embedded image


H





19(H8-7)


embedded image


H


embedded image


H





19(H8-8)


embedded image


H


embedded image


H



















TABLE 8B-2









embedded image
















Example No
R2
R3
R4
R5





19(H8-9) 


embedded image


H


embedded image


H





19(H8-10)


embedded image


H
H
H





19(H8-11)


embedded image


H


embedded image


H





19(H8-12)


embedded image


H


embedded image


H





19(H8-13)


embedded image


H


embedded image


H





19(H8-14)


embedded image


H


embedded image


H





19(H8-15)


embedded image


H


embedded image


H





19(H8-16)


embedded image


H


embedded image


H



















TABLE 8B-3









embedded image
















Example No
R2
R3
R4
R5





19(H8-17)


embedded image


H
H
H





19(H8-18)


embedded image


H


embedded image


H





19(H8-19)


embedded image


H


embedded image


H





19(H8-20)


embedded image


H


embedded image


H





19(H8-21)


embedded image


H


embedded image


H





19(H8-22)


embedded image


H


embedded image


H





19(H8-23)


embedded image


H


embedded image


H





19(H8-24)


embedded image


H
H
H



















TABLE 8B-4









embedded image
















Example No
R2
R3
R4
R5





19(H8-25)


embedded image


H


embedded image


H





19(H8-26)


embedded image


H


embedded image


H





19(H8-27)


embedded image


H


embedded image


H





19(H8-28)


embedded image


H


embedded image


H





19(H8-29)


embedded image


H


embedded image


H





19(H8-30)


embedded image


H


embedded image


H





19(H8-31)


embedded image


H
H
H





19(H8-32)


embedded image


H


embedded image


H



















TABLE 8B-5









embedded image
















Example No
R2
R3
R4
R5





19(H8-33)


embedded image


H


embedded image


H





19(H8-34)


embedded image


H


embedded image


H





19(H8-35)


embedded image


H


embedded image


H





19(H8-36)


embedded image


H


embedded image


H





19(H8-37)


embedded image


H


embedded image


H





19(H8-38)


embedded image


H
H
H





19(H8-39)


embedded image


H


embedded image


H





19(H8-40)


embedded image


H


embedded image


H



















TABLE 8B-6









embedded image
















Example No
R2
R3
R4
R5





19(H8-41)


embedded image


H


embedded image


H





19(H8-42)


embedded image


H


embedded image


H





19(H8-43)


embedded image


H


embedded image


H





19(H8-44)


embedded image


H


embedded image


H





19(H8-45)


embedded image


H
H
H





19(H8-46)


embedded image


H


embedded image


H





19(H8-47)


embedded image


H


embedded image


H





19(H8-48)


embedded image


H


embedded image


H



















TABLE 8B-7









embedded image
















Example No
R2
R3
R4
R5





19(H8-49)


embedded image


H


embedded image


H





19(H8-50)


embedded image


H


embedded image


H





19(H8-51)


embedded image


H
H
H





19(H8-52)


embedded image


H


embedded image


H





19(H8-53)


embedded image


H


embedded image


H





19(H8-54)


embedded image


H


embedded image


H





19(H8-55)


embedded image


H


embedded image


H





19(H8-56)


embedded image


H


embedded image


H



















TABLE 8B-8









embedded image
















Example No
R2
R3
R4
R5





19(H8-57)


embedded image


H


embedded image


H



















TABLE 9B-1









embedded image















Example No
R2







19(H9-1)


embedded image









19(H9-2)


embedded image









19(H9-3)


embedded image









19(H9-4)


embedded image









19(H9-5)


embedded image









19(H9-6)


embedded image









19(H9-7)


embedded image









19(H9-8)


embedded image






















TABLE 9B-2









embedded image















Example No
R2







19(H9-9) 


embedded image









19(H9-10)


embedded image









19(H9-11)


embedded image









19(H9-12)


embedded image









19(H9-13)


embedded image









19(H9-14)


embedded image









19(H9-15)


embedded image









19(H9-16)


embedded image






















TABLE 9B-3









embedded image















Example No
R2







19(H9-17)


embedded image









19(H9-18)


embedded image









19(H9-19)


embedded image









19(H9-20)


embedded image









19(H9-21)


embedded image









19(H9-22)


embedded image









19(H9-23)


embedded image









19(H9-24)


embedded image






















TABLE 9B-4









embedded image















Example No
R2







19(H9-25)


embedded image









19(H9-26)


embedded image









19(H9-27)


embedded image









19(H9-28)


embedded image









19(H9-29)


embedded image









19(H9-30)


embedded image









19(H9-31)


embedded image









19(H9-32)


embedded image






















TABLE 9B-5









embedded image















Example No
R2







19(H9-33)


embedded image









19(H9-34)


embedded image









19(H9-35)


embedded image









19(H9-36)


embedded image









19(H9-37)


embedded image









19(H9-38)


embedded image









19(H9-39)


embedded image









19(H9-40)


embedded image









19(H9-41)


embedded image









19(H9-42)


embedded image









19(H9-43)


embedded image






















TABLE 9B-6









embedded image















Example No
R2







19(H9-44)


embedded image









19(H9-45)


embedded image









19(H9-46)


embedded image









19(H9-47)


embedded image









19(H9-48)


embedded image









19(H9-49)


embedded image









19(H9-50)


embedded image









19(H9-51)


embedded image









19(H9-52)


embedded image









19(H9-53)


embedded image









19(H9-54)


embedded image






















TABLE 9B-7









embedded image















Example No
R2







19(H9-55)


embedded image









19(H9-56)


embedded image









19(H9-57)


embedded image









19(H9-58)


embedded image









19(H9-59)


embedded image









19(H9-60)


embedded image









19(H9-61)


embedded image









19(H9-62)


embedded image






















TABLE 10B-1









embedded image















Example No
R2







19(H10-1)


embedded image









19(H10-2)


embedded image









19(H10-3)


embedded image









19(H10-4)


embedded image









19(H10-5)


embedded image









19(H10-6)


embedded image









19(H10-7)


embedded image









19(H10-8)


embedded image






















TABLE 10B-2









embedded image















Example No
R2







19(H10-9) 


embedded image









19(H10-10)


embedded image









19(H10-11)


embedded image









19(H10-12)


embedded image









19(H10-13)


embedded image









19(H10-14)


embedded image









19(H10-15)


embedded image









19(H10-16)


embedded image






















TABLE 10B-3









embedded image















Example No
R2







19(H10-17)


embedded image









19(H10-18)


embedded image









19(H10-19)


embedded image









19(H10-20)


embedded image









19(H10-21)


embedded image









19(H10-22)


embedded image









19(H10-23)


embedded image









19(H10-24)


embedded image






















TABLE 10B-4









embedded image















Example No
R2







19(H10-25)


embedded image









19(H10-26)


embedded image









19(H10-27)


embedded image









19(H10-28)


embedded image









19(H10-29)


embedded image









19(H10-30)


embedded image









19(H10-31)


embedded image









19(H10-32)


embedded image






















TABLE 10B-5









embedded image















Example No
R2







19(H10-33)


embedded image









19(H10-34)


embedded image









19(H10-35)


embedded image









19(H10-36)


embedded image









19(H10-37)


embedded image









19(H10-38)


embedded image









19(H10-39)


embedded image









19(H10-40)


embedded image









19(H10-41)


embedded image






















TABLE 10B-6









embedded image















Example No
R2







19(H10-42)


embedded image









19(H10-43)


embedded image









19(H10-44)


embedded image









19(H10-45)


embedded image









19(H10-46)


embedded image









19(H10-47)


embedded image









19(H10-48)


embedded image









19(H10-49)


embedded image









19(H10-50)


embedded image









19(H10-51)


embedded image









19(H10-52)


embedded image









19(H10-53)


embedded image






















TABLE 10B-7









embedded image















Example No
R2







19(H10-54)


embedded image









19(H10-55)


embedded image









19(H10-56)


embedded image









19(H10-57)


embedded image









19(H10-58)


embedded image









19(H10-59)


embedded image









19(H10-60)


embedded image









19(H10-61)


embedded image









19(H10-62)


embedded image






















TABLE 10B-8









embedded image















Example No
R2







19(H10-63)


embedded image









19(H10-64)


embedded image









19(H10-65)


embedded image









19(H10-66)


embedded image









19(H10-67)


embedded image









19(H10-68)


embedded image






















TABLE 11B-1









embedded image















Example No
R2







19(H11-1)


embedded image









19(H11-2)


embedded image









19(H11-3)


embedded image









19(H11-4)


embedded image









19(H11-5)


embedded image









19(H11-6)


embedded image









19(H11-7)


embedded image









19(H11-8)


embedded image






















TABLE 11B-2









embedded image















Example No
R2







19(H11-9) 


embedded image









19(H11-10)


embedded image









19(H11-11)


embedded image









19(H11-12)


embedded image









19(H11-13)


embedded image









19(H11-14)


embedded image









19(H11-15)


embedded image









19(H11-16)


embedded image






















TABLE 11B-3









embedded image















Example No
R2







19(H11-17)


embedded image









19(H11-18)


embedded image









19(H11-19)


embedded image









19(H11-20)


embedded image









19(H11-21)


embedded image









19(H11-22)


embedded image









19(H11-23)


embedded image









19(H11-24)


embedded image






















TABLE 11B-4









embedded image















Example No
R2







19(H11-25)


embedded image









19(H11-26)


embedded image









19(H11-27)


embedded image









19(H11-28)


embedded image









19(H11-29)


embedded image









19(H11-30)


embedded image









19(H11-31)


embedded image









19(H11-32)


embedded image









19(H11-33)


embedded image






















TABLE 11B-5









embedded image















Example No
R2







19(H11-34)


embedded image









19(H11-35)


embedded image









19(H11-36)


embedded image









19(H11-37)


embedded image









19(H11-38)


embedded image









19(H11-39)


embedded image









19(H11-40)


embedded image









19(H11-41)


embedded image









19(H11-42)


embedded image









19(H11-43)


embedded image









19(H11-44)


embedded image









19(H11-45)


embedded image






















TABLE 11B-6









embedded image















Example No
R2







19(H11-46)


embedded image









19(H11-47)


embedded image









19(H11-48)


embedded image









19(H11-49)


embedded image









19(H11-50)


embedded image









19(H11-51)


embedded image









19(H11-52)


embedded image









19(H11-53)


embedded image









19(H11-54)


embedded image









19(H11-55)


embedded image






















TABLE 11B-7









embedded image















Example No
R2







19(H11-56)


embedded image









19(H11-57)


embedded image









19(H11-58)


embedded image






















TABLE 12B-1









embedded image















Example No
R2







19(H12-1)


embedded image









19(H12-2)


embedded image









19(H12-3)


embedded image









19(H12-4)


embedded image









19(H12-5)


embedded image









19(H12-6)


embedded image









19(H12-7)


embedded image









19(H12-8)


embedded image






















TABLE 12B-2









embedded image















Example No
R2







19(H12-9)


embedded image









19(H12-9)


embedded image









19(H12-9)


embedded image









19(H12-9)


embedded image









19(H12-9)


embedded image









19(H12-9)


embedded image









19(H12-9)


embedded image









19(H12-9)


embedded image






















TABLE 12B-3









embedded image















Example No
R2







19(H12-17)


embedded image









19(H12-18)


embedded image









19(H12-19)


embedded image









19(H12-20)


embedded image









19(H12-21)


embedded image









19(H12-22)


embedded image









19(H12-23)


embedded image









19(H12-24)


embedded image






















TABLE 12B-4









embedded image















Example No
R2







19(H12-25)


embedded image









19(H12-26)


embedded image









19(H12-27)


embedded image









19(H12-28)


embedded image









19(H12-29)


embedded image









19(H12-30)


embedded image









19(H12-31)


embedded image









19(H12-32)


embedded image






















TABLE 12B-5









embedded image















Example No
R2







19(H12-33)


embedded image









19(H12-34)


embedded image









19(H12-35)


embedded image









19(H12-36)


embedded image









19(H12-37)


embedded image









19(H12-38)


embedded image









19(H12-39)


embedded image









19(H12-40)


embedded image









19(H12-41)


embedded image






















TABLE 12B-6









embedded image















Example No
R2







19(H12-42)


embedded image









19(H12-43)


embedded image









19(H12-44)


embedded image









19(H12-45)


embedded image









19(H12-46)


embedded image









19(H12-47)


embedded image









19(H12-48)


embedded image









19(H12-49)


embedded image









19(H12-50)


embedded image









19(H12-51)


embedded image









19(H12-52)


embedded image









19(H12-53)


embedded image






















TABLE 12B-7









embedded image















Example No
R2







19(H12-54)


embedded image









19(H12-54)


embedded image









19(H12-54)


embedded image









19(H12-54)


embedded image









19(H12-54)


embedded image









19(H12-54)


embedded image









19(H12-54)


embedded image









19(H12-54)


embedded image









19(H12-54)


embedded image









19(H12-54)


embedded image






















TABLE 12B-8









embedded image















Example No
R2







19(H12-64)


embedded image









19(H12-65)


embedded image









19(H12-66)


embedded image









19(H12-67)


embedded image









19(H12-68


embedded image









19(H12-69)


embedded image






















TABLE 13B-1









embedded image















Example No
R2







19(H13-1)


embedded image









19(H13-2)


embedded image









19(H13-3)


embedded image









19(H13-4)


embedded image









19(H13-5)


embedded image









19(H13-6)


embedded image









19(H13-7)


embedded image









19(H13-8)


embedded image






















TABLE 13B-2









embedded image















Example No
R2







19(H13-9)


embedded image









19(H13-10)


embedded image









19(H13-11)


embedded image









19(H13-12)


embedded image









19(H13-13)


embedded image









19(H13-14)


embedded image









19(H13-15)


embedded image









19(H13-16)


embedded image






















TABLE 13B-3









embedded image















Example No
R2







19(H13-17)


embedded image









19(H13-18)


embedded image









19(H13-19)


embedded image









19(H13-20)


embedded image









19(H13-21)


embedded image









19(H13-22)


embedded image









19(H13-23)


embedded image









19(H13-24)


embedded image






















TABLE 13B-4









embedded image















Example No
R2







19(H13-25)


embedded image









19(H13-26)


embedded image









19(H13-27)


embedded image









19(H13-28)


embedded image









19(H13-29)


embedded image









19(H13-31)


embedded image









19(H13-32)


embedded image






















TABLE 13B-5









embedded image















Example No
R2







19(H13-33)


embedded image









19(H13-34)


embedded image









19(H13-35)


embedded image









19(H13-36)


embedded image









19(H13-37)


embedded image









19(H13-38)


embedded image









19(H13-39)


embedded image









19(H13-40)


embedded image









19(H13-41)


embedded image









19(H13-42)


embedded image









19(H13-43)


embedded image









19(H13-44)


embedded image






















TABLE 13B-6









embedded image















Example No
R2







19(H13-45)


embedded image









19(H13-46)


embedded image









19(H13-47)


embedded image









19(H13-48)


embedded image









19(H13-49)


embedded image









19(H13-50)


embedded image









19(H13-51)


embedded image









19(H13-52)


embedded image









19(H13-53)


embedded image









19(H13-54)


embedded image






















TABLE 13B-7









embedded image















Example No
R2







19(H13-55)


embedded image









19(H13-56)


embedded image









19(H13-57)


embedded image









19(H13-58)


embedded image









19(H13-59)


embedded image









19(H13-60)


embedded image









19(H13-61)


embedded image









19(H13-62)


embedded image


























TABLE 1C-1







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















19(H1-1)
F
3.16
410 (M + H)+.
ESI (Pos., 20 V)


19(H1-2)
F
3.17
483 (M + H)+.
ESI (Pos., 20 V)


19(H1-3)
F
4.24
502 (M + H)+.
ESI (Pos., 20 V)


19(H1-4)
F
2.83
358 (M + H)+.
ESI (Pos., 20 V)


19(H1-5)
F
3.09
415 (M + H)+.
ESI (Pos., 20 V)


19(H1-6)
F
3.11
448 (M + H)+.
ESI (Pos., 20 V)


19(H1-7)
F
3.11
487 (M + H)+.
ESI (Pos., 20 V)


19(H1-8)
F
3.17
478 (M + H)+.
ESI (Pos., 20 V)


19(H1-9)
F
3.23
506 (M + H)+.
ESI (Pos., 20 V)


19(H1-10)
F
3.25
563 (M + H)+.
ESI (Pos., 20 V)


19(H1-11)
F
3.35
473 (M + H)+.
ESI (Pos., 20 V)


19(H1-12)
F
3.32
546 (M + H)+.
ESI (Pos., 20 V)


19(H1-13)
F
3.37
537 (M + H)+.
ESI (Pos., 20 V)


19(H1-14)
F
3.01
364 (M + H)+.
ESI (Pos., 20 V)


19(H1-15)
F
3.25
420 (M + H)+.
ESI (Pos., 20 V)


19(H1-16)
F
3.24
454 (M + H)+.
ESI (Pos., 20 V)


19(H1-17)
F
3.23
493 (M + H)+.
ESI (Pos., 20 V)


19(H1-18)
F
3.29
484 (M + H)+.
ESI (Pos., 20 V)


19(H1-19)
F
3.36
512 (M + H)+.
ESI (Pos., 20 V)


19(H1-20)
F
3.38
569 (M + H)+.
ESI (Pos., 20 V)


19(H1-21)
F
3.26
454 (M + H)+.
ESI (Pos., 20 V)


19(H1-22)
F
3.52
510 (M + H)+.
ESI (Pos., 20 V)


19(H1-23)
F
3.51
544 (M + H)+.
ESI (Pos., 20 V)


19(H1-24)
F
3.48
583 (M + H)+.
ESI (Pos., 20 V)


19(H1-25)
F
3.53
574 (M + H)+.
ESI (Pos., 20 V)


19(H1-26)
F
3.59
602 (M + H)+.
ESI (Pos., 20 V)























TABLE 1C-2







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















19(H1-27)
F
3.56
659 (M + H)+.
ESI (Pos., 20 V)


19(H1-28)
F
3.07
378 (M + H)+.
ESI (Pos., 20 V)


19(H1-29)
F
3.31
434 (M + H)+.
ESI (Pos., 20 V)


19(H1-30)
F
3.30
468 (M + H)+.
ESI (Pos., 20 V)


19(H1-31)
F
3.29
507 (M + H)+.
ESI (Pos., 20 V)


19(H1-32)
F
3.35
498 (M + H)+.
ESI (Pos., 20 V)


19(H1-33)
F
3.40
526 (M + H)+.
ESI (Pos., 20 V)


19(H1-34)
F
3.41
583 (M + H)+.
ESI (Pos., 20 V)


19(H1-35)
F
2.84
316 (M + H)+.
ESI (Pos., 20 V)


19(H1-36)
F
3.11
372 (M + H)+.
ESI (Pos., 20 V)


19(H1-37)
F
3.11
406 (M + H)+.
ESI (Pos., 20 V)


19(H1-38)
F
3.09
445 (M + H)+.
ESI (Pos., 20 V)


19(H1-39)
F
3.18
436 (M + H)+.
ESI (Pos., 20 V)


19(H1-40)
F
3.22
464 (M + H)+.
ESI (Pos., 20 V)


19(H1-41)
F
3.26
521 (M + H)+.
ESI (Pos., 20 V)


19(H1-42)
F
3.04
402 (M + H)+.
ESI (Pos., 20 V)


19(H1-43)
F
3.34
458 (M + H)+.
ESI (Pos., 20 V)


19(H1-44)
F
3.36
492 (M + H)+.
ESI (Pos., 20 V)


19(H1-45)
F
3.30
531 (M + H)+.
ESI (Pos., 20 V)


19(H1-46)
F
3.35
522 (M + H)+.
ESI (Pos., 20 V)


19(H1-47)
F
3.39
550 (M + H)+.
ESI (Pos., 20 V)


19(H1-48)
F
3.40
607 (M + H)+.
ESI (Pos., 20 V)


19(H1-49)
F
2.85
433 (M + H)+.
ESI (Pos., 20 V)


19(H1-50)
F
3.03
489 (M + H)+.
ESI (Pos., 20 V)


19(H1-51)
F
3.05
523 (M + H)+.
ESI (Pos., 20 V)


19(H1-52)
F
3.06
562 (M + H)+.
ESI (Pos., 20 V)























TABLE 1C-3







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















19(H1-53)
F
3.11
553 (M + H)+.
ESI (Pos., 20 V)


19(H1-54)
F
3.14
581 (M + H)+.
ESI (Pos., 20 V)


19(H1-55)
F
3.16
638 (M + H)+.
ESI (Pos., 20 V)























TABLE 2C-1







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















19(H2-1)
B
10.20
368 (M + H)+.
APCI (Pos., 40 V)


19(H2-2)
F
3.23
497 (M + H)+.
ESI (Pos., 20 V)


19(H2-3)
F
3.73
488 (M + H)+.
ESI (Pos., 20 V)


19(H2-4)
F
3.72
516 (M + H)+.
ESI (Pos., 20 V)


19(H2-5)
C
14.80
573 (M + H)+,
APCI (Pos., 40 V)





465.


19(H2-6)
F
2.91
372 (M + H)+.
ESI (Pos., 20 V)


19(H2-7)
F
3.15
428 (M + H)+.
ESI (Pos., 20 V)


19(H2-8)
F
3.17
462 (M + H)+.
ESI (Pos., 20 V)


19(H2-9)
F
3.17
501 (M + H)+.
ESI (Pos., 20 V)


19(H2-10)
F
3.24
492 (M + H)+.
ESI (Pos., 20 V)


19(H2-11)
F
3.26
520 (M + H)+.
ESI (Pos., 20 V)


19(H2-12)
F
3.30
577 (M + H)+.
ESI (Pos., 20 V)


19(H2-13)
F
3.16
431 (M + H)+.
ESI (Pos., 20 V)


19(H2-14)
F
3.37
487 (M + H)+.
ESI (Pos., 20 V)


19(H2-15)
B
17.50
521 (M + H)+,
APCI (Pos., 40 V)





144.


19(H2-16)
F
3.34
560 (M + H)+.
ESI (Pos., 20 V)


19(H2-17)
F
3.41
551 (M + H)+.
ESI (Pos., 20 V)


19(H2-18)
F
3.44
579 (M + H)+.
ESI (Pos., 20 V)


19(H2-19)
C
15.70
636 (M + H)+,
APCI (Pos., 40 V)





528, 279.


19(H2-20)
F
3.07
378 (M + H)+.
ESI (Pos., 20 V)


19(H2-21)
F
3.30
434 (M + H)+.
ESI (Pos., 20 V)


19(H2-22)
F
3.31
468 (M + H)+.
ESI (Pos., 20 V)


19(H2-23)
F
3.30
507 (M + H)+.
ESI (Pos., 20 V)


19(H2-24)
F
3.36
498 (M + H)+.
ESI (Pos., 20 V)


19(H2-25)
F
3.41
526 (M + H)+.
ESI (Pos., 20 V)


19(H2-26)
F
3.42
583 (M + H)+.
ESI (Pos.. 20 V)























TABLE 2C-2







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















19(H2-27)
F
3.33
468 (M + H)+.
ESI (Pos., 20 V)


19(H2-28)
F
3.57
524 (M + H)+.
ESI (Pos., 20 V)


19(H2-29)
F
3.55
558 (M + H)+.
ESI (Pos., 20 V)


19(H2-30)
F
3.54
597 (M + H)+.
ESI (Pos., 20 V)


19(H2-31)
F
3.60
588 (M + H)+.
ESI (Pos., 20 V)


19(H2-32)
F
3.65
616 (M + H)+.
ESI (Pos., 20 V)


19(H2-33)
F
3.60
673 (M + H)+.
ESI (Pos., 20 V)


19(H2-34)
F
3.13
392 (M + H)+.
ESI (Pos., 20 V)


19(H2-35)
F
3.37
448 (M + H)+.
ESI (Pos., 20 V)


19(H2-36)
F
3.37
482 (M + H)+.
ESI (Pos., 20 V)


19(H2-37)
F
3.35
521 (M + H)+.
ESI (Pos., 20 V)


19(H2-38)
F
3.42
512 (M + H)+.
ESI (Pos., 20 V)


19(H2-39)
F
3.46
540 (M + H)+.
ESI (Pos., 20 V)


19(H2-40)
F
3.50
597 (M + H)+.
ESI (Pos., 20 V)


19(H2-41)
F
2.92
330 (M + H)+.
ESI (Pos., 20 V)


19(H2-42)
F
3.20
386 (M + H)+.
ESI (Pos., 20 V)


19(H2-43)
F
3.17
420 (M + H)+.
ESI (Pos., 20 V)


19(H2-44)
F
3.17
459 (M + H)+.
ESI (Pos., 20 V)


19(H2-45)
F
3.26
450 (M + H)+.
ESI (Pos., 20 V)


19(H2-46)
F
3.30
478 (M + H)+.
ESI (Pos., 20 V)


19(H2-47)
F
3.32
535 (M + H)+.
ESI (Pos., 20 V)


19(H2-48)
F
3.11
416 (M + H)+.
ESI (Pos., 20 V)


19(H2-49)
F
3.36
472 (M + H)+.
ESI (Pos., 20 V)


19(H2-50)
F
3.34
506 (M + H)+.
ESI (Pos., 20 V)


19(H2-51)
F
3.33
545 (M + H)+.
ESI (Pos., 20 V)


19(H2-52)
F
3.41
536 (M + H)+.
ESI (Pos., 20 V)























TABLE 2C-3







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















19(H2-53)
F
3.50
564 (M + H)+.
ESI (Pos., 20 V)


19(H2-54)
F
3.50
621 (M + H)+.
ESI (Pos., 20 V)


19(H2-55)
F
2.92
447 (M + H)+.
ESI (Pos., 20 V)


19(H2-56)
F
3.09
503 (M + H)+.
ESI (Pos., 20 V)


19(H2-57)
F
3.09
537 (M + H)+.
ESI (Pos., 20 V)


19(H2-58)
F
3.11
576 (M + H)+.
ESI (Pos., 20 V)


19(H2-59)
F
3.18
567 (M + H)+.
ESI (Pos., 20 V)


19(H2-60)
F
3.20
595 (M + H)+.
ESI (Pos., 20 V)


19(H2-61)
F
3.24
652 (M + H)+.
ESI (Pos., 20 V)























TABLE 3C-1







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















19(H3-1)
B
10.80
382 (M + H)+.
APCI (Pos., 40 V)


19(H3-2)
F
3.27
438 (M + H)+.
ESI (Pos., 20 V)


19(H3-3)
F
3.28
472 (M + H)+.
ESI (Pos., 20 V)


19(H3-4)
F
3.27
511 (M + H)+.
ESI (Pos., 20 V)


19(H3-5)
F
3.35
502 (M + H)+.
ESI (Pos., 20 V)


19(H3-6)
F
3.37
530 (M + H)+.
ESI (Pos., 20 V)


19(H3-7)
F
2.98
386 (M + H)+.
ESI (Pos., 20 V)


19(H3-8)
F
3.22
442 (M + H)+.
ESI (Pos., 20 V)


19(H3-9)
F
3.23
476 (M + H)+.
ESI (Pos., 20 V)


19(H3-10)
F
3.23
476 (M + H)+.
ESI (Pos., 20 V)


19(H3-11)
F
3.22
515 (M + H)+.
ESI (Pos., 20 V)


19(H3-12)
F
3.29
506 (M + H)+.
ESI (Pos., 20 V)


19(H3-13)
F
3.31
534 (M + H)+.
ESI (Pos., 20 V)


19(H3-14)
F
3.34
591 (M + H)+.
ESI (Pos., 20 V)


19(H3-15)
F
3.20
445 (M + H)+.
ESI (Pos., 20 V)


19(H3-16)
F
3.43
501 (M + H)+.
ESI (Pos., 20 V)


19(H3-17)
F
3.40
535 (M + H)+.
ESI (Pos., 20 V)


19(H3-18)
F
3.39
571 (M + H)+.
ESI (Pos., 20 V)


19(H3-19)
F
3.45
565 (M + H)+.
ESI (Pos., 20 V)


19(H3-20)
F
3.49
593 (M + H)+.
ESI (Pos., 20 V)


19(H3-21)
F
3.49
650 (M + H)+.
ESI (Pos., 20 V)


19(H3-22)
F
3.13
392 (M + H)+.
ESI (Pos., 20 V)


19(H3-23)
F
3.35
448 (M + H)+.
ESI (Pos., 20 V)


19(H3-24)
F
3.34
482 (M + H)+.
ESI (Pos., 20 V)


19(H3-25)
F
3.34
521 (M + H)+.
ESI (Pos., 20 V)


19(H3-26)
F
3.42
512 (M + H)+.
ESI (Pos., 20 V)























TABLE 3C-2







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















19(H3-27)
F
3.45
540 (M + H)+.
ESI (Pos., 20 V)


19(H3-28)
F
3.46
597 (M + H)+.
ESI (Pos., 20 V)


19(H3-29)
F
3.37
482 (M + H)+.
ESI (Pos., 20 V)


19(H3-30)
F
3.61
538 (M + H)+.
ESI (Pos., 20 V)


19(H3-31)
F
3.61
572 (M + H)+.
ESI (Pos., 20 V)


19(H3-32)
F
3.57
611 (M + H)+.
ESI (Pos., 20 V)


19(H3-33)
F
3.64
602 (M + H)+.
ESI (Pos., 20 V)


19(H3-34)
F
3.68
630 (M + H)+.
ESI (Pos., 20 V)


19(H3-35)
F
3.66
687 (M + H)+.
ESI (Pos., 20 V)


19(H3-36)
F
3.20
406 (M + H)+.
ESI (Pos., 20 V)


19(H3-37)
F
3.43
462 (M + H)+.
ESI (Pos., 20 V)


19(H3-38)
F
3.42
496 (M + H)+.
ESI (Pos., 20 V)


19(H3-39)
F
3.40
535 (M + H)+.
ESI (Pos., 20 V)


19(H3-40)
F
3.48
526 (M + H)+.
ESI (Pos., 20 V)


19(H3-41)
F
3.50
554 (M + H)+.
ESI (Pos., 20 V)


19(H3-42)
F
3.51
611 (M + H)+.
ESI (Pos., 20 V)


19(H3-43)
F
3.01
344 (M + H)+.
ESI (Pos., 20 V)


19(H3-44)
F
3.23
400 (M + H)+.
ESI (Pos., 20 V)


19(H3-45)
F
3.24
434 (M + H)+.
ESI (Pos., 20 V)


19(H3-46)
F
3.25
473 (M + H)+.
ESI (Pos., 20 V)


19(H3-47)
F
3.30
464 (M + H)+.
ESI (Pos., 20 V)


19(H3-48)
F
3.33
492 (M + H)+.
ESI (Pos., 20 V)


19(H3-49)
F
3.37
549 (M + H)+.
ESI (Pos., 20 V)


19(H3-50)
F
3.18
430 (M + H)+.
ESI (Pos., 20 V)


19(H3-51)
F
3.40
486 (M + H)+.
ESI (Pos., 20 V)


19(H3-52)
F
3.40
520 (M + H)+.
ESI (Pos., 20 V)























TABLE 3C-3







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















19(H3-53)
F
3.40
559 (M + H)+.
ESI (Pos., 20 V)


19(H3-54)
F
3.45
550 (M + H)+.
ESI (Pos., 20 V)


19(H3-55)
F
3.49
578 (M + H)+.
ESI (Pos., 20 V)


19(H3-56)
F
3.51
635 (M + H)+.
ESI (Pos., 20 V)


19(H3-57)
F
2.98
461 (M + H)+.
ESI (Pos., 20 V)


19(H3-58)
F
3.14
517 (M + H)+.
ESI (Pos., 20 V)


19(H3-59)
F
3.14
551 (M + H)+.
ESI (Pos., 20 V)


19(H3-60)
F
3.15
590 (M + H)+.
ESI (Pos., 20 V)


19(H3-61)
F
3.21
581 (M + H)+.
ESI (Pos., 20 V)


19(H3-62)
F
3.24
609 (M + H)+.
ESI (Pos., 20 V)


19(H3-63)
F
3.27
666 (M + H)+.
ESI (Pos., 20 V)























TABLE 4C-1







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition







19(H4-1)
F
3.14
396 (M + H)+.
ESI (Pos., 20 V)


19(H4-2)
F
3.36
453 (M + H)+.
ESI (Pos., 20 V)


19(H4-3)
F
3.35
486 (M + H)+.
ESI (Pos., 20 V)


19(H4-4)
F
3.36
525 (M + H)+.
ESI (Pos., 20 V)


19(H4-5)
F
3.41
516 (M + H)+.
ESI (Pos., 20 V)


19(H4-6)
F
3.45
544 (M + H)+.
ESI (Pos., 20 V)


19(H4-7)
F
3.45
601 (M + H)+.
ESI (Pos., 20 V)


19(H4-8)
F
3.05
400 (M + H)+.
ESI (Pos., 20 V)


19(H4-9)
F
3.29
456 (M + H)+.
ESI (Pos., 20 V)


19(H4-10)
F
3.29
490 (M + H)+.
ESI (Pos., 20 V)


19(H4-11)
F
3.29
529 (M + H)+.
ESI (Pos., 20 V)


19(H4-12)
F
3.36
520 (M + H)+.
ESI (Pos., 20 V)


19(H4-13)
F
3.38
548 (M + H)+.
ESI (Pos., 20 V)


19(H4-14)
F
3.42
605 (M + H)+.
ESI (Pos., 20 V)


19(H4-15)
F
3.26
459 (M + H)+.
ESI (Pos., 20 V)


19(H4-16)
F
3.47
515 (M + H)+.
ESI (Pos., 20 V)


19(H4-17)
F
3.47
549 (M + H)+.
ESI (Pos., 20 V)


19(H4-18)
F
3.44
588 (M + H)+.
ESI (Pos., 20 V)


19(H4-19)
F
3.51
579 (M + H)+.
ESI (Pos., 20 V)


19(H4-20)
F
3.54
607 (M + H)+.
ESI (Pos., 20 V)


19(H4-21)
F
3.55
664 (M + H)+.
ESI (Pos., 20 V)


19(H4-22)
F
3.20
406 (M + H)+.
ESI (Pos., 20 V)


19(H4-23)
F
3.44
462 (M + H)+.
ESI (Pos., 20 V)


19(H4-24)
F
3.42
496 (M + H)+.
ESI (Pos., 20 V)


19(H4-25)
F
3.42
535 (M + H)+.
ESI (Pos., 20 V)


19(H4-26)
F
3.47
526 (M + H)+.
ESI (Pos., 20 V)























TABLE 4C-2







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















19(H4-27)
F
3.51
554 (M + H)+.
ESI (Pos., 20 V)


19(H4-28)
F
3.52
611 (M + H)+.
ESI (Pos., 20 V)


19(H4-29)
F
3.42
496 (M + H)+.
ESI (Pos., 20 V)


19(H4-30)
F
3.66
552 (M + H)+.
ESI (Pos., 20 V)


19(H4-31)
F
3.66
586 (M + H)+.
ESI (Pos., 20 V)


19(H4-32)
F
3.62
625 (M + H)+.
ESI (Pos., 20 V)


19(H4-33)
F
3.68
616 (M + H)+.
ESI (Pos., 20 V)


19(H4-34)
F
3.72
644 (M + H)+.
ESI (Pos., 20 V)


19(H4-35)
F
3.69
701 (M + H)+.
ESI (Pos., 20 V)


19(H4-36)
F
3.26
420 (M + H)+.
ESI (Pos., 20 V)


19(H4-37)
F
3.48
476 (M + H)+.
ESI (Pos., 20 V)


19(H4-38)
F
3.46
510 (M + H)+.
ESI (Pos., 20 V)


19(H4-39)
F
3.46
549 (M + H)+.
ESI (Pos., 20 V)


19(H4-40)
F
3.55
540 (M + H)+.
ESI (Pos., 20 V)


19(H4-41)
F
3.56
568 (M + H)+.
ESI (Pos., 20 V)


19(H4-42)
F
3.57
625 (M + H)+.
ESI (Pos., 20 V)


19(H4-43)
F
3.09
358 (M + H)+.
ESI (Pos., 20 V)


19(H4-44)
F
3.31
414 (M + H)+.
ESI (Pos., 20 V)


19(H4-45)
F
3.31
448 (M + H)+.
ESI (Pos., 20 V)


19(H4-46)
F
3.31
487 (M + H)+.
ESI (Pos., 20 V)


19(H4-47)
F
3.38
478 (M + H)+.
ESI (Pos., 20 V)


19(H4-48)
F
3.40
506 (M + H)+.
ESI (Pos., 20 V)


19(H4-49)
F
3.43
563 (M + H)+.
ESI (Pos., 20 V)


19(H4-50)
F
3.25
444 (M + H)+.
ESI (Pos., 20 V)


19(H4-51)
F
3.50
500 (M + H)+.
ESI (Pos., 20 V)


19(H4-52)
F
3.47
534 (M + H)+.
ESI (Pos., 20 V)























TABLE 4C-3







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















19(H4-53)
F
3.46
573 (M + H)+.
ESI (Pos., 20 V)


19(H4-54)
F
3.53
564 (M + H)+.
ESI (Pos., 20 V)


19(H4-55)
F
3.55
592 (M + H)+.
ESI (Pos., 20 V)


19(H4-56)
F
3.56
649 (M + H)+.
ESI (Pos., 20 V)


19(H4-57)
F
3.05
475 (M + H)+.
ESI (Pos., 20 V)


19(H4-58)
F
3.19
531 (M + H)+.
ESI (Pos., 20 V)


19(H4-59)
F
3.20
565 (M + H)+.
ESI (Pos., 20 V)


19(H4-60)
F
3.22
604 (M + H)+.
ESI (Pos., 20 V)


19(H4-61)
F
3.27
595 (M + H)+.
ESI (Pos., 20 V)


19(H4-62)
F
3.30
623 (M + H)+.
ESI (Pos., 20 V)


19(H4-63)
F
3.33
680 (M + H)+.
ESI (Pos., 20 V)























TABLE 5C-1







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















19(H5-1)
F
2.89
340 (M + H)+.
ESI (Pos., 20 V)


19(H5-2)
F
3.17
396 (M + H)+.
ESI (Pos., 20 V)


19(H5-3)
F
3.16
430 (M + H)+.
ESI (Pos., 20 V)


19(H5-4)
F
3.14
469 (M + H)+.
ESI (Pos., 20 V)


19(H5-5)
F
3.23
460 (M + H)+.
ESI (Pos., 20 V)


19(H5-6)
F
3.29
488 (M + H)+.
ESI (Pos., 20 V)


19(H5-7)
F
3.31
545 (M + H)+.
ESI (Pos., 20 V)


19(H5-8)
F
2.79
344 (M + H)+.
ESI (Pos., 20 V)


19(H5-9)
F
3.07
400 (M + H)+.
ESI (Pos., 20 V)


19(H5-10)
F
3.09
434 (M + H)+.
ESI (Pos., 20 V)


19(H5-11)
F
3.07
473 (M + H)+.
ESI (Pos., 20 V)


19(H5-12)
F
3.16
464 (M + H)+.
ESI (Pos., 20 V)


19(H5-13)
F
3.20
492 (M + H)+.
ESI (Pos., 20 V)


19(H5-14)
F
3.22
549 (M + H)+.
ESI (Pos., 20 V)


19(H5-15)
F
3.08
403 (M + H)+.
ESI (Pos., 20 V)


19(H5-16)
F
3.34
459 (M + H)+.
ESI (Pos., 20 V)


19(H5-17)
F
3.31
493 (M + H)+.
ESI (Pos., 20 V)


19(H5-18)
F
3.29
532 (M + H)+.
ESI (Pos., 20 V)


19(H5-19)
F
3.36
523 (M + H)+.
ESI (Pos., 20 V)


19(H5-20)
F
3.42
551 (M + H)+.
ESI (Pos., 20 V)


19(H5-21)
F
3.42
608 (M + H)+.
ESI (Pos., 20 V)


19(H5-22)
F
3.00
350 (M + H)+.
ESI (Pos., 20 V)


19(H5-23)
F
3.27
406 (M + H)+.
ESI (Pos., 20 V)


19(H5-24)
F
3.25
440 (M + H)+.
ESI (Pos., 20 V)


19(H5-25)
F
3.23
479 (M + H)+.
ESI (Pos., 20 V)


19(H5-26)
F
3.31
470 (M + H)+.
ESI (Pos., 20 V)























TABLE 5C-2







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















19(H5-27)
F
3.38
498 (M + H)+.
ESI (Pos., 20 V)


19(H5-28)
F
3.38
555 (M + H)+.
ESI (Pos., 20 V)


19(H5-29)
F
3.31
440 (M + H)+.
ESI (Pos., 20 V)


19(H5-30)
F
3.61
496 (M + H)+.
ESI (Pos., 20 V)


19(H5-31)
F
3.57
530 (M + H)+.
ESI (Pos., 20 V)


19(H5-32)
F
3.51
569 (M + H)+.
ESI (Pos., 20 V)


19(H5-33)
F
3.61
560 (M + H)+.
ESI (Pos., 20 V)


19(HS-34)
F
3.66
588 (M + H)+.
ESI (Pos., 20 V)


19(H5-35)
F
3.62
645 (M + H)+.
ESI (Pos., 20 V)


19(H5-36)
F
3.07
364 (M + H)+.
ESI (Pos., 20 V)


19(H5-37)
F
3.36
420 (M + H)+.
ESI (Pos., 20 V)


19(H5-38)
F
3.33
454 (M + H)+.
ESI (Pos., 20 V)


19(H5-39)
F
3.29
493 (M + H)+.
ESI (Pos., 20 V)


19(H5-40)
F
3.38
484 (M + H)+.
ESI (Pos., 20 V)


19(H5-41)
F
3.44
512 (M + H)+.
ESI (Pos., 20 V)


19(H5-42)
F
3.44
569 (M + H)+.
ESI (Pos., 20 V)


19(H5-43)
F
2.81
302 (M + H)+.
ESI (Pos., 20 V)


19(H5-44)
F
3.11
358 (M + H)+.
ESI (Pos., 20 V)


19(H5-45)
F
3.09
392 (M + H)+.
ESI (Pos., 20 V)


19(H5-46)
F
3.09
431 (M + H)+.
ESI (Pos., 20 V)


19(H5-47)
F
3.18
422 (M + H)+.
ESI (Pos., 20 V)


19(H5-48)
F
3.22
450 (M + H)+.
ESI (Pos., 20 V)


19(H5-49)
F
3.25
507 (M + H)+.
ESI (Pos., 20 V)


19(H5-50)
F
3.03
388 (M + H)+.
ESI (Pos., 20 V)


19(H5-51)
F
3.33
444 (M + H)+.
ESI (Pos., 20 V)


19(H5-52)
F
3.29
478 (M + H)+.
ESI (Pos., 20 V)























TABLE 5C-3







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















19(H5-53)
F
3.27
517 (M + H)+.
ESI (Pos., 20 V)


19(H5-54)
F
3.36
508 (M + H)+.
ESI (Pos., 20 V)


19(H5-55)
F
3.42
536 (M + H)+.
ESI (Pos., 20 V)


19(H5-56)
F
3.42
593 (M + H)+.
ESI (Pos., 20 V)


19(H5-57)
F
3.05
475 (M + H)+.
ESI (Pos., 20 V)


19(H5-58)
A
3.07
509 (M + H)+.
APCI (Pos., 40 V)


19(H5-59)
F
3.11
548 (M + H)+.
ESI (Pos., 20 V)


19(H5-60)
F
3.11
539 (M + H)+.
ESI (Pos., 20 V)


19(H5-61)
F
3.18
566 (M + H)+.
ESI (Pos., 20 V)


19(H5-62)
F
3.46
624 (M + H)+.
ESI (Pos., 20 V)























TABLE 6C-1







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















19(H6-1)
C
14.10
410 (M + H)+.
APCI (Pos., 40 V)


19(H6-2)
D
15.20
530 (M + H)+,
APCI (Pos., 40 V)





279.


19(H6-3)
D
12.60
414 (M + H)+,
ARCI (Pos., 40 V)





264.


19(H6-4)
C
15.40
470 (M + H)+,
APCI (Pos., 40 V)





215.


19(H6-5)
D
15.00
504 (M + H)+,
APCI (Pos., 40 V)





354.


19(H6-6)
D
14.60
543 (M + H)+,
APCI (Pos., 40 V)





279.


19(H6-7)
D
15.30
534 (M + H)+,
APCI (Pos., 40 V)





426, 279.


19(H6-8)
D
15.30
562 (M + H)+,
APCI (Pos., 40 V)





244.


19(H6-9)
D
15.50
619 (M + H)+,
APCI (Pos., 40 V)





511, 281.


19(H6-10)
F
3.38
473 (M + H)+.
ESI (Pos., 20 V)


19(H6-11)
F
3.59
529 (M + H)+.
ESI (Pos., 20 V)


19(H6-12)
C
16.50
563 (M + H)+,
APCI (Pos., 40 V)





144.


19(H6-13)
F
3.55
602 (M + H)+.
ESI (Pos., 20 V)


19(H6-14)
D
15.80
593 (M + H)+.
APCI (Pos., 40 V)


19(H6-15)
F
3.64
621 (M + H)+.
ESI (Pos., 20 V)


19(H6-16)
F
3.65
678 (M + H)+.
ESI (Pos., 20 V)


19(H6-17)
C
14.90
420 (M + H)+,
APCI (Pos., 40 V)





270.


19(H6-18)
F
3.55
476 (M + H)+.
ESI (Pos., 20 V)


19(H6-19)
F
3.55
510 (M + H)+.
ESI (Pos., 20 V)


19(H6-20)
C
15.80
549 (M + H)+,
APCI (Pos., 40 V)





279.


19(H6-21)
D
15.70
540 (M + H)+.
ARCI (Pos., 40 V)


19(H6-22)
F
3.62
568 (M + H)+.
ESI (Pos., 20 V)


19(H6-23)
F
3.62
625 (M + H)+.
ESI (Pos., 20 V)


19(H6-24)
F
3.55
510 (M + H)+.
ESI (Pos., 20 V)


19(H6-25)
F
3.79
566 (M + H)+.
ESI (Pos., 20 V)


19(H6-26)
F
3.78
600 (M + H)+.
ESI (Pos., 20 V)























TABLE 6C-2






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















19(H6-27)
F
3.74
639 (M + H)+.
ESI (Pos., 20 V)


19(H6-28)
D
17.20
630 (M + H)+,
APCI (Pos., 40 V)





480, 279.


19(H6-29)
F
3.84
658 (M + H)+.
ESI (Pos., 20 V)


19(H6-30)
F
3.80
715 (M + H)+.
ESI (Pos., 20 V)


19(H6-31)
C
15.50
434 (M + H)+,
APCI (Pos., 40 V)





284.


19(H6-32)
F
3.60
490 (M + H)+.
ESI (Pos., 20 V)


19(H6-33)
F
3.60
524 (M + H)+.
ESI (Pos., 20 V)


19(H6-34)
F
3.56
563 (M + H)+.
ESI (Pos., 20 V)


19(H6-35)
C
17.20
554 (M + H)+,
APCI (Pos., 40 V)





446.


19(H6-36)
F
3.67
582 (M + H)+.
ESI (Pos., 20 V)


19(H6-37)
F
3.67
639 (M + H)+.
ESI (Pos., 20 V)


19(H6-38)
F
3.22
372 (M + H)+.
ESI (Pos., 20 V)


19(H6-39)
D
14.30
428 (M + H)+,
APCI (Pos., 40 V)





279.


19(H6-40)
F
3.44
462 (M + H)+.
ESI (Pos., 20 V)


19(H6-41)
F
3.42
501 (M + H)+.
ESI (Pos., 20 V)


19(H6-42)
D
15.20
492 (M + H)+,
APCI (Pos., 40 V)





384, 279


19(H6-43)
C
16.20
520 (M + H)+,
APCI (Pos., 40 V)





224.


19(H6-44)
C
16.40
577 (M + H)+,
APCI (Pos., 40 V)





469, 281.


19(H6-45)
F
3.36
458 (M + H)+.
ESI (Pos., 20 V)


19(H6-46)
F
3.60
514 (M + H)+.
ESI (Pos., 20 V)


19(H6-47)
F
3.59
548 (M + H)+.
ESI (Pos., 20 V)


19(H6-48)
F
3.57
587 (M + H)+.
ESI (Pos., 20 V)


19(H6-49)
D
16.20
578 (M + H)+,
APCI (Pos., 40 V)





522.


19(H6-50)
C
17.20
606 (M + H)+,
APCI (Pos., 40 V)





550.


19(H6-51)
F
3.66
663 (M + H)+.
ESI (Pos., 20 V)


19(H6-52)
F
3.16
489 (M + H)+.
ESI (Pos., 20 V)























TABLE 6C-3






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















19(H6-53)
F
3.33
545 (M + H)+.
ESI (Pos., 20 V)


19(H6-54)
C
15.20
579 (M + H)+,
APCI (Pos., 40 V)




15.70
420, 158.


19(H6-55)
F
3.33
618 (M + H)+.
ESI (Pos., 20 V)


19(H6-56)
C
15.60
609 (M + H)+,
APCI (Pos., 40 V)




16.00
501, 279, 158.


19(H6-57)
F
3.40
637 (M + H)+.
ESI (Pos., 20 V)


19(H6-58)
F
3.44
694 (M + H)+.
ESI (Pos., 20 V)























TABLE 7C-1







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















19(H7-1)
C
15.20
424 (M + H)+.
APCI (Pos., 40 V)


19(H7-2)
D
14.90
480 (M + H)+.
APCI (Pos., 40 V)


19(H7-3)
F
3.57
514 (M + H)+.
ESI (Pos., 20 V)


19(H7-4)
F
3.55
553 (M + H)+.
ESI (Pos., 20 V)


19(H7-5)
C
17.10
544 (M + H)+.
APCI (Pos., 40 V)


19(H7-6)
C
15.20
428 (M + H)+,
APCI (Pos., 40 V)





264.


19(H7-7)
D
15.00
484 (M + H)+.
APCI (Pos., 40 V)


19(H7-8)
F
3.51
518 (M + H)+.
ESI (Pos., 20 V)


19(H7-9)
F
3.49
557 (M + H)+.
ESI (Pos., 20 V)


19(H7-10)
F
3.56
548 (M + H)+.
ESI (Pos., 20 V)


19(H7-11)
C
17.20
576 (M + H)+,
APCI (Pos., 40 V)





197.


19(H7-12)
F
3.59
633 (M + H)+.
ESI (Pos., 20 V)


19(H7-13)
C
16.20
487 (M + H)+,
APCI (Pos., 40 V)





279.


19(H7-14)
D
15.70
543 (M + H)+,
APCI (Pos., 40 V)





274.


19(H7-15)
F
3.64
577 (M + H)+.
ESI (Pos., 20 V)


19(H7-16)
F
3.62
616 (M + H)+.
ESI (Pos., 20 V)


19(H7-17)
F
3.68
607 (M + H)+.
ESI (Pos., 20 V)


19(H7-18)
F
3.72
635 (M + H)+.
ESI (Pos., 20 V)


19(H7-19)
C
17.70
692 (M + H)+,
APCI (Pos., 40 V)





584.


19(H7-20)
C
15.60
434 (M + H)+,
APCI (Pos., 40 V)





270.


19(H7-21)
C
17.20
490 (M + H)+,
APCI (Pos., 40 V)





326, 221.


19(H7-22)
C
17.20
524 (M + H)+,
APCI (Pos., 40 V)





360, 255.


19(H7-23)
C
16.90
563 (M + H)+.
APCI (Pos., 40 V)


19(H7-24)
C
17.50
554 (M + H)+,
APCI (Pos., 40 V)





285.


19(H7-25)
C
17.70
582 (M + H)+,
APCI (Pos., 40 V)





313, 149.


19(H7-26)
C
17.70
639 (M + H)+,
APCI (Pos., 40 V)





531, 370, 213.























TABLE 7C-2






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















19(H7-27)
C
17.70
524 (M + H)+,
APCI (Pos., 40 V)





360, 255, 181.


19(H7-28)
D
17.10
580 (M + H)+,
APCI (Pos., 40 V)





416, 181.


19(H7-29)
F
3.86
614 (M + H)+.
ESI (Pos., 20 V)


19(H7-30)
F
3.80
653 (M + H)+.
ESI (Pos., 20 V)


19(H7-31)
C
19.00
644 (M + H)+,
APCI (Pos., 40 V)





149.


19(H7-32)
F
3.91
672 (M + H)+.
ESI (Pos., 20 V)


19(H7-33)
F
3.87
729 (M + H)+.
ESI (Pos., 20 V)


19(H7-34)
D
16.10
504 (M + H)+,
APCI (Pos., 40 V)





235.


19(H7-35)
F
3.67
538 (M + H)+.
ESI (Pos., 20 V)


19(H7-36)
F
3.66
577 (M + H)+.
ESI (Pos., 20 V)


19(H7-37)
F
3.73
568 (M + H)+.
ESI (Pos., 20 V)


19(H7-38)
F
3.76
596 (M + H)+.
ESI (Pos., 20 V)


19(H7-39)
F
3.72
653 (M + H)+.
ESI (Pos., 20 V)


19(H7-40)
C
15.20
386 (M + H)+,
APCI (Pos., 40 V)





222.


19(H7-41)
D
14.90
442 (M + H)+,
APCI (Pos., 40 V)





278.


19(H7-42)
D
15.20
476 (M + H)+,
APCI (Pos., 40 V)





312.


19(H7-43)
C
16.40
515 (M + H)+,
APCI (Pos., 40 V)





488, 404, 351,





256, 220, 146,





130.


19(H7-44)
D
15.50
506 (M + H)+,
APCI (Pos., 40 V)





398.


19(H7-45)
D
15.50
534 (M + H)+.
APCI (Pos., 40 V)


19(H7-46)
D
15.80
591 (M + H)+,
APCI (Pos., 40 V)





483.


19(H7-47)
C
16.60
472 (M + H)+,
APCI (Pos., 40 V)





416, 279


19(H7-48)
C
17.40
528 (M + H)+,
APCI (Pos., 40 V)





499, 473, 452,





415, 247, 203,





149.


19(H7-49)
F
3.69
562 (M + H)+.
ESI (Pos., 20 V)


19(H7-50)
F
3.66
601 (M + H)+.
ESI (Pos., 20 V)


19(H7-51)
F
3.71
592 (M + H)+.
ESI (Pos., 20 V)























TABLE 7C-3






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















19(H7-52)
F
3.74
620 (M + H)+.
ESI (Pos., 20 V)


19(H7-53)
F
3.75
677 (M + H)+.
ESI (Pos., 20 V)


19(H7-54)
C
14.70
503 (M + H)+,
APCI (Pos., 40 V)





344.


19(H7-55)
D
14.20
559 (M + H)+,
APCI (Pos., 40 V)





400, 279, 158.


19(H7-56)
F
3.39
593 (M + H)+.
ESI (Pos., 20 V)


19(H7-57)
F
3.39
632 (M + H)+.
ESI (Pos., 20 V)


19(H7-58)
F
3.46
623 (M + H)+.
ESI (Pos., 20 V)


19(H7-59)
F
3.48
651 (M + H)+.
ESI (Pos., 20 V)


19(H7-60)
F
3.51
708 (M + H)+.
ESI (Pos., 20 V)























TABLE 8C-1






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















19(H8-1)
C
10.70
368 (M + H)+,
APCI (Pos., 40 V)





250.


19(H8-2)
F
2.98
407 (M + H)+.
ESI (Pos., 20 V)


19(H8-3)
F
0.67
282 (M + H)+.
ESI (Pos., 20 V)


19(H8-4)
C
9.60
338 (M + H)+.
APCI (Pos., 40 V)




10.30


19(H8-5)
F
2.90
372 (M + H)+.
ESI (Pos., 20 V)


19(H8-6)
F
2.92
411 (M + H)+.
ESI (Pos., 20 V)


19(H8-7)
F
2.98
402 (M + H)+.
ESI (Pos., 20 V)


19(H8-8)
F
3.03
452 (M + Na)+,
ESI (Pos., 20 V)





430 (M + H)+.


19(H8-9)
F
3.09
509 (M + Na)+,
ESI (Pos., 20 V)





487 (M + H)+.


19(H8-10)
C
9.20
341 (M + H)+.
APCI (Pos., 40 V)


19(H8-11)
F
3.14
397 (M + H)+.
ESI (Pos., 20 V)


19(H8-12)
F
3.12
431 (M + H)+.
ESI (Pos., 20 V)


19(H8-13)
F
3.12
470 (M + H)+.
ESI (Pos., 20 V)


19(H8-14)
F
3.18
461 (M + H)+.
ESI (Pos., 20 V)


19(H8-15)
F
3.23
489 (M + H)+.
ESI (Pos., 20 V)


19(H8-16)
F
3.27
546 (M + H)+.
ESI (Pos., 20 V)


19(H8-17)
F
2.63
288 (M + H)+.
ESI (Pos., 20 V)


19(H8-18)
C
12.00
344 (M + H)+,
APCI (Pos., 40 V)





215, 124.


19(H8-19)
F
3.01
378 (M + H)+.
ESI (Pos., 20 V)


19(H8-20)
F
3.03
417 (M + H)+.
ESI (Pos., 20 V)


19(H8-21)
F
3.10
408 (M + H)+.
ESI (Pos., 20 V)


19(H8-22)
F
3.16
436 (M + H)+.
ESI (Pos., 20 V)


19(H8-23)
F
3.20
493 (M + H)+.
ESI (Pos., 20 V)


19(H8-24)
F
3.07
378 (M + H)+.
ESI (Pos., 20 V)


19(H8-25)
F
3.34
434 (M + H)+.
ESI (Pos., 20 V)























TABLE 8C-2






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















19(H8-26)
C
16.00
468 (M + H)+.
APCI (Pos., 40 V)


19(H8-27)
F
3.33
507 (M + H)+.
ESI (Pos., 20 V)


19(H8-28)
F
3.38
498 (M + H)+.
ESI (Pos., 20 V)


19(H8-29)
F
3.44
526 (M + H)+.
ESI (Pos., 20 V)


19(H8-30)
F
3.42
583 (M + H)+.
ESI (Pos., 20 V)


19(H8-31)
C
8.90
302 (M + H)+,
APCI (Pos., 40 V)





123.


19(H8-32)
F
3.12
358 (M + H)+.
ESI (Pos., 20 V)


19(H8-33)
F
3.11
392 (M + H)+.
ESI (Pos., 20 V)


19(H8-34)
C
13.40
431 (M + H)+.
APCI (Pos., 40 V)


19(H8-35)
F
3.18
422 (M + H)+.
ESI (Pos., 20 V)


19(H8-36)
F
3.23
450 (M + H)+.
ESI (Pos., 20 V)


19(H8-37)
F
3.23
507 (M + H)+.
ESI (Pos., 20V)


19(H8-38)
F
0.65
240 (M + H)+.
ESI (Pos., 20 V)


19(H8-39)
D
8.60
296 (M + H)+.
APCI (Pos., 40 V)


19(H8-40)
F
2.87
330 (M + H)+.
ESI (Pos., 20 V)


19(H8-41)
F
2.89
369 (M + H)+.
ESI (Pos., 20 V)


19(H8-42)
F
2.94
360 (M + H)+.
ESI (Pos., 20V)


19(H8-43)
F
3.01
388 (M + H)+.
ESI (Pos., 20V)


19(H8-44)
F
3.07
445 (M + H)+.
ESI (Pos., 20V)


19(H8-45)
F
2.79
326 (M + H)+.
ESI (Pos., 20 V)


19(H8-46)
F
3.09
416 (M + H)+.
ESI (Pos., 20 V)


19(H8-47)
F
3.11
455 (M + H)+.
ESI (Pos., 20 V)


19(H8-48)
F
3.16
446 (M + H)+.
ESI (Pos., 20 V)


19(H8-49)
C
14.60
474 (M + H)+,
APCI (Pos., 40 V)





418.


19(H8-50)
F
3.23
531 (M + H)+.
ESI (Pos., 20 V)


19(H8-51)
F
1.95
357 (M + H)+.
ESI (Pos., 20 V)























TABLE 8C-3






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















19(H8-52)
F
3.01
413 (M + H)+.
ESI (Pos., 20 V)


19(H8-53)
F
3.00
447 (M + H)+.
ESI (Pos., 20 V)


19(H8-54)
F
3.03
486 (M + H)+.
ESI (Pos., 20 V)


19(H8-55)
F
3.07
477 (M + H)+.
ESI (Pos., 20 V)


19(H8-56)
F
3.12
505 (M + H)+.
ESI (Pos., 20 V)


19(H8-57)
C
12.50
562 (M + H)+,
APCI (Pos., 40 V)





454.























TABLE 9C-1






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















19(H9-1)
D
12.30
533 (M + H)+,
APCI(Pos., 40 V)





388.


19(H9-2)
D
13.36
547 (M + H)+,
APCI (Pos., 40 V)





439, 181.


19(H9-3)
D
16.15
629 (M + H)+,
APCI (Pos., 40 V)





521.


19(H9-4)
D
13.78
561 (M + H)+,
APCI (Pos., 40 V)


19(H9-5)
D
14.20
575 (M + H)+,
APCI (Pos., 40 V)





460.


19(H9-6)
D
14.90
589 (M + H)+.
APCI (Pos., 40 V)


19(H9-7)
D
11.36
604 (M + H)+.
APCI (Pos., 40 V)


19(H9-8)
D
11.26
604 (M + H)+,
APCI (Pos., 40 V)





496.


19(H9-9)
D
13.90
609 (M + H)+.
APCI (Pos., 40 V)


19(H9-10)
D
14.40
589 (M + H)+,
APCI (Pos., 40 V)





474.


19(H9-11)
D
13.52
589 (M + H)+,
APCI (Pos., 40 V)





481.


19(H9-12)
D
11.05
606 (M + H)+,
APCI (Pos., 40 V)





498.


19(H9-13)
D
11.06
620 (M + H)+,
APCI (Pos., 40 V)





512.


19(H9-14)
D
11.31
598 (M + H)+,
APCI (Pos., 40 V)





490.


19(H9-15)
D
11.05
584 (M + H)+,
APCI (Pos., 40 V)





476.


19(H9-16)
D
10.99
584 (M + H)+.
APCI (Pos., 40 V)


19(H9-17)
D
13.62
648 (M + H)+.
APCI (Pos., 40 V)


19(H9-18)
D
11.68
604 (M + H)+,
APCI (Pos., 40 V)





496.


19(H9-19)
D
14.41
597 (M + H)+.
APCI (Pos., 40 V)


19(H9-20)
D
12.89
535 (M + H)+.
APCI (Pos., 40 V)


19(H9-21)
D
14.41
577 (M + H)+.
APCI (Pos., 40 V)


19(H9-22)
D
14.05
625 (M + H)+.
APCI (Pos., 40 V)


19(H9-23)
D
13.68
549 (M + H)+.
APCI (Pos., 40 V)


19(H9-24)
D
14.05
563 (M + H)+.
APCI (Pos., 40 V)


19(H9-25)
D
13.73
601 (M + H)+,
APCI (Pos., 40 V)





493.


19(H9-26)
D
13.89
613 (M + H)+,
APCI (Pos., 40 V)





505.























TABLE 9C-2






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















19(H9-27)
D
13.99
601 (M + H)+,
APCI (Pos., 40 V)





493.


19(H9-28)
D
13.89
613 (M + H)+,
APCI (Pos., 40 V)





505.


19(H9-29)
D
14.05
601 (M + H)+,
APCI (Pos., 40 V)





493.


19(H9-30)
D
13.73
613 (M + H)+,
APCI (Pos., 40 V)





505.


19(H9-31)
D
14.41
597 (M + H)+,
APCI (Pos., 40 V)





489.


19(H9-32)
D
14.31
563 (M + H)+,
APCI (Pos., 40 V)





455.


19(H9-33)
D
14.68
611 (M + H)+,
APCI (Pos., 40 V)




14.95
503.


19(H9-34)
D
13.57
549 (M + H)+,
APCI (Pos., 40 V)





441.


19(H9-35)
D
14.20
563 (M + H)+,
APCI (Pos., 40 V)





455.


19(H9-36)
D
13.84
583 (M + H)+,
APCI (Pos., 40 V)





475.


19(H9-37)
D
11.10
564 (M + H)+,
APCI (Pos., 40 V)





456.


19(H9-38)
D
12.35
551 (M + H)+,
APCI (Pos., 40 V)





443.


19(H9-39)
D
12.04
531 (M + H)+,
APCI (Pos., 40 V)





423.


19(H9-40)
D
12.56
533 (M + H)+,
APCI (Pos., 40 V)





425.


19(H9-41)
D
11.78
551 (M + H)+,
APCI (Pos., 40 V)





443.


19(H9-42)
D
14.20
563 (M + H)+,
APCI (Pos., 40 V)





455.


19(H9-43)
D
12.99
535 (M + H)+,
APCI (Pos., 40 V)





427.


19(H9-44)
D
11.21
578 (M + H)+,
APCI (Pos., 40 V)





470.


19(H9-45)
D
13.20
579 (M + H)+,
APCI (Pos., 40 V)





471.


19(H9-46)
D
14.83
611 (M + H)+,
APCI (Pos., 40 V)





503.


19(H9-47)
D
15.31
625 (M + H)+,
APCI (Pos., 40 V)





517.


19(H9-48)
D
14.36
563 (M + H)+,
APCI (Pos., 40 V)





563.


19(H9-49)
D
11.04
601 (M + H)+,
APCI (Pos., 40 V)





493.


19(H9-50)
D
13.56
549 (M + H)+,
APCI (Pos., 40 V)





441.


19(H9-51)
D
15.26
601 (M + H)+,
APCI (Pos., 40 V)





493.























TABLE 9C-3






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















19(H9-52)
D
13.15
547 (M + H)+,
APCI (Pos., 40 V)





439.


19(H9-53)
D
12.19
521 (M + H)+,
APCI (Pos., 40 V)





413.


19(H9-54)
D
12.63
565 (M + H)+,
APCI (Pos., 40 V)





457.


19(H9-55)
D
11.00
598 (M + H)+,
APCI (Pos., 40 V)





493.


19(H9-56)
D
14.57
617 (M + H)+,
APCI (Pos., 40 V)





509.


19(H9-57)
D
13.36
581 (M + H)+,
APCI (Pos., 40 V)





473.


19(H9-58)
D
13.98
603 (M + H)+,
APCI (Pos., 40 V)





495.


19(H9-59)
D
14.57
609 (M + H)+,
APCI (Pos., 40 V)





501.


19(H9-60)
D
14.05
607 (M + H)+.
APCI (Pos., 40 V)


19(H9-61)
D
13.68
587 (M + H)+.
APCI (Pos., 40 V)


19(H9-62)
D
11.21
598 (M + H)+,
APCI (Pos., 40 V)





490.























TABLE 10C-1






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















19(H10-1)
F
3.39
519 (M + H)+.
ESI (Pos., 20 V)


19(H10-2)
F
3.47
532 (M + H)+.
ESI (Pos., 20 V)


19(H10-3)
F
3.79
615 (M + H)+.
ESI (Pos., 20 V)


19(H10-4)
F
3.49
547 (M + H)+.
ESI (Pos., 20 V)


19(H10-5)
F
3.55
561 (M + H)+.
ESI (Pos., 20 V)


19(H10-6)
F
3.62
575 (M + H)+.
ESI (Pos., 20 V)


19(H10-7)
F
3.64
589 (M + H)+.
ESI (Pos., 20 V)


19(H10-8)
F
3.22
590 (M + H)+.
ESI (Pos., 20 V)


19(H10-9)
F
3.22
590 (M + H)+.
ESI (Pos., 20 V)


19(H10-10)
F
3.58
595 (M + H)+.
ESI (Pos., 20 V)


19(H10-11)
F
3.58
575 (M + H)+.
ESI (Pos., 20 V)


19(H10-12)
F
3.49
575 (M + H)+.
ESI (Pos., 20 V)


19(H10-13)
F
3.20
592 (M + H)+.
ESI (Pos., 20 V)


19(H10-14)
F
3.20
606 (M + H)+.
ESI (Pos., 20 V)


19(H10-15)
F
3.20
584 (M + H)+.
ESI (Pos., 20 V)


19(H10-16)
F
3.18
570 (M + H)+.
ESI (Pos., 20 V)


19(H10-17)
F
3.18
570 (M + H)+.
ESI (Pos., 20 V)


19(H10-18)
F
3.45
634 (M + H)+.
ESI (Pos., 20 V)


19(H10-19)
F
3.23
590 (M + H)+.
ESI (Pos., 20 V)


19(H10-20)
F
3.44
555 (M + H)+.
ESI (Pos., 20 V)


19(H10-21)
F
3.57
583 (M + H)+.
ESI (Pos., 20 V)


19(H10-22)
F
3.40
521 (M + H)+.
ESI (Pos., 20 V)


19(H10-23)
F
3.58
563 (M + H)+.
ESI (Pos., 20 V)


19(H10-24)
F
3.66
611 (M + H)+.
ESI (Pos., 20 V)


19(H10-25)
F
3.47
535 (M + H)+.
ESI (Pos., 20 V)


19(H10-26)
D
13.62
549 (M + H)+.
APCI (Pos., 40 V)























TABLE 10C-2






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















19(H10-27)
F
3.55
549 (M + H)+.
ESI (Pos., 20 V)


19(H10-28)
F
3.53
587 (M + H)+.
ESI (Pos., 20 V)


19(H10-29)
F
3.53
599 (M + H)+.
ESI (Pos., 20 V)


19(H10-30)
F
3.55
587 (M + H)+.
ESI (Pos., 20 V)


19(H10-31)
F
3.53
599 (M + H)+.
ESI (Pos., 20 V)


19(H10-32)
F
3.55
587 (M + H)+.
ESI (Pos., 20 V)


19(H10-33)
F
3.53
599 (M + H)+.
ESI (Pos., 20 V)


19(H10-34)
F
3.58
583 (M + H)+.
ESI (Pos., 20 V)


19(H10-35)
F
3.56
549 (M + H)+.
ESI (Pos., 20 V)


19(H10-36)
F
3.60
597 (M + H)+.
ESI (Pos., 20 V)


19(H10-37)
F
3.45
535 (M + H)+.
ESI (Pos., 20 V)


19(H10-38)
F
3.53
549 (M + H)+.
ESI (Pos., 20 V)


19(H10-39)
F
3.51
569 (M + H)+.
ESI (Pos., 20 V)


19(H10-40)
F
3.18
550 (M + H)+.
ESI (Pos., 20 V)


19(H10-41)
F
3.34
537 (M + H)+.
ESI (Pos., 20 V)


19(H10-42)
F
3.36
517 (M + H)+.
ESI (Pos., 20 V)


19(H10-43)
F
3.40
519 (M + H)+.
ESI (Pos., 20 V)


19(H10-44)
F
3.27
537 (M + H)+.
ESI (Pos., 20 V)


19(H10-45)
F
3.53
549 (M + H)+.
ESI (Pos., 20 V)


19(H10-46)
F
3.40
521 (M + H)+.
ESI (Pos., 20 V)


19(H10-47)
F
3.18
564 (M + H)+.
ESI (Pos., 20 V)


19(H10-48)
F
3.40
565 (M + H)+.
ESI (Pos., 20 V)


19(H10-49)
F
3.60
597 (M + H)+.
ESI (Pos., 20 V)


19(H10-50)
F
3.67
611 (M + H)+.
ESI (Pos., 20 V)


19(H10-51)
F
3.53
549 (M + H)+.
ESI (Pos., 20 V)


19(H10-52)
F
3.18
587 (M + H)+.
ESI (Pos., 20 V)























TABLE 10C-3






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















19(H10-53)
F
3.47
535 (M + H)+.
ESI (Pos., 20 V)


19(H10-54)
F
3.64
587 (M + H)+.
ESI (Pos., 20 V)


19(H10-55)
F
3.44
533 (M + H)+.
ESI (Pos., 20 V)


19(H10-56)
F
3.34
507 (M + H)+.
ESI (Pos., 20 V)


19(H10-57)
F
3.36
551 (M + H)+.
ESI (Pos., 20 V)


19(H10-58)
F
3.45
640 (M + H)+.
ESI (Pos., 20 V)


19(H10-59)
F
3.18
584 (M + H)+.
ESI (Pos., 20 V)


19(H10-60)
F
3.60
603 (M + H)+.
ESI (Pos., 20 V)


19(H10-61)
F
3.45
567 (M + H)+.
ESI (Pos., 20 V)


19(H10-62)
F
3.53
589 (M + H)+.
ESI (Pos., 20 V)


19(H10-63)
F
3.60
595 (M + H)+.
ESI (Pos., 20 V)


19(H10-64)
F
3.53
593 (M + H)+.
ESI (Pos., 20 V)


19(H10-65)
F
3.29
537 (M + H)+.
ESI (Pos., 20 V)


19(H10-66)
F
3.49
573 (M + H)+.
ESI (Pos., 20 V)


19(H10-67)
F
3.60
597 (M + H)+.
ESI (Pos., 20 V)


19(H10-68)
F
3.20
584 (M + H)+.
ESI (Pos., 20 V)























TABLE 11C-1






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















19(H11-1)
D
12.10
412 (M + H)+.
APCI (Pos., 40 V)


19(H11-2)
D
13.52
426 (M + H)+.
APCI (Pos., 40 V)


19(H11-3)
D
16.47
508 (M + H)+.
APCI (Pos., 40 V)


19(H11-4)
D
14.03
440 (M + H)+.
APCI (Pos., 40 V)


19(H11-5)
D
14.36
454 (M + H)+.
APCI (Pos., 40 V)


19(H11-6)
D
15.15
468 (M + H)+.
APCI (Pos., 40 V)


19(H11-7)
D
10.66
483 (M + H)+.
APCI (Pos., 40 V)


19(H11-8)
D
10.52
483 (M + H)+.
APCI (Pos., 40 V)


19(H11-9)
D
13.94
488 (M + H)+.
APCI (Pos., 40 V)


19(H11-10)
D
15.02
468 (M + H)+.
APCI (Pos., 40 V)


19(H11-11)
D
13.36
468 (M + H)+.
APCI (Pos., 40 V)


19(H11-12)
D
10.31
485 (M + H)+.
APCI (Pos., 40 V)


19(H11-13)
D
10.52
499 (M + H)+.
APCI (Pos., 40 V)


19(H11-14)
D
10.73
477 (M + H)+.
APCI (Pos., 40 V)


19(H11-15)
D
10.36
463 (M + H)+.
APCI (Pos., 40 V)


19(H11-16)
D
10.26
463 (M + H)+.
APCI (Pos., 40 V)


19(H11-17)
D
13.76
527 (M + H)+.
APCI (Pos., 40 V)


19(H11-18)
D
10.89
483 (M + H)+.
APCI (Pos., 40 V)


19(H11-19)
D
13.92
476 (M + H)+.
APCI (Pos., 40 V)


19(H11-20)
D
12.78
414 (M + H)+.
APCI (Pos., 40 V)


19(H11-21)
D
13.47
480 (M + H)+.
APCI (Pos., 40 V)


19(H11-22)
D
13.84
492 (M + H)+.
APCI (Pos., 40 V)


19(H11-23)
D
13.84
480 (M + H)+.
APCI (Pos., 40 V)


19(H11-24)
D
13.84
492 (M + H)+.
APCI (Pos., 40 V)


19(H11-25)
D
14.05
480 (M + H)+.
APCI (Pos., 40 V)


19(H11-26)
D
13.57
492 (M + H)+.
APCI (Pos., 40 V)























TABLE 11C-2






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















19(H11-27)
D
14.52
476 (M + H)+.
APCI (Pos., 40 V)


19(H11-28)
D
14.41
442 (M + H)+.
APCI (Pos., 40 V)


19(H11-29)
D
14.92
490 (M + H)+.
APCI (Pos., 40 V)




15.50


19(H11-30)
D
13.62
428 (M + H)+.
APCI (Pos., 40 V)


19(H11-31)
D
14.36
442 (M + H)+.
APCI (Pos., 40 V)


19(H11-32)
D
13.78
462 (M + H)+.
APCI (Pos., 40 V)


19(H11-33)
D
10.31
443 (M + H)+.
APCI (Pos., 40 V)


19(H11-34)
D
12.10
430 (M + H)+.
APCI (Pos., 40 V)


19(H11-35)
D
11.63
410 (M + H)+.
APCI (Pos., 40 V)


19(H11-36)
D
12.42
412 (M + H)+.
APCI (Pos., 40 V)


19(H11-37)
D
11.31
430 (M + H)+.
APCI (Pos., 40 V)


19(H11-38)
D
14.26
442 (M + H)+.
APCI (Pos., 40 V)


19(H11-39)
D
12.89
414 (M + H)+.
APCI (Pos., 40 V)


19(H11-40)
D
10.52
457 (M + H)+.
APCI (Pos., 40 V)


19(H11-41)
D
13.10
458 (M + H)+.
APCI (Pos., 40 V)


19(H11-42)
D
15.04
490 (M + H)+.
APCI (Pos., 40 V)


19(H11-43)
D
15.57
504 (M + H)+.
APCI (Pos., 40 V)


19(H11-44)
D
14.57
442 (M + H)+.
APCI (Pos., 40 V)


19(H11-45)
D
10.52
480 (M + H)+.
APCI (Pos., 40 V)


19(H11-46)
D
13.73
428 (M + H)+.
APCI (Pos., 40 V)


19(H11-47)
D
15.47
480 (M + H)+.
APCI (Pos., 40 V)


19(H11-48)
D
13.10
426 (M + H)+.
APCI (Pos., 40 V)


19(H11-49)
D
11.94
400 (M + H)+.
APCI (Pos., 40 V)


19(H11-50)
D
12.36
444 (M + H)+.
APCI (Pos., 40 V)


19(H11-51)
D
10.63
477 (M + H)+.
APCI (Pos., 40 V)























TABLE 11C-3






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















19(H11-52)
D
14.57
496 (M + H)+.
APCI (Pos., 40 V)


19(H11-53)
D
13.15
460 (M + H)+.
APCI (Pos., 40 V)


19(H11-54)
D
13.99
482 (M + H)+.
APCI (Pos., 40 V)


19(H11-55)
D
14.73
488 (M + H)+.
APCI (Pos., 40 V)


19(H11-56)
D
14.05
486 (M + H)+.
APCI (Pos., 40 V)


19(H11-57)
D
13.68
466 (M + H)+.
APCI (Pos., 40 V)


19(H11-58)
D
10.73
477 (M + H)+.
APCI (Pos., 40 V)























TABLE 12C-1






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















19(H12-1)
F
3.45
426 (M + H)+.
ESI (Pos., 20 V)


19(H12-2)
F
3.56
440 (M + H)+.
ESI (Pos., 20 V)


19(H12-3)
F
3.93
522 (M + H)+.
ESI (Pos., 20 V)


19(H12-4)
F
3.60
454 (M + H)+.
ESI (Pos., 20 V)


19(H12-5)
F
3.66
468 (M + H)+.
ESI (Pos., 20 V)


19(H12-6)
F
3.75
482 (M + H)+.
ESI (Pos., 20 V)


19(H12-7)
F
3.71
516 (M + H)+.
ESI (Pos., 20 V)


19(H12-8)
F
3.77
496 (M + H)+.
ESI (Pos., 20 V)


19(H12-9)
F
3.25
497 (M + H)+.
ESI (Pos., 20 V)


19(H12-10)
F
3.27
497 (M + H)+.
ESI (Pos., 20 V)


19(H12-11)
F
3.67
502 (M + H)+.
ESI (Pos., 20 V)


19(H12-12)
F
3.69
482 (M + H)+.
ESI (Pos., 20 V)


19(H12-13)
F
3.60
482 (M + H)+.
ESI (Pos., 20 V)


19(H12-14)
F
3.23
499 (M + H)+.
ESI (Pos., 20 V)


19(H12-15)
F
3.23
513 (M + H)+.
ESI (Pos., 20 V)


19(H12-16)
F
3.23
491 (M + H)+.
ESI (Pos., 20 V)


19(H12-17)
F
3.22
477 (M + H)+.
ESI (Pos., 20 V)


19(H12-18)
F
3.22
477 (M + H)+.
ESI (Pos., 20 V)


19(H12-19)
F
3.27
497 (M + H)+.
ESI (Pos., 20 V)


19(H12-20)
F
3.49
462 (M + H)+.
ESI (Pos., 20 V)


19(H12-21)
F
3.64
490 (M + H)+.
ESI (Pos., 20 V)


19(H12-22)
F
3.49
428 (M + H)+.
ESI (Pos., 20 V)


19(H12-23)
F
3.69
470 (M + H)+.
ESI (Pos., 20 V)


19(H12-24)
F
3.77
518 (M + H)+.
ESI (Pos., 20 V)


19(H12-25)
F
3.54
442 (M + H)+.
ESI (Pos., 20 V)


19(H12-26)
F
3.62
456 (M + H)+.
ESI (Pos., 20 V)























TABLE 12C-2






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















19(H12-27)
F
3.64
456 (M + H)+.
ESI (Pos., 20 V)


19(H12-28)
F
3.62
494 (M + H)+.
ESI (Pos., 20 V)


19(H12-29)
F
3.62
506 (M + H)+.
ESI (Pos., 20 V)


19(H12-30)
F
3.62
494 (M + H)+.
ESI (Pos., 20 V)


19(H12-31)
F
3.61
506 (M + H)+.
ESI (Pos., 20 V)


19(H12-32)
F
3.64
494 (M + H)+.
ESI (Pos., 20 V)


19(H12-33)
F
3.60
506 (M + H)+.
ESI (Pos., 20 V)


19(H12-34)
F
3.66
490 (M + H)+.
ESI (Pos., 20 V)


19(H12-35)
F
3.64
456 (M + H)+.
ESI (Pos., 20 V)


19(H12-36)
F
3.71
504 (M + H)+.
ESI (Pos., 20 V)


19(H12-37)
F
3.57
442 (M + H)+.
ESI (Pos., 20 V)


19(H12-38)
F
3.63
456 (M + H)+.
ESI (Pos., 20 V)


19(H12-39)
F
3.60
476 (M + H)+.
ESI (Pos., 20 V)


19(H12-40)
F
3.19
457 (M + H)+.
ESI (Pos., 20 V)


19(H12-41)
F
3.42
444 (M + H)+.
ESI (Pos., 20 V)


19(H12-42)
F
3.43
424 (M + H)+.
ESI (Pos., 20 V)


19(H12-43)
F
3.45
426 (M + H)+.
ESI (Pos., 20 V)


19(H12-44)
F
3.32
444 (M + H)+.
ESI (Pos., 20 V)


19(H12-45)
F
3.62
456 (M + H)+.
ESI (Pos., 20 V)


19(H12-46)
F
3.49
428 (M + H)+.
ESI (Pos., 20 V)


19(H12-47)
F
3.20
471 (M + H)+.
ESI (Pos., 20 V)


19(H12-48)
F
3.49
472 (M + H)+.
ESI (Pos., 20 V)


19(H12-49)
F
3.70
504 (M + H)+.
ESI (Pos., 20 V)


19(H12-50)
F
3.77
518 (M + H)+.
ESI (Pos., 20 V)


19(H12-51)
F
3.62
456 (M + H)+.
ESI (Pos., 20 V)


19(H12-52)
F
3.21
494 (M + H)+.
ESI (Pos., 20 V)























TABLE 12C-4






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















19(H12-53)
F
3.56
442 (M + H)+.
ESI (Pos., 20 V)


19(H12-54)
F
3.75
494 (M + H)+.
ESI (Pos., 20 V)


19(H12-55)
F
3.51
440 (M + H)+.
ESI (Pos., 20 V)


19(H12-56)
F
3.40
414 (M + H)+.
ESI (Pos., 20 V)


19(H12-57)
F
3.75
484 (M + H)+.
ESI (Pos., 20 V)


19(H12-58)
F
3.42
458 (M + H)+.
ESI (Pos., 20 V)


19(H12-59)
F
3.20
491 (M + H)+.
ESI (Pos., 20 V)


19(H12-60)
F
3.68
510 (M + H)+.
ESI (Pos., 20 V)


19(H12-61)
F
3.52
474 (M + H)+.
ESI (Pos., 20 V)


19(H12-62)
F
3.62
496 (M + H)+.
ESI (Pos., 20 V)


19(H12-63)
F
3.67
502 (M + H)+.
ESI (Pos., 20 V)


19(H12-64)
F
3.60
500 (M + H)+.
ESI (Pos., 20 V)


19(H12-65)
F
3.33
444 (M + H)+.
ESI (Pos., 20 V)


19(H12-66)
F
3.33
444 (M + H)+.
ESI (Pos., 20 V)


19(H12-67)
F
3.57
480 (M + H)+.
ESI (Pos., 20 V)


19(H12-68)
F
3.68
504 (M + H)+.
ESI (Pos., 20 V)


19(H12-69)
F
3.20
491 (M + H)+.
ESI (Pos., 20 V)























TABLE 13C-1






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















19(H13-1)
F
3.48
440 (M + H)+.
ESI (Pos., 20 V)


19(H13-2)
F
3.60
454 (M + H)+.
ESI (Pos., 20 V)


19(H13-3)
F
3.94
536 (M + H)+.
ESI (Pos., 20 V)


19(H13-4)
F
3.64
468 (M + H)+.
ESI (Pos., 20 V)


19(H13-5)
F
3.69
482 (M + H)+.
ESI (Pos., 20 V)


19(H13-6)
F
3.78
496 (M + H)+.
ESI (Pos., 20 V)


19(H13-7)
F
3.74
530 (M + H)+.
ESI (Pos., 20 V)


19(H13-8)
F
3.79
510 (M + H)+.
ESI (Pos., 20 V)


19(H13-9)
F
3.29
511 (M + H)+.
ESI (Pos., 20 V)


19(H13-10)
F
3.32
511 (M + H)+.
ESI (Pos., 20 V)


19(H13-11)
F
3.72
516 (M + H)+.
ESI (Pos., 20 V)


19(H13-12)
F
3.73
496 (M + H)+.
ESI (Pos., 20 V)


19(H13-13)
F
3.64
496 (M + H)+.
ESI (Pos., 20 V)


19(H13-14)
F
3.26
513 (M + H)+.
ESI (Pos., 20 V)


19(H13-15)
F
3.28
527 (M + H)+.
ESI (Pos., 20 V)


19(H13-16)
F
3.28
505 (M + H)+.
ESI (Pos., 20 V)


19(H13-17)
F
3.27
491 (M + H)+.
ESI (Pos., 20 V)


19(H13-18)
F
3.58
555 (M + H)+.
ESI (Pos., 20 V)


19(H13-19)
F
3.32
511 (M + H)+.
ESI (Pos., 20 V)


19(H13-20)
F
3.66
504 (M + H)+.
ESI (Pos., 20 V)


19(H13-21)
F
3.66
470 (M + H)+.
ESI (Pos., 20 V)


19(H13-22)
F
3.74
484 (M + H)+.
ESI (Pos., 20 V)


19(H13-23)
F
3.67
470 (M + H)+.
ESI (Pos., 20 V)


19(H13-24)
F
3.66
508 (M + H)+.
ESI (Pos., 20 V)


19(H13-25)
F
3.67
520 (M + H)+.
ESI (Pos., 20 V)


19(H13-26)
F
3.69
508 (M + H)+.
ESI (Pos., 20 V)























TABLE 13C-2






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















19(H13-27)
F
3.64
520 (M + H)+.
ESI (Pos., 20 V)


19(H13-28)
F
3.68
508 (M + H)+.
ESI (Pos., 20 V)


19(H13-29)
F
3.64
520 (M + H)+.
ESI (Pos., 20 V)


19(H13-30)
F
3.72
504 (M + H)+.
ESI (Pos., 20 V)


19(H13-31)
F
3.70
470 (M + H)+.
ESI (Pos., 20 V)


19(H13-32)
F
3.76
518 (M + H)+.
ESI (Pos,, 20 V)


19(H13-33)
F
3.61
456 (M + H)+.
ESI (Pos., 20 V)


19(H13-34)
F
3.68
470 (M + H)+.
ESI (Pos., 20 V)


19(H13-35)
F
3.65
490 (M + H)+.
ESI (Pos., 20 V)


19(H13-36)
F
3.24
471 (M + H)+.
ESI (Pos., 20 V)


19(H13-37)
F
3.47
458 (M + H)+.
ESI (Pos., 20 V)


19(H13-38)
F
3.51
438 (M + H)+.
ESI (Pos., 20 V)


19(H13-39)
F
3.51
440 (M + H)+.
ESI (Pos., 20 V)


19(H13-40)
F
3.39
458 (M + H)+.
ESI (Pos., 20 V)


19(H13-41)
F
3.67
470 (M + H)+.
ESI (Pos., 20 V)


19(H13-42)
F
3.54
442 (M + H)+.
ESI (Pos., 20 V)


19(H13-43)
F
3.25
485 (M + H)+.
ESI (Pos., 20 V)


19(H13-44)
F
3.55
486 (M + H)+.
ESI (Pos., 20 V)


19(H13-45)
F
3.75
518 (M + H)+.
ESI (Pos., 20 V)


19(H13-46)
F
3.80
532 (M + H)+.
ESI (Pos., 20 V)


19(H13-47)
F
3.69
470 (M + H)+.
ESI (Pos., 20 V)


19(H13-48)
F
3.25
508 (M + H)+.
ESI (Pos., 20 V)


19(H13-49)
F
3.62
456 (M + H)+.
ESI (Pos., 20 V)


19(H13-50)
F
3.80
508 (M + H)+.
ESI (Pos., 20 V)


19(H13-51)
F
3.58
454 (M + H)+.
ESI (Pos., 20 V)


19(H13-52)
F
3.46
428 (M + H)+.
ESI (Pos., 20 V)























TABLE 13C-3






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















19(H13-53)
F
3.80
498 (M + H)+.
ESI (Pos., 20 V)


19(H13-54)
F
3.47
472 (M + H)+.
ESI (Pos., 20 V)


19(H13-55)
F
3.26
505 (M + H)+.
ESI (Pos., 20 V)


19(H13-56)
F
3.73
524 (M + H)+.
ESI (Pos., 20 V)


19(H13-57)
F
3.58
488 (M + H)+.
ESI (Pos., 20 V)


19(H13-58)
F
3.67
510 (M + H)+.
ESI (Pos., 20 V)


19(H13-59)
F
3.73
516 (M + H)+.
ESI (Pos., 20 V)


19(H13-60)
F
3.64
514 (M + H)+.
ESI (Pos., 20 V)


19(H13-61)
F
3.62
494 (M + H)+.
ESI (Pos., 20 V)


19(H13-62)
F
3.25
505 (M + H)+.
ESI (Pos., 20 V)









EXAMPLE 20
(3S)-1-propyl-2,5-dioxo-3-(4-(benzylcarbonylamino)butyl)-9-(2,4,6-trimethoxybenzyl)-1,4,9-triazaspiro[5.5]undecane



embedded image


To a solution of the compound prepared in Example 8 (0.01 g) in dichloroethane (0.2 ml) were added 2,4,6-trimethoxybenzaldehyde (0.013 g), sodium triacetoxyborohydride (0.015 g) and dimethylformamide (0.2 ml). The reaction mixture was stirred for 50 hours at room temperature. The reaction mixture was loaded on ion exchange resin (OASIS MCX, Waters, 60 mg) washed with methanol (3 ml) prior to use. The resin was washed with methanol (2 ml), and was eluted with 10% triethylamine-methanol solution (2 ml). The elution was concentrated to give the compound of the present invention (4.4 mg) having the following physical data.


TLC: Rf 0.33 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.33 (m, 5H), 6.21 (s, 2H), 5.05 (s, 2H), 4.00 (m, 1H), 3.80 (s, 9H), 3.59 (s, 2H), 3.40 (m, 2H), 3.11 (t, J=6.6 Hz, 2H), 3.05–2.75 (m, 4H), 2.40–2.00 (m, 2H), 2.00–1.70 (m, 4H), 1.65–1.25 (m, 6H), 0.90 (t, J=7.2 Hz, 3H).


EXAMPLE 20(1)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzylcarbonylamino)butyl)-9-(2,2-dimethylpropyl)-1,4,9-triazaspiro[5.5]undecane



embedded image


By the same procedure as described in Example 20 using the compound prepared in Example 8 (0.01 g) and pivalaldehyde (8 μl), the compound of the present invention (2.5 mg) having the following physical data was obtained.


TLC: Rf 0.53 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.33 (m, 5H), 5.06 (s, 2H), 4.02 (m, 1H), 3.50–3.30 (m, 2H), 3.20–3.00 (m, 4H), 3.00–2.60 (m, 4H), 2.20–2.00 (m, 2H), 1.90–1.70 (m, 3H), 1.70–1.20 (m, 7H), 0.92 (t, J=7.4 Hz, 3H), 0.90 (s, 9H).


EXAMPLE 20(H14-1)˜20(H15-77)

By the same procedure as described in Example 20 using the compound prepared in Example 8 or 8(1) and the corresponding aldehyde derivatives, the compounds of the present invention, whose names were shown in the following Table 14A-1˜15A-10, and whose structures were shown in the following Table 14B-1˜15B-12, were obtained. Also, physical data of the above compounds were shown in the following Table 14C-1˜15C-3.










TABLE 14A-1





Example



No
Compound Name







20(H14-1)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2,4,6-trimethoxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-2)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(3-cyanophenylmethyl)-1,4,9-triazaspiro-



[5.5]undecane


20(H14-3)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(3-methylbutyl)-1,4,9-triazaspiro-



[5.5]undecane


20(H14-4)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-(1-carboxymethyloxy)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-5)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(4-dimethylaminophenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-6)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(3-phenoxyphenylmethyl)-1,4,9-triazaspiro-



[5.5]undecane


20(H14-7)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2E)-2-methylbutenyl)-1,4,9-triazaspiro-



[5.5]undecane




















TABLE 14A-2





Example



No
Compound Name







20(H14-8)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((1S,5S)-6,6-dimethylbicyclo[3.3.1]-



2-hepten-2-ylmethyl)-1,4,9-triazaspiro[5.5]-



undecane


20(H14-9)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(1-carboxymethyl)-1,4,9-triazaspiro[5.5]-



undecane


20(H14-10)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-cyclopropylmethyl-1,4,9-triazaspiro[5.5]-



undecane


20(H14-11)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(3-methylthiopropyl)-1,4,9-triazaspiro[5.5]-



undecane


20(H14-12)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(3-carboxypropyl)-1,4,9-triazaspiro[5.5]-



undecane


20(H14-13)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2,6-dimethyl-5-heptenyl)-1,4,9-triazaspiro-



[5.5]undecane


20(H14-14)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(quinolin-2-yl)-1,4,9-triazaspiro[5.5]-



undecane




















TABLE 14A-3





Example



No
Compound Name







20(H14-15)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2S,3R,4R,5R)-2-acetylamino-3,4,5,6-



tetrahydroxyhexanyl)-1,4,9-triazaspiro[5.5]-



undecane


20(H14-16)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2,2-dimethylpropyl)-1,4,9-triazaspiro[5.5]-



undecane


20(H14-17)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4Z)-decenyl)-1,4,9-triazaspiro[5.5]-



undecane


20(H14-18)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(3-phenylpropyl)-1,4,9-triazaspiro[5.5]-



undecane


20(H14-19)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-butyl-1,4,9-triazaspiro[5.5]undecane


20(H14-20)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-benzyl-1,4,9-triazaspiro[5.5]undecane


20(H14-21)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2E)-3-(4-dimethylaminophenyl)propenyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 14A-4





Example



No
Compound Name







20(H14-22)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)9-((2E)-3-(furan-2-yl)propenyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-23)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(3-hydroxyphenylmethyl)-1,4,9-triazaspiro-



[5.5]undecane


20(H14-24)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-hydroxyphenylmethyl)-1,4,9-triazaspiro-



[5.5]undecane


20(H14-25)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(4-dihydroxyboranephenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-26)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(4-heptyloxyphenylmethyl)-1,4,9-triazaspiro-



[5.5]undecane


20(H14-27)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(benzofuran-2-ylmethyl)-1,4,9-triazaspiro-



[5.5]undecane


20(H14-28)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(3-methylbenzothiophen-2-ylmethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 14A-5





Example



No
Compound Name







20(H14-29)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-(4-chlorophenylthio)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-30)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(3,7-dimethyl-6-octenyl)-1,4,9-triazaspiro-



[5.5]undecane


20(H14-31)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(4-(pyrrolidin-1-yl)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-32)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-methyl-3-(4-(2,2-dimethylpropyl)phenyl)-



propyl)-1,4,9-triazaspiro[5.5]undecane


20(H14-33)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-benzyloxyphenylmethyl)-1,4,9-triazaspiro-



[5.5]undecane


20(H14-34)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(4-hydroxy-3,5-bis(1,1-dimethylethyl)-



phenylmethyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 14A-6





Example



No
Compound Name







20(H14-35)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-methyl-3-(4-(1-methylethyl)phenyl)propyl)-



1,4,9-triazaspiro[5.5]undecane


20(H14-36)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(3,4-di-(benzyloxy)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-37)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(4-octyloxyphenylmethyl)-1,4,9-triazaspiro-



[5.5]undecane


20(H14-38)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(3,5,5-trimethylhexyl)-1,4,9-triazaspiro-



[5.5]undecane


20(H14-39)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-butyloxycarbonylmethyl-1,4,9-triazaspiro-



[5.5]undecane


20(H14-40)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(4-(4-hydroxy-4-methylpentyl)-3-cyclohexenyl-



methyl)-1,4,9-triazaspiro[5.5]undecane


20(H14-41)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(5-hydroxypentyl)-1,4,9-triazaspiro[5.5]-



undecane




















TABLE 14A-7





Example



No
Compound Name







20(H14-42)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-((1R,2S,3R,5R)-2-hydroxy-4,6,8-trioxaspiro-



[bicyclo[3.3.0]octan-7,1′-cyclohexan]-



3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane


20(H14-43)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(3-phenylpyrazol-4-ylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-44)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(4-(1,1-dimethylethyl)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-45)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-46)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-(2,2,6-trimethyl-1-cyclohexenyl)ethyl)-



1,4,9-triazaspiro[5.5]undecane


20(H14-47)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(4-(3-dimethylaminopropyloxy)phenylmethyl)-



1,4,9-triazaspiro[5.5]undecane




















TABLE 14A-8





Example



No
Compound Name







20(H14-48)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(furan-2-ylmethyl)-1,4,9-triazaspiro[5.5]-



undecane


20(H14-49)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-methylpropyl)-1,4,9-triazaspiro[5.5]undecane


20(H14-50)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-cyclohexylmethyl-1,4,9-triazaspiro[5.5]undecane


20(H14-51)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(thiazol-2-ylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-52)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(4-acetylaminophenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-53)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-methoxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-54)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(4-methoxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 14A-9





Example



No
Compound Name







20(H14-55)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(4-biphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-56)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2E,6E)-3,7-dimethyl-2,6-octadienyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-57)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(4-dimethylaminophenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-58)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-ethylhexyl)-1,4,9-triazaspiro[5.5]undecane


20(H14-59)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(3-fluorophenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-60)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-hydroxyethyl)-1,4,9-triazaspiro[5.5]undecane


20(H14-61)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(naphthalen-1-ylmethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 14A-10





Example



No
Compound Name







20(H14-62)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-propyl-1,4,9-triazaspiro[5.5]undecane


20(H14-63)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2S,3S,4R)-2,3,4,5-tetrahydroxypentyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-64)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(thiophen-2-ylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-65)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2E)-decenyl)-1,4,9-triazaspiro[5.5]undecane


20(H14-66)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(4-chlorophenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-67)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(1,3-benzodioxolen-4-ylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-68)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((3S,4R)-3,4,5-trihydroxypentyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 14A-11





Example



No
Compound Name







20(H14-69)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2,3-dimethyl-5-oxo-1-phenyl-3-pyrazolin-4-



ylmethyl)-1,4,9-triazaspiro[5.5]undecane


20(H14-70)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(4-((2E)-4-methylpentenyl)-3-cyclohexenyl-



methyl)-1,4,9-triazaspiro[5.5]undecane


20(H14-71)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(3-methoxy-4-hexyloxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-72)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(4-fluorophenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-73)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(3,5,6-trimethyl-3-cyclohexenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-74)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-



1,4,9-triazaspiro[5.5]undecane


20(H14-75)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-benzyloxyethyl)-1,4,9-triazaspiro[5.5]-



undecane




















TABLE 14A-12





Example



No
Compound Name







20(H14-76)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(3-methoxy-4-benzyloxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-77)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(3-benzyloxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-78)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(4-benzyloxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-79)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H14-80)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(4-allyloxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 15A-1





Example



No
Compound Name







20(H15-1)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2,4,6-



trimethoxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-2)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-



cyanophenylmethyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-3)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-



methylbutyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-4)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-(1-



carboxymethyloxy)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-5)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



dimethylaminophenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-6)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-



phenoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-7)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2E)-2-



methylbutenyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-8)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((1S,5S)-



6,6-dimethylbicyclo[3.3.1]-2-hepten-2-ylmethyl)-



1,4,9-triazaspiro[5.5]undecane




















TABLE 15A-2





Example



No
Compound Name







20(H15-9)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(1-



carboxymethyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-10)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-



cyclopropylmethyl-1,4,9-triazaspiro[5.5]undecane


20(H15-11)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-



methylthiopropyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-12)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-



carboxypropyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-13)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2,6-



dimethyl-5-heptenyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-14)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(quinolin-



2-yl)-1,4,9-triazaspiro[5.5]undecane


20(H15-15)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2S,3R,4R,5R)-



2-acetylamino-3,4,5,6-tetrahydroxyhexanyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-16)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2,2-



dimethylpropyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-17)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4Z)-decenyl)-



1,4,9-triazaspiro[5.5]undecane




















TABLE 15A-3





Example



No
Compound Name







20(H15-18)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-phenylpropyl)-



1,4,9-triazaspiro[5.5]undecane


20(H15-19)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-butyl-1,4,9-



triazaspiro[5.5]undecane


20(H15-20)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-benzyl-1,4,9-



triazaspiro[5.5]undecane


20(H15-21)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2E)-3-(furan-2-



yl)propenyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-22)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-



hydroxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-23)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-



hydroxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-24)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



dihydroxyboranephenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-25)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



heptyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-26)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(benzofuran-2-



ylmethyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 15A-4





Example



No
Compound Name







20(H15-27)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-



methylbenzothiophen-2-ylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-28)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-(4-



chlorophenylthio)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-29)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,7-dimethyl-



6-octenyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-30)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(pyrrolidin-



1-yl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-31)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-methyl-3-



(4-(2,2-dimethylpropyl)phenyl)propyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-32)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-



benzyloxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-33)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-hydroxy-



3,5-di-(1,1-dimethylethyl)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-34)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-methyl-3-(4-



(1-methylethyl)phenyl)propyl)-1,4,9-



triazaspiro[5.5]undecane






















TABLE 15A-5







Example




No
Compound Name









20(H15-35)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,4-di-




(benzyloxy)phenylmethyl)-1,4,9-




triazaspiro[5.5]undecane



20(H15-36)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-




octyloxyphenylmethyl)-1,4,9-




triazaspiro[5.5]undecane



20(H15-37)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5,5-




trimethylhexyl)-1,4,9-triazaspiro[5.5]undecane



20(H15-38)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




butyloxycarbonylmethyl-1,4,9-




triazaspiro[5.5]undecane



20(H15-39)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-




hydroxy-4-methylpentyl)-3-cyclohexenylmethyl)-




1,4,9-triazaspiro[5.5]undecane



20(H15-40)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-




hydroxypentyl)-1,4,9-triazaspiro[5.5]undecane



20(H15-41)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-




((1R,2S,3R,5R)-2-hydroxy-4,6,8-




trioxaspiro[bicyclo[3.3.0]octan-7,1′-




cyclohexan]-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



20(H15-42)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-




phenylpyrazol-4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane





















TABLE 15A-6





Example



No
Compound Name







20(H15-43)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(1,1-



dimethylethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-44)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(1,4-benzodioxan-



6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-45)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-(2,2,6-



trimethyl-1-cyclohexenyl)ethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-46)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(3-



dimethylaminopropyloxy)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-47)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(furan-2-



ylmethyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-48)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-



methylpropyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-49)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-



cyclohexylmethyl-1,4,9-triazaspiro[5.5]undecane


20(H15-50)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(thiazol-2-



ylmethyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 15A-7





Example



No
Compound Name







20(H15-51)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



acetylaminophenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-52)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-



methoxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-53)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



methoxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-54)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



biphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-55)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-



ethylhexyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-56)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-



fluorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-57)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-



hydroxyethyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-58)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-



(naphthalen-1-ylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-59)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-



propyl-1,4,9-triazaspiro[5.5]undecane




















TABLE 15A-8





Example



No
Compound Name







20(H15-60)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2S,3S,4R)-



2,3,4,5-tetrahydroxypentyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-61)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(thiophen-2-



ylmethyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-62)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2E)-decenyl)-



1,4,9-triazaspiro[5.5]undecane


20(H15-63)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



chlorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-64)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(1,3-



benzodioxolen-4-ylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-65)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((3S,4R)-3,4,5-



trihydroxypentyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-66)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2,3-dimethyl-



5-oxo-1-phenyl-3-pyrazolin-4-ylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-67)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-((2E)-4-



methylpentenyl)-3-cyclohexenylmethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 15A-9





Example



No
Compound Name







20(H15-68)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-methoxy-



4-hexyloxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-69)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



fluorophenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-70)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5,6-



trimethyl-3-cyclohexenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-71)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-



dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-72)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-benzyl-



oxyethyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-73)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-methoxy-



4-benzyloxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-74)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-



benzyloxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


20(H15-75)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



benzyloxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 15A-10





Example



No
Compound Name







20(H15-76)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


20(H15-77)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



allyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane



















TABLE 14B-1









embedded image















Example No
R1







20(H14-1)


embedded image









20(H14-2)


embedded image









20(H14-3)


embedded image









20(H14-4)


embedded image









20(H14-5)


embedded image









20(H14-6)


embedded image






















TABLE 14B-2









embedded image















Example No
R1







20(H14-7)


embedded image









20(H14-8)


embedded image









20(H14-9)


embedded image









20(H14-10)


embedded image









20(H14-11)


embedded image









20(H14-12)


embedded image









20(H14-13)


embedded image









20(H14-14)


embedded image






















TABLE 14B-3









embedded image













Example No
R1





20(H14-15)


embedded image







20(H14-16)


embedded image







20(H14-17)


embedded image







20(H14-18)


embedded image







20(H14-19)


embedded image







20(H14-20)


embedded image







20(H14-21)


embedded image







20(H14-22)


embedded image





















TABLE 14B-4









embedded image










Example No
R1





20(H14-23)


embedded image







20(H14-24)


embedded image







20(H14-25)


embedded image







20(H14-26)


embedded image







20(H14-27)


embedded image







20(H14-28)


embedded image







20(H14-29)


embedded image





















TABLE 14B-5









embedded image















Example No
R1







20(H14-30)


embedded image









20(H14-31)


embedded image









20(H14-32)


embedded image









20(H14-33)


embedded image









20(H14-34)


embedded image









20(H14-35)


embedded image






















TABLE 14B-6









embedded image













Example No
R1





20(H14-36)


embedded image







20(H14-37)


embedded image







20(H14-38)


embedded image







20(H14-39)


embedded image







20(H14-40)


embedded image







20(H14-41)


embedded image







20(H14-42)


embedded image





















TABLE 14B-7









embedded image













Example No
R1





20(H14-43)


embedded image







20(H14-44)


embedded image







20(H14-45)


embedded image







20(H14-46)


embedded image







20(H14-48)


embedded image







20(H14-49)


embedded image





















TABLE 14B-8









embedded image













Example No
R1





20(H14-50)


embedded image







20(H14-51)


embedded image







20(H14-52)


embedded image







20(H14-53)


embedded image







20(H14-54)


embedded image







20(H14-55)


embedded image







20(H14-56)


embedded image







20(H14-57)


embedded image





















TABLE 14B-9









embedded image













Example No
R1





20(H14-58)


embedded image







20(H14-59)


embedded image







20(H14-60)


embedded image







20(H14-61)


embedded image







20(H14-62)


embedded image







20(H14-63)


embedded image







20(H14-64)


embedded image







20(H14-65)


embedded image







20(H14-66)


embedded image





















TABLE 14B-10









embedded image













Example No
R1





20(H14-67)


embedded image







20(H14-68)


embedded image







20(H14-69)


embedded image







20(H14-70)


embedded image







20(H14-71)


embedded image







20(H14-72)


embedded image







20(H14-73)


embedded image





















TABLE 14B-11









embedded image













Example No
R1





20(H14-74)


embedded image







20(H14-75)


embedded image







20(H14-76)


embedded image







20(H14-77)


embedded image







20(H14-78)


embedded image







20(H14-79)


embedded image







20(H14-80)


embedded image





















TABLE 15B-1









embedded image













Example No
R1





20(H15-1)


embedded image







20(H15-2)


embedded image







20(H15-3)


embedded image







20(H15-4)


embedded image







20(H15-5)


embedded image







20(H15-6)


embedded image





















TABLE 15B-2









embedded image













Example No
R1





20(H15-7) 


embedded image







20(H15-8) 


embedded image







20(H15-9) 


embedded image







20(H15-10)


embedded image







20(H15-11)


embedded image







20(H15-12)


embedded image







20(H15-13)


embedded image







20(H15-14)


embedded image





















TABLE 15B-3









embedded image













Example No
R1





20(H15-15)


embedded image







20(H15-16)


embedded image







20(H15-17)


embedded image







20(H15-18)


embedded image







20(H15-19)


embedded image







20(H15-20)


embedded image







20(H15-21)


embedded image







20(H15-22)


embedded image





















TABLE 15B-4









embedded image













Example No
R1





20(H15-23)


embedded image







20(H15-24)


embedded image







20(H15-25)


embedded image







20(H15-26)


embedded image







20(H15-27)


embedded image







20(H15-28)


embedded image







20(H15-29)


embedded image





















TABLE 15B-5









embedded image













Example No
R1





20(H15-30)


embedded image







20(H15-31)


embedded image







20(H15-32)


embedded image







20(H15-33)


embedded image







20(H15-34)


embedded image





















TABLE 15B-6









embedded image













Example No
R1





20(H15-35)


embedded image







20(H15-36)


embedded image







20(H15-37)


embedded image







20(H15-38)


embedded image







20(H15-39)


embedded image







20(H15-40)


embedded image







20(H15-41)


embedded image





















TABLE 15B-7









embedded image













Example No
R1





20(H15-42)


embedded image







20(H15-43)


embedded image







20(H15-44)


embedded image







20(H15-45)


embedded image







20(H15-46)


embedded image







20(H15-47)


embedded image







20(H15-48)


embedded image





















TABLE 15B-8









embedded image













Example No
R1





20(H15-49)


embedded image







20(H15-50)


embedded image







20(H15-51)


embedded image







20(H15-52)


embedded image







20(H15-53)


embedded image







20(H15-54)


embedded image







20(H15-55)


embedded image





















TABLE 15B-9









embedded image













Example No
R1





20(H15-56)


embedded image







20(H15-57)


embedded image







20(H15-58)


embedded image







20(H15-59)


embedded image







20(H15-60)


embedded image







20(H15-61)


embedded image







20(H15-62)


embedded image







20(H15-63)


embedded image







20(H15-64)


embedded image





















TABLE 15B-10









embedded image













Example No
R1





20(H15-65)


embedded image







20(H15-66)


embedded image







20(H15-67)


embedded image







20(H15-68)


embedded image







20(H15-69)


embedded image







20(H15-70)


embedded image





















TABLE 15B-11









embedded image













Example No
R1





20(H15-71)


embedded image







20(H15-72)


embedded image







20(H15-73)


embedded image







20(H15-74)


embedded image







20(H15-75)


embedded image







20(H15-76)


embedded image





















TABLE 15B-12









embedded image















Example No
R1







20(H15-77)


embedded image


























TABLE 14C-1






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















20(H14-1)
F
3.40
611 (M + H)+.
ESI (Pos., 20 V)


20(H14-2)
F
3.27
546 (M + H)+.
ESI (Pos., 20 V)


20(H14-3)
F
3.29
501 (M + H)+.
ESI (Pos., 20 V)


20(H14-4)
F
3.25
595 (M + H)+.
ESI (Pos., 20 V)


20(H14-5)
F
3.12
564 (M + H)+.
ESI (Pos., 20 V)


20(H14-6)
F
3.52
613 (M + H)+.
ESI (Pos., 20 V)


20(H14-7)
F
3.25
499 (M + H)+.
ESI (Pos., 20 V)


20(H14-8)
F
3.49
565 (M + H)+.
ESI (Pos., 20 V)


20(H14-9)
F
3.09
489 (M + H)+.
ESI (Pos., 20 V)


20(H14-10)
F
3.18
485 (M + H)+.
ESI (Pos., 20 V)


20(H14-11)
F
3.23
519 (M + H)+.
ESI (Pos., 20 V)


20(H14-12)
F
3.12
517 (M + H)+.
ESI (Pos., 20 V)


20(H14-13)
F
3.53
555 (M + H)+.
ESI (Pos., 20 V)


20(H14-14)
F
3.33
572 (M + H)+.
ESI (Pos., 20 V)


20(H14-15)
F
3.03
636 (M + H)+.
ESI (Pos., 20 V)


20(H14-16)
F
3.25
501 (M + H)+.
ESI (Pos., 20 V)


20(H14-17)
F
3.66
569 (M + H)+.
ESI (Pos., 20 V)


20(H14-18)
F
3.38
549 (M + H)+.
ESI (Pos., 20 V)


20(H14-19)
F
3.22
487 (M + H)+.
ESI (Pos., 20 V)


20(H14-20)
F
3.29
521 (M + H)+.
ESI (Pos., 20 V)


20(H14-21)
F
3.11
590 (M + H)+.
ESI (Pos., 20 V)


20(H14-22)
F
3.31
537 (M + H)+.
ESI (Pos., 20 V)


20(H14-23)
F
3.20
537 (M + H)+.
ESI (Pos., 20 V)


20(H14-24)
F
3.23
537 (M + H)+.
ESI (Pos., 20 V)


20(H14-25)
F
3.16
565 (M + H)+.
ESI (Pos., 20 V)


20(H14-26)
F
3.82
635 (M + H)+.
ESI (Pos., 20 V)























TABLE 14C-2






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















20(H14-27)
F
3.36
561 (M + H)+.
ESI (Pos., 20 V)


20(H14-28)
F
3.44
591 (M + H)+.
ESI (Pos., 20 V)


20(H14-29)
F
3.62
663 (M + H)+.
ESI (Pos., 20 V)


20(H14-30)
F
3.60
569 (M + H)+.
ESI (Pos., 20 V)


20(H14-31)
F
3.40
590 (M + H)+.
ESI (Pos., 20 V)


20(H14-32)
F
3.67
619 (M + H)+.
ESI (Pos., 20 V)


20(H14-33)
F
3.51
627 (M + H)+.
ESI (Pos., 20 V)


20(H14-34)
F
3.66
649 (M + H)+.
ESI (Pos., 20 V)


20(H14-35)
F
3.64
605 (M + H)+.
ESI (Pos., 20 V)


20(H14-36)
F
3.71
733 (M + H)+.
ESI (Pos., 20 V)


20(H14-37)
F
3.91
649 (M + H)+.
ESI (Pos., 20 V)


20(H14-38)
F
3.56
557 (M + H)+.
ESI (Pos., 20 V)


20(H14-39)
F
3.33
545 (M + H)+.
ESI (Pos., 20 V)


20(H14-40)
F
3.38
625 (M + H)+.
ESI (Pos., 20 V)


20(H14-41)
F
3.12
517 (M + H)+.
ESI (Pos., 20 V)


20(H14-42)
F
3.34
643 (M + H)+.
ESI (Pos., 20 V)


20(H14-43)
F
3.23
587 (M + H)+.
ESI (Pos., 20 V)


20(H14-44)
F
3.53
577 (M + H)+.
ESI (Pos., 20 V)


20(H14-45)
F
3.31
579 (M + H)+.
ESI (Pos., 20 V)


20(H14-46)
F
3.60
581 (M + H)+.
ESI (Pos., 20 V)


20(H14-47)
F
3.09
622 (M + H)+.
ESI (Pos., 20 V)


20(H14-48)
F
3.22
511 (M + H)+.
ESI (Pos., 20 V)


20(H14-49)
F
3.20
487 (M + H)+.
ESI (Pos., 20 V)


20(H14-50)
F
3.36
527 (M + H)+.
ESI (Pos., 20 V)


20(H14-51)
F
3.14
528 (M + H)+.
ESI (Pos., 20 V)


20(H14-52)
F
3.16
578 (M + H)+.
ESI (Pos., 20 V)























TABLE 14C-3






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















20(H14-53)
F
3.31
551 (M + H)+.
ESI (Pos., 20 V)


20(H14-54)
F
3.31
551 (M + H)+.
ESI (Pos., 20 V)


20(H14-55)
F
3.51
597 (M + H)+.
ESI (Pos., 20 V)


20(H14-56)
F
3.55
567 (M + H)+.
ESI (Pos., 20 V)


20(H14-57)
F
3.09
592 (M + H)+.
ESI (Pos., 20 V)


20(H14-58)
F
3.51
543 (M + H)+.
ESI (Pos., 20 V)


20(H14-59)
F
3.31
539 (M + H)+.
ESI (Pos., 20 V)


20(H14-60)
F
3.07
475 (M + H)+.
ESI (Pos., 20 V)


20(H14-61)
F
3.40
571 (M + H)+.
ESI (Pos., 20 V)


20(H14-62)
F
3.15
473 (M + H)+.
ESI (Pos., 20 V)


20(H14-63)
F
3.04
565 (M + H)+.
ESI (Pos., 20 V)


20(H14-64)
F
3.25
527 (M + H)+.
ESI (Pos., 20 V)


20(H14-65)
F
3.69
569 (M + H)+.
ESI (Pos., 20 V)


20(H14-66)
F
3.38
555 (M + H)+.
ESI (Pos., 20 V)


20(H14-67)
F
3.29
565 (M + H)+.
ESI (Pos., 20 V)


20(H14-68)
F
3.03
549 (M + H)+.
ESI (Pos., 20 V)


20(H14-69)
F
3.22
631 (M + H)+.
ESI (Pos., 20 V)


20(H14-70)
F
3.69
607 (M + H)+.
ESI (Pos., 20 V)


20(H14-71)
F
3.66
651 (M + H)+.
ESI (Pos., 20 V)


20(H14-72)
F
3.31
539 (M + H)+.
ESI (Pos., 20 V)


20(H14-73)
F
3.50
567 (M + H)+.
ESI (Pos., 20 V)


20(H14-74)
F
3.31
615 (M + H)+.
ESI (Pos., 20 V)


20(H14-75)
F
3.35
565 (M + H)+.
ESI (Pos., 20 V)


20(H14-76)
F
3.51
657 (M + H)+.
ESI (Pos., 20 V)


20(H14-77)
F
3.55
627 (M + H)+.
ESI (Pos., 20 V)


20(H14-78)
F
3.55
627 (M + H)+.
ESI (Pos., 20 V)























TABLE 14C-4






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















20(H14-79)
F
3.53
613 (M + H)+.
ESI (Pos., 20 V)


20(H14-80)
F
3.42
577 (M + H)+.
ESI (Pos., 20 V)























TABLE 15C-1






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















20(H15-1)
D
12.20
462 (M + H)+,
APCI (Pos., 40 V)





282, 181.


20(H15-2)
D
10.20
397 (M + H)+.
APCI (Pos., 40 V)


20(H15-3)
D
10.50
352 (M + H)+.
APCI (Pos., 40 V)


20(H15-4)
D
10.90
446 (M + H)+.
APCI (Pos., 40 V)


20(H15-5)
D
9.47
415 (M + H)+,
APCI (Pos., 40 V)





282, 150.


20(H15-6)
D
13.90
464 (M + H)+.
APCI (Pos., 40 V)


20(H15-7)
D
10.50
350 (M + H)+.
APCI (Pos., 40 V)


20(H15-8)
D
13.70
416 (M + H)+.
APCI (Pos., 40 V)


20(H15-9)
D
8.05
340 (M + H)+,
APCI (Pos., 40 V)





282.


20(H15-10)
D
9.26
336 (M + H)+.
APCI (Pos., 40 V)


20(H15-11)
D
9.73
370 (M + H)+,
APCI (Pos., 40 V)





282.


20(H15-12)
D
8.36
368 (M + H)+,
APCI (Pos., 40 V)





310, 282.


20(H15-13)
D
13.70
406 (M + H)+.
APCI (Pos., 40 V)


20(H15-14)
D
12.40
423 (M + H)+,
APCI (Pos., 40 V)





158.


20(H15-15)
D
7.94
487 (M + H)+,
APCI (Pos., 40 V)





310, 282.


20(H15-16)
D
9.94
352 (M + H)+,
APCI (Pos., 40 V)





310.


20(H15-17)
D
15.10
420 (M + H)+.
APCI (Pos., 40 V)


20(H15-18)
D
11.80
400 (M + H)+.
APCI (Pos., 40 V)


20(H15-19)
D
9.80
338 (M + H)+.
APCI (Pos., 40 V)


20(H15-20)
D
10.80
372 (M + H)+.
APCI (Pos., 40 V)


20(H15-21)
D
11.20
388 (M + H)+.
APCI (Pos., 40 V)


20(H15-22)
D
10.10
388 (M + H)+.
APCI (Pos., 40 V)


20(H15-23)
D
10.70
388 (M + H)+,
APCI (Pos., 40 V)





282.


20(H15-24)
D
9.80
416 (M + H)+,
APCI (Pos., 40 V)





372, 310, 282.


20(H15-25)
D
16.40
486 (M + H)+.
APCI (Pos., 40 V)


20(H15-26)
D
12.30
412 (M + H)+.
APCI (Pos., 40 V)























TABLE 15C-2






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















20(H15-27)
D
13.20
442 (M + H)+.
APCI (Pos., 40 V)


20(H15-28)
D
14.90
514 (M + H)+.
APCI (Pos., 40 V)


20(H15-29)
D
14.40
420 (M + H)+.
APCI (Pos., 40 V)


20(H15-30)
D
13.20
441 (M + H)+,
APCI (Pos., 40 V)





282, 160.


20(H15-31)
D
15.40
470 (M + H)+.
APCI (Pos., 40 V)


20(H15-32)
D
13.80
478 (M + H)+.
APCI (Pos., 40 V)


20(H15-33)
D
15.10
500 (M + H)+,
APCI (Pos., 40 V)





282, 219.


20(H15-34)
D
14.90
456 (M + H)+.
APCI (Pos., 40 V)


20(H15-35)
D
15.60
584 (M + H)+.
APCI (Pos., 40 V)


20(H15-36)
D
17.10
500 (M + H)+.
APCI (Pos., 40 V)


20(H15-37)
D
14.30
408 (M + H)+.
APCI (Pos., 40 V)


20(H15-38)
D
11.60
396 (M + H)+.
APCI (Pos., 40 V)


20(H15-39)
D
13.30
476 (M + H)+,
APCI (Pos., 40 V)





458.


20(H15-40)
D
8.94
368 (M + H)+,
APCI (Pos., 40 V)





310, 282.


20(H15-41)
D
13.30
516 (M + Na)+,
APCI (Pos., 40 V)





494 (M + H)+.


20(H15-42)
D
11.10
438 (M + H)+,
APCI (Pos., 40 V)





282, 189, 173.


20(H15-43)
D
14.40
428 (M + H)+.
APCI (Pos., 40 V)


20(H15-44)
D
11.10
430 (M + H)+.
APCI (Pos., 40 V)


20(H15-45)
D
14.50
432 (M + H)+.
APCI (Pos., 40 V)


20(H15-46)
D
9.21
473 (M + H)+.
APCI (Pos., 40 V)


20(H15-47)
D
9.84
362 (M + H)+.
APCI (Pos., 40 V)


20(H15-48)
D
9.57
338 (M + H)+.
APCI (Pos., 40 V)


20(H15-49)
D
11.70
378 (M + H)+.
APCI (Pos., 40 V)


20(H15-50)
D
9.42
379 (M + H)+.
APCI (Pos., 40 V)


20(H15-51)
D
10.00
429 (M + H)+.
APCI (Pos., 40 V)


20(H15-52)
D
11.40
402 (M + H)+.
APCI (Pos., 40 V)























TABLE 15C-3






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















20(H15-53)
D
11.30
402 (M + H)+.
APCI (Pos., 40 V)


20(H15-54)
D
14.00
448 (M + H)+.
APCI (Pos., 40 V)


20(H15-55)
D
13.50
394 (M + H)+.
APCI (Pos., 40 V)


20(H15-56)
D
11.10
390 (M + H)+.
APCI (Pos., 40 V)


20(H15-57)
D
8.00
326 (M + H)+,
APCI (Pos., 40 V)





296.


20(H15-58)
D
12.90
422 (M + H)+.
APCI (Pos., 40 V)


20(H15-59)
D
9.05
324 (M + H)+.
APCI (Pos., 40 V)


20(H15-60)
D
8.00
414 (M + H)+,
APCI (Pos., 40 V)





340, 310, 282.


20(H15-61)
D
10.40
378 (M + H)+,
APCI (Pos., 40 V)





310.


20(H15-62)
D
15.70
420 (M + H)+.
APCI (Pos., 40 V)


20(H15-63)
D
12.30
406 (M + H)+.
APCI (Pos., 40 V)


20(H15-64)
D
11.10
416 (M + H)+.
APCI (Pos., 40 V)


20(H15-65)
D
7.79
400 (M + H)+,
APCI (Pos., 40 V)





310, 282.


20(H15-66)
D
10.60
482 (M + H)+,
APCI (Pos., 40 V)





282.


20(H15-67)
D
15.60
458 (M + H)+.
APCI (Pos., 40 V)


20(H15-68)
D
15.40
502 (M + H)+,
APCI (Pos., 40 V)





137.


20(H15-69)
D
11.20
390 (M + H)+.
APCI (Pos., 40 V)


20(H15-70)
D
13.60
418 (M + H)+.
APCI (Pos., 40 V)


20(H15-71)
D
11.40
466 (M + H)+,
APCI (Pos., 40 V)





217.


20(H15-72)
D
12.40
416 (M + H)+.
APCI (Pos., 40 V)


20(H15-73)
D
13.70
508 (M + H)+.
APCI (Pos., 40 V)


20(H15-74)
D
14.20
478 (M + H)+.
APCI (Pos., 40 V)


20(H15-75)
D
14.20
478 (M + H)+.
APCI (Pos., 40 V)


20(H15-76)
D
13.70
464 (M + H)+,
APCI (Pos., 40 V)





205.


20(H15-77)
D
12.60
428 (M + H)+.
APCI (Pos., 40 V)









EXAMPLE 21
(3S)-1-propyl-2,5-dioxo-3-(4-(benzylcarbonylamino) butyl)-9-(3-phenylpropanoyl)-1,4,9-triazaspiro[5.5]undecane



embedded image


To a solution of the compound prepared in Example 8 (0.01 g) in dichloroethane (0.2 ml) were added diisopropylethylamine (6 μl), 3-phenylpropanoyl chloride (5 μl). The reaction mixture was stirred for 1 hour at room temperature. The reaction mixture was passed through the column with aminomethylated polystyrene-2% divinylbenzene copolymer resin (NovaBiochem, AM Resin, 50 mg). The resin was washed with dichloroethane and filtrated. The filtrate was concentrated to give the compound of the present invention (14 mg) having the following physical data.


TLC: Rf 0.55 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.40–7.10 (m, 10H), 5.06 (s, 2H), 4.03 (m, 1H), 3.70–3.55 (m, 2H), 3.28–3.00 (m, 5H), 3.00–2.80 (m, 3H), 2.80–2.60 (m, 2H), 2.00–1.65 (m, 6H), 1.65–1.40 (m, 6H), 0.90 (t, J=7.2 Hz, 3H).


EXAMPLE 21(1)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzylcarbonylamino)butyl)-9-benzenesulfonyl-1,4,9-triazaspiro[5.5]undecane



embedded image


By the same procedure as described in Example 21 using the compound prepared in Example 8 (0.01 g), diisopropylethylamine (6 μl) and benzenesulfonyl chloride (4.5 μl), the compound of the present invention (16 mg) having the following physical data was obtained.


TLC: Rf 0.58 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.80 (m, 2H), 7.63 (m, 3H), 7.33 (m, 5H), 5.04 (s, 2H), 3.98 (t, J=4.8 Hz, 1H), 3.60–3.35 (m, 2H), 3.28–2.90 (m, 6H), 2.20–1.65 (m, 6H), 1.65–1.20 (m, 6H), 0.89 (t, J=7.2 Hz, 3H).


EXAMPLE 21(2)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzylcarbonylamino) butyl)-9-benzylaminocarbonyl-1,4,9-triazaspiro[5.5]undecane



embedded image


By the same procedure as described in Example 21 using the compound prepared in Example 8 (0.01 g) and benzyl isocyanate (4 μl), the compound of the present invention (16 mg) having the following physical data was obtained.


TLC: Rf 0.45 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.40–7.10 (m, 10H), 5.05 (s, 2H), 4.37 (s, 2H), 4.10–3.90 (m, 3H), 3.60–3.45 (m, 2H), 3.30–3.00 (m, 4H), 2.10–1.70 (m, 6H), 1.65–1.20 (m, 6H), 0.87 (t, J=7.4 Hz, 3H).


EXAMPLE 21 (H16-1)˜21 (H19-71)

By the same procedure as described in Example 21, 21(1) or 21(2), using the compound prepared in Example 8 or 8(1) and the corresponding acid chloride derivatives, sulfonyl chloride derivatives or isocyanate derivatives, the compounds of the present invention, whose names were shown in the following Table 16A-1˜19A-9, and whose structures were shown in the following Table 16B-1˜19B-11, were obtained. Also, physical data of the above compounds were shown in the following Table 16C-1˜19C-3.










TABLE 16A-1





Example



No
Compound Name







21(H16-1)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-phenylphenyl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-2)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-dimethylaminophenyl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-3)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((3-(2-chlorophenyl)-5-methylisooxazol-4-



yl)carbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H16-4)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-fluorophenyl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-5)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((3-fluorophenyl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-6)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2-fluorophenyl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-7)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(cyclopentylcarbonyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 16A-2





Example



No
Compound Name







21(H16-8)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((3-methylphenyl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-9)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((3-methoxyphenyl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-10)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2,2-dimethylpropanoyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-11)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(pyridin-3-ylcarbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-12)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(pyridin-4-ylcarbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-13)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(pyridin-2-ylcarbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-14)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-phenylacetyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 16A-3





Example



No
Compound Name







21(H16-15)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-phenyloxyacetyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-16)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-ethyl-2,3-dioxopiperazinyl)carbonyl)-



1,4,9-triazaspiro[5.5]undecane


21(H16-17)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2-phenylthiopyridin-3-yl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-18)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2-phenyloxypyridin-3-yl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-19)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2-methoxyphenyl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-20)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-(thiophen-2-yl)acetyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-21)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-hexanoyl-1,4,9-triazaspiro[5.5]undecane




















TABLE 16A-4





Example



No
Compound Name







21(H16-22)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-methylphenyl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-23)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-methylpropanoyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-24)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(3-cyclopentylpropanoyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-25)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2E)3-phenyl-2-propenoyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-26)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2-methylphenyl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-27)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(3,3-dimethylbutenoyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-28)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(cyclohexylcarbonyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 16A-5





Example



No
Compound Name







21(H16-29)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(phenylcarbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-30)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(thiophen-2-ylcarbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-31)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2,6,6-trimethyl-1-cyclohexenyl)carbonyl)-



1,4,9-triazaspiro[5.5]undecane


21(H16-32)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(ethoxyoxalyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-33)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((3-phenyl-5-methylisooxazol-4-yl)carbonyl)-



1,4,9-triazaspiro[5.5]undecane


21(H16-34)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((5-methyl-2-phenyl-1,2,3-triazol-4-



yl)carbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H16-35)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-(3-methoxyphenyl)acetyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 16A-6





Example



No
Compound Name







21(H16-36)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(4-methoxyphenylcarbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-37)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((furan-2-yl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-38)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-benzyloxyacetyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-39)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(cyclobutylcarbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-40)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-(4-methoxyphenyl)acetyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-41)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-acetyl-1,4,9-triazaspiro[5.5]undecane


21(H16-42)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(4-methylpentanoyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 16A-7





Example



No
Compound Name







21(H16-43)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-methoxyacetyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-44)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(3-methylthiopropanoyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-45)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((isooxazol-5-yl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-46)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-cyclopentylacetyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-47)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-pentanoyl-1,4,9-



triazaspiro[5.5]undecane


21(H16-48)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(3-methylbutanoyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-49)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-phenylthioacetyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 16A-8





Example



No
Compound Name







21(H16-50)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-methyl-1,2,3-thiadiazol-5-yl)carbonyl)-



1,4,9-triazaspiro[5.5]undecane


21(H16-51)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((3-cyanophenyl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-52)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-butanoyl-1,4,9-triazaspiro[5.5]undecane


21(H16-53)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-propanoyl-1,4,9-triazaspiro[5.5]undecane


21(H16-54)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(cyclopropylcarbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-55)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2H-benzo[3,4-d]1,3-dioxolan-5-



ylcarbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H16-56)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((1-phenyl-5-propylpyrazol-4-yl)carbonyl)-



1,4,9-triazaspiro[5.5]undecane




















TABLE 16A-9





Example



No
Compound Name







21(H16-57)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((5-(1,1-dimethylethyl)-2-methylfuran-3-yl)-



carbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H16-58)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((1-(1,1-dimethylethyl)-3-methylpyrazol-5-yl)-



carbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H16-59)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-methylsulfonyl-1,4,9-triazaspiro[5.5]undecane


21(H16-60)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-pentylsulfonyl-1,4,9-triazaspiro[5.5]undecane


21(H16-61)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((1-methylethyl)sulfonyl)-1,4,9-triazaspiro[5.5]-



undecane


21(H16-62)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-chlorophenyl)sulfonyl)-1,4,9-triazaspiro[5.5]-



undecane


21(H16-63)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2-iodophenyl)sulfonyl)-1,4,9-triazaspiro[5.5]-



undecane




















TABLE 16A-10





Example



No
Compound Name







21(H16-64)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-nitrophenyl)sulfonyl)-1,4,9-triazaspiro[5.5]-



undecane


21(H16-65)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-methylsulfonylphenyl)sulfonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-66)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-trifluoromethylphenyl)sulfonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-67)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-biphenyl)sulfonyl)-1,4,9-triazaspiro[5.5]-



undecane


21(H16-68)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2-biphenyl)sulfonyl)-1,4,9-triazaspiro[5.5]-



undecane


21(H16-69)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2-methoxycarbonylphenyl)sulfonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-70)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((3,4-difluorophenyl)sulfonyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 16A-11





Example



No
Compound Name







21(H16-71)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2,6-difluorophenyl)sulfonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-72)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2,5-difluorophenyl)sulfonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-73)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2,5-dimethoxyphenyl)sulfonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-74)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2-chloro-4-trifluoromethylphenyl)sulfonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-75)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(2-naphthylsulfonyl)-1,4,9-triazaspiro[5.5]-



undecane


21(H16-76)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(((1E)-2-phenylvinyl)sulfonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H16-77)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((furan-2-yl)sulfonyl)-1,4,9-triazaspiro[5.5]-



undecane




















TABLE 16A-12





Example



No
Compound Name







21(H16-78)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((thiophen-2-yl)sulfonyl)-1,4,9-triazaspiro[5.5]-



undecane




















TABLE 17A-1





Example



No
Compound Name







21(H17-1)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-bromo-2,5-dichlorothiophen-3-yl)sulfonyl)-



1,4,9-triazaspiro[5.5]undecane


21(H17-2)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((5-phenylsulfonylthiophen-2-yl)sulfonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-3)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((7-chlorobenzofurazan-4-yl)sulfonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-4)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-methyl-2-acetylaminothiazol-5-yl)sulfonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-5)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2-methoxy-dibenzofuran-3-yl)sulfonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-6)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((3,4-dichlorophenyl)sulfonyl)-1,4,9-triazaspiro[5.5]-



undecane


21(H17-7)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-methoxyphenyl)sulfonyl)-1,4,9-triazaspiro[5.5]-



undecane




















TABLE 17A-2





Example



No
Compound Name







21(H17-8)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-benzylsulfonyl-1,4,9-triazaspiro[5.5]undecane


21(H17-9)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((ethylamino)carbonyl)-1,4,9-triazaspiro[5.5]-



undecane


21(H17-10)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((propylamino)carbonyl)-1,4,9-triazaspiro[5.5]-



undecane


21(H17-11)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((1-methylethylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-12)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((ethoxycarbonylmethylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-13)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((butylamino)carbonyl)-1,4,9-triazaspiro[5.5]-



undecane


21(H17-14)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-chlorophenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 17A-3





Example



No
Compound Name







21(H17-15)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((phenylamino)carbonyl)-1,4,9-triazaspiro[5.5]-



undecane


21(H17-16)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-methylphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-17)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((hexylamino)carbonyl)-1,4,9-triazaspiro[5.5]-



undecane


21(H17-18)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-fluorophenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-19)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((benzylamino)carbonyl)-1,4,9-triazaspiro[5.5]-



undecane


21(H17-20)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((cyclohexylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-21)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((3-methylphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 17A-4





Example



No
Compound Name







21(H17-22)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((octylamino)carbonyl)-1,4,9-triazaspiro[5.5]-



undecane


21(H17-23)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-bromophenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-24)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2-(thiophen-2-yl)ethylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-25)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-(1-methylethyl)phenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-26)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((3-chlorophenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-27)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2,4,5-trimethylphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-28)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2,4,6-trimethylphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 17A-5





Example



No
Compound Name







21(H17-29)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-phenyloxyphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-30)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-butyloxyphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-31)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-phenylphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-32)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2-phenylphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-33)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-trifluoromethylphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-34)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((3,4-dichlorophenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-35)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-butyloxycarbonylphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 17A-6





Example



No
Compound Name







21(H17-36)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2,6-di(1-methylethyl)phenylamino)carbonyl)-



1,4,9-triazaspiro[5.5]undecane


21(H17-37)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2,5-dimethylphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-38)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2-ethyl-6-(1-methylethyl)phenylamino)carbonyl)-



1,4,9-triazaspiro[5.5]undecane


21(H17-39)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2,4,6-trichlorophenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-40)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((3,4-dimethylphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-41)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2-methylthiophenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-42)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-methylthiophenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 17A-7





Example



No
Compound Name







21(H17-43)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((4-butylphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-44)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2-chloro-5-trifluoromethylphenylamino)carbon-



yl)-1,4,9-triazaspiro[5.5]undecane


21(H17-45)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2,6-dibromo-4-ethylphenylamino)carbonyl)-



1,4,9-triazaspiro[5.5]undecane


21(H17-46)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((1-ethoxycarbonyl-2-methylpropylamino)carbon-



yl)-1,4,9-triazaspiro[5.5]undecane


21(H17-47)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((phenylcarbonylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-48)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2,4,6-tribromophenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-49)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2,5-difluorophenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 17A-8





Example



No
Compound Name







21(H17-50)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((3,5-bis(methoxycarbonyl)phenylamino)carbonyl)-



1,4,9-triazaspiro[5.5]undecane


21(H17-51)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((6,7-methylenedioxycoumarin-4-ylmethylamino)-



carbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H17-52)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2,6-dimethylphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-53)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2-methylpropyloxy)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-54)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2-ethylhexyloxy)carbonyl)-1,4,9-triazaspiro[5.5]-



undecane


21(H17-55)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(ethoxycarbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H17-56)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(allyloxycarbonyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 17A-9





Example



No
Compound Name







21(H17-57)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(propyloxycarbonyl)-1,4,9-triazaspiro[5.5]-



undecane


21(H17-58)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(butyloxycarbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H17-59)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(hexyloxycarbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H17-60)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2,2,2-trichloroethyloxy)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-61)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((fluoren-9-ylmethyloxy)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-62)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((1R,5R,2S)-5-methyl-2-(1-methylethyl)cyclohex-



yloxycarbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H17-63)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2-methoxyethoxy)carbonyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 17A-10





Example



No
Compound Name







21(H17-64)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(pentyloxycarbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H17-65)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((1-methylethyloxy)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-66)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((3-butenyloxy)carbonyl)-1,4,9-triazaspiro[5.5]-



undecane


21(H17-67)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((2R,1S,5S)-methyl-2-(1-methylethyl)cyclohexyl-



oxycarbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H17-68)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(cyclopentyloxycarbonyl)-1,4,9-triazaspiro[5.5]-



undecane


21(H17-69)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((1,1-dimethylethyloxy)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-70)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(benzyloxycarbonyl)-1,4,9-triazaspiro[5.5]-



undecane




















TABLE 17A-11





Example



No
Compound Name







21(H17-71)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((N,N-diphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-72)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((N-phenyl-N-methylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-73)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((N,N-dimethylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-74)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((N,N-diethylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-75)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-((N,N-bis(1-methylethyl)amino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H17-76)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(morpholin-4-ylcarbonyl)-1,4,9-triazaspiro[5.5]-



undecane


21(H17-77)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(carbazol-9-ylcarbonyl)-1,4,9-triazaspiro[5.5]-



undecane




















TABLE 17A-12





Example



No
Compound Name







21(H17-78)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)-



butyl)-9-(pyrrolidin-1-ylcarbonyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 18A-1





Example



No
Compound Name







21(H18-1)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-



biphenyl)carbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-2)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4,7,7-



trimethyl-2-oxa-3-oxobicyclo[2.2.1]heptan-1-yl)-



carbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-3)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-



dimethylaminophenyl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H18-4)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((3-(2-



chlorophenyl)-5-methylisooxazol-4-yl)carbonyl)-



1,4,9-triazaspiro[5.5]undecane


21(H18-5)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-



fluorophenyl)carbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-6)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((3-



fluorophenyl)carbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-7)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2-



fluorophenyl)carbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-8)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-



(cyclopentylcarbonyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 18A-2





Example



No
Compound Name







21(H18-9)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((3-



methylphenyl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H18-10)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((3-



methoxyphenyl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H18-11)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2,2-



dimethylpropanoyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-12)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(pyridin-3-



ylcarbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-13)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(pyridin-2-



ylcarbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-14)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-phenylacetyl)-



1,4,9-triazaspiro[5.5]undecane


21(H18-15)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-



phenyloxyacetyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-16)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-ethyl-



2,3-dioxopiperazinyl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H18-17)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2-



phenylthiopyridin-3-yl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 18A-3





Example



No
Compound Name







21(H18-18)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2-



phenyloxypyridin-3-yl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H18-19)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2-



methoxyphenyl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H18-20)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-(thiophen-2-



yl)acetyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-21)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-hexanoyl-1,4,9-



triazaspiro[5.5]undecane


21(H18-22)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-



methylphenyl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H18-23)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-



methylpropanoyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-24)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-



cyclopentylpropanoyl)-1,4,9-



triazaspiro[5.5]undecane


21(H18-25)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2E)-3-



phenyl-2-propenoyl)-1,4,9-



triazaspiro[5.5]undecane


21(H18-26)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2-



methylphenyl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 18A-4





Example



No
Compound Name







21(H18-27)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,3-



dimethylbutanoyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-28)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-



cyclohexylcarbonyl-1,4,9-triazaspiro[5.5]undecane


21(H18-29)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-



phenylcarbonyl-1,4,9-triazaspiro[5.5]undecane


21(H18-30)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(thiophen-



2-ylcarbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-31)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2,6,6-



trimethyl-1-cyclohexenyl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H18-32)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-



((ethoxycarbonyl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H18-33)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((3-phenyl-



5-methylisooxazol-4-yl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H18-34)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((5-methyl-



2-phenyl-1,2,3-triazol-4-yl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 18A-5





Example



No
Compound Name







21(H18-35)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-(3-



methoxyphenyl)acetyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-36)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



methoxyphenylcarbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-37)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((furan-2-



yl)carbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-38)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-



benzyloxyacetyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-39)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-



(cyclobutylcarbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-40)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-(4-



methoxyphenyl)acetyl)-1,4,9-



triazaspiro[5.5]undecane


21(H18-41)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-acetyl-1,4,9-



triazaspiro[5.5]undecane


21(H18-42)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



methylpentanoyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-43)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-



methoxyacetyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 18A-6





Example



No
Compound Name







2l(H18-44)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-



methylthiopropanoyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-45)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((isooxazol-



5-yl)carbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-46)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-



cyclopentylacetyl)-1,4,9-triazaspiro[5.5]-



undecane


21(H18-47)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-pentanoyl-



1,4,9-triazaspiro[5.5]undecane


21(H18-48)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-



methylpropanoyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-49)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-



phenylthioacetyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-50)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-methyl-



1,2,3-thiadiazol-5-yl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H18-51)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((3-



cyanophenyl)carbonyl)-1,4,9-triazaspiro[5.5]-



undecane


21(H18-52)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-butanoyl-



1,4,9-triazaspiro[5.5]undecane




















TABLE 18A-7





Example



No
Compound Name







21(H18-53)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-propanoyl-



1,4,9-triazaspiro[5.5]undecane


21(H18-54)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-



cyclopropylcarbonyl-1,4,9-triazaspiro[5.5]undecane


21(H18-55)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2H-benzo[3,4-



d]1,3-dioxolan-5-ylcarbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H18-56)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((1-phenyl-



5-propylpyrazol-4-yl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H18-57)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((5-(1,1-



dimethylethyl)-2-methylfuran-3-yl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H18-58)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((1-(1,1-



dimethylethyl)-3-methylpyrazol-5-yl)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H18-59)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-



methylsulfonyl-1,4,9-triazaspiro[5.5]undecane


21(H18-60)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-



pentylsulfonyl-1,4,9-triazaspiro[5.5]undecane






















TABLE 18A-8







Example




No
Compound Name









21(H18-61)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((1-




methylethyl)sulfonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H18-62)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2-




iodophenyl)sulfonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H18-63)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-




methylsulfonylphenyl)sulfonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H18-64)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-




trifluoromethylphenyl)sulfonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H18-65)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-




phenylphenyl)sulfonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H18-66)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2-




phenylphenyl)sulfonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H18-67)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2-




methoxycarbonylphenyl)sulfonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H18-68)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((3,4-




difluorophenyl)sulfonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H18-69)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2,6-




difluorophenyl)sulfonyl)-1,4,9-




triazaspiro[5.5]undecane





















TABLE 18A-9





Example



No
Compound Name







21(H18-70)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2,5-



difluorophenyl)sulfonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H18-71)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2,5-



dimethoxyphenyl)sulfonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H18-72)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-



naphthylsulfonyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-73)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(((1E)-2-



phenylvinyl)sulfonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H18-74)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((furan-2-yl)-



sulfonyl)-1,4,9-triazaspiro[5.5]undecane


21(H18-75)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((thiophen-2-



yl)sulfonyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 19A-1





Example



No
Compound Name







21(H19-1)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-methyl-2-



acetylaminothiazol-5-yl)sulfonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-2)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2-methoxy-



dibenzofuran-3-yl)sulfonyl)-1,4,9-triazaspiro[5.5]-



undecane


21(H19-3)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-



methoxyphenyl)sulfonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-4)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-benzylsulfonyl-



1,4,9-triazaspiro[5.5]undecane


21(H19-5)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-



((ethylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-6)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-



((propylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-7)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((1-



methylethylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-8)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-



((ethoxycarbonylmethylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane






















TABLE 19A-2







Example




No
Compound Name









21(H19-9)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




((butylamino)carbonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H19-10)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-




chlorophenylamino)carbonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H19-11)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




((phenylamino)carbonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H19-12)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-




methylphenylamino)carbonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H19-13)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




((hexylamino)carbonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H19-14)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-




fluorophenylamino)carbonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H19-15)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




((benzylamino)carbonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H19-16)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




((cyclohexylamino)carbonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H19-17)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((3-




methylphenylamino)carbonyl)-1,4,9-




triazaspiro[5.5]undecane





















TABLE 19A-3





Example



No
Compound Name







21(H19-18)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-



((octylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-19)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-



bromophenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-20)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2-(thiophen-



2-yl)ethylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-21)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-(1-



methylethyl)phenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-22)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((3-



chlorophenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-23)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2,4,5-



trimethylphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-24)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2,4,6-



trimethylphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-25)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-



phenyloxyphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane






















TABLE 19A-4







Example




No
Compound Name









21(H19-26)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-




butyloxyphenylamino)carbonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H19-27)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-




phenylphenylamino)carbonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H19-28)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2-




phenylphenylamino)carbonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H19-29)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-




trifluoromethylphenylamino)carbonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H19-30)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((3,4-




dichlorophenylamino)carbonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H19-31)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-




butyloxycarbonylphenylamino)carbonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H19-32)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2,6-




bis(1-methylethyl)phenylamino)carbonyl)-1,4,9-




triazaspiro[5.5]undecane



21(H19-33)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2,5-




dimethylphenylamino)carbonyl)-1,4,9-




triazaspiro[5.5]undecane





















TABLE 19A-5





Example



No
Compound Name







21(H19-34)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2-ethyl-



6-(1-methylethyl)phenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-35)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2,4,6-



trichlorophenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-36)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((3,4-



dimethylphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-37)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2-



methylthiophenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-38)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-



methylthiophenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-39)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-



butylphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-40)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2,6-



dibromo-4-ethylphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-41)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((1-



ethoxycarbonyl-2-methylpropylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 19A-6





Example



No
Compound Name







21(H19-42)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-



((phenylcarbonylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-43)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2,4,6-



tribromophenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-44)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2,5-



difluorophenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-45)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((3,5-



bis(methoxycarbonyl)phenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-46)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((6,7-



methylenedioxycoumarin-4-ylmethylamino)carbonyl)-



1,4,9-triazaspiro[5.5]undecane


21(H19-47)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2,6-



dimethylphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-48)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2-



methylpropyloxy)carbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H19-49)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2-



ethylhexyloxy)carbonyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 19A-7





Example



No
Compound Name







21(H19-50)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-ethoxy-



carbonyl-1,4,9-triazaspiro[5.5]undecane


21(H19-51)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-allyloxy-



carbonyl-1,4,9-triazaspiro[5.5]undecane


21(H19-52)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-propyloxy-



carbonyl-1,4,9-triazaspiro[5.5]undecane


21(H19-53)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-butyloxy-



carbonyl-1,4,9-triazaspiro[5.5]undecane


21(H19-54)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-hexyloxy-



carbonyl-1,4,9-triazaspiro[5.5]undecane


21(H19-55)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((fluoren-



9-ylmethyloxy)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-56)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((1R,5R,2S)-



5-methyl-2-(1-methylethyl)cyclohexyloxycarbonyl)-



1,4,9-triazaspiro[5.5]undecane


21(H19-57)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2-



methoxyethoxy)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-58)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-pentyloxy-



carbonyl-1,4,9-triazaspiro[5.5]undecane




















TABLE 19A-8





Example



No
Compound Name







21(H19-59)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((1-



methylethyloxy)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-60)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((3-



butenyloxy)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-61)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((2R,1S,5S)-



methyl-2-(1-methylethyl)cyclohexyloxycarbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-62)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-



cyclopentyloxycarbonyl-1,4,9-



triazaspiro[5.5]undecane


21(H19-63)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-benzyloxy-



carbonyl-1,4,9-triazaspiro[5.5]undecane


21(H19-64)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((N,N-



diphenylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-65)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((N-phenyl-



N-methylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-66)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((N,N-



dimethylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-67)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((N,N-



diethylamino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 19A-9





Example



No
Compound Name







21(H19-68)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-((N,N-bis(1-



methylethyl)amino)carbonyl)-1,4,9-



triazaspiro[5.5]undecane


21(H19-69)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(morpholin-4-



ylcarbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H19-70)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(carbazol-9-



ylcarbonyl)-1,4,9-triazaspiro[5.5]undecane


21(H19-71)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(pyrrolidin-



1-ylcarbonyl)-1,4,9-triazaspiro[5.5]undecane



















TABLE 16B-1









embedded image















Example No
R1







21(H16-1)


embedded image









21(H16-2)


embedded image









21(H16-3)


embedded image









21(H16-4)


embedded image









21(H16-5)


embedded image






















TABLE 16B-2









embedded image















Example No
R1







21(H16-6)


embedded image









21(H16-7)


embedded image









21(H16-8)


embedded image









21(H16-9)


embedded image









21(H16-10)


embedded image









21(H16-11)


embedded image






















TABLE 16B-3









embedded image















Example No
R1







21(H16-12)


embedded image









21(H16-13)


embedded image









21(H16-14)


embedded image









21(H16-15)


embedded image









21(H16-16)


embedded image









21(H16-17)


embedded image






















TABLE 16B-4









embedded image















Example No
R1







21(H16-18)


embedded image









21(H16-19)


embedded image









21(H16-20)


embedded image









21(H16-21)


embedded image









21(H16-22)


embedded image









21(H16-23)


embedded image









21(H16-24)


embedded image






















TABLE 16B-5









embedded image















Example No
R1







21(H16-25)


embedded image









21(H16-26)


embedded image









21(H16-27)


embedded image









21(H16-28)


embedded image









21(H16-29)


embedded image









21(H16-30)


embedded image









21(H16-31)


embedded image






















TABLE 16B-6









embedded image















Example No
R1







21(H16-32)


embedded image









21(H16-33)


embedded image









21(H16-34)


embedded image









21(H16-35)


embedded image









21(H16-36)


embedded image









21(H16-37)


embedded image









21(H16-38)


embedded image






















TABLE 16B-7









embedded image















Example No
R1







21(H16-39)


embedded image









21(H16-40)


embedded image









21(H16-41)


embedded image









21(H16-42)


embedded image









21(H16-43)


embedded image









21(H16-44)


embedded image









21(H16-45)


embedded image









21(H16-46)


embedded image






















TABLE 16B-8









embedded image















Example No
R1







21(H16-47)


embedded image









21(H16-48)


embedded image









21(H16-49)


embedded image









21(H16-50)


embedded image









21(H16-51)


embedded image









21(H16-52)


embedded image









21(H16-53)


embedded image









21(H16-54)


embedded image






















TABLE 16B-9









embedded image















Example No
R1







21(H16-55)


embedded image









21(H16-56)


embedded image









21(H16-57)


embedded image









21(H16-58)


embedded image









21(H16-59)


embedded image









21(H16-60)


embedded image






















TABLE 16B-10









embedded image















Example No
R1







21(H16-61)


embedded image









21(H16-62)


embedded image









21(H16-63)


embedded image









21(H16-64)


embedded image









21(H16-65)


embedded image









21(H16-66)


embedded image









21(H16-67)


embedded image









21(H16-68)


embedded image






















TABLE 16B-11









embedded image















Example No
R1







21(H16-69)


embedded image









21(H16-70)


embedded image









21(H16-71)


embedded image









21(H16-72)


embedded image









21(H16-73)


embedded image









21(H16-74)


embedded image






















TABLE 16B-12









embedded image















Example No
R1







21(H16-75)


embedded image









21(H16-76)


embedded image









21(H16-77)


embedded image









21(H16-78)


embedded image






















TABLE 17B-1









embedded image















Example No
R1







21(H17-1)


embedded image









21(H17-2)


embedded image









21(H17-3)


embedded image









21(H17-4)


embedded image









21(H17-5)


embedded image









21(H17-6)


embedded image






















TABLE 17B-2









embedded image















Example No
R1







21(H17-7)


embedded image









21(H17-8)


embedded image









21(H17-9)


embedded image









21(H17-10)


embedded image









21(H17-11)


embedded image









21(H17-12)


embedded image









21(H17-13)


embedded image









21(H17-14)


embedded image






















TABLE 17B-3









embedded image















Example No
R1







21(H17-15)


embedded image









21(H17-16)


embedded image









21(H17-17)


embedded image









21(H17-18)


embedded image









21(H17-19)


embedded image









21(H17-20)


embedded image









21(H17-21)


embedded image






















TABLE 17B-4









embedded image













Example No
R1





21(H17-22)


embedded image







21(H17-23)


embedded image







21(H17-24)


embedded image







21(H17-25)


embedded image







21(H17-26)


embedded image







21(H17-27)


embedded image







21(H17-28)


embedded image





















TABLE 17B-5









embedded image













Example No
R1





21(H17-29)


embedded image







21(H17-30)


embedded image







21(H17-31)


embedded image







21(H17-32)


embedded image







21(H17-33)


embedded image







21(H17-34)


embedded image





















TABLE 17B-6









embedded image













Example No
R1





21(H17-35)


embedded image







21(H17-36)


embedded image







21(H17-37)


embedded image







21(H17-38)


embedded image







21(H17-39)


embedded image





















TABLE 17B-7









embedded image















Example No
R1







21(H17-40)


embedded image









21(H17-41)


embedded image









21(H17-42)


embedded image









21(H17-43)


embedded image









21(H17-44)


embedded image









21(H17-45)


embedded image






















TABLE 17B-8









embedded image















Example No
R1







21(H17-46)


embedded image









21(H17-47)


embedded image









21(H17-48)


embedded image









21(H17-49)


embedded image









21(H17-50)


embedded image









21(H17-51)


embedded image






















TABLE 17B-9









embedded image















Example No
R1







21(H17-52)


embedded image









21(H17-53)


embedded image









21(H17-54)


embedded image









21(H17-55)


embedded image









21(H17-56)


embedded image









21(H17-57)


embedded image









21(H17-58)


embedded image









21(H17-59)


embedded image






















TABLE 17B-10









embedded image















Example No
R1







21(H17-60)


embedded image









21(H17-61)


embedded image









21(H17-62)


embedded image









21(H17-63)


embedded image









21(H17-64)


embedded image









21(H17-65)


embedded image









21(H17-66)


embedded image






















TABLE 17B-11









embedded image















Example No
R1







21(H17-67)


embedded image









21(H17-68)


embedded image









21(H17-69)


embedded image









21(H17-70)


embedded image









21(H17-71)


embedded image









21(H17-72)


embedded image






















TABLE 17B-12









embedded image















Example No
R1







21(H17-73)


embedded image









21(H17-74)


embedded image









21(H17-75)


embedded image









21(H17-76)


embedded image









21(H17-77)


embedded image









21(H17-78)


embedded image






















TABLE 18B-1









embedded image















Example No
R1







21(H18-1)


embedded image









21(H18-2)


embedded image









21(H18-3)


embedded image









21(H18-4)


embedded image









21(H18-5)


embedded image






















TABLE 18B-2









embedded image















Example No
R1







21(H18-6)


embedded image









21(H18-7)


embedded image









21(H18-8)


embedded image









21(H18-9)


embedded image









21(H18-10)


embedded image









21(H18-11)


embedded image









21(H18-12)


embedded image






















TABLE 18B-3









embedded image















Example No
R1







21(H18-13)


embedded image









21(H18-14)


embedded image









21(H18-15)


embedded image









21(H18-16)


embedded image









21(H18-17)


embedded image









21(H18-18)


embedded image






















TABLE18B-4









embedded image















Example No
R1







21(H18-19)


embedded image









21(H18-20)


embedded image









21(H18-21)


embedded image









21(H18-22)


embedded image









21(H18-23)


embedded image









21(H18-24)


embedded image









21(H18-25)


embedded image






















TABLE 18B-5









embedded image















Example No
R1







21(H18-26)


embedded image









21(H18-27)


embedded image









21(H18-28)


embedded image









21(H18-29)


embedded image









21(H18-30)


embedded image









21(H18-31)


embedded image









21(H18-32)


embedded image






















TABLE 18B-6









embedded image















Example No
R1







21(H18-33)


embedded image









21(H18-34)


embedded image









21(H18-35)


embedded image









21(H18-36)


embedded image









21(H18-37)


embedded image









21(H18-38)


embedded image









21(H18-39)


embedded image






















TABLE 18B-7









embedded image















Example No
c R1







21(H18-40)


embedded image









21(H18-41)


embedded image









21(H18-42)


embedded image









21(H18-43)


embedded image









21(H18-44)


embedded image









21(H18-45)


embedded image









21(H18-46)


embedded image









21(H18-47)


embedded image









21(H18-48)


embedded image






















TABLE 18B-8









embedded image















Example No
R1







21(H18-49)


embedded image









21(H18-50)


embedded image









21(H18-51)


embedded image









21(H18-52)


embedded image









21(H18-53)


embedded image









21(H18-54)


embedded image









21(H18-55)


embedded image






















TABLE 18B-9









embedded image















Example No
R1







21(H18-56)


embedded image









21(H18-57)


embedded image









21(H18-58)


embedded image









21(H18-59)


embedded image









21(H18-60)


embedded image









21(H18-61)


embedded image









21(H18-62)


embedded image






















TABLE 18D-10









embedded image















Example No
R1







21(H18-63)


embedded image









21(H18-64)


embedded image









21(H18-65)


embedded image









21(H18-66)


embedded image









21(H18-67)


embedded image









21(H18-68)


embedded image









21(H18-69)


embedded image






















TABLE 18B-11









embedded image















Example No
R1







21(H18-70)


embedded image









21(H18-71)


embedded image









21(H18-72)


embedded image









21(H18-73)


embedded image









21(H18-74)


embedded image









21(H18-75)


embedded image






















TABLE 19B-1









embedded image















Example No
R1







21(H19-1)


embedded image









21(H19-2)


embedded image









21(H19-3)


embedded image









21(H19-4)


embedded image









21(H19-5)


embedded image









21(H19-6)


embedded image









21(H19-7)


embedded image









21(H19-8)


embedded image






















TABLE 19B-2









embedded image















Example No
R1







21(H19-9)


embedded image









21(H19-10)


embedded image









21(H19-11)


embedded image









21(H19-12)


embedded image









21(H19-13)


embedded image









21(H19-14)


embedded image









21(H19-15)


embedded image






















TABLE 19B-3









embedded image













Example No
R1





21(H19-16)


embedded image







21(H19-17)


embedded image







21(H19-18)


embedded image







21(H19-19)


embedded image







21(H19-20)


embedded image







21(H19-21)


embedded image







21(H19-22)


embedded image





















TABLE 19B-4









embedded image













Example No
R1





21(H19-23)


embedded image







21(H19-24)


embedded image







21(H19-25)


embedded image







21(H19-26)


embedded image







21(H19-27)


embedded image







21(H19-28)


embedded image





















TABLE 19B-5









embedded image













Example No
R1





21(H19-29)


embedded image







21(H19-30)


embedded image







21(H19-31)


embedded image







21(H19-32)


embedded image







21(H19-33)


embedded image





















TABLE 19B-6









embedded image















Example No
R1







21(H19-34)


embedded image









21(H19-35)


embedded image









21(H19-36)


embedded image









21(H19-37)


embedded image









21(H19-38)


embedded image









21(H19-39)


embedded image






















TABLE 19B-7









embedded image















Example No
R1







21(H19-40)


embedded image









21(H19-41)


embedded image









21(H19-42)


embedded image









21(H19-43)


embedded image









21(H19-44)


embedded image









21(H19-45)


embedded image






















TABLE 19B-8









embedded image













Example No
R1





21(H19-46)


embedded image







21(H19-47)


embedded image







21(H19-48)


embedded image







21(H19-49)


embedded image







21(H19-50)


embedded image







21(H19-51)


embedded image







21(H19-52)


embedded image







21(H19-53)


embedded image





















TABLE 19B-9









embedded image















Example No
R1







21(H19-54)


embedded image









21(H19-55)


embedded image









21(H19-56)


embedded image









21(H19-57)


embedded image









21(H19-58)


embedded image









21(H19-59)


embedded image









21(H19-60)


embedded image






















TABLE 19B-10









embedded image













Example No
R1





21(H19-61)


embedded image







21(H19-62)


embedded image







21(H19-63)


embedded image







21(H19-64)


embedded image







21(H19-65)


embedded image







21(H19-66)


embedded image





















TABLE 19B-11









embedded image













Example No
R1





21(H19-67)


embedded image







21(H19-68)


embedded image







21(H19-69)


embedded image







21(H19-70)


embedded image







21(H19-71)


embedded image

























TABLE 16C-1






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















21(H16-1)
F
3.84
611 (M + H)+.
ESI (Pos., 20 V)


21(H16-2)
F
3.28
578 (M + H)+.
ESI (Pos., 20 V)


21(H16-3)
F
3.70
651 (M + H)+.
ESI (Pos., 20 V)


21(H16-4)
F
3.59
553 (M + H)+.
ESI (Pos., 20 V)


21(H16-5)
F
3.59
553 (M + H)+.
ESI (Pos., 20 V)


21(H16-6)
F
3.57
553 (M + H)+.
ESI (Pos., 20 V)


21(H16-7)
F
3.60
527 (M + H)+.
ESI (Pos., 20 V)


21(H16-8)
F
3.63
549 (M + H)+.
ESI (Pos., 20 V)


21(H16-9)
F
3.56
565 (M + H)+.
ESI (Pos., 20 V)


21(H16-10)
F
3.59
515 (M + H)+.
ESI (Pos., 20 V)


21(H16-11)
F
3.16
536 (M + H)+,
ESI (Pos., 20 V)





431.


21(H16-12)
F
3.15
536 (M + H)+,
ESI (Pos., 20 V)





431.


21(H16-13)
F
3.32
536 (M + H)+.
ESI (Pos., 20 V)


21(H16-14)
F
3.60
549 (M + H)+.
ESI (Pos., 20 V)


21(H16-15)
F
3.62
565 (M + H)+.
ESI (Pos., 20 V)


21(H16-16)
F
3.29
599 (M + H)+.
ESI (Pos., 20 V)


21(H16-17)
F
3.63
644 (M + H)+.
ESI (Pos., 20 V)


21(H16-18)
F
3.59
628 (M + H)+.
ESI (Pos., 20 V)


21(H16-19)
F
3.53
565 (M + H)+.
ESI (Pos., 20 V)


21(H16-20)
F
3.56
555 (M + H)+.
ESI (Pos., 20 V)


21(H16-21)
F
3.68
529 (M + H)+.
ESI (Pos., 20 V)


21(H16-22)
F
3.64
549 (M + H)+.
ESI (Pos., 20 V)


21(H16-23)
F
3.47
501 (M + H)+.
ESI (Pos., 20 V)


21(H16-24)
F
3.81
555 (M + H)+.
ESI (Pos., 20 V)


21(H16-25)
F
3.67
561 (M + H)+.
ESI (Pos., 20 V)


21(H16-26)
F
3.59
549 (M + H)+.
ESI (Pos., 20 V)























TABLE 16C-2






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















21(H16-27)
F
3.64
529 (M + H)+.
ESI (Pos., 20 V)


21(H16-28)
F
3.68
541 (M + H)+.
ESI (Pos., 20 V)


21(H16-29)
F
3.53
535 (M + H)+.
ESI (Pos., 20 V)


21(H16-30)
F
3.54
541 (M + H)+.
ESI (Pos., 20 V)


21(H16-31)
F
3.84
581 (M + H)+.
ESI (Pos., 20 V)


21(H16-32)
F
3.52
531 (M + H)+.
ESI (Pos., 20 V)


21(H16-33)
F
3.67
616 (M + H)+.
ESI (Pos., 20 V)


21(H16-34)
F
3.84
616 (M + H)+.
ESI (Pos., 20 V)


21(H16-35)
F
3.59
579 (M + H)+.
ESI (Pos., 20 V)


21(H16-36)
F
3.55
565 (M + H)+.
ESI (Pos., 20 V)


21(H16-37)
F
3.45
525 (M + H)+.
ESI (Pos., 20 V)


21(H16-38)
F
3.63
579 (M + H)+.
ESI (Pos., 20 V)


21(H16-39)
F
3.52
513 (M + H)+.
ESI (Pos., 20 V)


21(H16-40)
F
3.57
579 (M + H)+.
ESI (Pos., 20 V)


21(H16-41)
F
3.30
473 (M + H)+.
ESI (Pos., 20 V)


21(H16-42)
F
3.65
529 (M + H)+.
ESI (Pos., 20 V)


21(H16-43)
F
3.28
503 (M + H)+.
ESI (Pos., 20 V)


21(H16-44)
F
3.49
533 (M + H)+.
ESI (Pos., 20 V)


21(H16-45)
F
3.43
526 (M + H)+.
ESI (Pos., 20 V)


21(H16-46)
F
3.70
541 (M + H)+.
ESI (Pos., 20 V)


21(H16-47)
F
3.58
515 (M + H)+.
ESI (Pos., 20 V)


21(H16-48)
F
3.55
515 (M + H)+.
ESI (Pos., 20 V)


21(H16-49)
F
3.69
581 (M + H)+.
ESI (Pos., 20 V)


21(H16-50)
F
3.47
557 (M + H)+.
ESI (Pos., 20 V)


21(H16-51)
F
3.53
560 (M + H)+.
ESI (Pos., 20 V)


21(H16-52)
F
3.46
501 (M + H)+.
ESI (Pos., 20 V)























TABLE 16C-3






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















21(H16-53)
F
3.37
487 (M + H)+.
ESI (Pos., 20 V)


21(H16-54)
F
3.42
499 (M + H)+.
ESI (Pos., 20 V)


21(H16-55)
F
3.54
579 (M + H)+.
ESI (Pos., 20 V)


21(H16-56)
F
3.71
643 (M + H)+.
ESI (Pos., 20 V)


21(H16-57)
F
3.89
595 (M + H)+.
ESI (Pos., 20 V)


21(H16-58)
F
3.60
595 (M + H)+.
ESI (Pos., 20 V)


21(H16-59)
F
3.45
509 (M + H)+.
ESI (Pos., 20 V)


21(H16-60)
F
3.81
565 (M + H)+.
ESI (Pos., 20 V)


21(H16-61)
F
3.56
537 (M + H)+.
ESI (Pos., 20 V)


21(H16-62)
F
3.87
605 (M + H)+.
ESI (Pos., 20 V)


21(H16-63)
F
3.86
697 (M + H)+.
ESI (Pos., 20 V)


21(H16-64)
F
3.79
616 (M + H)+.
ESI (Pos., 20 V)


21(H16-65)
F
3.63
649 (M + H)+.
ESI (Pos., 20 V)


21(H16-66)
F
3.93
639 (M + H)+.
ESI (Pos., 20 V)


21(H16-67)
F
4.00
647 (M + H)+.
ESI (Pos., 20 V)


21(H16-68)
F
3.97
647 (M + H)+.
ESI (Pos., 20 V)


21(H16-69)
F
3.71
629 (M + H)+.
ESI (Pos., 20 V)


21(H16-70)
F
3.82
607 (M + H)+.
ESI (Pos., 20 V)


21(H16-71)
F
3.76
607 (M + H)+.
ESI (Pos., 20 V)


21(H16-72)
F
3.81
607 (M + H)+.
ESI (Pos., 20 V)


21(H16-73)
F
3.71
631 (M + H)+.
ESI (Pos., 20 V)


21(H16-74)
F
4.01
673 (M + H)+.
ESI (Pos., 20 V)


21(H16-75)
F
3.91
621 (M + H)+.
ESI (Pos., 20 V)


21(H16-76)
F
3.82
597 (M + H)+.
ESI (Pos., 20 V)


21(H16-77)
F
3.67
561 (M + H)+.
ESI (Pos., 20 V)


21(H16-78)
F
3.73
577 (M + H)+.
ESI (Pos., 20 V)























TABLE 17C-1






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















21(H17-1)
F
4.08
724 (M + H)+.
ESI (Pos., 20 V)


21(H17-2)
F
3.90
717 (M + H)+.
ESI (Pos., 20 V)


21(H17-3)
F
3.87
647 (M + H)+.
ESI (Pos., 20 V)


21(H17-4)
F
3.59
649 (M + H)+.
ESI (Pos., 20 V)


21(H17-5)
F
3.98
691 (M + H)+.
ESI (Pos., 20 V)


21(H17-6)
F
4.01
639 (M + H)+.
ESI (Pos., 20 V)


21(H17-7)
F
3.76
601 (M + H)+.
ESI (Pos., 20 V)


21(H17-8)
F
3.72
585 (M + H)+.
ESI (Pos., 20 V)


21(H17-9)
F
3.33
502 (M + H)+.
ESI (Pos., 20 V)


21(H17-10)
F
3.42
516 (M + H)+.
ESI (Pos., 20 V)


21(H17-11)
F
3.43
516 (M + H)+.
ESI (Pos., 20 V)


21(H17-12)
F
3.40
560 (M + H)+.
ESI (Pos., 20 V)


21(H17-13)
F
3.54
530 (M + H)+.
ESI (Pos., 20 V)


21(H17-14)
F
3.72
584 (M + H)+.
ESI (Pos., 20 V)


21(H17-15)
F
3.59
550 (M + H)+.
ESI (Pos., 20 V)


21(H17-16)
F
3.66
564 (M + H)+.
ESI (Pos., 20 V)


21(H17-17)
F
3.73
558 (M + H)+.
ESI (Pos., 20 V)


21(H17-18)
F
3.60
568 (M + H)+.
ESI (Pos., 20 V)


21(H17-19)
F
3.57
564 (M + H)+.
ESI (Pos., 20 V)


21(H17-20)
F
3.62
556 (M + H)+.
ESI (Pos., 20 V)


21(H17-21)
F
3.66
564 (M + H)+.
ESI (Pos., 20 V)


21(H17-22)
F
3.96
586 (M + H)+.
ESI (Pos., 20 V)


21(H17-23)
F
3.76
628 (M + H)+.
ESI (Pos., 20 V)


21(H17-24)
F
3.59
584 (M + H)+.
ESI (Pos., 20 V)


21(H17-25)
F
3.85
592 (M + H)+.
ESI (Pos., 20 V)


21(H17-26)
F
3.75
584 (M + H)+.
ESI (Pos., 20 V)























TABLE 17C-2






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















21(H17-27)
F
3.74
592 (M + H)+.
ESI (Pos., 20 V)


21(H17-28)
F
3.69
592 (M + H)+.
ESI (Pos., 20 V)


21(H17-29)
F
3.85
642 (M + H)+.
ESI (Pos., 20 V)


21(H17-30)
F
3.86
622 (M + H)+.
ESI (Pos., 20 V)


21(H17-31)
F
3.86
626 (M + H)+.
ESI (Pos., 20 V)


21(H17-32)
F
3.78
626 (M + H)+.
ESI (Pos., 20 V)


21(H17-33)
F
3.82
618 (M + H)+.
ESI (Pos., 20 V)


21(H17-34)
F
3.86
618 (M + H)+.
ESI (Pos., 20 V)


21(H17-35)
F
3.90
650 (M + H)+.
ESI (Pos., 20 V)


21(H17-36)
F
3.89
634 (M + H)+.
ESI (Pos., 20 V)


21(H17-37)
F
3.66
578 (M + H)+.
ESI (Pos., 20 V)


21(H17-38)
F
3.80
620 (M + H)+.
ESI (Pos., 20 V)


21(H17-39)
F
3.76
652 (M + H)+.
ESI (Pos., 20 V)


21(H17-40)
F
3.72
578 (M + H)+.
ESI (Pos., 20 V)


21(H17-41)
F
3.64
596 (M + H)+.
ESI (Pos., 20 V)


21(H17-42)
F
3.68
596 (M + H)+.
ESI (Pos., 20 V)


21(H17-43)
F
3.97
606 (M + H)+.
ESI (Pos., 20 V)


21(H17-44)
F
3.90
652 (M + H)+.
ESI (Pos., 20 V)


21(H17-45)
F
3.83
736 (M + H)+.
ESI (Pos., 20 V)


21(H17-46)
F
3.65
602 (M + H)+.
ESI (Pos., 20 V)


21(H17-47)
F
3.48
578 (M + H)+.
ESI (Pos., 20 V)


21(H17-48)
F
3.80
785 (M + H)+.
ESI (Pos., 20 V)


21(H17-49)
F
3.64
586 (M + H)+.
ESI (Pos., 20 V)


21(H17-50)
F
3.68
666 (M + H)+.
ESI (Pos., 20 V)


21(H17-51)
F
3.51
676 (M + H)+.
ESI (Pos., 20 V)


21(H17-52)
F
3.61
578 (M + H)+.
ESI (Pos., 20 V)























TABLE 17C-3






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















21(H17-53)
F
3.79
531 (M + H)+.
ESI (Pos., 20 V)


21(H17-54)
F
4.24
587 (M + H)+.
ESI (Pos., 20 V)


21(H17-55)
F
3.57
503 (M + H)+.
ESI (Pos., 20 V)


21(H17-56)
F
3.62
515 (M + H)+.
ESI (Pos., 20 V)


21(H17-57)
F
3.67
517 (M + H)+.
ESI (Pos., 20 V)


21(H17-58)
F
3.79
531 (M + H)+.
ESI (Pos., 20 V)


21(H17-59)
F
4.03
559 (M + H)+.
ESI (Pos., 20 V)


21(H17-60)
F
3.89
605 (M + H)+.
ESI (Pos., 20 V)


21(H17-61)
F
4.06
653 (M + H)+.
ESI (Pos., 20 V)


21(H17-62)
F
4.35
613 (M + H)+.
ESI (Pos., 20 V)


21(H17-63)
F
3.44
533 (M + H)+.
ESI (Pos., 20 V)


21(H17-64)
F
3.90
545 (M + H)+.
ESI (Pos., 20 V)


21(H17-65)
F
3.67
517 (M + H)+.
ESI (Pos., 20 V)


21(H17-66)
F
3.72
529 (M + H)+.
ESI (Pos., 20 V)


21(H17-67)
F
4.35
613 (M + H)+.
ESI (Pos., 20 V)


21(H17-68)
F
3.78
543 (M + H)+.
ESI (Pos., 20 V)


21(H17-69)
F
3.79
531 (M + H)+.
ESI (Pos., 20 V)


21(H17-70)
F
3.81
565 (M + H)+.
ESI (Pos., 20 V)


21(H17-71)
F
3.86
626 (M + H)+.
ESI (Pos., 20 V)


21(H17-72)
F
3.65
564 (M + H)+.
ESI (Pos., 20 V)


21(H17-73)
F
3.39
502 (M + H)+.
ESI (Pos., 20 V)


21(H17-74)
F
3.58
530 (M + H)+.
ESI (Pos., 20 V)


21(H17-75)
F
3.79
558 (M + H)+.
ESI (Pos., 20 V)


21(H17-76)
F
3.34
544 (M + H)+.
ESI (Pos., 20 V)


21(H17-77)
F
4.03
624 (M + H)+.
ESI (Pos., 20 V)


21(H17-78)
F
3.49
528 (M + H)+.
ESI (Pos., 20 V)























TABLE 18C-1






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















21(H18-1)
F
3.82
923 (2M + H)+,
ESI (Pos., 20 V)





462 (M + H)+.


21(H18-2)
F
3.81
462 (M + H)+.
ESI (Pos., 20 V)


21(H18-3)
F
3.12
857 (2M + H)+,
ESI (Pos., 20 V)





429 (M + H)+.


21(H18-4)
F
3.62
501 (M + H)+.
ESI (Pos., 20 V)


21(H18-5)
F
3.49
807 (2M + H)+,
ESI (Pos., 20 V)





404 (M + H)+.


21(H18-6)
F
3.51
807 (2M + H)+,
ESI (Pos., 20 V)





404 (M + H)+.


21(H18-7)
F
3.49
807 (2M + H)+,
ESI (Pos., 20 V)





404 (M + H)+.


21(H18-8)
F
3.51
755 (2M + H)+,
ESI (Pos., 20 V)





378 (M + H)+.


21(H18-9)
F
3.56
799 (2M + H)+,
ESI (Pos., 20 V)





400 (M + H)+.


21(H18-10)
F
3.49
831 (2M + H)+,
ESI (Pos., 20 V)





416 (M + H)+.


21(H18-11)
F
3.49
753 (2M + H)+,
ESI (Pos., 20 V)





366 (M + H)+.


21(H18-12)
F
3.00
773 (2M + H)+,
ESI (Pos., 20 V)





387 (M + H)+.


21(H18-13)
F
3.16
387 (M + H)+.
ESI (Pos., 20 V)


21(H18-14)
F
3.50
799 (2M + H)+,
ESI (Pos., 20 V)





400 (M + H)+.


21(H18-15)
F
3.53
831 (2M + H)+,
ESI (Pos., 20 V)





416 (M + H)+.


21(H18-16)
F
3.13
450 (M + H)+.
ESI (Pos., 20 V)


21(H18-17)
F
3.57
989 (2M + H)+,
ESI (Pos., 20 V)





495 (M + H)+.


21(H18-18)
F
3.53
957 (2M + H)+,
ESI (Pos., 20 V)





479 (M + H)+.


21(H18-19)
F
3.44
831 (2M + H)+,
ESI (Pos., 20 V)





416 (M + H)+.


21(H18-20)
F
3.45
811 (2M + H)+,
ESI (Pos., 20 V)





406 (M + H)+.


21(H18-21)
F
3.61
759 (2M + H)+,
ESI (Pos., 20 V)





380 (M + H)+.


21(H18-22)
F
3.56
799 (2M + H)+,
ESI (Pos., 20 V)





400 (M + H)+.


21(H18-23)
F
3.32
703 (2M + H)+,
ESI (Pos., 20 V)





352 (M + H)+.


21(H18-24)
F
3.75
811 (2M + H)+,
ESI (Pos., 20 V)





406 (M + H)+.


21(H18-25)
F
3.60
823 (2M + H)+,
ESI (Pos., 20 V)





412 (M + H)+.


21(H18-26)
F
3.51
799 (2M + H)+,
ESI (Pos., 20 V)





400 (M + H)+.























TABLE 18C-2






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















21(H18-27)
F
3.55
759 (2M + H)+,
ESI (Pos., 20 V)





380 (M + H)+.


21(H18-28)
F
3.58
783 (2M + H)+,
ESI (Pos., 20 V)





392 (M + H)+.


21(H18-29)
F
3.45
771 (2M + H)+,
ESI (Pos., 20 V)





386 (M + H)+.


21(H18-30)
F
3.44
783 (2M + H)+,
ESI (Pos., 20 V)





392 (M + H)+.


21(H18-31)
F
3.79
432 (M + H)+.
ESI (Pos., 20 V)


21(H18-32)
F
3.41
382 (M + H)+.
ESI (Pos., 20 V)


21(H18-33)
F
3.61
933 (2M + H)+,
ESI (Pos., 20 V)





467 (M + H)+.


21(H18-34)
F
3.80
933 (2M + H)+,
ESI (Pos., 20 V)





467 (M + H)+.


21(H18-35)
F
3.48
859 (2M + H)+,
ESI (Pos., 20 V)





430 (M + H)+.


21(H18-36)
F
3.46
831 (2M + H)+,
ESI (Pos., 20 V)





416 (M + H)+.


21(H18-37)
F
3.35
751 (2M + H)+,
ESI (Pos., 20 V)





376 (M + H)+.


21(H18-38)
F
3.53
430 (M + H)+.
ESI (Pos., 20 V)


21(H18-39)
F
3.40
727 (2M + H)+,
ESI (Pos., 20 V)





364 (M + H)+.


21(H18-40)
F
3.48
859 (2M + H)+,
ESI (Pos., 20 V)





430 (M + H)+.


21(H18-41)
F
3.11
647 (2M + H)+,
ESI (Pos., 20 V)





324 (M + H)+.


21(H18-42)
F
3.60
759 (2M + H)+,
ESI (Pos., 20 V)





380 (M + H)+.


21(H18-43)
F
3.13
354 (M + H)+.
ESI (Pos., 20 V)


21(H18-44)
F
3.35
767 (2M + H)+,
ESI (Pos., 20 V)





384 (M + H)+.


21(H18-45)
F
3.28
753 (2M + H)+,
ESI (Pos., 20 V)





377 (M + H)+.


21(H18-46)
F
3.60
783 (2M + H)+,
ESI (Pos., 20 V)





392 (M + H)+.


21(H18-47)
F
3.47
731 (2M + H)+,
ESI (Pos., 20 V)





366 (M + H)+.


21(H18-48)
F
3.44
731 (2M + H)+,
ESI (Pos., 20 V)





366 (M + H)+.


21(H18-49)
F
3.62
863 (2M + H)+,
ESI (Pos., 20 V)





432 (M + H)+.


21(H18-50)
F
3.34
815 (2M + H)+,
ESI (Pos., 20 V)





408 (M + H)+.


21(H18-51)
F
3.42
821 (2M + H)+,
ESI (Pos., 20 V)





411 (M + H)+.


21(H18-52)
F
3.33
703 (2M + H)+,
ESI (Pos., 20 V)





352 (M + H)+.























TABLE 18C-3






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















21(H18-53)
F
3.22
675 (2M + H)+,
ESI (Pos., 20 V)





338 (M + H)+.


21(H18-54)
F
3.27
699 (2M + H)+,
ESI (Pos., 20 V)





350 (M + H)+.


21(H18-55)
F
3.45
859 (2M + H)+,
ESI (Pos., 20 V)





430 (M + H)+.


21(H18-56)
F
3.64
987 (2M + H)+,
ESI (Pos., 20 V)





494 (M + H)+.


21(H18-57)
F
3.86
891 (2M + H)+,
ESI (Pos., 20 V)





446 (M + H)+.


21(H18-58)
F
3.51
446 (M + H)+.
ESI (Pos., 20 V)


21(H18-59)
F
3.29
360 (M + H)+.
ESI (Pos., 20 V)


21(H18-60)
F
3.76
416 (M + H)+.
ESI (Pos., 20 V)


21(H18-61)
F
3.45
797 (2M + Na)+,
ESI (Pos., 20 V)





388 (M + H)+.


21(H18-62)
F
3.82
548 (M + H)+.
ESI (Pos., 20 V)


21(H18-63)
F
3.55
500 (M + H)+.
ESI (Pos., 20 V)


21(H18-64)
F
3.90
490 (M + H)+.
ESI (Pos., 20 V)


21(H18-65)
F
3.99
498 (M + H)+.
ESI (Pos., 20 V)


21(H18-66)
F
3.97
498 (M + H)+.
ESI (Pos., 20 V)


21(H18-67)
F
3.62
480 (M + H)+.
ESI (Pos., 20 V)


21(H18-68)
F
3.77
458 (M + H)+.
ESI (Pos., 20 V)


21(H18-69)
F
3.70
458 (M + H)+.
ESI (Pos., 20 V)


21(H18-70)
F
3.76
458 (M + H)+.
ESI (Pos., 20 V)


21(H18-71)
F
3.62
985 (2M + Na)+,
ESI (Pos., 20 V)





482 (M + H)+.


21(H18-72)
F
3.89
472 (M + H)+.
ESI (Pos., 20 V)


21(H18-73)
F
3.79
448 (M + H)+.
ESI (Pos., 20 V)


21(H18-74)
F
3.58
412 (M + H)+.
ESI (Pos., 20 V)


21(H18-75)
F
3.65
428 (M + H)+.
ESI (Pos., 20 V)























TABLE 19C-1






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















21(H19-1)
F
3.48
500 (M + H)+.
ESI (Pos., 20 V)


21(H19-2)
F
3.96
542 (M + H)+.
ESI (Pos., 20 V)


21(H19-3)
F
3.68
452 (M + H)+.
ESI (Pos., 20 V)


21(H19-4)
F
3.64
436 (M + H)+.
ESI (Pos., 20 V)


21(H19-5)
F
3.13
353 (M + H)+.
ESI (Pos., 20 V)


21(H19-6)
F
3.25
367 (M + H)+.
ESI (Pos., 20 V)


21(H19-7)
F
3.26
367 (M + H)+.
ESI (Pos., 20 V)


21(H19-8)
F
3.21
411 (M + H)+.
ESI (Pos., 20 V)


21(H19-9)
F
3.37
381 (M + H)+.
ESI (Pos., 20 V)


21(H19-10)
F
3.63
435 (M + H)+.
ESI (Pos., 20 V)


21(H19-11)
F
3.45
401 (M + H)+.
ESI (Pos., 20 V)


21(H19-12)
F
3.55
415 (M + H)+.
ESI (Pos., 20 V)


21(H19-13)
F
3.65
409 (M + H)+.
ESI (Pos., 20 V)


21(H19-14)
F
3.49
419 (M + H)+.
ESI (Pos., 20 V)


21(H19-15)
F
3.43
415 (M + H)+.
ESI (Pos., 20 V)


21(H19-16)
F
3.50
407 (M + H)+.
ESI (Pos., 20 V)


21(H19-17)
F
3.54
415 (M + H)+.
ESI (Pos., 20 V)


21(H19-18)
F
3.90
437 (M + H)+.
ESI (Pos., 20 V)


21(H19-19)
F
3.67
481 (M + H)+.
ESI (Pos., 20 V)


21(H19-20)
F
3.46
435 (M + H)+.
ESI (Pos., 20 V)


21(H19-21)
F
3.77
443 (M + H)+.
ESI (Pos., 20 V)


21(H19-22)
F
3.64
435 (M + H)+.
ESI (Pos., 20 V)


21(H19-23)
F
3.64
443 (M + H)+.
ESI (Pos., 20 V)


21(H19-24)
F
3.58
443 (M + H)+.
ESI (Pos., 20 V)


21(H19-25)
F
3.79
493 (M + H)+.
ESI (Pos., 20 V)


21(H19-26)
F
3.78
473 (M + H)+.
ESI (Pos., 20 V)























TABLE 19C-2






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















21(H19-27)
F
3.80
477 (M + H)+.
ESI (Pos., 20 V)


21(H19-28)
F
3.70
477 (M + H)+.
ESI (Pos., 20 V)


21(H19-29)
F
3.74
469 (M + H)+.
ESI (Pos., 20 V)


21(H19-30)
F
3.79
469 (M + H)+.
ESI (Pos., 20 V)


21(H19-31)
F
3.85
501 (M + H)+.
ESI (Pos., 20 V)


21(H19-32)
F
3.81
485 (M + H)+.
ESI (Pos., 20 V)


21(H19-33)
F
3.56
429 (M + H)+.
ESI (Pos., 20 V)


21(H19-34)
F
3.72
471 (M + H)+.
ESI (Pos., 20 V)


21(H19-35)
F
3.67
505 (M + H)+.
ESI (Pos., 20 V)


21(H19-36)
F
3.63
429 (M + H)+.
ESI (Pos., 20 V)


21(H19-37)
F
3.57
447 (M + H)+.
ESI (Pos., 20 V)


21(H19-38)
F
3.59
447 (M + H)+.
ESI (Pos., 20 V)


21(H19-39)
F
3.91
457 (M + H)+.
ESI (Pos., 20 V)


21(H19-40)
F
3.77
587 (M + H)+.
ESI (Pos., 20 V)


21(H19-41)
F
3.50
453 (M + H)+.
ESI (Pos., 20 V)


21(H19-42)
F
3.34
429 (M + H)+.
ESI (Pos., 20 V)


21(H19-43)
F
3.75
638 (M + H)+.
ESI (Pos., 20 V)


21(H19-44)
F
3.54
437 (M + H)+.
ESI (Pos., 20 V)


21(H19-45)
F
3.58
517 (M + H)+.
ESI (Pos., 20 V)


21(H19-46)
F
3.35
527 (M + H)+.
ESI (Pos., 20 V)


21(H19-47)
F
3.47
429 (M + H)+.
ESI (Pos., 20 V)


21(H19-48)
F
3.70
382 (M + H)+.
ESI (Pos., 20 V)


21(H19-49)
F
4.22
438 (M + H)+.
ESI (Pos., 20 V)


21(H19-50)
F
3.43
354 (M + H)+.
ESI (Pos., 20 V)


21(H19-51)
F
3.50
366 (M + H)+.
ESI (Pos., 20 V)


21(H19-52)
F
3.57
368 (M + H)+.
ESI (Pos., 20 V)























TABLE 19C-3






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















21(H19-53)
F
3.72
382 (M + H)+.
ESI (Pos., 20 V)


21(H19-54)
F
3.99
410 (M + H)+.
ESI (Pos., 20 V)


21(H19-55)
F
4.03
504 (M + H)+.
ESI (Pos., 20 V)


21(H19-56)
F
4.37
464 (M + H)+.
ESI (Pos., 20 V)


21(H19-57)
F
3.28
384 (M + H)+.
ESI (Pos., 20 V)


21(H19-58)
F
3.86
396 (M + H)+.
ESI (Pos., 20 V)


21(H19-59)
F
3.56
368 (M + H)+.
ESI (Pos., 20 V)


21(H19-60)
F
3.60
380 (M + H)+.
ESI (Pos., 20 V)


21(H19-61)
F
4.39
464 (M + H)+.
ESI (Pos., 20 V)


21(H19-62)
F
3.71
394 (M + H)+.
ESI (Pos., 20 V)


21(H19-63)
F
3.74
416 (M + H)+.
ESI (Pos., 20 V)


21(H19-64)
F
3.81
477 (M + H)+.
ESI (Pos., 20 V)


21(H19-65)
F
3.55
415 (M + H)+.
ESI (Pos., 20 V)


21(H19-66)
F
3.22
353 (M + H)+.
ESI (Pos., 20 V)


21(H19-67)
F
3.46
381 (M + H)+.
ESI (Pos., 20 V)


21(H19-68)
F
3.71
409 (M + H)+.
ESI (Pos., 20 V)


21(H19-69)
F
3.17
395 (M + H)+.
ESI (Pos., 20 V)


21(H19-70)
F
3.97
475 (M + H)+.
ESI (Pos., 20 V)


21(H19-71)
F
3.34
379 (M + H)+.
ESI (Pos., 20 V)









EXAMPLE 22
(3S)-1-propyl-2,5-dioxo-3-(4-(3-phenylpropanoyl)aminobutyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane



embedded image


To a solution of the compound prepared in Example 14 (5 mg) in dichloroethane (0.5 ml) were added pyridine (2 μl), 3-phenylpropanoyl chloride (4 μl). The reaction mixture was stirred for 3 hours at room temperature. To the reaction mixture was added methanol, and it was loaded on ion exchange resin (OASIS MCX, Waters, 60 mg) washed with methanol (3 ml) prior to use. The resin was washed with methanol (2 ml), and was eluted with 10% triethylamine-methanol solution (2 ml). The elution was concentrated to give the compound of the present invention (1.6 mg) having the following physical data.


TLC: Rf 0.49 (chloroform:methanol=10:1);


NMR (CD3OD): 67.40–7.10 (m, 10H), 4.03 (m, 1H), 3.60–3.30 (m, 2H), 3.14 (m, 2H), 3.06–2.90 (m, 3H), 2.90–2.75 (m, 4H), 2.75–2.60 (m, 3H), 2.45 (t, J=7.4 Hz, 2H), 2.30–2.00 (m, 2H), 2.00–1.70 (m, 4H), 1.70–1.20 (m, 6H), 0.93 (t, J=7.2 Hz, 3H).


EXAMPLE 22(1)
(3S)-1-propyl-2,5-dioxo-3-(4-benzenesulfonylaminobutyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane



embedded image


By the same procedure as described in Example 22 using the compound prepared in Example 14 (5 mg), pyridine (2 μl), benzenesulfonyl chloride (3 μl), the compound of the present invention (4.4 mg) having the following physical data was obtained.


TLC: Rf 0.49 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.84 (m, 2H), 7.59 (m, 3H), 7.34–7.10 (m, 5H), 4.01 (t, J=5.0 Hz, 1H), 3.55–3.30 (m, 2H), 3.05–2.90 (m, 3H), 2.90–2.75 (m, 4H), 2.75 –2.60 (m, 3H), 2.30–2.00 (m, 2H), 1.96 (m, 2H), 1.88–1.70 (m, 2H), 1.70–1.20 (m, 6H), 0.94 (t, J=7.4 Hz, 3H).


EXAMPLE 22(2)
(3S)-1-propyl-2,5-dioxo-3-(4-(N-benzylcarbamoyl)aminobutyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane



embedded image


By the same procedure as described in Example 22 using the compound prepared in Example 14 (5 mg), and benzyl isocyanate (3 μl), the compound of the present invention (7 mg) having the following physical data was obtained.


TLC: Rf 0.46 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.40–7.10 (m, 10H), 4.30 (s, 2H), 4.04 (t, J=5.0 Hz, 1H), 3.55–3.30 (m, 2H), 3.15 (t, J=6.6 Hz, 3H), 3.05–2.90 (m, 3H), 2.90–2.75 (m, 3H), 2.75–2.60 (m, 2H), 2.35–2.05 (m, 2H), 2.02–1.70 (m, 4H), 1.70–1.20 (m, 6H), 0.93 (t, J=7.4 Hz, 3H).


EXAMPLE 22(H20-1)˜22(H21-77)

By the same procedure as described in Example 22, 22(1) or 22(2) using the compound prepared in Example 14 and the corresponding acid chloride derivatives, sulfonyl chloride derivatives or isocyanate derivatives, the compounds of the present invention, whose names were shown in the following Table 20A-1˜21A-11, and whose structures were shown in the following Table 20B-1˜21B-12, were obtained. Also, physical data of the above compounds were shown in the following Table 20C-1˜21C-3.










TABLE 20A-1





Example



No
Compound Name







22(H20-1)
(3S)-1-propyl-2,5-dioxo-3-(4-((4-biphenyl)carbon-



ylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-2)
(3S)-1-propyl-2,5-dioxo-3-(4-((4,7,7-trimethyl-2-



oxa-3-oxobicyclo[2.2.1]heptan-1-yl)carbonyl-



amino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-3)
(3S)-1-propyl-2,5-dioxo-3-(4-((4-dimethylamino-



phenyl)carbonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H20-4)
(3S)-1-propyl-2,5-dioxo-3-(4-((3-(2-chlorophenyl)-



5-methylisooxazol-4-yl)carbonylamino)butyl)-9-



(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H20-5)
(3S)-1-propyl-2,5-dioxo-3-(4-((4-fluorophenyl)carbon-



ylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-6)
(3S)-1-propyl-2,5-dioxo-3-(4-((3-fluorophenyl)carbon-



ylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-7)
(3S)-1-propyl-2,5-dioxo-3-(4-((2-fluorophenyl)carbon-



ylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 20A-2





Example



No
Compound Name







22(H20-8)
(3S)-1-propyl-2,5-dioxo-3-(4-(cyclopentylcarbon-



ylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-9)
(3S)-1-propyl-2,5-dioxo-3-(4-((3-methylphenyl)carbon-



ylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-10)
(3S)-1-propyl-2,5-dioxo-3-(4-((3-methoxyphenyl)carbon-



ylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-11)
(3S)-1-propyl-2,5-dioxo-3-(4-(2,2-dimethylpro-



panoylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-12)
(3S)-1-propyl-2,5-dioxo-3-(4-(pyridin-3-ylcarbonyl-



amino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-13)
(3S)-1-propyl-2,5-dioxo-3-(4-(pyridin-2-



ylcarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-14)
(3S)-1-propyl-2,5-dioxo-3-(4-(2-phenylacetyl-



amino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 20A-3





Example



No
Compound Name







22(H20-15)
(3S)-1-propyl-2,5-dioxo-3-(4-(2-phenyloxyacetyl-



amino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-16)
(3S)-1-propyl-2,5-dioxo-3-(4-((4-ethyl-2,3-



dioxopiperazinyl)carbonylamino)butyl)-9-



(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H20-17)
(3S)-1-propyl-2,5-dioxo-3-(4-((2-phenylthiopyridin-3-



yl)carbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-18)
(3S)-1-propyl-2,5-dioxo-3-(4-((2-phenyloxypyridin-3-



yl)carbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-19)
(3S)-1-propyl-2,5-dioxo-3-(4-((2-methoxyphenyl)carbon-



ylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-20)
(3S)-1-propyl-2,5-dioxo-3-(4-(2-(thiophen-2-



yl)acetylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-21)
(3S)-1-propyl-2,5-dioxo-3-(4-(hexanoylamino)butyl)-9-



(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 20A-4





Example



No
Compound Name







22(H20-22)
(3S)-1-propyl-2,5-dioxo-3-(4-((4-methylphenyl)carbon-



ylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-23)
(3S)-1-propyl-2,5-dioxo-3-(4-(2-methylpropanoyl-



amino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-24)
(3S)-1-propyl-2,5-dioxo-3-(4-(3-cyclopentylpropanoyl-



amino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-25)
(3S)-1-propyl-2,5-dioxo-3-(4-((2E)-3-phenyl-2-



propenoylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-26)
(3S)-1-propyl-2,5-dioxo-3-(4-((2-



methylphenyl)carbonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H20-27)
(3S)-1-propyl-2,5-dioxo-3-(4-(3,3-



dimethylbutanoylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H20-28)
(3S)-1-propyl-2,5-dioxo-3-(4-



(cyclohexylcarbonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane




















TABLE 20A-5





Example



No
Compound Name







22(H20-29)
(3S)-1-propyl-2,5-dioxo-3-(4-(phenylcarbonyl-



amino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-30)
(3S)-1-propyl-2,5-dioxo-3-(4-(thiophen-2-



ylcarbonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H20-31)
(3S)-1-propyl-2,5-dioxo-3-(4-((2,6,6-trimethyl-



1-cyclohexenyl)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H20-32)
(3S)-1-propyl-2,5-dioxo-3-(4-((3-phenyl-5-methyl-



isooxazol-4-yl)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H20-33)
(3S)-1-propyl-2,5-dioxo-3-(4-((5-methyl-2-phenyl-



1,2,3-triazol-4-yl)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H20-34)
(3S)-1-propyl-2,5-dioxo-3-(4-(2-(3-



methoxyphenyl)acetylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H20-35)
(3S)-1-propyl-2,5-dioxo-3-(4-(4-



methoxyphenylcarbonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane




















TABLE 20A-6





Example



No
Compound Name







22(H20-36)
(3S)-1-propyl-2,5-dioxo-3-(4-((furan-2-



yl)carbonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H20-37)
(3S)-1-propyl-2,5-dioxo-3-(4-(2-benzyloxyacetyl-



amino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-38)
(3S)-1-propyl-2,5-dioxo-3-(4-(cyclobutylcarbonyl-



amino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-39)
(3S)-1-propyl-2,5-dioxo-3-(4-(2-(4-methoxy-



phenyl)acetylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H20-40)
(3S)-1-propyl-2,5-dioxo-3-(4-(acetylamino)butyl)-



9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H20-41)
(3S)-1-propyl-2,5-dioxo-3-(4-(4-methylpentanoyl-



amino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-42)
(3S)-1-propyl-2,5-dioxo-3-(4-(2-methoxyacetyl-



amino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 20A-7





Example



No
Compound Name







22(H20-43)
(3S)-1-propyl-2,5-dioxo-3-(4-(3-



methylthiopropanoylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H20-44)
(3S)-1-propyl-2,5-dioxo-3-(4-(2-



cyclopentylacetylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H20-45)
(3S)-1-propyl-2,5-dioxo-3-(4-(pentanoylamino)butyl)-



9-(2-phenylethyl)-1,4,9-tri-



azaspiro[5.5]undecane


22(H20-46)
(3S)-1-propyl-2,5-dioxo-3-(4-(3-methylpropanoyl-



amino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-47)
(3S)-1-propyl-2,5-dioxo-3-(4-(2-phenylthioacetyl-



amino)butyl)-9-(2-phenylethyl)-1,4,9-tri-



azaspiro[5.5]undecane


22(H20-48)
(3S)-1-propyl-2,5-dioxo-3-(4-((4-methyl-1,2,3-



thiadiazol-5-yl)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H20-49)
(3S)-1-propyl-2,5-dioxo-3-(4-((3-



cyanophenyl)carbonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane




















TABLE 20A-8





Example



No
Compound Name







22(H20-50)
(3S)-1-propyl-2,5-dioxo-3-(4-(butanoylamino)butyl)-



9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-51)
(3S)-1-propyl-2,5-dioxo-3-(4-(propanoylamino)butyl)-



9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-52)
(3S)-1-propyl-2,5-dioxo-3-(4-



(cyclopropylcarbonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H20-53)
(3S)-1-propyl-2,5-dioxo-3-(4-(2H-



benzo[3,4-d]1,3-dioxolan-5-ylcarbonyl-



amino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-54)
(3S)-1-propyl-2,5-dioxo-3-(4-((1-phenyl-5-



propylpyrazol-4-yl)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H20-55)
(3S)-1-propyl-2,5-dioxo-3-(4-((5-(1,1-dimethyl-



ethyl)-2-methylfuran-3-yl)carbonylamino)butyl)-9-



(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H20-56)
(3S)-1-propyl-2,5-dioxo-3-(4-((1-(1,1-dimethyl-



ethyl)-3-methylpyrazol-5-yl)carbonylamino)butyl)-9-



(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 20A-9





Example



No
Compound Name







22(H20-57)
(3S)-1-propyl-2,5-dioxo-3-(4-(methylsulfonylamino)butyl)-



9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H20-58)
(3S)-1-propyl-2,5-dioxo-3-(4-(pentylsulfonylamino)butyl)-



9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H20-59)
(3S)-1-propyl-2,5-dioxo-3-(4-(1-



methylethylsulfonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H20-60)
(3S)-1-propyl-2,5-dioxo-3-(4-(4-chlorophenyl-



sulfonyl)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-61)
(3S)-1-propyl-2,5-dioxo-3-(4-(2-



iodophenylsulfonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-62)
(3S)-1-propyl-2,5-dioxo-3-(4-(4-



nitrophenylsulfonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-63)
(3S)-1-propyl-2,5-dioxo-3-(4-(4-



(methylsulfonyl)phenylsulfonylamino)butyl)-9-(2-phenyl-



ethyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 20A-10





Example



No
Compound Name







22(H20-64)
(3S)-1-propyl-2,5-dioxo-3-(4-(4-



trifluoromethylphenylsulfonylamino)butyl)-9-(2-phenyl-



ethyl)-1,4,9-triazaspiro[5.5]undecane


22(H20-65)
(3S)-1-propyl-2,5-dioxo-3-(4-(4-



phenylphenylsulfonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H20-66)
(3S)-1-propyl-2,5-dioxo-3-(4-(2-



phenylphenylsulfonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H20-67)
(3S)-1-propyl-2,5-dioxo-3-(4-(3,4-



difluorophenylsulfonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H20-68)
(3S)-1-propyl-2,5-dioxo-3-(4-(2,6-



difluorophenylsulfonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H20-69)
(3S)-1-propyl-2,5-dioxo-3-(4-(2,5-



difluorophenylsulfonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H20-70)
(3S)-1-propyl-2,5-dioxo-3-(4-(2,5-



dimethoxyphenylsulfonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane




















TABLE 20A-11





Example



No
Compound Name







22(H20-71)
(3S)-1-propyl-2,5-dioxo-3-(4-(2-chloro-4-



trifluoromethylphenylsulfonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H20-72)
(3S)-1-propyl-2,5-dioxo-3-(4-(2-naphthylsulfonyl-



amino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-73)
(3S)-1-propyl-2,5-dioxo-3-(4-((1E)-2-



phenylvinylsulfonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H20-74)
(3S)-1-propyl-2,5-dioxo-3-(4-(furan-2-ylsulfonyl-



amino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H20-75)
(3S)-1-propyl-2,5-dioxo-3-(4-(thiophen-2-



ylsulfonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 21A-1





Example



No
Compound Name







22(H21-1)
(3S)-1-propyl-2,5-dioxo-3-(4-(4-bromo-2,5-dichloro-



thiophen-3-ylsulfonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H21-2)
(3S)-1-propyl-2,5-dioxo-3-(4-(5-phenylsulfonyl-



thiophen-2-ylsulfonylamino)butyl)-9-(2-phenyl-



ethyl)-1,4,9-triazaspiro[5.5]undecane


22(H21-3)
(3S)-1-propyl-2,5-dioxo-3-(4-(7-chlorobenzofurazan-



4-ylsulfonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H21-4)
(3S)-1-propyl-2,5-dioxo-3-(4-(4-methyl-2-acetylamino-



thiazol-5-ylsulfonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H21-5)
(3S)-1-propyl-2,5-dioxo-3-(4-(2-methoxy-dibenzofuran-



3-ylsulfonylamino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H21-6)
(3S)-1-propyl-2,5-dioxo-3-(4-(3,4-



dichlorophenylsulfonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H21-7)
(3S)-1-propyl-2,5-dioxo-3-(4-(4-



methoxyphenylsulfonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane




















TABLE 21A-2





Example



No
Compound Name







22(H21-8)
(3S)-1-propyl-2,5-dioxo-3-(4-(benzylsulfonyl-



amino)butyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H21-9)
(3S)-1-propyl-2,5-dioxo-3-(4-



((ethylamino)carbonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H21-10)
(3S)-1-propyl-2,5-dioxo-3-(4-



((propylamino)carbonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H21-11)
(3S)-1-propyl-2,5-dioxo-3-(4-((1-



methylethylamino)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H21-12)
(3S)-1-propyl-2,5-dioxo-3-(4-



((butylamino)carbonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H21-13)
(3S)-1-propyl-2,5-dioxo-3-(4-((4-



chlorophenylamino)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H21-14)
(3S)-1-propyl-2,5-dioxo-3-(4-



((phenylamino)carbonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane




















TABLE 21A-3





Example



No
Compound Name







22(H21-15)
(3S)-1-propyl-2,5-dioxo-3-(4-((4-



methylphenylamino)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H21-16)
(3S)-1-propyl-2,5-dioxo-3-(4-



((hexylamino)carbonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H21-17)
(3S)-1-propyl-2,5-dioxo-3-(4-((4-



fluorophenylamino)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H21-18)
(3S)-1-propyl-2,5-dioxo-3-(4-



((benzylamino)carbonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H21-19)
(3S)-1-propyl-2,5-dioxo-3-(4-



((cyclohexylamino)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H21-20)
(3S)-1-propyl-2,5-dioxo-3-(4-((3-



methylphenylamino)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H21-21)
(3S)-1-propyl-2,5-dioxo-3-(4-



((octylamino)carbonylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane




















TABLE 21A-4





Example



No
Compound Name







22(H21-22)
(3S)-1-propyl-2,5-dioxo-3-(4-((4-



bromophenylamino)carbonylamino)butyl)-9-



(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H21-23)
(3S)-1-propyl-2,5-dioxo-3-(4-((2-(thiophen-



2-yl)ethylamino)carbonylamino)butyl)-



9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H21-24)
(3S)-1-propyl-2,5-dioxo-3-(4-((4-(1-



methylethyl)phenylamino)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H21-25)
(3S)-1-propyl-2,5-dioxo-3-(4-((3-



chlorophenylamino)carbonylamino)butyl)-9-



(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H21-26)
(3S)-1-propyl-2,5-dioxo-3-(4-((2,4,5-



trimethylphenylamino)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H21-27)
(3S)-1-propyl-2,5-dioxo-3-(4-((2,4,6-



trimethylphenylamino)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H21-28)
(3S)-1-propyl-2,5-dioxo-3-(4-((4-



phenyloxyphenylamino)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 21A-5





Example



No
Compound Name







22(H21-29)
(3S)-1-propyl-2,5-dioxo-3-(4-((4-



butyloxyphenylamino)carbonylamino)butyl)-9-



(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H21-30)
(3S)-1-propyl-2,5-dioxo-3-(4-((4-



phenylphenylamino)carbonylamino)butyl)-9-



(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H21-31)
(3S)-1-propyl-2,5-dioxo-3-(4-((2-



phenylphenylamino)carbonylamino)butyl)-9-



(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H21-32)
(3S)-1-propyl-2,5-dioxo-3-(4-((4-



trifluoromethylphenylamino)carbonylamino)butyl)-



9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H21-33)
(3S)-1-propyl-2,5-dioxo-3-(4-((3,4-



dichlorophenylamino)carbonylamino)butyl)-



9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


22(H21-34)
(3S)-1-propyl-2,5-dioxo-3-(4-((4-



butyloxycarbonylphenylamino)carbonylamino)butyl)-



9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H21-35)
(3S)-1-propyl-2,5-dioxo-3-(4-((2,6-bis(1-



methylethyl)phenylamino)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 21A-6





Example



No
Compound Name







22(H21-36)
(3S)-1-propyl-2,5-dioxo-3-(4-((2,5-



dimethylphenylamino)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H21-37)
(3S)-1-propyl-2,5-dioxo-3-(4-((2-ethyl-6-(1-



methylethyl)phenylamino)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H21-38)
(3S)-1-propyl-2,5-dioxo-3-(4-((2,4,6-



trichlorophenylamino)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H21-39)
(3S)-1-propyl-2,5-dioxo-3-(4-((3,4-



dimethylphenylamino)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H21-40)
(3S)-1-propyl-2,5-dioxo-3-(4-((2-



methylthiophenylamino)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H21-41)
(3S)-1-propyl-2,5-dioxo-3-(4-((4-



methylthiophenylamino)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H21-42)
(3S)-1-propyl-2,5-dioxo-3-(4-((4-



butylphenylamino)carbonylamino)butyl)-9-(2-



phenylethyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 21A-7





Example



No
Compound Name







22(H21-43)
(3S)-1-propyl-2,5-dioxo-3-(4-((2-chloro-5-



trifluoromethylphenylamino)carbonylamino)butyl)-



9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H21-44)
(3S)-1-propyl-2,5-dioxo-3-(4-((2,6-dibromo-4-



ethylphenylamino)carbonylamino)butyl)-9-



(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H21-45)
(3S)-1-propyl-2,5-dioxo-3-(4-((1-ethoxycarbonyl-2-



methylpropylamino)carbonylamino)butyl)-9-



(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane


22(H21-46)
(3S)-1-propyl-2,5-dioxo-3-(4-



((phenylcarbonylamino)carbonylamino)butyl)-



9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H21-47)
(3S)-1-propyl-2,5-dioxo-3-(4-((2,4,6-



tribromophenylamino)carbonylamino)butyl)-



9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H21-48)
(3S)-1-propyl-2,5-dioxo-3-(4-((2,5-



difluorophenylamino)carbonylamino)butyl)-



9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


22(H21-49)
(3S)-1-propyl-2,5-dioxo-3-(4-((3,5-



bis(methoxycarbonyl)phenylamino)carbon-



ylamino)butyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane






















TABLE 21A-8







Example




No
Compound Name









22(H21-50)
(3S)-1-propyl-2,5-dioxo-3-(4-((6,7-




methylenedioxycoumarin-4-




ylmethylamino)carbonylamino)butyl)-9-




(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-51)
(3S)-1-propyl-2,5-dioxo-3-(4-((2,6-




dimethylphenylamino)carbonylamino)butyl)-9-




(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-52)
(3S)-1-propyl-2,5-dioxo-3-(4-((2-




methylpropyloxy)carbonylamino)butyl)-9-




(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-53)
(3S)-1-propyl-2,5-dioxo-3-(4-((2-




ethylhexyloxy)carbonylamino)butyl)-9-




(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-54)
(3S)-1-propyl-2,5-dioxo-3-(4-




(ethoxycarbonylamino)butyl)-




9-(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-55)
(3S)-1-propyl-2,5-dioxo-3-(4-




(allyloxycarbonylamino)butyl)-




9-(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-56)
(3S)-1-propyl-2,5-dioxo-3-(4-




(propyloxycarbonylamino)butyl)-




9-(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 21A-9







Example




No
Compound Name









22(H21-57)
(3S)-1-propyl-2,5-dioxo-3-(4-




(butyloxycarbonylamino)butyl)-




9-(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-58)
(3S)-1-propyl-2,5-dioxo-3-(4-




(hexyloxycarbonylamino)butyl)-




9-(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-59)
(3S)-1-propyl-2,5-dioxo-3-(4-((2,2,2-




trichloroethyloxy)carbonylamino)butyl)-




9-(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-60)
(3S)-1-propyl-2,5-dioxo-3-(4-((fluoren-9-




ylmethyloxy)carbonylamino)butyl)-9-




(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-61)
(3S)-1-propyl-2,5-dioxo-3-(4-((1S,5S,2R)-




5-methyl-2-(1-




methylethyl)cyclohexyloxycarbonylamino)butyl)-




9-(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-62)
(3S)-1-propyl-2,5-dioxo-3-(4-((2-




methoxyethoxy)carbonylamino)butyl)-




9-(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-63)
(3S)-1-propyl-2,5-dioxo-3-(4-




(pentyloxycarbonylamino)butyl)-




9-(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 21A-10







Example




No
Compound Name









22(H21-64)
(3S)-1-propyl-2,5-dioxo-3-(4-((1-




methylethyloxy)carbonylamino)butyl)-9-




(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-65)
(3S)-1-propyl-2,5-dioxo-3-(4-((3-




butenyloxy)carbonylamino)butyl)-9-




(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-66)
(3S)-1-propyl-2,5-dioxo-3-(4-




((2S,1R,5R)-methyl-2-(1-




methylethyl)cyclohexyloxycarbonylamino)butyl)-




9-(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-67)
(3S)-1-propyl-2,5-dioxo-3-(4-




(cyclopentyloxycarbonylamino)butyl)-9-




(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-68)
(3S)-1-propyl-2,5-dioxo-3-(4-((1,1-




dimethylethyloxy)carbonylamino)butyl)-9-




(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-69)
(3S)-1-propyl-2,5-dioxo-3-(4-




(benzyloxycarbonylamino)butyl)-




9-(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-70)
(3S)-1-propyl-2,5-dioxo-3-(4-((N,N-




diphenylamino)carbonylamino)butyl)-




9-(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 21A-11







Example




No
Compound Name









22(H21-71)
(3S)-1-propyl-2,5-dioxo-3-(4-((N-phenyl-N-




methylamino)carbonylamino)butyl)-9-




(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-72)
(3S)-1-propyl-2,5-dioxo-3-(4-((N,N-




dimethylamino)carbonylamino)butyl)-9-




(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-73)
(3S)-1-propyl-2,5-dioxo-3-(4-((N,N-




diethylamino)carbonylamino)butyl)-9-




(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-74)
(3S)-1-propyl-2,5-dioxo-3-(4-((N,N-bis(1-




methylethyl)amino)carbonylamino)butyl)-9-




(2-phenylethyl)-




1,4,9-triazaspiro[5.5]undecane



22(H21-75)
(3S)-1-propyl-2,5-dioxo-3-(4-(morpholin-4-




ylcarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-76)
(3S)-1-propyl-2,5-dioxo-3-(4-(carbazol-9-




ylcarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane



22(H21-77)
(3S)-1-propyl-2,5-dioxo-3-(4-(pyrrolidin-1-




ylcarbonylamino)butyl)-9-(2-phenylethyl)-1,4,9-




triazaspiro[5.5]undecane




















TABLE 20B-1









embedded image














Example No
R3
R4





22(H20-1)
H


embedded image







22(H20-2)
H


embedded image







22(H20-3)
H


embedded image







22(H20-4)
H


embedded image







22(H20-5)
H


embedded image





















TABLE 20B-2









embedded image














Example No
R3
R4





22(H20-6)
H


embedded image







22(H20-7)
H


embedded image







22(H20-8)
H


embedded image







22(H20-9)
H


embedded image







22(H20-10)
H


embedded image







22(H20-11)
H


embedded image





















TABLE 20B-3









embedded image














Example




No
R3
R4





22(H20-12)
H


embedded image







22(H20-13)
H


embedded image







22(H20-14)
H


embedded image







22(H20-15)
H


embedded image







22(H20-16)
H


embedded image







22(H20-17)
H


embedded image





















TABLE 20B-4









embedded image














Example No
R3
R4





22(H20-18)
H


embedded image







22(H20-19)
H


embedded image







22(H20-20)
H


embedded image







22(H20-21)
H


embedded image







22(H20-22)
H


embedded image







22(H20-23)
H


embedded image





















TABLE 20B-5









embedded image














Example No
R3
R4





22(H20-24)
H


embedded image







22(H20-25)
H


embedded image







22(H20-26)
H


embedded image







22(H20-27)
H


embedded image







22(H20-28)
H


embedded image







22(H20-29)
H


embedded image







22(H20-30)
H


embedded image





















TABLE 20B-6









embedded image














Example No
R3
R4





22(H20-31)
H


embedded image







22(H20-32)
H


embedded image







22(H20-33)
H


embedded image







22(H20-34)
H


embedded image







22(H20-35)
H


embedded image







22(H20-36)
H


embedded image





















TABLE 20B-7









embedded image














Example No
R3
R4





22(H20-37)
H


embedded image







22(H20-38)
H


embedded image







22(H20-39)
H


embedded image







22(H20-40)
H


embedded image







22(H20-41)
H


embedded image







22(H20-42)
H


embedded image







22(H20-43)
H


embedded image







22(H20-44)
H


embedded image





















TABLE 20B-8









embedded image














Example No
R3
R4





22(H20-45)
H


embedded image







22(H20-46)
H


embedded image







22(H20-47)
H


embedded image







22(H20-48)
H


embedded image







22(H20-49)
H


embedded image







22(H20-50)
H


embedded image







22(H20-51)
H


embedded image







22(H20-52)
H


embedded image





















TABLE 20B-9









embedded image














Example No
R3
R4





22(H20-53)
H


embedded image







22(H20-54)
H


embedded image







22(H20-55)
H


embedded image







22(H20-56)
H


embedded image







22(H20-57)
H


embedded image







22(H20-58)
H


embedded image







22(H20-59)
H


embedded image





















TABLE 20B-10









embedded image














Example No
R3
R4





22(H20-60)
H


embedded image







22(H20-61)
H


embedded image







22(H20-62)
H


embedded image







22(H20-63)
H


embedded image







22(H20-64)
H


embedded image







22(H20-65)
H


embedded image





















TABLE 20B-11









embedded image














Example No
R3
R4





22(H20-66)
H


embedded image







22(H20-67)
H


embedded image







22(H20-68)
H


embedded image







22(H20-69)
H


embedded image







22(H20-70)
H


embedded image







22(H20-71)
H


embedded image





















TABLE 20B-12









embedded image














Example No
R3
R4





22(H20-72)
H


embedded image







22(H20-73)
H


embedded image







22(H20-74)
H


embedded image







22(H20-75)
H


embedded image





















TABLE 21B-1









embedded image














Example No
R3
R4





22(H21-1)
H


embedded image







22(H21-2)
H


embedded image







22(H21-3)
H


embedded image







22(H21-4)
H


embedded image







22(H21-5)
H


embedded image







22(H21-6)
H


embedded image







22(H21-7)
H


embedded image





















TABLE 21B-2









embedded image














Example No
R3
R4





22(H21-8) 
H


embedded image







22(H21-9) 
H


embedded image







22(H21-10)
H


embedded image







22(H21-11)
H


embedded image







22(H21-12)
H


embedded image







22(H21-13)
H


embedded image







22(H21-14)
H


embedded image







22(H21-15)
H


embedded image





















TABLE 21B-3









embedded image














Example No
R3
R4





22(H21-16)
H


embedded image







22(H21-17)
H


embedded image







22(H21-18)
H


embedded image







22(H21-19)
H


embedded image







22(H21-20)
H


embedded image







22(H21-21)
H


embedded image







22(H21-22)
H


embedded image







22(H21-23)
H


embedded image





















TABLE 21B-4









embedded image














Example No
R3
R4





22(H21-24)
H


embedded image







22(H21-25)
H


embedded image







22(H21-26)
H


embedded image







22(H21-27)
H


embedded image







22(H21-28)
H


embedded image







22(H21-29)
H


embedded image







22(H21-30)
H


embedded image





















TABLE 21B-5









embedded image














Example No
R3
R4





22(H21-31)
H


embedded image







22(H21-32)
H


embedded image







22(H21-33)
H


embedded image







22(H21-34)
H


embedded image







22(H21-35)
H


embedded image







22(H21-36)
H


embedded image





















TABLE 21B-6









embedded image














Example No
R3
R4





22(H21-37)
H


embedded image







22(H21-38)
H


embedded image







22(H21-39)
H


embedded image







22(H21-40)
H


embedded image







22(H21-41)
H


embedded image







22(H21-42)
H


embedded image





















TABLE 21B-7









embedded image














Example No
R3
R4





22(H21-43)
H


embedded image







22(H21-44)
H


embedded image







22(H21-45)
H


embedded image







22(H21-46)
H


embedded image







22(H21-47)
H


embedded image







22(H21-48)
H


embedded image





















TABLE 21B-8









embedded image














Example No
R3
R4





22(H21-49)
H


embedded image







22(H21-50)
H


embedded image







22(H21-51)
H


embedded image







22(H21-52)
H


embedded image







22(H21-53)
H


embedded image







22(H21-54)
H


embedded image





















TABLE 21B-9









embedded image














Example No
R3
R4





22(H21-55)
H


embedded image







22(H21-56)
H


embedded image







22(H21-57)
H


embedded image







22(H21-58)
H


embedded image







22(H21-59)
H


embedded image







22(H21-60)
H


embedded image







22(H21-61)
H


embedded image





















TABLE 21B-10









embedded image














Example No
R3
R4





22(H21-62)
H


embedded image







22(H21-63)
H


embedded image







22(H21-64)
H


embedded image







22(H21-65)
H


embedded image







22(H21-66)
H


embedded image







22(H21-67)
H


embedded image







22(H21-68)
H


embedded image





















TABLE 21B-11









embedded image














Example No
R3
R4





22(H21-69)
H


embedded image







22(H21-70)
H


embedded image







22(H21-71)
H


embedded image







22(H21-72)
H


embedded image







22(H21-73)
H


embedded image







22(H21-74)
H


embedded image





















TABLE 21B-12









embedded image














Example




No
R3
R4





22(H21-75)
H


embedded image







22(H21-76)
H


embedded image







22(H21-77)
H


embedded image

























TABLE 20C-1







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















22(H20-1)
F
3.43
581 (M + H)+.
ESI (Pos., 20 V)


22(H20-2)
F
3.43
581 (M + H)+.
ESI (Pos., 20 V)


22(H20-3)
F
3.09
548 (M + H)+.
ESI (Pos., 20 V)


22(H20-4)
F
3.32
620 (M + H)+.
ESI (Pos., 20 V)


22(H20-5)
F
3.24
523 (M + H)+.
ESI (Pos., 20 V)


22(H20-6)
F
3.23
523 (M + H)+.
ESI (Pos., 20 V)


22(H20-7)
F
3.20
523 (M + H)+.
ESI (Pos., 20 V)


22(H20-8)
F
3.17
497 (M + H)+.
ESI (Pos., 20 V)


22(H20-9)
F
3.26
519 (M + H)+.
ESI (Pos., 20 V)


22(H20-10)
F
3.20
535 (M + H)+.
ESI (Pos., 20 V)


22(H20-11)
F
3.16
485 (M + H)+.
ESI (Pos., 20 V)


22(H20-12)
F
2.95
506 (M + H)+.
ESI (Pos., 20 V)


22(H20-13)
F
3.11
506 (M + H)+.
ESI (Pos., 20 V)


22(H20-14)
F
3.20
519 (M + H)+.
ESI (Pos., 20 V)


22(H20-15)
F
3.25
535 (M + H)+.
ESI (Pos., 20 V)


22(H20-16)
F
3.05
569 (M + H)+.
ESI (Pos., 20 V)


22(H20-17)
F
3.25
614 (M + H)+.
ESI (Pos., 20 V)


22(H20-18)
F
3.31
598 (M + H)+.
ESI (Pos., 20 V)


22(H20-19)
F
3.23
535 (M + H)+.
ESI (Pos., 20 V)


22(H20-20)
F
3.17
525 (M + H)+.
ESI (Pos., 20 V)


22(H20-21)
F
3.24
499 (M + H)+.
ESI (Pos., 20 V)


22(H20-22)
F
3.25
519 (M + H)+.
ESI (Pos., 20 V)


22(H20-23)
F
3.06
471 (M + H)+.
ESI (Pos., 20 V)


22(H20-24)
F
3.33
525 (M + H)+.
ESI (Pos., 20 V)


22(H20-25)
F
3.28
531 (M + H)+.
ESI (Pos., 20 V)


22(H20-26)
F
3.20
519 (M + H)+.
ESI (Pos., 20 V)























TABLE 20C-2







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















22(H20-27)
F
3.20
499 (M + H)+.
ESI (Pos., 20 V)


22(H20-28)
F
3.23
511 (M + H)+.
ESI (Pos., 20 V)


22(H20-29)
F
3.18
505 (M + H)+.
ESI (Pos., 20 V)


22(H20-30)
F
3.16
511 (M + H)+.
ESI (Pos., 20 V)


22(H20-31)
F
3.36
551 (M + H)+.
ESI (Pos., 20 V)


22(H20-32)
F
3.27
586 (M + H)+.
ESI (Pos., 20 V)


22(H20-33)
F
3.42
586 (M + H)+.
ESI (Pos., 20 V)


22(H20-34)
F
3.20
549 (M + H)+.
ESI (Pos., 20 V)


22(H20-35)
F
3.20
535 (M + H)+.
ESI (Pos., 20 V)


22(H20-36)
F
3.09
495 (M + H)+.
ESI (Pos., 20 V)


22(H20-37)
F
3.27
549 (M + H)+.
ESI (Pos., 20 V)


22(H20-38)
F
3.11
483 (M + H)+.
ESI (Pos., 20 V)


22(H20-39)
F
3.20
549 (M + H)+.
ESI (Pos., 20 V)


22(H20-40)
F
2.96
443 (M + H)+.
ESI (Pos., 20 V)


22(H20-41)
F
3.22
499 (M + H)+.
ESI (Pos., 20 V)


22(H20-42)
F
3.00
473 (M + H)+.
ESI (Pos., 20 V)


22(H20-43)
F
3.07
503 (M + H)+.
ESI (Pos., 20 V)


22(H20-44)
F
3.23
511 (M + H)+.
ESI (Pos., 20 V)


22(H20-45)
F
3.16
485 (M + H)+.
ESI (Pos., 20 V)


22(H20-46)
F
3.12
485 (M + H)+.
ESI (Pos., 20 V)


22(H20-47)
F
3.27
551 (M + H)+.
ESI (Pos., 20 V)


22(H20-48)
F
3.11
527 (M + H)+.
ESI (Pos., 20 V)


22(H20-49)
F
3.20
530 (M + H)+.
ESI (Pos., 20 V)


22(H20-50)
F
3.07
471 (M + H)+.
ESI (Pos., 20 V)


22(H20-51)
F
3.01
457 (M + H)+.
ESI (Pos., 20 V)


22(H20-52)
F
3.07
469 (M + H)+.
ESI (Pos., 20 V)























TABLE 20C-3







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















22(H20-53)
F
3.18
549 (M + H)+.
ESI (Pos., 20 V)


22(H20-54)
F
3.34
613 (M + H)+.
ESI (Pos., 20 V)


22(H20-55)
F
3.49
565 (M + H)+.
ESI (Pos., 20 V)


22(H20-56)
F
3.22
565 (M + H)+.
ESI (Pos., 20 V)


22(H20-57)
F
3.03
479 (M + H)+.
ESI (Pos., 20 V)


22(H20-58)
F
3.34
535 (M + H)+.
ESI (Pos., 20 V)


22(H20-59)
F
3.14
507 (M + H)+.
ESI (Pos., 20 V)


22(H20-60)
F
3.40
575 (M + H)+.
ESI (Pos., 20 V)


22(H20-61)
F
3.38
667 (M + H)+.
ESI (Pos., 20 V)


22(H20-62)
F
3.35
586 (M + H)+.
ESI (Pos., 20 V)


22(H20-63)
F
3.22
619 (M + H)+.
ESI (Pos., 20 V)


22(H20-64)
F
3.45
609 (M + H)+.
ESI (Pos., 20 V)


22(H20-65)
F
3.51
617 (M + H)+.
ESI (Pos., 20 V)


22(H20-66)
F
3.49
617 (M + H)+.
ESI (Pos., 20 V)


22(H20-67)
F
3.38
557 (M + H)+.
ESI (Pos., 20 V)


22(H20-68)
F
3.29
577 (M + H)+.
ESI (Pos., 20 V)


22(H20-69)
F
3.33
577 (M + H)+.
ESI (Pos., 20 V)


22(H20-70)
F
3.29
601 (M + H)+.
ESI (Pos., 20 V)


22(H20-71)
F
3.51
643 (M + H)+.
ESI (Pos., 20 V)


22(H20-72)
F
3.42
591 (M + H)+.
ESI (Pos., 20 V)


22(H20-73)
F
3.39
567 (M + H)+.
ESI (Pos., 20 V)


22(H20-74)
F
3.22
531 (M + H)+.
ESI (Pos., 20 V)


22(H20-75)
F
3.23
547 (M + H)+.
ESI (Pos., 20 V)























TABLE 21C-1







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















22(H21-1)
F
3.51
694 (M + H)+.
ESI (Pos., 20 V)


22(H21-2)
F
3.45
687 (M + H)+.
ESI (Pos., 20 V)


22(H21-3)
F
3.40
617 (M + H)+.
ESI (Pos., 20 V)


22(H21-4)
F
3.17
619 (M + H)+.
ESI (Pos., 20 V)


22(H21-5)
F
3.52
661 (M + H)+.
ESI (Pos., 20 V)


22(H21-6)
F
3.47
609 (M + H)+.
ESI (Pos., 20 V)


22(H21-7)
F
3.28
571 (M + H)+.
ESI (Pos., 20 V)


22(H21-8)
F
3.29
555 (M + H)+.
ESI (Pos., 20 V)


22(H21-9)
F
3.03
472 (M + H)+.
ESI (Pos., 20 V)


22(H21-10)
F
3.09
486 (M + H)+.
ESI (Pos., 20 V)


22(H21-11)
F
3.07
486 (M + H)+.
ESI (Pos., 20 V)


22(H21-12)
F
3.16
500 (M + H)+.
ESI (Pos., 20 V)


22(H21-13)
F
3.33
554 (M + H)+.
ESI (Pos., 20 V)


22(H21-14)
F
3.22
520 (M + H)+.
ESI (Pos., 20 V)


22(H21-15)
F
3.27
534 (M + H)+.
ESI (Pos., 20 V)


22(H21-16)
F
3.34
528 (M + H)+.
ESI (Pos., 20 V)


22(H21-17)
F
3.25
538 (M + H)+.
ESI (Pos., 20 V)


22(H21-18)
F
3.22
534 (M + H)+.
ESI (Pos., 20 V)


22(H21-19)
F
3.25
526 (M + H)+.
ESI (Pos., 20 V)


22(H21-20)
F
3.29
534 (M + H)+.
ESI (Pos., 20 V)


22(H21-21)
F
3.52
556 (M + H)+.
ESI (Pos., 20 V)


22(H21-22)
F
3.37
600 (M + H)+.
ESI (Pos., 20 V)


22(H21-23)
F
3.24
554 (M + H)+.
ESI (Pos., 20 V)


22(H21-24)
F
3.44
562 (M + H)+.
ESI (Pos., 20 V)


22(H21-25)
F
3.34
554 (M + H)+.
ESI (Pos., 20 V)


22(H21-26)
F
3.36
562 (M + H)+.
ESI (Pos., 20 V)























TABLE 21C-2







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















22(H21-27)
F
3.31
562(M + H)+.
ESI (Pos., 20 V)


22(H21-28)
F
3.47
612(M + H)+.
ESI (Pos., 20 V)


22(H21-29)
F
3.47
592(M + H)+.
ESI (Pos., 20 V)


22(H21-30)
F
3.47
596(M + H)+.
ESI (Pos., 20 V)


22(H21-31)
F
3.40
596(M + H)+.
ESI (Pos., 20 V)


22(H21-32)
F
3.42
588(M + H)+.
ESI (Pos., 20 V)


22(H21-33)
F
3.44
588(M + H)+.
ESI (Pos., 20 V)


22(H21-34)
F
3.49
620(M + H)+.
ESI (Pos., 20 V)


22(H21-35)
F
3.47
604(M + H)+.
ESI (Pos., 20 V)


22(H21-36)
F
3.31
548(M + H)+.
ESI (Pos., 20 V)


22(H21-37)
F
3.42
590(M + H)+.
ESI (Pos., 20 V)


22(H21-38)
F
3.36
623(M + H)+.
ESI (Pos., 20 V)


22(H21-39)
F
3.33
548(M + H)+.
ESI (Pos., 20 V)


22(H21-40)
F
3.29
566(M + H)+.
ESI (Pos., 20 V)


22(H21-41)
F
3.31
566(M + H)+.
ESI (Pos., 20 V)


22(H21-42)
F
3.53
576(M + H)+.
ESI (Pos., 20 V)


22(H21-43)
F
3.49
622(M + H)+.
ESI (Pos., 20 V)


22(H21-44)
F
3.42
706(M + H)+.
ESI (Pos., 20 V)


22(H21-45)
F
3.25
572(M + H)+.
ESI (Pos., 20 V)


22(H21-46)
F
3.23
548(M + H)+.
ESI (Pos., 20 V)


22(H21-47)
F
3.40
757(M + H)+.
ESI (Pos., 20 V)


22(H21-48)
F
3.33
556(M + H)+.
ESI (Pos., 20 V)


22(H21-49)
F
3.33
636(M + H)+.
ESI (Pos., 20 V)


22(H21-50)
F
3.18
646(M + H)+.
ESI (Pos., 20 V)


22(H21-51)
F
3.23
548(M + H)+.
ESI (Pos., 20 V)


22(H21-52)
F
3.30
501(M + H)+.
ESI (Pos., 20 V)























TABLE 21C-3







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















22(H21-53)
F
3.64
557 (M + H)+.
ESI (Pos., 20 V)


22(H21-54)
F
3.13
473 (M + H)+.
ESI (Pos., 20 V)


22(H21-55)
F
3.20
485 (M + H)+.
ESI (Pos., 20 V)


22(H21-56)
F
3.21
487 (M + H)+.
ESI (Pos., 20 V)


22(H21-57)
F
3.31
501 (M + H)+.
ESI (Pos., 20 V)


22(H21-58)
F
3.49
529 (M + H)+.
ESI (Pos., 20 V)


22(H21-59)
F
3.38
575 (M + H)+.
ESI (Pos., 20 V)


22(H21-60)
F
3.57
623 (M + H)+.
ESI (Pos., 20 V)


22(H21-61)
F
3.69
583 (M + H)+.
ESI (Pos., 20 V)


22(H21-62)
F
3.09
503 (M + H)+.
ESI (Pos., 20 V)


22(H21-63)
F
3.40
515 (M + H)+.
ESI (Pos., 20 V)


22(H21-64)
F
3.22
487 (M + H)+.
ESI (Pos., 20 V)


22(H21-65)
F
3.25
499 (M + H)+.
ESI (Pos., 20 V)


22(H21-66)
F
3.69
583 (M + H)+.
ESI (Pos., 20 V)


22(H21-67)
F
3.31
513 (M + H)+.
ESI (Pos., 20 V)


22(H21-68)
F
3.28
501 (M + H)+.
ESI (Pos., 20 V)


22(H21-69)
F
3.34
535 (M + H)+.
ESI (Pos., 20 V)


22(H21-70)
F
3.40
596 (M + H)+.
ESI (Pos., 20 V)


22(H21-71)
F
3.23
534 (M + H)+.
ESI (Pos., 20 V)


22(H21-72)
F
3.01
472 (M + H)+.
ESI (Pos., 20 V)


22(H21-73)
F
3.12
500 (M + H)+.
ESI (Pos., 20 V)


22(H21-74)
F
3.27
528 (M + H)+.
ESI (Pos., 20 V)


22(H21-75)
F
3.01
514 (M + H)+.
ESI (Pos., 20 V)


22(H21-76)
F
3.49
574 (M + H)+.
ESI (Pos., 20 V)


22(H21-77)
F
3.07
498 (M + H)+.
ESI (Pos., 20 V)









EXAMPLE 23
1-cyclopropylmethyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenoxyphenyl)-1,3,9-triazaspiro[5.5]undecane.acetate



embedded image


To a suspension of Resin (3) prepared in Reference Example 2 (0.5 g) in tetrahydrofuran/methanol (1:1; 5 ml) were added N-allyloxycarbonyl-4-piperidone (0.396 g), cyclopropylmethylamine (0.189 ml) and N-(t-butyloxycarbonyl)leucine (0.542 g), and it was stirred for 18 hours at 65° C. The reaction solution was cooled to room temperature and the resin was collected by filtration. The obtained resin was washed with dimethylformamide (5 ml×2), dichloromethane (5 ml×2), methanol (5 ml×2) and dichloromethane (5 ml×2). To a suspension of the obtained resin in dichloromethane (5 ml) were added acetic acid (0.149 ml), tributyltin hydride (0.351 ml) and tetrakis(triphenylphosphine)palladium (0) complex (50 mg), and it was stirred for 6 hours at room temperature. The resin was collected by filtration from the reaction solution, and was washed with dichloromethane (5 ml×4) and dimethylformamide (5 ml×3). The obtained resin was suspended in 1% acetic acid-dimethylformamide solution (5 ml), and 4-phenyloxybenzaldehyde (0.252 g), and sodium triacetoxyborohydride (0.277 g) were added thereto. It was stirred for 15 hours at room temperature. The resin was collected by filtration from reaction mixture, and was washed with methanol (5 ml×1), dimethylformamide (5 ml×3), methanol (5 ml×4) and dichloromethane (5 ml×4). The obtained resin was suspended in 50% trifluoroacetic acid-dichloromethane solution (5 ml), and it was stirred for 5 minutes at room temperature. The reaction solution was filtrated, and the obtained resin was suspended in 50% trifluoroacetic acid-dichloromethane solution (5 ml), and it was stirred for 30 minutes at room temperature. The obtained resin by filtration from the reaction solution was washed with dichloromethane (5 ml×3) and 1.25M acetic acid-toluene solution (5 ml×3). The obtained resin was suspended in 1.25M acetic acid-toluene solution (5 ml), and it was stirred for 23 hours at 90° C. The reaction solution was filtrated. The obtained resin was washed with chloroform-methanol (1:1; 2 ml×2). The filtrate and the washings were concentrated to give the compound of the present invention (274 mg) having the following physical data.


TLC: Rf 0.40 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.49 (m, 2H), 7.40 (m, 2H), 7.18 (m, 2H), 7.04 (m, 3H), 4.33 (s, 2H), 4.04 (dd, J=8.1, 4.8 Hz, 1H), 3.78 (m, 2H), 3.52 (m, 2H), 3.35 (m, 2H), 2.45–2.10 (m, 4H), 1.98 (s, 3H, CH3COOH), 1.97–1.58 (m, 4H), 0.94 (d, J=6.0 Hz, 6H), 0.51 (m, 2H), 0.36 (m, 2H).


EXAMPLE 23(1)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenoxyphenyl)-1,3,9-triazaspiro[5.5]undecane.acetate



embedded image


By the same procedure as described in Example 23 using Resin (3) prepared in Reference Example 2 (0.5 g), N-allyloxycarbonyl-4-piperidone (0.396 g), thiophen-2-ylmethylamine (0.205 ml) and N-(t-butyloxycarbonyl)leucine (0.542 g), 4-phenoxybenzaldehyde (0.252 g), the compound of the present invention (274 mg) having the following physical data was obtained.


TLC: Rf 0.39 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.48 (m, 2H), 7.39 (m, 2H), 7.28 (m, 1H), 7.18 (m, 2H), 7.04 (m, 4H), 6.91 (m, 1H), 4.86 (s, 2H), 4.32 (s, 2H), 4.12 (dd, J=8.1, 4.5 Hz, 1H), 3.77 (m, 2H), 3.49 (m, 2H), 2.60–2.30 (m, 2H), 2.19 (m, 2H), 1.98 (s, 3H), 1.97–1.58 (m, 3H), 0.94 (d, J=6.0 Hz, 6H).


EXAMPLE 23(H22-1)˜23(H31-31)

By the same procedure as described in Example 23 or 23(1), using Resin (3) prepared in Reference Example 2, the corresponding 4-piperidone derivatives, the corresponding amine derivatives, the corresponding amino acid derivatives, and the corresponding aldehyde derivatives, the compounds of the present invention, whose names were shown in the following Table 22A-1˜31A-4, and whose structures were shown in the following Table 22B-1˜31B-5, were obtained. Also, physical data of the above compound were shown in the followings Table 22C-1˜31C-2.










TABLE 22A-1





Example



No
Compound Name







23(H22-1)
(3S)-1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-



(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


23(H22-2)
(3R)-1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


23(H22-3)
(3S)-1-propyl-2,5-dioxo-3-methyl-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


23(H22-4)
(3S)-1-propyl-2,5-dioxo-3-benzyl-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


23(H22-5)
(3S)-1-propyl-2,5-dioxo-3-(1-(benzyloxymethyl)imidazol-5-



ylmethyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane


23(H22-6)
(3S)-1-propyl-2,5-dioxo-3-(benzyloxymethyl)-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


23(H22-7)
(3S)-1-propyl-2,5-dioxo-3-(4-methoxyphenylmethyl)-9-(6-



phenylhexyl)-1,4,9-triazaspiro[5.5]undecane


23(H22-8)
(3S)-1-propyl-2,5-dioxo-3-((1R)-1-



(benzyloxy)ethyl)-9-(6-phenylhexyl)-1,4,9-



triazaspiro[5.5]undecane






















TABLE 22A-2







Example




No
Compound Name









23(H22-9)
(3S)-1-propyl-2,5-dioxo-3-(pyridin-3-




ylmethyl)-9-(6-phenylnexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-10)
(3S)-1-propyl-2,5-dioxo-3-butyl-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-11)
(3S)-1-propyl-2,5-dioxo-3-




(cyclohexyloxycarbonylmethyl)-




9-(6-phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-12)
(3S)-1-propyl-2,5-dioxo-3-




(cyclohexylmethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-13)
(3R)-1-propyl-2,5-dioxo-3-




(cyclohexyloxycarbonylmethyl)-




9-(6-phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-14)
(3R)-1-propyl-2,5-dioxo-3-(2-




(cyclohexyloxycarbonyl)ethyl)-




9-(6-phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-15)
(3R)-1-propyl-2,5-dioxo-3-(4-




(benzyloxy)phenylmethyl)-




9-(6-phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-16)
(3S)-1-propyl-2,5-dioxo-3-




hydroxymethyl-9-(6-phenylhexyl)-




1,4,9-triazaspiro[5.5]undecane























TABLE 22A-3







Example




No
Compound Name









23(H22-17)
(3S)-1-propyl-2,5-dioxo-3-(4-




(benzyloxy)phenylmethyl)-




9-(6-phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-18)
(3R)-1-propyl-2,5-dioxo-3-butyl-9-




(6-phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-19)
(3R)-1-propyl-2,5-dioxo-3-




(cyclohexylmethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-20)
(3R)-1-propyl-2,5-dioxo-3-((1S)-1-




(benzyloxy)ethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-21)
(3R)-1-propyl-2,5-dioxo-3-




(benzyloxymethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-22)
(3R)-1-propyl-2,5-dioxo-3-((4-




methoxyphenylmethylthio)methyl)-9-




(6-phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-23)
(3R)-1-propyl-2,5-dioxo-3-




(benzylthiomethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-24)
(3S)-1-propyl-2,5-dioxo-9-




(6-phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 22A-4







Example




No
Compound Name









23(H22-25)
(3S)-1-propyl-2,5-dioxo-3-




(imidazol-4-ylmethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-26)
(3S)-1-propyl-2,5-dioxo-3-




hydroxymethyl-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-27)
(3R)-1-propyl-2,5-dioxo-3-




((3-nitropyridin-2-




yl)disulfanylmethyl)-9-




(6-phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-28)
(3S)-1-propyl-2,5-dioxo-3-(1-benzylimidazol-




4-ylmethyl)-9-(6-phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-29)
(3R)-1-propyl-2,5-dioxo-3-(4-




hydroxyphenylmethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-30)
(3S)-1-propyl-2,5-dioxo-3-(4-




(benzyloxycarbonylamino)phenylmethyl)-




9-(6-phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-31)
(3R)-1-propyl-2,5-dioxo-3-(3-




(aminocarbonylamino)propyl)-




9-(6-phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-32)
(3R)-1-propyl-2,5-dioxo-3-(1-




naphthylmethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 22A-5







Example




No
Compound Name









23(H22-33)
(3S)-1-propyl-2,5-dioxo-3-




(3,4-dichlorophenylmethyl)-




9-(6-phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-34)
(3R)-1-propyl-2,5-dioxo-3-((1,1-




dimethylethylthio)methyl)-




9-(6-phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-35)
(3S)-1-propyl-2,5-dioxo-3-




(2-methylpropyl)-4-methyl-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-36)
(3S)-1-propyl-2,5-dioxo-3-propyl-9-




(6-phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-37)
(3S)-1-propyl-2,5-dioxo-3-




(4-benzyloxyphenylmethyl)-4-




methyl-9-(6-phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-38)
(3S)-1-propyl-2,5-dioxo-3-




((1R)-1-hydroxyethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-39)
(3S)-1-propyl-2,5-dioxo-3-




(aminocarbonylmethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-40)
(3S)-1-propyl-2,5-dioxo-3-




((1R)-1-hydroxyethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-41)
(3R)-1-propyl-2,5-dioxo-3-




methyl-9-(6-phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 22A-6







Example




No
Compound Name









23(H22-42)
(3R)-1-propyl-2,5-dioxo-3-




(pyridin-3-ylmethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-43)
(3S)-1-propyl-2,5-dioxo-3-




(carboxymethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-44)
(3S)-1-propyl-2,5-dioxo-3-




(4-hydroxyphenylmethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-45)
(3S)-1-propyl-2,5-dioxo-3-




(2-methylthioethyl)-9-(6-




phenylnexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-46)
(3R)-1-propyl-2,5-dioxo-3-




((methylcarbonylamino)-




methylthiomethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-47)
(3R)-1-propyl-2,5-dioxo-3-




((1S)-1-hydroxyethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-48)
(3S)-1-propyl-2,5-dioxo-3-




(2-chlorophenylmethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-49)
(3S)-1-propyl-2,5-dioxo-3-




(1-naphthylmethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-50)
(3S)-1-propyl-2,5-dioxo-3-




(4-fluorophenylmethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 22A-7







Example




No
Compound Name









23(H22-51)
(3S)-1-propyl-2,5-dioxo-3-




(cyanomethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-52)
(3R)-1-propyl-2,5-dioxo-3-




(indol-3-ylmethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-53)
(3S)-1-propyl-2,5-dioxo-3-(4-(2-




chlorophenylmethyloxycarbonylamino)-




butyl)-9-(6-phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-54)
(3R)-1-propyl-2,5-dioxo-3-




(benzyloxycarbonylmethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-55)
(3S)-1-propyl-2,5-dioxo-3-




(3-(1-imino-1-(2,4,6-




trimethylphenylsulfonylamino)-




methylamino)propyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-56)
(3S)-1-propyl-2,5-dioxo-3-




(benzyloxycarbonylmethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-57)
(3S)-1-propyl-2,5-dioxo-3-




(4-(benzyloxycarbonylamino)butyl)-




9-(6-phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-58)
(3R)-1-propyl-2,5-dioxo-3-




(4-methoxyphenylmethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 22A-8







Example




No
Compound Name









23(H22-59)
(3R)-1-propyl-2,5-dioxo-3-(4-




(benzyloxycarbonylamino)butyl)-9-




(6-phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-60)
(3S)-1-propyl-2,5-dioxo-3-(3-




(benzyloxycarbonylamino)propyl)-9-




(6-phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-61)
(3R)-1-propyl-2,5-dioxo-3-(1-




(benzyloxymethyl)imidazol-4-




ylmethyl)-9-(6-phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-62)
(3R)-1-propyl-2,5-dioxo-3-




(4-ethoxyphenylmethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-63)
(3S)-1-propyl-2,5-dioxo-3-




(4-phenylphenylmethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane



23(H22-64)
(3S)-1-propyl-2,5-dioxo-3-




(1,1-diphenylmethyl)-9-(6-




phenylhexyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 23A-1







Example




No
Compound Name









23(H23-1)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-




9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H23-2)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-




methoxyphenylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H23-3)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-




diethylaminophenylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H23-4)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(3,5-dimethyl-1-




phenylpyrazol-4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H23-5)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-




benzyloxyphenylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H23-6)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-




phenyloxyphenylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H23-7)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-




allyloxyphenylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H23-8)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(dibenzofuran-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H23-9)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-




phenylimidazol-4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 23A-2







Example




No
Compound Name









23(H23-10)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(1,4-benzodioxan-6-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H23-11)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-




methoxyphenylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H23-12)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-




diethylaminophenylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H23-13)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(3,5-dimethyl-1-phenylpyrazol-4-




ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H23-14)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-




benzyloxyphenylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H23-15)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-




phenyloxyphenylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H23-16)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-




allyloxyphenylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H23-17)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(dibenzofuran-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H23-18)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(2-phenylimidazol-4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 24A-1







Example




No
Compound Name









23(H24-1)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(1,4-benzodioxan-6-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H24-2)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(3,5-dimethyl-1-phenylpyrazol-




4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H24-3)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-methylfuran-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H24-4)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-bromothiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H24-5)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(3-methylthiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H24-6)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-ethylfuran-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H24-7)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(pyridin-4-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H24-8)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(1-methylindol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H24-9)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(4-methylimidazol-5-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 24A-2







Example




No
Compound Name









23(H24-10)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(2,4-dioxo-1,3-dihydropyrimidin-5-




ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H24-11)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-(2-




chlorophenyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H24-12)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-(3-




chlorophenyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H24-13)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(indol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H24-14)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-




(hydroxymethyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H24-15)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-(carboxy)thiophen-2-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H24-16)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-(carboxy)furan-2-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H24-17)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-ethylthiophen-2-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H24-18)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-(1-




methylbenzimidazol-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 24A-3







Example




No
Compound Name









23(H24-19)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-(2-




trifluoromethoxyphenyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H24-20)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-(6-




(methoxycarbonyl)indol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H24-21)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-




(2,6-dichloro-4-trifluoromethylphenyl)




furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H24-22)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(4-bromothiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H24-23)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-(2-chloro-5-trifluoromethylphenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H24-24)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-(3-trifluoromethylphenyl)furan-2-




ylmethyl)-1,4,9-triazaspiro[5.5]undecane



23(H24-25)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(1-acetylindol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 24A-4







Example




No
Compound Name









23(H24-26)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-(3,5-bis(trifluoromethyl)phenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H24-27)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-chloro-3-methyl-1-




phenylpyrazol-4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H24-28)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-(4-methoxyphenyl)thiophen-2-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H24-29)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-(2-trifluoromethylphenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H24-30)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-




9-(2,5-dimethyl-1-(4-




carboxyphenyl)pyrrol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H24-31)
1-ethyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-(4-chlorophenyl)furan-2-ylmethyl)-




1,4,9-triazaspiro[5.6]undecane























TABLE 25A-1







Example




No
Compound Name









23(H25-1)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




(1,4-benzodioxan-6-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H25-2)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H25-3)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-methylfuran-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H25-4)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-bromothiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H25-5)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




(3-methylthiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H25-6)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-ethylfuran-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H25-7)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




(1-methylindol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H25-8)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




(4-methylimidazol-5-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 25A-2







Example




No
Compound Name









23(H25-9)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




(2,4-dioxo-1,3-dihydropyrimidin-5-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H25-10)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-(2-chlorophenyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H25-11)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




(indol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H25-12)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-




(hydroxymethyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H25-13)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-(carboxy)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H25-14)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-ethylthiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H25-15)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(1-




methylbenzimidazol-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H25-16)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-(2-




trifluoromethoxyphenyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 25A-3







Example




No
Compound Name









23(H25-17)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(6-




(methoxycarbonyl)indol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H25-18)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-




(2,6-dichloro-4-trifluoromethylphenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H25-19)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




(4-bromothiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H25-20)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-(2-chloro-5-trifluoromethylphenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H25-21)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-(3-




trifluoromethylphenyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H25-22)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




(1-acetylindol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H25-23)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-(3,5-bis(trifluoromethyl)phenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 25A-4







Example




No
Compound Name









23(H25-24)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-chloro-3-methyl-




1-phenylpyrazol-4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H25-25)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-(4-methoxyphenyl)thiophen-2-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H25-26)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-(2-trifluoromethylphenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H25-27)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




(2,5-dimethyl-1-(4-carboxyphenyl)pyrrol-3-




ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H25-28)
1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-(4-chlorophenyl)furan-2-ylmethyl)-




1,4,9-triazaspiro[5.6]undecane























TABLE 26A-1







Example




No
Compound Name









23(H26-1)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(1,4-benzodioxan-6-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-2)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H26-3)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-methylfuran-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-4)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-bromothiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-5)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(3-methylthiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-6)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-ethylfuran-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-7)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(pyridin-4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-8)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(1-methylindol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-9)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(4-methylimidazol-5-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 26A-2







Example




No
Compound Name









23(H26-10)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(2,4-dioxo-1,3-dihydropyrimidin-5-




ylmethyl)-1,4,9-triazaspiro[5.5]undecane



23(H26-11)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-(2-chlorophenyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-12)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-(3-




chlorophenyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-13)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(indol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-14)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-




(hydroxymethyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-15)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-




(carboxy)thiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-16)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-(carboxy)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-17)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-ethylthiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-18)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(1-




methylbenzimidazol-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 26A-3







Example




No
Compound Name









23(H26-19)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-(2-




trifluoromethoxyphenyl)furan-2-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H26-20)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(6-




(methoxycarbonyl)indol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-21)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-(2,6-




dichloro-4-trifluoromethylphenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-22)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(4-bromothiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-23)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-(2-chloro-5-trifluoromethylphenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-24)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-(3-




trifluoromethylphenyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-25)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(1-acetylindol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 26A-4







Example




No
Compound Name









23(H26-26)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-(3,5-bis(trifluoromethyl)phenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-27)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-chloro-3-methyl-1-




phenylpyrazol-4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-28)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-(4-methoxyphenyl)thiophen-2-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H26-29)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-(2-




trifluoromethylphenyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-30)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(2,5-dimethyl-1-(4-carboxyphenyl)




pyrrol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H26-31)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-




(5-(4-chlorophenyl)furan-2-ylmethyl)-




1,4,9-triazaspiro[5.6]undecane























TABLE 27A-1







Example




No
Compound Name









23(H27-1)
1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-




benzyl-1,4,9-triazaspiro[5.5]undecane



23(H27-2)
1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-




methoxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-3)
1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-




(1,4-benzodioxan-6-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-4)
1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-




phenoxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-5)
1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-((4-




benzyloxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-6)
1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-




(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H27-7)
1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-




(2-phenylimidazol-5-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-8)
1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-




((4-hydroxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-9)
1-((2-methoxyphenyl)methyl)-2,5-dioxo-3-




(2-methylpropyl)-9-benzyl-1,4,9-




triazaspiro[5.5]undecane























TABLE 27A-2







Example




No
Compound Name









23(H27-10)
1-((2-methoxyphenyl)methyl)-2,5-dioxo-3-




(2-methylpropyl)-9-




((4-methoxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-11)
1-((2-methoxyphenyl)methyl)-2,5-dioxo-3-




(2-methylpropyl)-9-




(1,4-benzodioxan-6-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-12)
1-((2-methoxyphenyl)methyl)-2,5-dioxo-3-




(2-methylpropyl)-9-




((4-phenoxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-13)
1-((2-methoxyphenyl)methyl)-2,5-dioxo-3-




(2-methylpropyl)-9-




((4-benzyloxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-14)
1-((2-methoxyphenyl)methyl)-2,5-dioxo-3-




(2-methylpropyl)-9-




(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-15)
1-((2-methoxyphenyl)methyl)-2,5-dioxo-3-




(2-methylpropyl)-9-




(2-phenylimidazol-5-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-16)
1-((2-methoxyphenyl)methyl)-2,5-dioxo-3-




(2-methylpropyl)-9-




((4-hydroxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 27A-3







Example




No
Compound Name









23(H27-17)
1-((3-methoxyphenyl)methyl)-2,5-dioxo-3-




(2-methylpropyl)-9-




benzyl-1,4,9-triazaspiro[5.5]undecane



23(H27-18)
1-((3-methoxyphenyl)methyl)-2,5-dioxo-3-




(2-methylpropyl)-9-




((4-methoxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-19)
1-((3-methoxyphenyl)methyl)-2,5-dioxo-3-




(2-methylpropyl)-9-




((4-phenoxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-20)
1-((3-methoxyphenyl)methyl)-2,5-dioxo-3-




(2-methylpropyl)-9-




((4-benzyloxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-21)
1-((3-methoxyphenyl)methyl)-2,5-dioxo-3-




(2-methylpropyl)-9-(3,5-dimethyl-1-




phenylpyrazol-4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-22)
1-((3-methoxyphenyl)methyl)-2,5-dioxo-3-




(2-methylpropyl)-9-(2-phenylimidazol-5-




ylmethyl)-1,4,9-triazaspiro[5.5]undecane



23(H27-23)
1-((3-methoxyphenyl)methyl)-2,5-dioxo-3-




(2-methylpropyl)-9-((4-hydroxyphenyl)methyl)-




1,4,9-triazaspiro[5.5]undecane























TABLE 27A-4







Example




No
Compound Name









23(H27-24)
1-((4-methoxyphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-benzyl-1,4,9-




triazaspiro[5.5]undecane



23(H27-25)
1-((4-methoxyphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-(1,4-benzodioxan-




6-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-26)
1-((4-methoxyphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




((4-phenoxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-27)
1-((4-methoxyphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




((4-benzyloxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-28)
1-((4-methoxyphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-(3,5-dimethyl-1-




phenylpyrazol-4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-29)
1-((4-methoxyphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-(2-phenylimidazol-




5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane



23(H27-30)
1-((4-methoxyphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




((4-hydroxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 27A-5







Example




No
Compound Name









23(H27-31)
1-(pyridin-2-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-benzyl-1,4,9-




triazaspiro[5.5]undecane



23(H27-32)
1-(pyridin-2-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-((4-




methoxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-33)
1-(pyridin-2-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




(2H,3H-benzo[3,4-e]1,4-dioxan-




6-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-34)
1-(pyridin-2-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-((4-




phenoxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-35)
1-(pyridin-2-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-((4-




benzyloxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-36)
1-(pyridin-2-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-(3,5-




dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-37)
1-(pyridin-2-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-(2-




phenylimidazol-5-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 27A-6







Example




No
Compound Name









23(H27-38)
1-(pyridin-2-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-((4-




hydroxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-39)
1-(pyridin-3-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-benzyl-1,4,9-




triazaspiro[5.5]undecane



23(H27-40)
1-(pyridin-3-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-((4-




methoxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-41)
1-(pyridin-3-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-(1,4-




benzodioxan-6-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-42)
1-(pyridin-3-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-((4-




phenoxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-43)
1-(pyridin-3-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-((4-




benzyloxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-44)
1-(pyridin-3-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-(3,5-




dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 27A-7







Example




No
Compound Name









23(H27-45)
1-(pyridin-3-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-(2-




phenylimidazol-5-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-46)
1-(pyridin-3-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-((4-




hydroxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-47)
1-(pyridin-4-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-benzyl-1,4,9-




triazaspiro[5.5]undecane



23(H27-48)
1-(pyridin-4-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-((4-




methoxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-49)
1-(pyridin-4-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-(1,4-




benzodioxan-6-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-50)
1-(pyridin-4-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-((4-




phenoxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-51)
1-(pyridin-4-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-((4-




benzyloxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 27A-8







Example




No
Compound Name









23(H27-52)
1-(pyridin-4-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-(3,5-




dimethyl-1-phenylpyrazol-4-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H27-53)
1-(pyridin-4-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-(2-




phenylimidazol-5-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-54)
1-(pyridin-4-ylmethyl)-2,5-dioxo-




3-(2-methylpropyl)-9-((4-




hydroxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-55)
1-((2-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-benzyl-1,4,9-




triazaspiro[5.5]undecane



23(H27-56)
1-((2-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




((4-methoxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-57)
1-((2-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




(1,4-benzodioxan-6-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-58)
1-((2-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




((4-phenoxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 27A-9







Example




No
Compound Name









23(H27-59)
1-((2-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




((4-benzyloxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-60)
1-((2-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-61)
1-((2-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




(2-phenylimidazol-5-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-62)
1-((2-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




((4-hydroxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-63)
1-((3-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




benzyl-1,4,9-triazaspiro[5.5]undecane



23(H27-64)
1-((3-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




((4-methoxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-65)
1-((3-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




(1,4-benzodioxan-6-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 27A-10







Example




No
Compound Name









23(H27-66)
1-((3-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




((4-phenoxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-67)
1-((3-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




((4-benzyloxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-68)
1-((3-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-(3,5-dimethyl-1-




phenylpyrazol-4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-69)
1-((3-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




(2-phenylimidazol-5-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-70)
1-((3-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




((4-hydroxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-71)
1-((4-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-benzyl-1,4,9-




triazaspiro[5.5]undecane



23(H27-72)
1-((4-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-((4-




methoxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 27A-11







Example




No
Compound Name









23(H27-73)
1-((4-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




(1,4-benzodioxan-6-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-74)
1-((4-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




((4-phenoxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-75)
1-((4-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




((4-benzyloxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-76)
1-((4-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-(3,5-dimethyl-




1-phenylpyrazol-4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-77)
1-((4-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




(2-phenylimidazol-5-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H27-78)
1-((4-methylphenyl)methyl)-2,5-dioxo-




3-(2-methylpropyl)-9-




((4-hydroxyphenyl)methyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 28A-1







Example




No
Compound Name









23(H28-1)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-




(1,4-benzodioxan-6-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H28-2)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-




(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H28-3)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-methylfuran-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H28-4)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-bromothiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H28-5)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-




(3-methylthiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H28-6)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-ethylfuran-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H28-7)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-




(pyridin-4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H28-8)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-




(1-methylindol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H28-9)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-




(4-methylimidazol-5-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 28A-2







Example




No
Compound Name









23(H28-10)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-




(2,4-dioxo-1,3-dihydropyrimidin-5-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H28-11)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-(5-(2-




chlorophenyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H28-12)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-(5-(3-




chlorophenyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H28-13)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-(5-




(hydroxymethyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H28-14)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-(5-




(carboxy)thiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H28-15)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-(carboxy)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H28-16)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-ethylthiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H28-17)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-(1-




methylbenzimidazol-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 28A-3







Example




No
Compound Name









23(H28-18)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-(2-trifluoromethoxyphenyl)furan-2-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H28-19)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-(6-




(methoxycarbonyl)indol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H28-20)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-




9-(5-(2,6-dichloro-4-




trifluoromethylphenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H28-21)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-




(4-bromothiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H28-22)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-(2-chloro-5-trifluoromethylphenyl)




furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H28-23)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-(3-trifluoromethylphenyl)furan-2-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H28-24)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-




(1-acetylindol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 28A-4







Example




No
Compound Name









23(H28-25)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-




9-(5-(3,5-bis(trifluoromethyl)phenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H28-26)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-




9-(5-chloro-3-methyl-




1-phenylpyrazol-4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H28-27)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-(4-methoxyphenyl)thiophen-2-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H28-28)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-(2-trifluoromethylphenyl)furan-2-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H28-29)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-




(2,5-dimethyl-1-(4-carboxyphenyl)pyrrol-




3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H28-30)
1-propyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-(4-chlorophenyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.6]undecane























TABLE 29A-1







Example




No
Compound Name









23(H29-1)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(1,4-benzodioxan-6-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H29-2)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H29-3)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-methylfuran-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H29-4)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-bromothiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H29-5)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(3-methylthiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H29-6)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-ethylfuran-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H29-7)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(pyridin-4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H29-8)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(1-methylindol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H29-9)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(4-methylimidazol-5-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 29A-2







Example




No
Compound Name









23(H29-10)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(2,4-dioxo-1,3-dihydropyrimidin-5-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H29-11)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(5-(2-




chlorophenyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H29-12)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(5-(3-




chlorophenyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H29-13)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(indol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H29-14)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(5-




(hydroxymethyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H29-15)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-(carboxy)thiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H29-16)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-(carboxy)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H29-17)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-ethylthiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H29-18)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(1-methylbenzimidazol-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 29A-3







Example




No
Compound Name









23(H29-19)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(5-(2-




trifluoromethoxyphenyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H29-20)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(6-




(methoxycarbonyl)indol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H29-21)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-(2,6-dichloro-4-trifluoromethylphenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H29-22)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(4-bromothiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H29-23)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-(2-chloro-5-trifluoromethylphenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H29-24)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-(3-trifluoromethylphenyl)furan-2-




ylmethyl)-1,4,9-triazaspiro[5.5]undecane



23(H29-25)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-




(1-acetylindol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane





















TABLE 29A-4





Example



No
Compound Name







23(H29-26)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-



(5-(3,5-bis(trifluoromethylmethyl)phenyl)furan-



2-ylmethyl)-1,4,9-



triazaspiro[5.5]undecane


23(H29-27)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-



(5-chloro-3-methyl-1-



phenylpyrazol-4-ylmethyl)-1,4,9-



triazaspiro[5.5]undecane


23(H29-28)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-



(5-(4-methoxyphenyl)thiophen-2-ylmethyl)-1,4,9-



triazaspiro[5.5]undecane


23(H29-29)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(5-(2-



trifluoromethylmethylphenyl)furan-2-ylmethyl)-1,4,9-



triazaspiro[5.5]undecane


23(H29-30)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-



(2,5-dimethyl-1-(4-carboxyphenyl)pyrrol-



3-ylmethyl)-1,4,9-



triazaspiro[5.5]undecane


23(H29-31)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(5-(4-



chlorophenyl)furan-2-ylmethyl)-1,4,9-



triazaspiro[5.6]undecane






















TABLE 30A-1







Example




No
Compound Name









23(H30-1)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(1,4-




benzodioxan-6-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-2)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(3,5-




dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-3)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(5-




methylfuran-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-4)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(5-




bromothiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-5)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(3-




methylthiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-6)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(5-




ethylfuran-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-7)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(pyridin-




4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane



23(H30-8)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(1-




methylindol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 30A-2







Example




No
Compound Name









23(H30-9)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(4-




methylimidazol-5-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-10)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(2,4-




dioxo-1,3-dihydropyrimidin-5-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-11)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(5-(2-




chlorophenyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-12)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(5-(3-




chlorophenyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-13)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(indol-3-




ylmethyl)-1,4,9-triazaspiro[5.5]undecane



23(H30-14)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(5-




(hydroxymethyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-15)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(5-




(carboxy)thiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 30A-3







Example




No
Compound Name









23(H30-16)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(5-




(carboxy)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-17)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(5-




ethylthiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-18)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(1-




methylbenzimidazol-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-19)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(5-(2-




trifluoromethoxyphenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-20)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(6-




(methoxycarbonyl)indol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-21)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(5-(2,6-




dichloro-4-trifluoromethylphenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-22)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(4-




bromothiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 30A-4







Example




No
Compound Name









23(H30-23)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(5-(2-




chloro-5-trifluoromethylphenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-24)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(5-(3-




trifluoromethylphenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-25)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(1-




acetylindol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-26)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(5-(3,5-




bis(trifluoromethyl)phenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-27)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(5-chloro-




3-methyl-1 -phenylpyrazol-




4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-28)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(5-(4-




methoxyphenyl)thiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-29)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(5-(2-




trifluoromethylphenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 30A-5







Example




No
Compound Name









23(H30-30)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(2,5-




dimethyl-1-(4-carboxyphenyl)pyrrol-




3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H30-31)
1-(2-methoxyethyl)-2,5-dioxo-




3-cyclohexylmethyl-9-(5-(4-




chlorophenyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.6]undecane























TABLE 31A-1







Example




No
Compound Name









23(H31-1)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(1,4-benzodioxan-6-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-2)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H31-3)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-methylfuran-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-4)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-bromothiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-5)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(3-methylthiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-6)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-ethylfuran-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-7)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(pyridin-4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-8)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(1-methylindol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-9)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(4-methylimidazol-5-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 31A-2







Example




No
Compound Name









23(H31-10)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(2,4-dioxo-1,3-dihydropyrimidin-5-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H31-11)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-(2-chlorophenyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-12)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-(3-chlorophenyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-13)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(indol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-14)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-(5-




(hydroxymethyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-15)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-(5-




(carboxy)thiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-16)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-(5-




(carboxy)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-17)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-ethylthiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-18)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-(1-




methylbenzimidazol-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 31A-3







Example




No
Compound Name









23(H31-19)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-(2-trifluoromethoxyphenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-20)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-(6-




(methoxycarbonyl)indol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-21)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-(2,6-dichloro-4-trifluoromethylphenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-22)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(4-bromothiophen-2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-23)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-(2-chloro-5-trifluoromethylphenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-24)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-(3-trifluoromethylphenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-25)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(1-acetylindol-3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane























TABLE 31A-4







Example




No
Compound Name









23(H31-26)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-(3,5-bis(trifluoromethyl)phenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-27)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-chloro-3-methyl-




1-phenylpyrazol-4-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-28)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-(4-methoxyphenyl)thiophen-2-ylmethyl)-




1,4,9-triazaspiro[5.5]undecane



23(H31-29)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-(2-trifluoromethylphenyl)furan-




2-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-30)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(2,5-dimethyl-1-(4-carboxyphenyl)pyrrol-




3-ylmethyl)-1,4,9-




triazaspiro[5.5]undecane



23(H31-31)
1-benzyl-2,5-dioxo-3-cyclohexylmethyl-9-




(5-(4-chlorophenyl)furan-2-ylmethyl)-1,4,9-




triazaspiro[5.6]undecane




















TABLE 22B-1









embedded image















Example





No
R3
R4
R5





23(H22-1)
H


embedded image


H





23(H22-2)
H


embedded image


H





23(H22-3)
H


embedded image


H





23(H22-4)
H


embedded image


H





23(H22-5)
H


embedded image


H





23(H22-6)
H


embedded image


H





23(H22-7)
H


embedded image


H





23(H22-8)
H


embedded image


H



















TABLE 22B-2









embedded image















Example No
R3
R4
R5





23(H22-9) 
H


embedded image


H





23(H22-10)
H


embedded image


H





23(H22-11)
H


embedded image


H





23(H22-12)
H


embedded image


H





23(H22-13)
H


embedded image


H





23(H22-14)
H


embedded image


H





23(H22-15)
H


embedded image


H





23(H22-16)
H


embedded image


H



















TABLE 22B-3









embedded image















Example





No
R3
R4
R5





23(H22-17)
H


embedded image


H





23(H22-18)
H


embedded image


H





23(H22-19)
H


embedded image


H





23(H22-20)
H


embedded image


H





23(H22-21)
H


embedded image


H





23(H22-22)
H


embedded image


H





23(H22-23)
H


embedded image


H





23(H22-24)
H
H
H



















TABLE 22B-4









embedded image















Example





No
R3
R4
R5





23(H22-25)
H


embedded image


H





23(H22-26)
H


embedded image


H





23(H22-27)
H


embedded image


H





23(H22-28)
H


embedded image


H





23(H22-29)
H


embedded image


H





23(H22-30)
H


embedded image


H





23(H22-31)
H


embedded image


H



















TABLE 22B-5









embedded image















Example No
R3
R4
R5





23(H22-32)
H


embedded image


H





23(H22-33)
H


embedded image


H





23(H22-34)
H


embedded image


H





23(H22-35)
H


embedded image


X5—CH3





23(H22-36)
H


embedded image


H





23(H22-37)
H


embedded image


X5—CH3





23(H22-38)
H


embedded image


H





23(H22-39)
H


embedded image


H



















TABLE 22B-6









embedded image

















Example No
R3
R4
R5







23(H22-40)
H


embedded image


H







23(H22-41)
H


embedded image


H







23(H22-42)
H


embedded image


H







23(H22-43)
H


embedded image


H







23(H22-44)
H


embedded image


H







23(H22-45)
H


embedded image


H







23(H22-46)
H


embedded image


H







23(H22-47)
H


embedded image


H







23(H22-48)
H


embedded image


H




















TABLE 22B-7









embedded image















Example No
R3
R4
R5





23(H22-49)
H


embedded image


H





23(H22-50)
H


embedded image


H





23(H22-51)
H


embedded image


H





23(H22-52)
H


embedded image


H





23(H22-53)
H


embedded image


H





23(H22-54)
H


embedded image


H





23(H22-55)
H


embedded image


H



















TABLE 22B-8









embedded image















Example No
R3
R4
R5





23(H22-56)
H


embedded image


H





23(H22-57)
H


embedded image


H





23(H22-58)
H


embedded image


H





23(H22-59)
H


embedded image


H





23(H22-60)
H


embedded image


H





23(H22-61)
H


embedded image


H



















TABLE 22B-9









embedded image















Example No
R3
R4
R5





23(H22-62)
H


embedded image


H





23(H22-63)
H


embedded image


H





23(H22-64)
H


embedded image


H



















TABLE 23B-1









embedded image















Example No
R1
R3
R4





23(H23-1)


embedded image


H


embedded image







23(H23-2)


embedded image


H


embedded image







23(H23-3)


embedded image


H


embedded image







23(H23-4)


embedded image


H


embedded image







23(H23-5)


embedded image


H


embedded image







23(H23-6)


embedded image


H


embedded image







23(H23-7)


embedded image


H


embedded image







23(H23-8)


embedded image


H


embedded image





















TABLE 23B-2









embedded image















Example No
R1
R3
R4





23(H23-9)


embedded image


H


embedded image







23(H23-10)


embedded image


H


embedded image







23(H23-11)


embedded image


H


embedded image







23(H23-12)


embedded image


H


embedded image







23(H23-13)


embedded image


H


embedded image







23(H23-14)


embedded image


H


embedded image







23(H23-15)


embedded image


H


embedded image





















TABLE 23B-3









embedded image















Example No
R1
R3
R4





23(H23-16)


embedded image


H


embedded image







23(H23-17)


embedded image


H


embedded image







23(H23-18)


embedded image


H


embedded image





















TABLE 24B-1









embedded image















Example No
R1







23(H24-1)


embedded image









23(H24-2)


embedded image









23(H24-3)


embedded image









23(H24-4)


embedded image









23(H24-5)


embedded image









23(H24-6)


embedded image









23(H24-7)


embedded image









23(H24-8)


embedded image






















TABLE 24B-2









embedded image















Example No
R1







23(H24-9)


embedded image









23(H24-10)


embedded image









23(H24-11)


embedded image









23(H24-12)


embedded image









23(H24-13)


embedded image









23(H24-14)


embedded image









23(H24-15)


embedded image









23(H24-16)


embedded image






















TABLE 24B-3









embedded image















Example No
R1







23(H24-17)


embedded image









23(H24-18)


embedded image









23(H24-19)


embedded image









23(H24-20)


embedded image









23(H24-21)


embedded image









23(H24-22)


embedded image






















TABLE 24B-4









embedded image















Example No
R1







23(H24-23)


embedded image









23(H24-24)


embedded image









23(H24-25)


embedded image









23(H24-26)


embedded image









23(H24-27)


embedded image









23(H24-28)


embedded image






















TABLE 24B-5









embedded image















Example No
R1







23(H24-29)


embedded image









23(H24-30)


embedded image









23(H24-31)


embedded image






















TABLE 25B-1









embedded image















Example No
R1







23(H25-1)


embedded image









23(H25-2)


embedded image









23(H25-3)


embedded image









23(H25-4)


embedded image









23(H25-5)


embedded image









23(H25-6)


embedded image









23(H25-7)


embedded image









23(H25-8)


embedded image






















TABLE 25B-2









embedded image















Example No
R1







23(H25-9)


embedded image









23(H25-10)


embedded image









23(H25-11)


embedded image









23(H25-12)


embedded image









23(H25-13)


embedded image









23(H25-14)


embedded image









23(H25-15)


embedded image






















TABLE 25B-3









embedded image













Example No
R1





23(H25-16)


embedded image







23(H25-17)


embedded image







23(H25-18)


embedded image







23(H25-19)


embedded image







23(H25-20)


embedded image







23(H25-21)


embedded image





















TABLE 25B-4









embedded image













Example No
R1





23(H25-22)


embedded image







23(H25-23)


embedded image







23(H25-24)


embedded image







23(H25-25)


embedded image







23(H25-26)


embedded image







23(H25-27)


embedded image





















TABLE 25B-5









embedded image













Example No
R1





23(H25-28)


embedded image





















TABLE 26B-1









embedded image













Example No
R1





23(H26-1)


embedded image







23(H26-2)


embedded image







23(H26-3)


embedded image







23(H26-4)


embedded image







23(H26-5)


embedded image







23(H26-6)


embedded image







23(H26-7)


embedded image







23(H26-8)


embedded image





















TABLE 26B-2









embedded image













Example No
R1





23(H26-9) 


embedded image







23(H26-10)


embedded image







23(H26-11)


embedded image







23(H26-12)


embedded image







23(H26-13)


embedded image







23(H26-14)


embedded image







23(H26-15)


embedded image





















TABLE 26B-3









embedded image













Example No
R1





23(H26-16)


embedded image







23(H26-17)


embedded image







23(H26-18)


embedded image







23(H26-19)


embedded image







23(H26-20)


embedded image







23(H26-21)


embedded image







23(H26-22)


embedded image





















TABLE 26B-4









embedded image













Example No
R1





23(H26-23)


embedded image







23(H26-24)


embedded image







23(H26-25)


embedded image







23(H26-26)


embedded image







23(H26-27)


embedded image





















TABLE 26B-5









embedded image













Example No
R1





23(H26-28)


embedded image







23(H26-29)


embedded image







23(H26-30)


embedded image







23(H26-31)


embedded image





















TABLE 27B-1









embedded image














Example No
R1
R2





23(H27-1)


embedded image




embedded image







23(H27-2)


embedded image




embedded image







23(H27-3)


embedded image




embedded image







23(H27-4)


embedded image




embedded image







23(H27-5)


embedded image




embedded image







23(H27-6)


embedded image




embedded image







23(H27-7)


embedded image




embedded image







23(H27-8)


embedded image




embedded image





















TABLE 27B-2









embedded image














Example No
R1
R2





23(H27-9) 


embedded image




embedded image







23(H27-10)


embedded image




embedded image







23(H27-11)


embedded image




embedded image







23(H27-12)


embedded image




embedded image







23(H27-13)


embedded image




embedded image







23(H27-14)


embedded image




embedded image





















TABLE 27B-3









embedded image














Example No
R1
R2





23(H27-15)


embedded image




embedded image







23(H27-16)


embedded image




embedded image







23(H27-17)


embedded image




embedded image







23(H27-18)


embedded image




embedded image







23(H27-19)


embedded image




embedded image







23(H27-20)


embedded image




embedded image







23(H27-21)


embedded image




embedded image





















TABLE 27B-4









embedded image














Example No
R1
R2





23(H27-22)


embedded image




embedded image







23(H27-23)


embedded image




embedded image







23(H27-24)


embedded image




embedded image







23(H27-25)


embedded image




embedded image







23(H27-26)


embedded image




embedded image







23(H27-27)


embedded image




embedded image







23(H27-28)


embedded image




embedded image







23(H27-29)


embedded image




embedded image





















TABLE 27B-5









embedded image














Example No
R1
R2





23(H27-30)


embedded image




embedded image







23(H27-31)


embedded image




embedded image







23(H27-32)


embedded image




embedded image







23(H27-33)


embedded image




embedded image







23(H27-34)


embedded image




embedded image







23(H27-35)


embedded image




embedded image







23(H27-36)


embedded image




embedded image







23(H27-37)


embedded image




embedded image





















TABLE 27B-6









embedded image














Example No
R1
R2





23(H27-38)


embedded image




embedded image







23(H27-39)


embedded image




embedded image







23(H27-40)


embedded image




embedded image







23(H27-41)


embedded image




embedded image







23(H27-42)


embedded image




embedded image







23(H27-43)


embedded image




embedded image







23(H27-44)


embedded image




embedded image







23(H27-45)


embedded image




embedded image





















TABLE 27B-7









embedded image














Example No
R1
R2





23(H27-46)


embedded image




embedded image







23(H27-47)


embedded image




embedded image







23(H27-48)


embedded image




embedded image







23(H27-49)


embedded image




embedded image







23(H27-50)


embedded image




embedded image







23(H27-51)


embedded image




embedded image







23(H27-52)


embedded image




embedded image







23(H27-53)


embedded image




embedded image





















TABLE 27B-8









embedded image














Example No
R1
R2





23(H27-54)


embedded image




embedded image







23(H27-55)


embedded image




embedded image







23(H27-56)


embedded image




embedded image







23(H27-57)


embedded image




embedded image







23(H27-58)


embedded image




embedded image







23(H27-59)


embedded image




embedded image







23(H27-60)


embedded image




embedded image





















TABLE 27B-9









embedded image














Example No
R1
R2





23(H27-61)


embedded image




embedded image







23(H27-62)


embedded image




embedded image







23(H27-63)


embedded image




embedded image







23(H27-64)


embedded image




embedded image







23(H27-65)


embedded image




embedded image







23(H27-66)


embedded image




embedded image







23(H27-67)


embedded image




embedded image





















TABLE 27B-10









embedded image














Example No
R1
R2





23(H27-68)


embedded image




embedded image







23(H27-69)


embedded image




embedded image







23(H27-70)


embedded image




embedded image







23(H27-71)


embedded image




embedded image







23(H27-72)


embedded image




embedded image







23(H27-73)


embedded image




embedded image







23(H27-74)


embedded image




embedded image







23(H27-75)


embedded image




embedded image





















TABLE 27B-11









embedded image














Example No
R1
R2





23(H27-76)


embedded image




embedded image







23(H27-77)


embedded image




embedded image







23(H27-78)


embedded image




embedded image





















TABLE 28B-1









embedded image













Example No
R1





23(H28-2)


embedded image







23(H28-2)


embedded image







23(H28-3)


embedded image







23(H28-4)


embedded image







23(H28-5)


embedded image







23(H28-6)


embedded image







23(H28-7)


embedded image







23(H28-8)


embedded image





















TABLE 28B-2









embedded image













Example No.
R1





23(H28-9) 


embedded image







23(H28-10)


embedded image







23(H28-11)


embedded image







23(H28-12)


embedded image







23(H28-13)


embedded image







23(H28-14)


embedded image







23(H28-15)


embedded image







23(H28-16)


embedded image





















TABLE 28B-3









embedded image













Example No
R1





23(H28-17)


embedded image







23(H28-18)


embedded image







23(H28-19)


embedded image







23(H28-20)


embedded image







23(H28-21)


embedded image







23(H28-22)


embedded image





















TABLE 28B-4









embedded image













Example No
R1





23(H28-23)


embedded image







23(H28-24)


embedded image







23(H28-25)


embedded image







23(H28-26)


embedded image







23(H28-27)


embedded image







23(H28-28)


embedded image





















TABLE 28B-5









embedded image













Example No
R1





23(H28-29)


embedded image







23(H28-30)


embedded image





















TABLE 29B-1









embedded image













Example No
R1





23(H29-1)


embedded image







23(H29-2)


embedded image







23(H29-3)


embedded image







23(H29-4)


embedded image







23(H29-5)


embedded image







23(H29-6)


embedded image







23(H29-7)


embedded image





















TABLE 29B-2









embedded image













Example No
R1





23(H29-8) 


embedded image







23(H29-9) 


embedded image







23(H29-10)


embedded image







23(H29-11)


embedded image







23(H29-12)


embedded image







23(H29-13)


embedded image







23(H29-14)


embedded image





















TABLE 29B-3









embedded image













Example No
R1





23(H29-15)


embedded image







23(H29-16)


embedded image







23(H29-17)


embedded image







23(H29-18)


embedded image







23(H29-19)


embedded image







23(H29-20)


embedded image







23(H29-21)


embedded image





















TABLE 29B-4









embedded image













Example No
R1





23(H29-22)


embedded image







23(H29-23)


embedded image







23(H29-24)


embedded image







23(H29-25)


embedded image







23(H29-26)


embedded image





















TABLE 29B-5









embedded image













Example No
R1





23(H29-27)


embedded image







23(H29-28)


embedded image







23(H29-29)


embedded image







23(H29-30)


embedded image







23(H29-31)


embedded image





















TABLE 30B-1









embedded image













Example No
R1





23(H30-1)


embedded image







23(H30-2)


embedded image







23(H30-3)


embedded image







23(H30-4)


embedded image







23(H30-5)


embedded image







23(H30-6)


embedded image







23(H30-7)


embedded image





















TABLE 30B-2









embedded image















Example No
R1







23(H30-8) 


embedded image









23(H30-9) 


embedded image









23(H30-10)


embedded image









23(H30-11)


embedded image









23(H30-12)


embedded image









23(H30-13)


embedded image









23(H30-14)


embedded image






















TABLE 30B-3









embedded image















Example No
R1







23(H30-15)


embedded image









23(H30-16)


embedded image









23(H30-17)


embedded image









23(H30-18)


embedded image









23(H30-19)


embedded image









23(H30-20)


embedded image






















TABLE 30B-4









embedded image















Example No
R1







23(H30-21)


embedded image









23(H30-22)


embedded image









23(H30-23)


embedded image









23(H30-24)


embedded image









23(H30-25)


embedded image






















TABLE 30B-5









embedded image















Example No
R1







23(H30-26)


embedded image









23(H30-27)


embedded image









23(H30-28)


embedded image









23(H30-29)


embedded image









23(H30-30)


embedded image









23(H30-31)


embedded image






















TABLE 31B-1









embedded image















Example No
R1







23(H31-1)


embedded image









23(H31-2)


embedded image









23(H31-3)


embedded image









23(H31-4)


embedded image









23(H31-5)


embedded image









23(H31-6)


embedded image









23(H31-7)


embedded image






















TABLE 31B-2









embedded image















Example No
R1







23(H31-8) 


embedded image









23(H31-9) 


embedded image









23(H31-10)


embedded image









23(H31-11)


embedded image









23(H31-12)


embedded image









23(H31-13)


embedded image









23(H31-14)


embedded image






















TABLE 31B-3









embedded image















Example No
R1







23(H31-15)


embedded image









23(H31-16)


embedded image









23(H31-17)


embedded image









23(H31-18)


embedded image









23(H31-19)


embedded image









23(H31-20)


embedded image









23(H31-21)


embedded image






















TABLE 31B-4









embedded image















Example No
R1







23(H31-22)


embedded image









23(H31-23)


embedded image









23(H31-24)


embedded image









23(H31-25)


embedded image









23(H31-26)


embedded image






















TABLE 31B-5









embedded image















Example No
R1







23(H31-27)


embedded image









23(H31-28)


embedded image









23(H31-29)


embedded image









23(H31-30)


embedded image









23(H31-31)


embedded image


























TABLE 22C-1






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















23(H22-1)
E
3.67
442 (M + H)+,
APCI (Pos., 40 V)





369.


23(H22-2)
E
3.67
442 (M + H)+,
APCI (Pos., 40 V)





440, 369.


23(H22-3)
E
3.22
400 (M + H)+,
APCI (Pos., 40 V)





398, 370, 327.


23(H22-4)
E
3.76
476 (M + H)+,
APCI (Pos., 40 V)





400.


23(H22-5)
E
3.36
586 (M + H)+.
APCI (Pos., 40 V)


23(H22-6)
E
3.78
506 (M + H)+,
APCI (Pos., 40 V)





398.


23(H22-7)
E
3.73
506 (M + H)+.
APCI (Pos., 40 V)


23(H22-8)
E
3.97
520 (M + H)+,
APCI (Pos., 40 V)





412, 356.


23(H22-9)
E
2.99
477 (M + H)+,
APCI (Pos., 40 V)





400.


23(H22-10)
E
3.70
442 (M + H)+,
APCI (Pos., 40 V)





412, 369.


23(H22-11)
E
4.03
526 (M + H)+,
APCI (Pos., 40 V)





453, 372.


23(H22-12)
E
4.06
482 (M + H)+,
APCI (Pos., 40 V)





409.


23(H22-13)
E
4.04
526 (M + H)+,
APCI (Pos., 40 V)





453, 372.


23(H22-14)
E
4.10
540 (M + H)+,
APCI (Pos., 40 V)





416.


23(H22-15)
E
4.29
582 (M + H)+,
APCI (Pos., 40 V)





492.


23(H22-16)
E
3.15
416 (M + H)+,
APCI (Pos., 40 V)





398.


23(H22-17)
E
4.29
582 (M + H)+,
APCI (Pos., 40 V)





492.


23(H22-18)
E
3.71
442 (M + H)+,
APCI (Pos., 40 V)





440, 412, 369.


23(H22-19)
E
4.05
482 (M + H)+,
APCI (Pos., 40 V)





452, 409.


23(H22-20)
E
3.97
520 (M + H)+,
APCI (Pos., 40 V)





478, 412.


23(H22-21)
E
3.89
506 (M + H)+,
APCI (Pos., 40 V)





398.


23(H22-22)
E
4.02
552 (M + H)+,
APCI (Pos., 40 V)





398.


23(H22-23)
E
4.03
522 (M + H)+,
APCI (Pos., 40 V)





432, 398.


23(H22-24)
E
3.20
386 (M + H)+.
APCI (Pos., 40 V)


23(H22-25)
E
2.93
466 (M + H)+.
APCI (Pos., 40 V)


23(H22-26)
E
3.79
416 (M + H)+.
APCI (Pos., 40 V)























TABLE 22C-2






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















23(H22-27)
E
4.16
586 (M + H)+,
APCI (Pos., 40 V)





432, 398, 295.


23(H22-28)
E
3.34
556 (M + H)+.
APCI (Pos., 40 V)


23(H22-29)
E
3.33
492 (M + H)+.
APCI (Pos., 40 V)


23(H22-30)
E
4.12
625 (M + H)+,
APCI (Pos., 40 V)





491.


23(H22-31)
E
3.10
486 (M + H)+,
APCI (Pos., 40 V)





484.


23(H22-32)
E
4.06
526 (M + H)+.
APCI (Pos., 40 V)


23(H22-33)
E
4.22
544 (M + H)+.
APCI (Pos., 40 V)


23(H22-34)
E
3.90
488 (M + H)+,
APCI (Pos., 40 V)





398.


23(H22-35)
E
3.82
456 (M + H)+.
APCI (Pos., 40 V)


23(H22-36)
E
3.11
428 (M + H)+,
APCI (Pos., 40 V)





355.


23(H22-37)
E
4.39
596 (M + H)+.
APCI (Pos., 40 V)


23(H22-38)
E
3.18
430 (M + H)+,
APCI (Pos., 40 V)





386


23(H22-39)
E
3.12
443 (M + H)+.
APCI (Pos., 40 V)


23(H22-40)
E
3.18
430 (M + H)+,
APCI (Pos., 40 V)





386, 356.


23(H22-41)
E
3.22
400 (M + H)+,
APCI (Pos., 40 V)





398, 370, 327.


23(H22-42)
E
2.98
477 (M + H)+.
APCI (Pos., 40 V)


23(H22-43)
E
3.17
444 (M + H)+,
APCI (Pos., 40 V)





398.


23(H22-44)
E
3.32
492 (M + H)+.
APCI (Pos., 40 V)


23(H22-45)
E
4.53
460 (M + H)+.
APCI (Pos., 40 V)


23(H22-46)
E
2.26
503 (M + H)+,
APCI (Pos., 40 V)





432, 398, 263.


23(H22-47)
E
3.20
430 (M + H)+,
APCI (Pos., 40 V)





386.


23(H22-48)
E
3.87
510 (M + H)+,
APCI (Pos., 40 V)





472.


23(H22-49)
E
4.11
526 (M + H)+.
APCI (Pos., 40 V)


23(H22-50)
E
3.89
494 (M + H)+.
APCI (Pos., 40 V)


23(H22-51)
E
3.27
425 (M + H)+.
APCI (Pos., 40 V)


23(H22-52)
E
3.74
515 (M + H)+.
APCI (Pos., 40 V)























TABLE 22C-3






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















23(H22-53)
E
4.19
625 (M + H)+.
APCI (Pos., 40 V)


23(H22-54)
E
3.93
534 (M + H)+,
APCI (Pos., 40 V)





458.


23(H22-55)
E
4.08
667 (M + H)+.
APCI (Pos., 40 V)


23(H22-56)
E
3.94
534 (M + H)+,
APCI (Pos., 40 V)





458.


23(H22-57)
E
4.02
591 (M + H)+,
APCI (Pos., 40 V)





457.


23(H22-58)
E
3.79
506 (M + H)+.
APCI (Pos., 40 V)


23(H22-59)
E
4.01
591 (M + H)+.
APCI (Pos., 40 V)


23(H22-60)
E
3.91
577 (M + H)+.
APCI (Pos., 40 V)


23(H22-61)
E
3.47
586 (M + H)+.
APCI (Pos., 40 V)


23(H22-62)
E
3.94
520 (M + H)+.
APCI (Pos., 40 V)


23(H22-63)
E
4.33
552 (M + H)+.
APCI (Pos., 40 V)


23(H22-64)
E
4.21
552 (M + H)+.
APCI (Pos., 40 V)























TABLE 23C






HPLC
Retention




Example
condi-
time


No
tion
(min)
Mass data
Mass condition



















23(H23-1)
E
3.00
444 (M + H)+.
APCI (Pos., 40 V)


23(H23-2)
E
3.07
416 (M + H)+.
APCI (Pos., 40 V)


23(H23-3)
E
2.52
457 (M + H)+,
APCI (Pos., 40 V)





296, 162.


23(H23-4)
E
3.17
480 (M + H)+,
APCI (Pos., 40 V)





296, 217, 185.


23(H23-5)
E
3.80
492 (M + H)+.
APCI (Pos., 40 V)


23(H23-6)
E
3.79
478 (M + H)+.
APCI (Pos., 40 V)


23(H23-7)
E
3.43
442 (M + H)+,
APCI (Pos., 40 V)





402, 336, 296.


23(H23-8)
E
3.86
498 (M + Na)+,
APCI (Pos., 40 V)





476 (M + H)+.


23(H23-9)
E
2.90
452 (M + H)+,
APCI (Pos., 40 V)





296.


23(H23-10)
E
3.57
484 (M + H)+,
APCI (Pos., 40 V)





332.


23(H23-11)
E
3.62
456 (M + H)+.
APCI (Pos., 40 V)


23(H23-12)
E
3.22
497 (M + H)+,
APCI (Pos., 40 V)





336, 162.


23(H23-13)
E
3.69
520 (M + H)+,
APCI (Pos., 40 V)





185.


23(H23-14)
E
4.16
532 (M + H)+.
APCI (Pos., 40 V)


23(H23-15)
E
4.16
518 (M + H)+.
APCI (Pos., 40 V)


23(H23-16)
E
3.89
482 (M + H)+,
APCI (Pos., 40 V)





442, 376, 336.


23(H23-17)
E
4.21
516 (M + H)+.
APCI (Pos., 40 V)


23(H23-18)
E
3.48
492 (M + H)+,
APCI (Pos., 40 V)





336, 189, 157.























TABLE 24C-1







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















23(H24-1)
F
3.07
416 (M + H)+.
ESI (Pos., 20 V)


23(H24-2)
F
3.11
452 (M + H)+.
ESI (Pos., 20 V)


23(H24-3)
F
3.04
362 (M + H)+.
ESI (Pos., 20 V)


23(H24-4)
F
3.16
442 (M + H)+.
ESI (Pos., 20 V)


23(H24-5)
F
3.07
378 (M + H)+.
ESI (Pos., 20 V)


23(H24-6)
F
3.12
376 (M + H)+.
ESI (Pos., 20 V)


23(H24-7)
F
2.74
359 (M + H)+.
ESI (Pos., 20 V)


23(H24-8)
F
3.18
411 (M + H)+.
ESI (Pos., 20 V)


23(H24-9)
F
2.76
362 (M + H)+.
ESI (Pos., 20 V)


23(H24-10)
F
2.76
392 (M + H)+.
ESI (Pos., 20 V)


23(H24-11)
F
3.35
458 (M + H)+.
ESI (Pos., 20 V)


23(H24-12)
F
3.38
458 (M + H)+.
ESI (Pos., 20 V)


23(H24-13)
F
3.12
397 (M + H)+.
ESI (Pos., 20 V)


23(H24-14)
F
2.87
378 (M + H)+.
ESI (Pos., 20 V)


23(H24-15)
F
2.92
408 (M + H)+.
ESI (Pos., 20 V)


23(H24-16)
F
2.89
392 (M + H)+.
ESI (Pos., 20 V)


23(H24-17)
F
3.18
392 (M + H)+.
ESI (Pos., 20 V)


23(H24-18)
F
3.01
412 (M + H)+.
ESI (Pos., 20 V)


23(H24-19)
F
3.44
508 (M + H)+.
ESI (Pos., 20 V)


23(H24-20)
F
3.11
455 (M + H)+.
ESI (Pos., 20 V)


23(H24-21)
F
3.53
560 (M + H)+.
ESI (Pos., 20 V)


23(H24-22)
F
3.12
442 (M + H)+.
ESI (Pos., 20 V)


23(H24-23)
F
3.49
526 (M + H)+.
ESI (Pos., 20 V)


23(H24-24)
F
3.42
492 (M + H)+.
ESI (Pos., 20 V)


23(H24-25)
F
3.16
439 (M + H)+.
ESI (Pos., 20 V)


23(H24-26)
F
3.57
560 (M + H)+.
ESI (Pos., 20 V)























TABLE 24C-2







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















23(H24-27)
F
3.18
472 (M + H)+.
ESI (Pos., 20 V)


23(H24-28)
F
3.33
470 (M + H)+.
ESI (Pos., 20 V)


23(H24-29)
F
3.38
492 (M + H)+.
ESI (Pos., 20 V)


23(H24-30)
F
3.16
495 (M + H)+.
ESI (Pos., 20 V)


23(H24-31)
F
3.38
458 (M + H)+.
ESI (Pos., 20 V)























TABLE 25C-1







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















230H25-1)
F
3.16
430 (M + H)+.
ESI (Pos., 20 V)


23(H25-2)
F
3.18
466 (M + H)+.
ESI (Pos., 20 V)


23(H25-3)
F
3.11
376 (M + H)+.
ESI (Pos., 20 V)


23(H25-4)
F
3.23
456 (M + H)+.
ESI (Pos., 20 V)


23(H25-5)
F
3.16
392 (M + H)+.
ESI (Pos., 20 V)


23(H25-6)
F
3.20
390 (M + H)+.
ESI (Pos., 20 V)


23(H25-7)
F
3.28
425 (M + H)+.
ESI (Pos., 20 V)


23(H25-8)
F
2.85
376 (M + H)+.
ESI (Pos., 20 V)


23(H25-9)
F
2.89
406 (M + H)+.
ESI (Pos., 20 V)


23(H25-10)
F
3.44
472 (M + H)+.
ESI (Pos., 20 V)


23(H25-11)
F
3.18
411 (M + H)+.
ESI (Pos., 20 V)


23(H25-12)
F
3.45
392 (M + H)+.
ESI (Pos., 20 V)


23(H25-13)
F
2.96
406 (M + H)+.
ESI (Pos., 20 V)


23(H25-14)
F
3.27
406 (M + H)+.
ESI (Pos., 20 V)


23(H25-15)
F
3.09
426 (M + H)+.
ESI (Pos., 20 V)


23(H25-16)
F
3.53
522 (M + H)+.
ESI (Pos., 20 V)


23(H25-17)
F
3.18
469 (M + H)+.
ESI (Pos., 20 V)


23(H25-18)
F
3.60
574 (M + H)+.
ESI (Pos., 20 V)


23(H25-19)
F
3.22
456 (M + H)+.
ESI (Pos., 20 V)


23(H25-20)
F
3.55
540 (M + H)+.
ESI (Pos., 20 V)


23(H25-21)
F
3.49
506 (M + H)+.
ESI (Pos., 20 V)


23(H25-22)
F
3.25
453 (M + H)+.
ESI (Pos., 20 V)


23(H25-23)
F
3.64
574 (M + H)+.
ESI (Pos., 20 V)


23(H25-24)
F
3.25
486 (M + H)+.
ESI (Pos., 20 V)


23(H25-25)
F
3.42
484 (M + H)+.
ESI (Pos., 20 V)


23(H25-26)
F
3.47
506 (M + H)+.
ESI (Pos., 20 V)























TABLE 25C-2







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















23(H25-27)
F
3.24
509 (M + H)+.
ESI (Pos., 20 V)


23(H25-28)
F
3.47
472 (M + H)+.
ESI (Pos., 20 V)























TABLE 26C-1







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















23(H26-1)
F
3.25
444 (M + H)+.
ESI (Pos., 20 V)


23(H26-2)
F
3.26
480 (M + H)+.
ESI (Pos., 20 V)


23(H26-3)
F
3.22
390 (M + H)+.
ESI (Pos., 20 V)


23(H26-4)
F
3.33
470 (M + H)+.
ESI (Pos., 20 V)


23(H26-5)
F
3.23
406 (M + H)+.
ESI (Pos., 20 V)


23(H26-6)
F
3.29
404 (M + H)+.
ESI (Pos., 20 V)


23(H26-7)
F
2.93
387 (M + H)+.
ESI (Pos., 20 V)


23(H26-8)
F
3.34
439 (M + H)+.
ESI (Pos., 20 V)


23(H26-9)
F
2.93
390 (M + H)+.
ESI (Pos., 20 V)


23(H26-10)
F
2.97
420 (M + H)+.
ESI (Pos., 20 V)


23(H26-11)
F
3.50
486 (M + H)+.
ESI (Pos., 20 V)


23(H26-12)
F
3.52
486 (M + H)+.
ESI (Pos., 20 V)


23(H26-13)
F
3.28
425 (M + H)+.
ESI (Pos., 20 V)


23(H26-14)
F
3.04
406 (M + H)+.
ESI (Pos., 20 V)


23(H26-15)
F
3.11
436 (M + H)+.
ESI (Pos., 20 V)


23(H26-16)
F
3.04
420 (M + H)+.
ESI (Pos., 20 V)


23(H26-17)
F
3.35
420 (M + H)+.
ESI (Pos., 20 V)


23(H26-18)
F
3.20
440 (M + H)+.
ESI (Pos., 20 V)


23(H26-19)
F
3.58
536 (M + H)+.
ESI (Pos., 20 V)


23(H26-20)
F
3.25
483 (M + H)+.
ESI (Pos., 20 V)


23(H26-21)
F
3.68
588 (M + H)+.
ESI (Pos., 20 V)


23(H26-22)
F
3.30
472 (M + H)+.
ESI (Pos., 20 V)


23(H26-23)
F
3.62
554 (M + H)+.
ESI (Pos., 20 V)


23(H26-24)
F
3.57
520 (M + H)+.
ESI (Pos., 20 V)


23(H26-25)
F
3.33
467 (M + H)+.
ESI (Pos., 20 V)


23(H26-26)
F
3.71
588 (M + H)+.
ESI (Pos., 20 V)























TABLE 26C-2







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















23(H26-27)
F
3.33
500 (M + H)+.
ESI (Pos., 20 V)


23(H26-28)
F
3.49
498 (M + H)+.
ESI (Pos., 20 V)


23(H26-29)
F
3.52
520 (M + H)+.
ESI (Pos., 20 V)


23(H26-30)
F
3.32
523 (M + H)+.
ESI (Pos., 20 V)


23(H26-31)
F
3.55
486 (M + H)+.
ESI (Pos., 20 V)























TABLE 27C-1







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















23(H27-1)
F
3.31
420 (M + H)+.
ESI (Pos., 20 V)


23(H27-2)
F
3.33
450 (M + H)+.
ESI (Pos., 20 V)


23(H27-3)
F
3.31
478 (M + H)+.
ESI (Pos., 20 V)


23(H27-4)
F
3.55
512 (M + H)+.
ESI (Pos., 20 V)


23(H27-5)
F
3.58
526 (M + H)+.
ESI (Pos., 20 V)


23(H27-6)
F
3.33
514 (M + H)+.
ESI (Pos., 20 V)


23(H27-7)
F
3.16
486 (M + H)+.
ESI (Pos., 20 V)


23(H27-8)
F
3.18
436 (M + H)+.
ESI (Pos., 20 V)


23(H27-9)
F
3.31
450 (M + H)+.
ESI (Pos., 20 V)


23(H27-10)
F
3.33
480 (M + H)+.
ESI (Pos., 20 V)


23(H27-11)
F
3.33
508 (M + H)+.
ESI (Pos., 20 V)


23(H27-12)
F
3.58
542 (M + H)+.
ESI (Pos., 20 V)


23(H27-13)
F
3.60
556 (M + H)+.
ESI (Pos., 20 V)


23(H27-14)
F
3.34
544 (M + H)+.
ESI (Pos., 20 V)


23(H27-15)
F
3.18
516 (M + H)+.
ESI (Pos., 20 V)


23(H27-16)
F
3.22
466 (M + H)+.
ESI (Pos., 20 V)


23(H27-17)
F
3.29
450 (M + H)+.
ESI (Pos., 20 V)


23(H27-18)
F
3.33
480 (M + H)+.
ESI (Pos., 20 V)


23(H27-19)
F
3.56
542 (M + H)+.
ESI (Pos., 20 V)


23(H27-20)
F
3.58
556 (M + H)+.
ESI (Pos., 20 V)


23(H27-21)
F
3.33
544 (M + H)+.
ESI (Pos., 20 V)


23(H27-22)
F
3.18
516 (M + H)+.
ESI (Pos., 20 V)


23(H27-23)
F
3.20
466 (M + H)+.
ESI (Pos., 20 V)


23(H27-24)
F
3.29
450 (M + H)+.
ESI (Pos., 20 V)


23(H27-25)
F
3.31
508 (M + H)+.
ESI (Pos., 20 V)


23(H27-26)
F
3.55
542 (M + H)+.
ESI (Pos., 20 V)























TABLE 27C-2







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















23(H27-27)
F
3.56
556 (M + H)+.
ESI (Pos., 20 V)


23(H27-28)
F
3.33
544 (M + H)+.
ESI (Pos., 20 V)


23(H27-29)
F
3.17
516 (M + H)+.
ESI (Pos., 20 V)


23(H27-30)
F
3.20
466 (M + H)+.
ESI (Pos., 20 V)


23(H27-31)
F
2.92
421 (M + H)+.
ESI (Pos., 20 V)


23(H27-32)
F
2.97
451 (M + H)+.
ESI (Pos., 20 V)


23(H27-33)
F
2.96
479 (M + H)+.
ESI (Pos., 20 V)


23(H27-34)
F
3.22
513 (M + H)+.
ESI (Pos., 20 V)


23(H27-35)
F
3.25
527 (M + H)+.
ESI (Pos., 20 V)


23(H27-36)
F
3.00
515 (M + H)+.
ESI (Pos., 20 V)


23(H27-37)
F
2.87
487 (M + H)+.
ESI (Pos., 20 V)


23(H27-38)
F
2.83
437 (M + H)+.
ESI (Pos., 20 V)


23(H27-39)
F
2.90
421 (M + H)+.
ESI (Pos., 20 V)


23(H27-40)
F
2.94
451 (M + H)+.
ESI (Pos., 20 V)


23(H27-41)
F
2.92
479 (M + H)+.
ESI (Pos., 20 V)


23(H27-42)
F
3.16
513 (M + H)+.
ESI (Pos., 20 V)


23(H27-43)
F
3.20
527 (M + H)+.
ESI (Pos., 20 V)


23(H27-44)
F
2.98
515 (M + H)+.
ESI (Pos., 20 V)


23(H27-45)
F
2.85
487 (M + H)+.
ESI (Pos., 20 V)


23(H27-46)
F
2.81
437 (M + H)+.
ESI (Pos., 20 V)


23(H27-47)
F
2.89
421 (M + H)+.
ESI (Pos., 20 V)


23(H27-48)
F
2.94
451 (M + H)+.
ESI (Pos., 20 V)


23(H27-49)
F
2.92
479 (M + H)+.
ESI (Pos., 20 V)


23(H27-50)
F
3.16
513 (M + H)+.
ESI (Pos., 20 V)


23(H27-51)
F
3.18
527 (M + H)+.
ESI (Pos., 20 V)


23(H27-52)
F
2.98
515 (M + H)+.
ESI (Pos., 20 V)























TABLE 27C-3







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















23(H27-53)
F
2.83
487 (M + H)+.
ESI (Pos., 20 V)


23(H27-54)
F
2.81
437 (M + H)+.
ESI (Pos., 20 V)


23(H27-55)
F
3.33
434 (M + H)+.
ESI (Pos., 20 V)


23(H27-56)
F
3.36
464 (M + H)+.
ESI (Pos., 20 V)


23(H27-57)
F
3.34
492 (M + H)+.
ESI (Pos., 20 V)


23(H27-58)
F
3.60
526 (M + H)+.
ESI (Pos., 20 V)


23(H27-59)
F
3.62
540 (M + H)+.
ESI (Pos., 20 V)


23(H27-60)
F
3.36
528 (M + H)+.
ESI (Pos., 20 V)


23(H27-61)
F
3.20
500 (M + H)+.
ESI (Pos., 20 V)


23(H27-62)
F
3.23
450 (M + H)+.
ESI (Pos., 20 V)


23(H27-63)
F
3.36
434 (M + H)+.
ESI (Pos., 20 V)


23(H27-64)
F
3.38
464 (M + H)+.
ESI (Pos., 20 V)


23(H27-65)
F
3.36
492 (M + H)+.
ESI (Pos., 20 V)


23(H27-66)
F
3.62
526 (M + H)+.
ESI (Pos., 20 V)


23(H27-67)
F
3.62
540 (M + H)+.
ESI (Pos., 20 V)


23(H27-68)
F
3.38
528 (M + H)+.
ESI (Pos., 20 V)


23(H27-69)
F
3.23
500 (M + H)+.
ESI (Pos., 20 V)


23(H27-70)
F
3.25
450 (M + H)+.
ESI (Pos., 20 V)


23(H27-71)
F
3.36
434 (M + H)+.
ESI (Pos., 20 V)


23(H27-72)
F
3.38
464 (M + H)+.
ESI (Pos., 20 V)


23(H27-73)
F
3.36
492 (M + H)+.
ESI (Pos., 20 V)


23(H27-74)
F
3.62
526 (M + H)+.
ESI (Pos., 20 V)


23(H27-75)
F
3.62
540 (M + H)+.
ESI (Pos., 20 V)


23(H27-76)
F
3.36
528 (M + H)+.
ESI (Pos., 20 V)


23(H27-77)
F
3.22
500 (M + H)+.
ESI (Pos., 20 V)


23(H27-78)
F
3.23
450 (M + H)+.
ESI (Pos., 20 V)























TABLE 28C-1







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















23(H28-1)
F
3.36
470 (M + H)+.
ESI (Pos., 20 V)


23(H28-2)
F
3.37
506 (M + H)+.
ESI (Pos., 20 V)


23(H28-3)
F
3.31
416 (M + H)+.
ESI (Pos., 20 V)


23(H28-4)
F
3.42
498 (M + H)+.
ESI (Pos., 20 V)


23(H28-5)
F
3.35
432 (M + H)+.
ESI (Pos., 20 V)


23(H28-6)
F
3.41
430 (M + H)+.
ESI (Pos., 20 V)


23(H28-7)
F
3.04
413 (M + H)+.
ESI (Pos., 20 V)


23(H28-8)
F
3.45
465 (M + H)+.
ESI (Pos., 20 V)


23(H28-9)
F
3.03
416 (M + H)+.
ESI (Pos., 20 V)


23(H28-10)
F
3.77
446 (M + H)+.
ESI (Pos., 20 V)


23(H28-11)
F
3.61
512 (M + H)+.
ESI (Pos., 20 V)


23(H28-12)
F
3.61
512 (M + H)+.
ESI (Pos., 20 V)


23(H28-13)
F
3.15
432 (M + H)+.
ESI (Pos., 20 V)


23(H28-14)
F
3.22
462 (M + H)+.
ESI (Pos., 20 V)


23(H28-15)
F
3.16
446 (M + H)+.
ESI (Pos., 20 V)


23(H28-16)
F
3.46
446 (M + H)+.
ESI (Pos., 20 V)


23(H28-17)
F
3.29
466 (M + H)+.
ESI (Pos., 20 V)


23(H28-18)
F
3.68
562 (M + H)+.
ESI (Pos., 20 V)


23(H28-19)
F
3.36
509 (M + H)+.
ESI (Pos., 20 V)


23(H28-20)
F
3.76
614 (M + H)+.
ESI (Pos., 20 V)


23(H28-21)
F
3.42
498 (M + H)+.
ESI (Pos., 20 V)


23(H28-22)
F
3.71
580 (M + H)+.
ESI (Pos., 20 V)


23(H28-23)
F
3.66
546 (M + H)+.
ESI (Pos., 20 V)


23(H28-24)
F
3.44
493 (M + H)+.
ESI (Pos., 20 V)


23(H28-25)
F
3.79
614 (M + H)+.
ESI (Pos., 20 V)


23(H28-26)
F
3.42
526 (M + H)+.
ESI (Pos., 20 V)























TABLE 28C-2







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















23(H28-27)
F
3.58
524 (M + H)+.
ESI (Pos., 20 V)


23(H28-28)
F
3.62
546 (M + H)+.
ESI (Pos., 20 V)


23(H28-29)
F
3.42
549 (M + H)+.
ESI (Pos., 20 V)


23(H28-30)
F
3.62
512 (M + H)+.
ESI (Pos., 20 V)























TABLE 29C-1







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















23(H29-1)
F
3.44
484 (M + H)+.
ESI (Pos., 20 V)


23(H29-2)
F
3.44
520 (M + H)+.
ESI (Pos., 20 V)


23(H29-3)
F
3.42
430 (M + H)+.
ESI (Pos., 20 V)


23(H29-4)
F
3.53
512 (M + H)+.
ESI (Pos., 20 V)


23(H29-5)
F
3.44
446 (M + H)+.
ESI (Pos., 20 V)


23(H29-6)
F
3.49
444 (M + H)+.
ESI (Pos., 20 V)


23(H29-7)
F
3.09
427 (M + H)+.
ESI (Pos., 20 V)


23(H29-8)
F
3.53
479 (M + H)+.
ESI (Pos., 20 V)


23(H29-9)
F
3.11
430 (M + H)+.
ESI (Pos., 20 V)


23(H29-10)
F
3.14
460 (M + H)+.
ESI (Pos., 20 V)


23(H29-11)
F
3.67
526 (M + H)+.
ESI (Pos., 20 V)


23(H29-12)
F
3.69
526 (M + H)+.
ESI (Pos., 20 V)


23(H29-13)
F
3.47
465 (M + H)+.
ESI (Pos., 20 V)


23(H29-14)
F
3.23
446 (M + H)+.
ESI (Pos., 20 V)


23(H29-15)
F
3.29
476 (M + H)+.
ESI (Pos., 20 V)


23(H29-16)
F
3.24
460 (M + H)+.
ESI (Pos., 20 V)


23(H29-17)
F
3.55
460 (M + H)+.
ESI (Pos., 20 V)


23(H29-18)
F
3.35
480 (M + H)+.
ESI (Pos., 20 V)


23(H29-19)
F
3.73
576 (M + H)+.
ESI (Pos., 20 V)


23(H29-20)
F
3.44
523 (M + H)+.
ESI (Pos., 20 V)


23(H29-21)
F
3.83
628 (M + H)+.
ESI (Pos., 20 V)


23(H29-22)
F
3.49
510 (M + H)+.
ESI (Pos., 20 V)


23(H29-23)
F
3.77
594 (M + H)+.
ESI (Pos., 20 V)


23(H29-24)
F
3.72
560 (M + H)+.
ESI (Pos., 20 V)


23(H29-25)
F
3.52
507 (M + H)+.
ESI (Pos., 20 V)


23(H29-26)
F
3.85
628 (M + H)+.
ESI (Pos., 20 V)























TABLE 29C-2







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















23(H29-27)
F
3.51
540 (M + H)+.
ESI (Pos., 20 V)


23(H29-28)
F
3.66
538 (M + H)+.
ESI (Pos., 20 V)


23(H29-29)
F
3.69
560 (M + H)+.
ESI (Pos., 20 V)


23(H29-30)
F
3.47
563 (M + H)+.
ESI (Pos., 20 V)


23(H29-31)
F
3.68
526 (M + H)+.
ESI (Pos., 20 V)























TABLE 30C-1







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















23(H30-1)
F
3.27
486 (M + H)+.
ESI (Pos., 20 V)


23(H30-2)
F
3.31
522 (M + H)+.
ESI (Pos., 20 V)


23(H30-3)
F
3.24
432 (M + H)+.
ESI (Pos., 20 V)


23(H30-4)
F
3.34
512 (M + H)+.
ESI (Pos., 20 V)


23(H30-5)
F
3.29
448 (M + H)+.
ESI (Pos., 20 V)


23(H30-6)
F
3.33
446 (M + H)+.
ESI (Pos., 20 V)


23(H30-7)
F
2.98
429 (M + H)+.
ESI (Pos., 20 V)


23(H30-8)
F
3.38
481 (M + H)+.
ESI (Pos., 20 V)


23(H30-9)
F
2.98
432 (M + H)+.
ESI (Pos., 20 V)


23(H30-10)
F
3.01
462 (M + H)+.
ESI (Pos., 20 V)


23(H30-11)
F
3.51
528 (M + H)+.
ESI (Pos., 20 V)


23(H30-12)
F
3.55
528 (M + H)+.
ESI (Pos., 20 V)


23(H30-13)
F
3.33
467 (M + H)+.
ESI (Pos., 20 V)


23(H30-14)
F
3.09
448 (M + H)+.
ESI (Pos., 20 V)


23(H30-15)
F
3.16
478 (M + H)+.
ESI (Pos., 20 V)


23(H30-16)
F
3.09
462 (M + H)+.
ESI (Pos., 20 V)


23(H30-17)
F
3.36
462 (M + H)+.
ESI (Pos., 20 V)


23(H30-18)
F
3.22
482 (M + H)+.
ESI (Pos., 20 V)


23(H30-19)
F
3.60
578 (M + H)+.
ESI (Pos., 20 V)


23(H30-20)
F
3.31
525 (M + H)+.
ESI (Pos., 20 V)


23(H30-21)
F
3.69
630 (M + H)+.
ESI (Pos., 20 V)


23(H30-22)
F
3.33
512 (M + H)+.
ESI (Pos., 20 V)


23(H30-23)
F
3.64
596 (M + H)+.
ESI (Pos., 20 V)


23(H30-24)
F
3.59
562 (M + H)+.
ESI (Pos., 20 V)


23(H30-25)
F
3.34
509 (M + H)+.
ESI (Pos., 20 V)


23(H30-26)
F
3.71
630 (M + H)+.
ESI (Pos., 20 V)























TABLE 30C-2







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















23(H30-27)
F
3.34
542 (M + H)+.
ESI (Pos., 20 V)


23(H30-28)
F
3.51
540 (M + H)+.
ESI (Pos., 20 V)


23(H30-29)
F
3.53
562 (M + H)+.
ESI (Pos., 20 V)


23(H30-30)
F
3.34
565 (M + H)+.
ESI (Pos., 20 V)


23(H30-31)
F
3.55
528 (M + H)+.
ESI (Pos., 20 V)























TABLE 31C-1







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















23(H31-1)
F
3.47
518 (M + H)+.
ESI (Pos., 20 V)


23(H31-2)
F
3.47
554 (M + H)+.
ESI (Pos., 20 V)


23(H31-3)
F
3.45
464 (M + H)+.
ESI (Pos., 20 V)


23(H31-4)
F
3.55
544 (M + H)+.
ESI (Pos., 20 V)


23(H31-5)
F
3.47
480 (M + H)+.
ESI (Pos., 20 V)


23(H31-6)
F
3.53
478 (M + H)+.
ESI (Pos., 20 V)


23(H31-7)
F
3.14
461 (M + H)+.
ESI (Pos., 20 V)


23(H31-8)
F
3.56
513 (M + H)+.
ESI (Pos., 20 V)


23(H31-9)
F
3.14
464 (M + H)+.
ESI (Pos., 20 V)


23(H31-10)
F
3.20
494 (M + H)+.
ESI (Pos., 20 V)


23(H31-11)
F
3.69
560 (M + H)+.
ESI (Pos., 20 V)


23(H31-12)
F
3.71
560 (M + H)+.
ESI (Pos., 20 V)


23(H31-13)
F
3.51
499 (M + H)+.
ESI (Pos., 20 V)


23(H31-14)
F
3.27
480 (M + H)+.
ESI (Pos., 20 V)


23(H31-15)
F
3.33
510 (M + H)+.
ESI (Pos., 20 V)


23(H31-16)
F
3.29
494 (M + H)+.
ESI (Pos., 20 V)


23(H31-17)
F
3.58
494 (M + H)+.
ESI (Pos., 20 V)


23(H31-18)
F
3.40
514 (M + H)+.
ESI (Pos., 20 V)


23(H31-19)
F
3.75
610 (M + H)+.
ESI (Pos., 20 V)


23(H31-20)
F
3.49
557 (M + H)+.
ESI (Pos., 20 V)


23(H31-21)
F
3.86
662 (M + H)+.
ESI (Pos., 20 V)


23(H31-22)
F
3.53
544 (M + H)+.
ESI (Pos., 20 V)


23(H31-23)
F
3.80
628 (M + H)+.
ESI (Pos., 20 V)


23(H31-24)
F
3.75
594 (M + H)+.
ESI (Pos., 20 V)


23(H31-25)
F
3.57
541 (M + H)+.
ESI (Pos., 20 V)


23(H31-26)
F
3.86
662 (M + H)+.
ESI (Pos., 20 V)























TABLE 31C-2







Retention




Example
HPLC
time


No
condition
(min)
Mass data
Mass condition



















23(H31-27)
F
3.53
574 (M + H)+.
ESI (Pos., 20 V)


23(H31-28)
F
3.67
572 (M + H)+.
ESI (Pos., 20 V)


23(H31-29)
F
3.71
594 (M + H)+.
ESI (Pos., 20 V)


23(H31-30)
F
3.51
597 (M + H)+.
ESI (Pos., 20 V)


23(H31-31)
F
3.73
560 (M + H)+.
ESI (Pos., 20 V)









EXAMPLE 24(1)˜24(119)

By the same procedure as described in Reference Example 3→Reference Example 4 using Resin (3) prepared in Reference Example 2 and N-allyloxycarbonyl-4-piperidone, using the corresponding compounds respectively instead of n-propylamine and N-(t-butyloxycarbonyl) leucine, and furthermore by the same procedure as described in Reference Example 5→Reference Example 6→Example 1 using the corresponding compound instead of 3,5-dimethyl-1-phenyl-4-formylpyrazole, the following compounds of the present invention were obtained.


EXAMPLE 24(1)
(3S)-1-butyl-2,5-dioxo-3-(4-methoxyphenylmethyl)-9-cyclohexyl methyl-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.44 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.06 (d, J=9.0 Hz, 2H), 6.84 (d, J=9.0 Hz, 2H), 4.31 (dd, J=4.5, 3.6 Hz, 1H), 3.82–3.67 (m, 4H), 3.49–3.30 (m, 3H), 3.25 (dd, J=13.8, 3.6 Hz, 1H), 3.23–3.10 (m, 2H), 2.95–2.87 (m, 2H), 2.87 (dd, J=13.8, 4.5 Hz, 1H), 2.31 (m, 1H), 2.05 (m, 1H), 1.91–1.64 (m, 7H), 1.56–1.14 (m, 7H), 1.09–0.91 (m, 5H), 0.26 (m, 1H).


EXAMPLE 24(2)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-(4-chlorophenyl)thiophen-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.60 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.65 (d, J=8.7 Hz, 2H), 7.42 (d, J=8.7 Hz, 2H), 7.42 (d, J=3.6 Hz, 1H), 7.34 (d, J=3.6 Hz, 1H), 4.61 (brs, 2H), 4.01 (dd, J=7.8, 4.5 Hz, 1H), 3.95–3.72 (m, 2H), 3.65–3.50 (m, 2H), 3.44–3.34 (m, 2H), 2.50–2.12 (m, 4H), 1.89–1.45 (m, 5H), 1.45–1.28 (m, 2H), 1.13–0.89 (m, 9H).


EXAMPLE 24(3)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-(4-methoxyphenyl)thiophen-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.60 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.57 (d, J=9.0 Hz, 2H), 7.33-7.26 (m, 2H), 6.97 (d, J=9.0 Hz, 2H), 4.58 (brs, 2H), 4.01 (dd, J=7.5, 4.5 Hz, 1H), 3.93-3.71 (m, 5H), 3.64–3.50 (m, 2H), 3.44–3.34 (m, 2H), 2.49–2.12 (m, 4H), 1.90–1.45 (m, 5H), 1.45–1.28 (m, 2H), 1.03–0.88 (m, 9H).


EXAMPLE 24(4)
1-((2E)-2-butenyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.32 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.52 (d, J=8.7 Hz, 2H), 7.44–7.35 (m, 2H), 7.22–7.14 (m, 1H), 7.06 (d, J=8.7 Hz, 2H), 7.10–7.00 (m, 2H), 5.75–5.60 (m, 1H), 5.52–5.38 (m, 1H), 4.33 (s, 2H), 4.15–3.93 (m, 2H), 4.03 (dd, J=7.8, 4.5 Hz, 1H), 3.88–3.66 (m, 2H), 3.55–3.42 (m, 2H), 2.52–2.35 (m, 2H), 2.28–2.08 (m, 2H), 1.90–1.57 (m, 3H), 1.65 (dd, J=6.3, 1.5 Hz, 3H), 0.95 (d, J=6.6 Hz, 3H), 0.94 (d, J=6.6 Hz, 3H).


EXAMPLE 24(5)
1-(furan-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.33 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.52 (d, J=8.7 Hz, 2H), 7.43–7.36 (m, 3H), 7.18 (t, J=7.2 Hz, 1H), 7.09–6.99 (m, 4H), 6.33 (m, 1H), 6.28 (d, J=3.0 Hz, 1H), 4.69 (s, 2H), 4.33 (s, 2H), 4.08 (dd, J=7.8, 4.5 Hz, 1H), 3.87–3.72 (m, 2H), 3.57–3.42 (m, 2H), 2.65–2.38 (m, 2H), 2.30–2.12 (m, 2H), 1.90–1.56 (m, 3H), 0.93 (d, J=6.6 Hz, 3H), 0.91 (d, J=6.6 Hz, 3H).


EXAMPLE 24(6)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.39 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.53 (d, J=8.7 Hz, 2H), 7.43–7.34 (m, 2H), 7.27 (dd, J=5.1, 1.2 Hz, 1H), 7.18 (t, J=7.2 Hz, 1H), 7.09–7.00 (m, 5H), 6.91 (dd, J=5.1, 3.3 Hz, 1H), 4.92 (brs, 2H), 4.32 (s, 2H), 4.11 (dd, J=7.8, 4.5 Hz, 1H), 3.84–3.66 (m, 2H), 3.53–3.41 (m, 2H), 2.68–2.46 (m, 2H), 2.23–2.06 (m, 2H), 1.95–1.59 (m, 3H), 0.95 (d, J=6.6 Hz, 6H).


EXAMPLE 24(7)
1-cyclopropylmethyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.40 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.53 (d, J=8.7 Hz, 2H), 7.43–7.35 (m, 2H), 7.18 (t, J=7.2 Hz, 1H), 7.08–7.00 (m, 4H), 4.33 (s, 2H), 4.04 (dd, J=7.8, 4.5 Hz, 1H), 3.87–3.68 (m, 2H), 3.56–3.43 (m, 2H), 3.46–3.35 (m 2H), 2.56–2.35 (m, 2H), 2.23–2.12 (m, 2H), 1.95–1.58 (m, 3H), 1.10–0.95 (m, 1H), 0.95 (d, J=6.6 Hz, 6H), 0.56–0.45 (m, 2H), 0.42–0.34 (m, 2H).


EXAMPLE 24(8)
1-(2-fluorophenylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.43 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.48 (d, J=9.0 Hz, 2H), 7.42–7.34 (m, 2H), 7.32–7.21 (m, 1H), 7.17 (t, J=7.5 Hz, 1H), 7.14–7.06 (m, 3H), 7.06–6.98 (m, 4H), 4.80 (brs, 2H), 4.30 (s, 2H), 4.18 (dd, J=8.1, 4.8 Hz, 1H), 3.86–3.68 (m, 2H), 3.50–3.35 (m, 2H), 2.50–2.30 (m, 1H), 2.30–2.14 (m, 3H), 1.94–1.62 (m, 3H), 0.97 (d, J=6.3 Hz, 6H).


EXAMPLE 24(9)
1-(3-methyl-2-butenyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.29 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.52 (d, J=8.4 Hz, 2H), 7.43–7.35 (m, 2H), 7.18 (t, J=7.5 Hz, 1H), 7.09–7.00 (m, 4H), 4.97 (br, 1H), 4.32 (s, 2H), 4.20–4.00 (m, 2H), 4.02 (dd, J=7.8, 4.5 Hz, 1H), 3.90–3.68 (m, 2H), 3.55–3.45 (m, 2H), 2.52–2.32 (m, 2H), 2.30–2.08 (m, 2H), 1.90–1.56 (m, 3H), 1.74 (s, 3H), 1.69 (s, 3H), 0.94 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H).


EXAMPLE 24(10)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(quinolin-3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.25 (chloroform:methanol=20:1);


NMR (CD3OD): δ 9.52 (d, J=1.5 Hz, 1H), 9.35 (d, J=1.5 Hz, 1H), 8.35 (d, J=8.7 Hz, 1H), 8.27 (d, J=8.7 Hz, 1H), 8.24–8.16 (m, 1H), 8.04–7.96 (m, 1H), 4.76 (s, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 4.00–3.85 (m, 2H), 3.68–3.55 (m, 2H), 3.55–3.43 (m, 2H), 2.76–2.56 (m, 2H), 2.27–2.05 (m, 2H), 1.82–1.10 (m, 15H), 1.05–0.83 (m, 2H), 0.92 (t, J=7.2 Hz, 3H).


EXAMPLE 24(11)
1-butyl-2,5-dioxo-3-(benzyloxycarbonylmethyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.74 (chloroform:methanol=9:1);


NMR (CD3OD): δ 7.52 (d, J=7.0 Hz, 2H), 7.40 (t, J=7.5 Hz, 2H), 7.33 (m, 5H), 7.18 (t, J=7.5 Hz, 1H), 7.05 (m, 4H), 5.12 (s, 2H), 4.33 (s, 2H), 4.31 (m, 1H), 3.88 (m, 1H), 3.66 (m, 1H), 3.50–3.35 (m, 4H), 3.08 (dd, J=17.7, 4.8 Hz, 1H), 2.86 (dd, J=17.7, 3.0 Hz, 1H), 2.34 (m, 2H), 2.25 (m, 2H), 1.50 (m, 2H), 1.36 (m, 2H), 0.94 (t, J=7.5 Hz, 3H).


EXAMPLE 24(12)
1-(3-methyl-2-butenyl)-2,5-dioxo-3-cyclohexylmethyl-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.63 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.04 (d, J=2.1 Hz, 1H), 6.96 (dd, J=8.1, 2.1 Hz, 1H), 6.92 (d, J=8.1 Hz, 1H), 4.96 (m, 1H), 4.26 (s, 4H), 4.22 (s, 2H), 4.10–4.00 (m, 3H), 3.84–3.68 (m, 2H), 3.52–3.40 (m, 2H), 2.43–2.08 (m, 4H), 1.84–1.42 (m, 13H), 1.38–1.12 (m, 4H), 1.04–0.85 (m, 2H).


EXAMPLE 24(13)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-((2E)-3-phenyl-2-propenyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.28 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.53–7.48 (m, 2H), 7.30–7.40 (m, 3H), 6.95 (d, J=16.2 Hz, 1H), 6.36 (dd, J=16.2, 8.1 Hz, 1H), 4.07 (dd, J=7.5, 4.5 Hz, 1H), 3.96 (d, J=8.1 Hz, 2H), 3.86–3.75 (m, 2H), 3.60–3.52 (m, 2H), 3.42–3.34 (m, 2H), 2.42–2.18 (m, 4H), 1.82–1.14 (m, 15H), 0.96 (t, J=7.2 Hz, 3H), 0.96 (m, 2H).


EXAMPLE 24(14)
(3S)-1-butyl-2,5-dioxo-3-(1,1-dimethylethyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.50 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.54 (d, J=8.5 Hz, 2H), 7.39 (m, 2H), 7.18 (t, J=7.5 Hz, 1H), 7.08–7.02 (m, 4H), 4.34 (s, 2H), 3.88 (m, 2H), 3.62 (s, 1H), 3.46 (m, 4H), 2.45 (m, 2H), 2.13 (m, 2H), 1.66–1.47 (m, 2H), 1.36 (m, 2H), 1.02 (s, 9H), 0.95 (t, J=7.0 Hz, 3H).


EXAMPLE 24(15)
(3S)-1-butyl-2,5-dioxo-3-(1,1-dimethylethyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.47 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.07 (m, 1H), 6.99 (d, J=8.0 Hz, 1H), 6.91 (d, J=8.0 Hz, 1H), 4.26 (m, 4H), 4.24 (s, 2H), 3.83 (m, 2H), 3.62 (s, 1H), 3.45 (m, 4H), 2.42 (m, 2H), 2.11 (m, 2H), 1.64–1.5 (m, 2H), 1.38 (m, 2H), 1.01 (s, 9H), 0.95 (t, J=7.0 Hz, 3H).


EXAMPLE 24(16)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-methylthiazol-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.67 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.34 (s, 1H), 4.73 (s, 2H), 4.01 (dd, J=8.0, 4.5 Hz, 1H), 3.93 (m, 2H), 3.65 (m, 2H), 3.41 (m, 2H), 2.53–2.41 (m, 2H), 2.48 (s, 3H), 2.23 (m, 2H), 1.85–1.52 (m, 5H), 1.38 (m, 2H), 0.96 (t, J=7.0 Hz, 3H), 0.94 (d, J=6.5 Hz, 3H), 0.93 (d, J=6.5 Hz, 3H).


EXAMPLE 24(17)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(5-methylthiazol-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.66 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.34 (s, 1H), 4.72 (s, 2H), 4.04 (dd, J=7.5, 4.5 Hz, 1H), 3.98–3.86 (m, 2H), 3.67–3.63 (m, 2H), 3.44–3.38 (m, 2H), 2.56–2.42 (m, 2H), 2.48 (s, 3H), 2.30–2.14 (m, 2H), 1.84–1.18 (m, 15H), 0.96 (t, J=7.2 Hz, 3H), 0.96 (m, 2H).


EXAMPLE 24(18)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-methylthiazol-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.63 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.63 (s, 1H), 4.69 (s, 2H), 4.03 (dd, J=7.3, 4.5 Hz, 1H), 3.96–3.82 (m, 2H), 3.72–3,58 (m, 2H), 3.42–3.37 (m, 2H), 2.52 (s, 3H), 2.56–2.36 (m, 2H), 2.28–2.12 (m, 2H), 1.80–1.12 (m, 15H), 0.96 (t, J=7.5 Hz, 3H), 0.96 (m, 2H).


EXAMPLE 24(19)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-methylthiazol-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.70 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.63 (s, 1H), 4.69 (brs, 2H), 4.01 (dd, J=7.8, 4.5 Hz, 1H), 3.99–3.83 (m, 2H), 3.70–3.58 (m, 2H), 3.44–3.34 (m, 2H), 2.53 (s, 3H), 2.50–2.33 (m, 2H), 2.32–2.12 (m, 2H), 1.88–1.46 (m, 5H), 1.45–1.31 (m, 2H), 1.01–0.90 (m, 9H).


EXAMPLE 24(20)
(3R)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.59 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.04 (d, J=2.0 Hz, 1H), 6.97 (dd, J=8.5, 2.0 Hz, 1H), 6.93 (d, J=8.5 Hz, 1H), 4.26 (s, 4H), 4.24 (s, 2H), 4.04 (dd, J=7.5, 5.0 Hz, 1H), 3.76 (m, 2H), 3.46 (m, 4H), 2.39–2.11 (m, 4H), 1.78–1.17 (m, 15H), 0.95 (t, J=7.0 Hz, 3H), 0.95 (m, 2H).


HPLC condition


Column: YMC CHIRAL-CD BR, 0.46×25 cm, YMC, DB12S05-2546WTI;


Flow rate: 0.5 mL/min;


Eluent


Component A: 0.1 M potassium dihydrogenphosphate aqueous solution


Component B: acetonitrile


A:B=84:16;


UV: 235 nm;


Retention time: 18 min.


EXAMPLE 24(21)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.59 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.04 (d, J=2.0 Hz, 1H), 6.97 (dd, J=8.5, 2.0 Hz, 1H), 6.93 (d, J=8.5 Hz, 1H), 4.26 (s, 4H), 4.24 (s, 2H), 4.04 (dd, J=7.5, 5.0 Hz, 1H), 3.76 (m, 2H), 3.46 (m, 4H), 2.39–2.11 (m, 4H), 1.78–1.17 (m, 15H), 0.95 (t, J=7.0 Hz, 3H), 0.95 (m, 2H).


HPLC condition


Column: YMC CHIRAL-CD BR, 0.46×25 cm, YMC, DB12S05-2546WTI;


Flow rate: 0.5 mL/min;


Eluent


Component A: 0.1 M potassium dihydrogenphosphate aqueous solution


Component B: acetonitrile


A: B=84:16;


UV: 235 nm;


Retention time: 20 min.


EXAMPLE 24(22)
(3R)-1-butyl-2,5-dioxo-3-((1R)-1-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.59 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.53 (d, J=8.5 Hz, 2H), 7.39 (m, 2H), 7.18 (t, J=7.5 Hz, 1H), 7.08–7.01 (m, 4H), 4.33 (s, 2H), 3.96 (d, J=2.5 Hz, 1H), 3.92 (m, 1H), 3.75 (m, 1H), 3.53–3.44 (m, 4H), 2.49–2.32 (m, 2H), 2.16 (m, 2H), 2.06–1.98 (m, 1H), 1.61–1.21 (m, 6H), 1.00–0.89 (m, 9H).


EXAMPLE 24(23)
(3S)-1-butyl-2,5-dioxo-3-((1S)-1-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.59 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.53 (d, J=8.5 Hz, 2H), 7.39 (m, 2H), 7.18 (t, J=7.5 Hz, 1H), 7.08–7.01 (m, 4H), 4.33 (s, 2H), 3.96 (d, J=2.5 Hz, 1H), 3.92 (m, 1H), 3.75 (m, 1H), 3.53–3.44 (m, 4H), 2.49–2.32 (m, 2H), 2.16 (m, 2H), 2.06–1.98 (m, 1H), 1.61–1.21 (m, 6H), 1.00–0.89 (m, 9H).


EXAMPLE 24(24)
1-(2-butynyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.70 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.51 (d, J=8.7 Hz, 2H), 7.39 (dd, J=8.7, 7.2 Hz, 2H), 7.18 (t, J=7.2 Hz, 1H), 7.09–7.00 (m, 4H), 4.33 (brs, 2H), 4.28–4.10 (m, 2H), 4.05 (dd, J=7.8, 4.5 Hz, 1H), 3.86–3.70 (m, 2H), 3.56–3.43 (m, 2H), 2.59–2.40 (m, 2H), 2.34–2.15 (m, 2H), 1.89–1.57 (m, 6H), 0.94 (d, J=6.6 Hz, 3H), 0.93 (d, J=6.6 Hz, 3H).


EXAMPLE 24(25)
1-(2-butynyl)-2,5-dioxo-3-cyclohexylmethyl-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.52 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.04 (d, J=2.1 Hz, 1H), 6.97 (dd, J=8.4, 2.1 Hz, 1H), 6.93 (d, J=8.4 Hz, 1H), 4.26 (s, 4H), 4.23 (s, 2H), 4.18 (brs, 2H), 4.07 (dd, J=6.9, 4.8 Hz, 1H), 3.84–3.68 (m, 2H), 3.55–3.42 (m, 2H), 2.57–2.40 (m, 2H), 2.32–2.12 (m, 2H), 1.85–1.42 (m, 11H), 1.38–1.13 (m, 3H), 1.04–0.85 (m, 2H).


EXAMPLE 24(26)
1-pentyl-2,5-dioxo-3-cyclohexylmethyl-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.61 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.04 (d, J=2.1 Hz, 1H), 6.97 (dd, J=8.4, 2.1 Hz, 1H), 6.92 (d, J=8.4 Hz, 1H), 4.26 (s, 4H), 4.22 (brs, 2H), 4.03 (dd, J=7.2, 4.5 Hz, 1H), 3.84–3.67 (m, 2H), 3.52–3.33 (m, 4H), 2.43–2.07 (m, 4H), 1.83–1.42 (m, 9H), 1.41–1.13 (m, 8H), 1.04–0.85 (m, 5H).


EXAMPLE 24(27)
1-(3-methoxyphenylmethyl)-2,5-dioxo-3-(benzyloxymethyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.45 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.60–7.43 (m, 5H), 7.38–7.24 (m, 5H), 7.14 (t, J=8.4 Hz, 1H), 6.83–6.72 (m, 3H), 4.96–4.70 (m, 2H), 4.60 (d, J=11.4 Hz, 1H), 4.50 (d, J=11.4 Hz, 1H), 4.29 (t, J=2.4 Hz, 1H), 4.24 (s, 2H), 4.02 (dd, J=9.6, 2.4 Hz, 1H), 3.93–3.79 (m, 1H), 3.72 (s, 3H), 3.70 (dd, J=9.6, 2.4 Hz, 1H), 3.70–3.60 (m, 1H), 3.55–3.44 (m, 1H), 3.35–3.23 (m, 1H), 2.58–2.05 (m, 10H).


EXAMPLE 24(28)
(3R)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.29 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.54 (d, J=8.7 Hz, 2H), 7.42–7.36 (m, 2H), 7.18 (m, 1H), 7.05 (d, J=8.7 Hz, 2H), 7.05–7.02 (m, 2H), 4.32 (s, 2H), 4.01 (dd, J=7.8, 4.8 Hz, 1H), 3.85–3.72 (m, 2H), 3.50–3.39 (m, 4H), 2.52–2.38 (m, 2H), 2.24–2.11 (m, 2H), 1.84–1.20 (m, 7H), 0.95 (t, J=7.2 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H), 0.93 (d, J=6.3 Hz, 3H).


HPLC condition


Column: CHIRALCEL OD-R, 0.46×25 cm, DAICEL, ODROCE-HD028;


Flow rate: 0.4 mL/min;


Eluent


Component A: 0.2M potassium dihydrogenphosphate aqueous solution


Component B: acetonitrile


A:B=64:36;


UV: 235 nm;


Retention time: 30 min.


EXAMPLE 24(29)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.29 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.54 (d, J=8.7 Hz, 2H), 7.42–7.36 (m, 2H), 7.18 (m, 1H), 7.05 (d, J=8.7 Hz, 2H), 7.05–7.02 (m, 2H), 4.33 (s, 2H), 3.98 (dd, J=8.1, 4.5 Hz, 1H), 3.86–3.72 (m, 2H), 3.53–3.37 (m, 4H), 2.47–2.36 (m, 2H), 2.24–2.12 (m, 2H), 1.80–1.30 (m, 7H), 0.95 (t, J=7.2 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H), 0.93 (d, J=6.3 Hz, 3H).


HPLC condition


Column: CHIRALCEL OD-R, 0.46×25 cm, DAICEL, ODROCE-HD028;


Flow rate: 0.4 mL/min;


Eluent


Component A: 0.2M potassium dihydrogenphosphate aqueous solution


Component B: acetonitrile


A:B=64:36;


UV: 235 nm;


Retention time: 28 min.


EXAMPLE 24(30)
1-butyl-2,5-dioxo-3-cyclopentylmethyl-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.53 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.05 (d, J=2.0 Hz, 1H), 6.98 (dd, J=8.5, 2.0 Hz, 1H), 6.93 (d, J=8.5 Hz, 1H), 4.26 (s, 4H), 4.23 (s, 2H), 3.99 (t, J=6.0 Hz, 1H), 3.77 (m, 2H), 3.46 (m, 2H), 3.37 (m, 2H), 2.36 (m, 2H), 2.15 (m, 2H), 1.96 (m, 1H), 1.81 (m, 4H), 1.59 (m, 6H), 1.36 (m, 2H), 1.15 (m, 2H), 0.95 (t, J=7.0 Hz, 3H).


EXAMPLE 24(31)
1-propyl-2,5-dioxo-3-(cyclohexylmethyloxymethyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.63 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.59–7.46(m, 5H), 4.33 (s, 2H), 4.08 (m, 1H), 4.00 (m, 1H), 3.83 (m, 1H), 3.77 (m, 1H), 3.59 (m, 2H), 3.52 (m, 1H), 3.25 (d, J=6.5 Hz, 2H), 2.53 (m, 2H), 2.42 (m, 1H), 2.40 (s, 3H), 2.39 (s, 3H), 2.21 (m, 2H), 1.69 (m, 6H), 1.52 (m, 2H), 1.21 (m, 4H), 0.95 (t, J=7.0 Hz, 3H), 0.88 (m, 2H).


EXAMPLE 24(32)
(3S)-1-butyl-2,5-dioxo-3-(1-methylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.47 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.06–6.90 (m, 3H), 4.26 (s, 4H), 4.23 (s, 2H), 3.95 (d, J=3.3 Hz, 1H), 3.87 (m, 1H), 3.70 (m, 1H), 3.58–3.42 (m, 4H), 2.56–2.30 (m, 2H), 2.20–1.98 (m, 2H), 1.54–1.00 (m, 7H), 0.99 (d, J=7.2 Hz, 3H), 0.95 (t, J=7.5 Hz, 3H), 0.91 (t, J=7.5 Hz, 3H).


EXAMPLE 24(33)
(3R)-1-butyl-2,5-dioxo-3-(1-methylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.47 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.06–6.91 (m, 3H), 4.26 (s, 4H), 4.23 (s, 2H), 3.95 (d, J=3.3 Hz, 1H), 3.87 (m, 1H), 3.70 (m, 1H), 3.56–3.40 (m, 4H), 2.50–2.32 (m, 2H), 2.18–1.96 (m, 2H), 1.62–1.17 (m, 7H), 0.99 (d, J=7.2 Hz, 3H), 0.95 (t, J=7.2 Hz, 3H), 0.91 (t, J=7.5 Hz, 3H).


EXAMPLE 24(34)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-phenylmethylthiophen-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.56 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.32–7.21 (m, 5H), 7.17 (d, J=3.6 Hz, 1H), 6.89 (d, J=3.6 Hz, 1H), 4.51 (s, 2H), 4.17 (s, 2H), 4.00 (dd, J=7.8 Hz, 4.5 Hz, 1H), 3.84–3.72 (m, 2H), 3.56–3.44 (m, 2H), 3.38–3.32 (m, 2H), 2.42–2.14 (m, 4H), 1.84–1.30 (m, 7H), 0.95 (t, J=6.9 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H), 0.92 (d, J=6.3 Hz, 3H).


EXAMPLE 24(35)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-phenylmethylthiophen-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.59 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.32–7.21 (m, 5H), 7.18 (d, J=3.6 Hz, 1H), 6.89 (d, J=3.6 Hz, 1H), 4.51 (s, 2H), 4.17 (s, 2H), 4.03 (dd, J=7.8, 4.8 Hz, 1H), 3.84–3.72 (m, 2H), 3.58–3.44 (m, 2H), 3.40–3.36 (m, 2H), 2.44–2.08 (m, 4H), 1.81–1.07 (m, 15H), 0.95 (t, J=7.2 Hz, 3H), 0.95 (m, 2H).


EXAMPLE 24(36)
(3R)-1-butyl-2,5-dioxo-3-(2,2-dimethylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.41 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.05 (s, 1H), 6.98 (d, J=8.4 Hz, 1H), 6.92 (d, J=8.4 Hz, 1H), 4.26 (s, 4H), 4.23 (s, 2H), 4.00 (dd, J=7.0, 3.0 Hz, 1H), 3.83–3.64 (m, 2H), 3.50 (m, 2H), 3.38 (m, 2H), 2.35 (m, 2H), 2.25 (m, 2H), 1.99 (m, 1H), 1.55 (m, 1H), 1.50 (m, 2H), 1.35 (m, 2H), 0.99 (s, 9H), 0.95 (t, J=7.0 Hz, 3H).


EXAMPLE 24(37)
(3S)-1-butyl-2,5-dioxo-3-(2,2-dimethylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.41 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.05 (s, 1H), 6.98 (d, J=8.4 Hz, 1H), 6.92 (d, J=8.4 Hz, 1H), 4.26 (s, 4H), 4.23 (s, 2H), 4.00 (dd, J=7.0, 3.0 Hz, 1H), 3.83–3.63 (m, 2H), 3.50 (m, 2H), 3.38 (m, 2H), 2.35 (m, 2H), 2.25 (m, 2H), 1.99 (dd, J=14.0, 3.0 Hz, 1H), 1.55 (dd, J=14.0, 7.0 Hz, 1H), 1.50 (m, 2H), 1.35 (m, 2H), 0.99 (s, 9H), 0.95 (t, J=7.0 Hz, 3H).


EXAMPLE 24(38)
(3R)-1-(2-butynyl)-2,5-dioxo-3-(2,2-dimethylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.60 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.51 (d, J=8.7 Hz, 2H), 7.39 (dd, J=8.7, 7.5 Hz, 2H), 7.18 (t, J=7.5 Hz, 1H), 7.10–7.00 (m, 4H), 4.33 (brs, 2H), 4.33–4.09 (m, 2H), 4.03 (dd, J=6.9, 3.3 Hz, 1H), 3.85–3.68 (m, 2H), 3.58–3.43 (m, 2H), 2.59–2.41 (m, 2H), 2.40–2.20 (m, 2H), 2.03 (dd, J=14.4, 3.3 Hz, 1H), 1.75 (brs, 3H), 1.56 (dd, J=14.4, 6.9 Hz, 1H), 0.99 (s, 9H).


EXAMPLE 24(39)
(3S)-1-(2-butynyl)-2,5-dioxo-3-(2,2-dimethylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.60 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.51 (d, J=8.7 Hz, 2H), 7.39 (dd, J=8.7, 7.5 Hz, 2H), 7.18 (t, J=7.5 Hz, 1H), 7.10–7.00 (m, 4H), 4.33 (brs, 2H), 4.33–4.09 (m, 2H), 4.03 (dd, J=6.9, 3.3 Hz, 1H), 3.85–3.68 (m, 2H), 3.58–3.43 (m, 2H), 2.59–2.41 (m, 2H), 2.40–2.20 (m, 2H), 2.03 (dd, J=14.4, 3.3 Hz, 1H), 1.75 (brs, 3H), 1.56 (dd, J=14.4, 6.9 Hz, 1H), 0.99 (s, 9H).


EXAMPLE 24(40)
1-butyl-2,5-dioxo-3-cycloheptylmethyl-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.70 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.04 (d, J=2.1 Hz, 1H), 6.97 (dd, J=8.4, 2.1 Hz, 1H), 6.93 (d, J=8.4 Hz, 1H), 4.26 (s, 4H), 4.24 (s, 2H), 3.99 (dd, J=8.1, 4.2 Hz, 1H), 3.84–3.70 (m, 2H), 3.45 (m, 2H), 3.36 (m, 2H), 2.37–2.11 (m, 4H), 1.80–1.49 (m, 15H), 1.36(m, 2H), 1.22 (m, 2H), 0.95 (t, J=7.5 Hz, 3H).


EXAMPLE 24(41)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2,4,6-trimethoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.55 (chloroform:methanol=10:1);


NMR (CD3OD): δ 6.31 (s, 2H), 4.26 (s, 2H), 4.03 (dd, J=7.8, 4.5 Hz, 1H), 3.89 (s, 6H), 3.84 (s, 3H), 3.84–3.73 (m, 2H), 3.54–3.33 (m, 4H), 2.44–2.25 (m, 2H), 2.24–2.03 (m, 2H), 1.84–1.12 (m, 15H), 1.06–0.85 (m, 5H).


EXAMPLE 24(42)
1-butyl-2,5-dioxo-3-(3-cyclohexylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.71 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.05–6.91 (m, 3H), 4.26 (s, 4H), 4.22 (s, 2H), 4.04 (t, J=5.4 Hz, 1H), 3.84 (m, 1H), 3.67 (m, 1H), 3.54–3.40 (m, 3H), 3.35 (m, 1H), 2.44–2.08 (m, 4H), 1.90–1.16 (m, 19H), 0.95 (t, J=7.5 Hz, 3H), 0.95 (m, 2H).


EXAMPLE 24(43)
1-butyl-2,5-dioxo-3-(3-cyclohexylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.76 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.53–7.49 (m, 2H), 7.42–7.36 (m, 2H), 7.18 (m, 1H), 7.10–7.02 (m, 4H), 4.32 (s, 2H), 4.04 (t, J=4.8 Hz, 1H), 3.87 (m, 1H), 3.71 (m, 1H), 3.56–3.40 (m, 3H), 3.35 (m, 1H), 2.48–2.12 (m, 4H), 1.86–1.10 (m, 19H), 0.95 (t, J=7.5 Hz, 3H), 0.95 (m, 2H).


EXAMPLE 24(44)
1-butyl-2,5-dioxo-3-(3-cyclohexylpropyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.64 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.59–7.45 (m, 5H), 4.31 (s, 2H), 4.06 (t, J=5.0 Hz, 1H), 3.92 (m, 1H), 3.77 (m, 1H), 3.63–3.37 (m, 4H), 2.44 (m, 2H), 2.39 (s, 3H), 2.38 (s, 3H), 2.21 (m, 2H), 1.85–1.68 (m, 7H), 1.54 (m, 2H), 1.39 (m, 4H), 1.23 (m, 6H), 0.96 (t, J=7.5 Hz, 3H), 0.89 (m, 2H).


EXAMPLE 24(45)
1-butyl-2,5-dioxo-3-(2-hydroxy-2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.52 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.50 (d, J=8.7 Hz, 2H), 7.39 (dd, J=8.7, 7.5 Hz, 2H), 7.18 (t, J=7.5 Hz, 1H), 7.09–7.00 (m, 4H), 4.32 (brs, 2H), 4.29 (dd, J=9.9, 3.0 Hz, 1H), 4.04–3.88 (m, 2H), 3.59–3.40 (m, 4H), 2.46–2.21 (m, 4H), 2.18 (dd, J=14.4, 3.0 Hz, 1H), 1.75 (dd, J=14.4, 9.9 Hz, 1H), 1.61–1.43 (m, 2H), 1.42–1.29 (m, 2H), 1.28 (s, 6H), 0.95 (t, J=7.5 Hz, 3H).


EXAMPLE 24(46)
1-(2-butynyl)-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.41 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.61–7.45 (m, 5H), 4.32 (s, 2H), 4.31–4.18 (m, 2H), 4.06 (dd, J=7.8, 4.5 Hz, 1H), 3.93–3.77 (m, 2H), 3.68–3.57 (m, 2H), 2.72–2.57 (m, 2H), 2.40 (s, 3H), 2.38 (s, 3H), 2.36–2.16,(m, 2H), 1.92–1.59 (m, 6H), 0.95 (d, J=6.6 Hz, 3H), 0.94 (d, J=6.6 Hz, 3H).


EXAMPLE 24(47)
1-(2-butynyl)-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-phenyl pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.37 (chloroform:methanol=10:1);


NMR (CD3OD): 7.60–7.43 (m, 5H), 4.32 (s, 2H), 4.23 (d, J=2.1 Hz, 2H), 4.09 (dd, J=7.2, 4.8 Hz, 1H), 3.92–3.78 (m, 2H), 3.68–3.56 (m, 2H), 2.66–2.51 (m, 2H), 2.38 (s, 3H), 2.36 (s, 3H), 2.36–2.16 (m, 2H), 1.83–1.60 (m, 10H), 1.59–1.43 (m, 1H), 1.38–1.12 (m, 3H), 1.06–0.87 (m, 2H).


EXAMPLE 24(48)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.35 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.63–7.48 (m, 5H), 4.33 (s, 2H), 4.05 (dd, J=7.8, 4.5 Hz, 1H), 3.95–3.74 (m, 2H), 3.67–3.56 (m, 2H), 3.48 (m, 2H), 2.72–2.58 (m, 2H), 2.45 (s, 3H), 2.41 (s, 3H), 2.30–2.07 (m, 2H), 1.84–1.10 (m, 15H), 1.02–0.92 (m, 2H), 0.96 (t, J=7.2 Hz, 3H).


EXAMPLE 24(49)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-phenyloxypyridin-3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.23 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.19 (m, 1H), 8.07 (m, 1H), 7.47–7.42 (m, 2H), 7.29–7.19 (m, 4H), 4.55 (s, 2H), 4.03 (dd, J=7.8, 4.5 Hz, 1H), 3.94 (m, 2H), 3.64 (m, 2H), 3.38 (m, 2H), 2.54–2.16 (m, 4H), 1.90–1.28 (m, 7H), 0.96 (t, J=6.9 Hz, 3H), 0.96 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H).


EXAMPLE 24(50)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-phenyloxypyridin-3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.62 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.19 (m, 1H), 8.09 (m, 1H), 7.47–7.42 (m, 2H), 7.29–7.19 (m, 4H), 4.55 (s, 2H), 4.05 (dd, J=7.8, 4.8 Hz, 1H), 3.96 (m, 2H), 3.64 (m, 2H), 3.42 (m, 2H), 2.48 (m, 2H), 2.36–2.16 (m, 2H), 1.82–1.14 (m, 15H), 0.96 (t, J=7.5 Hz, 3H), 0.95–0.84 (m, 2H).


EXAMPLE 24(51)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-methylbenzomorpholin-7-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.69 (chloroform:methanol=10:1);


NMR (CDCl3): δ 6.93 (d, J=8.7 Hz, 1H), 6.86 (s, 1H), 6.75 (d, J=8.7 Hz, 1H), 4.28–4.25 (m, 2H), 4.17 (s, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.80–3.65 (m, 2H), 3.50–3.40 (m, 2H), 3.40–3.30 (m, 2H), 2.91 (s, 3H), 2.38–2.06 (m, 4H), 1.78–1.63 (m, 8H), 1.63–1.42 (m, 3H), 1.40–1.18 (m, 6H), 1.05–0.90 (m, 2H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 24(52)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-methylbenzomorpholin-7-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.56 (chloroform:methanol=10:1);


NMR (CDCl3): δ 7.00 (d, J=7.2 Hz, 1H), 6.94 (s, 1H), 6.85 (d, J=7.2 Hz, 1H), 4.31–4.29 (m, 2H), 4.19 (s, 2H), 4.00 (dd, J=7.8, 4.5 Hz, 1H), 3.79–3.66 (m, 2H), 3.47–3.34 (m, 6H), 2.97 (s, 3H), 2.45–2.34 (m, 2H), 2.22–2.10 (m, 2H), 1.84–1.75 (m, 1H), 1.71–1.46 (m, 4H), 1.42–1.32 (m, 2H), 0.97–0.92 (m, 9H).


EXAMPLE 24(53)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(N-methyl-N-phenylamino)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.40 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.40–7.28 (m, 4H), 7.19–7.10 (m, 3H), 6.94–6.86 (m, 2H), 4.23 (s, 2H), 4.00 (dd, J=7.8, 4.5 Hz, 1H), 3.86–3.63 (m, 2H), 3.55–3.30 (m, 4H), 3.31 (s, 3H), 2.46–2.27 (m, 2H), 2.26–2.06 (m, 2H), 1.90–1.42 (m, 5H), 1.44–1.26 (m, 2H), 0.98–0.91 (m, 9H).


EXAMPLE 24(54)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(N-methyl-N-phenylamino) phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.52 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.40–7.28 (m, 4H), 7.20–7.12 (m, 3H), 6.93–6.86 (m, 2H), 4.24 (s, 2H), 4.03 (dd, J=7.5, 4.8 Hz, 1H), 3.85–3.66 (m, 2H), 3.55–3.40 (m, 2H), 3.40–3.30 (m, 2H), 3.32 (s, 3H), 2.44–2.07 (m, 4H), 1.84–1.40 (m, 10H), 1.40–1.10 (m, 5H), 1.06–0.85 (m, 2H), 0.95 (t, J=7.5 Hz, 3H).


EXAMPLE 24(55)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-(3,5-dimethylpyrazol-1-yl)-5-methoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.58 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.53 (d, J=3.0 Hz, 1H), 7.44 (d, J=8.7 Hz, 1H), 7.22 (dd, J=8.7, 3.0 Hz, 1H), 6.29 (s, 1H), 4.09 (s, 2H), 4.02 (dd, J=7.5, 4.5 Hz, 1H), 3.94 (s, 3H), 3.74 (m, 2H), 3.42 (m, 4H), 2.44 (m, 2H), 2.37 (s, 3H), 2.22 (s, 3H), 2.22 (m, 2H), 1.86–1.30 (m, 7H), 0.96 (t, J=7.8 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H).


EXAMPLE 24(56)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-(3,5-dimethylpyrazol-1-yl)-5-methoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.61 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.43 (d, J=8.7 Hz, 1H), 7.40 (d, J=2.7 Hz, 1H), 7.22 (dd, J=8.7, 2.7 Hz, 1H), 6.22 (s, 1H), 4.09 (s, 2H), 4.06 (dd, J=7.5, 4.2 Hz, 1H), 3.93 (s, 3H), 3.80 (m, 2H), 3.42 (m, 4H), 2.38 (m, 2H), 2.34 (s, 3H), 2.22 (s, 3H), 2.20 (m, 2H), 1.80–1.16 (m, 15H), 0.96 (t, J=7.2 Hz, 3H), 0.96 (m, 2H).


EXAMPLE 24(57)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-diethyl-1-(4-chlorophenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.47 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.53 (d, J=9.0 Hz, 2H), 7.49 (d, J=9.0 Hz, 2H), 4.31 (s, 2H), 4.02 (dd, J=7.8, 4.5 Hz, 1H), 3.94–3.73 (m, 2H), 3.65–3.54 (m, 2H), 3.49–3.38 (m, 2H), 2.88 (q, J=7.5 Hz, 2H), 2.77 (q, J=7.5 Hz, 2H), 2.58–2.38 (m, 2H), 2.30–2.12 (m, 2H), 1.90–1.56 (m, 5H), 1.55–1.30 (m, 2H), 1.31 (t, J=7.5 Hz, 3H), 0.99–0.94 (m, 12H).


EXAMPLE 24(58)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-diethyl-1-(4-chlorophenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.51 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.58 (d, J=9.0 Hz, 2H), 7.48 (d, J=9.0 Hz, 2H), 4.31 (s, 2H), 4.05 (dd, J=7.5, 4.5 Hz, 1H), 3.94–3.73 (m, 2H), 3.65–3.54 (m, 2H), 3.50–3.38 (m, 2H), 2.88 (q, J=7.5 Hz, 2H), 2.77 (q, J=7.5 Hz, 2H), 2.60–2.60 (m, 2H), 2.28–2.09 (m, 2H), 1.85–1.10 (m, 15H), 1.31 (t, J=7.5 Hz, 3H), 1.04–0.85 (m, 2H), 0.96 (t, J=7.5 Hz, 3H), 0.94 (t, J=7.5 Hz, 3H).


EXAMPLE 24(59)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(6-phenyloxypyridin-3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.65 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.32 (s, 1H), 8.06 (m, 1H), 7.44 (t, J=7.5 Hz, 2H), 7.26 (t, J=7.5 Hz, 1H), 7.14 (d, J=7.5 Hz, 2H), 7.06 (d, J=8.7 Hz, 1H), 4.39 (s, 2H), 4.01 (dd, J=7.5, 4.5 Hz, 1H), 3.90–3.70 (m, 2H), 3.53–3.41 (m, 4H), 2.45 (m, 2H), 2.25–2.12 (m, 2H), 1.78 (m, 1H), 1.72–1.50 (m, 4H), 1.36 (m, 2H), 0.97–0.93 (m, 9H).


EXAMPLE 24(60)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(6-phenyloxypyridin-3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.67 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.31 (s, 1H), 8.07 (d, J=8.3 Hz, 1H), 7.44 (t, J=7.5 Hz, 2H), 7.26 (t, J=7.5 Hz, 1H), 7.14 (d, J=7.5 Hz, 2H), 7.06 (d, J=8.3 Hz, 1H), 4.39 (s, 2H), 4.04 (dd, J=7.8, 4.6 Hz, 1H), 3.90–3.76 (m, 2H), 3.52–3.38 (m, 4H), 2.58–2.36 (m, 2H), 2.25–2.11 (m, 2H), 1.80–1.42 (m, 10H), 1.42–1.17 (m, 5H), 1.05–0.85 (m, 2H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 24(61)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(1,3-benzodioxolan-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.38 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.05–7.00 (m, 2H), 6.92 (m, 1H), 6.03 (s, 2H), 4.26 (s, 2H), 4.02 (dd, J=7.5, 4.5 Hz, 1H), 3.84–3.68 (m, 2H), 3.52–3.36 (m, 4H), 2.42–2.10 (m, 4H), 1.88–1.32 (m, 7H), 0.96 (t, J=6.9 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H).


EXAMPLE 24(62)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(1,3-benzodioxolan-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.42 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.06–7.01 (m, 2H), 6.92 (m, 1H), 6.03 (s, 2H), 4.27 (s, 2H), 4.04 (dd, J=7.5, 4.5 Hz, 1H), 3.82–3.70 (m, 2H), 3.56–3.36 (m, 4H), 2.48–2.10 (m, 4H), 1.82–1.16 (m, 15H), 0.96 (t, J=7.5 Hz, 3H), 0.96 (m, 2H).


EXAMPLE 24(63)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-hydroxy-4-methoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.88 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.26 (d, J=8.5 Hz, 1H), 6.51 (dd, J=8.5, 2.5 Hz, 1H), 6.48 (d, J=2.5 Hz, 1H), 4.26 (s, 2H), 4.03 (m, 1H), 3.77 (m, 5H), 3.47 (m, 2H), 3.37 (m, 2H), 2.34 (m, 2H), 2.15 (m, 2H), 1.69 (m, 6H), 1.52 (m, 4H), 1.31 (m,5H), 0.95 (m, 5H).


EXAMPLE 24(64)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-methylthiophenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.83 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.44 (d, J=8.7 Hz, 2H), 7.36 (d, J=8.7 Hz, 2H), 4.32 (s, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.80 (m, 2H), 3.49 (m, 2H), 3.34 (m, 2H), 2.50 (s, 3H), 2.36–2.11 (m, 4H), 1.69 (m, 10H), 1.39–1.23 (m, 5H), 0.95 (m, 5H).


EXAMPLE 24(65)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(N,N-diphenylamino)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.48 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.40–7.25 (m, 6H), 7.13–7.01 (m, 8H), 4.27 (s, 2H), 4.01 (dd, J=7.8, 4.5 Hz, 1H), 3.87–3.68 (m, 2H), 3.56–3.44 (m, 2H), 3.44–3.32 (m, 2H), 2.48–2.32 (m, 2H), 2.29–2.10 (m, 2H), 1.90–1.44 (m, 5H), 1.44–1.30 (m, 2H), 0.96 (t, J=6.9 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H).


EXAMPLE 24(66)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(N,N-diphenylamino) phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.53 (chloroform:methanol=20:1);


NMR (CD3OD): 67.41–7.26 (m, 6H), 7.14–7.00 (m, 8H), 4.27 (s, 2H), 4.04 (dd, J=7.5, 4.5 Hz, 1H), 3.88–3.68 (m, 2H), 3.57–3.45 (m, 2H), 3.44–3.36 (m, 2H), 2.48–2.32 (m, 2H), 2.28–2.07 (m, 2H), 1.84–1.44 (m, 10H), 1.44–1.14 (m, 5H), 1.00–0.90 (m, 2H), 0.96 (t, J=6.9 Hz, 3H).


EXAMPLE 24(67)
(3S)-1-(2-butynyl)-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-phenyl pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.32 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.59–7.46 (m, 5H), 4.32 (s, 2H), 4.24 (s, 2H), 4.09 (dd, J=7.5, 4.5 Hz, 1H), 3.86 (m, 2H), 3.65 (m, 2H), 2.60 (m, 2H), 2.39 (s, 3H), 2.38 (s, 3H), 2.26 (m, 2H), 1.88–1.66 (m, 10H), 1.53 (m, 1H), 1.25 (m, 3H), 0.96 (m, 2H).


EXAMPLE 24(68)
(3S)-1-(2-butynyl)-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.43 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.60–7.46 (m, 5H), 4.32 (s, 2H), 4.26 (m, 2H), 4.06 (dd, J=7.5, 4.5 Hz, 1H), 3.85 (m, 2H), 3.62 (m, 2H), 2.60 (m, 2H), 2.39 (s, 3H), 2.38 (s, 3H), 2.27 (m, 2H), 1.89–1.61 (m, 6H), 0.95 (d, J=6.5 Hz, 3H), 0.94 (d, J=6.5 Hz, 3H).


EXAMPLE 24(69)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.57 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.59–7.45 (m, 5H), 4.32 (s, 2H), 4.06 (dd, J 7.8, 4.5 Hz, 1H), 3.85 (m, 2H), 3.60 (m, 2H), 3.43 (m, 2H), 2.53–2.44 (m, 2H), 2.45 (s,3H), 2.41 (s, 3H), 2.32–2.16 (m, 2H), 1.80–1.17 (m, 15H), 1.02–0.93 (m, 2H), 0.96 (d, J=7.0 Hz, 3H).


EXAMPLE 24(70)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-methylphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.46 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.36 (d, J=8.4 Hz, 2H), 7.31 (d, J=8.4 Hz, 2H), 4.30 (s, 2H), 4.02 (dd, J=7.8, 4.8 Hz, 1H), 3.84 (m, 2H), 3.60 (m, 2H), 3.38 (m, 2H), 2.42 (s, 3H), 2.37 (s, 3H), 2.35 (s, 3H), 2.52–2.18 (m, 4H), 1.90–1.32 (m, 7H), 0.96 (t, J=7.8 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H).


EXAMPLE 24(71)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-methylphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.51 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.38 (d, J=8.4 Hz, 2H), 7.33 (d, J=8.4 Hz, 2H), 4.31 (s, 2H), 4.06 (dd, J=7.5, 4.5 Hz, 1H), 3.82 (m, 2H), 3.60 (m, 2H), 3.42 (m, 2H), 2.43 (s, 3H), 2.38 (s, 3H), 2.36 (s, 3H), 2.56–2.14 (m, 3H), 1.84–1.16 (m, 15H), 0.97 (t, J=7.2 Hz, 3H), 0.97 (m, 2H).


EXAMPLE 24(72)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-chlorophenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.30 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.57 (d, J=9.0 Hz, 2H), 7.49 (d, J=9.0 Hz, 2H), 4.31 (s, 2H), 4.02 (dd, J=7.8, 4.5 Hz, 1H), 3.91–3.80 (m, 2H), 3.60 (m, 2H), 3.46 (m, 2H), 2.52 (m, 2H), 2.40 (s, 3H), 2.39 (s, 3H), 2.27–2.15 (m, 2H), 1.86–1.81 (m, 1H), 1.76–1.51 (m, 4H), 1.44–1.32 (m, 2H), 0.96 (t, J=7.0 Hz, 3H), 0.95 (d, J=6.0 Hz, 3H), 0.94 (d, J=6.0 Hz, 3H).


EXAMPLE 24(73)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-chlorophenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.27 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.57 (d, J=8.5 Hz, 2H), 7.48 (d, J=8.5 Hz, 2H), 4.31 (s, 2H), 4.04 (dd, J=7.8, 4.5 Hz, 1H), 3.91–3.77 (m, 2H), 3.60 (m, 2H), 3.45 (m, 2H), 2.50 (m, 2H), 2.39 (s, 6H), 2.27–2.14 (m, 2H), 1.80–1.51 (m, 9H), 1.44–1.17 (m, 6H), 1.03–0.89 (m, 5H).


EXAMPLE 24(74)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-trifluoromethylphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.23 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.87 (d, J=8.7 Hz, 2H), 7.72 (d, J=8.7 Hz, 2H), 4.32 (s, 2H), 4.02 (dd, J=7.8, 4.5 Hz, 1H), 3.93–3.78 (m, 2H), 3.60 (m, 2H), 3.43 (m, 2H), 2.50 (m, 2H), 2.45 (s, 3H), 2.40 (s, 3H), 2.29–2.16 (m, 2H), 1.86–1.77 (m, 1H), 1.74–1.54 (m, 4H), 1.44–1.34 (m, 2H), 0.96 (t, J=7.0 Hz, 3H), 0.95 (d, J=6.0 Hz, 3H), 0.94 (d, J=6.0 Hz, 3H).


EXAMPLE 24(75)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-trifluoromethylphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.37 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.87 (d, J=8.4 Hz, 2H), 7.72 (d, J=8.4 Hz, 2H), 4.32 (s, 2H), 4.05 (dd, J=7.8, 4.5 Hz, 1H), 3.92–3.78 (m, 2H), 3.60 (m, 2H), 3.45 (m, 2H), 2.50 (m, 2H), 2.45 (s, 3H), 2.40 (s, 3H), 2.28–2.15 (m, 2H), 1.80–1.51 (m, 9H), 1.44–1.21 (m, 6H), 1.03–0.93 (m, 5H).


EXAMPLE 24(76)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-diethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.70 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.61–7.53 (m, 3H), 7.53–7.46 (m, 2H), 4.32 (s, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.95–3.79 (m, 2H), 3.65–3.58 (m, 2H), 3.50–3.38 (m, 2H), 2.85–2.75 (m, 4H), 2.47 (br, 2H), 2.28–2.16 (m, 2H), 1.83–1.46 (m, 3H), 1.41–1.29 (m, 4H), 0.98–0.91 (m, 15H).


EXAMPLE 24(77)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-diethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.67 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.61–7.53 (m, 3H), 7.53–7.46 (m, 2H), 4.32 (s, 2H), 4.05 (dd, J=7.5, 4.5 Hz, 1H), 3.95–3.79 (m, 2H), 3.70–3.55 (m, 2H), 3.47–3.31 (m, 2H), 2.91–2.75 (m, 4H), 2.60–2.45 (m, 2H), 2.30–2.14 (m, 2H), 1.80–1.43 (m, 9H), 1.43–1.15 (m, 8H), 0.98–0.91 (m, 9H).


EXAMPLE 24(78)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-phenylthiazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.62 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.03–8.00 (m, 2H), 7.87 (s, 1H), 7.52–7.49 (m, 3H), 4.54 (s, 2H), 4.04 (dd, J=7.6, 4.8 Hz, 1H), 4.04–3.87 (m, 2H), 3.70–3.58 (m, 2H), 3.51–3.39 (m, 2H), 2.58–2.38 (m, 2H), 2.26–2.13 (m, 2H), 1.78–1.43 (m, 9H), 1.40–1.15 (m, 6H), 1.10–0.90 (m, 5H).


EXAMPLE 24(79)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-phenylthiazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.38 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.02–8.01 (m, 2H), 7.85 (s, 1H), 7.51–7.50 (m, 3H), 4.55 (s, 2H), 4.03–3.86 (m, 3H), 3.68–3.59 (m, 2H), 3.45–3.36 (m, 2H), 2.50–2.34 (m, 2H), 2.29–2.16 (m, 2H), 1.88–1.45 (m, 5H), 1.36 (q, J=7.2 Hz, 2H), 0.97–0.93 (m, 9H).


EXAMPLE 24(80)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-(1,4-benzodioxan-2-yl)thiazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.36 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.88 (s, 1H), 7.00 (m, 1H), 6.94–6.87 (m, 3H), 5.66 (dd, J=6.0, 2.7 Hz, 1H), 4.62 (dd, J=11.7, 2.7 Hz, 1H), 4.51 (s, 2H), 4.42 (dd, J=11.7, 6.0 Hz, 1H), 4.02 (dd, J=7.5, 4.5 Hz, 1H), 3.88 (m, 2H), 3.58 (m, 2H), 3.40 (m, 2H), 2.48–2.16 (m, 4H), 1.90–1.28 (m, 7H), 0.97 (t, J=7.5 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H).


EXAMPLE 24(81)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-trifluoromethyl-2-(morpholin-1-yl)thiazol-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.78 (chloroform:methanol=10:1);


NMR (CD3OD): δ 4.63 (s, 2H), 4.03 (dd, J=7.8, 4,8 Hz, 1H), 3.86–3.78 (m, 6H), 3.58 (m, 6H), 3.40 (m, 2H), 2.44 (m, 2H), 2.22 (m, 2H), 1.88–1.32 (m, 8H), 0.97 (t, J=7.2 Hz, 3H), 0.95 (d, J=6.6 Hz, 3H), 0.94 (d, J=6.6 Hz, 3H).


EXAMPLE 24(82)
1-butyl-2,5-dioxo-3-(tetrahydropyran-4-ylmethyl)-9-(3,5-dimethyl-1-phenyl pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.31 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.60–7.46 (m, 5H), 4.33 (s, 2H), 4.09 (dd, J=7.5, 4.5 Hz, 1H), 3.98–3.78 (m, 4H), 3.68–3.56 (m, 2H), 3.50–3.36 (m, 4H), 2.58–2.16 (m, 4H), 2.40 (s, 3H), 2.39 (s, 3H), 1.84–1.20 (m, 11H), 0.97 (t, J=7.2 Hz, 3H).


EXAMPLE 24(83)
1-butyl-2,5-dioxo-3-(tetrahydropyran-4-ylmethyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.34 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.06–6.92 (m, 3H), 4.27 (s, 4H), 4,24 (s, 2H), 4.07 (dd, J=7.5, 4.5 Hz, 1H), 3.96–3.86 (m, 2H), 3.84–3.68 (m, 2H), 3.52–3.36 (m, 6H), 2.44–2.10 (m, 4H), 1.82–1.22 (m, 11H), 0.96 (t, J=7.2 Hz, 3H).


EXAMPLE 24(84)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-carboxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.58 (chloroform:methanol:acetic acid=20:2:1);


NMR (CD3OD): δ 8.14 (d, J=8.4 Hz, 2H), 7.68 (d, J=8.4 Hz, 2H), 4.45 (s, 2H), 4.04 (dd, J=7.5, 4.5 Hz, 1H), 3.94–3.76 (m, 2H), 3.56–3.43 (m, 2H), 3.43–3.34 (m, 2H), 2.50–2.31 (m, 2H), 2.28–2.08 (m, 2H), 1.84–1.12 (m, 15H), 1.06–0.90 (m, 2H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 24(85)
1-butyl-2,5-dioxo-3-(2-cyclohexylethyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.47 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.56–7.45 (m, 5H), 4.32 (s, 2H), 4.02 (t, J=4.8 Hz, 1H), 3.98–3.85 (m, 1H), 3.85–3.70 (m, 1H), 3.65–3.56 (m, 2H), 3.56–3.42 (m, 1H), 3.42–3.30 (m, 1H), 2.55–2.37 (m, 2H), 2.38 (s, 3H), 2.37 (s, 3H), 2.30–2.13 (m, 2H), 1.92–1.78 (m, 2H), 1.78–1.60 (m, 5H), 1.60–1.48 (m, 2H), 1.48–1.32 (m, 2H), 1.32–1.08 (m, 6H), 0.96 (t, J=7.2 Hz, 3H), 0.96–0.85 (m, 2H).


EXAMPLE 24(86)
1-butyl-2,5-dioxo-3-(2-cyclohexylethyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.50 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.05 (d, J=2.1 Hz, 1H), 6.98 (dd, J 8.1, 2.1 Hz, 1H), 6.92 (d, J=8.1 Hz, 1H), 4.26 (s, 4H), 4.23 (s, 2H), 4.03 (t, J=4.8 Hz, 1H), 3.90–3.79 (m, 1H), 3.76–3.62 (m, 1H), 3.50–3.38 (m, 3H), 3.38–3.30 (m, 1H), 2.43–2.06 (m, 4H), 1.92–1.78 (m, 2H), 1.78–1.60 (m, 5H), 1.60–1.45 (m, 2H), 1.42–1.30 (m, 2H), 1.30–1.08 (m, 6H), 0.95 (t, J=7.2 Hz, 3H), 0.97–0.88 (m, 2H).


EXAMPLE 24(87)
(3R)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.43 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.61–7.48 (m, 5H), 4.33 (s, 2H), 4.06 (dd, J=7.5, 4.5 Hz, 1H), 3.95–3.78 (m, 2H), 3.68–3.58 (m, 2H), 3.50–3.40 (m, 2H), 2.62–2.45 (m, 2H), 2.42 (s, 3H), 2.40 (s, 3H), 2.30–2.12 (m, 2H), 1.82–1.12 (m, 15H), 0.97 (t, J=7.2 Hz, 3H), 0.97 (m, 2H).


EXAMPLE 24(88)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-methyl-2-phenylthiazol-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.75 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.98–7.95 (m, 2H), 7.55–7.50 (m, 3H), 4.69 (s, 2H), 4.01 (dd, J=7.5, 4.5 Hz, 1H), 3.98–3.78 (m, 2H), 3.65–3.56 (m, 2H), 3.50–3.40 (m, 2H), 2.58 (s, 3H), 2.60–2.48 (m, 2H), 2.27–2.14 (m, 2H), 1.88–1.48 (m, 5H), 1.48–1.30 (m, 2H), 0.97–0.93 (m, 9H).


EXAMPLE 24(89)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-(thiophen-1-yl)thiazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.60 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.81 (s, 1H), 7.67 (d, J=3.9 Hz, 1H), 7.60 (d, J=5.4 Hz, 1H), 7.14 (dd, J=5.4, 3.9 Hz, 1H), 4.49 (s, 2H), 4.00 (dd, J=7.8, 4.5 Hz, 1H), 3.98–3.82 (m, 2H), 3.62–3.55 (m, 2H), 3.42 (t, J=7.5 Hz, 2H), 2.58–2.40 (m, 2H), 2.28–2.10 (m, 2H), 1.86–1.42 (m, 5H), 1.46–1.30 (m, 2H), 0.97–0.93 (m, 9H).


EXAMPLE 24(90)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-(pyridin-4-yl)thiazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.51 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.98 (d, J=6.9 Hz, 2H), 8.71 (d, J=6.9 Hz, 2H), 8.37 (s, 1H), 4.66 (s, 2H), 4.01 (dd, J=7.8, 4.8 Hz, 1H), 4.00–3.87 (m, 2H), 3.70–3.59 (m, 2H), 3.50 (t, J=7.8 Hz, 2H), 2.72–2.58 (m, 2H), 2.25–2.08 (m, 2H), 1.88–1.46 (m, 5H), 1.46–1.35 (m, 2H), 0.97–0.92 (m, 9H).


EXAMPLE 24(91)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,4-dimethoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.28 (chloroform:methanol=10:1);


NMR (CD3OD): a 7.23 (s, 1H), 7.09 (d, J=8.4 Hz, 1H), 7.03 (d, J=8.4 Hz, 1H), 4.29 (s, 2H), 4.04 (dd, J=7.5, 4.8 Hz, 1H), 3.90 (s, 3H), 3.86 (s, 3H), 3.88–3.64 (m, 2H), 3.56–3.38 (m, 4H), 2.58–2.37 (m, 2H), 2.24–2.08 (m, 2H), 1.82–1.10 (m, 15H), 0.96 (t, J=7.2 Hz, 3H), 0.96 (m, 2H).


EXAMPLE 24(92)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.31 (chloroform:methanol=10:1);


NMR (CD3OD): δ 6.74 (d, J=1.8 Hz, 2H), 6.60 (t, J=1.8 Hz, 1H), 4.28 (s, 2H), 4.04 (dd, J=7.8, 4.8 Hz, 1H), 3.86–3.70 (m, 2H), 3.83 (s, 6H), 3.58–3.36 (m, 4H), 2.52–2.36 (m, 2H), 2.24–2.08 (m, 2H), 1.82–1.10 (m, 15H), 0.96 (t, J=7.2 Hz, 3H), 0.96 (m, 2H).


EXAMPLE 24(93)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-(pyridin-2-yl)furan-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 Hydrochloride



embedded image


TLC: Rf 0.39 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.76 (dd, J=5.4, 1.5 Hz, 1H), 8.51 (ddd, J=8.1, 7.5, 1.5 Hz, 1H), 8.39 (d, J=7.5 Hz, 1H), 7.85 (dd, J=8.1, 5.4 Hz, 1H), 7.61 (d, J=3.6 Hz, 1H), 7.08 (d, J=3.6 Hz, 1H), 4.63 (s, 2H), 4.00 (dd, J=7.8, 4.5 Hz, 1H), 3.98–3.81 (m, 2H), 3.65–3.55 (m, 2H), 3.49 (t, J=8.1 Hz, 2H), 2.72–2.55 (m, 2H), 2.28–2.10 (m, 2H), 1.90–1.27 (m, 7H), 1.00–0.89 (m, 9H).


EXAMPLE 24(94)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-(pyridin-3-yl)furan-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.45 (chloroform:methanol=10:1);


NMR (CD3OD): δ 9.34 (d, J=1.8 Hz, 1H), 8.94 (dd, J=8.1, 1.8 Hz, 1H), 8.75 (d, J=5.4 Hz, 1H), 8.10 (dd, J=8.1, 5.4 Hz, 1H), 7.34 (d, J=3.6 Hz, 1H), 6.98 (d, J=3.6 Hz, 1H), 4.57 (s, 2H), 4.00 (dd, J=7.8, 4.5 Hz, 1H), 3.98–3.77 (m, 2H), 3.63–3.43 (m, 4H), 2.73–2.55 (m, 2H), 2.28–2.09 (m, 2H), 1.89–1.27 (m, 7H), 1.00–0.89 (m, 9H).


EXAMPLE 24(95)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(3,5-dimethylpyrazol-1-yl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.52 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.94 (d, J=8.1 Hz, 2H), 7.71 (d, J=8.1 Hz, 2H), 6.51 (s, 1H), 4.49 (s, 2H), 4.01 (dd, J=7.8, 4.5 Hz, 1H), 3.85–3.76 (m, 2H), 3.58–3.48 (m, 4H), 2.72–2.58 (m, 2H), 2.45 (s, 3H), 2.39 (s, 3H), 2.23–2.06 (m, 2H), 1.88–1.45 (m, 5H), 1.45–1.34 (m, 2H), 0.97–0.92 (m, 9H).


EXAMPLE 24(96)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(5-chloropyridin-3-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.57 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.54 (bs, 1H), 8.45 (bs, 1H), 7.87 (bs, 1H), 7.71 (d, J=8.4 Hz, 2H), 7.26 (d, J=8.4 Hz, 2H), 4.39 (s, 2H), 4.01 (dd, J=7.8, 4.8 Hz, 1H), 3.90–3.73 (m, 2H), 3.56–3.40 (m, 4H), 2.64–2.46 (m, 2H), 2.24–2.09 (m, 2H), 1.86–1.42 (m, 5H), 1.42–1.30 (m, 2H), 0.97–0.92 (m, 9H).


EXAMPLE 24(97)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(pyrimidin-2-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.61 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.62 (d, J=4.8 Hz, 2H), 7.68 (d, J=8.4 Hz, 2H), 7.32 (d, J=8.4 Hz, 2H), 7.26 (t, J=4.8 Hz, 1H), 4.40 (s, 2H), 4.02 (dd, J=7.5, 4.5 Hz, 1H), 3.93–3.72 (m, 2H), 3.60–3.35 (m, 4H), 2.58–2.40 (m, 2H), 2.28–2.07 (m, 2H), 1.90–1.45 (m, 5H), 1.45–1.36 (m, 2H), 0.98–0.90 (m, 9H).


EXAMPLE 24(98)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(pyridin-3-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.61 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.76 (d, J=2.7 Hz, 1H), 8.63 (d, J=5.7 Hz, 1H), 8.28 (dd, J=8.7, 2.7 Hz, 1H), 8.07 (dd, J=8.7, 5.7 Hz, 1H), 7.78 (d, J=8.4 Hz, 2H), 7.35 (d, J=8.4 Hz, 2H), 4.41 (s, 2H), 4.02 (dd, J=7.8, 4.5 Hz, 1H), 3.93–3.72 (m, 2H), 3.58–3.40 (m, 4H), 2.68–2.48 (m, 2H), 2.26–2.06 (m, 2H), 1.90–1.46 (m, 5H), 1.46–1.30 (m, 2H), 0.98–0.91 (m, 9H).


EXAMPLE 24(99)
1-(2-butynyl)-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-methylphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.28 (chloroform:methanol=19:1);


NMR (CD3OD): δ 7.39–7.29 (m, 4H), 4.31 (s, 2H), 4.27–4.20 (m, 2H), 4.06 (dd, J=7.5, 4.8 Hz, 1H), 3.84 (m, 2H), 3.62 (m, 2H), 2.59 (m, 2H), 2.42 (s, 3H), 2.37 (s, 3H), 2.34 (s, 3H), 2.28 (m, 2H), 1.92–1.60 (m, 6H), 0.96 (d, J=6.3 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H).


EXAMPLE 24(100)
(3R)-1-(2-butynyl)-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.29 (chloroform:methanol=19:1);


NMR (CD3OD): δ 7.59–7.43 (m, 5H), 4.31 (s, 2H), 4.25 (q, J=2.1 Hz, 2H), 4.09 (dd, J=7.2, 4.8 Hz, 1H), 3.85 (dt, J=3.0, 12.3 Hz, 2H), 3.68–3.56 (m, 2H), 2.61 (m, 2H), 2.38 (s, 3H), 2.37 (s, 3H), 2.26 (m, 2H), 1.83–1.43 (m, 8H), 1.75 (t, J=2.1 Hz, 3H), 1.38–1.12 (m, 3H), 0.96 (m, 2H).


EXAMPLE 24(101)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-hydroxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.46 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.47 (d, J=9.0 Hz, 2H), 6.97 (d, J=9.0 Hz, 2H), 6.88 (d, J=9.0 Hz, 2H), 6.80 (d, J=9.0 Hz, 2H), 4.30 (s, 2H), 4.00 (dd, J=7.5, 4.8 Hz, 1H), 3.86–3.70 (m, 2H), 3.52–3.34 (m, 4H), 2.48–2.30 (m, 2H), 2.28–2.10 (m, 2H), 1.88–1.44 (m, 5H), 1.44–1.28 (m, 2H), 0.97–0.92 (m, 9H).


EXAMPLE 24(102)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(pyridin-2-yl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.50 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.89 (d, J=7.8 Hz, 1H), 8.70 (t, J=7.8 Hz, 1H), 8.43 (d, J=8.4 Hz, 1H), 8.10–8.06 (m, 3H), 7.98 (d, J=8.7 Hz, 2H), 4.51 (s, 2H), 4.01 (dd, J=7.8, 4.8 Hz, 1H), 3.96–3.78 (m, 2H), 3.56–3.45 (m, 4H), 2.72–2.58 (m, 2H), 2.24–2.08 (m, 2H), 1.84–1.44 (m, 5H), 1.44–1.34 (m, 2H), 0.97–0.92 (m, 9H).


EXAMPLE 24(103)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(pyridin-3-yl) phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.47 (chloroform:methanol=10:1);


NMR (CD3OD): δ 9.24 (s, 1H), 8.98 (d, J=8.4 Hz, 1H), 8.88 (d, J=8.4 Hz, 1H), 8.21 (dd, J=8.4, 5.7 Hz, 1H), 7.96 (d, J=8.4 Hz, 2H), 7.87 (d, J=8.4 Hz, 2H), 4.47 (s, 2H), 4.01 (dd, J=7.5, 4.8 Hz, 1H), 3.96–3.75 (m, 2H), 3.58–3.44 (m, 4H), 2.64–2.50 (m, 2H), 2.25–2.08 (m, 2H), 1.88–1.48 (m, 5H), 1.48–1.32 (m, 2H), 0.97–0.92 (m, 9H).


EXAMPLE 24(104)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-carboxyphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.27 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.19 (d, J=8.4 Hz, 2H), 7.61 (d, J=8.4 Hz, 2H), 4.32 (s, 2H), 4.03 dd, J=7.5, 4.5 Hz, 1H), 3.96–3.74 (m, 2H), 3.66–3.55 (m, 2H), 3.48–3.36 (m, 2H), 2.58–2.40 (m, 2H), 2.45 (s, 3H), 2.40 (s, 3H), 2.32–2.14 m, 2H), 1.90–1.46 (m, 5H), 1.46–1.30 (m, 2H), 0.99–0.95 (m, 9H).


EXAMPLE 24(105) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(pyrazin-2-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.48 (chloroform:methanol=20:1);


NMR (CD3OD): δ 8.47 d, J=1.5 Hz, 1H), 8.32 (d, J=2.7 Hz, 1H), 8.13 (dd, J=2.7, 1.5 Hz, 1H), 7.65 (d, J=8.4 Hz, 2H), 7.32 (d, J=8.4 Hz, 2H), 4.40 (s, 2H), 4.02 (dd, J=7.5, 4.5 Hz, 1H), 3.94–3.73 (m, 2H), 3.58–3.46 (m, 2H),


3.44–3.34 (m, 2H), 2.52–2.34 (m, 2H), 2.30–2.10 (m, 2H), 1.90–1.43 (m, 5H), 1.43–1.26 (m, 2H), 0.99–0.90 (m, 9H).


EXAMPLE 24(106)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-carboxyphenyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.20 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.11 (d, J=8.4 Hz, 2H), 7.83 (d, J=8.4 Hz, 2H), 7.77 (d, J=8.4 Hz, 2H), 7.69 (d, J=8.4 Hz, 2H), 4.43 (s, 2H), 4.01 (dd, J=7.8, 4.5 Hz, 1H), 3.96–3.74 (m, 2H), 3.58–3.36 (m, 4H), 2.55–2.38 (m, 2H), 2.28–2.10 (m, 2H), 1.88–1.44 (m, 5H), 1.44–1.30 (m, 2H), 0.97–0.92 (m, 9H).


EXAMPLE 24(107)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(pyridin-4-yl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.50 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.91 (d, J=6.9 Hz, 2H), 8.45 (d, J=6.9 Hz, 2H), 8.11 (d, J=7.8 Hz, 2H), 7.91 (d, J=7.8 Hz, 2H), 4.49 (s, 2H), 4.01 (dd, J=7.8, 4.8 Hz, 1H), 3.96–3.78 (m, 2H), 3.58–3.40 (m, 4H), 2.64–2.48 (m, 2H), 2.26–2.08 (m, 2H), 1.90–1.28 (m, 7H), 0.96–0.93 (m, 9H).


EXAMPLE 24(108)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(pyridin-2-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.46 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.44–8.15 (m, 2H), 7.82 (d, J=7.2 Hz, 2H), 7.60–7.40 (m, 1H), 7.42 (d, J=7.2 Hz, 2H), 7.27–7.24 (m, 1H), 4.43 (s, 2H), 4.02 (dd, J=7.5, 4.5 Hz, 1H), 3.92–3.70 (m, 2H), 3.58–3.40 (m, 4H), 2.64-2.42 (m, 2H), 2.28–2.06 (m, 2H), 1.92–1.28 (m, 7H), 0.97–0.94 (m, 9H).


EXAMPLE 24(109)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(naphthalen-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.71 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.08–7.93 (m, 4H), 7.64–7.57 (m, 3H), 4.54 (s, 2H), 4.04 (dd, J=7.5, 4.8 Hz, 1H), 3.96–3.80 (m, 2H), 3.60–3.44 (m, 2H), 3.42–3.36 (m, 2H), 2.42–2.08 (m, 4H), 1.82–1.16 (m, 15H), 0.95 (t, J=7.5 Hz, 3H), 0.95 (m, 2H).


EXAMPLE 24(110)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(6-methoxynaphthalen-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.75 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.98 (s, 1H), 7.91 (d, J=8.7 Hz, 1H), 7.85 (d, J=8.7 Hz, 1H), 7.58 (d, J=8.7 Hz, 1H), 7.31 (d, J=2.4 Hz, 1H), 7.22 (dd, J=8.7, 2.4 Hz, 1H), 4.48 (s, 2H), 4.04 (dd, J=7.8, 4.8 Hz, 1H), 3.94–3.78 (m, 2H), 3.93 (s, 3H), 3.58–3.44 (m, 2H), 3.42–3.36 (m, 2H), 2.48–2.30 (m, 2H), 2.24–2.08 (m, 2H), 1.82–1.10 (m, 15H), 0.95 (t, J=7.2 Hz, 3H), 0.95 (m, 2H).


EXAMPLE 24(111)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-carboxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.27 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.03 (d, J=8.7 Hz, 2H), 7.63 (d, J=8.4 Hz, 2H), 7.17 (d, J=8.4 Hz, 2H), 7.07 (d, J=8.7 Hz, 2H), 4.37 (s, 2H), 4.01 (dd, J=7.5, 4.5 Hz, 1H), 3.90–3.70 (m, 2H), 3.56–3.36 (m, 4H), 2.56–2.38 (m, 2H), 2.25–2.10 (m, 2H), 1.84–1.44 (m, 5H), 1.44–1.39 (m, 2H), 0.98–0.93 (m, 9H).


EXAMPLE 24(112)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-(pyridin-4-yl)furan-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.39 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.80 (d, J=6.9 Hz, 2H), 8.39 (d, J=6.9 Hz, 2H), 7.69 (d, J=3.6 Hz, 1H), 7.08 (d, J=3.6 Hz, 1H), 4.62 (s, 2H), 4.00 (dd, J=7.8, 4.5, Hz, 1H), 3.99–3.79 (m, 2H), 3.65–3.43 (m, 4H), 2.72–2.54 (m, 2H), 2.30–2.10 (m, 2H), 1.88–1.26 (m, 7H), 1.00–0.84 (m, 9H).


EXAMPLE 24(113)
1-butyl-2,5-dioxo-3-cyclopentylmethyl-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.66 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.52 (d, J=8.5 Hz, 2H), 7.40 (t, J=7.5 Hz, 2H), 7.18 (t, J=7.5 Hz, 1H), 7.05 (m, 4H), 4.34 (s, 2H), 4.00 (t, J=6.0 Hz, 1H), 3.82 (m, 2H), 3.49 (m, 2H), 3.39 (m, 2H), 2.37 (m, 2H), 2.17 (m, 2H), 1.96 (m, 1H), 1.81 (m, 4H), 1.58 (m, 6H), 1.38 (m, 2H), 1.17 (m, 2H), 0.95 (t, J=7.0 Hz, 3H).


EXAMPLE 24(114)
(3R)-1-butyl-2,5-dioxo-3-(2,2-dimethylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.52 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.52 (d, J=9.0 Hz, 2H), 7.40 (t, J=7.5 Hz, 2H), 7.18 (t, J=7.5 Hz, 1H), 7.04 (m, 4H), 4.33 (s, 2H), 4.01 (dd, J=7.2, 3.3 Hz, 1H), 3.82 (m, 1H), 3.71 (m, 1H), 3.50 (m, 2H), 3.43 (m, 2H), 2.38 (m, 2H), 2.24 (m, 2H), 2.00 (dd, J=14.0, 3.3 Hz, 1H), 1.55 (dd, J=14.0, 7.2 Hz, 1H), 1.50 (m, 2H), 1.36 (m, 2H), 0.99 (s, 9H), 0.95 (t, J=7.0 Hz, 3H).


EXAMPLE 24(115)
(3S)-1-butyl-2,5-dioxo-3-(2,2-dimethylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.52 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.52 (d, J=9.0 Hz, 2H), 7.40 (t, J=7.5 Hz, 2H), 7.18 (t, J=7.5 Hz, 1H), 7.04 (m, 4H), 4.33 (s, 2H), 4.01 (dd, J=7.2, 3.3 Hz, 1H), 3.82 (m, 1H), 3.71 (m, 1H), 3.50 (m, 2H), 3.43 (m, 2H), 2.38 (m, 2H), 2.24 (m, 2H), 2.00 (dd, J=14.0, 3.3 Hz, 1H), 1.55 (dd, J=14.0, 7.2 Hz, 1H), 1.50 (m, 2H), 1.36 (m, 2H), 0.99 (s, 9H), 0.95 (t, J=7.0 Hz, 3H).


EXAMPLE 24(116)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-nitrophenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.68 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.33 (d, J=8.7 Hz, 2H), 7.78 (d, J=8.7 Hz, 2H), 4.49 (s, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.93–3.76 (m, 2H), 3.55–3.43 (m, 2H), 3.40–3.31 (m, 2H), 2.45–2.28 (m, 2H), 2.27–2.08 (m, 2H), 1.83–1.14 (m, 15H), 1.04–0.86 (m, 5H).


EXAMPLE 24(117)
(3R)-1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-phenylmethyl-9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.55 (chloroform:methanol=10:1);


NMR (CDCl3): δ 7.38–7.14 (m, 10H), 6.00–5.75 (m, 1H), 4.40–4.15 (m, 2H), 3.92–3.58 (m, 3H), 3.58–2.25 (m, 13H), 2.18–1.45 (m, 10H).


EXAMPLE 24(118)
(3S)-1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-phenylmethyl-9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.55 (chloroform:methanol=10:1);


NMR (CDCl3): δ 7.40–7.15 (m, 10H), 6.05–5.80 (m, 1H), 4.40–4.10 (m, 2H), 3.90–3.55 (m, 3H), 3.55–2.20 (m, 13H), 2.18–1.45 (m, 10H).


EXAMPLE 24(119)
(3S)-1-propyl-2,5-dioxo-3-(3-(benzyloxycarbonyl amino) propyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.32 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.40–7.20 (m, 10H), 5.06 (s, 2H), 4.09 (dd, J=5.2, 4.6 Hz, 1H), 4.00–3.70 (m, 2H), 3.70–3.55 (m, 2H), 3.50–3.30 (m, 4H), 3.20–3.00 (m, 4H), 2.65–2.35 (m, 2H), 2.30–2.10 (m, 2H), 2.00–1.75 (m, 2H), 1.70–1.40 (m, 4H), 0.96 (t, J=7.4 Hz, 3H).


EXAMPLE 25
1-butyl-2,5-dioxo-3-(carboxymethyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


To a solution of the compound prepared in Example 24(11) (173 mg) in methanol (5 mL) was added 2N aqueous solution of sodium hydroxide (2 ml). The reaction mixture was stirred for 3 hours at room temperature. The reaction mixture was acidified to pH 4 by adding 2N hydrochloric acid, and was extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate and concentrated. The obtained residue was dissolved in 1,4-dioxane, and 4N hydrogen chloride-1,4-dioxane solution was added thereto. The reaction mixture was concentrated. The obtained residue was washed with diethyl ether and dried to give the compound of the present invention (127 mg) having the following physical data.


TLC: Rf 0.51 (chloroform:methanol:acetic acid=20:4:1);


NMR (CD3OD): 7.55–7.53 (m, 2H), 7.42–7.36 (m, 2H), 7.20–7.15 (m, 1H), 7.07–7.02 (m, 4H), 4.33 (s, 2H), 4.27 (t, J=4.5 Hz, 1H), 3.96–3.90 (m, 1H), 3.72–3.66 (m, 1H), 3.54–3.38 (m, 4H), 2.97 (dd, J=18.0,4.8Hz, 1H), 2.79 (dd, J=18.0, 4.8 Hz, 1H), 2.50–2.36 (m, 3H), 2.27–2.16 (m, 1H), 1.62–1.48 (m, 2H), 1.41–1.30 (m, 2H), 0.94 (t, J=7.2 Hz, 3H).


EXAMPLE 26(1)˜26(3)

By the same procedure as described in Reference Example 3→Reference Example 4 using Resin (3) prepared in Reference Example 2 and N-allyloxycarbonyl-4-piperidone, using the corresponding compounds respectively instead of n-propylamine and N-(t-butyloxycarbonyl) leucine, and furthermore by the same procedure as described in Reference Example 5→Reference Example 6→Example 1 using the corresponding compound instead of 3,5-dimethyl-1-phenyl-4-formylpyrazole, and furthermore by the same procedure as described in Example 25 because of acetylation of a part of hydroxy group, the following compounds of the present invention were obtained.


EXAMPLE 26(1)
1-(3-hydroxybutyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.49 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.54 (d, J=8.5 Hz, 2H), 7.39 (t, J=7.5 Hz, 2H), 7.18 (t, J=7.5 Hz, 1H), 7.04 (m, 4H), 4.33 (s, 2H), 4.02 (m, 1H), 3.80 (m, 3H), 3.51 (m, 4H), 2.46 (m, 2H), 2.19 (m, 2H), 1.85–1.57 (m, 5H), 1.17 (d, J=6.0 Hz, 3H), 0.94 (d, J=9.0 Hz, 6H).


EXAMPLE 26(2)
1-(3-hydroxypropyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.46 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.51 (d, J=8.5 Hz, 2H), 7.40 (t, J=7.5 Hz, 2H), 7.18 (t, J=7.5 Hz, 1H), 7.04 (m, 4H), 4.34 (s, 2H), 4.02 (dd, J=7.5, 4.0 Hz, 1H), 3.80 (m, 2H), 3.60 (t, J=6.0 Hz, 2H), 3.48 (m, 4H), 2.40 (m, 2H), 2.20 (m, 2H), 1.82–1.58 (m, 5H), 0.94 (d, J=6.0 Hz, 3H), 0.93 (d, J=6.0 Hz, 3H).


EXAMPLE 26(3)
1-(2-hydroxybutyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.49 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.50 (d, J=8.7 Hz, 2H), 7.39 (dd, J=8.7, 7.5 Hz, 2H), 7.18 (t, J=7.5 Hz, 1H), 7.10–7.00 (m, 4H), 4.32 (s, 2H), 4.03 (dd, J=8.1, 4.8 Hz, 1H), 3.96–3.41 (m, 6H), 3.27–3.14 (m, 1H), 2.68–2.53 (m, 1H), 2.37–2.26 (m, 3H), 1.94–1.24 (m, 5H), 1.08–0.82 (m, 9H).


EXAMPLE 27
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-aminophenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


Under an atmosphere of argon, to a solution of the compound prepared in Example 24(116) (50 mg) in methanol was added 5% palladium on carbon (10 mg). Under an atmosphere of hydrogen, the reaction mixture was stirred for 20 minutes at room temperature. The reaction mixture was filtrated through Celite (brand name). The filtrate was concentrated. The residue was purified by column chromatography on silica gel (chloroform:methanol=50:1→30:1→20:1). The obtained compound was dissolved in methanol, and 4N-hydrogen chloride/ethyl acetate solution was added thereto. It was concentrated. The obtained residue was washed with diethyl ether and dried to give the compound of the present invention (34 mg) having the following physical data.


TLC: Rf 0.21 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.80 (d, J=8.4 Hz, 2H), 7.47 (d, J=8.4 Hz, 2H), 4.41 (s, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.86–3.74 (m, 2H), 3.52–3.45 (m, 4H), 2.65–2.52 (m, 2H), 2.24–2.08 (m, 2H), 1.80–1.16 (m, 15H), 0.94 (t, J=7.5 Hz, 3H), 0.94 (m, 2H).


EXAMPLE 28
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-((4-methylphenyl)sulfonylamino)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


To a solution of the compound prepared in Example 28 (33 mg) in pyridine (2 ml) was added p-toluenesulfonyl chloride (21 mg). The reaction mixture was stirred for 27 hours at room temperature. The reaction mixture was concentrated, and saturated aqueous solution of sodium hydrogen carbonate was added thereto. It was extracted with ethyl acetate. The extract was washed with saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography on silica gel (chloroform:methanol=10:1). The obtained compound was dissolved in methanol, and 4N hydrogen chloride/ethyl acetate solution was added thereto, and it was concentrated. The residue was washed with diethyl ether and dried to give the compound of the present invention (27 mg) having the following physical data.


TLC: Rf 0.63 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.70 (d, J=8.4 Hz, 2H), 7.41 (d, J=8.4 Hz, 2H), 7.30 (d, J=8.4 Hz, 2H), 7.22 (d, J=8.4 Hz, 2H), 4.25 (s, 2H), 4.03 (dd, J=7.2, 4.5 Hz, 1H), 3.78 (m, 2H), 3.42 (m, 4H), 2.42–2.06 (m, 4H), 2.37 (s, 3H), 1.82–1.10 (m, 15H), 0.95 (t, J=7.2 Hz, 3H), 0.95 (m, 2H).


EXAMPLE 28(1)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(phenylcarbonylamino)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


By the same procedure as described in Example 28 using benzoyl chloride instead of p-toluenesulfonyl chloride, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.43 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.93 (d, J=8.4 Hz, 2H), 7.88 (d, J=8.4 Hz, 2H), 7.61–7.50 (m, 5H), 4.34 (s, 2H), 4.05 (dd, J=7.8, 4.5 Hz, 1H), 3.80 (m, 2H), 3.42 (m, 4H), 2.24 (m, 4H), 1.82–1.16 (m, 15H), 0.96 (t, J=7.2 Hz, 3H), 0.96 (m, 2H).


EXAMPLE 29
(3S)-1-butyl-2,5-dioxo-3-benzyloxymethyl-9-benzyloxycarbonyl-1,4,9-triazaspiro[5.5]undecane



embedded image


By the same procedure as described in Reference Example 3→Reference Example 6→Example 1 using Resin (3) prepared in Reference Example 2 and N-benzyloxycarbonyl-4-piperidone, O-benzyl-N-(t-butyloxycarbonyl)-L-serine, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.66 (chloroform:methanol=20:1);


NMR (CDCl3): δ 7.40–7.25 (m, 10H), 6.09 (brs, 1H), 5.15 (s, 2H), 4.54 (s, 2H), 4.20–3.98 (br, 2H), 4.18(dd, J=8.4, 3.6 Hz, 1H), 3.93 (dd, J=9.3, 3.6 Hz, 1H), 3.80–3.56 (br, 1H), 3.66 (dd, J=9.3, 8.4, Hz, 1H), 3.45–3.12 (m, 3H), 2.02–1.75 (m, 4H), 1.57–1.39 (m, 2H), 1.38–1.20.(m, 2H), 0.91 (t, J=7.2 Hz, 3H).


EXAMPLE 30
(3S)-1-butyl-2,5-dioxo-3-hydroxymethyl-9-benzyloxycarbonyl-1,4,9-triazaspiro[5.5]undecane



embedded image


To a solution of the compound prepared in Example 29 (245 mg) in dichloromethane (5 ml) was added a 1 M solution of tribromoborane in dichloromethane (1.4 ml) at −40° C., and it was stirred for 3 hours at −20° C. To the reaction mixture were added water and saturated aqueous solution of sodium hydrogen carbonate, and it was extracted with ethyl acetate. The extract was washed with water and saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography on silica gel (chloroform:methanol=30:1) to give the compound of the present invention (173 mg) having the following physical data.


TLC: Rf 0.29 (chloroform:methanol=20:1);


NMR (CDCl3): δ 7.42–7.27 (m, 5H), 6.26–6.15 (br, 1H), 5.16 (s, 2H), 4.26–4.00 (m, 2H), 3.98–3.82 (m, 2H), 3.84–3.60 (br, 1H), 3.43–3.13 (m, 4H), 2.80–2.68 (br, 1H), 2.05–1.75 (m, 4H), 1.58–1.40 (m, 2H), 1.40–1.20 (m, 2H), 0.92 (t, J=7.5 Hz, 3H).


EXAMPLE 31
(3S)-1-butyl-2,5-dioxo-3-hydroxymethyl-1,4,9-triazaspiro[5.5]undecane



embedded image


By the same procedure as described in Example 9 using the compound prepared in Example 30, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.21 (chloroform: methanol: acetic acid=20:4:1);


NMR (d6-DMSO): δ 7.83 (brs, 1H), 5.10–4.90 (br, 1H), 3.88–3.78 (m, 1H), 3.76–3.65 (m, 1H), 3.58–3.48 (m, 1H), 3.28–3.18 (m, 1H), 3.18–3.04 (m, 3H), 2.88–2.75 (m, 2H), 1.94–1.83 (m, 1H), 1.83–1.64 (m, 3H), 1.56–1.42 (m, 1H), 1.42–1.20 (m, 3H), 0.88 (t, J=7.2 Hz, 3H).


EXAMPLE 32(1)
(3S)-1-butyl-2,5-dioxo-3-hydroxymethyl-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


By the same procedure as described in Example 10 using 4-phenyloxybenzaldehyde and the compound prepared in Example 31, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.49 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.52 (d, J=8.7 Hz, 2H), 7.43–7.35 (m, 2H), 7.22–7.14 (m, 1H), 7.06 (d, J=8.7 Hz, 2H), 7.06–7.00 (m, 2H), 4.33 (s, 2H), 4.03–3.90 (m, 3H), 3.79–3.66 (m, 1H), 3.65 (dd, J=10.5, 2.4 Hz, 1H), 3.61–3.42 (m, 3H), 3.30–3.18 (m, 1H), 2.50–2.24 (m, 3H), 2.24–2.12 (m, 1H), 1.76–1.58 (m, 1H), 1.54–1.26 (m, 3H), 0.95 (t, J=7.5 Hz, 3H).


EXAMPLE 32(2)
(3S)-1-butyl-2,5-dioxo-3-hydroxymethyl-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


By the same procedure as described in Example 10 using 1-phenyl-3,5-dimethyl-4-formylpyrazole and the compound prepared in Example 31, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.47 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.61–7.46 (m, 5H), 4.32 (s, 2H), 4.08–3.92 (m, 3H), 3.83–3.70 (m, 1H), 3.66 (dd, J=10.5, 2.4 Hz, 1H), 3.66–3.52 (m, 3H), 3.40–3.25 (m, 1H), 2.64–2.50 (m, 1H), 2.50–2.40 (m, 2H), 2.41 (s, 3H), 2.39 (s, 3H), 2.28–2.15 (m, 1H), 1.80–1.58 (m, 1H), 1.58–1.30 (m, 3H), 0.96 (t, J=7.5 Hz, 3H).


REFERENCE EXAMPLE 11
Preparation of Compound (7)



embedded image


By the same procedure as described in Reference Example 3→Reference Example 4 using Resin (3) prepared in Reference Example 2 and N-allyloxycarbonyl-4-piperidone, n-butylamine and N-(t-butyloxycarbonyl)leucine, and furthermore by the same procedure as described in Reference Example 5 using 4-hydroxybenzaldehyde instead of 3,5-dimethyl-1-phenyl-4-formylpyrazole, compound (7) was obtained.


REFERENCE EXAMPLE 12
Preparation of Compound (8)



embedded image


To a suspension of the compound prepared in Reference Example 11 (60 mg) in dichloromethane (2 ml) were added triphenylphosphine (80 mg), 1M cyclopentanol-dichloromethane solution (0.302 ml) and diethylazodicarboxylate (0.137 ml). The reaction mixture was stirred for 18 hours at room temperature. The reaction solution was filtrated. The obtained resin was washed with dichloromethane (2 ml×4), methanol (2 ml×3), and dichloromethane (3 ml×4) to give compound (8).


EXAMPLE 33
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-cyclopentyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


By the same procedure as described in Reference Example 6→Example 1 using the compound prepared in Reference Example 12, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.49 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.41 (d, J=8.7 Hz, 2H), 6.98 (d, J=8.7 Hz, 2H), 4.83 (m, 1H), 4.25 (brs, 2H), 4.00 (dd, J=7.8, 4.5 Hz, 1H), 3.86–3.65 (m, 2H), 3.53–3.27 (m, 4H), 2.40–2.06 (m, 4H), 2.02–1.43 (m, 13H), 1.43–1.24 (m, 2H), 1.01–0.90 (m, 9H).


EXAMPLE 33(1)˜33(6)

By the same procedure as described in Reference Example 11 using the corresponding compounds instead of n-butylamine and N-(t-butyloxycarbonyl)leucine, and by the same procedure as described in Reference Example 12→Example 33 using the corresponding compounds instead of cyclopentanol, the following compounds of the present invention were obtained.


EXAMPLE 33(1)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(2-diethylaminoethyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.54 (chloroform:methanol: 28% NH4OH=80:10:1);


NMR (CD3OD): δ 7.57 (d, J=8.7 Hz, 2H), 7.12 (d, J=8.7 Hz, 2H), 4.40 (t, J=4.8 Hz, 2H), 4.30 (s, 2H), 4.03 (dd, J=7.5, 5.1 Hz, 1H), 3.84–3.67 (m, 2H), 3.63 (t, J=4.8 Hz, 2H), 3.50–3.40 (m, 4H), 3.40–3.31 (m, 4H), 2.58–2.41 (m, 2H), 2.23–2.04 (m, 2H), 1.82–1.42 (m, 10H), 1.41–1.12 (m, 11H), 1.04–0.87 (m, 5H).


EXAMPLE 33(2)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(2-dimethylaminoethyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.46 (chloroform:methanol: 28% NH4OH=80:10:1);


NMR (CD3OD): δ 7.57 (d, J=8.7 Hz, 2H), 7.13 (d, J=8.7 Hz, 2H), 4.39 (t, J=4.8 Hz, 2H), 4.30 (s, 2H), 4.02 (dd, J=7.5, 4.5 Hz, 1H), 3.84–3.67 (m, 2H), 3.61 (t, J=4.8 Hz, 2H), 3.50–3.38 (m, 4H), 2.98 (s, 6H), 2.59–2.42 (m, 2H), 2.24–2.03 (m, 2H), 1.83–1.12 (m, 15H), 1.04–0.86 (m, 5H).


EXAMPLE 33(3)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-propyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.59 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.43 (d, J=8.7 Hz, 2H), 7.01 (d, J=8.7 Hz, 2H), 4.27 (brs, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.96 (t, J=6.6 Hz, 2H), 3.85–3.67 (m, 2H), 3.53–3.33 (m, 4H), 2.45–2.27 (m, 2H), 2.26–2.07 (m, 2H), 1.86–1.14 (m, 17H), 1.03 (t, J=7.2 Hz, 3H), 1.00–0.89 (m, 5H).


EXAMPLE 33(4)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-cyclohexylmethyl-9-(4-cyclopropylmethyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.61 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.42 (d, J=8.7 Hz, 2H), 7.27 (dd, J=5.4, 0.9 Hz, 1H), 7.06–6.97 (m, 3H), 6.91 (dd, J=5.4, 3.6 Hz, 1H), 4.95–4.85 (m, 2H), 4.27 (brs, 2H), 4.14 (dd, J=7.5, 4.5 Hz, 1H), 3.84 (d, J=6.6 Hz, 2H), 3.84–3.66 (m, 2H), 3.51–3.39 (m, 2H), 2.59–2.36 (m, 2H), 2.24–2.07 (m, 2H), 1.84–1.44 (m, 8H), 1.35–1.12 (m, 4H), 1.04–0.85 (m, 2H), 0.66–0.57 (m, 2H), 0.38–0.31 (m, 2H).


EXAMPLE 33(5)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-cyclopropylmethyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.61 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.42 (d, J=8.4 Hz, 2H), 7.01 (d, J=8.4 Hz, 2H), 4.26 (brs, 2H), 4.03 (dd, J=7.8, 4.8 Hz, 1H), 3.84 (d, J=6.9 Hz, 2H), 3.83–3.66 (m, 2H), 3.51–3.33 (m, 4H), 2.44–2.26 (m, 2H), 2.25–2.06 (m, 2H), 1.82–1.12 (m, 16H), 1.04–0.86 (m, 5H), 0.66–0.57 (m, 2H), 0.38–0.31 (m, 2H).


EXAMPLE 33(6)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-cyclopropylmethyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.55 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.42 (d, J=8.7 Hz, 2H), 7.01 (d, J=8.7 Hz, 2H), 4.26 (brs, 2H), 4.00 (dd, J=7.8, 4.5 Hz, 1H), 3.84 (d, J=6.9 Hz, 2H), 3.84–3.66 (m, 2H), 3.50–3.33 (m, 4H), 2.43–2.26 (m, 2H), 2.26–2.08 (m, 2H), 1.89–1.43 (m, 5H), 1.43–1.17 (m, 3H), 1.00–0.88 (m, 9H), 0.66–0.58 (m, 2H), 0.38–0.31 (m, 2H).


EXAMPLE 34
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(dimethylamino)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


By the same procedure as described in Example 10 using 4-dimethylaminobenzaldehyde and the compound prepared in Example 9(1), the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.26 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.78 (d, J=8.7 Hz, 2H), 7.59 (d, J=8.7 Hz, 2H), 4.39 (s, 2H), 4.03 (dd, J=7.5, 4.8, Hz, 1H), 3.90–3.70 (m, 2H), 3.52–3.40 (m, 4H), 3.26 (s, 6H), 2.64–2.47 (m, 2H), 2.24–2.04 (m, 2H), 1.82–1.12 (m, 15H), 1.04–0.88 (m, 5H).


EXAMPLE 34(1)
1-butyl-2,5-dioxo-3-cyclohexyl methyl-9-(4-(diethylamino) phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


By the same procedure as described in Example 34 using 4-diethylaminobenzaldehyde instead of 4-dimethylaminobenzaldehyde, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.28 (chloroform:methanol: acetic acid=10:1);


NMR (CD3OD): δ 7.94–7.78 (m, 2H), 7.72–7.52 (m, 2H), 4.43 (s, 2H), 4.03 (dd, J=7.5, 4.8, Hz, 1H), 3.92–3.73 (m, 2H), 3.73–3.60 (m, 4H), 3.54–3.40 (m, 4H), 2.63–2.45 (m, 2H), 2.25–2.05 (m, 2H), 1.82–1.10 (m, 21H), 1.04–0.86 (m, 5H).


EXAMPLE 35
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-benzyloxycarbonyl-1,4,9-triazaspiro[5.5]undecane



embedded image


By the same procedure as described in Reference Example 3→Reference Example 6→Example 1 using Resin (3) prepared in Reference Example 2, N-benzyloxycarbonyl-4-piperidone, n-butylamine and N-(t-butyloxycarbonyl)-L-leucine, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.67 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.35 (m, 5H), 6.50 (brs, 1H), 5.15 (s, 2H), 4.08 (m, 2H), 3.96 (m, 1H), 3.62 (brs, 1H), 3.44(brs, 1H), 3.26 (m, 2H), 1.95–1.76 (m, 4H), 1.61–1.45 (m, 5H), 1.31 (m, 2H), 0.96 (d, J=6.3 Hz, 3H), 0.93 (d, J=6.3 Hz, 3H), 0.91 (t, J=7.2 Hz, 3H).


EXAMPLE 36
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


By the same procedure as described in Example 9 using the compound prepared in Example 35, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.18 (chloroform:methanol=4:1);


NMR (CD3OD): δ 4.02 (dd, J=7.8, 4.6 Hz, 1H), 3.80 (dd, J=12.5, 4.0 Hz, 1H), 3.72 (dd, J=12.5, 4.0 Hz, 1H), 3.39 (m, 4H), 2.34–2.09 (m, 4H), 1.88–1.50 (m, 5H), 1.37 (m, 2H), 0.96 (t, J=7.5 Hz, 3H), 0.95 (d, J=6.5 Hz, 3H), 0.94 (d, J=6.5 Hz, 3H).


EXAMPLE 37(1)˜37(88)

By the same procedure as described in Example 10 using the compound prepared in Example 36 and the corresponding aldehyde derivatives, the following compounds of the present invention were obtained.


EXAMPLE 37(1)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-(3-methyl-4-chlorophenyl)-1-(4-methylphenylmethyl) pyrazol-3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.46 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.42 (d, J=8.1 Hz, 1H), 7.28 (d, J=1.5 Hz, 1H), 7.19 (dd, J=8.1, 1.5 Hz, 1H), 7.11 (d, J=8.1 Hz, 2H), 6.92 (d, J=8.1 Hz, 2H), 6.65 (s, 1H), 5.35 (s, 2H), 4.40 (s, 2H), 4.02 (dd, J=7.5, 4.5 Hz, 1H), 3.97–3.76 (m, 2H), 3.64–3.52 (m, 2H), 3.46–3.35 (m, 2H), 2.56–2.38 (m, 2H), 2.35 (s, 3H), 2.28 (s, 3H), 2.30–2.10 (m, 2H), 1.91–1.46 (m, 5H), 1.46–1.30 (m, 2H), 0.96 (t, J=6.9 Hz, 3H), 0.95 (d, J=6.3 Hz, 6H).


EXAMPLE 37(2)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-dimethylaminophenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.47 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.78 (d, J=8.7 Hz, 2H), 7.58 (d, J=8.7 Hz, 2H), 4.40 (s, 2H), 4.01 (dd, J=7.8, 4.5 Hz, 1H), 3.82 (m, 2H), 3.42 (m, 4H), 3.26 (s, 6H), 2.56 (m, 2H), 2.18 (m, 2H), 1.88–1.30 (m, 7H), 0.95 (t, J=7.2 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H).


EXAMPLE 37(3)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-diethylaminophenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.34 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.96–7.82 (m, 2H), 7.74–7.55 (m, 2H), 4.40 (s, 2H), 4.00 (dd, J=7.5, 4.5 Hz, 1H), 3.93–3.60 (m, 6H), 3.55–3.40 (m, 4H), 2.65–2.48 (m, 2H), 2.25–2.06 (m, 2H), 1.89–1.26 (m, 7H), 1.15 (t, J=7.2 Hz, 6H), 1.00–0.87 (m, 9H).


EXAMPLE 37(4)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-cyclohexyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.61 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.45–7.42 (m, 2H), 7.02–6.99 (m, 2H), 4.40–4.31 (m, 1H), 4.27 (s, 2H), 4.00 (dd, J=8.0, 4.5 Hz, 1H), 3.83–3.70 (m, 2H), 3.47 (brd, 2H), 3.42–3.35 (m, 2H), 2.43–2.32 (m, 2H), 2.24–2.11 (m, 2H), 2.00–1.93 (m, 2H), 1.86–1.32 (m, 15H), 0.97–0.92 (m, 9H).


EXAMPLE 37(5)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-methylphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.70 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.52–7.47 (m, 2H), 7.22–7.19 (m, 2H), 7.04–7.00 (m, 2H), 6.94–6.90 (m, 2H), 4.32 (s, 2H), 4.01 (dd, J=8.0, 4.5 Hz, 1H), 3.86–3.73 (m, 2H), 3.48 (brd, 2H), 3.42–3.34 (m, 2H), 2.45–2.33 (m, 5H), 2.25–2.12 (m, 2H), 1.85–1.48 (m, 5H), 1.41–1.31 (m, 2H), 0.97–0.92 (m, 9H).


EXAMPLE 37(6)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-methoxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.65 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.49–7.46 (m, 2H), 7.00–6.94 (m, 6H), 4.31 (s, 2H), 4.01 (dd, J=8.0, 4.5 Hz, 1H), 3.84–3.71 (m, 5H), 3.48 (brd, 2H), 3.40–3.31 (m, 2H), 2.42–2.30 (m, 2H), 2.25–2.12 (m, 2H), 1.83–1.48 (m, 5H), 1.41–1.30 (m, 2H), 0.97–0.92 (m, 9H).


EXAMPLE 37(7)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-butyl phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.35 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.46 (d, J=8.1 Hz, 2H), 7.32 (d, J=8.1 Hz, 2H), 4.31 (s, 2H), 4.01 (dd, J=7.8, 4.5 Hz, 1H), 3.84–3.68 (m, 2H), 3.54–3.36 (m, 4H), 2.67 (t, J=7.8 Hz, 2H), 2.48–2.30 (m, 2H), 2.26–2.08 (m, 2H), 1.90–1.28 (m, 11H), 0.96 (t, J=7.2 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H), 0.94 (t, J=7.2 Hz, 3H).


EXAMPLE 37(8)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(2-methylpropyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.38 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.47 (d, J=6.9 Hz, 2H), 7.30 (d, J=6.9 Hz, 2H), 4.33 (s, 2H), 4.01 (dd, J=7.5, 4.5 Hz, 1H), 3.90–3.70 (m, 2H), 3.56–3.34 (m, 4H), 2.53 (d, J=7.2 Hz, 2H), 2.53–2.30 (m, 2H), 2.24–2.08 (m, 2H), 1.96–1.26 (m, 8H), 0.95 (t, J=7.8 Hz, 3H), 0.95 (d, J=6.6 Hz, 3H), 0.94 (d, J=6.6 Hz, 3H), 0.91 (d, J=6.6 Hz, 6H).


EXAMPLE 37(9)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-fluorophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.36 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.53 (d, J=8.4 Hz, 2H), 7.17 (d, J=8.4 Hz, 2H), 7.16–7.04 (m, 4H), 4.33 (s, 2H), 4.02 (dd, J=7.8, 4.8 Hz, 1H), 3.88–3.68 (m, 2H), 3.58–3.36 (m, 4H), 2.46–2.10 (m, 4H), 1.90–1.24(m, 7H), 0.96 (t, J=6.9 Hz, 3H), 0.95 (d, J=6.6 Hz, 3H), 0.94 (d, J=6.6 Hz, 3H).


EXAMPLE 37(10)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-hydroxy-4-methoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.20 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.03–6.94 (m, 3H), 4.23 (s, 2H), 4.01 (dd, J=7.8, 4.5 Hz, 1H), 3.89 (s, 3H), 3.84–3.68 (m, 2H), 3.56–3.36 (m, 4H), 2.42–2.08 (m, 4H), 1.88–1.24(m, 7H), 0.96 (t, J=7.2 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H).


EXAMPLE 37(11)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-fluorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.48 (hexane:ethyl acetate=1:1);


NMR (CD3OD): δ 7.64–7.54 (m, 2H), 7.37–7.27 (m, 2H), 4.45 (s, 2H), 4.01 (dd, J=7.5, 4.5 Hz, 1H), 3.94–3.81 (m, 2H), 3.54 (m, 2H), 3.36 (m, 2H), 2.38 (m, 2H), 2.19 (m, 2H), 1.82–1.49 (m, 5H), 1.35 (m, 2H), 0.95 (t, J=7.5 Hz, 3H), 0.94 (d, J=6.5 Hz, 3H), 0.93 (d, J=6.5 Hz, 3H).


EXAMPLE 37(12)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-fluorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.52 (hexane:ethyl acetate=1:1);


NMR (CD3OD): δ 7.52 (dt, J=8.3, 6.0 Hz, 1H), 7.41–7.37 (m, 2H), 7.26 (t, J=8.3 Hz, 1H), 4.39 (s, 2H), 4.01 (dd, J=7.5, 4.5 Hz, 1H), 3.89–3.76 (m, 2H), 3.50–3.38 (m, 4H), 2.48–2.38 (m, 2H), 2.25–2.12 (m, 2H), 1.84–1.75 (m, 1H), 1.72–1.46 (m, 4H), 1.42–1.28 (m, 2H), 0.99–0.92 (m, 9H).


EXAMPLE 37(13)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-fluorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.33 (hexane:ethyl acetate=1:1);


NMR (CD3OD): δ 7.60 (dd, J=8.7, 5.4 Hz, 2H), 7.24 (t, J=8.7 Hz, 2H), 4.36 (s, 2H), 3.99 (dd, J=7.5, 4.5 Hz, 1H), 3.78 (m, 2H), 3.49–3.35 (m, 4H), 2.44–2.13 (m, 4H), 1.84–1.46 (m, 5H), 1.37 (m, 2H), 0.99–0.95 (m, 9H).


EXAMPLE 37(14)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-chlorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.62 (hexane:ethyl acetate=1:1);


NMR (CD3OD): δ 7.72 (d, J=7.0 Hz, 1H), 7.60 (dd, J=8.0, 1.5 Hz, 1H), 7.56–7.45 (m, 2H), 4.55 (s, 2H), 4.00 (dd, J=7.5, 4.5 Hz, 1H), 3.94 (m, 2H), 3.55 (m, 2H), 3.42–3.32 (m, 2H), 2.43–2.37 (m, 2H), 2.26–2.13 (m, 2H), 1.85–1.46 (m, 5H), 1.35 (m, 2H), 0.97–0.92 (m, 9H).


EXAMPLE 37(15)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-chlorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.50 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.55 (d, J=8.7 Hz, 2H), 7.51 (d, J=8.7 Hz, 2H), 4.34 (s, 2H), 4.00 (dd, J=7.8, 4.5, Hz, 1H), 3.88–3.68 (m, 2H), 3.51–3.34 (m, 4H), 2.49–2.52 (m, 2H), 2.26–2.08 (m, 2H), 1.90–1.44 (m, 5H), 1.44–1.29 (m, 2H), 1.00–0.89 (m, 9H).


EXAMPLE 37(16)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-chlorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.55 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.68–7.64 (m, 1H), 7.56–7.45 (m, 3H), 4.37 (s, 2H), 4.00 (dd, J=7.8, 4.5 Hz, 1H), 3.91–3.72 (m, 2H), 3.54–3.32 (m, 4H), 2.53–2.34 (m, 2H), 2.27–2.08 (m, 2H), 1.90–1.44 (m, 5H), 1.44–1.27 (m, 2H), 0.99–0.89 (m, 9H).


EXAMPLE 37(17)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-methyl-4-methoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.34 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.38–7.30 (m, 2H), 6.99 (d, J=8.1 Hz, 1H), 4.25 (s, 2H), 4.00 (dd, J=7.8, 4.5 Hz, 1H), 3.85 (s, 3H), 3.85–3.65 (m, 2H), 3.52–3.33 (m, 4H), 2.50–2.30 (m, 2H), 2.22 (s, 3H), 2.20–2.07 (m, 2H), 1.90–1.43 (m, 5H), 1.43–1.28 (m, 2H), 0.99–0.88 (m, 9H).


EXAMPLE 37(18)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(7-methoxy-1,3-benzodioxolan-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.36 (chloroform:methanol=20:1);


NMR (CD3OD): δ 6.85 (d, J=1.8 Hz, 1H), 6.74 (d, J=1.8 Hz, 1H), 5.99 (s, 2H), 4.25 (s, 2H), 4.01 (dd, J=7.8, 4.5 Hz, 1H), 3.92 (s, 3H), 3.87–3.66 (m, 2H), 3.52–3.32 (m, 4H), 2.52–2.34 (m, 2H), 2.26–2.08 (m, 2H), 1.90–1.43 (m, 5H), 1.43–1.29 (m, 2H), 0.99–0.90 (m, 9H).


EXAMPLE 37(19)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenylthiophenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.52 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.50–7.36 (m, 7H), 7.30 (d, J=8.7 Hz, 2H), 4.31 (s, 2H), 4.00 (dd, J=7.8, 4.5 Hz, 1H), 3.88–3.68 (m, 2H), 3.53–3.32 (m, 4H), 2.50–2.30 (m, 2H), 2.26–2.06 (m, 2H), 1.90–1.42 (m, 5H), 1.42–1.27 (m, 2H), 0.98–0.89 (m, 9H).


EXAMPLE 37(20)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-methylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.41 (chloroform:methanol=19:1);


NMR (CD3OD): δ 7.57 (d, J=7.8 Hz, 1H), 7.42–7.28 (m, 3H), 4.41 (s, 2H), 4.01 (dd, J=7.8, 4.8 Hz, 1H), 3.89 (m, 2H), 3.53 (m, 2H), 3.42 (m, 2H), 2.48 (s, 3H), 2.48 (m, 2H), 2.16 (m, 2H), 1.90–1.42 (m, 5H), 1.36 (sextet, J=7.2 Hz, 2H), 0.94 (d, J=6.6 Hz, 3H), 0.94 (t, J=7.2 Hz, 3H), 0.93 (d, J=6.6 Hz, 3H).


EXAMPLE 37(21)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-methylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.31 (chloroform:methanol=19:1);


NMR (CD3OD): δ 7.41–7.29 (m, 4H), 4.31 (s, 2H), 4.00 (dd, J=7.8, 4.8 Hz, 1H), 3.79 (m, 2H), 3.52–3.34 (m, 4H), 2.40 (m, 2H), 2.40 (s, 3H), 2.17 (m, 2H), 1.90–1.44 (m, 5H), 1.36 (sextet, J=7.5 Hz, 2H), 0.94 (t, J=7.5 Hz, 3H), 0.94 (d, J=6.6 Hz, 3H), 0.93 (d, J=6.6 Hz, 3H).


EXAMPLE 37(22)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-methylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.31 (chloroform:methanol=19:1);


NMR (CD3OD): δ 7.43 (d, J=7.8 Hz, 2H), 7.31 (d, J=7.8 Hz, 2H), 4.31 (s, 2H), 4.00 (dd, J=7.8, 4.8 Hz, 1H), 3.78 (m, 2H), 3.52–3.35 (m, 4H), 2.40 (m, 2H), 2.37 (s, 3H), 2.17 (m, 2H), 1.88–1.44 (m, 5H), 1.36 (sextet, J=7.5 Hz, 2H), 0.94 (t, J=7.5 Hz, 3H), 0.94 (d, J=6.6 Hz, 3H), 0.93 (d, J=6.6 Hz, 3H).


EXAMPLE 37(23)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(1-methylethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.49 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.48 (d, J=8.4 Hz, 2H), 7.38 (d, J=8.4 Hz, 2H), 4.32 (s, 2H), 4.01 (dd, J=7.8, 4.5 Hz, 1H), 3.88–3.70 (m, 2H), 3.54–3.36 (m, 4H), 3.04–2.88 (m, 1H), 2.48–2.30 (m, 2H), 2.28–2.08 (m, 2H), 1.90–1.28(m, 7H), 1.26 (d, J=6.9 Hz, 6H), 0.95 (t, J=7.2 Hz, 3H), 0.95 (d, J=6.9 Hz, 3H), 0.94 (d, J=6.9 Hz, 3H).


EXAMPLE 37(24)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-fluoro-4-methoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.44 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.40–7.32 (m, 2H), 7.21 (m, 1H), 4.31 (s, 2H), 4.01 (dd, J=7.5, 4.5 Hz, 1H), 3.92 (s, 3H), 3.86–3.64 (m, 2H), 3.58–3.36 (m, 4H), 2.56–2.32 (m, 2H), 2.28–2.08 (m, 2H), 1.90–1.26(m, 7H), 0.96 (t, J=7.2 Hz, 3H), 0.95 (d, J=6.6 Hz, 3H), 0.94 (d, J=6.6 Hz, 3H).


EXAMPLE 37(25)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(2-hydroxyethyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.22 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.48 (d, J=8.7 Hz, 2H), 7.07 (d, J=8.7 Hz, 2H), 4.29 (s, 2H), 4.09 (t, J=5.1 Hz, 2H), 4.01 (dd, J=7.5, 4.5 Hz, 1H), 3.88 (t, J=5.1 Hz, 2H), 3.86–3.64 (m, 2H), 3.54–3.36 (m, 4H), 2.50–2.30 (m, 2H), 2.26–2.08 (m, 2H), 1.90–1.24(m, 7H), 0.96 (t, J=7.2 Hz, 3H), 0.95 (d, J=6.6 Hz, 3H), 0.94 (d, J=6.6 Hz, 3H).


EXAMPLE 37(26)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-hydroxy-3-methylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.66 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.24 (d, J=7.7 Hz, 2H), 6.89 (t, J=7.7 Hz, 1H), 4.36 (s, 2H), 4.02 (dd, J=7.5, 4.5 Hz, 1H), 3.95–3.76 (m, 2H), 3.58–3.36 (m, 4H), 2.44–2.08 (m, 4H), 2.89 (s, 3H), 1.90–1.24(m, 7H), 0.96 (t, J=7.2 Hz, 3H), 0.95 (d, J=6.6 Hz, 3H), 0.94 (d, J=6.6 Hz, 3H).


EXAMPLE 37(27)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-trifluoromethyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.49 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.71 (d, J=7.8 Hz, 2H), 7.42 (d, J=7.8 Hz, 2H), 4.41 (s, 2H), 4.01 (dd, J=7.8, 4.8 Hz, 1H), 3.90–3.72 (m, 2H), 3.56–3.36 (m, 4H), 2.56–2.36 (m, 2H), 2.26–2.08 (m, 2H), 1.90–1.28(m, 7H), 0.95 (t, J=7.5 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H).


EXAMPLE 37(28)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-methyl-5-chloro-1-phenyl pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.39 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.59–7.50 (m, 5H), 4.35 (s, 2H), 4.03 (dd, J=7.8, 4.5 Hz, 1H), 3.98–3.80 (m, 2H), 3.72–3.58 (m, 2H), 3.46–3.38 (m, 2H), 2.58–2.38 (m, 2H), 2.45 (s, 3H), 2.36–2.18 (m, 2H), 1.92–1.24 (m, 7H), 0.97 (t, J=7.5 Hz, 3H), 0.96 (d, J=6.6 Hz, 3H), 0.95 (d, J=6.6 Hz, 3H).


EXAMPLE 37(29)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(6-phenylpyridin-3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.28 (chloroform:methanol=10:1);


NMR (CD3OD): δ 9.17 (s, 1H), 8.80 (m, 1H), 8.39 (m, 1H), 8.03–7.97 (m, 2H), 7.73–7.65 (m, 3H), 4.65 (s, 2H), 4.03 (dd, J=7.2, 4.2 Hz, 1H), 4.02–3.82 (m, 2H), 3.64–3.42 (m, 2H), 3.78–3.56 (m, 2H), 2.30–2.08 (m, 2H), 1.88–1.24 (m, 7H), 0.96 (d, J=6.3 Hz, 3H), 0.95 (t, J=7.2 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H).


EXAMPLE 37(30)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-methylsulfonylaminophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.18 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.54 (d, J=8.7 Hz, 2H), 7.30 (d, J=9.0 Hz, 2H), 7.08 (d, J=8.7 Hz, 2H), 7.04 (d, J=9.0 Hz, 2H), 4.34 (s, 2H), 4.02 (dd, J 7.8, 4.5 Hz, 1H), 3.88–3.68 (m, 2H), 3.56–3.35 (m, 4H), 2.96 (s, 3H), 2.50–2.08 (m, 4H), 1.88–1.26 (m, 7H), 0.96 (t, J=6.9 Hz, 3H), 0.95 (d, J=6.6 Hz, 3H), 0.94 (d, J=6.6 Hz, 3H).


EXAMPLE 37(31)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-methylsulfonylaminophenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.15 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.49 (d, J=8.7 Hz, 2H), 7.43 (d, J=8.7 Hz, 2H), 4.33 (s, 2H), 4.03 (dd, J=7.8, 4.8 Hz, 1H), 3.96–3.76 (m, 2H), 3.66–3.58 (m, 2H), 3.56–3.42 (m, 2H), 3.05 (s, 3H), 2.68–2.46 (m, 2H), 2.44 (s, 3H), 2.41 (s, 3H), 2.32–2.10 (m, 2H), 1.90–1.28 (m, 7H), 0.97 (t, J=6.6 Hz, 3H), 0.96 (d, J=6.3 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H).


EXAMPLE 37(32)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(5-methylpyridin-2-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.29 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.12 (s, 1H), 7.93 (d, J=8.4 Hz, 1H), 7.68 (d, J=8.7 Hz, 2H), 7.30 (d, J=8.7 Hz, 2H), 7.06 (d, J=8.4 Hz, 1H), 4.40 (s, 2H), 4.03 (dd, J=7.8, 4.8 Hz, 1H), 3.94–3.76 (m, 2H), 3.58–3.40 (m, 4H), 2.56–2.36 (m, 2H), 2.38 (s, 3H), 2.30–2.08 (m, 2H), 1.88–1.24 (m, 7H), 0.96 (t, J=7.8 Hz, 3H), 0.96 (d, J=6.6 Hz, 3H), 0.95 (d, J=6.6 Hz, 3H).


EXAMPLE 37(33)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(6-methylpyridin-1-oxide-3-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.24 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.47 (s, 1H), 7.71 (d, J=8.7 Hz, 2H), 7.62–7.48 (m, 2H), 7.29 (d, J=8.7 Hz, 2H), 4.40 (s, 2H), 4.02 (dd, J=7.8, 4.5 Hz, 1H), 3.92–3.72 (m, 2H), 3.58–3.38 (m, 4H), 2.64–2.40 (m, 2H), 2.60 (s, 3H), 2.28–2.10 (m, 2H), 1.90–1.28 (m, 7H), 0.96 (t, J=7.8 Hz, 3H), 0.95 (d, J=6.6 Hz, 3H), 0.94 (d, J=6.6 Hz, 3H).


EXAMPLE 37(34)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(1-(2-methylpropyloxycarbonyl)indol-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.23 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.16 (d, J=8.4 Hz, 1H), 7.82 (d, J=1.5 Hz, 1H), 7.78 (d, J=3.6 Hz, 1H), 7.50 (dd, J=8.4, 1.5 Hz, 1H), 6.75 (d, J=3.6 Hz, 1H), 4.46 (s, 2H), 4.27 (d, J=6.6 Hz, 2H), 4.01 (dd, J=7.8, 4.5 Hz, 1H), 3.82–3.74 (m, 2H), 3.58–3.36 (m, 4H), 2.48–2.30 (m, 2H), 2.26–2.08 (m, 3H), 1.88–1.24 (m, 7H), 1.09 (s, 3H), 1.06 (s, 3H), 0.95 (t, J=7.2 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H).


EXAMPLE 37(35)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-phenyl-5-methyloxazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.32 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.05–8.02 (m, 2H), 7.52–7.50 (m, 3H), 4.35 (s, 2H), 4.02 (dd, J=7.8, 4.5 Hz, 1H), 3.98–3.80 (m, 2H), 3.70–3.58 (m, 2H), 3.44–3.38 (m, 2H), 2.53 (s, 3H), 2.53–2.36 (m, 2H), 2.34–2.14 (m, 2H), 1.90–1.26 (m, 7H), 0.96 (t, J=7.2 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H).


EXAMPLE 37(36)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(tetrahydropyran-4-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.33 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.47 (d, J=8.4 Hz, 2H), 7.07 (d, J=8.4 Hz, 2H), 4.64 (m, 1H), 4.29 (s, 2H), 4.01 (dd, J=7.5, 4.5 Hz, 1H), 3.98–3.91 (m, 2H), 3.84–3.68 (m, 2H), 3.64–3.56 (m, 2H), 3.50–3.37 (m, 4H), 2.50–2.30 (m, 2H), 2.24–1.98 (m, 4H), 1.88–1.26 (m, 9H), 0.95 (t, J=7.2 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H).


EXAMPLE 37(37)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(6-methylpyridin-3-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.22 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.55 (d, J=2.7 Hz, 1H), 8.10 (dd, J=9.0, 2.7 Hz, 1H), 7.84 (d, J=9.0 Hz, 1H), 7.72 (d, J=8.7 Hz, 2H), 7.29 (d, J=8.7 Hz, 2H), 4.40 (s, 2H), 4.02 (dd, J=7.8, 4.5 Hz, 1H), 3.94–3.70 (m, 2H), 3.58–3.38 (m, 4H), 2.74 (s, 3H), 2.60–2.42 (m, 2H), 2.28–2.08 (m, 2H), 1.90–1.26 (m, 7H), 0.96 (t, J=7.5 Hz, 3H), 0.96 (d, J=6.6 Hz, 3H), 0.95 (d, J=6.6 Hz, 3H).


EXAMPLE 37(38)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-fluorophenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.58 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.55–7.46 (m, 2H), 7.36–7.25 (m, 2H), 4.30 (s, 2H), 4.02 (dd, J=7.8, 4.5 Hz, 1H), 3.95–3.73 (m, 2H), 3.66–3.55 (m, 2H), 3.52–3.40 (m, 2H), 2.63–2.45 (m, 2H), 2.39 (s, 3H), 2.37 (s, 3H), 2.30–2.10 (m, 2H), 1.90–1.43 (m, 5H), 1.43–1.30 (m, 2H), 0.99–0.91 (m, 9H).


EXAMPLE 37(39)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(pyridin-2-yl) pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.52 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.55 (d, J=4.8 Hz, 1H), 8.12 (dd, J=8.4, 7.2 Hz, 1H), 7.87 (d, J=8.4 Hz, 1H), 7.50 (dd, J=7.2, 4.8 Hz, 1H), 4.32 (s, 2H), 4.02 (dd, J=7.8, 4.5 Hz, 1H), 3.96–3.73 (m, 2H), 3.67–3.55 (m, 2H), 3.54–3.40 (m, 2H), 2.69 (s, 3H), 2.70–2.48 (m, 2H), 2.44 (s, 3H), 2.28–2.08 (m, 2H), 1.92–1.43 (m, 5H), 1.43–1.26 (m, 2H), 0.99–0.90 (m, 9H).


EXAMPLE 37(40)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-hydroxyphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.48 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.30 (d, J=9.0 Hz, 2H), 6.95 (d, J=9.0 Hz, 2H), 4.33 (s, 2H), 4.02 (dd, J=7.5, 4.5 Hz, 1H), 3.92–3.77 (m, 2H), 3.61 (m, 2H), 3.47 (m, 2H), 2.58 (m, 2H), 2.45 (s, 3H), 2.36 (s, 3H), 2.20 (m, 2H), 1.88–1.76 (m, 1H), 1.73–1.32 (m, 6H), 0.96 (t, J=7.5 Hz, 3H), 0.95 (d, J=6.5 Hz, 3H), 0.94 (d, J=6.5 Hz, 3H).


EXAMPLE 37(41)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(2-carboxyethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.38 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.47 (d, J=8.0 Hz, 2H), 7.37 (d, J=8.0 Hz, 2H), 4.31 (s, 2H), 4.00 (dd, J=7.5, 4.5 Hz, 1H), 3.86–3.73 (m, 2H), 3.49–3.35 (m, 4H), 2.96 (t, J=7.5 Hz, 2H), 2.62 (t, J=7.5 Hz, 2H), 2.44–2.33 (m, 2H), 2.23–2.11 (m, 2H), 1.84–1.32 (m, 7H), 0.94 (t, J=7.5 Hz, 3H), 0.94 (d, J=6.5 Hz, 3H), 0.93 (d, J=6.5 Hz, 3H).


EXAMPLE 37(42)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-(dimethylaminosulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.54 (chloroform:methanol=9:1);


NMR (CD3OD): δ 7.96 (d, J=8.7 Hz, 2H), 7.77 (d, J=8.7 Hz, 2H), 4.32 (s, 2H), 4.02 (dd, J=7.8, 4.8 Hz, 1H), 3.95–3.75 (m, 2H), 3.66–3.56 (m, 2H), 3.47 (m, 2H), 2.74 (s, 6H), 2.56 (m, 2H), 2.48 (s, 3H), 2.41 (s, 3H), 2.30–2.12 (m, 2H), 1.90–1.46 (m, 5H), 1.38 (sextet, J=7.2 Hz, 2H), 0.98–0.93 (m, 9H).


EXAMPLE 37(43)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(5-methylpyridin-1-oxide-2-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.41 (chloroform:methanol=9:1);


NMR (CD3OD): δ 7.77 (brs, 1H), 7.65–7.59 (m, 2H), 7.56 (dd, J=9.3, 2.4 Hz, 1H), 7.03–6.97 (m, 2H), 6.73 (d, J=9.3 Hz, 1H), 4.33 (s, 2H), 4.00 (dd, J=7.8, 4.8 Hz, 1H), 3.86–3.68 (m, 2H), 3.51–3.36 (m, 4H), 2.46 (m, 2H), 2.25–2.07 (m, 2H), 2.18 (s, 3H), 1.90–1.44 (m, 5H), 1.36 (sextet, J=7.2 Hz, 2H), 0.97–0.91 (m, 9H).


EXAMPLE 37(44)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(2-carboxy-1-ethenyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.20 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.75 (d, J=8.4 Hz, 2H), 7.70 (d, J=16.2 Hz, 1H), 7.61 (d, J=8.4 Hz, 2H), 6.58 (d, J=16.2 Hz, 2H), 4.39 (s, 2H), 4.02 (dd, J=7.8, 4.5 Hz, 1H), 3.92–3.74 (m, 2H), 3.58–3.36 (m, 4H), 2.50–2.32 (m, 2H), 2.30–2.10 (m, 2H), 1.90–1.24 (m, 7H), 0.96 (t, J=7.2 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H).


EXAMPLE 37(45)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-(2-carboxy-1-ethenyl)phenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.34 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.69–7.57 (m, 5H), 7.14 (d, J=8.4 Hz, 2H), 7.05 (d, J=8.7 Hz, 2H), 6.42 (d, J=15.9 Hz, 1H), 4.36 (s, 2H), 4.01 (dd, J=7.8, 4.5 Hz, 1H), 3.92–3.70 (m, 2H), 3.56–3.35 (m, 4H), 2.48–2.30 (m, 2H), 2.30–2.12 (m, 2H), 1.88–1.25 (m, 7H), 0.98–0.88 (m, 9H).


EXAMPLE 37(46)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-aminocarbonylphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.38 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.90 (d, J=8.7 Hz, 2H), 7.60 (d, J=8.7 Hz, 2H), 7.15 (d, J=8.7 Hz, 2H), 7.07 (d, J=8.7 Hz, 2H), 4.36 (s, 2H), 4.01 (dd, J=7.8, 4.5, Hz, 1H), 3.90–3.70 (m, 2H), 3.58–3.35 (m, 4H), 2.54–2.36 (m, 2H), 2.30–2.10 (m, 2H), 1.90–1.26 (m, 7H), 1.00–0.86 (m, 9H).


EXAMPLE 37(47)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-aminosulfonylphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.41 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.90 (d, J=8.7 Hz, 2H), 7.57 (d, J=8.7 Hz, 2H), 7.17 (d, J=8.7 Hz, 2H), 7.13 (d, J=8.7 Hz, 2H), 4.28 (brs, 2H), 4.01 (dd, J=7.8, 4.5, Hz, 1H), 3.83–3.60 (m, 2H), 3.49–3.34 (m, 4H), 2.44–2.26 (m, 2H), 2.26–2.09 (m, 2H), 1.89–1.26 (m, 7H), 1.00–0.88 (m, 9H).


EXAMPLE 37(48)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-benzylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.40 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.41–7.33 (m, 3H), 7.21–7.19 (m, 2H), 5.45 (s, 2H), 4.30 (s, 2H), 4.01 (dd, J=7.5, 4.5 Hz, 1H), 3.89–3.73 (m, 2H), 3.60–3.46 (m, 4H), 2.61 (m, 2H), 2.48 (s, 3H), 2.46 (s, 3H), 2.23–2.11 (m, 2H), 1.87–1.31 (m, 7H), 0.95 (t, J=7.0 Hz, 3H), 0.94 (d, J=6.5 Hz, 3H), 0.93 (d, J=6.5 Hz, 3H).


EXAMPLE 37(49)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(2,4-difluorophenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.40 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.61–7.53 (m, 1H), 7.33–7.26 (m, 1H), 7.23–7.16 (m, 1H), 4.31 (s, 2H), 4.02 (dd, J=7.5, 4.5 Hz, 1H), 3.92–3.76 (m, 2H), 3.63–3.56 (m, 2H), 3.49–3.45 (m, 2H), 2.57 (m, 2H), 2.40 (s, 3H), 2.29 (s, 3H), 2.19 (m, 2H), 1.86–1.34 (m, 7H), 0.96 (t, J=7.0 Hz, 3H), 0.95 (d, J=6.5 Hz, 3H), 0.94 (d, J=6.5 Hz, 3H).


EXAMPLE 37(50)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(pyrrolidin-1-ylmethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.10 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.75 (d, J=8.4 Hz, 2H), 7.65 (d, J=8.4 Hz, 2H), 4.43 (s, 2H), 4.40 (s, 2H), 4.00 (dd, J 7.5, 4.5 Hz, 1H), 3.92–3.70 (m, 2H), 3.56–3.40 (m, 6H), 3.25–3.12 (m, 2H), 2.68–2.48 (m, 2H), 2.28–1.95 (m, 6H), 1.88–1.42 (m, 5H), 1.42–1.30 (m, 2H), 0.98–0.90 (m, 9H).


EXAMPLE 37(51)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-(morpholin-4-ylsulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.43 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.95 (d, J=8.7 Hz, 2H), 7.80 (d, J=8.7 Hz, 2H), 4.32 (s, 2H), 4.02 (dd, J=7.8, 4.8 Hz, 1H), 3.95–3.72 (m, 2H), 3.76–3.67 (m, 4H), 3.66–3.57 (m, 2H), 3.56–3.42 (m, 2H), 3.08–2.95 (m, 4H), 2.70–2.50 (m, 2H), 2.50 (s, 3H), 2.42 (s, 3H), 2.31–2.10 (m, 2H), 1.90–1.44 (m, 5H), 1.44–1.30 (m, 2H), 1.00–0.91 (m, 9H).


EXAMPLE 37(52)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-(methylaminosulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.21 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.01 (d, J=8.4 Hz, 2H), 7.73 (d, J=8.4 Hz, 2H), 4.34 (s, 2H), 4.04 (dd, J=7.8, 4.8 Hz, 1H), 3.98–3.78 (m, 2H), 3.66–3.58 (m, 2H), 3.44–3.30 (m, 2H), 2.59 (s, 3H), 2.54–2.38 (m, 2H), 2.47 (s, 3H), 2.40 (s, 3H), 2.36–2.16 (m, 2H), 1.90–1.26 (m, 7H), 0.97 (t, J=7.5 Hz, 3H), 0.96 (d, J=6.6 Hz, 6H).


EXAMPLE 37(53)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-cyanophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.30 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.75 (d, J=8.4 Hz, 2H), 7.66 (d, J=8.7 Hz, 2H), 7.21 (d, J=8.4 Hz, 2H), 7.14 (d, J=8.7 Hz, 2H), 4.39 (s, 2H), 4.02 (dd, J=7.8, 4.5 Hz, 1H), 3.94–3.72 (m, 2H), 3.58–3.36 (m, 4H), 2.58–2.38 (m, 2H), 2.28–2.08 (m, 2H), 1.88–1.24 (m, 7H), 0.96 (t, J=7.2 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H).


EXAMPLE 37(54)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(dimethylaminomethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.16 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.76 (d, J=8.1 Hz, 2H), 7.63 (d, J=8.1 Hz, 2H), 4.41 (s, 2H), 4.37 (s, 2H), 4.00 (dd, J=7.8, 4.8 Hz, 1H), 3.90–3.72 (m, 2H), 3.50–3.42 (m, 4H), 2.87 (s, 6H), 2.65–2.50 (m, 2H), 2.22–2.04 (m, 2H), 1.88–1.32 (m, 7H), 0.97–0.92 (m, 9H).


EXAMPLE 37(55)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-(2-dimethylaminoethylaminosulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.3hydrochloride



embedded image


TLC: Rf 0.13 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.07 (d, J=8.7 Hz, 2H), 7.78 (d, J=8.7 Hz, 2H), 4.31 (s, 2H), 4.01 (dd, J=8.1, 5.1 Hz, 1H), 3.95–3.74 (m, 2H), 3.68–3.45 (m, 4H), 3.40–3.20 (m, 4H), 2.95 (s, 6H), 2.70–2.50 (m, 2H), 2.49 (s, 3H), 2.41 (s, 3H), 2.28–2.12 (m, 2H), 1.88–1.34 (m, 7H), 0.98–0.92 (m, 9H).


EXAMPLE 37(56)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-(4-hydroxyphenyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.53 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.81 (s, 1H), 7.69 (d, J=7.5 Hz, 1H), 7.53 (d, J=9.0 Hz, 2H), 7.55–7.48 (m, 1H), 7.45 (d, J=7.5 Hz, 1H), 6.87 (d, J=9.0 Hz, 2H), 4.40 (s, 2H), 4.00 (dd, J=7.5, 4.5 Hz, 1H), 3.94–3.73 (m, 2H), 3.56–3.44 (m, 2H), 3.44–3.30 (m, 2H), 2.53–2.33 (m, 2H), 2.26–2.08 (m, 2H), 1.90–1.40 (m, 5H), 1.43–1.25 (m, 2H), 0.94 (d, J=6.3 Hz, 3H), 0.94 (t, J=7.2 Hz, 3H), 0.93 (d, J=6.3 Hz, 3H).


EXAMPLE 37(57)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(3-methoxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.54 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.53 (d, J=8.5 Hz, 2H), 7.28 (t, J=8.3 Hz, 1H), 7.07 (d, J=8.5 Hz, 2H), 6.75 (ddd, J=8.3, 2.3, 1.0 Hz, 1H), 6.60–6.57 (m, 2H), 4.33 (s, 2H), 4.01 (dd, J=7.5, 4.5 Hz, 1H), 3.86–3.73 (m, 2H), 3.77 (s, 3H), 3.51–3.34 (m, 4H), 2.41 (m, 2H), 2.42–2.12 (m, 2H), 1.84–1.33 (m, 7H), 0.95 (t, J=7.2 Hz, 3H), 0.94 (d, J=6.5 Hz, 3H), 0.93 (d, J=6.5 Hz, 3H).


EXAMPLE 37(58)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(quinoxalin-2-yl) pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.52 (chloroform:methanol=10:1);


NMR (CD3OD): δ 9.51 (s, 1H), 8.12 (d, J=8.0 Hz, 1H), 8.04 (d, J=8.0 Hz, 1H), 7.90–7.80 (m, 2H), 4.37 (s, 2H), 4.02 (dd, J=7.5, 4.5 Hz, 1H), 3.96–3.81 (m, 2H), 3.63 (m, 2H), 3.44 (m, 2H), 2.92 (s, 3H), 2.47 (s, 3H), 2.47 (m, 2H), 2.29–2.17 (m, 2H), 1.86–1.33 (m, 7H), 0.95 (t, J=7.2 Hz, 3H), 0.95 (d, J=6.5 Hz, 3H), 0.94 (d, J=6.5 Hz, 3H).


EXAMPLE 37(59)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenylcarbonylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.76 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.88 (d, J=8.4 Hz, 2H), 7.81–7.67 (m, 5H), 7.57–7.52 (m, 2H), 4.49 (s, 2H), 4.01 (dd, J=8.1, 4.8 Hz, 1H), 4.00–3.78 (m, 2H), 3.59–3.48 (m, 2H), 3.44–3.35 (m, 2H), 2.50–2.32 (m, 2H), 2.32–2.14 (m, 2H), 1.88–1.24 (m, 7H), 1.02–0.88 (m, 9H).


EXAMPLE 37(60)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-(N-(2-hydroxyethyl)-N-methylaminosulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.34 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.00 (d, J=8.7 Hz, 2H), 7.76 (d, J=8.7 Hz, 2H), 4.34 (s, 2H), 4.04 (dd, J=7.8, 4.5 Hz, 1H), 3.98–3.76 (m, 2H), 3.70 (t, J=5.7 Hz, 2H), 3.68–3.58 (m, 2H), 3.50–3.38 (m, 2H), 3.20 (t, J=5.7 Hz, 2H), 2.88 (s, 3H), 2.58–2.38 (m, 2H), 2.48 (s, 3H), 2.41 (s, 3H), 2.36–2.16 (m, 2H), 1.90–1.24 (m, 7H), 0.97 (t, J=6.9 Hz, 3H), 0.96 (d, J=6.3 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H).


EXAMPLE 37(61)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(2-phenylethyl) pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.24 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.31–7.23 (m, 3H), 7.10 (d, J=6.6 Hz, 2H), 4.44 (t, J=6.3 Hz, 2H), 4.21 (s, 2H), 4.03 (dd, J=7.8, 4.8 Hz, 1H), 3.82–3.60 (m, 2H), 3.58–3.32 (m, 4H), 3.13 (t, J=6.3 Hz, 2H), 2.72–2.52 (m, 2H), 2.50 (s, 3H), 2.24–2.04 (m, 2H), 1.99 (s, 3H), 1.90–1.36 (m, 7H), 0.97 (t, J=7.2 Hz, 3H), 0.96 (d, J=6.6 Hz, 3H), 0.95 (d, J=6.6 Hz, 3H).


EXAMPLE 37(62)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(1,3,5-trimethylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.43 (chloroform:methanol=10:1);


NMR (CD3OD): δ 4.28 (s, 2H), 4.00 (dd, J=7.8, 4.8 Hz, 1H), 3.87 (s, 3H), 3.87–3.69 (m, 2H), 3.60–3.43 (m, 4H), 2.69–2.50 (m, 2H), 2.46 (s, 3H), 2.44 (s, 3H), 2.26–2.08 (m, 2H), 1.90–1.28 (m, 7H), 0.98–0.85 (m, 9H).


EXAMPLE 37(63)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(morpholin-4-ylmethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.56 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.74 (d, J=8.4 Hz, 2H), 7.66 (d, J=8.4 Hz, 2H), 4.40 (s, 4H), 4.00 (dd, J=7.5, 4.5 Hz, 1H), 4.10–3.70 (m, 6H), 3.54–3.42 (m, 4H), 3.40–3.16 (m, 4H), 2.65–2.46 (m, 2H), 2.24–2.03 (m, 2H), 1.88–1.28 (m, 7H), 1.02–0.88 (m, 9H).


EXAMPLE 37(64)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-methylpiperazin-1-ylmethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.3hydrochloride



embedded image


TLC: Rf 0.64 (chloroform:methanol=5:1);


NMR (CD3OD): δ 7.45 (m, 4H), 4.55 (s, 2H), 4.42 (s, 2H), 4.01 (dd, J=7.5, 4.5 Hz, 1H), 3.88–3.56 (m, 10H), 3.53–3.43 (m, 4H), 3.01 (s, 3H), 2.59–2.47 (m, 2H), 2.22–2.09 (m, 2H), 1.85–1.33 (m, 7H), 0.94 (t, J=7.2 Hz, 3H), 0.94 (d, J=6.5 Hz, 3H), 0.93 (d, J=6.5 Hz, 3H).


EXAMPLE 37(65)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenylsulfonylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.70 (ethyl acetate:methanol=9:1);


NMR (CD3OD): δ 8.08 (d, J=8.4 Hz, 2H), 8.02–7.96 (m, 2H), 7.80 (d, J=8.4 Hz, 2H), 7.70–7.55 (m, 3H), 4.43 (s, 2H), 3.99 (dd, J=7.8, 4.8 Hz, 1H), 3.91–3.72 (m, 2H), 3.48–3.34 (m, 4H), 2.48–2.32 (m, 2H), 2.23–2.06 (m, 2H), 1.88–1.43 (m, 5H), 1.34 (sextet, J=7.2 Hz, 2H), 0.96–0.90 (m, 9H).


EXAMPLE 37(66)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-cyclohexylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.28 (ethyl acetate: methanol=9:1);


NMR (CD3OD): δ 4.35–4.20 (m, 3H), 4.01 (dd, J=7.8, 4.8 Hz, 1H), 3.90–3.68 (m, 2H), 3.58–3.41 (m, 4H), 2.60–2.46 (m, 2H), 2.45 (s, 3H), 2.40 (s, 3H), 2.26–2.08 (m, 2H), 1.98–1.26 (m, 17H), 0.98–0.91 (m, 9H).


EXAMPLE 37(67)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(3-carboxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.11 (ethyl acetate: methanol 9:1);


NMR (CD3OD): δ 7.83 (ddd, J=7.8, 1.5, 0.9 Hz, 1H), 7.61 (dd, J=2.4, 1.5 Hz, 1H), 7.58 (d, J=8.7 Hz, 2H), 7.51 (t, J=7.8 Hz, 1H), 7.29 (ddd, J=7.8, 2.4, 0.9 Hz, 1H), 7.11 (d, J=8.7 Hz, 2H), 4.35 (s, 2H), 4.01 (dd, J=7.8, 4.8 Hz, 1H), 3.90–3.72 (m, 2H), 3.57–3.36 (m, 4H), 2.50–2.34 (m, 2H), 2.28–2.09 (m, 2H), 1.89–1.44 (m, 5H), 1.36 (sextet, J=7.2 Hz, 2H), 0.98–0.91 (m, 9H).


EXAMPLE 37(68)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(piperidin-1-ylmethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.52 (chloroform:methanol=9:1);


NMR (CD3OD): δ 7.75 (d, J=8.4 Hz, 2H), 7.65 (d, J=8.4 Hz, 2H), 4.41 (s, 2H), 4.34 (s, 2H), 4.00 (dd, J=7.8, 4.5 Hz, 1H), 3.91–3.71 (m, 2H), 3.54–3.41 (m, 6H), 3.05–2.91 (m, 2H), 2.67–2.49 (m, 2H), 2.25–2.05 (m, 2H), 2.00–1.28 (m, 13H), 0.98–0.91 (m, 9H).


EXAMPLE 37(69)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-(pyrrolidin-1-ylsulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.36 (ethyl acetate: methanol=9:1);


NMR (CD3OD): δ 8.01 (d, J=8.7 Hz, 2H), 7.76 (d, J=8.7 Hz, 2H), 4.32 (s, 2H), 4.02 (dd, J=7.8, 4.8 Hz, 1H), 3.95–3.74 (m, 2H), 3.66–3.55 (m, 2H), 3.50–3.40 (m, 2H), 3.34–3.24 (m, 4H), 2.62–2.47 (m, 2H), 2.48 (s, 3H), 2.40 (s, 3H), 2.30–2.11 (m, 2H), 1.90–1.45 (m, 9H), 1.38 (sextet, J=7.2 Hz, 2H), 1.00–0.90 (m, 9H).


EXAMPLE 37(70)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2,3-dihydrobenzofuran-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.56 (ethyl acetate: methanol=9:1);


NMR (CD3OD): δ 7.40 (brs, 1H), 7.26 (dd, J=8.1, 1.8 Hz, 1H), 6.80 (d, J=8.1 Hz, 1H), 4.59 (t, J=8.7 Hz, 2H), 4.26 (s, 2H), 4.00 (dd, J=7.8, 4.8 Hz, 1H), 3.84–3.66 (m, 2H), 3.52–3.36 (m, 4H), 3.24 (t, J=8.7 Hz, 2H), 2.49–2.35 (m, 2H), 2.25–2.08 (m, 2H), 1.89–1.43 (m, 5H), 1.36 (sextet, J=7.2 Hz, 2H), 0.98–0.91 (m, 9H).


EXAMPLE 37(71)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-(2-hydroxyethylaminosulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.35 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.03 (d, J=8.7 Hz, 2H), 7.72 (d, J=8.7 Hz, 2H), 4.32 (s, 2H), 4.02 (dd, J=7.5, 4.5 Hz, 1H), 3.95–3.73 (m, 2H), 3.67–3.57 (m, 2H), 3.56 (t, J=5.7 Hz, 2H), 3.51–3.40 (m, 2H), 3.01 (t, J=5.7 Hz, 2H), 2.63–2.42 (m, 2H), 2.47 (s, 3H), 2.41 (s, 3H), 2.32–2.12 (m, 2H), 1.92–1.44 (m, 5H), 1.44–1.30 (m, 2H), 1.00–0.91 (m, 9H).


EXAMPLE 37(72)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(carboxymethyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.30 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.47 (d, J=8.7 Hz, 2H), 7.04 (d, J=8.7 Hz, 2H), 4.71 (s, 2H), 4.29 (s, 2H), 4.00 (dd, J=7.8, 4.5 Hz, 1H), 3.88–3.67 (m, 2H), 3.53–3.33 (m, 4H), 2.46–2.28 (m, 2H), 2.26–2.08 (m, 2H), 1.90–1.27 (m, 7H), 0.99–0.90 (m, 9H).


EXAMPLE 37(73)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(1-phenyl-1-hydroxymethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.23 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.62–7.18 (m, 9H), 5.82 (s, 1H), 4.33 (s, 2H), 4.00 (dd, J=7.8, 4.8 Hz, 1H), 3.88–3.68 (m, 2H), 3.56–3.36 (m, 4H), 2.48–2.28 (m, 2H), 2.24–2.06 (m, 2H), 1.88–1.24 (m, 7H), 0.95 (t, J=6.6 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H), 0.93 (d, J=6.3 Hz, 3H).


EXAMPLE 37(74)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-hydroxypiperidin-1-ylmethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.16 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.73 (d, J=7.8 Hz, 2H), 7.69–7.61 (m, 2H), 4.42 (s, 2H), 4.40–4.34 (m, 2H), 4.11–4.05 (m, 1H), 4.00 (dd, J=7.5, 4.5 Hz, 1H), 3.93–3.72 (m, 2H), 3.55–3.38 (m, 4H), 3.16–3.00 (m, 1H), 2.60–2.38 (m, 2H), 2.26–2.06(m, 3H), 2.00–1.88 (m, 2H), 1.88–1.43 (m, 9H), 1.43–1.14 (m, 2H), 0.98–0.90 (m, 9H).


EXAMPLE 37(75)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(3-carboxyphenylmethyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.58 (chloroform:methanol=5:1);


NMR (CD3OD): δ 8.10 (s, 1H), 7.98 (d, J=8.1 Hz, 1H), 7.68 (d, J=8.7 Hz, 1H), 7.50 (t, J=8.1 Hz, 1H), 7.47 (d, J=8.7 Hz, 2H), 7.13 (d, J=8.7 Hz, 2H), 5.22 (s, 2H), 4.29 (s, 2H), 4.01 (dd, J=7.5, 4.5 Hz, 1H), 3.86–3.68 (m, 2H), 3.54–3.32 (m, 4H), 2.42–2.08 (m, 4H), 1.90–1.28 (m, 7H), 0.95 (t, J=6.9 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H).


EXAMPLE 37(76)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(bis(methylsulfonyl)amino)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.64 (chloroform:methanol=5:1);


NMR (CD3OD): δ 7.72 (d, J=8.4 Hz, 2H), 7.61 (d, J=8.4 Hz, 2H), 4.44 (s, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.96–3.78 (m, 2H), 3.58–3.36 (m, 4H), 3.47 (s, 6H), 2.50–2.12 (m, 4H), 1.92–1.28 (m, 7H), 0.96 (t, J=6.9 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H).


EXAMPLE 37(77)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(1,4-benzodioxan-6-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.34 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.49 (d, J=8.7 Hz, 2H), 7.02 (d, J=8.7 Hz, 2H), 6.85 (m, 1H), 6.55–6.51 (m, 2H), 4.33 (s, 2H), 4.24 (s, 4H), 4.02 (dd, J=7.5, 4.8 Hz, 1H), 3.88–3.70 (m, 2H), 3.56–3.32 (m, 4H), 2.42–2.10 (m, 4H), 1.92–1.24 (m, 7H), 0.96 (t, J=7.2 Hz, 3H), 0.95 (d, J=6.6 Hz, 3H), 0.94 (d, J=6.6 Hz, 3H).


EXAMPLE 37(78)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-(3-hydroxyphenyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.19 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.83 (s, 1H), 7.74 (m, 1H), 7.59–7.51 (m, 2H), 7.28 (m, 1H), 7.16–7.09 (m, 2H), 6.81 (m, 1H), 4.44 (s, 2H), 4.01 (dd, J=7.8, 4.5 Hz, 1H), 3.94–3.76 (m, 2H), 3.58–3.32 (m, 4H), 2.50–2.32 (m, 2H), 2.28–2.08 (m, 2H), 1.88–1.26 (m, 7H), 0.95 (t, J=7.2 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H).


EXAMPLE 37(79)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(methylsulfonylamino)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.40 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.52 (d, J=8.4 Hz, 2H), 7.34 (d, J=8.4 Hz, 2H), 4.32 (s, 2H), 4.01 (dd, J=7.8, 4.8 Hz, 1H), 3.88–3.72 (m, 2H), 3.52–3.14 (m, 4H), 3.01 (s, 3H), 2.46–2.30 (m, 2H), 2.28–2.10 (m, 2H), 1.88–1.10 (m, 7H), 0.98–0.90 (m, 9H).


EXAMPLE 37(80)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(6-(4-methoxyphenyloxy)pyridin-3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.48 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.30 (m, 1H), 8.05 (m, 1H), 7.10–6.86 (m, 5H), 4.39 (s, 2H), 4.01 (dd, J=7.8, 4.8 Hz, 1H), 3.90–3.74 (m, 2H), 3.81 (s, 3H), 3.54–3.32 (m, 4H), 2.54–2.32 (m, 2H), 2.28–2.05 (m, 2H), 1.88–1.26 (m, 7H), 0.98–0.90 (m, 9H).


EXAMPLE 37(81)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-methylaminocarbonylphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.54 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.39 (brd, J=4.5 Hz, 1H), 7.84 (d, J=9.0 Hz, 2H), 7.59 (d, J=9.0 Hz, 2H), 7.15 (d, J=9.0 Hz, 2H), 7.07 (d, J=9.0 Hz, 2H), 4.35 (s, 2H), 4.01 (m, 1H), 3.86–3.73 (m, 2H), 3.53–3.41 (m, 4H), 2.91 (d, J=4.5 Hz, 3H), 2.55–2.30 (m, 2H), 2.30–2.10 (m, 2H), 1.90–1.30 (m, 7H), 0.95 (t, J=6.9 Hz, 3H), 0.94 (d, J=6.6 Hz, 3H), 0.93 (d, J=6.6 Hz, 3H).


EXAMPLE 37(82)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-chlorophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.59 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.53 (d, J=8.4 Hz, 2H), 7.38 (d, J=9.0 Hz, 2H), 7.08 (d, J=8.4 Hz, 2H), 7.02 (d, J=9.0 Hz, 2H), 4.31 (s, 2H), 4.01 (m, 1H), 3.90–3.70 (m, 2H), 3.60–3.30 (m, 4H), 2.50–2.10 (m, 4H), 1.90–1.30 (m, 7H), 0.95 (t, J=7.2 Hz, 3H), 0.94 (d, J=6.6 Hz, 3H), 0.93 (d, J=6.6 Hz, 3H).


EXAMPLE 37(83)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-(4-carboxyphenyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.60 (chloroform:methanol=5:1);


NMR (CD3OD): δ 8.13 (d, J=9.0 Hz, 2H), 7.93 (s, 1H), 7.84 (m, 1H), 7.81 (d, J=9.0 Hz, 2H), 7.66–7.56 (m, 2H), 4.46 (s, 2H), 4.02 (dd, J=7.5, 4.8 Hz, 1H), 3.96–3.74 (m, 2H), 3.58–3.36 (m, 4H), 2.48–2.08 (m, 4H), 1.88–1.24 (m, 7H), 0.95 (t, J=6.9 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H).


EXAMPLE 37(84)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(phenylaminocarbonyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.27 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.07 (d, J=8.4 Hz, 2H), 7.74 (d, J=8.4 Hz, 2H), 7.72–7.67 (m, 2H), 7.38 (t, J=7.5 Hz, 2H), 7.17 (t, J=7.5 Hz, 1H), 4.47 (s, 2H), 4.02 (dd, J=7.8, 4.5 Hz, 1H), 3.96–3.76 (m, 2H), 3.58–3.36 (m, 4H), 2.54–2.36 (m, 2H), 2.28–2.12 (m, 2H), 1.90–1.24 (m, 7H), 0.96 (t, J=7.2 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H).


EXAMPLE 37(85)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-methylthiophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.49 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.53 (d, J=8.7 Hz, 2H), 7.33 (d, J=8.7 Hz, 2H), 7.07 (d, J=8.7 Hz, 2H), 7.00 (d, J=8.7 Hz, 2H), 4.34 (s, 2H), 4.02 (dd, J=7.8, 4.5 Hz, 1H), 3.88–3.68 (m, 2H), 3.56–3.36 (m, 4H), 2.48 (s, 3H), 2.48–2.32 (m, 2H), 2.28–2.08 (m, 2H), 1.90–1.28 (m, 7H), 0.96 (t, J=7.2 Hz, 3H), 0.95 (d, J=6.3 Hz, 3H), 0.94 (d, J=6.3 Hz, 3H).


EXAMPLE 37(86)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-(2-dimethylaminoethylaminocarbonyl)phenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2hydrochloride



embedded image


TLC: Rf 0.11 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.93 (d, J=9.0 Hz, 2H), 7.64 (d, J=8.7 Hz, 2H), 7.15 (d, J=8.7 Hz, 2H), 7.10 (d, J=9.0 Hz, 2H), 4.36 (s, 2H), 4.01 (dd, J=7.8, 4.8 Hz, 1H), 3.88–3.70 (m, 4H), 3.54–3.36 (m, 6H), 2.98 (s, 6H), 2.62–2.44 (m, 2H), 2.24–2.08 (m, 2H), 1.88–1.30 (m, 7H), 0.98–0.90 (m, 9H).


EXAMPLE 37(87)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-aminocarbonylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.17 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.98 (d, J=8.7 Hz, 2H), 7.70 (d, J=8.7 Hz, 2H), 4.43 (s, 2H), 4.00 (dd, J=7.5, 4.5 Hz, 1H), 3.92–3.74 (m, 2H), 3.52–3.36 (m, 4H), 2.58–2.40 (m, 2H), 2.26–2.08 (m, 2H), 1.88–1.28 (m, 7H), 0.98–0.88 (m, 9H).


EXAMPLE 37(88)
(3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-dimethylaminocarbonylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.31 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.68 (d, J=8.1 Hz, 2H), 7.54 (d, J=8.1 Hz, 2H), 4.41 (s, 2H), 4.01 (dd, J=7.8, 4.8 Hz, 1H), 3.92–3.82 (m, 2H), 3.54–3.36 (m, 4H), 3.11 (s, 3H), 2.99 (s, 3H), 2.56–2.38 (m, 2H), 2.26–2.08 (m, 2H), 1.86–1.28 (m, 7H), 1.00–0.86 (m, 9H).


EXAMPLE 38
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-benzyloxycarbonyl-1,4,9-triazaspiro[5.5]undecane



embedded image


By the same procedure as described in Example 35 using N-(t-butyloxycarbonyl)-L-cyclohexylalanine instead of N-(t-butyloxycarbonyl-L-leucine, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.35 (hexane:ethyl acetate=1:1);


NMR (CDCl3): δ 7.39–7.31 (m, 5H), 6.48 (brs, 1H), 5.16 (s, 2H), 4.15 (brs, 2H), 4.00 (ddd, J=9.6, 4.8, 1.5 Hz, 1H), 3.76–3.16 (m, 4H), 2.02–1.12 (m, 19H), 1.08–0.88 (m, 2H), 0.92 (t, J=7.2 Hz, 3H).


EXAMPLE 39
(3S)-1-butyl-2,5-dioxo-3-cyclohexyl methyl-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


By the same procedure as described in Example 9 using the compound prepared in Example 38, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.08 (chloroform:methanol: acetic acid=90:10:1);


NMR (CD3OD): δ 4.05 (dd, J=7.8, 4.8 Hz, 1H), 3.84–3.68 (m, 2H), 3.46–3.34 (m, 4H), 2.40–2.04 (m, 4H), 1.83–1.46 (m, 10H), 1.39 (sextet, J=7.5 Hz, 2H), 1.33–1.15 (m, 3H), 1.05–0.86 (m, 2H), 0.97 (t, J=7.2 Hz, 3H).


EXAMPLE 40(1)˜40(90)

By the same procedure as described in Example 10 using the compound prepared in Example 39 and the corresponding aldehyde derivatives, the following compounds of the present invention were obtained.


EXAMPLE 40(1)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-methylphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.71 (ethyl acetate);


NMR (CD3OD): δ 7.50 (d, J=8.7 Hz, 2H), 7.19 (d, J=8.7 Hz, 2H), 7.02 (d, J=8.7 Hz, 2H), 6.92 (d, J=8.7 Hz, 2H), 4.32 (s, 2H), 4.04 (dd, J=7.5, 4.5 Hz, 1H), 3.87–3.69 (m, 2H), 3.55–3.42 (m, 2H), 3.42–3.34 (m, 2H), 2.49–2.30 (m, 2H), 2.33 (s, 3H), 2.30–2.08 (m, 2H), 1.82–1.10 (m, 15H), 1.05–0.85 (m, 2H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 40(2)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-methoxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.67 (ethyl acetate);


NMR (CD3OD): δ 7.49 (d, J=8.4 Hz, 2H), 7.02–6.92 (m, 6H), 4.31 (s, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.86–3.69 (m, 2H), 3.79 (s, 3H), 3.54–3.30 (m, 4H), 2.50–2.30 (m, 2H), 2.28–2.06 (m, 2H), 1.83–1.10 (m, 15H), 1.05–0.83 (m, 2H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 40(3)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-fluorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.38 (hexane:ethyl acetate=1:1);


NMR (CD3OD): δ 7.70–7.53 (m, 2H), 7.38–7.23 (m, 2H), 4.44 (s, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.95–3.77 (m, 2H), 3.60–3.45 (m, 2H), 3.45–3.30 (m, 2H), 2.53–2.34 (m, 2H), 2.28–2.08 (m, 2H), 1.83–1.10 (m, 15H), 1.05–0.82 (m, 2H), 0.94 (t, J=7.2 Hz, 3H).


EXAMPLE 40(4)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3-fluorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.40 (hexane:ethyl acetate=1:1);


NMR (CD3OD): δ 7.57–7.48 (m, 1H), 7.44–7.37 (m, 2H), 7.30–7.21 (m, 1H), 4.38 (s, 2H), 4.03 (dd, J=7.8, 4.8 Hz, 1H), 3.90–3.72 (m, 2H), 3.55–3.33 (m, 4H), 2.56–2.37 (m, 2H), 2.25–2.04 (m, 2H), 1.82–1.08 (m, 15H), 1.06–0.83 (m, 2H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 40(5)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-fluorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.27 (hexane:ethyl acetate=1:1);


NMR (CD3OD): δ 7.62 (dd, J=8.7, 5.1 Hz, 2H), 7.23 (dd, J=8.7, 8.7 Hz, 2H), 4.36 (s, 2H), 4.03 (dd, J=7.8, 4.8 Hz, 1H), 3.88–3.71 (m, 2H), 3.53–3.33 (m, 4H), 2.53–2.35 (m, 2H), 2.27–2.04 (m, 2H), 1.82–1.10 (m, 15H), 1.05–0.82 (m, 2H), 0.94 (t, J=7.2 Hz, 3H).


EXAMPLE 40(6)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3-chlorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.60 (hexane:ethyl acetate=1:1);


NMR (CD3OD): δ 7.65 (m, 1H), 7.55–7.49 (m, 3H), 4.37 (s, 2H), 4.04 (dd, J=7.0, 4.5 Hz, 1H), 3.83 (m, 2H), 3.54–3.47 (m, 2H), 3.41–3.35 (m, 2H), 2.38 (m, 2H), 2.18 (m, 2H), 1.78–1.47 (m, 9H), 1.42–1.17 (m, 6H), 0.95 (t, J=7.5 Hz, 3H), 0.97–0.92 (m, 2H).


EXAMPLE 40(7)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-cyclohexyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.36 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.41 (d, J=8.7 Hz, 2H), 7.00 (d, J=8.7 Hz, 2H), 4.36 (m, 1H), 4.24 (s, 2H), 4.03 (dd, J=7.8, 4.5 Hz, 1H), 3.82–3.65 (m, 2H), 3.50–3.30 (m, 4H), 2.42–2.25 (m, 2H), 2.25–2.06 (m, 2H), 2.02–1.92 (m, 2H), 1.84–1.14 (m, 23H), 1.04–0.89 (m, 5H).


EXAMPLE 40(8)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-methoxy-3-hydroxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.34 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.01 (d, J=7.8 Hz, 1H), 6.99–6.93 (m, 2H), 4.22 (s, 2H), 4.03 (dd, J=7.5, 4.8 Hz, 1H), 3.87 (s, 3H), 3.83–3.67 (m, 2H), 3.52–3.42 (m, 2H), 3.42–3.33 (m, 2H), 2.44–2.27 (m, 2H), 2.26–2.07 (m, 2H), 1.83–1.12 (m, 15H), 1.04–0.89 (m, 5H).


EXAMPLE 40(9)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-chlorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.77 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.69 (dd, J=7.5, 2.1 Hz, 1H), 7.60 (dd, J=7.5, 2.1 Hz, 1H), 7.51 (dt, J=2.1, 7.5 Hz, 1H), 7.47 (dt, J=2.1, 7.5 Hz, 1H), 4.52 (s, 2H), 4.04 (dd, J=7.8, 4.8 Hz, 1H), 4.00–3.82 (m, 2H), 3.60–3.48 (m, 2H), 3.43–3.34 (m, 2H), 2.48–2.29 (m, 2H), 2.28–2.07 (m, 2H), 1.83–1.44 (m, 10H), 1.43–1.12 (m, 5H), 1.04–0.88 (m, 5H).


EXAMPLE 40(10)
(3S)-1-butyl-2,5-dioxo-3-cyclohexyl methyl-9-(2-methylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.77 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.56 (d, J=7.2 Hz, 1H), 7.41–7.30 (m, 3H), 4.41 (s, 2H), 4.04 (dd, J=7.5, 4.5 Hz, 1H), 3.98–3.79 (m, 2H), 3.57–3.48 (m, 2H), 3.44–3.39 (m, 2H), 2.56–2.38 (m, 2H), 2.48 (s, 3H), 2.26–2.06 (m, 2H), 1.82–1.15 (m, 15H), 1.02–0.84 (m, 5H).


EXAMPLE 40(11)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3-methylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.58 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.40–7.28 (m, 4H), 4.31 (s, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.84–3.70 (m, 2H), 3.52–3.46 (m, 4H), 2.51–2.30 (m, 2H), 2.39 (s, 3H), 2.24–2.04 (m, 2H), 1.80–1.12 (m, 15H), 1.02–0.84 (m, 5H).


EXAMPLE 40(12)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-methylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.61 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.44 (d, J=8.4 Hz, 2H), 7.31 (d, J=8.4 Hz, 2H), 4.31 (s, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.88–3.70 (m, 2H), 3.52–3.36 (m, 4H), 2.48–2.30 (m, 2H), 2.38 (s, 3H), 2.30–2.08 (m, 2H), 1.81–1.10 (m, 15H), 1.04–0.82 (m, 5H).


EXAMPLE 40(13)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-phenylthiophenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.74 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.50–7.37 (m, 7H), 7.29 (d, J=8.4 Hz, 2H), 4.31 (s, 2H), 4.03 (dd, J=7.5, 4.8 Hz, 1H), 3.84–3.70 (m, 2H), 3.50–3.32 (m, 4H), 2.56–2.38 (m, 2H), 2.24–2.05 (m, 2H), 1.81–1.06 (m, 15H), 1.02–0.84 (m, 5H).


EXAMPLE 40(14)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3-(2-methylpropyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.41 (chloroform:methanol=19:1);


NMR (CD3OD): δ 7.47 (d, J=7.5 Hz, 2H), 7.29 (d, J=7.5 Hz, 2H), 4.32 (s, 2H), 4.03 (dd, J=7.8, 4.8 Hz, 1H), 3.80 (m, 2H), 3.56–3.36 (m, 4H), 2.52 (d, J=7.2 Hz, 2H), 2.45 (m, 2H), 2.16 (m, 2H), 1.96–1.14 (m, 16H), 0.97–0.89 (m, 11H).


EXAMPLE 40(15)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3-butylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.37 (chloroform:methanol=19:1);


NMR (CD3OD): δ 7.46 (d, J=8.4 Hz, 2H), 7.32 (d, J=8.4 Hz, 2H), 4.31 (s, 2H), 4.03 (dd, J=7.2, 4.8 Hz, 1H), 3.79 (m, 2H), 3.56–3.36 (m, 4H), 2.66 (t, J=7.5 Hz, 2H), 2.41 (m, 2H), 2.16 (m, 2H), 1.82–1.20 (m, 19H), 1.00–0.89 (m, 2H), 0.94 (t, J=7.2 Hz, 3H), 0.93 (t, J=7.2 Hz, 3H).


EXAMPLE 40(16)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-isopropylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.63 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.46 (d, J=8.4 Hz, 2H), 7.37 (d, J=8.4 Hz, 2H), 4.32 (s, 2H), 4.03 (dd, J=7.8, 4.8 Hz, 1H), 3.88–3.74 (m, 2H), 3.52–3.43 (m, 2H), 3.43–3.32 (m, 2H), 3.02–2.90 (m, 1H), 2.45–2.25 (m, 2H), 2.25–2.08 (m, 2H), 1.80–1.12 (m, 21H), 1.04–0.88 (m, 5H).


EXAMPLE 40(17)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-methoxy-3-fluorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.58 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.40–7.31 (m, 2H), 7.22–7.17 (m, 1H), 4.30 (s, 2H), 4.03 (dd, J=7.8, 4.8 Hz, 1H), 3.90 (s, 3H), 3.86–3.70 (m, 2H), 3.50–3.38 (m, 4H), 2.52–2.32 (m, 2H), 2.26–2.05 (m, 2H), 1.80–1.15 (m, 15H), 1.01–0.88 (m, 5H).


EXAMPLE 40(18)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(2-hydroxyethoxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.40 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.47 (d, J=8.7 Hz, 2H), 7.06 (d, J=8.7 Hz, 2H), 4.29 (s, 2H), 4.08–4.00 (m, 3H), 3.89–3.84 (m, 2H), 3.84–3.68 (m, 2H), 3.52–3.36 (m, 4H), 2.48–2.30 (m, 2H), 2.25–2.08 (m, 2H), 1.80–1.10 (m, 15H), 1.04–0.86 (m, 5H).


EXAMPLE 40(19)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-hydroxy-3-methyl phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.85 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.30–7.21 (m, 2H), 6.88 (t, J=7.5 Hz, 1H), 4.36 (s, 2H), 4.03 (dd, J=7.8, 4.2 Hz, 1H), 3.94–3.78 (m, 2H), 3.56–3.46 (m, 2H), 3.42–3.32 (m, 2H), 2.50–2.30 (m, 2H), 2.28 (s, 3H), 2.28–2.06 (m, 2H), 1.82–1.01 (m, 15H), 1.00–0.87 (m, 5H).


EXAMPLE 40(20)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-chlorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.60 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.57 (d, J=8.7 Hz, 2H), 7.51 (d, J=8.7 Hz, 2H), 4.36 (s, 2H), 4.03 (dd, J=7.5, 4.8 Hz, 1H), 3.89–3.71 (m, 2H), 3.53–3.33 (m, 4H), 2.52–2.32 (m, 2H), 2.26–2.07 (m, 2H), 1.83–1.06 (m, 15H), 1.04–0.84 (m, 2H), 0.95 (t, J=6.9 Hz, 3H).


EXAMPLE 40(21)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(7-methoxy-1,3-benzodioxolan-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.43 (chloroform:methanol=20:1);


NMR (CD3OD): δ 6.85 (s, 1H), 6.74 (s, 1H), 5.99 (s, 2H), 4.25 (s, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.92 (s, 3H), 3.87–3.67 (m, 2H), 3.54–3.34 (m, 4H), 2.53–2.30 (m, 2H), 2.25–2.05 (m, 2H), 1.83–1.10 (m, 15H), 1.06–0.83 (m, 2H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 40(22)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3-methyl-4-methoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.38 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.37–7.28 (m, 2H), 6.99 (d, J=8.1 Hz, 1H), 4.25 (s, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.85 (s, 3H), 3.84–3.66 (m, 2H), 3.52–3.32 (m, 4H), 2.48–2.28 (m, 2H), 2.22 (s, 3H), 2.22–2.05 (m, 2H), 1.83–1.10 (m, 15H), 1.06–0.83 (m, 2H), 0.94 (t, J=6.9 Hz, 3H).


EXAMPLE 40(23)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-fluorophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.53 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.53 (d, J=8.7 Hz, 2H), 7.18–7.00 (m, 6H), 4.33 (s, 2H), 4.04 (dd, J=7.5, 4.5 Hz, 1H), 3.87–3.69 (m, 2H), 3.55–3.32 (m, 4H), 2.52–2.32 (m, 2H), 2.28–2.08 (m, 2H), 1.83–1.12 (m, 15H), 1.06–0.83 (m, 2H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 40(24)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-trifluoromethoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.60 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.72–7.69 (m, 2H), 7.41 (d, J=7.8 Hz, 2H), 4.40 (s, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.90–3.75 (m, 2H), 3.52–3.38 (m, 4H), 2.54–2.32 (m, 2H), 2.28–2.10 (m, 2H), 1.80–1.10 (m, 15H), 1.02–0.88 (m, 5H).


EXAMPLE 40(25)
(3S)-1-butyl-2,5-dioxo-3-cyclohexyl methyl-9-(3-methyl-5-chloro-1-phenyl pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.50 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.56–7.50 (m, 5H), 4.33 (s, 2H), 4.05 (dd, J=7.8, 4.5 Hz, 1H), 3.98–3.80 (m, 2H), 3.70–3.59 (m, 2H), 3.50–3.40 (m, 2H), 2.60–2.38 (m, 2H), 2.45 (s, 3H), 2.32–2.14 (m, 2H), 1.82–1.14 (m, 15H), 1.02–0.86 (m, 5H),


EXAMPLE 40(26)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2,3-dimethyl-5-oxo-1-phenylpyrazolin-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.27 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.62–7.48 (m, 3H), 7.44–7.38 (m, 2H), 4.13 (s, 2H), 4.04 (dd, J=7.5, 4.5 Hz, 1H), 3.88–3.72 (m, 2H), 3.64–3.52 (m, 2H), 3.50–3.38 (m, 2H), 3.35 (s, 3H), 2.60–2.40 (m, 2H), 2.48 (s, 3H), 2.28–2.10 (m, 2H), 1.82–1.10 (m, 15H), 1.02–0.84 (m, 5H).


EXAMPLE 40(27)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(1-(2-methylpropyloxycarbonyl)indol-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.55 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.26 (d, J=8.4 Hz, 1H), 7.82 (s, 1H), 7.76 (d, J=3.6 Hz, 1H), 7.50 (dd, J=8.4, 1.8 Hz, 1H), 6.74 (d, J=3.6 Hz, 1H), 4.44 (s, 2H), 4.25 (d, J=6.6 Hz, 2H), 4.03 (dd, J=7.8, 4.8 Hz, 1H), 3.86–3.72 (m, 2H), 3.52–3.40 (m, 4H), 2.52–2.36 (m, 2H), 2.25–2.06 (m, 3H), 1.80–1.10 (m, 15H), 1.07 (d, J=9.0 Hz, 6H), 1.00–0.84 (m, 5H).


EXAMPLE 40(28)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(5-methyl-2-phenyloxazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.48 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.04–8.00 (m, 2H), 7.51–7.49 (m, 3H), 4.34 (s, 2H), 4.04 (dd, J=7.8, 4.8 Hz, 1H), 3.98–3.82 (m, 2H), 3.70–3.60 (m, 2H), 3.44–3.38 (m, 2H), 2.52 (s, 3H), 2.50–2.36 (m, 2H), 2.28–2.12 (m, 2H), 1.80–1.12 (m, 15H), 1.00–0.86 (m, 5H).


EXAMPLE 40(29)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-methylsulfonylaminophenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.32 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.47 (d, J=9.0 Hz, 2H), 7.41 (d, J=9.0 Hz, 2H), 4.32 (s, 2H), 4.04 (dd, J=7.8, 4.8 Hz, 1H), 3.92–3.76 (m, 2H), 3.65–3.58 (m, 2H), 3.52–3.45 (m, 2H), 3.04 (s, 3H), 2.64–2.50 (m, 2H), 2.43 (s, 3H), 2.40 (s, 3H), 2.28–2.12 (m, 2H), 1.82–1.10 (m, 15H), 1.00–0.88 (m, 5H).


EXAMPLE 40(30)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-methylsulfonylaminophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.42 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.53 (d, J=9.0 Hz, 2H), 7.29 (d, J=9.0 Hz, 2H), 7.08–7.00 (m, 4H), 4.33 (s, 2H), 4.03 (dd, J=7.5, 4.8 Hz, 1H), 3.85–3.72 (m, 2H), 3.54–3.36 (m, 4H), 2.95 (s, 3H), 2.48–2.34 (m, 2H), 2.25–2.08 (m, 2H), 1.80–1.14 (m, 15H), 0.98–0.88 (m, 5H).


EXAMPLE 40(31)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(6-methylpyridin-3-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.42 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.58 (d, J=2.7 Hz, 1H), 8.17 (m, 1H), 7.90 (d, J=8.4 Hz, 1H), 7.75 (d, J=9.0 Hz, 2H), 7.30 (d, J=9.0 Hz, 2H), 4.39 (s, 2H), 4.03 (dd, J=7.5, 4.8 Hz, 1H), 3.88–3.72 (m, 2H), 3.56–3.44 (m, 4H), 2.76 (s, 3H), 2.68–2.50 (m, 2H), 2.24–2.06 (m, 2H), 1.82–1.14 (m, 15H), 1.02–0.88 (m, 5H).


EXAMPLE 40(32)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(6-methylpyridin-1-oxide-3-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.38 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.40 (m, 1H), 7.69 (d, J=8.4 Hz, 2H), 7.69 (m, 1H), 7.54 (m, 1H), 7.27 (d, J=8.4 Hz, 2H), 4.39 (s, 2H), 4.04 (dd, J=7.5, 4.8 Hz, 1H), 3.88–3.72 (m, 2H), 3.58–3.39 (m, 4H), 2.59 (s, 3H), 2.58–2.40 (m, 2H), 2.28–2.06 (m, 2H), 1.82–1.10 (m, 15H), 1.02–0.84 (m, 5H).


EXAMPLE 40(33)
(3S)-1-butyl-2,5-dioxo-3-cyclohexyl methyl-9-(4-(tetrahydropyran-4-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.48 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.49 (d, J=8.4 Hz, 2H), 7.05 (d, J=8.4 Hz, 2H), 4.63 (m, 1H), 4.27 (s, 2H), 4.02 (dd, J=7.8, 4.8 Hz, 1H), 3.97–3.90 (m, 2H), 3.84–3.66 (m, 2H), 3.62–3.52 (m, 2H), 3.50–3.38 (m, 3H), 2.54–2.38 (m, 2H), 2.22–1.98 (m, 4H), 1.80–1.10 (m, 18H), 1.00–0.86 (m, 5H).


EXAMPLE 40(34)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(6-phenylpyridin-3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.50 (chloroform:methanol=10:1);


NMR (CD3OD): δ 9.14 (m, 1H), 8.75 (m, 1H), 8.36 (m, 1H), 8.02–7.99 (m, 2H) 7.68–7.62 (m, 3H), 4.63 (s, 2H), 4.05 (dd, J=7.5, 4.5 Hz, 1H), 4.02–3.94 (m, 2H), 3.64–3.42 (m, 4H), 2.72–2.56 (m, 2H), 2.25–2.06 (m, 2H), 1.80–1.10 (m, 15H), 1.00–0.86 (m, 5H).


EXAMPLE 40(35)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-fluorophenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.60 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.58–7.50 (m, 2H), 7.37–7.28 (m, 2H), 4.32 (s, 2H), 4.05 (dd, J=7.5, 4.5 Hz, 1H), 3.94–3.73 (m, 2H), 3.67–3.55 (m, 2H), 3.53–3.42 (m, 2H, 2.70–2.48 (m, 2H), 2.43 (s, 3H), 2.39 (s, 3H), 2.30–2.08 (m, 2H), 1.84–1.10 (m, 15H), 1.08–0.93 (m, 2H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 40(36)
(3S)-1-butyl-2,5-dioxo-3-cyclohexyl methyl-9-(3,5-dimethyl-1-(pyridin-2-yl) pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.60 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.53 (dd, J=4.8, 1.5 Hz, 1H), 8.11–8.00 (m, 1H), 7.84 (d, J=8.4 Hz, 1H), 7.49–7.41 (m, 1H), 4.32 (s, 2H), 4.05 (dd, J=7.5, 4.5 Hz, 1H), 3.95–3.74 (m, 2H), 3.66–3.54 (m, 2H), 3.50–3.37 (m, 2H), 2.68 (s, 3H), 2.64–2.40 (m, 2H), 2.43 (s, 3H), 2.30–2.08 (m, 2H), 1.93–1.10 (m, 15H), 1.08–0.92 (m, 2H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 40(37)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-hydroxyphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.48 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.34 (d, J=9.0 Hz, 2H), 6.96 (d, J=9.0 Hz, 2H),4.35 (s, 2H), 4.05 (dd, J=7.5, 4.5 Hz, 1H), 3.93–3.78 (m, 2H), 3.64–3.61 (m, 2H), 3.50 (t, J=8.0 Hz, 2H), 2.68–2.56 (m, 2H), 2.49 (s, 3H), 2.39 (s, 3H), 2.25–2.12 (m, 2H), 1.81–1.19 (m, 15H), 0.95 (t, J=7.5 Hz, 3H), 0.99–0.91 (m, 2H).


EXAMPLE 40(38)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(2-carboxyethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.43 (chloroform:methanol=10:1);


NMR (CD8OD): δ 7.46 (d, J=8.3 Hz, 2H), 7.38 (d, J=8.3 Hz, 2H),4.32 (s, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.85–3.74 (m, 2H), 3.50–3.46 (m, 2H), 3.40–3.35 (m, 2H), 2.96 (t, J=7.2 Hz, 2H), 2.62 (t, J=7.2 Hz, 2H), 2.42–2.30 (m, 2H), 2.34–2.10 (m, 2H), 1.78–1.18 (m, 15H), 0.94 (t, J=7.2 Hz, 3H), 0.94 (m, 2H).


EXAMPLE 40(39)
(3S)-1-butyl-2,5-dioxo-3-cyclohexyl methyl-9-(4-(4-hydroxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.54 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.47 (d, J=8.4 Hz, 2H), 6.97 (d, J=8.4 Hz, 2H), 6.88 (d, J=9.0 Hz, 2H), 6.80 (d, J=9.0 Hz, 2H), 4.30 (s, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.83–3.72 (m, 2H), 3.49–3.34 (m, 4H), 2.38 (m, 2H), 2.23–2.10 (m, 2H), 1.78–1.16 (m, 15H), 1.02–0.92 (m, 2H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 40(40)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-carboxyphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.25 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.19 (d, J=8.4 Hz, 2H), 7.61 (d, J=8.4 Hz, 2H), 4.33 (s, 2H), 4.06 (dd, J=7.5, 4.5 Hz, 1H), 3.93–3.80 (m, 2H), 3.61 (m, 2H), 3.43–3.38 (m, 2H), 2.44 (s, 3H), 2.40 (m, 2H), 2.39 (s, 3H), 2.21 (m, 2H), 1.75–1.18 (m, 15H), 0.96 (m, 2H), 0.96 (t, J=7.2 Hz, 3H).


EXAMPLE 40(41)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-(dimethylaminosulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.54 (chloroform:methanol=9:1);


NMR (CD3OD): δ 7.96 (d, J=8.7 Hz, 2H), 7.78 (d, J=8.7 Hz, 2H), 4.31 (s, 2H), 4.05 (dd, J=7.8, 4.5 Hz, 1H), 3.94–3.74 (m, 2H), 3.66–3.56 (m, 2H), 3.48 (m, 2H), 2.74 (s, 6H), 2.59 (m, 2H), 2.49 (s, 3H), 2.41 (s, 3H), 2.29–2.10 (m, 2H), 1.84–1.16 (m, 13H), 1.06–0.86 (m, 5H).


EXAMPLE 40(42)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(5-methylpyridin-1-oxide-2-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.49 (chloroform:methanol=9:1);


NMR (CD3OD): δ 7.77 (brs, 1H), 7.61 (d, J=7.5 Hz, 2H), 7.56 (dd, J 9.3, 2.4 Hz, 1H), 7.00 (d, J=7.5 Hz, 2H), 6.73 (d, J=9.3 Hz, 1H), 4.34 (s, 2H), 4.03 (dd, J=7.8, 4.8 Hz, 1H), 3.86–3.69 (m, 2H), 3.52–3.35 (m, 4H), 2.44 (m, 2H), 2.25–2.06 (m, 2H), 2.18 (s, 3H), 1.84–1.14 (m, 15H), 1.04–0.96 (m, 5H),


EXAMPLE 40(43)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(2-carboxy-1-ethynyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.17 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.75 (d, J=8.4 Hz, 2H), 7.70 (d, J=15.9 Hz, 1H), 7.61 (d, J=8.4 Hz, 2H), 6.57 (d, J=15.9 Hz, 1H), 4.39 (s, 2H),4.04 (dd, J=7.2, 4.8 Hz, 1H), 3.90–3.72 (m, 2H), 3.58–3.36 (m, 4H), 2.50–2.32 (m, 2H), 2.28–2.08 (m, 2H), 1.92–1.10 (m, 15H), 0.96 (t, J=7.2 Hz, 3H), 0.96 (m, 2H).


EXAMPLE 40(44)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-((1E)-2-carboxy-1-ethynyl) phenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.44 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.69–7.63 (m, 3H), 7.57 (d, J=8.7 Hz, 2H), 7.14 (d, J=8.7 Hz, 2H), 7.05 (d, J=8.4 Hz, 2H), 6.42 (d, J=15.9 Hz, 1H), 4.36 (s, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.90–3.74 (m, 2H), 3.55–3.36 (m, 4H), 2.50–2.30 (m, 2H), 2.30–2.08 (m, 2H), 1.82–1.10 (m, 15H), 1.02–0.88 (m, 5H).


EXAMPLE 40(45)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-aminocarbonylphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.41 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.90 (d, J=9.0 Hz, 2H), 7.60 (d, J=9.0 Hz, 2H), 7.15 (d, J=9.0 Hz, 2H), 7.07 (d, J=9.0 Hz, 2H), 4.36 (s, 2H), 4.04 (dd, J=7.5, 4.5, Hz, 1H), 3.90–3.72 (m, 2H), 3.56–3.35 (m, 4H), 2.53–2.35 (m, 2H), 2.28–2.08 (m, 2H), 1.84–1.13 (m, 15H), 1.06–0.86 (m, 5H).


EXAMPLE 40(46)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-aminosulfonylphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.33 (chloroform:methanol=10:1); NMR (d6-DMSO): δ 11.03 (brs, 1H), 8.42 (brs, 1H), 7.82 (d, J=8.7 Hz, 2H), 7.71 (d, J=8.7 Hz, 2H), 7.33 (brs, 2H), 7.16 (d, J=8.7 Hz, 4H), 4.38–4.23 (m, 2H), 3.91 (m, 1H), 3.61–3.23 (m, 6H), 2.58–2.30 (m, 2H), 2.18–1.91 (m, 2H), 1.76–1.00 (m, 15H), 0.98–0.71 (m, 5H).


EXAMPLE 40(47)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-benzylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.40 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.41–7.33 (m, 3H), 7.22–7.20 (m, 2H), 5.46 (s, 2H), 4.31 (s, 2H), 4.04 (dd, J=7.5, 4.5 Hz, 1H), 3.88–3.74 (m, 2H), 3.58–3.48 (m, 4H), 2.61 (m, 2H), 2.47 (s, 6H), 2.24–2.09 (m, 2H), 1.80–1.16 (m, 15H), 0.95 (t, J=7.2


EXAMPLE 40(48)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(2,4-difluorophenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.48 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.58–7.51 (m, 1H), 7.33–7.25 (m, 1H), 7.22–7.16 (m, 1H),4.31 (s, 2H), 4.05 (dd, J=7.5, 4.5 Hz, 1H), 3.91–3.78 (m, 2H), 3.59 (m, 2H), 3.44 (m, 2H), 2.49 (m, 2H), 2.38 (s, 3H), 2.28 (s, 3H), 2.27–2.15 (m, 2H), 1.81–1.16 (m, 15H), 0.96 (t, J=7.0 Hz, 3H), 0.96 (m, 2H).


EXAMPLE 40(49)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(pyrrolidin-1-ylmethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.14 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.74 (d, J=8.4 Hz, 2H), 7.65 (d, J=8.4 Hz, 2H), 4.43 (s, 2H), 4.40 (s, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.90–3.70 (m, 2H), 3.56–3.38 (m, 6H), 3.28–3.10 (m, 2H), 2.66–2.48 (m, 2H), 2.26–1.92 (m, 6H), 1.83–1.10 (m, 15H), 1.06–0.83 (m, 2H), 0.94 (t, J=7.2 Hz, 3H).


EXAMPLE 40(50)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-(morpholin-4-ylsulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.46 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.95 (d, J=8.7 Hz, 2H), 7.80 (d, J=8.7 Hz, 2H), 4.32 (s, 2H), 4.05 (dd, J=7.8, 4.5 Hz, 1H), 3.94–3.74 (m, 2H), 3.76–3.67 (m, 4H), 3.66–3.56 (m, 2H), 3.56–3.42 (m, 2H), 3.10–2.92 (m, 4H), 2.68–2.50 (m, 2H), 2.50 (s, 3H), 2.42 (s, 3H), 2.30–2.08 (m, 2H), 1.84–1.08 (m, 15H), 1.08–0.83 (m, 2H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 40(51)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-cyanophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.33 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.75 (d, J=9.3 Hz, 2H), 7.64 (d, J=9.0 Hz, 2H), 7.22 (d, J=9.0 Hz, 2H), 7.14 (d, J=9.3 Hz, 2H), 4.40 (s, 2H), 4.05 (dd, J=7.5, 4.8 Hz, 1H), 3.92–3.74 (m, 2H), 3.58–3.36 (m, 4H), 2.52–2.36 (m, 2H), 2.32–2.08 (m, 2H), 1.84–1.12 (m, 15H), 0.96 (t, J=7.2 Hz, 3H), 0.96 (m, 2H).


EXAMPLE 40(52)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-(N-(2-hydroxyethyl)-N-methylaminosulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.68 (chloroform:methanol=5:1);


NMR (CD3OD): δ 8.00 (d, J=8.7 Hz, 2H), 7.78 (d, J=8.7 Hz, 2H), 4.33 (s, 2H), 4.06 (dd, J=7.5, 4.5 Hz, 1H), 3.86–3.76 (m, 2H), 3.70 (t, J=5.7 Hz, 2H), 3.68–3.60 (m, 2H), 3.58–3.42 (m, 2H), 3.20 (t, J=5.7 Hz, 2H), 2.88 (s, 3H), 2.72–2.58 (m, 2H), 2.50 (s, 3H), 2.44 (s, 3H), 2.28–2.06 (m, 2H), 1.82–1.10 (m, 15H), 0.96 (t, J=7.2 Hz, 3H), 0.96 (m, 2H).


EXAMPLE 40(53)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(2-phenylethyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.24 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.28–7.23 (m, 3H), 7.10–7.07 (m, 2H), 4.40 (t, J=6.6 Hz, 2H), 4.19 (s, 2H), 4.06 (dd, J=7.2, 4.8 Hz, 1H), 3.80–3.60 (m, 2H), 3.58–3.36 (m, 4H), 3.12 (t, J=6.6 Hz, 2H), 2.64–2.45 (m, 2H), 2.45 (s, 3H), 2.26–2.04 (m, 2H), 1.95 (s, 3H), 1.84–1.14 (m, 15H), 0.97 (t, J=7.5 Hz, 3H), 0.97 (m, 2H),


EXAMPLE 40(54)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(dimethylaminomethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.16 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.76 (d, J=8.1 Hz, 2H), 7.63 (d, J=8.1 Hz, 2H), 4.41 (s, 2H), 4.37 (s, 2H), 4.03 (dd, J=7.8, 5.1 Hz, 1H), 3.90–3.75 (m, 2H), 3.52–3.38 (m, 4H), 2.87 (s, 6H), 2.64–2.48 (m, 2H), 2.22–2.04 (m, 2H), 1.80–1.15 (m, 15H), 1.00–0.86 (m, 5H).


EXAMPLE 40(55)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3-(4-hydroxyphenyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.58 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.81 (s, 1H), 7.69 (d, J=7.5 Hz, 1H), 7.54 (d, J=9.0 Hz, 2H), 7.55–7.48 (m, 1H), 7.45 (d, J=7.5 Hz, 1H), 6.87 (d, J=9.0 Hz, 2H), 4.40 (s, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.92–3.73 (m, 2H), 3.58–3.43 (m, 2H), 3.43–3.32 (m, 2H), 2.55–2.35 (m, 2H), 2.28–2.06 (m, 2H), 1.82–1.10 (m, 15H), 1.08–0.83 (m, 2H), 0.94 (t, J=7.2 Hz, 3H).


EXAMPLE 40(56)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(quinoxalin-2-yl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.67 (chloroform:methanol=10:1);


NMR (CD3OD): δ 9.51 (s, 1H), 8.13 (d, J=8.0 Hz, 1H),8.05 (d, J=8.0 Hz, 1H), 7.91–7.80 (m, 2H), 4.38 (s, 2H), 4.05 (dd, J=7.5, 4.5 Hz, 1H), 3.96–3.82 (m, 2H), 3.63 (m, 2H), 3.42 (m, 2H), 2.92 (s, 3H), 2.47 (s, 3H), 2.47 (m, 2H), 2.29–2.16 (m, 2H), 1.80–1.18 (m, 15H), 0.95 (t, J=7.2 Hz, 3H), 0.95 (m, 2H),


EXAMPLE 40(57)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(phenylcarbonyl) phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.68 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.87 (d, J=8.4 Hz, 2H), 7.82–7.74 (m, 4H), 7.67 (t, J=8.4 Hz, 1H), 7.57–7.51 (m, 2H), 4.48 (s, 2H), 4.04 (dd, J=7.8, 4.8 Hz, 1H), 3.84–3.78 (m, 2H), 3.58–3.38 (m, 4H), 2.58–2.40 (m, 2H), 2.30–2.10 (m, 2H), 1.82–1.14 (m, 15H), 1.02–0.86 (m, 5H).


EXAMPLE 40(58)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-methylaminosulfonylphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.30 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.01 (d, J=8.7 Hz, 2H), 7.74 (d, J=8.7 Hz, 2H), 4.33 (s, 2H), 4.06 (dd, J=7.8, 4.5 Hz, 1H), 3.86–3.78 (m, 2H), 3.68–3.58 (m, 2H), 3.52–3.36 (m, 2H), 2.59 (s, 3H), 2.59–2.38 (m, 2H), 2.48 (s, 3H), 2.41 (s, 3H), 2.34–2.10 (m, 2H), 1.84–1.16 (m, 15H), 0.97 (t, J=7.2 Hz, 3H), 0.97 (m, 2H),


EXAMPLE 40(59)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(1,3,5-trimethylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.43 (chloroform:methanol=10:1);


NMR (CD3OD): δ 4.28 (s, 2H), 4.03 (dd, J=7.8, 4.5 Hz, 1H), 3.87 (s, 3H), 3.87–3.69 (m, 2H), 3.61–3.43 (m, 4H), 2.69–2.50 (m, 2H), 2.46 (s, 3H), 2.44 (s, 3H), 2.25–2.06 (m, 2H), 1.83–1.12 (m, 15H), 1.05–0.86 (m, 5H).


EXAMPLE 40(60)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(morpholin-4-ylmethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.56 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.74 (d, J=8.4 Hz, 2H), 7.66 (d, J=8.4 Hz, 2H), 4.40 (s, 4H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 4.00–3.70 (m, 6H), 3.54–3.40 (m, 4H), 3.35–3.18 (m, 4H), 2.63–2.47 (m, 2H), 2.24–2.02 (m, 2H), 1.83–1.12 (m, 15H), 1.06–0.85 (m, 5H).


EXAMPLE 40(61)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(3-methoxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.57 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.53 (d, J=8.7 Hz, 2H), 7.28 (t, J=8.4 Hz, 1H), 7.07 (d, J=8.7 Hz, 2H), 6.75 (ddd, J=8.4, 2.4, 1.0 Hz, 1H), 6.61–6.57 (m, 2H), 4.34 (s, 2H), 4.04 (dd, J=7.5, 4.5 Hz, 1H), 3.85–3.55 (m, 2H), 3.77 (s, 3H), 3.53–3.47 (m, 2H), 3.40 (m, 2H), 2.50–2.35 (m, 2H), 2.25–2.11 (m, 2H), 1.80–1.23 (m, 15H), 0.95 (t, J=7.2 Hz, 3H), 0.95 (m, 2H).


EXAMPLE 40(62)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-methylpiperazin-1-ylmethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.3 hydrochloride



embedded image


TLC: Rf 0.69 (chloroform:methanol=5:1);


NMR (CD3OD): δ 7.74 (s, 4H), 4.54 (s, 2H), 4.41 (s, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.87–3.42 (m, 14H), 3.00 (s, 3H), 2.61–2.46 (m, 2H), 2.21–2.07 (m, 2H), 1.79–1.15 (m, 15H), 1.02–0.92 (m, 2H), 0.94 (t, J=7.2 Hz, 3H).


EXAMPLE 40(63)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(pyridin-1-oxide-3-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.42 (chloroform:methanol=9:1);


NMR (CD3OD): δ 8.45 (t, J=1.8 Hz, 1H), 8.37 (brd, J=6.3 Hz, 1H), 7.71 (dd, J=8.4, 6.3 Hz, 1H), 7.72 (d, J=8.7 Hz, 2H), 7.59 (brdd, J=8.4, 1.8 Hz, 1H), 7.31 (d, J=8.7 Hz, 2H), 4.40 (s, 2H), 4.04 (dd, J=7.8 Hz, 1H), 3.90–3.74 (m, 2H), 3.57–3.40 (m, 4H), 2.58–2.40 (m, 2H), 2.28–2.08 (m, 2H), 1.82–1.14 (m, 15H), 1.04–0.90 (m, 5H).


EXAMPLE 40(64)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-phenylsulfonylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.77 (ethyl acetate: methanol=9:1);


NMR (CD3OD): δ 8.08 (d, J=8.4 Hz, 2H), 8.02–7.96 (m, 2H), 7.80 (d, J=8.4 Hz, 2H), 7.70–7.55 (m, 3H), 4.43 (s, 2H), 4.02 (dd, J=7.8, 4.8 Hz, 1H), 3.89–3.73 (m, 2H), 3.49–3.34 (m, 4H), 2.48–2.33 (m, 2H), 2.23–2.04 (m, 2H), 1.82–1.14 (m, 15H), 1.03–0.85 (m, 5H).


EXAMPLE 40(65)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-cyclohexylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.32 (ethyl acetate: methanol=9:1);


NMR (CD3OD): δ 4.42–4.28 (m, 1H), 4.28 (s, 2H), 4.04 (dd, J=7.5, 4.5 Hz, 1H), 3.90–3.72 (m, 2H), 3.60–3.43 (m, 4H), 2.68–2.50 (m, 2H), 2.50 (s, 3H), 2.46 (s, 3H), 2.25–2.06 (m, 2H), 2.04–1.15 (m, 25H), 1.05–0.89 (m, 5H).


EXAMPLE 40(66)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(3-carboxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.16 (ethyl acetate: methanol=9:1);


NMR (CD3OD): δ 7.83 (ddd, J=7.8, 1.5, 1.2 Hz, 1H), 7.60 (dd, J=2.4, 1.5 Hz, 1H), 7.57 (d, J=8.7 Hz, 2H), 7.51 (t, J=7.8 Hz, 1H), 7.29 (ddd, J=7.8, 2.4, 1.2 Hz, 1H), 7.12 (d, J=8.7 Hz, 2H), 4.35 (s, 2H), 4.04 (dd, J 7.5, 4.5 Hz, 1H), 3.90–3.74 (m, 2H), 3.58–3.35 (m, 4H), 2.49–2.34 (m, 2H), 2.28–2.09 (m, 2H), 1.93–1.10 (m, 15H), 1.07–0.85 (m, 5H).


EXAMPLE 40(67)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(piperidin-1-ylmethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.56 (chloroform:methanol=9:1);


NMR (CD3OD): δ 7.75 (d, J=8.4 Hz, 2H), 7.64 (d, J=8.4 Hz, 2H), 4.40 (s, 2H), 4.34 (s, 2H), 4.03 (dd, J=7.8, 4.8 Hz, 1H), 3.90–3.72 (m, 2H), 3.53–3.38 (m, 6H), 3.05–2.91 (m, 2H), 2.66–2.49 (m, 2H), 2.24–2.04 (m, 2H), 2.00–1.13 (m, 21H), 1.04–0.86 (m, 5H).


EXAMPLE 40(68)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-(pyrrolidin-1-ylsulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.40 (ethyl acetate: methanol=9:1);


NMR (CD3OD): δ 8.01 (d, J=8.7 Hz, 2H), 7.76 (d, J=8.7 Hz, 2H), 4.32 (s, 2H), 4.05 (dd, J=7.5, 4.5 Hz, 1H), 3.94–3.75 (m, 2H), 3.66–3.56 (m, 2H), 3.49–3.41 (m, 2H), 3.32–3.25 (m, 4H), 2.60–2.46 (m, 2H), 2.48 (s, 3H), 2.40 (s, 3H), 2.30–2.11 (m, 2H), 1.83–1.14 (m, 19H), 1.05–0.87 (m, 5H).


EXAMPLE 40(69)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2,3-dihydrobenzofuran-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.61 (ethyl acetate: methanol=9:1);


NMR (CD3OD): δ 7.39 (d, J=1.8 Hz, 1H), 7.26 (dd, J=8.4, 1.8 Hz, 1H), 6.81 (d, J=8.4 Hz, 1H), 4.59 (t, J=8.7 Hz, 2H), 4.26 (s, 2H), 4.04 (dd, J=7.8, 4.8 Hz, 1H), 3.84–3.67 (m, 2H), 3.54–3.34 (m, 4H), 3.25 (t, J=8.7 Hz, 2H), 2.48–2.31 (m, 2H), 2.26–2.07 (m, 2H), 1.83–1.14 (m, 15H), 1.04–0.87 (m, 5H).


EXAMPLE 40(70)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-carboxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.55 (ethyl acetate: methanol=9:1);


NMR (CD3OD): δ 8.04 (d, J=8.7 Hz, 2H), 7.61 (d, J=8.7 Hz, 2H), 7.18 (d, J=8.7 Hz, 2H), 7.07 (d, J=8.7 Hz, 2H), 4.38 (s, 2H), 4.05 (dd, J=7.8, 4.8 Hz, 1H), 3.91–3.74 (m, 2H), 3.57–3.35 (m, 4H), 2.50–2.33 (m, 2H), 2.29–2.09 (m, 2H), 1.84–1.14 (m, 15H), 1.05–0.86 (m, 5H).


EXAMPLE 40(71)
(3S)-1-butyl-2,5-dioxo-3-cyclohexyl methyl-9-(3,5-dimethyl-1-(4-(2-hydroxyethylaminosulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.38 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.03 (d, J=8.7 Hz, 2H), 7.72 (d, J=8.7 Hz, 2H), 4.31 (s, 2H), 4.05 (dd, J=7.5, 4.5 Hz, 1H), 3.94–3.74 (m, 2H), 3.66–3.56 (m, 2H), 3.56 (t, J=5.7 Hz, 2H), 3.51–3.41 (m, 2H), 3.01 (t, J=5.7 Hz, 2H), 2.63–2.43 (m, 2H), 2.47 (s, 3H), 2.40 (s, 3H), 2.32–2.10 (m, 2H), 1.93–1.10 (m, 15H), 1.06–0.93 (m, 2H), 0.96 (t, J=7.2 Hz, 3H).


EXAMPLE 40(72)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-(2-dimethylaminoethylaminosulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.3 hydrochloride



embedded image


TLC: Rf 0.13 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.07 (d, J=8.7 Hz, 2H), 7.79 (d, J=8.7 Hz, 2H), 4.31 (s, 2H), 4.04 (dd, J=7.5, 4.2 Hz, 1H), 3.82–3.76 (m, 2H), 3.68–3.48 (m, 4H), 3.34–3.24 (m, 4H), 2.95 (s, 6H), 2.76–2.52 (m, 2H), 2.50 (s, 3H), 2.43 (s, 3H), 2.25–2.08 (m, 2H), 1.82–1.14 (m, 15H), 1.02–0.88 (m, 5H).


EXAMPLE 40(73)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(1-hydroxy-1-phenylmethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.30 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.62–7.18 (m, 9H), 5.82 (s, 1H), 4.34 (s, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.88–3.72 (m, 2H), 3.58–3.30 (m, 4H), 2.42–2.04 (m, 4H), 1.82–1.24 (m, 15H), 0.94 (t, J=7.2 Hz, 3H), 0.94 (m, 2H).


EXAMPLE 40(74)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(carboxymethyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.30 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.47 (d, J=8.7 Hz, 2H), 7.04 (d, J=8.7 Hz, 2H), 4.70 (s, 2H), 4.29 (s, 2H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.86–3.69 (m, 2H), 3.54–3.33 (m, 4H), 2.44–2.28 (m, 2H), 2.26–2.06 (m, 2H), 1.83–1.12 (m, 15H), 1.04–0.85 (m, 5H).


EXAMPLE 40(75)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-hydroxypiperidin-1-ylmethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.17 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.76 (d, J=7.8 Hz, 2H), 7.70–7.61 (m, 2H), 4.40 (s, 2H), 4.38–4.32 (m, 2H), 4.10–4.05 (m, 1H), 4.03 (dd, J=7.5, 4.5 Hz, 1H), 3.90–3.68 (m, 2H), 3.56–3.40 (m, 4H), 3.18–3.00 (m, 1H), 2.70–2.48 (m, 2H), 2.23–1.82 (m, 5H), 1.82–1.10 (m, 19H), 1.06–0.83 (m, 2H), 0.94 (t, J=7.2 Hz, 3H).


EXAMPLE 40(76)
(3S)-1-butyl-2,5-dioxo-3-cyclohexyl methyl-9-(4-(3-carboxyphenylmethyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.57 (chloroform:methanol=5:1);


NMR (CD3OD): δ 8.10 (s, 1H), 7.98 (d, J=7.8 Hz, 1H), 7.68 (d, J=7.8 Hz, 1H), 7.50 (t, J=7.8 Hz, 1H), 7.46 (d, J=8.7 Hz, 2H), 7.13 (d, J=8.7 Hz, 2H), 5.22 (s, 2H), 4.28 (s, 2H), 4.04 (dd, J=7.8, 4.8 Hz, 1H), 3.84–3.68 (m, 2H), 3.52–3.32 (m, 4H), 2.42–2.08 (m, 4H), 1.82–1.16 (m, 15H), 0.95 (t, J=7.8 Hz, 3H), 0.95 (m, 2H).


EXAMPLE 40(77)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(1,4-benzodioxan-6-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.41 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.48 (d, J=9.0 Hz, 2H), 7.02 (d, J=9.0 Hz, 2H), 6.86 (m, 1H), 6.55–6.51 (m, 2H), 4.31 (s, 2H), 4.24 (s, 4H), 4.05 (dd, J=7.5, 4.5 Hz, 1H), 3.86–3.70 (m, 2H), 3.58–3.36 (m, 4H), 2.42–2.08 (m, 4H), 1.82–1.12 (m, 15H), 0.96 (t, J=7.2 Hz, 3H), 0.96 (m, 2H).


EXAMPLE 40(78)
(3S)-1-butyl-2,5-dioxo-3-cyclohexyl methyl-9-(3-(3-hydroxyphenyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.24 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.81 (s, 1H), 7.74 (m, 1H), 7.60–7.50 (m, 2H), 7.28 (m, 1H), 7.15–7.08 (m, 2H), 6.82 (m, 1H), 4.43 (s, 2H), 4.04 (dd, J 7.5, 4.5 Hz, 1H), 3.86–3.78 (m, 2H), 3.58–3.34 (m, 4H), 2.48–2.08 (m, 4H), 1.84–1.12 (m, 15H), 0.95 (t, J=7.2 Hz, 3H), 0.95 (m, 2H).


EXAMPLE 40(79)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(methylsulfonylamino)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.40 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.53 (d, J=8.4 Hz, 2H), 7.34 (d, J=8.4 Hz, 2H), 4.32 (s, 2H), 4.03 (dd, J=7.8, 4.8 Hz, 1H), 3.86–3.72 (m, 2H), 3.52–3.34 (m, 4H), 3.01 (s, 3H), 2.50–2.32 (m, 2H), 2.24–2.06 (m, 2H), 1.82–1.10 (m, 15H), 1.02–0.86 (m, 5H).


EXAMPLE 40(80)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(6-(4-methoxyphenyl) pyridin-3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.67 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.26 (m, 1H), 8.02 (m, 1H), 7.08–6.84 (m, 5H), 4.38 (s, 2H), 4.04 (dd, J=7.8, 4.8 Hz, 1H), 3.90–3.72 (m, 2H), 3.81 (s, 3H), 3.56–3.44 (m, 2H), 3.42–3.32 (m, 2H), 2.50–2.30 (m, 2H), 2.30–2.08 (m, 2H), 1.82–1.14 (m, 15H), 1.02–0.88 (m, 5H).


EXAMPLE 40(81)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-methylaminocarbonylphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.46 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.39 (br d, J=4.5 Hz, 1H), 7.84 (d, J=9.0 Hz, 2H), 7.58 (d, J=8.4 Hz, 2H), 7.15 (d, J=8.4 Hz, 2H), 7.07 (d, J=9.0 Hz, 2H), 4.35 (s, 2H), 4.04 (m, 1H), 3.85–3.74 (m, 2H), 3.53–3.38 (m, 4H), 2.91 (d, J=4.5 Hz, 3H), 2.55–2.30 (m, 2H), 2.30–2.10 (m, 2H), 1.80–1.10 (m, 15H), 1.10–0.90 (m, 2H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 40(82)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-chlorophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.76 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.52 (d, J=9.0 Hz, 2H), 7.38 (d, J=9.0 Hz, 2H), 7.09 (d, J=9.0 Hz, 2H), 7.02 (d, J=9.0 Hz, 2H), 4.32 (s, 2H), 4.04 (m, 1H), 3.90–3.70 (m, 2H), 3.60–3.30 (m, 4H), 2.50–2.10 (m, 4H), 1.90–1.10 (m, 15H), 1.10–0.90 (m, 2H), 0.95 (t, J=7.5 Hz, 3H).


EXAMPLE 40(83)
(3S)-1-butyl-2,5-dioxo-3-cyclohexyl methyl-9-(4-bis(methylsulfonyl)aminophenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.60 (chloroform:methanol=5:1);


NMR (CD3OD): δ 7.69 (d, J=8.4 Hz, 2H), 7.60 (d, J=8.4 Hz, 2H), 4.41 (s, 2H), 4.05 (dd, J=7.8, 4.8 Hz, 1H), 3.92–3.70 (m, 2H), 3.56–3.36 (m, 4H), 3.47 (s, 6H), 2.46–2.08 (m, 4H), 1.84–1.16 (m, 15H), 0.96 (t, J=7.5 Hz, 3H), 0.96 (m, 2H).


EXAMPLE 40(84)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3-(4-carboxyphenyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.60 (chloroform:methanol=5:1);


NMR (CD3OD): δ 8.13 (d, J=9.0 Hz, 2H), 7.95 (s, 1H), 7.84 (m, 1H), 7.82 (d, J=9.0 Hz, 2H), 7.66–7.61 (m, 2H), 4.46 (s, 2H), 4.04 (dd, J=7.5, 4.5 Hz, 1H), 3.96–3.78 (m, 2H), 3.62–3.36 (m, 4H), 2.54–2.32 (m, 2H), 2.28–2.08 (m, 2H), 1.82–1.08 (m, 15H), 0.95 (t, J=7.2 Hz, 3H), 0.95 (m, 2H).


EXAMPLE 40(85)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(phenylaminocarbonyl) phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.25 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.07 (d, J=8.1 Hz, 2H), 7.73–7.67 (m, 2H), 7.71 (d, J=8.1 Hz, 2H), 7.38 (t, J=7.5 Hz, 2H), 7.17 (t, J=7.5 Hz, 1H), 4.45 (s, 2H), 4.05 (dd, J=7.8, 4.8 Hz, 1H), 3.92–3.72 (m, 2H), 3.58–3.36 (m, 4H), 2.50–2.08 (m, 4H), 1.84–1.08 (m, 15H), 0.96 (t, J=7.8 Hz, 3H), 0.96 (m, 2H).


EXAMPLE 40(86)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-methylthiophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.48 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.54 (d, J=8.7 Hz, 2H), 7.33 (d, J=8.7 Hz, 2H), 7.06 (d, J=8.7 Hz, 2H), 7.00 (d, J=8.7 Hz, 2H), 4.34 (s, 2H), 4.05 (dd, J=7.5, 4.5 Hz, 1H), 3.86–3.70 (m, 2H), 3.56–3.36 (m, 4H), 2.48 (s, 3H), 2.48–2.32 (m, 2H), 2.28–2.08 (m, 2H), 1.82–1.14 (m, 15H), 0.96 (t, J=7.2 Hz, 3H), 0.96 (m, 2H),


EXAMPLE 40(87)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-(2-dimethylaminoethylaminocarbonyl)phenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.11 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.94 (d, J=9.0 Hz, 2H), 7.64 (d, J=8.7 Hz, 2H), 7.15 (d, J=8.7 Hz, 2H), 7.10 (d, J=9.0 Hz, 2H), 4.36 (s, 2H), 4.04 (dd, J=7.8, 4.8 Hz, 1H), 3.88–3.72 (m, 4H), 3.52–3.36 (m, 6H), 2.98 (s, 6H), 2.62–2.44 (m, 2H), 2.24–2.08 (m, 2H), 1.80–1.10 (m, 15H), 1.00–0.88 (m, 5H).


EXAMPLE 40(88)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-aminocarbonylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.19 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.98 (d, J=8.4 Hz, 2H), 7.68 (d, J=8.4 Hz, 2H), 4.43 (s, 2H), 4.03 (dd, J=7.5, 4.8 Hz, 1H), 3.92–3.76 (m, 2H), 3.54–3.28 (m, 4H), 2.52–2.36 (m, 2H), 2.24–2.08 (m, 2H), 1.82–1.10 (m, 15H), 1.02–0.88 (m, 5H).


EXAMPLE 40(89)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(dimethylaminocarbonyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.33 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.67 (d, J=8.1 Hz, 2H), 7.54 (d, J=8.1 Hz, 2H), 4.41 (s, 2H), 4.04 (dd, J=7.5, 4.2 Hz, 1H), 3.92–3.76 (m, 2H), 3.54–3.32 (m, 4H), 3.11 (s, 3H), 2.99 (s, 3H), 2.52–2.32 (m, 2H), 2.26–2.08 (m, 2H), 1.82–1.10 (m, 15H), 1.02–0.86 (m, 5H).


EXAMPLE 40(90)
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane



embedded image


TLC: Rf 0.73 (chloroform:methanol=10:1);


NMR (CDCl3): δ 7.37–7.25 (m, 4H), 7.10 (m, 1H), 7.04–6.98 (m, 2H), 6.96 (d, J=8.7 Hz, 2H), 5.81 (brs, 1H), 3.99 (m, 1H), 3.52 (s, 2H), 3.52–3.32 (m, 2H), 2.92–2.74 (m, 3H), 2.57 (dt, J=12.0, 3.0 Hz, 1H), 2.18–1.88 (m, 5H), 1.76–1.13 (m, 14H), 1.07–0.88 (m, 2H), 0.93 (t, J=7.5 Hz, 3H).


EXAMPLE 41

By the same procedure as described in Reference Example 3→Reference Example 4 using Resin (3) prepared in Reference Example 2, N-allyloxycarbonyl-4-piperidone, n-butylamine and (2R*, 3R*)-N-(t-butyloxycarbonyl)-2-amino-3-hydroxy-4-methylpentanoic acid, and furthermore by the same procedure as described in Reference Example 5→Reference Example 6→Example 1 using 1,4-benzodioxan-6-carboxyaldehyde, the following compounds (1) and (2) of the present invention were obtained respectively.


EXAMPLE 40(1)
1-butyl-2,5-dioxo-3-(1-hydroxy-2-methylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


(Symbol * means the mixture of syn form and anti form (syn: anti=2:3.)

TLC: Rf 0.47 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.04 (d, J=2.1 Hz, 1H), 6.97 (dd, J=8.4, 2.1 Hz, 1H), 6.93 (d, J=8.4 Hz, 1H), 4.26 (s, 4H), 4.23 (s, 2H), 4.13 (d, J=2.1 Hz, 0.6H), 4.08 (d, J=1.2 Hz, 0.4H), 4.05–3.90 (m, 1H), 3.76–3.63 (m, 1H), 3.62–3.35 (m, 3.4H), 3.19 (dd, J=9.6, 2.1 Hz, 0.6H), 3.20–3.10 (m, 1H), 2.55–2.33 (m, 2H), 2.30–1.95 (m, 3H), 1.80–1.60 (m, 1H), 1.55–1.25 (m, 3H), 1.05–0.89 (m, 9H),


EXAMPLE 41(2)
(Z)-1-butyl-2,5-dioxo-3-(2-methylpropylidene)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.52 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.04 (d, J=2.1 Hz, 1H), 6.97 (dd, J=8.4, 2.1 Hz, 1H), 6.93 (d, J=8.4 Hz, 1H), 5.84 (d, J=10.5 Hz, 1H), 4.26 (s, 4H), 4.23 (s, 2H), 3.72–3.55 (m, 2H), 3.53–3.35 (m, 4H), 2.80–2.60 (m, 1H), 2.43–2.26 (m, 2H), 2.25–2.15 (m, 2H), 1.62–1.48 (m, 2H), 1.45–1.30 (m, 2H), 1.04 (d, J=6.6 Hz, 6H), 0.95 (t, J=7.5 Hz, 3H).


EXAMPLE 41(3)˜41(5)

By the same procedure as described in Example 41 using the corresponding compounds instead of (2R*, 3R*)-N-(t-butyloxycarbonyl)-2-amino-3-hydroxy-4-methylpentanoic acid, and the corresponding compounds instead of 1,4-benzodioxan-6-carboxyaldehyde, the following compounds of the present invention were obtained.


EXAMPLE 41(3)
(3S)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxyethyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.39 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.54 (d, J=8.7 Hz, 2H), 7.43–7.35 (m, 2H), 7.21–7.14 (m, 1H), 7.08–7.00 (m, 4H), 4.32 (s, 2H), 4.19 (dq, J=1.5, 6.9 Hz, 1H), 4.10–3.97 (m, 1H), 3.78 (d, J=1.5 Hz, 1H), 3.72–3.51 (m, 2H), 3.51–3.40 (m, 2H), 3.28–3.14 (m, 1H), 2.57–2.42 (m, 2H), 2.40–2.25 (m, 1H), 2.21–2.10 (m, 1H), 1.81–1.60 (m, 1H), 1.50–1.30 (m, 3H), 1.22 (d, J=6.9 Hz, 3H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 41(4)
(Z)-1-butyl-2,5-dioxo-3-ethylidene-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.29 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.53 (d, J=9.0 Hz, 2H), 7.43–7.35 (m, 2H), 7.18 (t, J=7.5 Hz, 1H), 7.09–7.00 (m, 4H), 6.08 (q, J=7.5 Hz, 1H), 4.33 (s, 2H), 3.76–3.61 (m, 2H), 3.57–3.40 (m, 4H), 2.45–2.30 (m, 2H), 2.28–2.15 (m, 2H), 1.77 (d, J=7.5 Hz, 3H), 1.62–1.46 (m, 2H), 1.44–1.28 (m, 2H), 0.96 (t, J=7.5 Hz, 3H).


EXAMPLE 41(5)
(Z)-1-butyl-2,5-dioxo-3-(2-methylpropylidene)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.42 (chloroform:methanol=20:1);


NMR (CD3OD): δ 7.51 (d, J=8.7 Hz, 2H), 7.43–7.35 (m, 2H), 7.18 (t, J=7.5 Hz, 1H), 7.06 (d, J=8.7 Hz, 2H), 7.08–7.01 (m, 2H), 5.85 (d, J=10.5 Hz, 1H), 4.34 (s, 2H), 3.78–3.64 (m, 2H), 3.57–3.40 (m, 4H), 2.78–2.62 (m, 1H), 2.43–2.18 (m, 4H), 1.62–1.48 (m, 2H), 1.46–1.30 (m, 2H), 1.04 (d, J=6.6 Hz, 6H), 0.96 (t, J=7.5 Hz, 3H).


EXAMPLE 42
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-benzyloxycarbonyl-1,4,9-triazaspiro[5.5]undecane



embedded image


By the same procedure as described in Example 35 using (2R*,3R*)-N-(t-butyloxycarbonyl)-2-amino-3-hydroxy-4-methyl pentanoic acid instead of N-(t-butyloxycarbonyl)-L-leucine, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.43 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.39–7.30 (m, 5H), 5.13 (br, 2H), 4.12 (d, J=2.5 Hz, 1H), 4.10–4.00 (m, 2H), 3.76–3.50 (m, 2H), 3.39–3.25 (m, 2H), 3.10–2.94 (m, 1H), 2.18 (m, 1H), 2.08–1.83 (m, 4H), 1.70–1.56 (m, 1H), 1.45–1.15 (m, 3H), 1.01–0.89 (m, 9H).


EXAMPLE 43
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


By the same procedure as described in Example 9 using the compound prepared in Example 42, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.08 (chloroform:methanol=10:1);


NMR (CD3OD): δ 4.15 (d, J=2.0 Hz, 1H), 3.96 (dt, J=13.0, 4.0 Hz, 1H), 3.71 (dt, J=13.0, 4.0 Hz, 1H), 3.57–3.47 (m, 1H), 3.40–3.34 (m, 2H), 3.23–3.12 (m, 2H), 2.47–2.30 (m, 2H), 2.25–1.98 (m, 3H), 1.79–1.66 (m, 1H), 1.52–1.28 (m, 3H), 1.07–0.94 (m, 9H).


EXAMPLE 44(1)˜44(13)

By the same procedure as described in Example 10 using the compound prepared in Example 43 and the corresponding aldehyde derivatives, the following compounds were obtained.


EXAMPLE 44(1)
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.51 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.52 (d, J=8.7 Hz, 2H), 7.44–7.35 (m, 2H), 7.18 (t, J=7.5 Hz, 1H), 7.10–7.00 (m, 4H), 4.33 (s, 2H), 4.14 (d, J=2.1 Hz, 1H), 4.06–3.93 (m, 1H), 3.80–3.67 (m, 1H), 3.56–3.40 (m, 3H), 3.19 (dd, J=9.3, 2.1 Hz, 1H), 3.20–3.10 (m, 1H), 2.53–2.35 (m, 2H), 2.35–2.20 (m, 1H), 2.19–2.08 (m, 1H), 2.07–1.91 (m, 1H), 1.80–1.70 (m, 1H), 1.50–1.25 (m, 3H), 0.99 (d, J=6.6 Hz, 3H), 0.97 (d, J=6.6 Hz, 3H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 44(2)
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.38 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.60–7.45 (m, 5H), 4.30 (s, 2H), 4.15 (d, J=2.4 Hz, 1H), 4.05 (m, 1H), 3.79 (m, 1H), 3.62–3.48 (m, 3H), 3.29–3.16 (m, 2H), 2.60–2.45 (m, 2H), 2.44–2.30 (m, 7H), 2.17 (m, 1H), 2.01 (m, 1H), 1.70 (m, 1H), 1.51–1.31 (m, 3H), 1.03–0.91 (m, 9H).


EXAMPLE 44(3)
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(6-phenyloxypyridin-3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.51 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.39 (d, J=2.1 Hz, 1H), 8.16 (dd, J=8.4, 2.1 Hz, 1H), 7.46 (t, J=7.8 Hz, 2H), 7.29 (t, J=7.8 Hz, 1H), 7.17 (d, J=7.8 Hz, 2H), 7.08 (d, J=8.4 Hz, 1H), 4.40 (s, 2H), 4.13 (d, J=2.1 Hz, 1H), 4.07–3.94 (m, 1H), 3.83–3.69 (m, 1H), 3.60–3.42 (m, 3H), 3.29–3.22 (m, 1H), 3.19 (dd, J=9.6, 2.1 Hz, 1H), 2.62–2.32 (m, 3H), 2.18–2.07 (m, 1H), 2.06–1.94 (m, 1H), 1.78–1.60 (m, 1H), 1.50–1.31 (m, 3H), 1.07–0.87 (m, 9H).


EXAMPLE 44(4)
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(4-(4-methylphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.46 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.47 (d, J=8.7 Hz, 2H), 7.20 (d, J=8.7 Hz, 2H), 7.02 (d, J=8.7 Hz, 2H), 6.92 (d, J=8.7 Hz, 2H), 4.29 (s, 2H), 4.14 (d, J=2.1 Hz, 1H), 3.97 (m, 1H), 3.72 (m, 1H), 3.56–3.39 (m, 2H), 3.25–3.09 (m, 3H), 2.53–2.08 (m, 7H), 2.01 (m, 1H), 1.70 (m, 1H), 1.48–1.28 (m, 3H), 1.05–0.88 (m, 9H).


EXAMPLE 44(5)
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(4-cyclohexyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.43 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.40 (d, J=8.7 Hz, 2H), 7.00 (d, J=8.7 Hz, 2H), 4.37 (m, 1H), 4.24 (brs, 2H), 4.13 (d, J=2.1 Hz, 1H), 3.94 (m, 1H), 3.68 (m, 1H), 3.52–3.34 (m, 2H), 3.29–3.07 (m, 3H), 2.52–1.92 (m, 7H), 1.85–1.27 (m, 12H), 1.04–0.89 (m, 9H).


EXAMPLE 44(6)
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(4-(tetrahydropyran-4-yl oxy) phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.20 (ethyl acetate: methanol=10:1);


NMR (CD3OD): δ 7.45 (d, J=8.7 Hz, 2H), 7.06 (d, J=8.7 Hz, 2H), 4.67–4.59 (m, 1H), 4.28 (s, 2H), 4.13 (d, J=2.5 Hz, 1H), 4.00–3.90 (m, 3H), 3.75–3.67 (m, 1H), 3.63–3.53 (m, 2H), 3.50–3.41 (m, 3H), 3.18 (dd, J=9.0, 2.0 Hz, 1H), 3.18 (m, 1H), 2.49–1.96 (m, 7H), 1.77–1.65 (m, 3H), 1.44–1.30 (m, 3H), 0.98 (d, J=6.5 Hz, 3H), 0.96 (d, J=6.5 Hz, 3H), 0.94 (t, J=7.2 Hz, 3H).


EXAMPLE 44(7)
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(4-(pyridin-3-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.22 (ethyl acetate:methanol=10:1);


NMR (CD3OD): δ 8.76 (d, J=2.5 Hz, 1H), 8.63 (d, J=6.0 Hz, 1H), 8.29 (dd, J=9.0, 2.5 Hz, 1H), 8.08 (dd, J=9.0, 6.0 Hz, 1H), 7.77 (d, J=9.0 Hz, 2H), 7.35 (d, J=9.0 Hz, 2H), 4.41 (s, 2H), 4.14 (d, J=2.0 Hz, 1H), 4.00 (m, 1H), 3.76 (m, 1H), 3.61–3.47 (m, 3H), 3.20 (dd, J=9.5, 2.0 Hz, 1H), 3.20 (m, 1H), 2.62 (m, 1H), 2.46 (m, 2H), 2.10 (m, 1H), 2.05–1.95 (m, 1H), 1.69 (m, 1H), 1.41–1.35 (m, 3H), 0.99 (d, J=6.5 Hz, 3H), 0.97 (d, J=6.5 Hz, 3H), 0.95 (t, J=7.5 Hz, 3H).


EXAMPLE 44(8)
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(4-isopropylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.55 (chloroform:methanol=10:1);


NMR (CD3OD) δ 7.47 (d, J=8.1 Hz, 2H), 7.37 (d, J=8.1 Hz, 2H), 4.31 (s, 2H), 4.13 (d, J=2.1 Hz, 1H), 4.05–3.91 (m, 1H), 3.80–3.65 (m, 1H), 3.57–3.38 (m, 3H), 3.26–3.13 (m, 1H), 3.19 (dd, J=9.3, 2.1 Hz, 1H), 3.03–2.86 (m, 1H), 2.53–2.38 (m, 2H), 2.38–2.23 (m, 1H), 2.16–2.05 (m, 1H), 2.06–1.92 (m, 1H), 1.77–1.56 (m, 1H), 1.49–1.26 (m, 3H), 1.25 (d, J=6.9 Hz, 6H), 0.98 (d, J=6.6 Hz, 3H), 0.97 (d, J=6.6 Hz, 3H), 0.94 (t, J=7.2 Hz, 3H).


EXAMPLE 44(9)
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(3,5-dimethyl-1-(4-methylphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.49 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.40 (s, 4H), 4.33 (s, 2H), 4.15 (d, J=2.1 Hz, 1H), 4.11–3.97 (m, 1H), 3.86–3.72 (m, 1H), 3.64–3.50 (m, 3H), 3.39–3.30 (m, 1H), 3.21 (dd, J=9.3, 2.1 Hz, 1H), 2.72–2.55 (m, 1H), 2.53–2.40 (m, 2H), 2.46 (s, 3H), 2.44 (s, 3H), 2.40 (s, 3H), 2.18–2.07 (m, 1H), 2.07–1.96 (m, 1H), 1.78–1.60 (m, 1H), 1.50–1.30 (m, 3H), 1.00 (d, J=6.6 Hz, 3H), 0.98 (d, J=6.6 Hz, 3H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 44(10)
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(3-methyl-5-chloro-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.56 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.58–7.47 (m, 5H), 4.33 (s, 2H), 4.15 (d, J=2.1 Hz, 1H), 4.15–4.02 (m, 1H), 3.89–3.75 (m, 1H), 3.65–3.48 (m, 3H), 3.30–3.20 (m, 1H), 3.20 (dd, J=9.6, 2.1 Hz, 1H), 2.64–2.46 (m, 2H), 2.44 (s, 3H), 2.44–2.32 (m, 1H), 2.21–2.10 (m, 1H), 2.08–1.93 (m, 1H), 1.80–1.60 (m, 1H), 1.52–1.30 (m, 3H), 0.99 (d, J=6.6 Hz, 3H), 0.98 (d, J=6.6 Hz, 3H), 0.96 (t, J=7.2 Hz, 3H).


EXAMPLE 44(11)
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(4-(4-carboxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.29 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.04 (d, J=9.0 Hz, 2H), 7.60 (d, J=8.7 Hz, 2H), 7.18 (d, J=8.7 Hz, 2H), 7.07 (d, J=9.0 Hz, 2H), 4.37 (s, 2H), 4.14 (d, J=2.1 Hz, 1H), 4.10–3.94 (m, 1H), 3.83–3.69 (m, 1H), 3.59–3.40 (m, 3H), 3.25–3.12 (m, 1H), 3.19 (dd, J=9.3, 2.1 Hz, 1H), 2.55–2.37 (m, 2H), 2.37–2.22 (m, 1H), 2.19–2.08 (m, 1H), 2.08–1.94 (m, 1H), 1.79–1.60 (m, 1H), 1.52–1.26 (m, 3H), 0.99 (d, J=6.6 Hz, 3H), 0.97 (d, J=6.6 Hz, 3H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 44(12)
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(3,5-dimethyl-1-(pyridin-2-yl) pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.28 (chloroform:methanol=10:1);


NMR (CD3OD): δ 8.53 (d, J=5.1 Hz, 1H), 8.05 (t, J=7.8 Hz, 1H), 7.81 (d, J=7.8 Hz, 1H), 7.44 (dd, J=7.8, 5.1 Hz, 1H), 4.33 (s, 2H), 4.16 (d, J=2.1 Hz, 1H), 4.06 (m, 1H), 3.78 (m, 1H), 3.62–3.44 (m, 3H), 3.26 (m, 1H), 3.21 (dd, J=9.6, 2.1 Hz, 1H), 2.68 (s, 3H), 2.60–2.30 (m, 3H), 2.42 (s, 3H), 2.16 (m, 1H), 2.02 (m, 1H), 1.72 (m, 1H), 1.50–1.26 (m, 3H), 1.00 (d, J=6.6 Hz, 3H), 0.99 (d, J=6.6 Hz, 3H), 0.96 (t, J=7.2 Hz, 3H).


EXAMPLE 44(13)
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(3,5-dimethyl-1-(4-carboxyphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.25 (chloroform:methanol: acetic acid=20:2:1);


NMR (CD3OD): δ 8.19 (d, J=8.7 Hz, 2H), 7.62 (d, J=8.7 Hz, 2H), 4.32 (s, 2H), 4.16 (d, J=2.1 Hz, 1H), 4.12–3.98 (m, 1H), 3.87–3.74 (m, 1H), 3.63–3.45 (m, 3H), 3.30–3.10 (m, 1H), 3.20 (dd, J=9.3, 2.1 Hz, 1H), 2.59–2.48 (m, 2H), 2.44 (s, 3H), 2.40–2.23 (m, 1H), 2.39 (s, 3H), 2.23–2.10 (m, 1H), 2.10–1.96 (m, 1H), 1.80–1.62 (m, 1H), 1.52–1.24 (m, 3H), 1.00 (d, J=6.6 Hz, 3H), 0.98 (d, J =6.6 Hz, 3H), 0.96 (t, J=7.2 Hz, 3H).


EXAMPLE 45
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-benzyloxycarbonyl-1,4,9-triazaspiro[5.5]undecane



embedded image


By the same procedure as described in Example 35 using (2R*,3R*)-N-(t-butyloxycarbonyl)-2-amino-3-hydroxy-3-cyclohexylpropanoic acid instead of N-(t-butyloxycarbonyl)-L-leucine, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.53 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.39–7.27 (m, 5H), 5.13 (m, 2H), 4.13 (d, J=2.5 Hz, 1H), 4.06–4.02 (m, 2H), 3.78–3.48 (m, 2H), 3.36–3.29 (m, 2H), 3.02 (br, 1H), 2.17 (m, 1H), 2.03–1.58 (m, 10H), 1.47–1.13 (m, 6H), 1.02–0.89 (m, 5H).


EXAMPLE 46
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-1,4,9-triazaspiro[5.5]undecane



embedded image


By the same procedure as described in Example 9 using the compound prepared in Example 45, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.33 (chloroform:methanol: acetic acid=20:6:1);


NMR (CD3OD): δ 4.13 (d, J=2.5 Hz, 1H), 3.48–3.22 (m, 5H), 2.97–2.89 (m, 2H), 2.12–1.65 (m, 10H), 1.56–1.16 (m, 7H), 1.03–0.85 (m, 5H).


EXAMPLE 47(1)˜47(8)

By the same procedure as described in Example 10 using the compound prepared in Example 46 and the corresponding aldehyde compounds, the following compounds of the present invention were obtained.


EXAMPLE 47(1)
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.44 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.55–7.51 (m, 2H), 7.42–7.36 (m, 2H), 7.18 (tt, J=7.5, 1.0 Hz, 1H), 7.08–7.01 (m, 4H), 4.32 (s, 2H), 4.15 (d, J=2.0 Hz, 1H), 3.98 (dt, J=3.5, 12.5 Hz, 1H), 3.73 (dt, J=3.5, 12.5 Hz, 1H), 3.57–3.39 (m, 3H), 3.26 (d, J=2.0 Hz, 1H), 3.20 (m, 1H), 2.52–2.39 (m, 2H), 2.30 (m, 1H), 2.12 (d, J=15.5 Hz, 1H), 2.04–1.92 (m, 2H), 1.80–1.62 (m, 5H), 1.48–1.11 (m, 6H), 1.01–0.82 (m, 5H).


EXAMPLE 47(2)
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexyl methyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.41 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.60–7.50 (m, 5H), 4.33 (s, 2H), 4.17 (d, J=2.5 Hz, 1H), 4.04 (m, 1H), 3.85–3.75 (m, 1H), 3.61–3.51 (m, 3H), 3.35–3.27 (m, 2H), 2.62 (m, 1H), 2.49–2.44 (m, 5H), 2.41 (s, 3H), 2.15 (m, 1H), 2.05–1.92 (m, 2H), 1.77–1.65 (m, 5H), 1.44–1.15 (m, 6H), 1.01–0.85 (m, 5H).


EXAMPLE 47(3)
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(4-isopropyl phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.69 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.48 (d, J=8.4 Hz, 2H), 7.36 (d, J=8.4 Hz, 2H), 4.31 (s, 2H), 4.14 (d, J=2.1 Hz, 1H), 3.98 (m, 1H), 3.72 (m, 1H), 3.55–3.40 (m, 3H), 3.29–3.16 (m, 2H), 2.95 (m, 1H), 2.52–2.24 (m, 3H), 2.15–1.86 (m, 3H), 1.80–1.60 (m, 5H), 1.48–1.10 (m, 6H), 1.25 (d, J=6.9 Hz, 6H), 1.02–0.82 (m, 5H).


EXAMPLE 47(4)
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(6-methylpyridin-3-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.51 (ethyl acetate: methanol=10:1);


NMR (CD3OD): δ 8.59 (d, J=2.7 Hz, 1H), 8.19 (dd, J=9.0, 2.7 Hz, 1H), 7.91 (d, J=9.0 Hz, 1H), 7.75 (d, J=8.4 Hz, 2H), 7.30 (d, J=8.4 Hz, 2H), 4.39 (s, 2H), 4.15 (d, J=2.0 Hz, 1H), 3.99 (m, 1H), 3.73 (m, 1H), 3.61–3.46 (m, 3H), 3.37–3.26 (m, 2H), 2.77 (s, 3H), 2.62 (m, 1H), 2.45 (m, 1H), 2.13–1.92 (m, 3H), 1.73 (m, 4H), 1.40–1.14 (m, 8H), 1.01–0.86 (m, 2H), 0.95 (t, J=7.0 Hz, 3H).


EXAMPLE 47(5)
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(3,5-dimethyl-1-(4-fluorophenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.49 (ethyl acetate:methanol=10:1);


NMR (CD3OD): δ 7.57 (m, 2H), 7.37–7.31 (m, 2H), 4.32 (s, 2H), 4.16 (d, J=2.0 Hz, 1H), 4.08–4.00 (m, 1H), 3.79 (m, 1H), 3.63–3.52 (m, 3H), 3.37–3.27 (m, 2H), 2.65 (m, 1H), 2.48 (m, 1H), 2.45 (s, 3H), 2.39 (s, 3H), 2.16–1.92 (m, 3H), 1.73 (m, 4H), 1.42–1.15 (m, 8H), 1.01–0.88 (m, 2H), 0.95 (t, J=7.0 Hz, 3H).


EXAMPLE 47(6)
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(4-methoxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.25 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.47 (d, J=9.0 Hz, 2H), 7.00 (d, J=9.0 Hz, 2H), 6.99–6.92 (m, 4H), 4.30 (s, 2H), 4.16 (d, J=2.1 Hz, 1H), 3.98 (m, 1H), 3.80 (s, 3H), 3.72 (m, 1H), 3.58–3.38 (m, 3H), 3.30–3.08 (m, 2H), 2.54–1.88 (m, 6H), 1.82–1.60 (m, 5H), 1.50–1.10 (m, 6H), 0.96 (t, J=7.5 Hz, 3H), 0.96 (m, 2H).


EXAMPLE 47(7)
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(4-fluorophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.28 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.51 (d, J=8.7 Hz, 2H), 7.13 (d, J=8.7 Hz, 2H), 7.10–7.04 (m, 4H), 4.33 (s, 2H), 4.16 (d, J=2.1 Hz, 1H), 4.00 (m, 1H), 3.72 (m, 1H), 3.58–3.40 (m, 3H), 3.30–3.08 (m, 2H), 2.56–1.88 (m, 6H), 1.82–1.60 (m, 5H), 1.54–1.10 (m, 6H), 0.96 (t, J=7.2 Hz, 3H), 0.96 (m, 2H).


EXAMPLE 47(8)
(3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(4-methylsulfonylaminophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.52 (ethyl acetate: methanol=10:1);


NMR (CD3OD): δ 7.53 (d, J=8.1 Hz, 2H), 7.30 (d, J=9.0 Hz, 2H), 7.08 (d, J=8.1 Hz, 2H), 7.04 (d, J=9.0 Hz, 2H), 4.34 (s, 2H), 4.16 (d, J=2.1 Hz, 1H), 4.00 (m, 1H), 3.76 (m, 1H), 3.58–3.42 (m, 3H), 3.30–3.08 (m, 2H), 2.96 (s, 3H), 2.54–1.88 (m, 6H), 1.82–1.62 (m, 5H), 1.50–1.14 (m, 6H), 0.96 (t, J=7.2 Hz, 3H), 0.96 (m, 2H).


EXAMPLE 48
(3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-allyloxycarbonyl-1,4,9-triazaspiro[5.5]undecane



embedded image


By the same procedure as described in Reference Example 3→Reference Example 6→Example 1 using Resin (3) prepared in Reference Example 2, N-allyloxycarbonyl-4-piperidone, 2-butynylamine, and (2R*,3R*)-N-(t-butyloxycarbonyl)-2-amino-3-hydroxy-3-cyclohexylpropanoic acid, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.32 (chloroform:methanol=15:1);


NMR (CD3OD): δ 6.04–5.91 (m, 1H), 5.35–5.27 (m, 1H), 5.23–5.19 (m, 1H), 4.60–4.58 (m, 2H), 4.27 (dq, J=17.5, 2.5 Hz, 1H), 4.19 (d, J=2.5 Hz, 1H), 4.07–4.01 (m, 2H), 3.89 (dq, J=17.5, 2.5 Hz, 1H), 3.75–3.50 (m, 2H), 3.38 (dd, J=9.0, 2.5 Hz, 1H), 2.32–2.17 (m, 2H), 2.07–1.70 (m, 11H), 1.33–1.14 (m, 3H), 1.00–0.85 (m, 2H).


EXAMPLE 49
(3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-1,4,9-triazaspiro[5.5]undecane



embedded image


By the same procedure as described in Reference Example 4 using the compound prepared in Example 48, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.33 (chloroform:methanol: acetic acid=20:6:1);


NMR (CD3OD): δ 4.28 (dq, J=17.5, 2.5 Hz, 1H), 4.18 (d, J=2.5 Hz, 1H), 4.03 (dq, J=17.5, 2.5 Hz, 1H), 3.48–3.29 (m, 3H), 2.99–2.90 (m, 2H), 2.26–1.73 (m, 14H), 1.32–1.18 (m, 3H), 1.01–0.91 (m, 2H).


EXAMPLE 50(1)˜50(6)

By the same procedure as described in Example 10 using the compound prepared in Example 49 and the corresponding aldehyde compounds, the following compounds of the present invention were obtained.


EXAMPLE 50(1)
(3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.37 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.60–7.50 (m, 5H), 4.42–4.33 (m, 3H), 4.21 (d, J=2.5 Hz, 1H), 4.08–3.99 (m, 2H), 3.85–3.75 (m, 1H), 3.65–3.57 (m, 2H), 3.32 (m, 1H), 2.79 (m, 1H), 2.48–2.43 (m, 5H), 2.40 (s, 3H), 2.22 (m, 1H), 2.05–1.93 (m, 2H), 1.80–1.64 (m, 7H), 1.39–1.11 (m, 3H), 1.03–0.84 (m, 2H).


EXAMPLE 50(2)
(3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(3,5-dimethyl-1-(4-methylphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.35 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.40 (s, 4H),4.45–4.30 (m, 3H), 4.20 (m, 1H), 4.16–3.98 (m, 2H), 3.78 (m, 1H), 3.68–3.56 (m, 2H), 3.30 (m, 1H), 2.82 (m, 1H), 2.56–2.42 (m, 8H), 2.39 (s, 3H), 2.28–1.88 (m, 3H), 1.80–1.60 (m, 7H), 1.40–1.10 (m, 3H), 1.12–0.82 (m, 2H).


EXAMPLE 50(3)
(3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(4-isopropylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.33 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.47 (d, J=8.1 Hz, 2H), 7.36 (d, J=8.1 Hz, 2H), 4.38–4.28 (m, 3H), 4.17 (m, 1H), 4.04–3.88 (m, 2H), 3.74 (m, 1H), 3.50–3.40 (m, 2H), 3.28 (m, 1H), 2.92 (m, 1H), 2.64 (m, 1H), 2.50–1.86 (m, 5H),1.80–1.62 (m, 7H), 1.36–1.04 (m, 3H), 1.25 (d, J=7.2 Hz, 6H), 1.00–0.82 (m, 2H).


EXAMPLE 50(4)
(3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.39 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.53 (d, J=9.0 Hz, 2H), 7.42–7.37 (m, 2H), 7.17 (t, J=7.5 Hz, 1H), 7.06–7.02 (m, 4H), 4.40–4.30 (m, 3H), 4.18 (m, 1H), 4.04–3.90 (m, 2H), 3.72 (m, 1H), 3.30–3.20 (m, 2H), 3.28 (m, 1H), 2.68 (m, 1H), 2.52–1.86 (m, 5H), 1.80–1.60 (m, 7H), 1.38–1.10 (m, 3H), 1.02–0.82 (m, 2H).


EXAMPLE 50(5)
(3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(4-methylphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.45 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.50 (d, J=8.4 Hz, 2H), 7.20 (d, J=8.7 Hz, 2H), 7.01 (d, J=8.7 Hz, 2H), 6.92 (d, J=8.4 Hz, 2H), 4.40–4.28 (m, 3H), 4.18 (m, 1H), 4.04–3.88 (m, 2H), 3.74 (m, 1H), 3.52–3.40 (m, 2H), 3.26 (m, 1H), 2.64 (m, 1H), 2.54–1.86 (m, 5H), 2.33 (s, 3H), 1.80–1.62 (m, 7H), 1.38–1.10 (m, 3H), 1.02–0.82 (m, 2H).


EXAMPLE 50(6)
(3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.33 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.04 (s, 1H), 6.99–6.91 (m, 2H), 4.35 (m, 1H), 4.27 (s, 4H), 4.24 (s, 2H), 4.18 (m, 1H), 4.04–3.84 (m, 2H), 3.70 (m, 1H), 3.56–3.38 (m, 2H), 3.28 (m, 1H), 2.68–1.88 (m, 6H), 1.80–1.60 (m, 7H), 1.40–1.10 (m, 3H), 1.02–0.80 (m, 2H).


EXAMPLE 51
(3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-1,4,9-triazaspiro[5.5]undecane.acetate



embedded image


By the same procedure as described in Example 48→Example 49 using (2R*,3R*)-N-(t-butyloxycarbonyl)-2-amino-3-hydroxy-4-methylpentanoic acid instead of (2R*,3R*)-N-(t-butyloxycarbonyl)-2-amino-3-hydroxy-3-cyclohexylpropanoic acid, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.22 (chloroform:methanol: acetic acid=20:6:1);


NMR (CD3OD): δ 4.36 (dq, J=17.0, 2.5 Hz, 1H), 4.19 (d, J=2.0 Hz, 1H), 3.95–3.79 (m, 2H), 3.62 (dt, J=3.5, 13.0 Hz, 1H), 3.34–3.26 (m, 2H), 3.22 (dd, J=9.5, 2.0 Hz, 1H), 2.54–2.43 (m, 1H), 2.37 (m, 1H), 2.20–1.98 (m, 3H), 1.91 (s, 3H), 1.75 (t, J=2.5 Hz, 3H), 1.01–0.97 (m, 6H).


EXAMPLE 52(1)˜52(5)

By the same procedure as described in Example 10 using the compound prepared in Example 51 and the corresponding aldehyde compounds, the following compounds of the present invention were obtained.


EXAMPLE 52(1)
(3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(3,5-dimethyl-1-(4-methylphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.28 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.38 (d, J=3.9 Hz, 2H), 7.35 (d, J=3.9 Hz, 2H), 4.33 (s, 2H), 4.20 (d, J=2.1 Hz, 1H), 4.10–3.90 (m, 2H), 3.78 (m, 1H), 3.68–3.52 (m, 2H), 3.22 (dd, J=9.3, 2.1 Hz, 1H), 2.74 (m, 1H), 2.54–2.20 (m, 3H), 2.44 (s, 3H), 2.40 (s, 3H), 2.36 (s, 3H), 1.98 (m, 1H), 1.75 (t, J=2.1 Hz, 3H), 1.01 (d, J=6.6 Hz, 3H), 0.99 (d, J=6.6 Hz, 3H).


EXAMPLE 52(2)
(3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(4-(4-methylphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.26 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.49 (d, J=9.0 Hz, 2H), 7.21 (d, J=8.4 Hz, 2H), 7.04 (d, J=9.0 Hz, 2H), 6.93 (d, J=8.4 Hz, 2H), 4.40 (m, 1H), 4.34 (s, 2H), 4.19 (d, J=2.1 Hz, 1H), 4.08–3.82 (m, 2H), 3.76 (m, 1H), 3.58–3.40 (m, 2H), 3.20 (dd, J=9.6, 2.1 Hz, 1H), 2.72–2.42 (m, 2H), 2.35 (s, 3H), 2.35–2.18 (m, 2H), 2.00 (m, 1H), 1.74 (t, J=2.1 Hz, 3H), 1.00 (d, J=6.6 Hz, 3H), 0.98 (d, J=6.6 Hz, 3H).


EXAMPLE 52(3)
(3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.34 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.06–6.92 (m, 3H), 4.38 (m, 1H), 4.28 (s, 4H), 4.25 (s, 2H), 4.19 (d, J=2.1 Hz, 1H), 4.02–3.84 (m, 2H), 3.70 (m, 1H), 3.52–3.36 (m, 2H), 3.20 (dd, J=9.6, 2.1 Hz, 1H), 2.60 (m, 1H), 2.48 (m, 1H), 2.32–2.16 (m, 2H), 2.00 (m, 1H), 1.74 (t, J=2.1 Hz, 3H), 1.00 (d, J=6.6 Hz, 3H), 0.98 (d, J=6.6 Hz, 3H).


EXAMPLE 52(4)
(3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(4-isopropylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.29 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.47 (d, J=8.1 Hz, 2H), 7.38 (d, J=8.1 Hz, 2H), 4.40 (m, 1H), 4.33 (s, 2H), 4.19 (d, J=2.1 Hz, 1H), 4.08–3.84 (m, 2H), 3.76 (m, 1H), 3.52–3.40 (m, 2H), 3.20 (dd, J=9.6, 2.1 Hz, 1H), 2.96 (m, 1H), 2.62 (m, 1H), 2.48 (m, 1H), 2.36–2.12 (m, 2H), 2.00 (m, 1H), 1.74 (t, J=2.1 Hz, 3H), 1.24 (d, J=7.2 Hz, 6H), 1.00 (d, J=6.6 Hz, 3H), 0.98 (d, J=6.6 Hz, 3H).


EXAMPLE 52(5)
(3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.24 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.52 (d, J=9.0 Hz, 2H), 7.41 (t, J=7.2 Hz, 2H), 7.19 (t, J=7.2 Hz, 1H), 7.09–7.03 (m, 4H), 4.40 (m, 1H), 4.35 (s, 2H), 4.19 (d, J=2.1 Hz, 1H), 4.08–3.84 (m, 2H), 3.78 (m, 1H), 3.58–3.42 (m, 2H), 3.21 (dd, J=9.6, 2.1 Hz, 1H), 2.72–2.42 (m, 2H), 2.38–2.18 (m, 2H), 2.00 (m, 1H), 1.74 (t, J=2.1 Hz, Hz, 3H), 1.00 (d, J=6.6 Hz, 3H), 0.98 (d, J=6.6 Hz, 3H).


EXAMPLE 53
(3R*)-1-butyl-2,5-dioxo-3-((1S*)-1-hydroxy-1-cyclohexylmethyl)-9-benzyl-1,4,9-triazaspiro[5.5]undecane



embedded image


By the same procedure as described in Reference Example 3→Reference Example 6→Example 1 using Resin (3) prepared in Reference Example 2, N-benzyl-4-piperidone, n-butylamine, (2R*,3S*)—N-(t-butyloxycarbonyl)-2-amino-3-hydroxy-3-cyclohexylpropanoic acid, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.33 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.40–7.20 (m, 5H), 4.04 (d, J=1.5 Hz, 1H), 3.65–3.45 (m, 2H), 3.57 (s, 2H), 3.30 (m, 1H), 3.05 (m 1H), 2.86–2.77 (m, 3H), 2.30–2.00 (m, 4H), 1.90–1.60 (m, 6H), 1.60–1.10 (m, 9H), 1.10–0.90 (m, 2H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 54
(3R*)-1-butyl-2,5-dioxo-3-((1 S*)-1-hydroxy-1-cyclohexylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


By the same procedure as described in Example 9 using the compound prepared in Example 53, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.59 (chloroform:methanol: acetic acid=10:2:1);


NMR (CD3OD): δ 4.08 (d, J=1.5 Hz, 1H), 4.03 (m, 1H), 3.70–3.12 (m, 7H), 2.50–2.02 (m, 5H), 1.85–1.66 (m, 5H), 1.55–1.10 (m, 7H), 1.10–0.85 (m, 2H), 0.97 (t, J=6.9 Hz, 3H).


EXAMPLE 55(1)˜55(3)

By the same procedure as described in Example 10 using the compound prepared in Example 54 and the corresponding aldehyde compounds, the following compounds of the present invention were obtained.


EXAMPLE 55(1)
(3R*)-1-butyl-2,5-dioxo-3-((1 S*)-1-hydroxy-1-cyclohexylmethyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.46 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.50 (d, J=8.7 Hz, 2H), 7.39 (dd, J=8.7, 7.5 Hz, 2H), 7.17 (t, J=7.5 Hz, 1H), 7.09–7.00 (m, 4H), 4.30 (brs, 2H), 4.08 (d, J=1.2 Hz, 1H), 4.04 (m, 1H), 3.74–3.36 (m, 5H), 3.16 (m, 1H), 2.55–2.33 (m, 2H), 2.32–2.09 (m, 2H), 2.04 (m, 1H), 1.84–1.61 (m, 5H), 1.53–1.12 (m, 7H), 1.04–0.86 (m, 5H).


EXAMPLE 55(2)
(3R*)-1-butyl-2,5-dioxo-3-((1 S*)-1-hydroxy-1-cyclohexylmethyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.41 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.04 (d, J=2.1 Hz, 1H), 6.97 (dd, J=8.1, 2.1 Hz, 1H), 6.92 (d, J=8.1 Hz, 1H), 4.26 (s, 4H), 4.21 (s, 2H), 4.07 (d, J=1.2 Hz, 1H), 4.01 (m, 1H), 3.70–3.34 (m, 5H), 3.16 (m, 1H), 2.53–2.32 (m, 2H), 2.31–2.08 (m, 2H), 2.03 (m, 1H), 1.84–1.60 (m, 5H), 1.52–1.12 (m, 7H), 1.04–0.85 (m, 5H).


EXAMPLE 55(3)
(3R*)-1-butyl-2,5-dioxo-3-((1 S*)-1-hydroxy-1-cyclohexylmethyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.31 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.61–7.44 (m, 5H), 4.31 (s, 2H), 4.19–4.06 (m, 2H), 3.73 (m 1H), 3.66–3.52 (m, 4H), 3.26 (m, 1H), 2.62–2.48 (m, 2H), 2.45–2.30 (m, 7H), 2.19 (m, 1H), 2.04 (m, 1H), 1.84–1.63 (m, 5H), 1.54–1.12 (m, 7H), 1.05–0.86 (m, 5H).


EXAMPLE 56
(3S)-1-butyl-2,5-dioxo-3-((1S)-1-hydroxy-2-methylpropyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


By the same procedure as described in Example 42→Example 43 using (2S,3S)—N-(t-butyloxycarbonyl)-2-amino-3-hydroxy-4-methylpentanoic acid instead of (2R*,3R*)-N-(t-butyloxycarbonyl)-2-amino-3-hydroxy-4-methylpentanoic acid, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.08 (chloroform:methanol=10:1);


NMR (CD3OD): δ 4.15 (d, J=2.0 Hz, 1H), 3.96 (dt, J=13.0, 4.0 Hz, 1H), 3.71 (dt, J=13.0, 4.0 Hz, 1H), 3.57–3.47 (m, 1H), 3.40–3.34 (m, 2H), 3.23–3.12 (m, 2H), 2.47–2.30 (m, 2H), 2.25–1.98 (m, 3H), 1.79–1.66 (m, 1H), 1.52–1.28 (m, 3H), 1.07–0.94 (m, 9H);


Optical rotation: [α]D−13.8 (c 1.00, methanol).


EXAMPLE 57(1)˜57(4)

By the same procedure as described in Example 10 using the compound prepared in Example 56 and the corresponding aldehyde compounds, the following compounds of the present invention were obtained.


EXAMPLE 57(1)
(3S)-1-butyl-2,5-dioxo-3-((1S)-1-hydroxy-2-methylpropyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.43 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.61–7.43 (m, 5H), 4.32 (s, 2H), 4.16 (d, J=2.1 Hz, 1H), 4.12–3.99 (m, 1H), 3.90–3.72 (m, 1H), 3.64–3.44 (m, 3H), 3.30–3.12 (m, 1H), 3.20 (dd, J=9.3, 2.1 Hz, 1H), 2.60–2.30 (m, 9H), 2.24–2.10 (m, 1H), 2.10–1.95 (m, 1H), 1.78–1.60 (m, 1H), 1.54–1.30 (m, 3H), 1.00 (d, J=6.6 Hz, 3H), 0.98 (d, J=6.6 Hz, 3H), 0.96 (t, J=6.9 Hz, 3H).


EXAMPLE 57(2)
(3S)-1-butyl-2,5-dioxo-3-((1S)-1-hydroxy-2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.51 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.52 (d, J=8.7 Hz, 2H), 7.43–7.36 (m, 2H), 7.21–7.14 (m, 1H), 7.10–7.00 (m, 4H), 4.33 (s, 2H), 4.14 (d, J=2.1 Hz, 1H), 4.06–3.92 (m, 1H), 3.81–3.66 (m, 1H), 3.58–3.40 (m, 3H), 3.30–3.10 (m, 1H), 3.19 (dd, J=9.6, 2.1 Hz, 1H), 2.53–2.37 (m, 2H), 2.37–2.18 (m, 1H), 2.18–2.08 (m, 1H), 2.06–1.95 (m, 1H), 1.78–1.60 (m, 1H), 1.50–1.26 (m, 3H), 0.99 (d, J=6.6 Hz, 3H), 0.97 (d, J=6.6 Hz, 3H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 57(3)
(3S)-1-butyl-2,5-dioxo-3-((1S)-1-hydroxy-2-methylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.43 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.06 (d, J=2.1 Hz, 1H), 6.98 (dd, J=8.1, 2.1 Hz, 1H), 6.92 (d, J=8.1 Hz, 1H), 4.26 (s, 4H), 4.23 (s, 2H), 4.13 (d, J=2.4 Hz, 1H), 4.02–3.87 (m, 1H), 3.77–3.62 (m, 1H), 3.57–3.35 (m, 3H), 3.28–3.08 (m, 1H), 3.19 (dd, J=9.6, 2.4 Hz, 1H), 2.51–2.35 (m, 2H), 2.35–2.18 (m, 1H), 2.17–2.05 (m, 1H), 2.05–1.90 (m, 1H), 1.80–1.58 (m, 1H), 1.50–1.26 (m, 3H), 0.98 (d, J=6.6 Hz, 3H), 0.97 (d, J=6.6 Hz, 3H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 57(4)
(3S)-1-butyl-2,5-dioxo-3-((1S)-1-hydroxy-2-methylpropyl)-9-(4-(4-methylsulfonylaminophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.35 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.53 (d, J=8.7 Hz, 2H), 7.29 (d, J=9.0 Hz, 2H), 7.10–7.00 (m, 4H), 4.33 (s, 2H), 4.14 (d, J=2.1 Hz, 1H), 4.06–3.92 (m, 1H), 3.81–3.66 (m, 1H), 3.58–3.40 (m, 3H), 3.25–3.10 (m, 1H), 3.19 (dd, J=9.6, 2.1 Hz, 1H), 2.95 (s, 3H),2.54–2.37 (m, 2H), 2.37–2.22 (m, 1H), 2.18–2.08 (m, 1H), 2.08–1.92 (m, 1H), 1.78–1.60 (m, 1H), 1.50–1.28 (m, 3H), 0.99 (d, J=6.6 Hz, 3H), 0.97 (d, J=6.6 Hz, 3H), 0.95 (t, J=7.5 Hz, 3H).


EXAMPLE 58
(3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-2-methylpropyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


By the same procedure as described in Example 42→Example 43 using (2R,3R)-N-(t-butyloxycarbonyl)-2-amino-3-hydroxy-4-methylpentanoic acid instead of (2R*,3R*)-N-(t-butyloxycarbonyl)-2-amino-3-hydroxy-4-methylpentanoic acid, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.08 (chloroform:methanol=10:1);


NMR (CD3OD): δ 4.15 (d, J=2.0 Hz, 1H), 3.96 (dt, J=13.0, 4.0 Hz, 1H), 3.71 (dt, J=13.0, 4.0 Hz, 1H), 3.57–3.47 (m, 1H), 3.40–3.34 (m, 2H), 3.23–3.12 (m, 2H), 2.47–2.30 (m, 2H), 2.25–1.98 (m, 3H), 1.79–1.66 (m, 1H), 1.52–1.28 (m, 3H), 1.07–0.94 (m, 9H);


Optical rotation: [α]D+13.9 (c 1.00, methanol).


EXAMPLE 59(1)˜59(4)

By the same procedure as described in Example 10 using the compound prepared in Example 58 and the corresponding aldehyde compounds, the following compounds of the present invention were obtained.


EXAMPLE 59(1)
(3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-2-methylpropyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.43 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.61–7.43 (m, 5H), 4.32 (s, 2H), 4.16 (d, J=2.1 Hz, 1H), 4.12–3.99 (m, 1H), 3.90–3.72 (m, 1H), 3.64–3.44 (m, 3H), 3.30–3.12 (m, 1H), 3.20 (dd, J=9.3, 2.1 Hz, 1H), 2.60–2.30 (m, 9H), 2.24–2.10 (m, 1H), 2.10–1.95 (m, 1H), 1.78–1.60 (m, 1H), 1.54–1.30 (m, 3H), 1.00 (d, J=6.6 Hz, 3H), 0.98 (d, J=6.6 Hz, 3H), 0.96 (t, J=6.9 Hz, 3H).


EXAMPLE 59(2)
(3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.51 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.52 (d, J=8.7 Hz, 2H), 7.43–7.36 (m, 2H), 7.21–7.14 (m, 1H), 7.10–7.00 (m, 4H), 4.33 (s, 2H), 4.14 (d, J=2.1 Hz, 1H), 4.06–3.92 (m, 1H), 3.81–3.66 (m, 1H), 3.58–3.40 (m, 3H), 3.30–3.10 (m, 1H), 3.19 (dd, J=9.6, 2.1 Hz, 1H), 2.53–2.37 (m, 2H), 2.37–2.18 (m, 1H), 2.18–2.08 (m, 1H), 2.06–1.95 (m, 1H), 1.78–1.60 (m, 1H), 1.50–1.26 (m, 3H), 0.99 (d, J=6.6 Hz, 3H), 0.97 (d, J=6.6 Hz, 3H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 59(3)
(3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-2-methylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.43 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.06 (d, J=2.1 Hz, 1H), 6.98 (dd, J=8.1, 2.1 Hz, 1H), 6.92 (d, J=8.1 Hz, 1H), 4.26 (s, 4H), 4.23 (s, 2H), 4.13 (d, J=2.4 Hz, 1H), 4.02–3.87 (m, 1H), 3.77–3.62 (m, 1H), 3.57–3.35 (m, 3H), 3.28–3.08 (m, 1H), 3.19 (dd, J=9.6, 2.4 Hz, 1H), 2.51–2.35 (m, 2H), 2.35–2.18 (m, 1H), 2.17–2.05 (m, 1H), 2.05–1.90 (m, 1H), 1.80–1.58 (m, 1H), 1.50–1.26 (m, 3H), 0.98 (d, J=6.6 Hz, 3H), 0.97 (d, J=6.6 Hz, 3H), 0.95 (t, J=7.2 Hz, 3H).


EXAMPLE 594(4)
(3R)-1-butyl-2,5-dioxo-3-((1R)-11-hydroxy-2-methylpropyl)-9-(4-(4-methylsulfonylaminophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.35 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.53 (d, J=8.7 Hz, 2H), 7.29 (d, J=9.0 Hz, 2H), 7.10–7.00 (m, 4H), 4.33 (s, 2H), 4.14 (d, J=2.1 Hz, 1H), 4.06–3.92 (m, 1H), 3.81–3.66 (m, 1H), 3.58–3.40 (m, 3H), 3.25–3.10 (m, 1H), 3.19 (dd, J=9.6, 2.1 Hz, 1H), 2.95 (s, 3H), 2.54–2.37 (m, 2H), 2.37–2.22 (m, 1H), 2.18–2.08 (m, 1H), 2.08–1.9 (m, 1H), 1.78–1.60 (m, 1H), 1.50–1.28 (m, 3H), 0.99 (d, J=6.6 Hz, 3H), 0.97 (d, J=6.6 Hz, 3H), 0.95 (t, J=7.5 Hz, 3H).


EXAMPLE 60
(3R)-1l-butyl-2,5-dioxo-3-((l S)-1l-hydroxy-2-methylpropyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


By the same procedure as described in Example 53→Example 54 using (2R,3S)—N-(t-butyloxycarbonyl)-2-amino-3-hydroxy-4-methyl pentanoic acid instead of (2 R*,3S*)-N-(t-butyloxycarbonyl)-2-amino-3-hydroxy-3-cyclohexylpropanoic acid, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.51 (chloroform:methanol: acetic acid=10:2:1);


NMR (CD3OD): δ 4.08 (d, J=1.5 Hz, 1H), 4.02 (dt, J=12.6, 3.9 Hz, 1H), 3.70–3.00 (m, 6H), 2.50–2.10 (m, 4H), 1.80–1.60 (m, 2H), 1.55–1.35 (m, 3H), 1.02 (d, J=6.6 Hz, 3H), 0.99 (t, J=6.6 Hz, 3H), 0.93 (d, J=6.6 Hz, 3H);


Optical rotation: [α]D+21.2 (c 1.00, methanol).


EXAMPLE 61(1)˜61(3)

By the same procedure as described in Example 10 using the compound prepared in Example 60 and the corresponding aldehyde compounds, the following compounds of the present invention were obtained.


EXAMPLE 61(1)
(3R)-1-butyl-2,5-dioxo-3-((1S)-1-hydroxy-2-methylpropyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.44 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.64–7.46 (m, 5H), 4.32 (s, 2H), 4.19–4.06 (m, 1H), 4.10 (d, J=1.5 Hz, 1H), 3.80–3.53 (m, 4H), 3.51 (dd, J=10.2, 1.5 Hz, 1H), 3.40–3.20 (m, 1H), 2.70–2.30 (m, 9H), 2.23–2.10 (m, 1H), 1.83–1.60 (m, 2H), 1.53–1.30 (m, 3H), 1.02 (d, J=6.6 Hz, 3H), 0.96 (t, J=7.2 Hz, 3H), 0.93 (d, J=6.6 Hz, 3H).


EXAMPLE 61(2)
(3R)-1-butyl-2,5-dioxo-3-((1S)-1-hydroxy-2-methylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.44 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.06 (d, J=2.1 Hz, 1H), 6.98 (dd, J=8.1, 2.1 Hz, 1H), 6.92 (d, J=8.1 Hz, 1H), 4.26 (s, 4H), 4.23 (s, 2H), 4.08 (d, J=1.5 Hz, 1H), 4.08–3.96 (m, 1H), 3.72–3.35 (m, 4H), 3.49 (dd, J=10.2, 1.5 Hz, 1H), 3.28–3.08 (m, 1H), 2.55–2.35 (m, 2H), 2.35–2.18 (m, 1H), 2.18–2.08 (m, 1H), 1.82–1.62 (m, 2H), 1.52–1.25 (m, 3H), 1.01 (d, J=6.6 Hz, 3H), 0.95 (t, J=7.2 Hz, 3H), 0.92 (d, J=6.6 Hz, 3H).


EXAMPLE 61(3)
(3R)-1-butyl-2,5-dioxo-3-((1S)-1-hydroxy-2-methylpropyl)-9-(4-(4-methylsulfonylaminophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.42 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.53 (d, J=8.7 Hz, 2H), 7.29 (d, J=9.0 Hz, 2H), 7.07 (d, J=8.7 Hz, 2H), 7.03 (d, J=9.0 Hz, 2H), 4.33 (s, 2H), 4.13–4.00 (m, 1H), 4.09 (d, J=1.5 Hz, 1H), 3.75–3.62 (m, 1H), 3.62–3.39 (m, 3H), 3.49 (dd, J=10.5, 1.5 Hz, 1H), 3.26–3.12 (m, 1H), 2.95 (s, 3H), 2.56–2.37 (m, 2H), 2.37–2.20 (m, 1H), 2.20–2.10 (m, 1H), 1.82–1.63 (m, 2H), 1.50–1.30 (m, 3H), 1.01 (d, J=6.6 Hz, 3H), 0.95 (t, J=7.2 Hz, 3H), 0.92 (d, J=6.6 Hz, 3H).


EXAMPLE 62
(3S)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-2-methylpropyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


By the same procedure as described in Example 53→Example 54 using (2S,3R)-N-(t-butyloxycarbonyl)-2-amino-3-hydroxy-4-methylpentanoic acid instead of (2R*,3S*)-N-(t-butyloxycarbonyl)-2-amino-3-hydroxy-3-cyclohexylpropanoic acid, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.51 (chloroform:methanol: acetic acid=10:2:1);


NMR (CD3OD): a 4.08 (d, J=1.5 Hz, 1H), 4.02 (dt, J=12.6, 3.9 Hz, 1H), 3.70–3.00 (m, 6H), 2.50–2.10 (m, 4H), 1.80–1.60 (m, 2H), 1.55–1.35 (m, 3H), 1.02 (d, J=6.6 Hz, 3H), 0.99 (t, J=6.6 Hz, 3H), 0.93 (d, J=6.6 Hz, 3H);


Optical rotation: [α]D−23.4 (c 1.00, methanol).


EXAMPLE 63(1)˜63(3)

By the same procedure as described in Example 10 using the compound prepared in Example 62 and the corresponding aldehyde compounds, the following compounds of the present invention were obtained.


EXAMPLE 63(1)
(3S)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-2-methylpropyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.2 hydrochloride



embedded image


TLC: Rf 0.44 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.64–7.46 (m, 5H), 4.32 (s, 2H), 4.19–4.06 (m, 1H), 4.10 (d, J=1.5 Hz, 1H), 3.80–3.53 (m, 4H), 3.51 (dd, J=10.2, 1.5 Hz, 1H), 3.40–3.20 (m, 1H), 2.70–2.30 (m, 9H), 2.23–2.10 (m, 1H), 1.83–1.60 (m, 2H), 1.53–1.3 (m, 3H), 1.02 (d, J=6.6 Hz, 3H), 0.96 (t, J=7.2 Hz, 3H), 0.93 (d, J=6.6 Hz, 3H).


EXAMPLE 63(2)
(3S)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-2-methylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.44 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.06 (d, J=2.1 Hz, 1H), 6.98 (dd, J=8.1, 2.1 Hz, 1H), 6.92 (d, J=8.1 Hz, 1H), 4.26 (s, 4H), 4.23 (s, 2H), 4.08 (d, J=1.5 Hz, 1H), 4.08–3.96 (m, 1H), 3.72–3.35 (m, 4H), 3.49 (dd, J=10.2, 1.5 Hz, 1H), 3.28–3.08 (m, 1H), 2.55–2.35 (m, 2H), 2.35–2.18 (m, 1H), 2.18–2.08 (m, 1H), 1.82–1.62 (m, 2H), 1.52–1.25 (m, 3H), 1.01 (d, J=6.6 Hz, 3H), 0.95 (t, J=7.2 Hz, 3H), 0.92 (d, J=6.6 Hz, 3H).


EXAMPLE 63(3)
(3S)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-2-methylpropyl)-9-(4-(4-methylsulfonylaminophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


TLC: Rf 0.42 (chloroform:methanol=10:1);


NMR (CD3OD): δ 7.53 (d, J=8.7 Hz, 2H), 7.29 (d, J=9.0 Hz, 2H), 7.07 (d, J=8.7 Hz, 2H), 7.03 (d, J=9.0 Hz, 2H), 4.33 (s, 2H), 4.13–4.00 (m, 1H), 4.09 (d, J=1.5 Hz, 1H), 3.75–3.62 (m, 1H), 3.62–3.39 (m, 3H), 3.49 (dd, J=10.5, 1.5 Hz, 1H), 3.26–3.12 (m, 1H), 2.95 (s, 3H), 2.56–2.37 (m, 2H), 2.37–2.20 (m, 1H), 2.20–2.10 (m, 1H), 1.82–1.63 (m, 2H), 1.50–1.30 (m, 3H), 1.01 (d, J=6.6 Hz, 3H), 0.95 (t, J=7.2 Hz, 3H), 0.92 (d, J=6.6 Hz, 3H).


EXAMPLE 64
(3S)-2,5-dioxo-3-(3-benzyloxycarbonylaminopropyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane.hydrochloride



embedded image


By the same procedure as described in Reference Example 9→Reference Example 10→Example 1 using Resin (3) prepared in Reference Example 2, N-(2-phenylethyl)-4-piperidone, 2,4,6-trimethoxybenzylamine and Nα-(t-butyloxycarbonyl)-Nδ-(benzyloxycarbonyl)-L-ornithine, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.33 (chloroform:methanol=10:1);


NMR (DMSO-d6): δ 10.80–10.00 (m, 1H), 8.65–8.45 (m, 1H), 8.33 (s, 1H), 7.50–7.20 (m, 10H), 5.01 (s, 2H), 4.01 (m, 1H), 3.70–3.45 (m, 3H), 3.45–3.20 (m, 3H), 3.15–2.90 (m, 4H), 2.50–2.30 (m, 2H), 2.10–1.90 (m, 1H), 1.87–1.60 (m, 3H), 1.60–1.35 (m, 2H).


EXAMPLE 65
(3S)-1-methyl-2,5-dioxo-3-(3-benzyloxycarbonylaminopropyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane.acetate



embedded image


By the same procedure as described in Example 19 using Resin (3) prepared in Reference Example 2, N-(2-phenylethyl)-4-piperidone, methylamine and Nα-(t-butyloxycarbonyl)-Nδ-(benzyloxycarbonyl)-L-ornithine, the compound of the present invention having the following physical data was obtained.


TLC: Rf 0.36 (chloroform:methanol=10:1);


MS (ESI, Pos., 40 V): 493 (M+H)+;


HPLC condition: F;


HPLC retention time: 3.36 min.


EXAMPLE 66
(3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-phenyloxyphenylmethyl)-9-oxide-1,4,9-triazaspiro[5.5]undecane



embedded image


To a solution of the compound prepared in Example 40(90) (104 mg) in acetone (4 ml) were added water (1 ml), sodium hydrogen carbonate (210 mg) and OXONE (615 mg) (brand name). The reaction mixture was stirred for 1 hour at room temperature. The reaction mixture was diluted with ethyl acetate, washed with saturated aqueous solution of sodium hydrogen carbonate, and saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and concentrated. The residue was purified by preparative thin layer chromatography (chloroform:methanol=30:1, 20:1) to give the compound of the present invention (73 mg) having the following physical data.


TLC: Rf 0.50 (chloroform:methanol=9:1);


NMR (CDCl3): δ 7.49 (dt, J=8.7, 2.1 Hz, 2H), 7.36 (ddt, J=8.7, 7.2, 2.1 Hz, 2H), 7.14 (tt, J=7.2, 1.2 Hz, 1H), 7.04 (dq, J=8.7, 1.2 Hz, 2H), 7.01 (dt, J=8.7, 2.1 Hz, 2H), 5.82 (brs, 1H), 4.32 (s, 2H), 4.07–3.85 (m, 3H), 3.55–3.46 (m, 2H), 3.19–2.97 (m, 4H), 2.02–1.49 (m, 11H), 1.48–1.12 (m, 6H), 1.08–0.90 (m, 2H), 0.90 (t, J=7.2 Hz, 3H).


EXAMPLE 67(H32-1)˜67(H34-15)

By the same procedure as described in Example 23 using Resin (3) prepared in Reference Example 2, the corresponding 4-piperidone derivatives, the corresponding amine derivatives, the corresponding amino acid derivatives, and the corresponding aldehyde derivatives, the compounds of the present invention, whose names were shown in the following Table 32A-1˜34A-2, and whose structures were shown in the following Table 32B-1˜34B-3, were obtained. Also, physical data of the above compounds were shown in the following Table 32C-1˜34C-1.










TABLE 32A-1





Example No
Compound Name







67(H32-1)
1-butyl-2,5-dioxo-3-benzyl-9-(4-methoxyphenylmethyl)-1,



4,9-triazaspiro[5.5]undecane


67(H32-2)
1-butyl-2,5-dioxo-3-benzyl-9-(1,4-benzodioxan-6-



ylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H32-3)
1-butyl-2,5-dioxo-3-benzyl-9-(4-phenyloxyphenylmethyl)-



1,4,9-triazaspiro[5.5]undecane


67(H32-4)
1-butyl-2,5-dioxo-3-benzyl-9-(4-benzyloxyphenylmethyl)



-1,4,9-triazaspiro[5.5]undecane


67(H32-5)
1-butyl-2,5-dioxo-3-benzyl-9-(3,5-dimethyl-1-



phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H32-6)
1-butyl-2,5-dioxo-3-benzyl-9-(2-phenylimidazol-4-



ylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H32-7)
1-(2-methoxyethyl)-2,5-dioxo-3-benzyl-9-(4-



methoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H32-8)
1-(2-methoxyethyl)-2,5-dioxo-3-benzyl-9-(1,4-



benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H32-9)
1-(2-methoxyethyl)-2,5-dioxo-3-benzyl-9-(4-



phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 32A-2





Example No
Compound Name







67(H32-10)
1-(2-methoxyethyl)-2,5-dioxo-3-benzyl-9-(4-



benzyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H32-11)
1-(2-methoxyethyl)-2,5-dioxo-3-benzyl-9-(3,5-dimethyl-1-



phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H32-12)
1-(2-methoxyethyl)-2,5-dioxo-3-benzyl-9-(2-



phenylimidazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H32-13)
1-benzyl-2,5-dioxo-3-benzyl-9-(4-methoxyphenylmethyl)-



1,4,9-triazaspiro[5.5]undecane


67(H32-14)
1-benzyl-2,5-dioxo-3-benzyl-9-(1,4-benzodioxan-6-



ylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H32-15)
1-benzyl-2,5-dioxo-3-benzyl-9-(4-phenyloxyphenylmethyl)-



1,4,9-triazaspiro[5.5]undecane


67(H32-16)
1-benzyl-2,5-dioxo-3-benzyl-9-(4-benzyloxyphenylmethyl)-



1,4,9-triazaspiro[5.5]undecane


67(H32-17)
1-benzyl-2,5-dioxo-3-benzyl-9-(3,5-dimethyl-1-



phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H32-18)
1-benzyl-2,5-dioxo-3-benzyl-9-(2-phenylimidazol-4-



ylmethyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 32A-3





Example No
Compound Name







67(H32-19)
(3S)-1-butyl-2,5-dioxo-3-(4-methoxybenzyl)-9-



cyclohexylmethyl-1,4,9-triazaspiro[5.5]undecane


67(H32-20)
(3S)-1-butyl-2,5-dioxo-3-(4-methoxybenzyl)-9-(2-



methylpropyl)-1,4,9-triazaspiro[5.5]undecane


67(H32-21)
(3R)-1-butyl-2,5-dioxo-3-(4-methoxybenzyl)-9-



cyclohexylmethyl-1,4,9-triazaspiro[5.5]undecane


67(H32-22)
(3R)-1-butyl-2,5-dioxo-3-(4-methoxybenzyl)-9-(2-



methylpropyl)-1,4,9-triazaspiro[5.5]undecane


67(H32-23)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-(4-



chlorophenyl)thiophen-2-ylmethyl)-1,4,9-



triazaspiro[5.5]undecane


67(H32-24)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-(4-



methoxyphenyl)thiophen-2-ylmethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 33A-1





Example No
Compound Name







67(H33-1)
1-(2-chlorophenylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-



(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H33-2)
1-(2-fluorophenylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-



(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H33-3)
1-(2-trifluoromethylphenylmethyl)-2,5-dioxo-3-(2-



methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


67(H33-4)
1-cyclopropylmethyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H33-5)
1-(2,2-dimethylpropyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H33-6)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H33-7)
1-(furan-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H33-8)
1-((2E)-2-butenyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 33A-2





Example No
Compound Name







67(H33-9)
1-(2-methoxyethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(5-



ethylthiophen-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H33-10)
1-(2-phenyloxyethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H33-11)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-cyclohexylmethyl-



9-(2-chloro-4-hydroxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


67(H33-12)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-chloro-4-



hydroxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H33-13)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-cyclohexylmethyl-9-



(4-hydroxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H33-14)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-



hydroxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H33-15)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(2-



chloro-4-hydroxyphenylmethyl)-1,4,9-triazaspiro[5.5]



undecane


67(H33-16)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-chloro-4-



hydroxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 33A-3





Example No
Compound Name







67(H33-17)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



hydroxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H33-18)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



hydroxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 34A-1





Example No
Compound Name







67(H34-1)
(3S)-1-butyl-2,5-dioxo-3-((1S)-1-methylpropyl)-9-(4-



phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H34-2)
(3S)-1-butyl-2,5-dioxo-3-((1S)-1-methylpropyl)-9-(1,4-



benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H34-3)
(3S)-1-(2-methoxyethyl)-2,5-dioxo-3-((1S)-1-



methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-



triazaspiro[5.5]


67(H34-4)
(3S)-1-(2-methoxyethyl)-2,5-dioxo-3-((1S)-1-



methylpropyl-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-



triazaspiro[5.5]undecane


67(H34-5)
(3S)-1-butyl-2,5-dioxo-3-(cyclohexylmethyloxymethyl)-9-



(4-phenyloxypheflylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H34-6)
(3S)-1-butyl-2,5-dioxo-3-(cyclohexylmethyloxymethyl)-9-



(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]



undecane


67(H34-7)
(3S)-1-(2-methoxyethyl)-2,5-dioxo-3-



(cyclohexylmethyloxymethyl)-9-(4-



phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 34A-2





Example No
Compound Name







67(H34-8)
(3S)-1-(2-methoxyethyl)-2,5-dioxo-3-



(cyclohexylmethyloxymethyl)-9-(1,4-benzodioxan-6-



ylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H34-9)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-chloro-1,3-



benzodioxolan-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H34-10)
1-(2-methoxyethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



chloro-1,3-benzodioxolan-5-ylmethyl)-1,4,9-triazaspiro[5.5]



undecane


67(H34-11)
1-(3-methyl-2-butenyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H34-12)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-((2E)-3-phenyl-2-



propenyl)-1,4,9-triazaspiro[5.5]undecane


67(H34-13)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-((2E)-3-phenyl-2-



propenyl)-1,4,9-triazaspiro[5.5]undecane


67(H34-14)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(quinolin-3-



ylmethyl)-1,4,9-triazaspiro[5.5]undecane


67(H34-15)
1-(3-methyl-2-butenyl)-2,5-dioxo-3-cyclohexylmethyl-9-(1,



4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane



















TABLE 32B-1









embedded image

















Example No
R1
R2
R3
R4
R5





67(H32-1)


embedded image




embedded image


H


embedded image


H





67(H32-2)


embedded image




embedded image


H


embedded image


H





67(H32-3)


embedded image




embedded image


H


embedded image


H





67(H32-4)


embedded image




embedded image


H


embedded image


H





67(H32-5)


embedded image




embedded image


H


embedded image


H





67(H32-6)


embedded image




embedded image


H


embedded image


H



















TABLE 32B-2









embedded image

















Example No
R1
R2
R3
R4
R5





67(H32-7) 


embedded image




embedded image


H


embedded image


H





67(H32-8) 


embedded image




embedded image


H


embedded image


H





67(H32-9) 


embedded image




embedded image


H


embedded image


H





67(H32-10)


embedded image




embedded image


H


embedded image


H





67(H32-11)


embedded image




embedded image


H


embedded image


H





67(H32-12)


embedded image




embedded image


H


embedded image


H



















TABLE 32B-3









embedded image

















Example No
R1
R2
R3
R4
R5





67(H32-13)


embedded image




embedded image


H


embedded image


H





67(H32-14)


embedded image




embedded image


H


embedded image


H





67(H32-15)


embedded image




embedded image


H


embedded image


H





67(H32-16)


embedded image




embedded image


H


embedded image


H





67(H32-17)


embedded image




embedded image


H


embedded image


H





67(H32-18)


embedded image




embedded image


H


embedded image


H





67(H32-19)


embedded image




embedded image


H


embedded image


H



















TABLE 32B-4









embedded image

















Example No
R1
R2
R3
R4
R5





67(H32-20)


embedded image




embedded image


H


embedded image


H





67(H32-21)


embedded image




embedded image


H


embedded image


H





67(H32-22)


embedded image




embedded image


H


embedded image


H





67(H32-23)


embedded image




embedded image


H


embedded image


H





67(H32-24)


embedded image




embedded image


H


embedded image


H



















TABLE 33B-1









embedded image

















Example No
R1
R2
R3
R4
R5





67(H33-1)


embedded image




embedded image


H


embedded image


H





67(H33-2)


embedded image




embedded image


H


embedded image


H





67(H33-3)


embedded image




embedded image


H


embedded image


H





67(H33-4)


embedded image




embedded image


H


embedded image


H





67(H33-5)


embedded image




embedded image


H


embedded image


H





67(H33-6)


embedded image




embedded image


H


embedded image


H



















TABLE 33B-2









embedded image

















Example No
R1
R2
R3
R4
R5





67(H33-7) 


embedded image




embedded image


H


embedded image


H





67(H33-8) 


embedded image




embedded image


H


embedded image


H





67(H33-9) 


embedded image




embedded image


H


embedded image


H





67(H33-10)


embedded image




embedded image


H


embedded image


H





67(H33-11)


embedded image




embedded image


H


embedded image


H





67(H33-12)


embedded image




embedded image


H


embedded image


H





67(H33-13)


embedded image




embedded image


H


embedded image


H



















TABLE 33B-3









embedded image

















Exam-







ple No
R1
R2
R3
R4
R5





67(H33-14)


embedded image




embedded image


H


embedded image


H





67(H33-15)


embedded image




embedded image


H


embedded image


H





67(H33-16)


embedded image




embedded image


H


embedded image


H





67(H33-17)


embedded image




embedded image


H


embedded image


H





67(H33-18)


embedded image




embedded image


H


embedded image


H



















TABLE 34B-1









embedded image

















Example No
R1
R2
R3
R4
R5





67(H34-1)


embedded image




embedded image


H


embedded image


H





67(H34-2)


embedded image




embedded image


H


embedded image


H





67(H34-3)


embedded image




embedded image


H


embedded image


H





67(H34-4)


embedded image




embedded image


H


embedded image


H





67(H34-5)


embedded image




embedded image


H


embedded image


H



















TABLE 34B-2









embedded image

















Example No
R1
R2
R3
R4
R5





67(H34-6)


embedded image




embedded image


H


embedded image


H





67(H34-7)


embedded image




embedded image


H


embedded image


H





67(H34-8)


embedded image




embedded image


H


embedded image


H





67(H34-9)


embedded image




embedded image


H


embedded image


H





67(H34-10)


embedded image




embedded image


H


embedded image


H





67(H34-11)


embedded image




embedded image


H


embedded image


H



















TABLE 34B-3









embedded image

















Example No
R1
R2
R3
R4
R5





67(H34-12)


embedded image




embedded image


H


embedded image


H





67(H34-13)


embedded image




embedded image


H


embedded image


H





67(H34-14)


embedded image




embedded image


H


embedded image


H





67(H34-15)


embedded image




embedded image


H


embedded image


H























TABLE 32C-1







Re-





HPLC
tention



con-
time


Example No
dition
(min)
Mass data
Mass condition



















67(H32-1)
F
3.42
450 (M + H)+, 121.
ESI (Pos., 40 V)


67(H32-2)
F
3.40
478 (M + H)+, 149.
ESI (Pos., 40 V)


67(H32-3)
F
3.72
512 (M + H)+, 183.
ESI (Pos., 40 V)


67(H32-4)
F
3.71
526 (M + H)+, 197.
ESI (Pos., 40 V)


67(H32-5)
F
3.42
514 (M + H)+,
ESI (Pos., 40 V)





303, 185.


67(H32-6)
F
3.31
486 (M + H)+.
ESI (Pos., 40 V)


67(H32-7)
F
3.27
452 (M + H)+, 121.
ESI (Pos., 40 V)


67(H32-8)
F
3.27
480 (M + H)+, 149.
ESI (Pos., 40 V)


67(H32-9)
F
3.55
514 (M + H)+,
ESI (Pos., 40 V)





339, 183.


67(H32-10)
F
3.58
528 (M + H)+,
ESI (Pos., 40 V)





339, 197.


67(H32-11)
F
3.29
516 (M + H)+, 185.
ESI (Pos., 40 V)


67(H32-12)
F
3.12
488 (M + H)+.
ESI (Pos., 40 V)


67(H32-13)
F
3.47
484 (M + H)+,
ESI (Pos., 40 V)





303, 121.


67(H32-14)
F
3.47
512 (M + H)+,
ESI (Pos., 40 V)





303, 148.


67(H32-15)
F
3.73
546 (M + H)+, 183.
ESI (Pos., 40 V)


67(H32-16)
F
3.75
560 (M + H)+, 197.
ESI (Pos., 40 V)


67(H32-17)
F
3.49
548 (M + H)+,
ESI (Pos., 40 V)





303, 185.


67(H32-18)
F
3.33
520 (M + H)+, 404.
ESI (Pos., 40 V)


67(H32-19)
F
3.52
456 (M + H)+.
ESI (Pos., 40 V)


67(H32-20)
F
3.29
416 (M + H)+.
ESI (Pos., 40 V)


67(H32-21)
F
3.49
456 (M + H)+.
ESI (Pos., 40 V)


67(H32-22)
F
3.31
416 (M + H)+.
ESI (Pos., 40 V)


67(H32-23)
F
3.78
502 (M + H)+, 206.
ESI (Pos., 40 V)


67(H32-24)
F
3.69
498 (M + H)+,
ESI (Pos., 40 V)





279, 203.























TABLE 33C-1







Retention





HPLC
time


Example No
condition
(min)
Mass data
Mass condition







67(H33-1)
F
3.78
546 (M + H)+,
ESI (Pos., 40 V)





183.


67(H33-2)
F
3.75
530 (M + H)+,
ESI (Pos., 40 V)





183.


67(H33-3)
F
3.84
580 (M + H)+.
ESI (Pos., 40 V)


67(H33-4)
F
3.66
476 (M + H)+,
ESI (Pos., 40 V)





339, 183.


67(H33-5)
F
3.80
492 (M + H)+,
ESI (Pos., 40 V)





183.


67(H33-6)
F
3.73
518 (M + H)+,
ESI (Pos., 40 V)





183.


67(H33-7)
F
3.67
502 (M + H)+,
ESI (Pos., 40 V)





182.


67(H33-8)
F
3.67
476 (M + H)+,
ESI (Pos., 40 V)





183.


67(H33-9)
F
3.36
422 (M + H)+,
ESI (Pos., 40 V)





298, 125.


67(H33-10)
F
3.80
542 (M + H)+,
ESI (Pos., 40 V)





183.


67(H33-11)
F
3.44
515 (M + H)+.
ESI (Pos., 20 V)


67(H33-12)
F
3.44
476 (M + H)+.
ESI (Pos., 20 V)


67(H33-13)
F
3.38
482 (M + H)+.
ESI (Pos., 20 V)


67(H33-14)
F
3.36
442 (M + H)+.
ESI (Pos., 20 V)


67(H33-15)
F
3.26
476 (M + H)+.
ESI (Pos., 20 V)


67(H33-16)
F
3.22
436 (M + H)+.
ESI (Pos., 20 V)


67(H33-17)
F
3.20
442 (M + H)+.
ESI (Pos., 20 V)


67(H33-18)
F
3.15
402 (M + H)+.
ESI (Pos., 20 V)























TABLE 34C-1







Retention





HPLC
time


Example No
condition
(min)
Mass data
Mass condition







67(H34-1)
F
3.71
478 (M + H)+,
ESI (Pos., 40 V)





279, 183.


67(H34-2)
F
3.42
444 (M + H)+,
ESI (Pos., 40 V)





149.


67(H34-3)
F
3.55
480 (M + H)+,
ESI (Pos., 40 V)





183.


67(H34-4)
F
3.23
446 (M + H)+,
ESI (Pos., 40 V)





149.


67(H34-5)
F
3.9
548 (M + H)+.
ESI (Pos., 40 V)


67(H34-6)
F
3.65
514 (M + H)+,
ESI (Pos., 40 V)





279, 149.


67(H34-7)
F
3.76
550 (M + H)+,
ESI (Pos., 40 V)





183.


67(H34-8)
F
3.49
516 (M + H)+,
ESI (Pos., 40 V)





149.


67(H34-9)
F
3.47
464 (M + H)+.
ESI (Pos., 40 V)


67(H34-10)
F
3.31
466 (M + H)+.
ESI (Pos., 40 V)


67(H34-11)
F
3.73
490 (M + H)+,
ESI (Pos., 40 V)





279, 183.


67(H34-12)
F
3.55
412 (M + H)+,
ESI (Pos., 40 V)





117.


67(H34-13)
F
3.72
452 (M + H)+,
ESI (Pos., 40 V)





379, 279, 117.


67(H34-14)
F
3.44
477 (M + H)+,
ESI (Pos., 40 V)





404, 345.


67(H34-15)
F
3.64
496 (M + H)+,
ESI (Pos., 40 V)





279, 149.









EXAMPLE 68(H35-1)˜H35-61)

By the same procedure as described in Reference Example 11 using Resin (3) prepared in Reference Example 2, the corresponding 4-piperidone derivatives, the corresponding amine derivatives, and the corresponding amino acid derivatives, and by the same procedure as described in Reference Example 12→Example 33 using the corresponding alcohol derivatives, and by cleavage from resin, the compounds of the present invention, whose names were shown in the following Table 35A-1˜35A-8, and whose structures were shown in the following Table 35B-1˜35B-13, were obtained. Also, physical data of the above compounds were shown in the following Table 35C-1˜35C-3.










TABLE 35A-1





Example No
Compound Name







68(H35-1)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-chloro-4-(2-



(N,N-diethylamino)ethyloxy)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


68(H35-2)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-cyclohexylmethyl-9-



(4-(2-(N,N-diethylamino)ethyloxy)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


68(H35-3)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(2-(N,N-



diethylamino)ethyloxy)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


68(H35-4)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(2-



chloro-4-(2-(N,N-diethylamino)ethyloxy)phenylmethyl)-1,



4,9-triazaspiro[5.5]undecane


68(H35-5)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-chloro-4-(2-



(N,N-diethylamino)ethyloxy)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


68(H35-6)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-



(4-(2-(N,N-diethylamino)ethyloxy)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


68(H35-7)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(2-(N,N-



diethylamino)ethyloxy)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 35A-2





Example No
Compound Name







68(H35-8)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-cyclohexylmethyl-9-



(2-chloro-4-methoxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


68(H35-9)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-chloro-4-



methoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-10)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-cyclohexylmethyl-9-



(4-methoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-11)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-



methoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-12)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(2-



chloro-4-methoxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


68(H35-13)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-chloro-4-



methoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-14)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



methoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-15)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-cyclohexylmethyl-9-



(2-chloro-4-ethoxyphenylmethyl)-1,4,9-triazaspiro[5.5]



undecane




















TABLE 35A-3





Example No
Compound Name







68(H35-16)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-chloro-4-



ethoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-17)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-cyclohexylmethyl-



9-(4-ethoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-18)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-



ethoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-19)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(2-



chloro-4-ethoxyphenylmethyl)-1,4,9-triazaspiro[5.5]



undecane


68(H35-20)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-chloro-4-



ethoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-21)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



ethoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-22)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



ethoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-23)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-cyclohexylmethyl-



9-(2-chloro-4-propyloxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 35A-4





Example No
Compound Name







68(H35-24)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-chloro-4-



propyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-25)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-cyclohexylmethyl-9-



(4-propyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-26)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-



propyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-27)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(2-



chloro-4-propyloxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


68(H35-28)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-chloro-4-



propyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-29)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



propyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-30)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-cyclohexylmethyl-9-



(2-chloro-4-isopropyloxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


68(H35-31)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-chloro-4-



isopropyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane




















TABLE 35A-5





Example



No
Compound Name







68(H35-32)
1-(thiophen-2-ylmethyl)-2,5-



dioxo-3-cyclohexylmethyl-9-(4-



isopropyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-33)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-



isopropyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-34)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(2-



chloro-4-isopropyloxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


68(H35-35)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-chloro-4-



isopropyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-36)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



isopropyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-37)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



isopropyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-38)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-cyclohexylmethyl-9-



(2-chloro-4-(cyclopropylmethyloxy)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 35A-6





Example No
Compound Name







68(H35-39)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-chloro-4-



(cyclopropylmethyloxy)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


68(H35-40)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-cyclohexylmethyl-9-



(4-(cyclopropylmethyloxy)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


68(H35-41)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-



(cyclopropylmethyloxy)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


68(H35-42)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(2-



chloro-4-(cyclopropylmethyloxy)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


68(H35-43)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-chloro-4-



(cyclopropylmethyloxy)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


68(H35-44)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



(cyclopropylmethyloxy)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


68(H35-45)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



(cyclopropylmethyloxy)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 35A-7





Example No
Compound Name







68(H35-46)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-cyclohexylmethyl-



9-(2-chloro-4-cyclobutyloxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


68(H35-47)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-chloro-4-



cyclobutyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-48)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-cyclohexylmethyl-9-



(4-cyclobutyloxyphenylmethyl)-1,4,9-triaza-



spiro[5.5]undecane


68(H35-49)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-cyclohexylmethyl-9-



(2-chloro-4-cyclopentyloxylmethyl)-1,4,9-



triazaspiro[5.5]undecane


68(H35-50)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-chloro-4-



cyclopentyloxyphenylmethyl)-1,4,9-triaza-



spiro[5.5]undecane


68(H35-51)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-cyclohexylmethyl-9-



(4-cyclopentyloxyphenylmethyl)-1,4,9-triaza-



spiro[5.5]undecane


68(H35-52)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-



cyclopentyloxyphenylmethyl)-1,4,9-triaza-



spiro[5.5]undecane


68(H35-53)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(2-



chloro-4-cyclopentyloxyphenylmethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 35A-8





Example No
Compound Name







68(H35-54)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-chloro-4-



cyclopentyloxyphenylmethyl)-1,4,9-triaza-



spiro[5.5]undecane


68(H35-55)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-



cyclopentyloxyphenylmethyl)-1,4,9-triaza-



spiro[5.5]undecane


68(H35-56)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



cyclopentyloxyphenylmethyl)-1,4,9-triaza-



spiro[5.5]undecane


68(H35-57)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-cyclohexylmethyl-9-



(2-chloro-4-(tetrahydropyran-4-yloxy)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


68(H35-58)
1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-chloro-4-



(tetrahydropyran-4-yloxy)phenylmethyl)-1,4,9-



triazaspiro[5.5]undecane


68(H35-59)
1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-



(2-chloro-4-(tetrahydropyran-4-yloxy)phenylmethyl)-



1,4,9-triazaspiro[5.5]undecane


68(H35-60)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-



cyclobutyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane


68(H35-61)
1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(tetrahydro-



pyran-4-yloxy)phenylmethyl)-1,4,9-triaza-



spiro[5.5]undecane



















TABLE 35B-1









embedded image

















Example







No
R1
R2
R3
R4
R5





68(H35-1)


embedded image




embedded image


H


embedded image


H





68(H35-2)


embedded image




embedded image


H


embedded image


H





68(H35-3)


embedded image




embedded image


H


embedded image


H





68(H35-4)


embedded image




embedded image


H


embedded image


H



















TABLE 35B-2









embedded image

















Example







No
R1
R2
R3
R4
R5





68(H35-5)


embedded image




embedded image


H


embedded image


H





68(H35-6)


embedded image




embedded image


H


embedded image


H





68(H35-7)


embedded image




embedded image


H


embedded image


H





68(H35-8)


embedded image




embedded image


H


embedded image


H





68(H35-9)


embedded image




embedded image


H


embedded image


H



















TABLE 35B-3









embedded image

















Example No
R1
R2
R3
R4
R5





68(H35-10)


embedded image




embedded image


H


embedded image


H





68(H35-11)


embedded image




embedded image


H


embedded image


H





68(H35-12)


embedded image




embedded image


H


embedded image


H





68(H35-13)


embedded image




embedded image


H


embedded image


H





68(H35-14)


embedded image




embedded image


H


embedded image


H





68(H35-15)


embedded image




embedded image


H


embedded image


H



















TABLE 35B-4









embedded image

















Example No
R1
R2
R3
R4
R5





68(H35-16)


embedded image




embedded image


H


embedded image


H





68(H35-17)


embedded image




embedded image


H


embedded image


H





68(H35-18)


embedded image




embedded image


H


embedded image


H





68(H35-19)


embedded image




embedded image


H


embedded image


H





68(H35-20)


embedded image




embedded image


H


embedded image


H



















TABLE 35B-5









embedded image

















Example No
R1
R2
R3
R4
R5





68(H35-21)


embedded image




embedded image


H


embedded image


H





68(H35-22)


embedded image




embedded image


H


embedded image


H





68(H35-23)


embedded image




embedded image


H


embedded image


H





68(H35-24)


embedded image




embedded image


H


embedded image


H





68(H35-25)


embedded image




embedded image


H


embedded image


H



















TABLE 35B-6









embedded image

















Example No
R1
R2
R3
R4
R5





68(H35-26)


embedded image




embedded image


H


embedded image


H





68(H35-27)


embedded image




embedded image


H


embedded image


H





68(H35-28)


embedded image




embedded image


H


embedded image


H





68(H35-29)


embedded image




embedded image


H


embedded image


H





68(H35-30)


embedded image




embedded image


H


embedded image


H



















TABLE 35B-7









embedded image

















Example







No
R1
R2
R3
R4
R5





68(H35-31)


embedded image




embedded image


H


embedded image


H





68(H35-32)


embedded image




embedded image


H


embedded image


H





68(H35-33)


embedded image




embedded image


H


embedded image


H





68(H35-34)


embedded image




embedded image


H


embedded image


H





68(H35-35)


embedded image




embedded image


H


embedded image


H



















TABLE 35B-8









embedded image

















Example No
R1
R2
R3
R4
R5





68(H35-36)


embedded image




embedded image


H


embedded image


H





68(H35-37)


embedded image




embedded image


H


embedded image


H





68(H35-38)


embedded image




embedded image


H


embedded image


H





68(H35-39)


embedded image




embedded image


H


embedded image


H





68(H35-40)


embedded image




embedded image


H


embedded image


H



















TABLE 35B-9









embedded image

















Example No
R1
R2
R3
R4
R5





68(H35-41)


embedded image




embedded image


H


embedded image


H





68(H35-42)


embedded image




embedded image


H


embedded image


H





68(H35-43)


embedded image




embedded image


H


embedded image


H





68(H35-44)


embedded image




embedded image


H


embedded image


H





68(H35-45)


embedded image




embedded image


H


embedded image


H



















TABLE 35B-10









embedded image

















Example No
R1
R2
R3
R4
R5





68(H35-46)


embedded image




embedded image


H


embedded image


H





68(H35-47)


embedded image




embedded image


H


embedded image


H





68(H35-48)


embedded image




embedded image


H


embedded image


H





68(H35-49)


embedded image




embedded image


H


embedded image


H





68(H35-50)


embedded image




embedded image


H


embedded image


H



















TABLE 35B-11









embedded image

















Example







No
R1
R2
R3
R4
R5





68(H35-51)


embedded image




embedded image


H


embedded image


H





68(H35-52)


embedded image




embedded image


H


embedded image


H





68(H35-53)


embedded image




embedded image


H


embedded image


H





68(H35-54)


embedded image




embedded image


H


embedded image


H





68(H35-55)


embedded image




embedded image


H


embedded image


H



















TABLE 35B-12









embedded image

















Example







No.
R1
R2
R3
R4
R5





68(H35-56)


embedded image




embedded image


H


embedded image


H





68(H35-57)


embedded image




embedded image


H


embedded image


H





68(H35-58)


embedded image




embedded image


H


embedded image


H





68(H35-59)


embedded image




embedded image


H


embedded image


H





68(H35-60)


embedded image




embedded image


H


embedded image


H



















TABLE 35B-13









embedded image

















Example No
R1
R2
R3
R4
R5





68(H35-61)


embedded image




embedded image


H


embedded image


H























TABLE 35C-1







Retention





HPLC
time


Example No
condition
(min)
Mass data
Mass condition



















68(H35-1)
F
3.31
575 (M + H)+.
ESI (Pos., 20 V)


68(H35-2)
F
3.24
581 (M + H)+.
ESI (Pos., 20 V)


68(H35-3)
F
3.22
541 (M + H)+.
ESI (Pos., 20 V)


68(H35-4)
F
3.11
575 (M + H)+.
ESI (Pos., 20 V)


68(H35-5)
F
3.11
534 (M + H)+.
ESI (Pos., 20 V)


68(H35-6)
F
3.09
540 (M + H)+.
ESI (Pos., 20 V)


68(H35-7)
F
3.05
501 (M + H)+.
ESI (Pos., 20 V)


68(H35-8)
F
3.57
530 (M + H)+.
ESI (Pos., 20 V)


68(H35-9)
F
3.57
548 (M + H)+.
ESI (Pos., 20 V)


68(H35-10)
F
3.51
496 (M + H)+.
ESI (Pos., 20 V)


68(H35-11)
F
3.49
456 (M + H)+.
ESI (Pos., 20 V)


68(H35-12)
F
3.40
490 (M + H)+.
ESI (Pos., 20 V)


68(H35-13)
F
3.36
450 (M + H)+.
ESI (Pos., 20 V)


68(H35-14)
F
3.29
415 (M + H)+.
ESI (Pos., 20 V)


68(H35-15)
F
3.66
544 (M + H)+.
ESI (Pos., 20 V)


68(H35-16)
F
3.64
504 (M + H)+.
ESI (Pos., 20 V)


68(H35-17)
F
3.58
510 (M + H)+.
ESI (Pos., 20 V)


68(H35-18)
F
3.59
469 (M + H)+.
ESI (Pos., 20 V)


68(H35-19)
F
3.47
504 (M + H)+.
ESI (Pos., 20 V)


68(H35-20)
F
3.45
463 (M + H)+.
ESI (Pos., 20 V)


68(H35-21)
F
3.40
470 (M + H)+.
ESI (Pos., 20 V)


68(H35-22)
F
3.38
430 (M + H)+.
ESI (Pos., 20 V)


68(H35-23)
F
3.76
558 (M + H)+.
ESI (Pos., 20 V)


68(H35-24)
F
3.74
518 (M + H)+.
ESI (Pos., 20 V)


68(H35-25)
F
3.68
524 (M + H)+.
ESI (Pos., 20 V)


68(H35-26)
F
3.66
484 (M + H)+.
ESI (Pos., 20 V)


68(H35-27)
F
3.58
518 (M + H)+.
ESI (Pos., 20 V)


68(H35-28)
F
3.57
478 (M + H)+.
ESI (Pos., 20 V)























TABLE 35C-2







Retention





HPLC
time


Example No
condition
(min)
Mass data
Mass condition



















68(H35-29)
F
3.51
484 (M + H)+.
ESI (Pos., 20 V)


68(H35-30)
F
3.71
558 (M + H)+.
ESI (Pos., 20 V)


68(H35-31)
F
3.70
518 (M + H)+.
ESI (Pos., 20 V)


68(H35-32)
F
3.66
524 (M + H)+.
ESI (Pos., 20 V)


68(H35-33)
F
3.64
484 (M + H)+.
ESI (Pos., 20 V)


68(H35-34)
F
3.55
518 (M + H)+.
ESI (Pos., 20 V)


68(H35-35)
F
3.52
478 (M + H)+.
ESI (Pos., 20 V)


68(H35-36)
F
3.48
484 (M + H)+.
ESI (Pos., 20 V)


68(H35-37)
F
3.45
444 (M + H)+.
ESI (Pos., 20 V)


68(H35-38)
F
3.71
570 (M + H)+.
ESI (Pos., 20 V)


68(H35-39)
F
3.72
530 (M + H)+.
ESI (Pos., 20 V)


68(H35-40)
F
3.66
536 (M + H)+.
ESI (Pos., 20 V)


68(H35-41)
F
3.64
496 (M + H)+.
ESI (Pos., 20 V)


68(H35-42)
F
3.55
530 (M + H)+.
ESI (Pos., 20 V)


68(H35-43)
F
3.53
490 (M + H)+.
ESI (Pos., 20 V)


68(H35-44)
F
3.48
496 (M + H)+.
ESI (Pos., 20 V)


68(H35-45)
F
3.47
456 (M + H)+.
ESI (Pos., 20 V)


68(H35-46)
F
3.78
570 (M + H)+.
ESI (Pos., 20 V)


68(H35-47)
F
3.77
530 (M + H)+.
ESI (Pos., 20 V)


68(H35-48)
F
3.54
557 (M + H)+.
ESI (Pos., 20 V)


68(H35-49)
F
3.81
584 (M + H)+.
ESI (Pos., 20 V)


68(H35-50)
F
3.83
545 (M + H)+.
ESI (Pos., 20 V)


68(H35-51)
F
3.74
550 (M + H)+.
ESI (Pos., 20 V)


68(H35-52)
F
3.74
510 (M + H)+.
ESI (Pos., 20 V)


68(H35-53)
F
3.64
544 (M + H)+.
ESI (Pos., 20 V)


68(H35-54)
F
3.65
504 (M + H)+.
ESI (Pos., 20 V)


68(H35-55)
F
3.57
510 (M + H)+.
ESI (Pos., 20 V)


68(H35-56)
F
3.57
470 (M + H)+.
ESI (Pos., 20 V)























TABLE 35C-3







Retention





HPLC
time


Example No
condition
(min)
Mass data
Mass condition



















68(H35-57)
F
3.53
600 (M + H)+.
ESI (Pos., 20 V)


68(H35-58)
F
3.59
560 (M + H)+.
ESI (Pos., 20 V)


68(H35-59)
F
3.42
560 (M + H)+.
ESI (Pos., 20 V)


68(H35-60)
F
3.66
456 (M + H)+,
ESI (Pos., 40 V)





279, 161.


68(H35-61)
F
3.45
586 (M + H)+,
ESI (Pos., 40 V)





369, 191.









EXAMPLE 69(H36-1)˜69(H36-24)

By the same procedure as described in Example 22 using the corresponding amine derivatives and acid chloride derivatives instead of the compound prepared in Example 14, the compounds of the present invention, whose names were shown in the following Table 36A-1˜36A-4, and whose structures were shown in the following Table 36B-1˜36B-5, were obtained. Also, physical data of the above compounds were shown in the following Table 36C-1.










TABLE 36A-1





Example



No
Compound Name







69(H36-1)
(3S)-1-propyl-2,5-dioxo-3-((2-



phenylphenyl)carbonylaminomethyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


69(H36-2)
(3S)-1-propyl-2,5-dioxo-3-((3-



phenylphenyl)carbonylaminomethyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


69(H36-3)
(3S)-1-propyl-2,5-dioxo-3-((4-



phenylphenyl)carbonylaminomethyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


69(H36-4)
(3S)-1-propyl-2,5-dioxo-3-((2-



phenylphenyl)acetylaminomethyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


69(H36-5)
(3S)-1-propyl-2,5-dioxo-3-((3-



phenylphenyl)acetylaminomethyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


69(H36-6)
(3S)-1-propyl-2,5-dioxo-3-((4-



phenylphenyl)acetylaminomethyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


69(H36-7)
(3S)-1-propyl-2,5-dioxo-3-(2-(2-



phenylphenyl)carbonylaminoethyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane




















TABLE 36A-2





Example No
Compound Name







69(H36-8)
(3S)-1-propyl-2,5-dioxo-3-(2-(3-



phenylphenyl)carbonylaminoethyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


69(H36-9)
(3S)-1-propyl-2,5-dioxo-3-(2-(4-



phenylphenyl)carbonylaminoethyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


69(H36-10)
(3S)-1-propyl-2,5-dioxo-3-(2-(2-



phenylphenyl)acetylaminoethyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


69(H36-11)
(3S)-1-propyl-2,5-dioxo-3-(2-(3-



phenylphenyl)acetylaminoethyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


69(H36-12)
(3S)-1-propyl-2,5-dioxo-3-(2-(4-



phenylphenyl)acetylaminoethyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


69(H36-13)
(3S)-1-propyl-2,5-dioxo-3-(3-(2-



phenylphenyl)carbonylaminopropyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


69(H36-14)
(3S)-1-propyl-2,5-dioxo-3-(3-(3-



phenylphenyl)carbonylaminopropyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane




















TABLE 36A-3





Example No
Compound Name







69(H36-15)
(3S)-1-propyl-2,5-dioxo-3-(3-(4-



phenylphenyl)carbonylaminopropyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


69(H36-16)
(3S)-1-propyl-2,5-dioxo-3-(3-(2-



phenylphenyl)acetylaminopropyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


69(H36-17)
(3S)-1-propyl-2,5-dioxo-3-(3-(3-



phenylphenyl)acetylaminopropyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


69(H36-18)
(3S)-1-propyl-2,5-dioxo-3-(3-(4-



phenylphenyl)acetylaminopropyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


69(H36-19)
(3S)-1-propyl-2,5-dioxo-3-(4-(2-



phenylphenyl)carbonylaminobutyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


69(H36-20)
(3S)-1-propyl-2,5-dioxo-3-(4-(3-



phenylphenyl)carbonylaminobutyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane


69(H36-21)
(3S)-1-propyl-2,5-dioxo-3-(4-(4-



phenylphenyl)carbonylaminobutyl)-9-(2-phenylethyl)-



1,4,9-triazaspiro[5.5]undecane




















TABLE 36A-4





Example No
Compound Name







69(H36-22)
(3S)-1-propyl-2,5-dioxo-3-(4-(2-



phenylphenyl)acetylaminobutyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane


69(H36-23)
(3S)-1-propyl-2,5-dioxo-3-(4-(3-



phenylphenyl)acetylaminobutyl)-9-(2-phenlyethyl)-1,4,9-



triazaspiro[5.5]undecane


69(H36-24)
(3S)-1-propyl-2,5-dioxo-3-(4-(4-



phenylphenyl)acetylaminobutyl)-9-(2-phenylethyl)-1,4,9-



triazaspiro[5.5]undecane



















TABLE 36B-1









embedded image















Example





No
R3
R4
R5





69(H36-1)
H


embedded image


H





69(H36-2)
H


embedded image


H





69(H36-3)
H


embedded image


H





69(H36-4)
H


embedded image


H





69(H36-5)
H


embedded image


H





69(H36-6)
H


embedded image


H



















TABLE 36B-2









embedded image















Example





No
R3
R4
R5





69(H36-7)
H


embedded image


H





69(H36-8)
H


embedded image


H





69(H36-9)
H


embedded image


H





69(H36-10)
H


embedded image


H





69(H36-11)
H


embedded image


H





69(H36-12)
H


embedded image


H





69(H36-13)
H


embedded image


H



















TABLE 36B-3









embedded image















Example No
R3
R4
R5





69(H36-14)
H


embedded image


H





69(H36-15)
H


embedded image


H





69(H36-16)
H


embedded image


H





69(H36-17)
H


embedded image


H



















TABLE 36B-4









embedded image















Example No
R3
R4
R5





69(H36-18)
H


embedded image


H





69(H36-19)
H


embedded image


H





69(H36-20)
H


embedded image


H





69(H36-21)
H


embedded image


H





69(H36-22)
H


embedded image


H



















TABLE 36B-5









embedded image















Example No
R3
R4
R5





69(H36-23)
H


embedded image


H





69(H36-24)
H


embedded image


H























TABLE 36C-1







Retention





HPLC
time


Example No
condition
(min)
Mass data
Mass condition



















69(H36-1)
F
3.38
539 (M + H)+.
ESI (Pos., 20 V)


69(H36-2)
F
3.47
539 (M + H)+.
ESI (Pos., 20 V)


69(H36-3)
F
3.47
539 (M + H)+.
ESI (Pos., 20 V)


69(H36-4)
F
3.45
553 (M + H)+.
ESI (Pos., 20 V)


69(H36-5)
F
3.44
553 (M + H)+.
ESI (Pos., 20 V)


69(H36-6)
F
3.44
553 (M + H)+.
ESI (Pos., 20 V)


69(H36-7)
F
3.40
553 (M + H)+.
ESI (Pos., 20 V)


69(H36-8)
F
3.49
553 (M + H)+.
ESI (Pos., 20 V)


69(H36-9)
F
3.49
553 (M + H)+.
ESI (Pos., 20 V)


69(H36-10)
F
3.47
567 (M + H)+.
ESI (Pos., 20 V)


69(H36-11)
F
3.49
567 (M + H)+.
ESI (Pos., 20 V)


69(H36-12)
F
3.49
567 (M + H)+.
ESI (Pos., 20 V)


69(H36-13)
F
3.36
567 (M + H)+.
ESI (Pos., 20 V)


69(H36-14)
F
3.47
567 (M + H)+.
ESI (Pos., 20 V)


69(H36-15)
F
3.47
567 (M + H)+.
ESI (Pos., 20 V)


69(H36-16)
F
3.45
581 (M + H)+.
ESI (Pos., 20 V)


69(H36-17)
F
3.47
581 (M + H)+.
ESI (Pos., 20 V)


69(H36-18)
F
3.47
581 (M + H)+.
ESI (Pos., 20 V)


69(H36-19)
F
3.40
581 (M + H)+.
ESI (Pos., 20 V)


69(H36-20)
F
3.49
581 (M + H)+.
ESI (Pos., 20 V)


69(H36-21)
F
3.43
581 (M + H)+.
ESI (Pos., 20 V)


69(H36-22)
F
3.47
595 (M + H)+.
ESI (Pos., 20 V)


69(H36-23)
F
3.49
595 (M + H)+.
ESI (Pos., 20 V)


69(H36-24)
F
3.49
595 (M + H)+.
ESI (Pos., 20 V)









FORMULATION EXAMPLE
FORMULATION EXAMPLE 1

The following components were admixed in a conventional technique, punched out to give 100 tablets each containing 50 mg of active ingredient.















9-((3,5-dimethyl-1-phenyl)-4-pyrazolyl)methyl)-2,5-dioxo-3-(2-
5.0 g


methyl-propyl)-1-propyl-1,4,9-triazaspiro[5.5]undecane.2


hydrochloride


calcium carboxymethylcellulose (disintegrant)
0.2 g


magnesium stearate (lubricant)
0.1 g


microcrystalline cellulose
4.7 g









FORMULATION EXAMPLE 2

The following components were admixed in a conventional technique. The solution was sterilized in a conventional technique, filled in ampoules 5 ml each and freeze-dried in a conventional technique to give 100 ampoules each containing 20 mg of active ingredient.
















9-((3,5-dimethyl-1-phenyl)-4-pyrazolyl)methyl)-2,5-dioxo-3-
2.0
g


(2-methyl-1-propyl)-1-propyl-1,4,9-triazaspiro[5.5]undecane.2


hydrochloride


mannitol
20
g


distilled water
500
ml








Claims
  • 1. A triazaspiro[5.5]undecane compound of the formula (I):
  • 2. A compound according to claim 1, in which R3 and R4 are hydrogen in the formula (I) described in claim 1, or a quarternary ammonium salt thereof, an N-oxide thereof or a non-toxic salt thereof.
  • 3. A compound according to claim 1, in which R3 is hydrogen, and R4 is (1) C1–8alkyl,(2) C2–8 alkenyl,(3) C2–8 alkynyl,(4) —COOR120,(5) —CONR121R122,(6) Cyc 4, or(7) C1–8 alkyl, C2–8 alkenyl or C2–8 alkynyl substituted by 1–5 substituents(s) selected from (a) halogen, (b) nitrile, (c) Cyc 4, (d) —COOR120, (e) —CONR121R122, (f) —OR123, (g) —SR124 (h) —NR125R126, (i) —NR127COR128, (j) —SO2NR129R130, (k) —OCOR131, (l) —NR132SO2R133, m) —NR134COOR135, (n) —NR136CONR137R138, (o) —S—SR139, (p) —NHC(═NH)NHR140, (q) keto, (r) —NR145CONR146COR147, or (s) —N(SO2R133)2, wherein all of the symbols have the same meanings as defined in claim 1, in the formula (I) described in claim 1,or a quaternary ammonium salt thereof, an N-oxide thereof or a non-toxic salt thereof.
  • 4. A compound according to claim 1, in which R3 and R4 are each independently, (1) C1–8alkyl,(2) C2–8 alkenyl,(3) C2–8 alkynyl,(4) —COOR120,(5) —CONR121R122,(6) Cyc 4, or(7) C1–8 alkyl, C2–8 alkenyl or C2–8 alkynyl substituted by 1–5 substituents(s) selected from (a) halogen, (b) nitrile, (c) Cyc 4, (d) —COOR120, (e) —CONR121R122, (f) —OR123, (g) —SR124, (h) —NR125R126, (i) —NR127COR128, (j) —SO2NR129R130, (k) —OCOR131, (l) —NR132SO2R133, m) —NR134COOR135, (n) —NR136CONR137R , (o) —S—SR139, (p) —NHC(═NH)NHR140, (4) keto, (r) —NR145CONR146COR147, or (s) —N(SO2R133)2, wherein all of the symbols have the same meanings as defined in claim 1, in the formula (I) described in claim 1,or a quarternary ammonium salt thereof, an N-oxide thereof or a non-toxic salt thereof.
  • 5. A compound according to claim 1, in which R3 and R4, taken together, are
  • 6. A compound according to claim 1, which is (1) 9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-2,5-dioxo-3-(2-methyl-1-propyl)-1-propyl-1,4,9-triazaspiro[5.5]undecane,(2) 9-(1,4-benzodioxan-6-ylmethyl)-1-butyl-3-cyclohexylmethyl-2,5-dioxo-1,4,9-triazaspiro[5.5]undecane,(3) 1-butyl-3-cyclohexylmethyl-2,5-dioxo-9-(2-phenylimidazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(4) 1-butyl-3-(2-methyl-1-propyl)-2,5-dioxo-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(5) (3S)-2,5-dioxo-3-(2-methylpropyl)-9-(6-phenylhexyl)-1-propyl-1,4,9-triazaspiro[5.5]undecane,(6) (3R)-2,5-dioxo-3-(2-methylpropyl)-9-(6-phenylhexyl)-1-propyl-1,4,9-triazaspiro[5.5]undecane,(7) 1-butyl-9-((3,5-dimethyl-1-phenyl)-4-pyrazolyl)methyl)-2,5-dioxo-3-(2-methyl-1-propyl)-1,4,9-triazaspiro[5.5]undecane,(8) 1-butyl-3-cyclohexylmethyl-2,5-dioxo-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(9) 9-(1,4-benzodioxan-6-ylmethyl)-1-butyl-3-(2-methyl-1-propyl)-2,5-dioxo-1,4,9-triazaspiro[5.5]undecane,(10) 9-(4-benzyloxyphenylmethyl)-1-butyl-2,5-dioxo-3-(2-methyl-1-propyl)-1,4,9-triazaspiro[5.5]undecane,(11) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(6-phenylhexyl)-1,4,9-triazaspiro[5.5]undecane,(12) (3S)-1-(2-methylpropyl)-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane,(13) (3S)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane,(14) (3R)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane,(15) (3S)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(3-phenylpropyl)-1,4,9-triazaspiro[5.5]undecane,(16) (3R)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(3-phenylpropyl)-1,4,9-triazaspiro[5.5]undecane,(17) (3S)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane,(18) (3R)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane,(19) (3S)-1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-benzyl-1,4,9-triazaspiro[5.5]undecane,(20) (3R)-1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-benzyl-1,4,9-triazaspiro[5.5]undecane,(21) (3S)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(2-(2-phenyl-5-methyloxazol-4-yl)ethyl)-1,4,9-triazaspiro[5.5]undecane,(22) (3S)-1-propyl-2,5-dioxo-3-(4-(N-(2-chlorophenylmethyl)oxycarbonyl)aminobutyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane,(23) (3S)-1-propyl-2,5-dioxo-3-[3-(3-(2,4,6-trimethylphenylsulfonyl)guanidino)propyl]-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane,(24) 1-propyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(25) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-methoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(26) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-allyloxyphenylmethyl)-1,4,9-triazaspirol[5.5]undecane,(27) (3S)-1-propyl-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-2,5-dioxo-3-(2-methyl-1-propyl)-1,4,9-triazaspiro[5.5]undecane,(28) (3R)-1-propyl-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-2,5-dioxo-3-(2-methyl-1-propyl)-1,4,9-triazaspiro[5.5]undecane,(29) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-phenylmethyl-1,4,9-triazaspiro[5.5]undecane,(30) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-benzyloxycarbonyl-1,4,9-triazaspiro[5.5]undecane,(31) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-benzyloxycarbonyl-1,4,9-triazaspiro[5.5]undecane,(32) 1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(33) 1-butyl-2,5-dioxo-3-propyl-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(34) 1-butyl-2,5-dioxo-3-methoxymethyl-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(35) 1-(1-methylpropyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(36) 1-(2-methylbutyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(37) 1-(2-methylpropyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(38) 1-(2-dimethylaminoethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(39) 1-(2-methoxyethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(40) 1-(2-methylthioethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(41) 1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(42) 1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-benzyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(43) 1-benzyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(44) 1-(3-methylphenylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(45) 1-(3-methylphenylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(46) 1-(1-methylbutyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(47) 1-(3-methylbutyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(48) 1-(2-methoxyphenylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-((3,5-dimethyl-1-phenyl)-4-pyrazolyl)methyl)-1,4,9-triazaspiro[5.5]undecane,(49) 1-(3-methoxyphenylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-((3,5-dimethyl-1-phenyl)-4-pyrazolyl)methyl)-1,4,9-triazaspiro[5.5]undecane,(50) 1-(2-methylphenylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(51) 1-(3-methylphenylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(52) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(5-ethylthiophen-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(53) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(5-ethylfuran-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(54) (3S)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(55) (3R)-1-butyl-2,5-dioxo-3-((1S)-1-hydroxy-2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(56) (3S)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-allyloxycarbonyl-1,4,9-triazaspiro[5.5]undecane,(57) (3S)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-1,4,9-triazaspiro[5.5]undecane,(58) 1-propyl-2,5-dioxo-3-(2-methylpropyl)-1,4,9-triazaspiro[5.5]undecane,(59) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-1,4,9-triazaspiro[5.5]undecane,(60) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-1,4,9-triazaspiro[5.5]undecane,(61) (3S)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(4-dihydroxyboranephenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(62) (3S)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(1,3-benzodioxalan-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(63) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(1-(1,4-benzodioxan-6-yl)ethyl)-1,4,9-triazaspiro[5.5]undecane,(64) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(1-(4-phenyloxyphenyl)ethyl)-1,4,9-triazaspiro[5.5]undecane,(65) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(1-(1,4-benzodioxan-6-yl)ethyl)-1,4,9-triazaspiro[5.5]undecane,(66) (3S)-1-propyl-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-allyl-1,4,9-triazaspiro[5.5]undecane,(67) (3S)-1-propyl-2,5-dioxo-3-(4-aminobutyl)-9-phenylethyl-1,4,9-triazaspiro[5.5]undecane,(68) (3S)-1-propyl-2,5-dioxo-3-(4-(N-(4-phenyl)phenylcarbonyl)aminobutyl)-9-phenylethyl-1,4,9-triazaspiro[5.5]undecane,(69) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-methyl-9-(1-(1,4-benzodioxan-6-yl)ethyl)-1,4,-diaza-9-azoniaspiro[5.5]undecane iodide,(70) (3S)-3-(4-(N-benzyloxycarbonyl)aminobutyl)-2,5-dioxo-9-(2-hydroxy-2-phenylethyl)-1-propyl-1,4,9-triazaspiro[5.5]undecane,(71) (3S)-3-(4-(N-benzyloxycarbonyl)aminobutyl)-2,5-dioxo-9-(2-oxo-2-phenylethyl)-1-propyl-1,4,9-triazaspiro[5.5]undecane,(72) (3S)-1-(2-methylpropyl)-2,5-dioxo-3-methyl-9-allyloxycarbonyl-1,4,9-triazaspiro[5.5]undecane,(73) (3S)-1-(2-methylpropyl)-2,5-dioxo-3-methyl-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane,(74) (3S)-1-(2-methylpropyl)-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane,(75) (3S)-1-(1-benzylpiperidin-4-yl)-2,5-dioxo-3-methyl-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane,(76) (3S)-1-(1-benzylpiperidin-4-yl)-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane,(77) (3S)-1-(2,2-diphenylpropyl)-2,5-dioxo-3-methyl-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane,(78) (3S)-1-(2,2-diphenylpropyl)-2,5-dioxo-3-(4-(N-benzyloxycarbonyl)aminobutyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane,(79) (3S)-1-propyl-2,5-dioxo-3-(4-benzyloxyphenylmethyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane,(80) (3S)-1-propyl-2,5-dioxo-3-(4-(benzylcarbonylamino)butyl)-9-(2,4,6-trimethoxybenzyl)-1,4,9-triazaspiro[5.5]undecane,(81) (3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)butyl)-9-(2,2-dimethylpropyl)-1,4,9-triazaspiro[5.5]undecane,(82) (3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)butyl)-9-(3-phenylpropanoyl)-1,4,9-triazaspiro[5.5]undecane,(83) (3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)butyl)-9-benzenesulfonyl-1,4,9-triazaspiro[5.5]undecane,(84) (3S)-1-propyl-2,5-dioxo-3-(4-(benzyloxycarbonylamino)butyl)-9-benzylaminocarbonyl-1,4,9-triazaspiro[5.5]undecane,(85) (3S)-1-propyl-2,5-dioxo-3-(4-(3-phenylpropanoyl)aminobutyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane,(86) (3S)-1-propyl-2,5-dioxo-3-(4-benzenesulfonylaminobutyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane,(87) (3S)-1-propyl-2,5-dioxo-3-(4-(N-benzylcarbamoyl)aminobutyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane,(88) (3S)-1-butyl-2,5-dioxo-3-(4-methoxyphenylmethyl)-9-cyclohexylmethyl-1,4,9-triazaspiro[5.5]undecane,(89) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-(4-chlorophenyl)thiophen-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(90) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-(4-methoxyphenyl)thiophen-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(91) 1-((2E)-butenyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(92) 1-(furan-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(93) 1-(thiophen-2-ylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(94) 1-cyclopropylmethyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(95) 1-(2-fluorophenylmethyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(96) 1-(3-methyl-2-butenyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl-1,4,9-triazaspiro[5.5]undecane,(97) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(quinolin-3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(98) 1-butyl-2,5-dioxo-3-(benzyloxycarbonylmethyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(99) 1-(3-methyl-2-butenyl)-2,5-dioxo-3-cyclohexylmethyl-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(100) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-((2E)-3-phenyl-2-propenyl)-1,4,9-triazaspiro[5.5]undecane,(101) (3S)-1-butyl-2,5-dioxo-3-(1,1-dimethylethyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(102) (3S)-1-butyl-2,5-dioxo-3-(1,1-dimethylethyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(103) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-methylthiazol-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(104) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(5-methylthiazol-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(105) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-methylthiazol-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(106) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-methylthiazol-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(107) (3R)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(108) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(109) (3R)-1-butyl-2,5-dioxo-3-((1R)-1-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(110) (3S)-1-butyl-2,5-dioxo-3-((1S)-1-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(111) 1-(2-butynyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(112) 1-(2-butynyl)-2,5-dioxo-3-cyclohexylmethyl-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(113) 1-pentyl-2,5-dioxo-3-cyclohexylmethyl-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(114) 1-(3-methoxyphenylmethyl)-2,5-dioxo-3-(benzyloxymethyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(115) (3R)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(116) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(117) 1-butyl-2,5-dioxo-3-cyclopentylmethyl-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(118) 1-propyl-2,5-dioxo-3-(cyclohexylmethyloxymethyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(119) (3S)-1-butyl-2,5-dioxo-3-(1-methylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(120) (3R)-1-butyl-2,5-dioxo-3-(1-methylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(121) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-phenylmethylthiophen-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(122) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-phenylmethylthiophen-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(123) (3R)-1-butyl-2,5-dioxo-3-(2,2-dimethylpropyl)-9-(1,4 -benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(124) (3S)-1-butyl-2,5-dioxo-3-(2,2-dimethylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(125) (3R)-1-(2-butynyl)-2,5-dioxo-3-(2,2-dimethylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(126) (3S)-1-(2-butynyl)-2,5-dioxo-3-(2,2-dimethylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(127) 1-butyl-2,5-dioxo-3-cycloheptylmethyl-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(128) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2,4,6-trimethoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(129) 1-butyl-2,5-dioxo-3-(3-cyclohexylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(130) 1-butyl-2,5-dioxo-3-(3-cyclohexylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(131) 1-butyl-2,5-dioxo-3-(3-cyclohexylpropyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(132) 1-butyl-2,5-dioxo-3-(2-hydroxy-2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(133) 1-(2-butynyl)-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(134) 1-(2-butynyl)-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(135) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(136) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-phenyloxypyridin-3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(137) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-phenyloxypyridin-3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(138) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-methylbenzomorpholin-7-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(139) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-methylbenzomorpholin-7-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(140) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(N-methyl-N-phenylamino)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(141) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(N-methyl-N-phenylamino)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(142) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-(3,5-dimethylpyrazol-1-yl)-5-methoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(143) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-(3,5-dimethylpyrazol-1-yl)-5-methoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(144) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-diethyl-1-(4-chlorophenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(145) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-diethyl-1-(4-chlorophenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(146) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(6-phenyloxypyridin-3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(147) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(6-phenyloxypyridin-3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(148) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(1,3-benzodioxolan-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(149) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(1,3-benzodioxolan-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(150) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-hydroxy-4-methoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(151) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-methylthiophenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(152) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(N,N-diphenylamino)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(153) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(N,N-diphenylamino)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(154) (3S)-1-(2-butynyl)-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(155) (3S)-1-(2-butynyl)-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(156) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(157) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-methylphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(158) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-methylphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(159) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-chlorophenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(160) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-chlorophenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(161) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-trifluoromethylphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(162) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-trifluoromethylphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(163) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-diethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(164) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-diethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(165) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-phenylthiazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(166) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-phenylthiazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(167) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-(1,4-benzodioxan-2-yl)thiazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(168) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-trifluoromethyl-2-(morpholin-1-yl)thiazol-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(169) 1-butyl-2,5-dioxo-3-(tetrahydropyran-4-ylmethyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(170) 1-butyl-2,5-dioxo-3-(tetrahydropyran-4-ylmethyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(171) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-carboxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(172) 1-butyl-2,5-dioxo-3-(2-cyclohexylethyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(173) 1-butyl-2,5-dioxo-3-(2-cyclohexylethyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(174) (3R)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(175) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-methyl-2-phenylthiazol-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(176) 1-butyl-2, S -dioxo-3-(2-methylpropyl)-9-(2-(thiophen-1-yl)thiazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(177) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-(pyridin-4-yl)thiazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(178) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,4-dimethoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(179) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(180) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-(pyridin-2-yl)furan-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(181) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-(pyridin-3-yl)furan-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(182) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(3,5-dimethylpyrazol-1-yl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(183) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(5-chloropyridin-3-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(184) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(pyrimidin-2-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(185) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(pyridin-3-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(186) 1-(2-butynyl)-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-methylphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(187) (3R)-1-(2-butynyl)-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(188) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-hydroxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(189) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(pyridin-2-yl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(190) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(pyridin-3-yl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(191) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-carboxyphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(192) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(pyrazin-2-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(193) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-carboxyphenyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(194) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(pyridin-4-yl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(195) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(pyridin-2-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(196) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(naphthalen-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(197) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(6-methoxynaphthalen-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(198) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-carboxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(199) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-(pyridin-4-yl)furan-2-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(200) 1-butyl-2,5-dioxo-3-cyclopentylmethyl-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(201) (3R)-1-butyl-2,5-dioxo-3-(2,2-dimethylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(202) (3S)-1-butyl-2,5-dioxo-3-(2,2-dimethylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(203) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-nitrophenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(204) (3R)-1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-phenylmethyl-9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane,(205) (3S)-1-(tetrahydrofuran-2-ylmethyl)-2,5-dioxo-3-phenylmethyl-9-(4-phenylbutyl)-1,4,9-triazaspiro[5.5]undecane,(206) (3S)-1-propyl-2,5-dioxo-3-(3-(benzyloxycarbonylamino)propyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane,(207) 1-butyl-2,5-dioxo-3-(carboxymethyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(208) 1-(3-hydroxybutyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(209) 1-(3-hydroxypropyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(210) 1-(2-hydroxybutyl)-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(211) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-aminophenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(212) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(phenylcarbonylamino)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(213) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-((4-methylphenyl)sulfonylamino)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(214) (3S)-1-butyl-2,5-dioxo-3-benzyloxymethyl-9-benzyloxycarbonyl-1,4,9-triazaspiro[5.5]undecane,(215) (3S)-1-butyl-2,5-dioxo-3-hydroxymethyl-9-benzyloxycarbonyl-1,4,9-triazaspiro[5.5]undecane,(216) (3S)-1-butyl-2,5-dioxo-3-hydroxymethyl-1,4,9-triazaspiro[5.5]undecane,(217) (3S)-1-butyl-2,5-dioxo-3-hydroxymethyl-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(218) (3S)-1-butyl-2,5-dioxo-3-hydroxymethyl-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(219) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-cyclopentyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(220) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(2-diethylaminoethyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(221) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(2-dimethylaminoethyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(222) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-propyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(223) 1-(thiophen-2-ylmethyl)-2,5-dioxo-3-cyclohexylmethyl-9-(4-cyclopropylmethyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(224) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-cyclopropylmethyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(225) 1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-cyclopropylmethyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(226) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(dimethylamino)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(227) 1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(diethylamino)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(228) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-benzyloxycarbonyl-1,4,9-triazaspiro[5.5]undecane,(229) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-1,4,9-triazaspiro[5.5]undecane,(230) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(5-(3-methyl-4-chlorophenyl)-1-(4-methylphenylmethyl)pyrazol-3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(231) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-dimethylaminophenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(232) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-diethylaminophenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(233) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-cyclohexyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(234) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-methylphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane, (235) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-methoxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(236) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-butylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(237) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(2-methylpropyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(238) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-fluorophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(239) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-hydroxy-4-methoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(240) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-fluorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(241) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-fluorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(242) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-fluorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(243) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-chlorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(244) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-chlorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(245) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-chlorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(246) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-methyl-4-methoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(247) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(7-methoxy-1,3-benzodioxolan-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(248) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenylthiophenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(249) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-methylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(250) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-methylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(251) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-methylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(252) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(1-methylethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(253) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-fluoro-4-methoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(254) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(2-hydroxyethyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(255) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-hydroxy-3-methylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(256) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-trifluoromethyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(257) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-methyl-5-chloro-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(258) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(6-phenylpyridin-3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(259) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-methylsulfonylaminophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(260) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-methylsulfonylaminophenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(261) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(5-methylpyridin-2-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(262) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(6-methylpyridin-1-oxide-3-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(263) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(1-(2-methylpropyloxycarbonyl)indol-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(264) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2-phenyl-5-methyloxazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(265) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(tetrahydropyran-4-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(266) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(6-methylpyridin-3-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(267) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-fluorophenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(268) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(pyridin-2-yl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(269) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-hydroxyphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(270) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(2-carboxyethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(271) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-(dimethylaminosulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(272) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(5-methylpyridin-1-oxide-2-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(273) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(2-carboxy-1-ethenyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(274) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-(2-carboxy-1-ethenyl)phenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(275) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-aminocarbonylphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(276) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-aminosulfonylphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(277) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-benzylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(278) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(2,4-difluorophenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(279) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(pyrrolidin-1-ylmethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(280) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-(morpholin-4-ylsulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(281) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-(methylaminosulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(282) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-cyanophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(283) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(dimethylaminomethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(284) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-(2-dimethylaminoethylaminosulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,3(285) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-(4-hydroxyphenyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(286) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(3-methoxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(287) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(quinoxalin-2-yl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(288) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenylcarbonylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(289) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-(N-(2-hydroxyethyl)-N-methylaminosulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(290) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(2-phenylethyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(291) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(1,3,5-trimethylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(292) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(morpholin-4-ylmethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(293) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-methylpiperazin-1-ylmethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,3(294) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-phenylsulfonylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(295) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-cyclohexylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(296) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(3-carboxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(297) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(piperidin-1-ylmethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(298) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-(pyrrolidin-1-ylsulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(299) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(2,3-dihydrobenzofuran-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(300) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3,5-dimethyl-1-(4-(2-hydroxyethylaminosulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(301) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(carboxymethyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(302) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(1-phenyl-1-hydroxymethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(303) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-hydroxypiperidin-1-ylmethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(304) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(3-carboxyphenylmethyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(305) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(bis(methylsulfonyl)amino)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(306) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(1,4-benzodioxan-6-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(307) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-(3-hydroxyphenyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(308) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(methylsulfonylamino)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(309) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(6-(4-methoxyphenyloxy)pyridin-3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(310) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-methylaminocarbonylphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(311) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-chlorophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(312) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(3-(4-carboxyphenyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(313) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(phenylaminocarbonyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(314) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-methylthiophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(315) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-(4-(2-dimethylaminoethylaminocarbonyl)phenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(316) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-aminocarbonylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(317) (3S)-1-butyl-2,5-dioxo-3-(2-methylpropyl)-9-(4-dimethylaminocarbonylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(318) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-benzyloxycarbonyl-1,4,9-triazaspiro[5.5]undecane,(319) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-1,4,9-triazaspiro[5.5]undecane,(320) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-methylphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(321) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-methoxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(322) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-fluorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(323) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3-fluorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(324) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-fluorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(325) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3-chlorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(326) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-cyclohexyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(327) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-methoxy-3-hydroxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(328) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-chlorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(329) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-methylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(330) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3-methylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(331) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-methylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(332) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-phenylthiophenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(333) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3-(2-methylpropyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(334) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3-butylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(335) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-isopropylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(336) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-methoxy-3-fluorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(337) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(2-hydroxyethoxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(338) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2-hydroxy-3-methylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(339) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-chlorophenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(340) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(7-methoxy-1,3-benzodioxolan-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(341) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3-methyl-4-methoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(342) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-fluorophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(343) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-trifluoromethoxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(344) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3-methyl-5-chloro-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(345) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2,3-dimethyl-5-oxo-1-phenylpyrazolin-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(346) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(1-(2-methylpropyloxycarbonyl)indol-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(347) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(5-methyl-2-phenyloxazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(348) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-methylsulfonylaminophenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(349) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-methylsulfonylaminophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(350) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(6-methylpyridin-3-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(351) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(6-methylpyridin-1-oxide-3-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(352) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(tetrahydropyran-4-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(353) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(6-phenylpyridin-3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(354) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-fluorophenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(355) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(pyridin-2-yl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(356) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-hydroxyphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(357) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(2-carboxyethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(358) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-hydroxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(359) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-carboxyphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(360) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-(dimethylaminosulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(361) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(5-methylpyridin-1-oxide-2-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(362) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(2-carboxy-1-ethynyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(363) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-((1E)-2-carboxy-1-ethynyl)phenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(364) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-aminocarbonylphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(365) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-aminosulfonylphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(366) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-benzylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(367) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(2,4-difluorophenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(368) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(pyrrolidin-1-ylmethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(369) (3S)- I -butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-(morpholin-4-ylsulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(370) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-cyanophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(371) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-(N-(2-hydroxyethyl)-N-methylaminosulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(372) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(2-phenylethyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(373) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(dimethylaminomethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(374) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3-(4-hydroxyphenyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(375) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(quinoxalin-2-yl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(376) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(phenylcarbonyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(377) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-methylaminosulfonylphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(378) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(1,3,5-trimethylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(379) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(morpholin-4-ylmethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(380) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(3-methoxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(381) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-methylpiperazin-1-ylmethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,3(382) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(pyridin-1-oxide-3-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(383) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-phenylsulfonylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(384) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-cyclohexylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(385) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(3-carboxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(386) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(piperidin-1-ylmethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(387) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-pyrrolidin-1-ylsulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(388) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(2,3-dihydrobenzofuran-5-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(389) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-carboxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(390) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-(2-hydroxyethylaminosulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(391) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3,5-dimethyl-1-(4-(2-dimethylaminoethylaminosulfonyl)phenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,3(392) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(1-hydroxy-1-phenylmethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(393) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(carboxymethyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(394) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-hydroxypiperidin-1-ylmethyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(395) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(3-carboxyphenylmethyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(396) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(1,4-benzodioxan-6-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(397) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3-(3-hydroxyphenyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(398) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(methylsulfonylamino)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(399) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(6-(4-methoxyphenyl)pyridin-3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(400) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-methylaminocarbonylphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(401) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-chlorophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(402) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-bis(methylsulfonyl)aminophenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(403) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(3-(4-carboxyphenyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(404) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(phenylaminocarbonyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(405) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-methylthiophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(406) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(4-(2-dimethylaminoethylaminocarbonyl)phenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(407) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-aminocarbonylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(408) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-(dimethylaminocarbonyl)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(409) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(410) 1-butyl-2,5-dioxo-3-(1-hydroxy-2-methylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(411) (Z)-1-butyl-2,5-dioxo-3-(2-methylpropylidene)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(412) (3S)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxyethyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(413) (Z)-1-butyl-2,5-dioxo-3-ethylidene9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(414) (Z)-1-butyl-2,5-dioxo-3-(2-methylpropylidene)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(415) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-benzyloxycarbonyl-1,4,9-triazaspiro[5.5]undecane,(416) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-1,4,9-triazaspiro[5.5]undecane,(417) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(418) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(419) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(6-phenyloxypyridin-3-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(420) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(4-(4-methylphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(421) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(4-cyclohexyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(422) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(4-(tetrahydropyran-4-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(423) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(4-(pyridin-3-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(424) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(4-isopropylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(425) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(3,5-dimethyl-1-(4-methylphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(426) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(3-methyl-5-chloro-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(427) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(4-(4-carboxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(428) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(3,5-dimethyl-1-(pyridin-2-yl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(429) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(3,5-dimethyl-1-(4-carboxyphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(430) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-benzyloxycarbonyl-1,4,9-triazaspiro[5.5]undecane,(431) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-1,4,9-triazaspiro[5.5]undecane,(432) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(433) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(434) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(4-isopropylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(435) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(6-methylpyridin-3-yloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(436) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(3,5-dimethyl-1-(4-fluorophenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(437) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(4-methoxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(438) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(4-fluorophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(439) (3R*)-1-butyl-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(4-methylsulfonylaminophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(440) (3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-allyloxycarbonyl-1,4,9-triazaspiro[5.5]undecane,(441) (3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-1,4,9-triazaspiro[5.5]undecane,(442) (3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(443) (3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(3,5-dimethyl-1-(4-methylphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(444) (3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(4-isopropylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(445) (3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(446) (3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(4-methylphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(447) (3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-1-cyclohexylmethyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(448) (3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-1,4,9-triazaspiro[5.5]undecane,(449) (3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(3,5-dimethyl-1-(4-methylphenyl)pyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(450) (3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(4-(4-methylphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(451) (3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(452) (3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(4-isopropylphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(453) (3R*)-1-(2-butynyl)-2,5-dioxo-3-((1R*)-1-hydroxy-2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(454) (3R*)-1-butyl-2,5-dioxo-3-((1S*)-1-hydroxy-1-cyclohexylmethyl)-9-benzyl-1,4,9-triazaspiro[5.5]undecane,(455) (3R*)-1-butyl-2,5-dioxo-3-((1S*)-1-hydroxy-1-cyclohexylmethyl)-1,4,9-triazaspiro[5.5]undecane,(456) (3R*)-1-butyl-2,5-dioxo-3-((1S*)-1-hydroxy-1-cyclohexylmethyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(457) (3R*)-1-butyl-2,5-dioxo-3-((1S*)-1-hydroxy-1-cyclohexylmethyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(458) (3R*)-1-butyl-2,5-dioxo-3-((1S*)-1-hydroxy-1-cyclohexylmethyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(459) (3S)-1-butyl-2,5-dioxo-3-((1S)-1-hydroxy-2-methylpropyl)-1,4,9-triazaspiro[5.5]undecane,(460) (3S)-1-butyl-2,5-dioxo-3-((1S)-1-hydroxy-2-methylpropyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(461) (3S)-1-butyl-2,5-dioxo-3-((1S)-1-hydroxy-2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(462) (3S)-1-butyl-2,5-dioxo-3-((1S)-1-hydroxy-2-methylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(463) (35)-1-butyl-2,5-dioxo-3-((15)-1-hydroxy-2-methylpropyl)-9-(4-(4-methylsulfonylaminophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(464) (3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-2-methylpropyl)-1,4,9-triazaspiro[5.5]undecane,(465) (3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-2-methylpropyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(466) (3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-2-methylpropyl)-9-(4-phenyloxyphenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(467) (3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-2-methylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(468) (3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-2-methylpropyl)-9-(4-(4-methylsulfonylaminophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(469) (3R)-1-butyl-2,5-dioxo-3-((1S)-1-hydroxy-2-methylpropyl)-1,4,9-triazaspiro[5.5]undecane,(470) (3R)-1-butyl-2,5-dioxo-3-((1S)-1-hydroxy-2-methylpropyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(471) (3R)-1-butyl-2,5-dioxo-3-((1S)-1-hydroxy-2-methylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(472) (3R)-1-butyl-2,5-dioxo-3-((1S)-1-hydroxy-2-methylpropyl)-9-(4-(4-methylsulfonylaminophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(473) (3S)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-2-methylpropyl)-1,4,9-triazaspiro[5.5]undecane,(474) (3S)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-2-methylpropyl)-9-(3,5-dimethyl-1-phenylpyrazol-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(475) (3S)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-2-methylpropyl)-9-(1,4-benzodioxan-6-ylmethyl)-1,4,9-triazaspiro[5.5]undecane,(476) (3S)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-2-methylpropyl)-9-(4-(4-methylsulfonylaminophenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane,(477) (3S)-2,5-dioxo-3-(3-benzyloxycarbonylaminopropyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane,(478) (3S)-1-methyl-2,5-dioxo-3-(3-benzyloxycarbonylaminopropyl)-9-(2-phenylethyl)-1,4,9-triazaspiro[5.5]undecane, or(479) (3S)-1-butyl-2,5-dioxo-3-cyclohexylmethyl-9-(4-phenyloxyphenylmethyl)-9-oxide-1,4,9-triazaspiro[5.5]undecane, a quaternary ammonium salt thereof, an N-oxide thereof or a non-toxic salt thereof.
  • 7. A pharmaceutical composition comprising a triazaspiro[5.5]undecane compound of the formula (I) described in claim 1, a quaternary ammonium salt thereof, an N-oxide thereof or a non-toxic salt thereof, as an active ingredient, and a carrier.
Priority Claims (4)
Number Date Country Kind
11-344967 Dec 1999 JP national
2000-018673 Jan 2000 JP national
2000-027968 Feb 2000 JP national
2000-147882 May 2000 JP national
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/JP00/08517 12/1/2000 WO 00 5/8/2003
Publishing Document Publishing Date Country Kind
WO01/40227 6/7/2001 WO A
US Referenced Citations (2)
Number Name Date Kind
6288083 Luly et al. Sep 2001 B1
6288084 Luly et al. Sep 2001 B1
Foreign Referenced Citations (5)
Number Date Country
268868 Jun 1988 EP
2127807 Apr 1984 GB
WO 9313101 Jul 1993 WO
WO 9711940 Apr 1997 WO
WO 9825605 Jun 1998 WO
Related Publications (1)
Number Date Country
20040097511 A1 May 2004 US